@prefix schema: <http://schema.org/> .
@prefix adms: <http://www.w3.org/ns/adms#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix org: <http://www.w3.org/ns/org#> .
@prefix xls2rdf: <https://xls2rdf.sparna.fr/vocabulary#> .
@prefix this: <http://www.limics.org/remiames_ontology/thesaurus_interactions#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix skosthes: <http://purl.org/iso25964/skos-thes#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix adm: <http://www.limics.org/remiames_ontology/administrations#> .
@prefix qb: <http://purl.org/linked-data/cube#> .
@prefix r: <http://www.limics.org/remiames_ontology#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix doap: <http://usefulinc.com/ns/doap#> .
@prefix sh: <http://www.w3.org/ns/shacl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix dcat: <http://www.w3.org/ns/dcat#> .
@prefix euvoc: <http://publications.europa.eu/ontology/euvoc#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix skosxl: <http://www.w3.org/2008/05/skos-xl#> .

<http://www.limics.org/remiames_ontology/thesaurus_interactions> a owl:Ontology;
  owl:imports <http://www.limics.org/remiames_ontology>, <http://www.limics.org/remiames_ontology/classes_et_groupes_substances>,
    <http://www.limics.org/remiames_ontology/administrations> .

this:IAM_10454-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10454";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247767906;
  r:natureDuRisque "Avec la lidocaïne utilisée par voie IV : augmentation des concentrations plasmatiques de lidocaïne avec possibilité d'effets indésirables neurologiques et cardiaques (diminution de la clairance hépatique de la lidocaïne)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations plasmatiques de lidocaïne pendant l'association et après l'arrêt du bêta-bloquant. Adaptation si besoin de la posologie de la lidocaïne."@fr;
  rdfs:comment "De nombreuses publications, souvent anciennes, évoquent une diminution de la clairance de la lidocaïne lorsque les bêta-bloquants sont pris conjointement, vraisemblablement en raison de la diminution du flux sanguin hépatique. De fait, ces publications ne"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247767915, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247767906 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247767907 .

_:807f36cf91fe4e8caa53aadeff9247767907 rdf:first _:807f36cf91fe4e8caa53aadeff9247767908;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767909 .

_:807f36cf91fe4e8caa53aadeff9247767908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff9247767909 rdf:first _:807f36cf91fe4e8caa53aadeff9247767910;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767911 .

_:807f36cf91fe4e8caa53aadeff9247767910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:807f36cf91fe4e8caa53aadeff9247767911 rdf:first _:807f36cf91fe4e8caa53aadeff9247767912;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247767912 a owl:Restriction;
  owl:onProperty r:patient;
  owl:someValuesFrom _:807f36cf91fe4e8caa53aadeff9247767913 .

_:807f36cf91fe4e8caa53aadeff9247767913 a owl:Restriction;
  owl:onProperty r:diabete;
  owl:hasValue r:Oui .

_:807f36cf91fe4e8caa53aadeff9247767915 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10454-XXX a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10454";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247767917;
  r:natureDuRisque "Avec la lidocaïne utilisée par voie IV : augmentation des concentrations plasmatiques de lidocaïne avec possibilité d'effets indésirables neurologiques et cardiaques (diminution de la clairance hépatique de la lidocaïne)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations plasmatiques de lidocaïne pendant l'association et après l'arrêt du bêta-bloquant. Adaptation si besoin de la posologie de la lidocaïne."@fr;
  rdfs:comment "De nombreuses publications, souvent anciennes, évoquent une diminution de la clairance de la lidocaïne lorsque les bêta-bloquants sont pris conjointement, vraisemblablement en raison de la diminution du flux sanguin hépatique. De fait, ces publications ne"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247767932, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247767917 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247767918 .

_:807f36cf91fe4e8caa53aadeff9247767918 rdf:first _:807f36cf91fe4e8caa53aadeff9247767919;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767920 .

_:807f36cf91fe4e8caa53aadeff9247767919 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff9247767920 rdf:first _:807f36cf91fe4e8caa53aadeff9247767921;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767922 .

_:807f36cf91fe4e8caa53aadeff9247767921 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:807f36cf91fe4e8caa53aadeff9247767922 rdf:first _:807f36cf91fe4e8caa53aadeff9247767923;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247767923 a owl:Restriction;
  owl:onProperty r:patient;
  owl:someValuesFrom _:807f36cf91fe4e8caa53aadeff9247767924 .

_:807f36cf91fe4e8caa53aadeff9247767924 a owl:Class;
  owl:unionOf _:807f36cf91fe4e8caa53aadeff9247767925 .

_:807f36cf91fe4e8caa53aadeff9247767925 rdf:first _:807f36cf91fe4e8caa53aadeff9247767926;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767927 .

_:807f36cf91fe4e8caa53aadeff9247767926 a owl:Restriction;
  owl:onProperty r:diabete;
  owl:hasValue r:Inconnu .

_:807f36cf91fe4e8caa53aadeff9247767927 rdf:first _:807f36cf91fe4e8caa53aadeff9247767928;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767929 .

_:807f36cf91fe4e8caa53aadeff9247767928 a owl:Restriction;
  owl:onProperty r:diabete;
  owl:hasValue r:Oui .

_:807f36cf91fe4e8caa53aadeff9247767929 rdf:first _:807f36cf91fe4e8caa53aadeff9247767930;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247767930 a owl:Restriction;
  owl:onProperty r:diabete;
  owl:hasValue r:Possible .

_:807f36cf91fe4e8caa53aadeff9247767932 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10443-1 a owl:Class;
  rdfs:label "BENZODIAZÉPINES ET APPARENTÉS <-> CLOZAPINE"@fr;
  dct:identifier "IAM_10443";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247767934;
  r:natureDuRisque "Risque accru de collapsus avec arrêt respiratoire et / ou cardiaque."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247767942, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247767934 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247767935 .

_:807f36cf91fe4e8caa53aadeff9247767935 rdf:first _:807f36cf91fe4e8caa53aadeff9247767936;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767937 .

_:807f36cf91fe4e8caa53aadeff9247767936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10049 .

_:807f36cf91fe4e8caa53aadeff9247767937 rdf:first _:807f36cf91fe4e8caa53aadeff9247767938;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767939 .

_:807f36cf91fe4e8caa53aadeff9247767938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:807f36cf91fe4e8caa53aadeff9247767939 rdf:first _:807f36cf91fe4e8caa53aadeff9247767940;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247767940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:minQualifiedCardinality "2"^^xsd:nonNegativeInteger;
  owl:onClass adm:Administration_GS_IAM_10220 .

_:807f36cf91fe4e8caa53aadeff9247767942 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10444-1 a owl:Class;
  rdfs:label "BENZODIAZÉPINES ET APPARENTÉS <-> MORPHINIQUES"@fr;
  dct:identifier "IAM_10444";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247767944;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247767950, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247767944 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247767945 .

_:807f36cf91fe4e8caa53aadeff9247767945 rdf:first _:807f36cf91fe4e8caa53aadeff9247767946;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767947 .

_:807f36cf91fe4e8caa53aadeff9247767946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10049 .

_:807f36cf91fe4e8caa53aadeff9247767947 rdf:first _:807f36cf91fe4e8caa53aadeff9247767948;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247767948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10109 .

_:807f36cf91fe4e8caa53aadeff9247767950 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10445-1 a owl:Class;
  rdfs:label "BÊTA-2 MIMÉTIQUES <-> HALOTHANE"@fr;
  dct:identifier "IAM_10445";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247767952;
  r:natureDuRisque "En cas d'intervention obstétricale, majoration de l'inertie utérine avec risque hémorragique ; par ailleurs, troubles du rythme ventriculaires graves, par augmentation de la réactivité cardiaque."@fr;
  r:conduiteATenir "Interrompre le traitement par bêta-2 mimétiques si l'anesthésie doit se faire sous halothane."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247767958, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247767952 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247767953 .

_:807f36cf91fe4e8caa53aadeff9247767953 rdf:first _:807f36cf91fe4e8caa53aadeff9247767954;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767955 .

_:807f36cf91fe4e8caa53aadeff9247767954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10052 .

_:807f36cf91fe4e8caa53aadeff9247767955 rdf:first _:807f36cf91fe4e8caa53aadeff9247767956;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247767956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10427 .

_:807f36cf91fe4e8caa53aadeff9247767958 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10446-1 a owl:Class;
  rdfs:label "BÊTA-2 MIMÉTIQUES <-> INSULINE"@fr;
  dct:identifier "IAM_10446";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247767960;
  r:natureDuRisque "Elévation de la glycémie par le bêta-2 mimétique."@fr;
  r:conduiteATenir "Renforcer la surveillance sanguine et urinaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247767966, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247767960 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247767961 .

_:807f36cf91fe4e8caa53aadeff9247767961 rdf:first _:807f36cf91fe4e8caa53aadeff9247767962;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767963 .

_:807f36cf91fe4e8caa53aadeff9247767962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10052 .

_:807f36cf91fe4e8caa53aadeff9247767963 rdf:first _:807f36cf91fe4e8caa53aadeff9247767964;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247767964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10105 .

_:807f36cf91fe4e8caa53aadeff9247767966 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10447-1 a owl:Class;
  rdfs:label "BÊTA-2 MIMÉTIQUES <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10447";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247767968;
  r:natureDuRisque "Elévation de la glycémie par le bêta-2 mimétique."@fr;
  r:conduiteATenir "Renforcer la surveillance sanguine et urinaire. Passer éventuellement à l'insuline, le cas échéant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247767974, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247767968 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247767969 .

_:807f36cf91fe4e8caa53aadeff9247767969 rdf:first _:807f36cf91fe4e8caa53aadeff9247767970;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767971 .

_:807f36cf91fe4e8caa53aadeff9247767970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10052 .

_:807f36cf91fe4e8caa53aadeff9247767971 rdf:first _:807f36cf91fe4e8caa53aadeff9247767972;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247767972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff9247767974 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10448-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> DIHYDROPYRIDINES"@fr;
  dct:identifier "IAM_10448";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247767976;
  r:natureDuRisque "Hypotension, défaillance cardiaque chez les patients en insuffisance cardiaque latente ou non contrôlée (addition des effets inotropes négatifs). Le bêta-bloquant peut par ailleurs minimiser la réaction sympathique réflexe mise en jeu en cas de répercussi"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247767982, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247767976 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247767977 .

_:807f36cf91fe4e8caa53aadeff9247767977 rdf:first _:807f36cf91fe4e8caa53aadeff9247767978;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767979 .

_:807f36cf91fe4e8caa53aadeff9247767978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff9247767979 rdf:first _:807f36cf91fe4e8caa53aadeff9247767980;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247767980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10062 .

_:807f36cf91fe4e8caa53aadeff9247767982 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10449-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10449";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247767984;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir "Une telle association ne doit se faire que sous surveillance clinique et ECG étroite, en particulier chez le sujet âgé ou en début de traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247767990, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247767984 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247767985 .

_:807f36cf91fe4e8caa53aadeff9247767985 rdf:first _:807f36cf91fe4e8caa53aadeff9247767986;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767987 .

_:807f36cf91fe4e8caa53aadeff9247767986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff9247767987 rdf:first _:807f36cf91fe4e8caa53aadeff9247767988;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247767988 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff9247767990 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10450-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> DIPYRIDAMOLE"@fr;
  dct:identifier "IAM_10450";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247767992;
  r:natureDuRisque "Avec le dipyridamole par voie injectable : majoration de l'effet antihypertenseur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247767998, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247767992 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247767993 .

_:807f36cf91fe4e8caa53aadeff9247767993 rdf:first _:807f36cf91fe4e8caa53aadeff9247767994;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247767995 .

_:807f36cf91fe4e8caa53aadeff9247767994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff9247767995 rdf:first _:807f36cf91fe4e8caa53aadeff9247767996;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247767996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10297 .

_:807f36cf91fe4e8caa53aadeff9247767998 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10451-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> GLINIDES"@fr;
  dct:identifier "IAM_10451";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768000;
  r:natureDuRisque "Tous les bêta-bloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768006, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768000 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768001 .

_:807f36cf91fe4e8caa53aadeff9247768001 rdf:first _:807f36cf91fe4e8caa53aadeff9247768002;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768003 .

_:807f36cf91fe4e8caa53aadeff9247768002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff9247768003 rdf:first _:807f36cf91fe4e8caa53aadeff9247768004;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10078 .

_:807f36cf91fe4e8caa53aadeff9247768006 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10394-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10394";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768008;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'atorvastatine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768014, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768008 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768009 .

_:807f36cf91fe4e8caa53aadeff9247768009 rdf:first _:807f36cf91fe4e8caa53aadeff9247768010;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768011 .

_:807f36cf91fe4e8caa53aadeff9247768010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff9247768011 rdf:first _:807f36cf91fe4e8caa53aadeff9247768012;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247768014 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10453-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> INSULINE"@fr;
  dct:identifier "IAM_10453";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768016;
  r:natureDuRisque "Tous les bêtabloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768022, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768016 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768017 .

_:807f36cf91fe4e8caa53aadeff9247768017 rdf:first _:807f36cf91fe4e8caa53aadeff9247768018;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768019 .

_:807f36cf91fe4e8caa53aadeff9247768018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff9247768019 rdf:first _:807f36cf91fe4e8caa53aadeff9247768020;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:807f36cf91fe4e8caa53aadeff9247768022 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10440-1 a owl:Class;
  rdfs:label "BÉDAQUILINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10440";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768024;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de bédaquiline par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768030, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768024 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768025 .

_:807f36cf91fe4e8caa53aadeff9247768025 rdf:first _:807f36cf91fe4e8caa53aadeff9247768026;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768027 .

_:807f36cf91fe4e8caa53aadeff9247768026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10105 .

_:807f36cf91fe4e8caa53aadeff9247768027 rdf:first _:807f36cf91fe4e8caa53aadeff9247768028;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768028 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff9247768030 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10455-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10455";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768032;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768038, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768032 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768033 .

_:807f36cf91fe4e8caa53aadeff9247768033 rdf:first _:807f36cf91fe4e8caa53aadeff9247768034;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768035 .

_:807f36cf91fe4e8caa53aadeff9247768034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff9247768035 rdf:first _:807f36cf91fe4e8caa53aadeff9247768036;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768036 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff9247768038 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10456-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10456";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768040;
  r:natureDuRisque "Tous les bêta-bloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768046, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768040 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768041 .

_:807f36cf91fe4e8caa53aadeff9247768041 rdf:first _:807f36cf91fe4e8caa53aadeff9247768042;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768043 .

_:807f36cf91fe4e8caa53aadeff9247768042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff9247768043 rdf:first _:807f36cf91fe4e8caa53aadeff9247768044;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768044 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff9247768046 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10457-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10457";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768048;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), trouble de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir "Une telle association ne doit se faire que sous surveillance clinique et ECG étroite, en particulier chez le sujet âgé ou en début de traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768054, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768048 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768049 .

_:807f36cf91fe4e8caa53aadeff9247768049 rdf:first _:807f36cf91fe4e8caa53aadeff9247768050;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768051 .

_:807f36cf91fe4e8caa53aadeff9247768050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff9247768051 rdf:first _:807f36cf91fe4e8caa53aadeff9247768052;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768052 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff9247768054 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10458-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10458";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768056;
  r:natureDuRisque "Troubles de l’automatisme (bradycardie, arrêt sinusal) et troubles de la conduction sino-auriculaire et auriculo-ventriculaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768062, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768056 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768057 .

_:807f36cf91fe4e8caa53aadeff9247768057 rdf:first _:807f36cf91fe4e8caa53aadeff9247768058;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768059 .

_:807f36cf91fe4e8caa53aadeff9247768058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff9247768059 rdf:first _:807f36cf91fe4e8caa53aadeff9247768060;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768060 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff9247768062 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10459-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> DIHYDROPYRIDINES"@fr;
  dct:identifier "IAM_10459";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768064;
  r:natureDuRisque "Hypotension, défaillance cardiaque chez les malades en insuffisance cardiaque latente ou non contrôlée (effet inotrope négatif in vitro des dihydropyridines plus ou moins marqué et susceptibles de s'additionner aux effets inotropes négatifs des bêta-bloqu"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768070, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768064 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768065 .

_:807f36cf91fe4e8caa53aadeff9247768065 rdf:first _:807f36cf91fe4e8caa53aadeff9247768066;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768067 .

_:807f36cf91fe4e8caa53aadeff9247768066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff9247768067 rdf:first _:807f36cf91fe4e8caa53aadeff9247768068;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768068 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10062 .

_:807f36cf91fe4e8caa53aadeff9247768070 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10460-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10460";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768072;
  r:natureDuRisque "Effet inotrope négatif avec risque de décompensation de l’insuffisance cardiaque, troubles de l'automatisme (bradycardie, arrêt sinusal) et troubles de la conduction sino-auriculaire et auriculo-ventriculaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768078, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768072 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768073 .

_:807f36cf91fe4e8caa53aadeff9247768073 rdf:first _:807f36cf91fe4e8caa53aadeff9247768074;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768075 .

_:807f36cf91fe4e8caa53aadeff9247768074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff9247768075 rdf:first _:807f36cf91fe4e8caa53aadeff9247768076;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768076 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff9247768078 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10461-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> GLINIDES"@fr;
  dct:identifier "IAM_10461";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768080;
  r:chapeau """A l’heure actuelle, 4 bêta-bloquants ont l'indication \"insuffisance cardiaque\" : le carvédilol, le bisoprolol, le métoprolol et le névibolol.
Les interactions médicamenteuses des bêta-bloquants, lorsqu’ils sont prescrits dans l’insuffisance cardiaque, pe"""@fr;
  r:natureDuRisque "Tous les bêtabloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768086, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768080 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768081 .

_:807f36cf91fe4e8caa53aadeff9247768081 rdf:first _:807f36cf91fe4e8caa53aadeff9247768082;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768083 .

_:807f36cf91fe4e8caa53aadeff9247768082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff9247768083 rdf:first _:807f36cf91fe4e8caa53aadeff9247768084;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768084 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10078 .

_:807f36cf91fe4e8caa53aadeff9247768086 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10462-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> INSULINE"@fr;
  dct:identifier "IAM_10462";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768088;
  r:natureDuRisque "Tous les bêtabloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768094, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768088 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768089 .

_:807f36cf91fe4e8caa53aadeff9247768089 rdf:first _:807f36cf91fe4e8caa53aadeff9247768090;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768091 .

_:807f36cf91fe4e8caa53aadeff9247768090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff9247768091 rdf:first _:807f36cf91fe4e8caa53aadeff9247768092;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768092 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:807f36cf91fe4e8caa53aadeff9247768094 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10463-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10463";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768096;
  r:natureDuRisque "Effet inotrope négatif avec risque de décompensation cardiaque."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768102, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768096 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768097 .

_:807f36cf91fe4e8caa53aadeff9247768097 rdf:first _:807f36cf91fe4e8caa53aadeff9247768098;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768099 .

_:807f36cf91fe4e8caa53aadeff9247768098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff9247768099 rdf:first _:807f36cf91fe4e8caa53aadeff9247768100;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768100 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:807f36cf91fe4e8caa53aadeff9247768102 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10452-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS (SAUF ESMOLOL) <-> GLIPTINES"@fr;
  dct:identifier "IAM_10452";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768104;
  r:natureDuRisque "Tous les bêtabloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer, surtout en début de traitement, l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768110, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768104 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768105 .

_:807f36cf91fe4e8caa53aadeff9247768105 rdf:first _:807f36cf91fe4e8caa53aadeff9247768106;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768107 .

_:807f36cf91fe4e8caa53aadeff9247768106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff9247768107 rdf:first _:807f36cf91fe4e8caa53aadeff9247768108;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768108 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10079 .

_:807f36cf91fe4e8caa53aadeff9247768110 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10430-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10430";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768112;
  r:natureDuRisque "Augmentation de la digoxinémie par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par l'azithromycine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768118, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768112 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768113 .

_:807f36cf91fe4e8caa53aadeff9247768113 rdf:first _:807f36cf91fe4e8caa53aadeff9247768114;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768115 .

_:807f36cf91fe4e8caa53aadeff9247768114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff9247768115 rdf:first _:807f36cf91fe4e8caa53aadeff9247768116;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768116 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff9247768118 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10521-1 a owl:Class;
  rdfs:label "CAFEINE <-> CIPROFLOXACINE"@fr;
  dct:identifier "IAM_10521";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768120;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de caféine, par diminution de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768126, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768120 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768121 .

_:807f36cf91fe4e8caa53aadeff9247768121 rdf:first _:807f36cf91fe4e8caa53aadeff9247768122;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768123 .

_:807f36cf91fe4e8caa53aadeff9247768122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff9247768123 rdf:first _:807f36cf91fe4e8caa53aadeff9247768124;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff9247768126 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10396-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10396";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768128;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’inhibiteur de l’HMG-CoA reductase)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768134, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768128 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768129 .

_:807f36cf91fe4e8caa53aadeff9247768129 rdf:first _:807f36cf91fe4e8caa53aadeff9247768130;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768131 .

_:807f36cf91fe4e8caa53aadeff9247768130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247768131 rdf:first _:807f36cf91fe4e8caa53aadeff9247768132;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff9247768134 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10397-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> RANOLAZINE"@fr;
  dct:identifier "IAM_10397";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768136;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par inhibition du métabolisme de l'atorvastatine par la ranolazine."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant ou une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768142, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768136 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768137 .

_:807f36cf91fe4e8caa53aadeff9247768137 rdf:first _:807f36cf91fe4e8caa53aadeff9247768138;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768139 .

_:807f36cf91fe4e8caa53aadeff9247768138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247768139 rdf:first _:807f36cf91fe4e8caa53aadeff9247768140;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:807f36cf91fe4e8caa53aadeff9247768142 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10398-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10398";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768144;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques d'atorvastatine, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768150, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768144 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768145 .

_:807f36cf91fe4e8caa53aadeff9247768145 rdf:first _:807f36cf91fe4e8caa53aadeff9247768146;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768147 .

_:807f36cf91fe4e8caa53aadeff9247768146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247768147 rdf:first _:807f36cf91fe4e8caa53aadeff9247768148;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff9247768150 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10399-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> ROXITHROMYCINE"@fr;
  dct:identifier "IAM_10399";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768152;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768158, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768152 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768153 .

_:807f36cf91fe4e8caa53aadeff9247768153 rdf:first _:807f36cf91fe4e8caa53aadeff9247768154;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768155 .

_:807f36cf91fe4e8caa53aadeff9247768154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247768155 rdf:first _:807f36cf91fe4e8caa53aadeff9247768156;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:807f36cf91fe4e8caa53aadeff9247768158 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10400-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10400";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768160;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768166, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768160 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768161 .

_:807f36cf91fe4e8caa53aadeff9247768161 rdf:first _:807f36cf91fe4e8caa53aadeff9247768162;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768163 .

_:807f36cf91fe4e8caa53aadeff9247768162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247768163 rdf:first _:807f36cf91fe4e8caa53aadeff9247768164;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff9247768166 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10401-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10401";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768168;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'atorvastatine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768174, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768168 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768169 .

_:807f36cf91fe4e8caa53aadeff9247768169 rdf:first _:807f36cf91fe4e8caa53aadeff9247768170;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768171 .

_:807f36cf91fe4e8caa53aadeff9247768170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247768171 rdf:first _:807f36cf91fe4e8caa53aadeff9247768172;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff9247768174 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10402-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_10402";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768176;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  rdfs:comment """La télithromycine est un inhibiteur du CYP3A4. Par conséquent, son administration est contre-indiquée avec des médicaments qui sont métabolisés par le CYP3A4 et qui ont un index thérapeutique étroit. 
L’association de la télithromycine avec la simvastatin"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768182, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768176 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768177 .

_:807f36cf91fe4e8caa53aadeff9247768177 rdf:first _:807f36cf91fe4e8caa53aadeff9247768178;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768179 .

_:807f36cf91fe4e8caa53aadeff9247768178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247768179 rdf:first _:807f36cf91fe4e8caa53aadeff9247768180;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff9247768182 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10412-1 a owl:Class;
  rdfs:label "AUTRES CORTICOÏDES, NOTAMMENT INHALÉS <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10412";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768184;
  r:natureDuRisque """En cas d’utilisation prolongée par voie orale ou inhalée : 
augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par le voriconazole, avec risque d’apparition d’un syndrome cushingoïde voire d’une insuffis"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768190, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768184 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768185 .

_:807f36cf91fe4e8caa53aadeff9247768185 rdf:first _:807f36cf91fe4e8caa53aadeff9247768186;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768187 .

_:807f36cf91fe4e8caa53aadeff9247768186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10047 .

_:807f36cf91fe4e8caa53aadeff9247768187 rdf:first _:807f36cf91fe4e8caa53aadeff9247768188;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff9247768190 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10442-1 a owl:Class;
  rdfs:label "BENZODIAZÉPINES ET APPARENTÉS <-> BUPRENORPHINE"@fr;
  dct:identifier "IAM_10442";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768192;
  r:natureDuRisque "Avec la buprénorphine utilisée en traitement de substitution : risque majoré de dépression respiratoire, pouvant être fatale."@fr;
  r:conduiteATenir "Evaluer attentivement le rapport bénéfice/risque de cette association. Informer le patient de la nécessité de respecter les doses prescrites."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768198, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768192 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768193 .

_:807f36cf91fe4e8caa53aadeff9247768193 rdf:first _:807f36cf91fe4e8caa53aadeff9247768194;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768195 .

_:807f36cf91fe4e8caa53aadeff9247768194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10049 .

_:807f36cf91fe4e8caa53aadeff9247768195 rdf:first _:807f36cf91fe4e8caa53aadeff9247768196;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff9247768198 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10429-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10429";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768200;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt du macrolide."@fr;
  rdfs:comment """En 2001, une publication évoquant une interaction entre azithromycine et ciclosporine n’avait pas été prise en compte car aucune autre observation n'allait dans ce sens.
Depuis, huit nouvelles observations ont été évaluées. Six d’entre elles sont bien doc"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768206, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768200 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768201 .

_:807f36cf91fe4e8caa53aadeff9247768201 rdf:first _:807f36cf91fe4e8caa53aadeff9247768202;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768203 .

_:807f36cf91fe4e8caa53aadeff9247768202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff9247768203 rdf:first _:807f36cf91fe4e8caa53aadeff9247768204;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff9247768206 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10441-1 a owl:Class;
  rdfs:label "BÉLATACEPT <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10441";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768208;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768214, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768208 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768209 .

_:807f36cf91fe4e8caa53aadeff9247768209 rdf:first _:807f36cf91fe4e8caa53aadeff9247768210;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768211 .

_:807f36cf91fe4e8caa53aadeff9247768210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff9247768211 rdf:first _:807f36cf91fe4e8caa53aadeff9247768212;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10106 .

_:807f36cf91fe4e8caa53aadeff9247768214 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10431-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> IVABRADINE"@fr;
  dct:identifier "IAM_10431";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768216;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaires, notamment de torsades de pointes. De plus, augmentation des concentrations plasmatiques de l’ivabradine par diminution de son métabolisme par l’azithromycine."@fr;
  r:conduiteATenir "Surveillance clinique et ECG pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768222, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768216 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768217 .

_:807f36cf91fe4e8caa53aadeff9247768217 rdf:first _:807f36cf91fe4e8caa53aadeff9247768218;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768219 .

_:807f36cf91fe4e8caa53aadeff9247768218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff9247768219 rdf:first _:807f36cf91fe4e8caa53aadeff9247768220;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff9247768222 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10432-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10432";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768224;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant ou une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768230, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768224 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768225 .

_:807f36cf91fe4e8caa53aadeff9247768225 rdf:first _:807f36cf91fe4e8caa53aadeff9247768226;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768227 .

_:807f36cf91fe4e8caa53aadeff9247768226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff9247768227 rdf:first _:807f36cf91fe4e8caa53aadeff9247768228;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff9247768230 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10433-1 a owl:Class;
  rdfs:label "AZITHROMYCINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10433";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768232;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes."""@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768238, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768232 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768233 .

_:807f36cf91fe4e8caa53aadeff9247768233 rdf:first _:807f36cf91fe4e8caa53aadeff9247768234;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768235 .

_:807f36cf91fe4e8caa53aadeff9247768234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff9247768235 rdf:first _:807f36cf91fe4e8caa53aadeff9247768236;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff9247768238 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10434-1 a owl:Class;
  rdfs:label "AZTREONAM <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_10434";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768240;
  r:natureDuRisque "Risque de survenue de crises convulsives, par diminution des concentrations plasmatiques de l'acide valproïque."@fr;
  r:conduiteATenir "Surveillance clinique, dosages plasmatiques et adaptation éventuelle de la posologie de l'anticonvulsivant pendant le traitement par l'anti-infectieux et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768246, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768240 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768241 .

_:807f36cf91fe4e8caa53aadeff9247768241 rdf:first _:807f36cf91fe4e8caa53aadeff9247768242;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768243 .

_:807f36cf91fe4e8caa53aadeff9247768242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff9247768243 rdf:first _:807f36cf91fe4e8caa53aadeff9247768244;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff9247768246 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10435-1 a owl:Class;
  rdfs:label "BACLOFENE <-> LEVODOPA"@fr;
  dct:identifier "IAM_10435";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768248;
  r:natureDuRisque "Risque d’aggravation du syndrome parkinsonien ou d’effets indésirables centraux (hallucinations visuelles, état confusionnel, céphalées)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768254, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768248 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768249 .

_:807f36cf91fe4e8caa53aadeff9247768249 rdf:first _:807f36cf91fe4e8caa53aadeff9247768250;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768251 .

_:807f36cf91fe4e8caa53aadeff9247768250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10102 .

_:807f36cf91fe4e8caa53aadeff9247768251 rdf:first _:807f36cf91fe4e8caa53aadeff9247768252;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff9247768254 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10436-1 a owl:Class;
  rdfs:label "BARBITURIQUES <-> BENZODIAZÉPINES ET APPARENTÉS"@fr;
  dct:identifier "IAM_10436";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768256;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768262, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768256 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768257 .

_:807f36cf91fe4e8caa53aadeff9247768257 rdf:first _:807f36cf91fe4e8caa53aadeff9247768258;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768259 .

_:807f36cf91fe4e8caa53aadeff9247768258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff9247768259 rdf:first _:807f36cf91fe4e8caa53aadeff9247768260;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10049 .

_:807f36cf91fe4e8caa53aadeff9247768262 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10437-1 a owl:Class;
  rdfs:label "BARBITURIQUES <-> MORPHINIQUES"@fr;
  dct:identifier "IAM_10437";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768264;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768270, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768264 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768265 .

_:807f36cf91fe4e8caa53aadeff9247768265 rdf:first _:807f36cf91fe4e8caa53aadeff9247768266;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768267 .

_:807f36cf91fe4e8caa53aadeff9247768266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff9247768267 rdf:first _:807f36cf91fe4e8caa53aadeff9247768268;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10109 .

_:807f36cf91fe4e8caa53aadeff9247768270 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10438-1 a owl:Class;
  rdfs:label "BÉDAQUILINE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10438";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768272;
  r:natureDuRisque "Diminution des concentrations plasmatiques de bédaquiline par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768278, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768272 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768273 .

_:807f36cf91fe4e8caa53aadeff9247768273 rdf:first _:807f36cf91fe4e8caa53aadeff9247768274;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768275 .

_:807f36cf91fe4e8caa53aadeff9247768274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff9247768275 rdf:first _:807f36cf91fe4e8caa53aadeff9247768276;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10105 .

_:807f36cf91fe4e8caa53aadeff9247768278 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10439-1 a owl:Class;
  rdfs:label "BÉDAQUILINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10439";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768280;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de bédaquiline par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  r:conduiteATenir "Si l’association est nécessaire, une surveillance ECG plus fréquente et une surveillance des transaminases sont recommandées."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768286, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768280 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768281 .

_:807f36cf91fe4e8caa53aadeff9247768281 rdf:first _:807f36cf91fe4e8caa53aadeff9247768282;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768283 .

_:807f36cf91fe4e8caa53aadeff9247768282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff9247768283 rdf:first _:807f36cf91fe4e8caa53aadeff9247768284;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10105 .

_:807f36cf91fe4e8caa53aadeff9247768286 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10466-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10466";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768288;
  r:natureDuRisque "Tous les bêta-bloquants peuvent masquer certains symptômes de l'hypoglycémie : palpitations et tachycardie."@fr;
  r:conduiteATenir "Prévenir le malade et renforcer, surtout au début du traitement, l'autosurveillance sanguine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768294, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768288 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768289 .

_:807f36cf91fe4e8caa53aadeff9247768289 rdf:first _:807f36cf91fe4e8caa53aadeff9247768290;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768291 .

_:807f36cf91fe4e8caa53aadeff9247768290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff9247768291 rdf:first _:807f36cf91fe4e8caa53aadeff9247768292;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff9247768294 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10428-1 a owl:Class;
  rdfs:label "AVANAFIL <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10428";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768296;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'avanafil, avec risque d’hypotension."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768296 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768297 .

_:807f36cf91fe4e8caa53aadeff9247768297 rdf:first _:807f36cf91fe4e8caa53aadeff9247768298;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768299 .

_:807f36cf91fe4e8caa53aadeff9247768298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff9247768299 rdf:first _:807f36cf91fe4e8caa53aadeff9247768300;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff9247768302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10499-1 a owl:Class;
  rdfs:label "BUPROPION <-> DESIPRAMINE"@fr;
  dct:identifier "IAM_10499";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768304;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la désipramine par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la désipramine pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768305 .

_:807f36cf91fe4e8caa53aadeff9247768305 rdf:first _:807f36cf91fe4e8caa53aadeff9247768306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768307 .

_:807f36cf91fe4e8caa53aadeff9247768306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff9247768307 rdf:first _:807f36cf91fe4e8caa53aadeff9247768308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10268 .

_:807f36cf91fe4e8caa53aadeff9247768310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10464-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> NEUROLEPTIQUES"@fr;
  dct:identifier "IAM_10464";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768312;
  r:natureDuRisque "Effet vasodilatateur et risque d'hypotension, notamment orthostatique (effet additif)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768313 .

_:807f36cf91fe4e8caa53aadeff9247768313 rdf:first _:807f36cf91fe4e8caa53aadeff9247768314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768315 .

_:807f36cf91fe4e8caa53aadeff9247768314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff9247768315 rdf:first _:807f36cf91fe4e8caa53aadeff9247768316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10124 .

_:807f36cf91fe4e8caa53aadeff9247768318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10408-1 a owl:Class;
  rdfs:label "AUTRES BRADYCARDISANTS <-> BRADYCARDISANTS"@fr;
  dct:identifier "IAM_10408";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768320;
  r:natureDuRisque "Risque de bradycardie excessive (addition des effets)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768322, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10051 .

_:807f36cf91fe4e8caa53aadeff9247768322 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10491-1 a owl:Class;
  rdfs:label "BRADYCARDISANTS <-> FINGOLIMOD"@fr;
  dct:identifier "IAM_10491";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768324;
  r:natureDuRisque "Potentialisation des effets bradycardisants pouvant avoir des conséquences fatales. Les bêta-bloquants sont d’autant plus à risque qu’ils empêchent les mécanismes de compensation adrénergique."@fr;
  r:conduiteATenir "Surveillance clinique et ECG continu pendant les 24 heures suivant la première dose."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768330, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768324 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768325 .

_:807f36cf91fe4e8caa53aadeff9247768325 rdf:first _:807f36cf91fe4e8caa53aadeff9247768326;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768327 .

_:807f36cf91fe4e8caa53aadeff9247768326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10051 .

_:807f36cf91fe4e8caa53aadeff9247768327 rdf:first _:807f36cf91fe4e8caa53aadeff9247768328;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768328 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10379 .

_:807f36cf91fe4e8caa53aadeff9247768330 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10492-1 a owl:Class;
  rdfs:label "BRADYCARDISANTS <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10492";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768332;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768338, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768332 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768333 .

_:807f36cf91fe4e8caa53aadeff9247768333 rdf:first _:807f36cf91fe4e8caa53aadeff9247768334;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768335 .

_:807f36cf91fe4e8caa53aadeff9247768334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10051 .

_:807f36cf91fe4e8caa53aadeff9247768335 rdf:first _:807f36cf91fe4e8caa53aadeff9247768336;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff9247768338 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10493-1 a owl:Class;
  rdfs:label "BRENTUXIMAB <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10493";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768340;
  r:natureDuRisque "Augmentation des concentrations du métabolite actif du brentuximab, avec risque de neutropénie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768346, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768340 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768341 .

_:807f36cf91fe4e8caa53aadeff9247768341 rdf:first _:807f36cf91fe4e8caa53aadeff9247768342;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768343 .

_:807f36cf91fe4e8caa53aadeff9247768342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff9247768343 rdf:first _:807f36cf91fe4e8caa53aadeff9247768344;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10133 .

_:807f36cf91fe4e8caa53aadeff9247768346 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10494-1 a owl:Class;
  rdfs:label "BUPRENORPHINE <-> FOSAMPRENAVIR"@fr;
  dct:identifier "IAM_10494";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768348;
  r:natureDuRisque "Risque de majoration ou de diminution des effets de la A prendre en compte buprénorphine, à la fois par inhibition et accélération de son métabolisme par l’inhibiteur de protéases."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768354, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768348 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768349 .

_:807f36cf91fe4e8caa53aadeff9247768349 rdf:first _:807f36cf91fe4e8caa53aadeff9247768350;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768351 .

_:807f36cf91fe4e8caa53aadeff9247768350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff9247768351 rdf:first _:807f36cf91fe4e8caa53aadeff9247768352;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768352 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:807f36cf91fe4e8caa53aadeff9247768354 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10495-1 a owl:Class;
  rdfs:label "BUPRENORPHINE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10495";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768356;
  r:natureDuRisque "Risque de majoration ou de diminution des effets de la buprénorphine, à la fois par inhibition et accélération de son métabolisme par l’inhibiteur de protéases."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768362, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768356 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768357 .

_:807f36cf91fe4e8caa53aadeff9247768357 rdf:first _:807f36cf91fe4e8caa53aadeff9247768358;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768359 .

_:807f36cf91fe4e8caa53aadeff9247768358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff9247768359 rdf:first _:807f36cf91fe4e8caa53aadeff9247768360;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768360 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff9247768362 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10496-1 a owl:Class;
  rdfs:label "BUPRENORPHINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10496";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768364;
  r:natureDuRisque "Augmentation des concentrations de buprénorphine par diminution de son métabolisme hépatique, avec risque de majoration de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la buprénorphine pendant le traitement par l'inhibiteur et, le cas échéant, après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768370, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768364 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768365 .

_:807f36cf91fe4e8caa53aadeff9247768365 rdf:first _:807f36cf91fe4e8caa53aadeff9247768366;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768367 .

_:807f36cf91fe4e8caa53aadeff9247768366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff9247768367 rdf:first _:807f36cf91fe4e8caa53aadeff9247768368;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768368 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff9247768370 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10497-1 a owl:Class;
  rdfs:label "BUPRENORPHINE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10497";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768372;
  r:natureDuRisque "Augmentation des concentrations de buprénorphine par diminution de son métabolisme hépatique, avec risque de majoration de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la buprénorphine pendant le traitement par l'inhibiteur et, le cas échéant, après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768378, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768372 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768373 .

_:807f36cf91fe4e8caa53aadeff9247768373 rdf:first _:807f36cf91fe4e8caa53aadeff9247768374;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768375 .

_:807f36cf91fe4e8caa53aadeff9247768374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff9247768375 rdf:first _:807f36cf91fe4e8caa53aadeff9247768376;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768376 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff9247768378 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10489-1 a owl:Class;
  rdfs:label "BOSENTAN <-> PROGESTATIFS NON CONTRACEPTIFS, ASSOCIÉS OU NON À UN ESTROGÈNE"@fr;
  dct:identifier "IAM_10489";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768380;
  r:natureDuRisque "Risque de diminution de l’efficacité du progestatif."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l’administration du bosentan et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768386, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768380 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768381 .

_:807f36cf91fe4e8caa53aadeff9247768381 rdf:first _:807f36cf91fe4e8caa53aadeff9247768382;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768383 .

_:807f36cf91fe4e8caa53aadeff9247768382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10135 .

_:807f36cf91fe4e8caa53aadeff9247768383 rdf:first _:807f36cf91fe4e8caa53aadeff9247768384;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff9247768386 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10498-1 a owl:Class;
  rdfs:label "BUPROPION <-> CLOMIPRAMINE"@fr;
  dct:identifier "IAM_10498";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768388;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la clomipramine par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la clomipramine pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768394, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768388 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768389 .

_:807f36cf91fe4e8caa53aadeff9247768389 rdf:first _:807f36cf91fe4e8caa53aadeff9247768390;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768391 .

_:807f36cf91fe4e8caa53aadeff9247768390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff9247768391 rdf:first _:807f36cf91fe4e8caa53aadeff9247768392;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10212 .

_:807f36cf91fe4e8caa53aadeff9247768394 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10488-1 a owl:Class;
  rdfs:label "BOSENTAN <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10488";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768396;
  r:natureDuRisque "Risque de diminution de l'efficacité du contraceptif hormonal par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768402, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768396 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768397 .

_:807f36cf91fe4e8caa53aadeff9247768397 rdf:first _:807f36cf91fe4e8caa53aadeff9247768398;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768399 .

_:807f36cf91fe4e8caa53aadeff9247768398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff9247768399 rdf:first _:807f36cf91fe4e8caa53aadeff9247768400;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff9247768402 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10511-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10511";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768404;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la buspirone par diminution de son métabolisme hépatique, avec majoration importante de la sédation."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768410, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768404 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768405 .

_:807f36cf91fe4e8caa53aadeff9247768405 rdf:first _:807f36cf91fe4e8caa53aadeff9247768406;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768407 .

_:807f36cf91fe4e8caa53aadeff9247768406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff9247768407 rdf:first _:807f36cf91fe4e8caa53aadeff9247768408;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768408 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff9247768410 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10512-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10512";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768412;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la buspirone par diminution de son métabolisme hépatique, avec majoration importante de la sédation."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768418, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768412 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768413 .

_:807f36cf91fe4e8caa53aadeff9247768413 rdf:first _:807f36cf91fe4e8caa53aadeff9247768414;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768415 .

_:807f36cf91fe4e8caa53aadeff9247768414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff9247768415 rdf:first _:807f36cf91fe4e8caa53aadeff9247768416;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768416 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff9247768418 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10513-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10513";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768420;
  r:natureDuRisque "Risque de majoration des effets indésirables de la buspirone par diminution de son métabolisme par le pamplemousse."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768426, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768420 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768421 .

_:807f36cf91fe4e8caa53aadeff9247768421 rdf:first _:807f36cf91fe4e8caa53aadeff9247768422;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768423 .

_:807f36cf91fe4e8caa53aadeff9247768422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff9247768423 rdf:first _:807f36cf91fe4e8caa53aadeff9247768424;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768424 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff9247768426 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10514-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10514";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768428;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la buspirone par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la buspirone pendant le traitement par rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768434, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768428 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768429 .

_:807f36cf91fe4e8caa53aadeff9247768429 rdf:first _:807f36cf91fe4e8caa53aadeff9247768430;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768431 .

_:807f36cf91fe4e8caa53aadeff9247768430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff9247768431 rdf:first _:807f36cf91fe4e8caa53aadeff9247768432;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768432 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff9247768434 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10515-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10515";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768436;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la buspirone par diminution de son métabolisme hépatique par le vérapamil, avec augmentation de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la buspirone si nécessaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768442, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768436 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768437 .

_:807f36cf91fe4e8caa53aadeff9247768437 rdf:first _:807f36cf91fe4e8caa53aadeff9247768438;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768439 .

_:807f36cf91fe4e8caa53aadeff9247768438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff9247768439 rdf:first _:807f36cf91fe4e8caa53aadeff9247768440;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768440 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff9247768442 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10516-1 a owl:Class;
  rdfs:label "BUSULFAN <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10516";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768444;
  r:natureDuRisque "Risque d’augmentation de la toxicité du busulfan par diminution de sa clairance par le déférasirox."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768450, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768444 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768445 .

_:807f36cf91fe4e8caa53aadeff9247768445 rdf:first _:807f36cf91fe4e8caa53aadeff9247768446;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768447 .

_:807f36cf91fe4e8caa53aadeff9247768446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10142 .

_:807f36cf91fe4e8caa53aadeff9247768447 rdf:first _:807f36cf91fe4e8caa53aadeff9247768448;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768448 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff9247768450 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10517-1 a owl:Class;
  rdfs:label "BUSULFAN <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10517";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768452;
  r:natureDuRisque "Avec le busulfan à fortes doses : doublement des concentrations de busulfan par l’itraconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768458, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768452 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768453 .

_:807f36cf91fe4e8caa53aadeff9247768453 rdf:first _:807f36cf91fe4e8caa53aadeff9247768454;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768455 .

_:807f36cf91fe4e8caa53aadeff9247768454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10142 .

_:807f36cf91fe4e8caa53aadeff9247768455 rdf:first _:807f36cf91fe4e8caa53aadeff9247768456;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768456 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff9247768458 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10518-1 a owl:Class;
  rdfs:label "BUSULFAN <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_10518";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768460;
  r:natureDuRisque "Avec le busulfan à fortes doses : doublement des concentrations de busulfan par le métronidazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768466, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768460 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768461 .

_:807f36cf91fe4e8caa53aadeff9247768461 rdf:first _:807f36cf91fe4e8caa53aadeff9247768462;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768463 .

_:807f36cf91fe4e8caa53aadeff9247768462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10142 .

_:807f36cf91fe4e8caa53aadeff9247768463 rdf:first _:807f36cf91fe4e8caa53aadeff9247768464;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768464 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:807f36cf91fe4e8caa53aadeff9247768466 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10519-1 a owl:Class;
  rdfs:label "CABAZITAXEL <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10519";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768468;
  r:natureDuRisque "Diminution des concentrations du cytotoxique par augmentation de son métabolisme par l’inducteur, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768474, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768468 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768469 .

_:807f36cf91fe4e8caa53aadeff9247768469 rdf:first _:807f36cf91fe4e8caa53aadeff9247768470;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768471 .

_:807f36cf91fe4e8caa53aadeff9247768470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff9247768471 rdf:first _:807f36cf91fe4e8caa53aadeff9247768472;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768472 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff9247768474 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10714-1 a owl:Class;
  rdfs:label "DACLATASVIR <-> DEXAMETHASONE"@fr;
  dct:identifier "IAM_10714";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768476;
  r:natureDuRisque "Avec la dexaméthasone à usage systémique, risque de diminution significative des concentrations plasmatiques de daclatasvir par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768482, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768476 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768477 .

_:807f36cf91fe4e8caa53aadeff9247768477 rdf:first _:807f36cf91fe4e8caa53aadeff9247768478;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768479 .

_:807f36cf91fe4e8caa53aadeff9247768478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:807f36cf91fe4e8caa53aadeff9247768479 rdf:first _:807f36cf91fe4e8caa53aadeff9247768480;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768480 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff9247768482 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10501-1 a owl:Class;
  rdfs:label "BUPROPION <-> IMAO-B"@fr;
  dct:identifier "IAM_10501";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768484;
  r:natureDuRisque "Risque de crises hypertensives."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768490, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768484 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768485 .

_:807f36cf91fe4e8caa53aadeff9247768485 rdf:first _:807f36cf91fe4e8caa53aadeff9247768486;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768487 .

_:807f36cf91fe4e8caa53aadeff9247768486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff9247768487 rdf:first _:807f36cf91fe4e8caa53aadeff9247768488;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff9247768490 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10477-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10477";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768492;
  r:natureDuRisque "En dehors de l’association éthinylestradiol (0,035mg)/noréthistérone (1mg), risque de diminution de l'efficacité contraceptive par augmentation du métabolisme hépatique du contraceptif hormonal par le bocéprévir"@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768498, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768492 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768493 .

_:807f36cf91fe4e8caa53aadeff9247768493 rdf:first _:807f36cf91fe4e8caa53aadeff9247768494;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768495 .

_:807f36cf91fe4e8caa53aadeff9247768494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff9247768495 rdf:first _:807f36cf91fe4e8caa53aadeff9247768496;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff9247768498 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10393-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10393";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768500;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'atorvastatine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768506, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768500 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768501 .

_:807f36cf91fe4e8caa53aadeff9247768501 rdf:first _:807f36cf91fe4e8caa53aadeff9247768502;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768503 .

_:807f36cf91fe4e8caa53aadeff9247768502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247768503 rdf:first _:807f36cf91fe4e8caa53aadeff9247768504;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff9247768506 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10467-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10467";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768508;
  r:natureDuRisque "Effet inotrope négatif avec risque de décompensation de l’insuffisance cardiaque, troubles de l'automatisme (bradycardie, arrêt sinusal) et troubles de la conduction sino-auriculaire et auriculo-ventriculaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768514, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768508 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768509 .

_:807f36cf91fe4e8caa53aadeff9247768509 rdf:first _:807f36cf91fe4e8caa53aadeff9247768510;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768511 .

_:807f36cf91fe4e8caa53aadeff9247768510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff9247768511 rdf:first _:807f36cf91fe4e8caa53aadeff9247768512;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff9247768514 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10468-1 a owl:Class;
  rdfs:label "BISPHOSPHONATES <-> CALCIUM"@fr;
  dct:identifier "IAM_10468";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768516;
  r:natureDuRisque "Pour les sels de calcium administrés par voie orale : diminution de l'absorption digestive des bisphosphonates."@fr;
  r:conduiteATenir "Prendre les sels de calcium et antiacides à distance des bisphosphonates (de 30 minutes au minimum à plus de 2 heures, si possible, selon le bisphosphonate)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768522, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768516 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768517 .

_:807f36cf91fe4e8caa53aadeff9247768517 rdf:first _:807f36cf91fe4e8caa53aadeff9247768518;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768519 .

_:807f36cf91fe4e8caa53aadeff9247768518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10050 .

_:807f36cf91fe4e8caa53aadeff9247768519 rdf:first _:807f36cf91fe4e8caa53aadeff9247768520;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff9247768522 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10469-1 a owl:Class;
  rdfs:label "BISPHOSPHONATES <-> FER"@fr;
  dct:identifier "IAM_10469";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768524;
  r:natureDuRisque "Pour les sels de fer administrés par voie orale : diminution de l'absorption digestive des bisphosphonates."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance des bisphosphonates (de 30 minutes au minimum à plus de 2 heures, si possible, selon le bisphosphonate)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768530, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768524 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768525 .

_:807f36cf91fe4e8caa53aadeff9247768525 rdf:first _:807f36cf91fe4e8caa53aadeff9247768526;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768527 .

_:807f36cf91fe4e8caa53aadeff9247768526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10050 .

_:807f36cf91fe4e8caa53aadeff9247768527 rdf:first _:807f36cf91fe4e8caa53aadeff9247768528;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff9247768530 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10470-1 a owl:Class;
  rdfs:label "BLEOMYCINE <-> BRENTUXIMAB"@fr;
  dct:identifier "IAM_10470";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768532;
  r:natureDuRisque "Risque de majoration de la toxicité pulmonaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768538, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768532 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768533 .

_:807f36cf91fe4e8caa53aadeff9247768533 rdf:first _:807f36cf91fe4e8caa53aadeff9247768534;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768535 .

_:807f36cf91fe4e8caa53aadeff9247768534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10123 .

_:807f36cf91fe4e8caa53aadeff9247768535 rdf:first _:807f36cf91fe4e8caa53aadeff9247768536;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10133 .

_:807f36cf91fe4e8caa53aadeff9247768538 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10471-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> DROSPIRENONE"@fr;
  dct:identifier "IAM_10471";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768540;
  r:natureDuRisque "Augmentation de plus du double des concentrations de drospérinone en association avec le bocéprévir."@fr;
  r:conduiteATenir "Préférer une contraception avec un autre progestatif, a fortiori en cas d’hyperkaliémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768546, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768540 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768541 .

_:807f36cf91fe4e8caa53aadeff9247768541 rdf:first _:807f36cf91fe4e8caa53aadeff9247768542;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768543 .

_:807f36cf91fe4e8caa53aadeff9247768542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff9247768543 rdf:first _:807f36cf91fe4e8caa53aadeff9247768544;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10313 .

_:807f36cf91fe4e8caa53aadeff9247768546 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10472-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> ESTROGÈNES NON CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10472";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768548;
  r:natureDuRisque "Diminution de l'efficacité de l'estrogène."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l'administration du bocéprévir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768554, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768548 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768549 .

_:807f36cf91fe4e8caa53aadeff9247768549 rdf:first _:807f36cf91fe4e8caa53aadeff9247768550;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768551 .

_:807f36cf91fe4e8caa53aadeff9247768550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff9247768551 rdf:first _:807f36cf91fe4e8caa53aadeff9247768552;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff9247768554 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10473-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> ESTROPROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10473";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768556;
  r:natureDuRisque "En dehors de l’association éthinylestradiol (0,035mg)/noréthistérone (1mg), risque de diminution de l'efficacité contraceptive par augmentation du métabolisme hépatique du contraceptif hormonal par le bocéprévir"@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768562, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768556 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768557 .

_:807f36cf91fe4e8caa53aadeff9247768557 rdf:first _:807f36cf91fe4e8caa53aadeff9247768558;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768559 .

_:807f36cf91fe4e8caa53aadeff9247768558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff9247768559 rdf:first _:807f36cf91fe4e8caa53aadeff9247768560;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff9247768562 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10474-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10474";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768564;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur (notable pour la ciclosporine, extrêmement importante pour le tacrolimus)."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768570, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768564 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768565 .

_:807f36cf91fe4e8caa53aadeff9247768565 rdf:first _:807f36cf91fe4e8caa53aadeff9247768566;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768567 .

_:807f36cf91fe4e8caa53aadeff9247768566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff9247768567 rdf:first _:807f36cf91fe4e8caa53aadeff9247768568;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff9247768570 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10490-1 a owl:Class;
  rdfs:label "BOSENTAN <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10490";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768572;
  r:natureDuRisque "Risque de diminution, importante pour la rifampicine, des concentrations plasmatiques de bosentan."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768578, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768572 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768573 .

_:807f36cf91fe4e8caa53aadeff9247768573 rdf:first _:807f36cf91fe4e8caa53aadeff9247768574;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768575 .

_:807f36cf91fe4e8caa53aadeff9247768574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff9247768575 rdf:first _:807f36cf91fe4e8caa53aadeff9247768576;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff9247768578 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10476-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> METHADONE"@fr;
  dct:identifier "IAM_10476";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768580;
  r:natureDuRisque "Diminution des concentrations plasmatiques de méthadone, avec risque d'apparition d'un syndrome de sevrage, par augmentation de son métabolisme hépatique par le bocéprévir."@fr;
  r:conduiteATenir "Surveillance clinique régulière et adaptation éventuelle de la posologie de méthadone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768586, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768580 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768581 .

_:807f36cf91fe4e8caa53aadeff9247768581 rdf:first _:807f36cf91fe4e8caa53aadeff9247768582;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768583 .

_:807f36cf91fe4e8caa53aadeff9247768582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff9247768583 rdf:first _:807f36cf91fe4e8caa53aadeff9247768584;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768584 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff9247768586 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10465-1 a owl:Class;
  rdfs:label "BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10465";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768588;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768594, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768588 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768589 .

_:807f36cf91fe4e8caa53aadeff9247768589 rdf:first _:807f36cf91fe4e8caa53aadeff9247768590;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768591 .

_:807f36cf91fe4e8caa53aadeff9247768590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff9247768591 rdf:first _:807f36cf91fe4e8caa53aadeff9247768592;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768592 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff9247768594 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10478-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10478";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768596;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de bocéprévir."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768602, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768596 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768597 .

_:807f36cf91fe4e8caa53aadeff9247768597 rdf:first _:807f36cf91fe4e8caa53aadeff9247768598;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768599 .

_:807f36cf91fe4e8caa53aadeff9247768598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff9247768599 rdf:first _:807f36cf91fe4e8caa53aadeff9247768600;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768600 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff9247768602 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10479-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10479";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768604;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par diminution du métabolisme de la simvastatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768610, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768604 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768605 .

_:807f36cf91fe4e8caa53aadeff9247768605 rdf:first _:807f36cf91fe4e8caa53aadeff9247768606;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768607 .

_:807f36cf91fe4e8caa53aadeff9247768606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff9247768607 rdf:first _:807f36cf91fe4e8caa53aadeff9247768608;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768608 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff9247768610 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10480-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_10480";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768612;
  r:natureDuRisque "Risque de diminution de l'efficacité du ténofovir alafénamide par diminution de son activité intracellulaire par le bocéprevir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768618, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768612 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768613 .

_:807f36cf91fe4e8caa53aadeff9247768613 rdf:first _:807f36cf91fe4e8caa53aadeff9247768614;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768615 .

_:807f36cf91fe4e8caa53aadeff9247768614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff9247768615 rdf:first _:807f36cf91fe4e8caa53aadeff9247768616;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff9247768618 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10481-1 a owl:Class;
  rdfs:label "BORTEZOMIB <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10481";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768620;
  r:natureDuRisque "Diminution des concentrations du cytotoxique par augmentation de son métabolisme par l’inducteur, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768626, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768620 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768621 .

_:807f36cf91fe4e8caa53aadeff9247768621 rdf:first _:807f36cf91fe4e8caa53aadeff9247768622;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768623 .

_:807f36cf91fe4e8caa53aadeff9247768622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff9247768623 rdf:first _:807f36cf91fe4e8caa53aadeff9247768624;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff9247768626 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10482-1 a owl:Class;
  rdfs:label "BORTEZOMIB <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10482";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768628;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment neurologiques, du bortezomib par diminution de son métabolisme."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du bortezomib pendant la durée du traitement par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768634, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768628 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768629 .

_:807f36cf91fe4e8caa53aadeff9247768629 rdf:first _:807f36cf91fe4e8caa53aadeff9247768630;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768631 .

_:807f36cf91fe4e8caa53aadeff9247768630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff9247768631 rdf:first _:807f36cf91fe4e8caa53aadeff9247768632;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff9247768634 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10483-1 a owl:Class;
  rdfs:label "BOSENTAN <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10483";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768636;
  r:natureDuRisque "Diminution importante des concentrations sanguines de la ciclosporine et augmentation des concentrations plasmatiques de bosentan."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768642, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768636 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768637 .

_:807f36cf91fe4e8caa53aadeff9247768637 rdf:first _:807f36cf91fe4e8caa53aadeff9247768638;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768639 .

_:807f36cf91fe4e8caa53aadeff9247768638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff9247768639 rdf:first _:807f36cf91fe4e8caa53aadeff9247768640;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff9247768642 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10484-1 a owl:Class;
  rdfs:label "BOSENTAN <-> CYPROTERONE"@fr;
  dct:identifier "IAM_10484";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768644;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Dans ses indications comme anti-androgène, surveillance clinique et si possible adaptation de la posologie de la cyprotérone pendant l'administration avec le bosentan et après son arrêt.

Dans son utilisation comme contraceptif hormonal, utiliser une méth"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768650, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768644 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768645 .

_:807f36cf91fe4e8caa53aadeff9247768645 rdf:first _:807f36cf91fe4e8caa53aadeff9247768646;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768647 .

_:807f36cf91fe4e8caa53aadeff9247768646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff9247768647 rdf:first _:807f36cf91fe4e8caa53aadeff9247768648;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff9247768650 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10485-1 a owl:Class;
  rdfs:label "BOSENTAN <-> ESTROPROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10485";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768652;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par augmentation du métabolisme hépatique du contraceptif hormonal."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768658, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768652 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768653 .

_:807f36cf91fe4e8caa53aadeff9247768653 rdf:first _:807f36cf91fe4e8caa53aadeff9247768654;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768655 .

_:807f36cf91fe4e8caa53aadeff9247768654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff9247768655 rdf:first _:807f36cf91fe4e8caa53aadeff9247768656;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff9247768658 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10486-1 a owl:Class;
  rdfs:label "BOSENTAN <-> GLIBENCLAMIDE"@fr;
  dct:identifier "IAM_10486";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768660;
  r:natureDuRisque "Risque de moindre efficacité du glibenclamide par diminution de ses concentrations plasmatiques, en raison de l'effet inducteur du bosentan. Par ailleurs, des cas d'hépatotoxicité ont été rapportés lors de l'association."@fr;
  r:conduiteATenir "Surveillance de la glycémie, adaptation du traitement si besoin, et surveillance des constantes biologiques hépatiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768666, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768660 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768661 .

_:807f36cf91fe4e8caa53aadeff9247768661 rdf:first _:807f36cf91fe4e8caa53aadeff9247768662;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768663 .

_:807f36cf91fe4e8caa53aadeff9247768662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff9247768663 rdf:first _:807f36cf91fe4e8caa53aadeff9247768664;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10414 .

_:807f36cf91fe4e8caa53aadeff9247768666 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10487-1 a owl:Class;
  rdfs:label "BOSENTAN <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10487";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768668;
  r:natureDuRisque "Risque majoré des effets indésirables du bosentan, notamment d’atteintes hépatiques, par diminution de son métabolisme par l'inhibiteur."@fr;
  r:conduiteATenir "Surveillance clinique et biologique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768674, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768668 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768669 .

_:807f36cf91fe4e8caa53aadeff9247768669 rdf:first _:807f36cf91fe4e8caa53aadeff9247768670;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768671 .

_:807f36cf91fe4e8caa53aadeff9247768670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff9247768671 rdf:first _:807f36cf91fe4e8caa53aadeff9247768672;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff9247768674 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10475-1 a owl:Class;
  rdfs:label "BOCEPREVIR <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10475";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768676;
  r:natureDuRisque "Diminution des concentrations du bocéprévir et du lopinavir (ou darunavir ou fosamprénavir), avec risque d’échec thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768682, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768676 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768677 .

_:807f36cf91fe4e8caa53aadeff9247768677 rdf:first _:807f36cf91fe4e8caa53aadeff9247768678;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768679 .

_:807f36cf91fe4e8caa53aadeff9247768678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff9247768679 rdf:first _:807f36cf91fe4e8caa53aadeff9247768680;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff9247768682 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10321-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CEFTRIAXONE"@fr;
  dct:identifier "IAM_10321";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768684;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la céphalosporine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768690, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768684 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768685 .

_:807f36cf91fe4e8caa53aadeff9247768685 rdf:first _:807f36cf91fe4e8caa53aadeff9247768686;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768687 .

_:807f36cf91fe4e8caa53aadeff9247768686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768687 rdf:first _:807f36cf91fe4e8caa53aadeff9247768688;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10172 .

_:807f36cf91fe4e8caa53aadeff9247768690 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10311-1 a owl:Class;
  rdfs:label "ANTI-TNF ALPHA <-> CANAKINUMAB"@fr;
  dct:identifier "IAM_10311";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768692;
  r:natureDuRisque "Risque de majoration des infections graves."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768698, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768692 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768693 .

_:807f36cf91fe4e8caa53aadeff9247768693 rdf:first _:807f36cf91fe4e8caa53aadeff9247768694;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768695 .

_:807f36cf91fe4e8caa53aadeff9247768694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10021 .

_:807f36cf91fe4e8caa53aadeff9247768695 rdf:first _:807f36cf91fe4e8caa53aadeff9247768696;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff9247768698 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10312-1 a owl:Class;
  rdfs:label "ANTI-TNF ALPHA <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10312";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768700;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768706, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768700 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768701 .

_:807f36cf91fe4e8caa53aadeff9247768701 rdf:first _:807f36cf91fe4e8caa53aadeff9247768702;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768703 .

_:807f36cf91fe4e8caa53aadeff9247768702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10021 .

_:807f36cf91fe4e8caa53aadeff9247768703 rdf:first _:807f36cf91fe4e8caa53aadeff9247768704;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff9247768706 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10313-1 a owl:Class;
  rdfs:label "ANTITUSSIFS MORPHINE-LIKE <-> METHADONE"@fr;
  dct:identifier "IAM_10313";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768708;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768714, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768708 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768709 .

_:807f36cf91fe4e8caa53aadeff9247768709 rdf:first _:807f36cf91fe4e8caa53aadeff9247768710;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768711 .

_:807f36cf91fe4e8caa53aadeff9247768710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10044 .

_:807f36cf91fe4e8caa53aadeff9247768711 rdf:first _:807f36cf91fe4e8caa53aadeff9247768712;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff9247768714 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10314-1 a owl:Class;
  rdfs:label "ANTITUSSIFS MORPHINIQUES VRAIS <-> METHADONE"@fr;
  dct:identifier "IAM_10314";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768716;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768722, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768716 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768717 .

_:807f36cf91fe4e8caa53aadeff9247768717 rdf:first _:807f36cf91fe4e8caa53aadeff9247768718;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768719 .

_:807f36cf91fe4e8caa53aadeff9247768718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff9247768719 rdf:first _:807f36cf91fe4e8caa53aadeff9247768720;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff9247768722 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10315-1 a owl:Class;
  rdfs:label "ANTITUSSIFS MORPHINIQUES VRAIS <-> MORPHINIQUES AGONISTES-ANTAGONISTES"@fr;
  dct:identifier "IAM_10315";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768724;
  r:natureDuRisque "Diminution de l'effet antalgique ou antitussif du morphinique, par blocage compétitif des récepteurs, avec risque d'apparition d'un syndrome de sevrage."@fr;
  rdfs:comment "L’association d’agonistes-antagonistes morphiniques (buprénorphine, nalbuphine, pentazocine) avec des analgésiques morphiniques agonistes a été contre-indiquée jusqu'à présent, et ce, quel que soit leur niveau (palier II ou III de la classification de l'O"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768730, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768724 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768725 .

_:807f36cf91fe4e8caa53aadeff9247768725 rdf:first _:807f36cf91fe4e8caa53aadeff9247768726;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768727 .

_:807f36cf91fe4e8caa53aadeff9247768726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff9247768727 rdf:first _:807f36cf91fe4e8caa53aadeff9247768728;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:807f36cf91fe4e8caa53aadeff9247768730 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10076-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10076";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768732;
  r:natureDuRisque "Variations possibles de l'effet anticoagulant, avec augmentation en cas d'intoxication aiguë ou diminution en cas d'alcoolisme chronique (métabolisme augmenté)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768738, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768732 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768733 .

_:807f36cf91fe4e8caa53aadeff9247768733 rdf:first _:807f36cf91fe4e8caa53aadeff9247768734;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768735 .

_:807f36cf91fe4e8caa53aadeff9247768734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768735 rdf:first _:807f36cf91fe4e8caa53aadeff9247768736;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff9247768738 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10316-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> APREPITANT"@fr;
  dct:identifier "IAM_10316";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768740;
  r:natureDuRisque "Risque de diminution de l’effet de l’antivitamine K par augmentation de son métabolisme hépatique par l’aprépitant."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation de la posologie de l’antivitamine K pendant et après l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768746, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768740 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768741 .

_:807f36cf91fe4e8caa53aadeff9247768741 rdf:first _:807f36cf91fe4e8caa53aadeff9247768742;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768743 .

_:807f36cf91fe4e8caa53aadeff9247768742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768743 rdf:first _:807f36cf91fe4e8caa53aadeff9247768744;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff9247768746 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10317-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> BOSENTAN"@fr;
  dct:identifier "IAM_10317";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768748;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768754, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768748 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768749 .

_:807f36cf91fe4e8caa53aadeff9247768749 rdf:first _:807f36cf91fe4e8caa53aadeff9247768750;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768751 .

_:807f36cf91fe4e8caa53aadeff9247768750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768751 rdf:first _:807f36cf91fe4e8caa53aadeff9247768752;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff9247768754 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10318-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CEFAMANDOLE"@fr;
  dct:identifier "IAM_10318";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768756;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la céphalosporine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768756 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768757 .

_:807f36cf91fe4e8caa53aadeff9247768757 rdf:first _:807f36cf91fe4e8caa53aadeff9247768758;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768759 .

_:807f36cf91fe4e8caa53aadeff9247768758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768759 rdf:first _:807f36cf91fe4e8caa53aadeff9247768760;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10169 .

_:807f36cf91fe4e8caa53aadeff9247768762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10395-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10395";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768764;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'hypolipémiant, avec risque de survenue d'effets indésirables, notamment musculaires."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768765 .

_:807f36cf91fe4e8caa53aadeff9247768765 rdf:first _:807f36cf91fe4e8caa53aadeff9247768766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768767 .

_:807f36cf91fe4e8caa53aadeff9247768766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff9247768767 rdf:first _:807f36cf91fe4e8caa53aadeff9247768768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247768770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10320-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CEFOTETAN"@fr;
  dct:identifier "IAM_10320";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768772;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la céphalosporine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768773 .

_:807f36cf91fe4e8caa53aadeff9247768773 rdf:first _:807f36cf91fe4e8caa53aadeff9247768774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768775 .

_:807f36cf91fe4e8caa53aadeff9247768774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768775 rdf:first _:807f36cf91fe4e8caa53aadeff9247768776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10171 .

_:807f36cf91fe4e8caa53aadeff9247768778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10308-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10308";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768780;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par diminution de son absorption."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768781 .

_:807f36cf91fe4e8caa53aadeff9247768781 rdf:first _:807f36cf91fe4e8caa53aadeff9247768782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768783 .

_:807f36cf91fe4e8caa53aadeff9247768782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff9247768783 rdf:first _:807f36cf91fe4e8caa53aadeff9247768784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff9247768786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10322-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10322";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768788;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation de l'effet de l'antivitamine K et du risque hémorragique (diminution de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la cimétidine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768789 .

_:807f36cf91fe4e8caa53aadeff9247768789 rdf:first _:807f36cf91fe4e8caa53aadeff9247768790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768791 .

_:807f36cf91fe4e8caa53aadeff9247768790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768791 rdf:first _:807f36cf91fe4e8caa53aadeff9247768792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff9247768794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10323-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CLINDAMYCINE"@fr;
  dct:identifier "IAM_10323";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768796;
  r:natureDuRisque "Augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par clindamycine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768797 .

_:807f36cf91fe4e8caa53aadeff9247768797 rdf:first _:807f36cf91fe4e8caa53aadeff9247768798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768799 .

_:807f36cf91fe4e8caa53aadeff9247768798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768799 rdf:first _:807f36cf91fe4e8caa53aadeff9247768800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10209 .

_:807f36cf91fe4e8caa53aadeff9247768802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10324-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> COLCHICINE"@fr;
  dct:identifier "IAM_10324";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768804;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la colchicine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768805 .

_:807f36cf91fe4e8caa53aadeff9247768805 rdf:first _:807f36cf91fe4e8caa53aadeff9247768806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768807 .

_:807f36cf91fe4e8caa53aadeff9247768806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768807 rdf:first _:807f36cf91fe4e8caa53aadeff9247768808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff9247768810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10325-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CYCLINES"@fr;
  dct:identifier "IAM_10325";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768812;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la cycline et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768813 .

_:807f36cf91fe4e8caa53aadeff9247768813 rdf:first _:807f36cf91fe4e8caa53aadeff9247768814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768815 .

_:807f36cf91fe4e8caa53aadeff9247768814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768815 rdf:first _:807f36cf91fe4e8caa53aadeff9247768816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:807f36cf91fe4e8caa53aadeff9247768818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10326-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CYTOTOXIQUES"@fr;
  dct:identifier "IAM_10326";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768820;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation du risque thrombotique et hémorragique au cours des affections tumorales. De surcroit, possible interaction entre les AVK et la chimiothérapie."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768821 .

_:807f36cf91fe4e8caa53aadeff9247768821 rdf:first _:807f36cf91fe4e8caa53aadeff9247768822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768823 .

_:807f36cf91fe4e8caa53aadeff9247768822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768823 rdf:first _:807f36cf91fe4e8caa53aadeff9247768824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10060 .

_:807f36cf91fe4e8caa53aadeff9247768826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10327-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> DANAZOL"@fr;
  dct:identifier "IAM_10327";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768828;
  r:natureDuRisque "Augmentation du risque hémorragique par effet direct sur la coagulation et/ou les systèmes fibrinolytiques."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation de la posologie de l’antivitamine K pendant le traitement par le danazol et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768829 .

_:807f36cf91fe4e8caa53aadeff9247768829 rdf:first _:807f36cf91fe4e8caa53aadeff9247768830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768831 .

_:807f36cf91fe4e8caa53aadeff9247768830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768831 rdf:first _:807f36cf91fe4e8caa53aadeff9247768832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:807f36cf91fe4e8caa53aadeff9247768834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10328-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10328";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768836;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768837 .

_:807f36cf91fe4e8caa53aadeff9247768837 rdf:first _:807f36cf91fe4e8caa53aadeff9247768838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768839 .

_:807f36cf91fe4e8caa53aadeff9247768838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768839 rdf:first _:807f36cf91fe4e8caa53aadeff9247768840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff9247768842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10329-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> DISULFIRAME"@fr;
  dct:identifier "IAM_10329";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768844;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation de la posologie de l'antivitamine K pendant le traitement par le disulfirame et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768845 .

_:807f36cf91fe4e8caa53aadeff9247768845 rdf:first _:807f36cf91fe4e8caa53aadeff9247768846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768847 .

_:807f36cf91fe4e8caa53aadeff9247768846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768847 rdf:first _:807f36cf91fe4e8caa53aadeff9247768848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:807f36cf91fe4e8caa53aadeff9247768850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10330-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10330";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768852;
  r:natureDuRisque "Augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par la dronédarone et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768858, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768852 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768853 .

_:807f36cf91fe4e8caa53aadeff9247768853 rdf:first _:807f36cf91fe4e8caa53aadeff9247768854;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768855 .

_:807f36cf91fe4e8caa53aadeff9247768854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768855 rdf:first _:807f36cf91fe4e8caa53aadeff9247768856;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff9247768858 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10319-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> CEFOPERAZONE"@fr;
  dct:identifier "IAM_10319";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768860;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la céphalosporine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768860 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768861 .

_:807f36cf91fe4e8caa53aadeff9247768861 rdf:first _:807f36cf91fe4e8caa53aadeff9247768862;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768863 .

_:807f36cf91fe4e8caa53aadeff9247768862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247768863 rdf:first _:807f36cf91fe4e8caa53aadeff9247768864;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10170 .

_:807f36cf91fe4e8caa53aadeff9247768866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11222-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11222";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768868;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768869 .

_:807f36cf91fe4e8caa53aadeff9247768869 rdf:first _:807f36cf91fe4e8caa53aadeff9247768870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768871 .

_:807f36cf91fe4e8caa53aadeff9247768870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff9247768871 rdf:first _:807f36cf91fe4e8caa53aadeff9247768872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff9247768874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11080-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11080";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768876;
  r:natureDuRisque "Augmentation des concentrations sanguines de l’immunosuppresseur (diminution de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768877 .

_:807f36cf91fe4e8caa53aadeff9247768877 rdf:first _:807f36cf91fe4e8caa53aadeff9247768878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768879 .

_:807f36cf91fe4e8caa53aadeff9247768878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff9247768879 rdf:first _:807f36cf91fe4e8caa53aadeff9247768880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff9247768882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11082-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11082";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768884;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768885 .

_:807f36cf91fe4e8caa53aadeff9247768885 rdf:first _:807f36cf91fe4e8caa53aadeff9247768886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768887 .

_:807f36cf91fe4e8caa53aadeff9247768886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff9247768887 rdf:first _:807f36cf91fe4e8caa53aadeff9247768888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff9247768890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11083-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11083";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768892;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768898, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768892 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768893 .

_:807f36cf91fe4e8caa53aadeff9247768893 rdf:first _:807f36cf91fe4e8caa53aadeff9247768894;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768895 .

_:807f36cf91fe4e8caa53aadeff9247768894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff9247768895 rdf:first _:807f36cf91fe4e8caa53aadeff9247768896;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff9247768898 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11084-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_11084";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768900;
  r:natureDuRisque "Risque de diminution des concentrations des immunosuppresseurs, avec pour conséquence un risque d’inefficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768906, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768900 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768901 .

_:807f36cf91fe4e8caa53aadeff9247768901 rdf:first _:807f36cf91fe4e8caa53aadeff9247768902;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768903 .

_:807f36cf91fe4e8caa53aadeff9247768902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff9247768903 rdf:first _:807f36cf91fe4e8caa53aadeff9247768904;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:807f36cf91fe4e8caa53aadeff9247768906 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11085-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11085";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768908;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique par le voriconazole."@fr;
  r:conduiteATenir """Association déconseillée
- avec l'évérolimus, le sirolimus, et le temsirolimus.

Précaution d'emploi
- avec la ciclosporine et le tacrolimus :
dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la p"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768914, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768908 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768909 .

_:807f36cf91fe4e8caa53aadeff9247768909 rdf:first _:807f36cf91fe4e8caa53aadeff9247768910;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768911 .

_:807f36cf91fe4e8caa53aadeff9247768910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff9247768911 rdf:first _:807f36cf91fe4e8caa53aadeff9247768912;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff9247768914 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11086-1 a owl:Class;
  rdfs:label "INDINAVIR <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_11086";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768916;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'indinavir."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768922, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768916 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768917 .

_:807f36cf91fe4e8caa53aadeff9247768917 rdf:first _:807f36cf91fe4e8caa53aadeff9247768918;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768919 .

_:807f36cf91fe4e8caa53aadeff9247768918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10455 .

_:807f36cf91fe4e8caa53aadeff9247768919 rdf:first _:807f36cf91fe4e8caa53aadeff9247768920;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff9247768922 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11088-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> IRINOTECAN"@fr;
  dct:identifier "IAM_11088";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768924;
  r:natureDuRisque """Diminution probable des concentrations plasmatiques du métabolite actif de l'irinotécan, avec risque d'échec du traitement
cytotoxique."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768930, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768924 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768925 .

_:807f36cf91fe4e8caa53aadeff9247768925 rdf:first _:807f36cf91fe4e8caa53aadeff9247768926;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768927 .

_:807f36cf91fe4e8caa53aadeff9247768926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff9247768927 rdf:first _:807f36cf91fe4e8caa53aadeff9247768928;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10486 .

_:807f36cf91fe4e8caa53aadeff9247768930 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11089-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> ISAVUCONAZOLE"@fr;
  dct:identifier "IAM_11089";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768932;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’isavuconazole par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768938, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768932 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768933 .

_:807f36cf91fe4e8caa53aadeff9247768933 rdf:first _:807f36cf91fe4e8caa53aadeff9247768934;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768935 .

_:807f36cf91fe4e8caa53aadeff9247768934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff9247768935 rdf:first _:807f36cf91fe4e8caa53aadeff9247768936;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10487 .

_:807f36cf91fe4e8caa53aadeff9247768938 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11090-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_11090";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768940;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’itraconazole, avec risque de perte d’efficacité, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768946, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768940 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768941 .

_:807f36cf91fe4e8caa53aadeff9247768941 rdf:first _:807f36cf91fe4e8caa53aadeff9247768942;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768943 .

_:807f36cf91fe4e8caa53aadeff9247768942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff9247768943 rdf:first _:807f36cf91fe4e8caa53aadeff9247768944;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff9247768946 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10310-1 a owl:Class;
  rdfs:label "ANTISPASMODIQUES URINAIRES <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10310";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768948;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Risque de majoration des effets indésirables."@fr;
  r:conduiteATenir """Contre-indication :
- avec la darifénacine
- avec la fésotérodine et la solifénacine, en cas d'insuffisance rénale ou hépatique, modérée à sévère.

Association déconseillée : 
- avec la toltérodine

Précaution d'emploi:
- avec la fésotérodine ou la solifé"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768954, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768948 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768949 .

_:807f36cf91fe4e8caa53aadeff9247768949 rdf:first _:807f36cf91fe4e8caa53aadeff9247768950;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768951 .

_:807f36cf91fe4e8caa53aadeff9247768950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10041 .

_:807f36cf91fe4e8caa53aadeff9247768951 rdf:first _:807f36cf91fe4e8caa53aadeff9247768952;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff9247768954 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11092-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> LURASIDONE"@fr;
  dct:identifier "IAM_11092";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768956;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la lurasidone par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768962, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768956 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768957 .

_:807f36cf91fe4e8caa53aadeff9247768957 rdf:first _:807f36cf91fe4e8caa53aadeff9247768958;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768959 .

_:807f36cf91fe4e8caa53aadeff9247768958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff9247768959 rdf:first _:807f36cf91fe4e8caa53aadeff9247768960;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10542 .

_:807f36cf91fe4e8caa53aadeff9247768962 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10309-1 a owl:Class;
  rdfs:label "ANTISEPTIQUES MERCURIELS <-> POVIDONE IODÉE"@fr;
  dct:identifier "IAM_10309";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768964;
  r:natureDuRisque """Erythèmes, phlyctènes, voire nécrose cutanéo-muqueuse 
(formation d'un complexe caustique en cas d'utilisation
concomitante d'antiseptiques iodés et mercuriels). L'interaction
dépend de la stabilité de l'organo-mercuriel au niveau cutané et de la sensibil"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768970, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768964 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768965 .

_:807f36cf91fe4e8caa53aadeff9247768965 rdf:first _:807f36cf91fe4e8caa53aadeff9247768966;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768967 .

_:807f36cf91fe4e8caa53aadeff9247768966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff9247768967 rdf:first _:807f36cf91fe4e8caa53aadeff9247768968;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10745 .

_:807f36cf91fe4e8caa53aadeff9247768970 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11224-1 a owl:Class;
  rdfs:label "LAMIVUDINE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_11224";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768972;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral par antagoniste compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768978, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768972 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768973 .

_:807f36cf91fe4e8caa53aadeff9247768973 rdf:first _:807f36cf91fe4e8caa53aadeff9247768974;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768975 .

_:807f36cf91fe4e8caa53aadeff9247768974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10506 .

_:807f36cf91fe4e8caa53aadeff9247768975 rdf:first _:807f36cf91fe4e8caa53aadeff9247768976;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:807f36cf91fe4e8caa53aadeff9247768978 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11225-1 a owl:Class;
  rdfs:label "LAMOTRIGINE <-> OXCARBAZEPINE"@fr;
  dct:identifier "IAM_11225";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768980;
  r:natureDuRisque "Diminution des concentrations de la lamotrigine avec risque de moindre efficacité, par augmentation de son métabolisme hépatique par l'oxcarbazépine."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques, avec adaptation de la posologie de la lamotrigine si besoin."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768986, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768980 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768981 .

_:807f36cf91fe4e8caa53aadeff9247768981 rdf:first _:807f36cf91fe4e8caa53aadeff9247768982;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768983 .

_:807f36cf91fe4e8caa53aadeff9247768982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:807f36cf91fe4e8caa53aadeff9247768983 rdf:first _:807f36cf91fe4e8caa53aadeff9247768984;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10674 .

_:807f36cf91fe4e8caa53aadeff9247768986 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11226-1 a owl:Class;
  rdfs:label "LAMOTRIGINE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11226";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768988;
  r:natureDuRisque "Risque majoré de réactions cutanées graves (syndrome de Lyell). Par ailleurs, augmentation des concentrations plasmatiques de lamotrigine (diminution de son métabolisme hépatique par le valproate de sodium)."@fr;
  r:conduiteATenir "Si l'association s'avère nécessaire, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247768994, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768988 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768989 .

_:807f36cf91fe4e8caa53aadeff9247768989 rdf:first _:807f36cf91fe4e8caa53aadeff9247768990;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768991 .

_:807f36cf91fe4e8caa53aadeff9247768990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff9247768991 rdf:first _:807f36cf91fe4e8caa53aadeff9247768992;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247768992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:807f36cf91fe4e8caa53aadeff9247768994 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11227-1 a owl:Class;
  rdfs:label "LANSOPRAZOLE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_11227";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247768996;
  r:natureDuRisque "Augmentation des concentrations sanguines du tacrolimus."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines du tacrolimus, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769002, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247768996 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247768997 .

_:807f36cf91fe4e8caa53aadeff9247768997 rdf:first _:807f36cf91fe4e8caa53aadeff9247768998;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247768999 .

_:807f36cf91fe4e8caa53aadeff9247768998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10509 .

_:807f36cf91fe4e8caa53aadeff9247768999 rdf:first _:807f36cf91fe4e8caa53aadeff9247769000;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff9247769002 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11228-1 a owl:Class;
  rdfs:label "LÉDIPASVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11228";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769004;
  r:natureDuRisque "Risque de diminution importante des concentrations plasmatiques du lédipasvir par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769010, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769004 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769005 .

_:807f36cf91fe4e8caa53aadeff9247769005 rdf:first _:807f36cf91fe4e8caa53aadeff9247769006;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769007 .

_:807f36cf91fe4e8caa53aadeff9247769006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff9247769007 rdf:first _:807f36cf91fe4e8caa53aadeff9247769008;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff9247769010 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10304-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10304";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769012;
  r:natureDuRisque "Risque d’inefficacité du traitement antisécrétoire par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769018, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769012 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769013 .

_:807f36cf91fe4e8caa53aadeff9247769013 rdf:first _:807f36cf91fe4e8caa53aadeff9247769014;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769015 .

_:807f36cf91fe4e8caa53aadeff9247769014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff9247769015 rdf:first _:807f36cf91fe4e8caa53aadeff9247769016;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff9247769018 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10305-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> MYCOPHENOLATE MOFETIL"@fr;
  dct:identifier "IAM_10305";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769020;
  r:natureDuRisque "Diminution des concentrations de l’acide mycophénolique d’environ un tiers, avec risque potentiel de baisse d’efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769026, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769020 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769021 .

_:807f36cf91fe4e8caa53aadeff9247769021 rdf:first _:807f36cf91fe4e8caa53aadeff9247769022;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769023 .

_:807f36cf91fe4e8caa53aadeff9247769022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff9247769023 rdf:first _:807f36cf91fe4e8caa53aadeff9247769024;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10609 .

_:807f36cf91fe4e8caa53aadeff9247769026 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10306-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10306";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769028;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  r:conduiteATenir """Association déconseillée:
- uniquement avec la forme suspension buvable de posaconazole."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769034, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769028 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769029 .

_:807f36cf91fe4e8caa53aadeff9247769029 rdf:first _:807f36cf91fe4e8caa53aadeff9247769030;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769031 .

_:807f36cf91fe4e8caa53aadeff9247769030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff9247769031 rdf:first _:807f36cf91fe4e8caa53aadeff9247769032;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff9247769034 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10307-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_10307";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769036;
  r:natureDuRisque "Diminution des concentrations plasmatiques de rilpivirine par l’inhibiteur de la pompe à protons (absorption diminuée en raison de l’augmentation du pH gastrique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769042, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769036 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769037 .

_:807f36cf91fe4e8caa53aadeff9247769037 rdf:first _:807f36cf91fe4e8caa53aadeff9247769038;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769039 .

_:807f36cf91fe4e8caa53aadeff9247769038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff9247769039 rdf:first _:807f36cf91fe4e8caa53aadeff9247769040;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:807f36cf91fe4e8caa53aadeff9247769042 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10333-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> FIBRATES"@fr;
  dct:identifier "IAM_10333";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769044;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par le fibrate et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769050, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769044 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769045 .

_:807f36cf91fe4e8caa53aadeff9247769045 rdf:first _:807f36cf91fe4e8caa53aadeff9247769046;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769047 .

_:807f36cf91fe4e8caa53aadeff9247769046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769047 rdf:first _:807f36cf91fe4e8caa53aadeff9247769048;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:807f36cf91fe4e8caa53aadeff9247769050 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11091-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> IVACAFTOR"@fr;
  dct:identifier "IAM_11091";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769052;
  r:natureDuRisque "Diminution importante des concentrations de l’ivacaftor, avec risque de perte d’efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769058, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769052 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769053 .

_:807f36cf91fe4e8caa53aadeff9247769053 rdf:first _:807f36cf91fe4e8caa53aadeff9247769054;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769055 .

_:807f36cf91fe4e8caa53aadeff9247769054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff9247769055 rdf:first _:807f36cf91fe4e8caa53aadeff9247769056;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10498 .

_:807f36cf91fe4e8caa53aadeff9247769058 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10382-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> EFAVIRENZ"@fr;
  dct:identifier "IAM_10382";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769060;
  r:natureDuRisque "Risque de baisse de l’efficacité de l’atazanavir par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Si l’association s’avère nécessaire, adaptation posologique de l’atazanavir avec surveillance clinique et biologique régulière, notamment en début d’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769066, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769060 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769061 .

_:807f36cf91fe4e8caa53aadeff9247769061 rdf:first _:807f36cf91fe4e8caa53aadeff9247769062;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769063 .

_:807f36cf91fe4e8caa53aadeff9247769062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff9247769063 rdf:first _:807f36cf91fe4e8caa53aadeff9247769064;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff9247769066 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10331-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> ECONAZOLE"@fr;
  dct:identifier "IAM_10331";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769068;
  r:natureDuRisque "Quelle que soit la voie d'administration de l'éconazole : augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par éconazole et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769074, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769068 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769069 .

_:807f36cf91fe4e8caa53aadeff9247769069 rdf:first _:807f36cf91fe4e8caa53aadeff9247769070;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769071 .

_:807f36cf91fe4e8caa53aadeff9247769070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769071 rdf:first _:807f36cf91fe4e8caa53aadeff9247769072;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10317 .

_:807f36cf91fe4e8caa53aadeff9247769074 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10372-1 a owl:Class;
  rdfs:label "APREPITANT <-> CYPROTERONE"@fr;
  dct:identifier "IAM_10372";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769076;
  r:natureDuRisque "Risque de diminution des concentrations de la cyprotérone avec risque de moindre efficacité contraceptive."@fr;
  r:conduiteATenir """Dans son utilisation comme contraceptif hormonal : 
Utiliser une méthode de contraception fiable, additionnelle ou alternative, pendant la durée de l'association."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769082, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769076 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769077 .

_:807f36cf91fe4e8caa53aadeff9247769077 rdf:first _:807f36cf91fe4e8caa53aadeff9247769078;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769079 .

_:807f36cf91fe4e8caa53aadeff9247769078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff9247769079 rdf:first _:807f36cf91fe4e8caa53aadeff9247769080;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff9247769082 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10373-1 a owl:Class;
  rdfs:label "APREPITANT <-> ESTROPROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10373";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769084;
  r:natureDuRisque "Diminution des concentrations de l’estroprogestatif ou du progestatif, avec risque de moindre efficacité contraceptive."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769084 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769085 .

_:807f36cf91fe4e8caa53aadeff9247769085 rdf:first _:807f36cf91fe4e8caa53aadeff9247769086;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769087 .

_:807f36cf91fe4e8caa53aadeff9247769086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff9247769087 rdf:first _:807f36cf91fe4e8caa53aadeff9247769088;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff9247769090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10374-1 a owl:Class;
  rdfs:label "APREPITANT <-> IFOSFAMIDE"@fr;
  dct:identifier "IAM_10374";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769092;
  r:natureDuRisque "Risque d’augmentation de la neurotoxicité de l’ifosfamide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769093 .

_:807f36cf91fe4e8caa53aadeff9247769093 rdf:first _:807f36cf91fe4e8caa53aadeff9247769094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769095 .

_:807f36cf91fe4e8caa53aadeff9247769094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff9247769095 rdf:first _:807f36cf91fe4e8caa53aadeff9247769096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10445 .

_:807f36cf91fe4e8caa53aadeff9247769098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10375-1 a owl:Class;
  rdfs:label "APREPITANT <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10375";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769100;
  r:natureDuRisque "Augmentation des concentrations d’aprépitant par diminution de son métabolisme hépatique par l’itraconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769101 .

_:807f36cf91fe4e8caa53aadeff9247769101 rdf:first _:807f36cf91fe4e8caa53aadeff9247769102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769103 .

_:807f36cf91fe4e8caa53aadeff9247769102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff9247769103 rdf:first _:807f36cf91fe4e8caa53aadeff9247769104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff9247769106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10376-1 a owl:Class;
  rdfs:label "APREPITANT <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10376";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769108;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769109 .

_:807f36cf91fe4e8caa53aadeff9247769109 rdf:first _:807f36cf91fe4e8caa53aadeff9247769110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769111 .

_:807f36cf91fe4e8caa53aadeff9247769110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff9247769111 rdf:first _:807f36cf91fe4e8caa53aadeff9247769112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff9247769114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10377-1 a owl:Class;
  rdfs:label "APREPITANT <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10377";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769116;
  r:natureDuRisque "(Sauf stérilet), diminution des concentrations du progestatif, avec risque de moindre efficacité contraceptive."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769122, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769116 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769117 .

_:807f36cf91fe4e8caa53aadeff9247769117 rdf:first _:807f36cf91fe4e8caa53aadeff9247769118;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769119 .

_:807f36cf91fe4e8caa53aadeff9247769118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff9247769119 rdf:first _:807f36cf91fe4e8caa53aadeff9247769120;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff9247769122 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10378-1 a owl:Class;
  rdfs:label "APREPITANT <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10378";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769124;
  r:natureDuRisque "Diminution très importante des concentrations d'aprépitant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769130, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769124 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769125 .

_:807f36cf91fe4e8caa53aadeff9247769125 rdf:first _:807f36cf91fe4e8caa53aadeff9247769126;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769127 .

_:807f36cf91fe4e8caa53aadeff9247769126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff9247769127 rdf:first _:807f36cf91fe4e8caa53aadeff9247769128;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff9247769130 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10379-1 a owl:Class;
  rdfs:label "ARIPIPRAZOLE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10379";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769132;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’aripiprazole."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l’aripiprazole pendant l’association et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769138, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769132 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769133 .

_:807f36cf91fe4e8caa53aadeff9247769133 rdf:first _:807f36cf91fe4e8caa53aadeff9247769134;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769135 .

_:807f36cf91fe4e8caa53aadeff9247769134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff9247769135 rdf:first _:807f36cf91fe4e8caa53aadeff9247769136;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff9247769138 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10370-1 a owl:Class;
  rdfs:label "APIXABAN <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10370";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769140;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’apixaban par la rifampicine, avec risque de diminution de l’effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769146, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769140 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769141 .

_:807f36cf91fe4e8caa53aadeff9247769141 rdf:first _:807f36cf91fe4e8caa53aadeff9247769142;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769143 .

_:807f36cf91fe4e8caa53aadeff9247769142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10078 .

_:807f36cf91fe4e8caa53aadeff9247769143 rdf:first _:807f36cf91fe4e8caa53aadeff9247769144;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff9247769146 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10381-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> CLARITHROMYCINE"@fr;
  dct:identifier "IAM_10381";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769148;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de clarithromycine et inhibition de la formation de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769154, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769148 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769149 .

_:807f36cf91fe4e8caa53aadeff9247769149 rdf:first _:807f36cf91fe4e8caa53aadeff9247769150;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769151 .

_:807f36cf91fe4e8caa53aadeff9247769150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff9247769151 rdf:first _:807f36cf91fe4e8caa53aadeff9247769152;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769154 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10369-1 a owl:Class;
  rdfs:label "APIXABAN <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10369";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769156;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’apixaban par l'inhibiteur, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769162, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769156 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769157 .

_:807f36cf91fe4e8caa53aadeff9247769157 rdf:first _:807f36cf91fe4e8caa53aadeff9247769158;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769159 .

_:807f36cf91fe4e8caa53aadeff9247769158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff9247769159 rdf:first _:807f36cf91fe4e8caa53aadeff9247769160;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10078 .

_:807f36cf91fe4e8caa53aadeff9247769162 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10383-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_10383";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769164;
  r:natureDuRisque "Risque de baisse de l’efficacité de l’atazanavir par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Si l’association s’avère nécessaire, adaptation posologique de l’atazanavir avec surveillance clinique et biologique régulière, notamment en début d’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769170, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769164 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769165 .

_:807f36cf91fe4e8caa53aadeff9247769165 rdf:first _:807f36cf91fe4e8caa53aadeff9247769166;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769167 .

_:807f36cf91fe4e8caa53aadeff9247769166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff9247769167 rdf:first _:807f36cf91fe4e8caa53aadeff9247769168;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff9247769170 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10384-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> TENOFOVIR DISOPROXIL"@fr;
  dct:identifier "IAM_10384";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769172;
  r:natureDuRisque "Diminution d’environ un tiers de l’exposition à l’atazanavir chez le patient en cas d’association au ténofovir, comparativement au sujet sain recevant la même association."@fr;
  r:conduiteATenir "Ne pas administrer l’atazanavir avec le ténofovir sans ritonavir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769178, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769172 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769173 .

_:807f36cf91fe4e8caa53aadeff9247769173 rdf:first _:807f36cf91fe4e8caa53aadeff9247769174;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769175 .

_:807f36cf91fe4e8caa53aadeff9247769174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff9247769175 rdf:first _:807f36cf91fe4e8caa53aadeff9247769176;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10896 .

_:807f36cf91fe4e8caa53aadeff9247769178 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10385-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> AZITHROMYCINE"@fr;
  dct:identifier "IAM_10385";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769180;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant ou une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769186, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769180 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769181 .

_:807f36cf91fe4e8caa53aadeff9247769181 rdf:first _:807f36cf91fe4e8caa53aadeff9247769182;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769183 .

_:807f36cf91fe4e8caa53aadeff9247769182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247769183 rdf:first _:807f36cf91fe4e8caa53aadeff9247769184;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff9247769186 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10386-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> BOCEPREVIR"@fr;
  dct:identifier "IAM_10386";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769188;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'atorvastatine."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20mg/jour d'atorvastatine. Si l'objectif thérapeutique n'est pas atteint à cette posologie, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769194, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769188 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769189 .

_:807f36cf91fe4e8caa53aadeff9247769189 rdf:first _:807f36cf91fe4e8caa53aadeff9247769190;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769191 .

_:807f36cf91fe4e8caa53aadeff9247769190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247769191 rdf:first _:807f36cf91fe4e8caa53aadeff9247769192;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff9247769194 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10387-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10387";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769196;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme de l'hypocholestérolémiant)."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 10mg/jour d'atorvastatine. Si l'objectif thérapeutique n'est pas atteint à cette posologie, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769202, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769196 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769197 .

_:807f36cf91fe4e8caa53aadeff9247769197 rdf:first _:807f36cf91fe4e8caa53aadeff9247769198;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769199 .

_:807f36cf91fe4e8caa53aadeff9247769198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247769199 rdf:first _:807f36cf91fe4e8caa53aadeff9247769200;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff9247769202 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10388-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> CLARITHROMYCINE"@fr;
  dct:identifier "IAM_10388";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769204;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholesterolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d'hypocholestérolémiant. Si l'objectif thérapeutique n'est pas atteint, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769210, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769204 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769205 .

_:807f36cf91fe4e8caa53aadeff9247769205 rdf:first _:807f36cf91fe4e8caa53aadeff9247769206;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769207 .

_:807f36cf91fe4e8caa53aadeff9247769206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247769207 rdf:first _:807f36cf91fe4e8caa53aadeff9247769208;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769210 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10389-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10389";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769212;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant ou une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769218, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769212 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769213 .

_:807f36cf91fe4e8caa53aadeff9247769213 rdf:first _:807f36cf91fe4e8caa53aadeff9247769214;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769215 .

_:807f36cf91fe4e8caa53aadeff9247769214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247769215 rdf:first _:807f36cf91fe4e8caa53aadeff9247769216;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff9247769218 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10390-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10390";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769220;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholesterolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d'hypocholestérolémiant. Si l'objectif thérapeutique n'est pas atteint, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769226, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769220 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769221 .

_:807f36cf91fe4e8caa53aadeff9247769221 rdf:first _:807f36cf91fe4e8caa53aadeff9247769222;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769223 .

_:807f36cf91fe4e8caa53aadeff9247769222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247769223 rdf:first _:807f36cf91fe4e8caa53aadeff9247769224;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff9247769226 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10391-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10391";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769228;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'atorvastatine)."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d'atorvastatine. Si l'objectif thérapeutique n'est pas atteint, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769234, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769228 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769229 .

_:807f36cf91fe4e8caa53aadeff9247769229 rdf:first _:807f36cf91fe4e8caa53aadeff9247769230;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769231 .

_:807f36cf91fe4e8caa53aadeff9247769230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff9247769231 rdf:first _:807f36cf91fe4e8caa53aadeff9247769232;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247769234 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10392-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10392";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769236;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'atorvastatine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769242, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769236 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769237 .

_:807f36cf91fe4e8caa53aadeff9247769237 rdf:first _:807f36cf91fe4e8caa53aadeff9247769238;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769239 .

_:807f36cf91fe4e8caa53aadeff9247769238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff9247769239 rdf:first _:807f36cf91fe4e8caa53aadeff9247769240;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff9247769242 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10380-1 a owl:Class;
  rdfs:label "ATAZANAVIR <-> BUPRENORPHINE"@fr;
  dct:identifier "IAM_10380";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769244;
  r:natureDuRisque "Risque de majoration ou de diminution des effets de la buprénorphine, à la fois par inhibition et accélération de son métabolisme par l’inhibiteur de protéases."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769250, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769244 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769245 .

_:807f36cf91fe4e8caa53aadeff9247769245 rdf:first _:807f36cf91fe4e8caa53aadeff9247769246;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769247 .

_:807f36cf91fe4e8caa53aadeff9247769246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff9247769247 rdf:first _:807f36cf91fe4e8caa53aadeff9247769248;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff9247769250 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10358-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> ROPINIROLE"@fr;
  dct:identifier "IAM_10358";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769252;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par ropinirole et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769258, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769252 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769253 .

_:807f36cf91fe4e8caa53aadeff9247769253 rdf:first _:807f36cf91fe4e8caa53aadeff9247769254;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769255 .

_:807f36cf91fe4e8caa53aadeff9247769254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769255 rdf:first _:807f36cf91fe4e8caa53aadeff9247769256;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10813 .

_:807f36cf91fe4e8caa53aadeff9247769258 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10522-1 a owl:Class;
  rdfs:label "CAFEINE <-> DIPYRIDAMOLE"@fr;
  dct:identifier "IAM_10522";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769260;
  r:natureDuRisque "Avec le dipyridamole par voie injectable : réduction de l’effet vasodilatateur du dipyridamole par la caféine."@fr;
  r:conduiteATenir "Interrompre un traitement à base de caféine au moins 5 jours avant une imagerie myocardique avec le dipyridamole et éviter la consommation de café, thé, chocolat ou cola dans les 24 heures qui précèdent le test."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769266, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769260 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769261 .

_:807f36cf91fe4e8caa53aadeff9247769261 rdf:first _:807f36cf91fe4e8caa53aadeff9247769262;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769263 .

_:807f36cf91fe4e8caa53aadeff9247769262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff9247769263 rdf:first _:807f36cf91fe4e8caa53aadeff9247769264;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10297 .

_:807f36cf91fe4e8caa53aadeff9247769266 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10334-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10334";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769268;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par le fluconazole et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769274, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769268 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769269 .

_:807f36cf91fe4e8caa53aadeff9247769269 rdf:first _:807f36cf91fe4e8caa53aadeff9247769270;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769271 .

_:807f36cf91fe4e8caa53aadeff9247769270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769271 rdf:first _:807f36cf91fe4e8caa53aadeff9247769272;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff9247769274 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10335-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> FLUOROQUINOLONES"@fr;
  dct:identifier "IAM_10335";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769276;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la fluoroquinolone et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769282, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769276 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769277 .

_:807f36cf91fe4e8caa53aadeff9247769277 rdf:first _:807f36cf91fe4e8caa53aadeff9247769278;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769279 .

_:807f36cf91fe4e8caa53aadeff9247769278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769279 rdf:first _:807f36cf91fe4e8caa53aadeff9247769280;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff9247769282 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10336-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES)"@fr;
  dct:identifier "IAM_10336";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769284;
  r:natureDuRisque "Augmentation importante de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Si elle ne peut être évitée, contrôle plus fréquent de l'INR. Adaptation de la posologie de l'antivitamine K pendant le traitement par le cytotoxique et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769290, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769284 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769285 .

_:807f36cf91fe4e8caa53aadeff9247769285 rdf:first _:807f36cf91fe4e8caa53aadeff9247769286;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769287 .

_:807f36cf91fe4e8caa53aadeff9247769286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769287 rdf:first _:807f36cf91fe4e8caa53aadeff9247769288;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:807f36cf91fe4e8caa53aadeff9247769290 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10337-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> GLUCOSAMINE"@fr;
  dct:identifier "IAM_10337";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769292;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adapation éventuelle de la posologie de l’antivitamine K."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769298, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769292 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769293 .

_:807f36cf91fe4e8caa53aadeff9247769293 rdf:first _:807f36cf91fe4e8caa53aadeff9247769294;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769295 .

_:807f36cf91fe4e8caa53aadeff9247769294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769295 rdf:first _:807f36cf91fe4e8caa53aadeff9247769296;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10418 .

_:807f36cf91fe4e8caa53aadeff9247769298 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10339-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10339";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769300;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Lors du relais de l'héparine par l'antivitamine K, renforcer la surveillance clinique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769306, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769300 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769301 .

_:807f36cf91fe4e8caa53aadeff9247769301 rdf:first _:807f36cf91fe4e8caa53aadeff9247769302;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769303 .

_:807f36cf91fe4e8caa53aadeff9247769302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769303 rdf:first _:807f36cf91fe4e8caa53aadeff9247769304;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769304 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:807f36cf91fe4e8caa53aadeff9247769306 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10338-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> GRISEOFULVINE"@fr;
  dct:identifier "IAM_10338";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769308;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique par la griséofulvine."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la griséofulvine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769314, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769308 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769309 .

_:807f36cf91fe4e8caa53aadeff9247769309 rdf:first _:807f36cf91fe4e8caa53aadeff9247769310;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769311 .

_:807f36cf91fe4e8caa53aadeff9247769310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769311 rdf:first _:807f36cf91fe4e8caa53aadeff9247769312;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769312 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10422 .

_:807f36cf91fe4e8caa53aadeff9247769314 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10340-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> IMATINIB"@fr;
  dct:identifier "IAM_10340";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769316;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite et mesure fréquente de l'INR."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769322, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769316 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769317 .

_:807f36cf91fe4e8caa53aadeff9247769317 rdf:first _:807f36cf91fe4e8caa53aadeff9247769318;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769319 .

_:807f36cf91fe4e8caa53aadeff9247769318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769319 rdf:first _:807f36cf91fe4e8caa53aadeff9247769320;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10448 .

_:807f36cf91fe4e8caa53aadeff9247769322 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10341-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10341";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769324;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769330, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769324 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769325 .

_:807f36cf91fe4e8caa53aadeff9247769325 rdf:first _:807f36cf91fe4e8caa53aadeff9247769326;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769327 .

_:807f36cf91fe4e8caa53aadeff9247769326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769327 rdf:first _:807f36cf91fe4e8caa53aadeff9247769328;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769328 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff9247769330 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10371-1 a owl:Class;
  rdfs:label "APOMORPHINE <-> ONDANSETRON"@fr;
  dct:identifier "IAM_10371";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769332;
  r:natureDuRisque "Des hypotensions sévères et des pertes de connaissance ont été rapportées lors de l’association d’ondansetron avec l’apomorphine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769338, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769332 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769333 .

_:807f36cf91fe4e8caa53aadeff9247769333 rdf:first _:807f36cf91fe4e8caa53aadeff9247769334;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769335 .

_:807f36cf91fe4e8caa53aadeff9247769334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10079 .

_:807f36cf91fe4e8caa53aadeff9247769335 rdf:first _:807f36cf91fe4e8caa53aadeff9247769336;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10665 .

_:807f36cf91fe4e8caa53aadeff9247769338 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10357-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10357";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769340;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la rifampicine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769346, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769340 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769341 .

_:807f36cf91fe4e8caa53aadeff9247769341 rdf:first _:807f36cf91fe4e8caa53aadeff9247769342;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769343 .

_:807f36cf91fe4e8caa53aadeff9247769342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769343 rdf:first _:807f36cf91fe4e8caa53aadeff9247769344;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff9247769346 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10332-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> EFAVIRENZ"@fr;
  dct:identifier "IAM_10332";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769348;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769354, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769348 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769349 .

_:807f36cf91fe4e8caa53aadeff9247769349 rdf:first _:807f36cf91fe4e8caa53aadeff9247769350;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769351 .

_:807f36cf91fe4e8caa53aadeff9247769350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769351 rdf:first _:807f36cf91fe4e8caa53aadeff9247769352;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769352 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff9247769354 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10359-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> SUCRALFATE"@fr;
  dct:identifier "IAM_10359";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769356;
  r:natureDuRisque "Diminution de l'absorption digestive de l'antivitamine K."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance de l'antivitamine K (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769362, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769356 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769357 .

_:807f36cf91fe4e8caa53aadeff9247769357 rdf:first _:807f36cf91fe4e8caa53aadeff9247769358;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769359 .

_:807f36cf91fe4e8caa53aadeff9247769358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769359 rdf:first _:807f36cf91fe4e8caa53aadeff9247769360;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769360 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:807f36cf91fe4e8caa53aadeff9247769362 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10360-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> SULFAFURAZOL"@fr;
  dct:identifier "IAM_10360";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769364;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement anti-infectieux et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769370, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769364 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769365 .

_:807f36cf91fe4e8caa53aadeff9247769365 rdf:first _:807f36cf91fe4e8caa53aadeff9247769366;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769367 .

_:807f36cf91fe4e8caa53aadeff9247769366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769367 rdf:first _:807f36cf91fe4e8caa53aadeff9247769368;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769368 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10868 .

_:807f36cf91fe4e8caa53aadeff9247769370 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10361-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> SULFAMETHIZOL"@fr;
  dct:identifier "IAM_10361";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769372;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement anti-infectieux et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769378, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769372 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769373 .

_:807f36cf91fe4e8caa53aadeff9247769373 rdf:first _:807f36cf91fe4e8caa53aadeff9247769374;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769375 .

_:807f36cf91fe4e8caa53aadeff9247769374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769375 rdf:first _:807f36cf91fe4e8caa53aadeff9247769376;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769376 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10870 .

_:807f36cf91fe4e8caa53aadeff9247769378 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10362-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> SULFAMETHOXAZOLE"@fr;
  dct:identifier "IAM_10362";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769380;
  r:natureDuRisque "Augmentation importante de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, contrôle plus fréquent de l’INR et adaptation de la posologie de l’antivitamine K pendant le traitement par cotrimoxazole et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769386, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769380 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769381 .

_:807f36cf91fe4e8caa53aadeff9247769381 rdf:first _:807f36cf91fe4e8caa53aadeff9247769382;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769383 .

_:807f36cf91fe4e8caa53aadeff9247769382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769383 rdf:first _:807f36cf91fe4e8caa53aadeff9247769384;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10871 .

_:807f36cf91fe4e8caa53aadeff9247769386 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10363-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_10363";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769388;
  r:natureDuRisque "Risque d'augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769394, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769388 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769389 .

_:807f36cf91fe4e8caa53aadeff9247769389 rdf:first _:807f36cf91fe4e8caa53aadeff9247769390;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769391 .

_:807f36cf91fe4e8caa53aadeff9247769390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769391 rdf:first _:807f36cf91fe4e8caa53aadeff9247769392;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:807f36cf91fe4e8caa53aadeff9247769394 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10364-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_10364";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769396;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769402, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769396 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769397 .

_:807f36cf91fe4e8caa53aadeff9247769397 rdf:first _:807f36cf91fe4e8caa53aadeff9247769398;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769399 .

_:807f36cf91fe4e8caa53aadeff9247769398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769399 rdf:first _:807f36cf91fe4e8caa53aadeff9247769400;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:807f36cf91fe4e8caa53aadeff9247769402 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10365-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> TIBOLONE"@fr;
  dct:identifier "IAM_10365";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769404;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la tibolone et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769410, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769404 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769405 .

_:807f36cf91fe4e8caa53aadeff9247769405 rdf:first _:807f36cf91fe4e8caa53aadeff9247769406;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769407 .

_:807f36cf91fe4e8caa53aadeff9247769406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769407 rdf:first _:807f36cf91fe4e8caa53aadeff9247769408;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769408 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10925 .

_:807f36cf91fe4e8caa53aadeff9247769410 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10366-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> TRAMADOL"@fr;
  dct:identifier "IAM_10366";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769412;
  r:natureDuRisque "Risque d’augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par le tramadol et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769418, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769412 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769413 .

_:807f36cf91fe4e8caa53aadeff9247769413 rdf:first _:807f36cf91fe4e8caa53aadeff9247769414;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769415 .

_:807f36cf91fe4e8caa53aadeff9247769414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769415 rdf:first _:807f36cf91fe4e8caa53aadeff9247769416;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769416 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff9247769418 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10367-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10367";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769420;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par voriconazole et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769426, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769420 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769421 .

_:807f36cf91fe4e8caa53aadeff9247769421 rdf:first _:807f36cf91fe4e8caa53aadeff9247769422;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769423 .

_:807f36cf91fe4e8caa53aadeff9247769422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769423 rdf:first _:807f36cf91fe4e8caa53aadeff9247769424;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769424 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff9247769426 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10368-1 a owl:Class;
  rdfs:label "APIXABAN <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10368";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769428;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'apixaban par le fluconazole, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769434, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769428 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769429 .

_:807f36cf91fe4e8caa53aadeff9247769429 rdf:first _:807f36cf91fe4e8caa53aadeff9247769430;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769431 .

_:807f36cf91fe4e8caa53aadeff9247769430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10078 .

_:807f36cf91fe4e8caa53aadeff9247769431 rdf:first _:807f36cf91fe4e8caa53aadeff9247769432;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769432 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff9247769434 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10342-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10342";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769436;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Variation de l'effet de l'antivitamine K, le plus souvent dans le sens d'une diminution."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant la durée du traitement."@fr;
  rdfs:comment """Il existe une interaction au niveau \"précaution d'emploi\" évoquant une modification de l'effet de l'anticoagulant oral, « le plus souvent dans le sens d’une diminution ». 
Il existe en effet une disproportion importante entre les cas rapportés : un seul c"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769442, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769436 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769437 .

_:807f36cf91fe4e8caa53aadeff9247769437 rdf:first _:807f36cf91fe4e8caa53aadeff9247769438;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769439 .

_:807f36cf91fe4e8caa53aadeff9247769438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff9247769439 rdf:first _:807f36cf91fe4e8caa53aadeff9247769440;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769440 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff9247769442 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10641-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> GLIMEPIRIDE"@fr;
  dct:identifier "IAM_10641";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769444;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation de l’absorption et des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par la clarithromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769450, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769444 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769445 .

_:807f36cf91fe4e8caa53aadeff9247769445 rdf:first _:807f36cf91fe4e8caa53aadeff9247769446;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769447 .

_:807f36cf91fe4e8caa53aadeff9247769446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769447 rdf:first _:807f36cf91fe4e8caa53aadeff9247769448;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769448 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10416 .

_:807f36cf91fe4e8caa53aadeff9247769450 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10632-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10632";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769452;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage, par diminution de son métabolisme hépatique par la ciprofloxacine."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769458, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769452 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769453 .

_:807f36cf91fe4e8caa53aadeff9247769453 rdf:first _:807f36cf91fe4e8caa53aadeff9247769454;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769455 .

_:807f36cf91fe4e8caa53aadeff9247769454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff9247769455 rdf:first _:807f36cf91fe4e8caa53aadeff9247769456;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769456 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff9247769458 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10633-1 a owl:Class;
  rdfs:label "CLADRIBINE <-> LAMIVUDINE"@fr;
  dct:identifier "IAM_10633";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769460;
  r:natureDuRisque "Risque de diminution de l’efficacité de la cladribine par la lamivudine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769466, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769460 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769461 .

_:807f36cf91fe4e8caa53aadeff9247769461 rdf:first _:807f36cf91fe4e8caa53aadeff9247769462;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769463 .

_:807f36cf91fe4e8caa53aadeff9247769462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10205 .

_:807f36cf91fe4e8caa53aadeff9247769463 rdf:first _:807f36cf91fe4e8caa53aadeff9247769464;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769464 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10506 .

_:807f36cf91fe4e8caa53aadeff9247769466 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10656-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_10656";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769468;
  r:natureDuRisque "Risque de majoration de la toxicité de l'antimitotique par diminution de son métabolisme hépatique par la clarithromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique étroite. Eventuellement, utiliser un autre antibiotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769474, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769468 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769469 .

_:807f36cf91fe4e8caa53aadeff9247769469 rdf:first _:807f36cf91fe4e8caa53aadeff9247769470;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769471 .

_:807f36cf91fe4e8caa53aadeff9247769470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff9247769471 rdf:first _:807f36cf91fe4e8caa53aadeff9247769472;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769472 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769474 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10645-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_10645";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769476;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le torsadogène associé. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769482, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769476 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769477 .

_:807f36cf91fe4e8caa53aadeff9247769477 rdf:first _:807f36cf91fe4e8caa53aadeff9247769478;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769479 .

_:807f36cf91fe4e8caa53aadeff9247769478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769479 rdf:first _:807f36cf91fe4e8caa53aadeff9247769480;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769480 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:807f36cf91fe4e8caa53aadeff9247769482 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10634-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> DEXAMETHASONE"@fr;
  dct:identifier "IAM_10634";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769484;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769490, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769484 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769485 .

_:807f36cf91fe4e8caa53aadeff9247769485 rdf:first _:807f36cf91fe4e8caa53aadeff9247769486;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769487 .

_:807f36cf91fe4e8caa53aadeff9247769486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769487 rdf:first _:807f36cf91fe4e8caa53aadeff9247769488;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff9247769490 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10635-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10635";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769492;
  r:natureDuRisque "Augmentation de la digoxinémie par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par la clarithromycine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769498, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769492 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769493 .

_:807f36cf91fe4e8caa53aadeff9247769493 rdf:first _:807f36cf91fe4e8caa53aadeff9247769494;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769495 .

_:807f36cf91fe4e8caa53aadeff9247769494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769495 rdf:first _:807f36cf91fe4e8caa53aadeff9247769496;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff9247769498 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10636-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> EBASTINE"@fr;
  dct:identifier "IAM_10636";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769500;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long congénital)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769506, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769500 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769501 .

_:807f36cf91fe4e8caa53aadeff9247769501 rdf:first _:807f36cf91fe4e8caa53aadeff9247769502;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769503 .

_:807f36cf91fe4e8caa53aadeff9247769502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769503 rdf:first _:807f36cf91fe4e8caa53aadeff9247769504;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:807f36cf91fe4e8caa53aadeff9247769506 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10637-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_10637";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769508;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’éribuline par la clarithromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769514, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769508 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769509 .

_:807f36cf91fe4e8caa53aadeff9247769509 rdf:first _:807f36cf91fe4e8caa53aadeff9247769510;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769511 .

_:807f36cf91fe4e8caa53aadeff9247769510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769511 rdf:first _:807f36cf91fe4e8caa53aadeff9247769512;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:807f36cf91fe4e8caa53aadeff9247769514 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10638-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> ETRAVIRINE"@fr;
  dct:identifier "IAM_10638";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769516;
  r:natureDuRisque "Dans le traitement des infections à Mycobacterium avium complex, risque de diminution de l’efficacité de la clarithromycine par augmentation de son métabolisme hépatique par l’étravirine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769522, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769516 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769517 .

_:807f36cf91fe4e8caa53aadeff9247769517 rdf:first _:807f36cf91fe4e8caa53aadeff9247769518;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769519 .

_:807f36cf91fe4e8caa53aadeff9247769518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769519 rdf:first _:807f36cf91fe4e8caa53aadeff9247769520;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10360 .

_:807f36cf91fe4e8caa53aadeff9247769522 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10607-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_10607";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769524;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration avec la ciclosporine, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769530, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769524 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769525 .

_:807f36cf91fe4e8caa53aadeff9247769525 rdf:first _:807f36cf91fe4e8caa53aadeff9247769526;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769527 .

_:807f36cf91fe4e8caa53aadeff9247769526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff9247769527 rdf:first _:807f36cf91fe4e8caa53aadeff9247769528;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff9247769530 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10640-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> GLIBENCLAMIDE"@fr;
  dct:identifier "IAM_10640";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769532;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation de l’absorption et des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par la clarithromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769538, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769532 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769533 .

_:807f36cf91fe4e8caa53aadeff9247769533 rdf:first _:807f36cf91fe4e8caa53aadeff9247769534;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769535 .

_:807f36cf91fe4e8caa53aadeff9247769534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769535 rdf:first _:807f36cf91fe4e8caa53aadeff9247769536;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10414 .

_:807f36cf91fe4e8caa53aadeff9247769538 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10629-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10629";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769540;
  r:natureDuRisque """Variation, éventuellement importante, des concentrations de
phénytoïne en cas de traitement par la ciprofloxacine."""@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de l’anticonvulsivant pendant le traitement par ciprofloxacine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769546, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769540 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769541 .

_:807f36cf91fe4e8caa53aadeff9247769541 rdf:first _:807f36cf91fe4e8caa53aadeff9247769542;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769543 .

_:807f36cf91fe4e8caa53aadeff9247769542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff9247769543 rdf:first _:807f36cf91fe4e8caa53aadeff9247769544;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff9247769546 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10642-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10642";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769548;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769554, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769548 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769549 .

_:807f36cf91fe4e8caa53aadeff9247769549 rdf:first _:807f36cf91fe4e8caa53aadeff9247769550;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769551 .

_:807f36cf91fe4e8caa53aadeff9247769550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff9247769551 rdf:first _:807f36cf91fe4e8caa53aadeff9247769552;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769554 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10643-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10643";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769556;
  r:natureDuRisque "Augmentation des concentrations de la clarithromycine et de son métabolite actif par diminution de son métabolisme hépatique par l'inhibiteur de protéases."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769562, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769556 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769557 .

_:807f36cf91fe4e8caa53aadeff9247769557 rdf:first _:807f36cf91fe4e8caa53aadeff9247769558;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769559 .

_:807f36cf91fe4e8caa53aadeff9247769558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff9247769559 rdf:first _:807f36cf91fe4e8caa53aadeff9247769560;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769562 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10644-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> LINEZOLIDE"@fr;
  dct:identifier "IAM_10644";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769564;
  r:natureDuRisque "Risque de majoration des effets indésirables du linézolide par la clarithromycine, par augmentation de son absorption."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769570, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769564 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769565 .

_:807f36cf91fe4e8caa53aadeff9247769565 rdf:first _:807f36cf91fe4e8caa53aadeff9247769566;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769567 .

_:807f36cf91fe4e8caa53aadeff9247769566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769567 rdf:first _:807f36cf91fe4e8caa53aadeff9247769568;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10526 .

_:807f36cf91fe4e8caa53aadeff9247769570 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10646-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_10646";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769572;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769578, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769572 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769573 .

_:807f36cf91fe4e8caa53aadeff9247769573 rdf:first _:807f36cf91fe4e8caa53aadeff9247769574;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769575 .

_:807f36cf91fe4e8caa53aadeff9247769574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769575 rdf:first _:807f36cf91fe4e8caa53aadeff9247769576;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:807f36cf91fe4e8caa53aadeff9247769578 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10647-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> PRAVASTATINE"@fr;
  dct:identifier "IAM_10647";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769580;
  r:natureDuRisque "Augmentation de la concentration plasmatique de la pravastatine par la clarithromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique pendant le traitement par l'antibiotique."@fr;
  rdfs:comment "La clarithromycine et l’érythromycine sont des inhibiteurs puissants du CYP3A4 et de la P-gp intestinale, transporteur qui intervient dans l’efflux de nombreux médicaments au niveau de la lumière intestinale et qui limite donc leur absorption digestive. L"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769586, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769580 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769581 .

_:807f36cf91fe4e8caa53aadeff9247769581 rdf:first _:807f36cf91fe4e8caa53aadeff9247769582;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769583 .

_:807f36cf91fe4e8caa53aadeff9247769582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769583 rdf:first _:807f36cf91fe4e8caa53aadeff9247769584;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769584 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10748 .

_:807f36cf91fe4e8caa53aadeff9247769586 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10648-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10648";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769588;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation des concentrations plasmatiques du répaglinide."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie de l'hypoglycémiant pendant le traitement par la clarithromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769594, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769588 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769589 .

_:807f36cf91fe4e8caa53aadeff9247769589 rdf:first _:807f36cf91fe4e8caa53aadeff9247769590;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769591 .

_:807f36cf91fe4e8caa53aadeff9247769590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769591 rdf:first _:807f36cf91fe4e8caa53aadeff9247769592;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769592 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:807f36cf91fe4e8caa53aadeff9247769594 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10649-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10649";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769596;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la rifabutine (uvéites) par augmentation de ses concentrations et de celle de son métabolite actif par la clarithromycine. De plus, augmentation du métabolisme de la clarithromycine par la rifabutine, avec"@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769602, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769596 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769597 .

_:807f36cf91fe4e8caa53aadeff9247769597 rdf:first _:807f36cf91fe4e8caa53aadeff9247769598;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769599 .

_:807f36cf91fe4e8caa53aadeff9247769598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769599 rdf:first _:807f36cf91fe4e8caa53aadeff9247769600;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769600 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff9247769602 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10650-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10650";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769604;
  r:natureDuRisque "Diminution des concentrations plasmatiques et risque de baisse de l'efficacité de la clarithromycine, notamment chez le patient HIV, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769610, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769604 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769605 .

_:807f36cf91fe4e8caa53aadeff9247769605 rdf:first _:807f36cf91fe4e8caa53aadeff9247769606;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769607 .

_:807f36cf91fe4e8caa53aadeff9247769606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769607 rdf:first _:807f36cf91fe4e8caa53aadeff9247769608;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769608 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff9247769610 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10651-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10651";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769612;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769618, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769612 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769613 .

_:807f36cf91fe4e8caa53aadeff9247769613 rdf:first _:807f36cf91fe4e8caa53aadeff9247769614;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769615 .

_:807f36cf91fe4e8caa53aadeff9247769614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769615 rdf:first _:807f36cf91fe4e8caa53aadeff9247769616;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff9247769618 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10639-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10639";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769620;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769626, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769620 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769621 .

_:807f36cf91fe4e8caa53aadeff9247769621 rdf:first _:807f36cf91fe4e8caa53aadeff9247769622;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769623 .

_:807f36cf91fe4e8caa53aadeff9247769622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769623 rdf:first _:807f36cf91fe4e8caa53aadeff9247769624;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:807f36cf91fe4e8caa53aadeff9247769626 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10619-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10619";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769628;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations plasmatiques de phénytoïne avec possibilité d'apparition des signes habituels de surdosage."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite, dosage des concentrations plasmatiques de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769634, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769628 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769629 .

_:807f36cf91fe4e8caa53aadeff9247769629 rdf:first _:807f36cf91fe4e8caa53aadeff9247769630;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769631 .

_:807f36cf91fe4e8caa53aadeff9247769630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff9247769631 rdf:first _:807f36cf91fe4e8caa53aadeff9247769632;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff9247769634 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10520-1 a owl:Class;
  rdfs:label "CABAZITAXEL <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10520";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769636;
  r:natureDuRisque "Risque de majoration des effets indésirables dose-dépendants du cabazitaxel par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du cabazitaxel pendant le traitement par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769642, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769636 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769637 .

_:807f36cf91fe4e8caa53aadeff9247769637 rdf:first _:807f36cf91fe4e8caa53aadeff9247769638;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769639 .

_:807f36cf91fe4e8caa53aadeff9247769638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff9247769639 rdf:first _:807f36cf91fe4e8caa53aadeff9247769640;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff9247769642 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10609-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> TICLOPIDINE"@fr;
  dct:identifier "IAM_10609";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769644;
  r:natureDuRisque "Diminution des concentrations sanguines de ciclosporine."@fr;
  r:conduiteATenir "Augmentation de la posologie de la ciclosporine sous contrôle des concentrations sanguines. Réduction de la posologie en cas d'arrêt de la ticlopidine."@fr;
  rdfs:comment """L'essentiel des publications repose sur des cas isolés, trois d'entre eux comportant la notion d'une réintroduction positive. 
Dans une étude chez 20 patients transplantés cardiaques recevant de la ticlopidine, les ciclosporinémies n'ont en moyenne pas va"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769650, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769644 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769645 .

_:807f36cf91fe4e8caa53aadeff9247769645 rdf:first _:807f36cf91fe4e8caa53aadeff9247769646;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769647 .

_:807f36cf91fe4e8caa53aadeff9247769646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff9247769647 rdf:first _:807f36cf91fe4e8caa53aadeff9247769648;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10928 .

_:807f36cf91fe4e8caa53aadeff9247769650 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10610-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> TRIMETHOPRIME"@fr;
  dct:identifier "IAM_10610";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769652;
  r:natureDuRisque """Avec le triméthoprime (seul ou associé) par voie orale : augmentation de la créatininémie avec diminution possible des concentrations sanguines de ciclosporine.

Avec le trimethoprime (seul ou associé) par voie IV : la diminution des concentrations sangui"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769658, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769652 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769653 .

_:807f36cf91fe4e8caa53aadeff9247769653 rdf:first _:807f36cf91fe4e8caa53aadeff9247769654;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769655 .

_:807f36cf91fe4e8caa53aadeff9247769654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff9247769655 rdf:first _:807f36cf91fe4e8caa53aadeff9247769656;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10955 .

_:807f36cf91fe4e8caa53aadeff9247769658 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10611-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10611";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769660;
  r:natureDuRisque "Augmentation des concentrations sanguines de la ciclosporine (diminution de son métabolisme hépatique), et majoration du risque de gingivopathies."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769666, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769660 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769661 .

_:807f36cf91fe4e8caa53aadeff9247769661 rdf:first _:807f36cf91fe4e8caa53aadeff9247769662;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769663 .

_:807f36cf91fe4e8caa53aadeff9247769662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff9247769663 rdf:first _:807f36cf91fe4e8caa53aadeff9247769664;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff9247769666 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10612-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> DIAZEPAM"@fr;
  dct:identifier "IAM_10612";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769668;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : risque accru de somnolence."@fr;
  r:conduiteATenir "Avertir les patients de l'augmentation du risque en cas de conduite automobile ou d'utilisation de machines."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769674, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769668 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769669 .

_:807f36cf91fe4e8caa53aadeff9247769669 rdf:first _:807f36cf91fe4e8caa53aadeff9247769670;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769671 .

_:807f36cf91fe4e8caa53aadeff9247769670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff9247769671 rdf:first _:807f36cf91fe4e8caa53aadeff9247769672;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10280 .

_:807f36cf91fe4e8caa53aadeff9247769674 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10613-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10613";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769676;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations plasmatiques de lidocaïne avec risque d'effets indésirables neurologiques et cardiaques (inhibition du métabolisme hépatique de la lidocaïne)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement des concentrations plasmatiques de la lidocaïne ; s'il y a lieu, adaptation de la posologie de la lidocaïne pendant le traitement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769682, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769676 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769677 .

_:807f36cf91fe4e8caa53aadeff9247769677 rdf:first _:807f36cf91fe4e8caa53aadeff9247769678;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769679 .

_:807f36cf91fe4e8caa53aadeff9247769678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff9247769679 rdf:first _:807f36cf91fe4e8caa53aadeff9247769680;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:807f36cf91fe4e8caa53aadeff9247769682 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10614-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> LOMUSTINE"@fr;
  dct:identifier "IAM_10614";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769684;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : toxicité médullaire accrue (inhibition du métabolisme de la lomustine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769690, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769684 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769685 .

_:807f36cf91fe4e8caa53aadeff9247769685 rdf:first _:807f36cf91fe4e8caa53aadeff9247769686;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769687 .

_:807f36cf91fe4e8caa53aadeff9247769686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff9247769687 rdf:first _:807f36cf91fe4e8caa53aadeff9247769688;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10534 .

_:807f36cf91fe4e8caa53aadeff9247769690 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10615-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> METHADONE"@fr;
  dct:identifier "IAM_10615";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769692;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de méthadone avec surdosage et risque majoré d’allongement de l’intervalle QT et de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique renforcée ; si besoin, adaptation de la posologie de la méthadone pendant le traitement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769698, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769692 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769693 .

_:807f36cf91fe4e8caa53aadeff9247769693 rdf:first _:807f36cf91fe4e8caa53aadeff9247769694;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769695 .

_:807f36cf91fe4e8caa53aadeff9247769694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff9247769695 rdf:first _:807f36cf91fe4e8caa53aadeff9247769696;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff9247769698 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10616-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10616";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769700;
  r:natureDuRisque "Avec le métoprolol utilisé dans l'insuffisance cardiaque, et la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations du métoprolol, pouvant être préjudiciables dans le cas du traitement de l'insuffisance cardi"@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par la cimétidine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769706, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769700 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769701 .

_:807f36cf91fe4e8caa53aadeff9247769701 rdf:first _:807f36cf91fe4e8caa53aadeff9247769702;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769703 .

_:807f36cf91fe4e8caa53aadeff9247769702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff9247769703 rdf:first _:807f36cf91fe4e8caa53aadeff9247769704;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff9247769706 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10631-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10631";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769708;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Surveillance clinique et électrocardiographique pendant
l'association."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769714, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769708 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769709 .

_:807f36cf91fe4e8caa53aadeff9247769709 rdf:first _:807f36cf91fe4e8caa53aadeff9247769710;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769711 .

_:807f36cf91fe4e8caa53aadeff9247769710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff9247769711 rdf:first _:807f36cf91fe4e8caa53aadeff9247769712;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff9247769714 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10618-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> NIFEDIPINE"@fr;
  dct:identifier "IAM_10618";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769716;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation de l'effet hypotenseur de la nifédipine par inhibition de son métabolisme hépatique par la cimétidine."@fr;
  r:conduiteATenir "Surveillance clinique accrue : adapter la posologie de la nifédipine pendant le tratiement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769722, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769716 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769717 .

_:807f36cf91fe4e8caa53aadeff9247769717 rdf:first _:807f36cf91fe4e8caa53aadeff9247769718;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769719 .

_:807f36cf91fe4e8caa53aadeff9247769718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff9247769719 rdf:first _:807f36cf91fe4e8caa53aadeff9247769720;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10633 .

_:807f36cf91fe4e8caa53aadeff9247769722 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10630-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> ROPINIROLE"@fr;
  dct:identifier "IAM_10630";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769724;
  r:natureDuRisque "Augmentation des concentrations de ropinirole avec risque de surdosage, par diminution de son métabolisme hépatique par la ciprofloxacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie du ropinirole pendant le traitement par la ciprofloxacine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769730, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769724 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769725 .

_:807f36cf91fe4e8caa53aadeff9247769725 rdf:first _:807f36cf91fe4e8caa53aadeff9247769726;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769727 .

_:807f36cf91fe4e8caa53aadeff9247769726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff9247769727 rdf:first _:807f36cf91fe4e8caa53aadeff9247769728;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10813 .

_:807f36cf91fe4e8caa53aadeff9247769730 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10620-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10620";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769732;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation de la théophyllinémie avec risque de surdosage (diminution du métabolisme de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie. S'il y a lieu, adaptation de la théophylline pendant le traitement par la cimétidine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769738, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769732 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769733 .

_:807f36cf91fe4e8caa53aadeff9247769733 rdf:first _:807f36cf91fe4e8caa53aadeff9247769734;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769735 .

_:807f36cf91fe4e8caa53aadeff9247769734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff9247769735 rdf:first _:807f36cf91fe4e8caa53aadeff9247769736;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff9247769738 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10621-1 a owl:Class;
  rdfs:label "CINACALCET <-> DEXTROMETHORPHANE"@fr;
  dct:identifier "IAM_10621";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769740;
  r:natureDuRisque "Augmentation très importante des concentrations plasmatiques de dextrométhorphane avec risque de surdosage, par diminution de son métabolisme hépatique par le cinacalcet."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769746, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769740 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769741 .

_:807f36cf91fe4e8caa53aadeff9247769741 rdf:first _:807f36cf91fe4e8caa53aadeff9247769742;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769743 .

_:807f36cf91fe4e8caa53aadeff9247769742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:807f36cf91fe4e8caa53aadeff9247769743 rdf:first _:807f36cf91fe4e8caa53aadeff9247769744;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10278 .

_:807f36cf91fe4e8caa53aadeff9247769746 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10622-1 a owl:Class;
  rdfs:label "CINACALCET <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10622";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769748;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de flécaïnide avec risque de surdosage, par diminution de son métabolisme hépatique par le cinacalcet."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du flécaïnide pendant le traitement par cinacalcet."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769754, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769748 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769749 .

_:807f36cf91fe4e8caa53aadeff9247769749 rdf:first _:807f36cf91fe4e8caa53aadeff9247769750;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769751 .

_:807f36cf91fe4e8caa53aadeff9247769750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:807f36cf91fe4e8caa53aadeff9247769751 rdf:first _:807f36cf91fe4e8caa53aadeff9247769752;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:807f36cf91fe4e8caa53aadeff9247769754 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10624-1 a owl:Class;
  rdfs:label "CINACALCET <-> METOPROLOL"@fr;
  dct:identifier "IAM_10624";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769756;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de métroprolol avec risque de surdosage, par diminution de son métabolisme hépatique par le cinacalcet."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du métroprolol pendant le traitement par cinacalcet."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769756 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769757 .

_:807f36cf91fe4e8caa53aadeff9247769757 rdf:first _:807f36cf91fe4e8caa53aadeff9247769758;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769759 .

_:807f36cf91fe4e8caa53aadeff9247769758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:807f36cf91fe4e8caa53aadeff9247769759 rdf:first _:807f36cf91fe4e8caa53aadeff9247769760;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff9247769762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10623-1 a owl:Class;
  rdfs:label "CINACALCET <-> MEQUITAZINE"@fr;
  dct:identifier "IAM_10623";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769764;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769765 .

_:807f36cf91fe4e8caa53aadeff9247769765 rdf:first _:807f36cf91fe4e8caa53aadeff9247769766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769767 .

_:807f36cf91fe4e8caa53aadeff9247769766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:807f36cf91fe4e8caa53aadeff9247769767 rdf:first _:807f36cf91fe4e8caa53aadeff9247769768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:807f36cf91fe4e8caa53aadeff9247769770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10625-1 a owl:Class;
  rdfs:label "CINACALCET <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10625";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769772;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de propafénone avec risque de surdosage, par diminution de son métabolisme hépatique par le cinacalcet."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de la propafénone pendant le traitement par cinacalcet."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769773 .

_:807f36cf91fe4e8caa53aadeff9247769773 rdf:first _:807f36cf91fe4e8caa53aadeff9247769774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769775 .

_:807f36cf91fe4e8caa53aadeff9247769774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:807f36cf91fe4e8caa53aadeff9247769775 rdf:first _:807f36cf91fe4e8caa53aadeff9247769776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff9247769778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10626-1 a owl:Class;
  rdfs:label "CINACALCET <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_10626";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769780;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution importante de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par le cinacalcet et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769781 .

_:807f36cf91fe4e8caa53aadeff9247769781 rdf:first _:807f36cf91fe4e8caa53aadeff9247769782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769783 .

_:807f36cf91fe4e8caa53aadeff9247769782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10197 .

_:807f36cf91fe4e8caa53aadeff9247769783 rdf:first _:807f36cf91fe4e8caa53aadeff9247769784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:807f36cf91fe4e8caa53aadeff9247769786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10627-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> CLOZAPINE"@fr;
  dct:identifier "IAM_10627";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769788;
  r:natureDuRisque "Augmentation des concentrations de clozapine avec risque de surdosage, par diminution de son métabolisme hépatique par la ciprofloxacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la clozapine pendant le traitement par la ciprofloxacine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769789 .

_:807f36cf91fe4e8caa53aadeff9247769789 rdf:first _:807f36cf91fe4e8caa53aadeff9247769790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769791 .

_:807f36cf91fe4e8caa53aadeff9247769790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff9247769791 rdf:first _:807f36cf91fe4e8caa53aadeff9247769792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:807f36cf91fe4e8caa53aadeff9247769794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10628-1 a owl:Class;
  rdfs:label "CIPROFLOXACINE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10628";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769796;
  r:natureDuRisque "Augmentation de la toxicité du méthotrexate par inhibition de sa sécrétion tubulaire rénale par la ciprofloxacine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769797 .

_:807f36cf91fe4e8caa53aadeff9247769797 rdf:first _:807f36cf91fe4e8caa53aadeff9247769798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769799 .

_:807f36cf91fe4e8caa53aadeff9247769798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff9247769799 rdf:first _:807f36cf91fe4e8caa53aadeff9247769800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff9247769802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10654-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10654";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769804;
  r:natureDuRisque "Risque d'augmentation de la théophyllinémie, particulièrement chez l'enfant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769805 .

_:807f36cf91fe4e8caa53aadeff9247769805 rdf:first _:807f36cf91fe4e8caa53aadeff9247769806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769807 .

_:807f36cf91fe4e8caa53aadeff9247769806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff9247769807 rdf:first _:807f36cf91fe4e8caa53aadeff9247769808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10617-1 a owl:Class;
  rdfs:label "CIMETIDINE <-> MOCLOBEMIDE"@fr;
  dct:identifier "IAM_10617";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769812;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations du moclobémide, par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique avec adaptation éventuelle de la posologie de moclobémide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769813 .

_:807f36cf91fe4e8caa53aadeff9247769813 rdf:first _:807f36cf91fe4e8caa53aadeff9247769814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769815 .

_:807f36cf91fe4e8caa53aadeff9247769814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff9247769815 rdf:first _:807f36cf91fe4e8caa53aadeff9247769816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10598 .

_:807f36cf91fe4e8caa53aadeff9247769818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10703-1 a owl:Class;
  rdfs:label "CYTOTOXIQUES <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10703";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769820;
  r:natureDuRisque "Risque de survenue de convulsions par diminution de l'absorption digestive de la seule phénytoïne par le cytotoxique, ou bien risque de majoration de la toxicité ou de perte d'efficacité du cytotoxique par augmentation de son métabolisme hépatique par la"@fr;
  rdfs:comment "Deux niveaux de contrainte distincts avaient été retenus entre les cytotoxiques et la phénytoïne, selon que l'anticonvulsivant était administré antérieurement à la chimiothérapie (conduisant alors à une précaution d’emploi) ou qu'il aurait pu être donné à"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769821 .

_:807f36cf91fe4e8caa53aadeff9247769821 rdf:first _:807f36cf91fe4e8caa53aadeff9247769822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769823 .

_:807f36cf91fe4e8caa53aadeff9247769822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10060 .

_:807f36cf91fe4e8caa53aadeff9247769823 rdf:first _:807f36cf91fe4e8caa53aadeff9247769824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff9247769826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10652-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10652";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769828;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes."""@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769829 .

_:807f36cf91fe4e8caa53aadeff9247769829 rdf:first _:807f36cf91fe4e8caa53aadeff9247769830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769831 .

_:807f36cf91fe4e8caa53aadeff9247769830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff9247769831 rdf:first _:807f36cf91fe4e8caa53aadeff9247769832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff9247769834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10693-1 a owl:Class;
  rdfs:label "CYCLINES <-> VITAMINE A"@fr;
  dct:identifier "IAM_10693";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769836;
  r:natureDuRisque "En cas d'apport de 10,000 UI/j et plus : risque d’hypertension intracrânienne."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769837 .

_:807f36cf91fe4e8caa53aadeff9247769837 rdf:first _:807f36cf91fe4e8caa53aadeff9247769838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769839 .

_:807f36cf91fe4e8caa53aadeff9247769838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:807f36cf91fe4e8caa53aadeff9247769839 rdf:first _:807f36cf91fe4e8caa53aadeff9247769840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10997 .

_:807f36cf91fe4e8caa53aadeff9247769842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10694-1 a owl:Class;
  rdfs:label "CYCLINES <-> ZINC"@fr;
  dct:identifier "IAM_10694";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769844;
  r:natureDuRisque "Diminution de l'absorption digestive des cyclines."@fr;
  r:conduiteATenir "Prendre les sels de zinc à distance des cyclines (plus de 2 heures si possible)."@fr;
  rdfs:comment """Le zinc est utilisé dans le traitement de l’acné inflammatoire macrokystique et/ou nodulaire ainsi que dans le traitement des acrodermatites entéropathiques. Comme le fer et le calcium, il peut chélater les tétracyclines et diminuer leur efficacité. 
Cett"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769845 .

_:807f36cf91fe4e8caa53aadeff9247769845 rdf:first _:807f36cf91fe4e8caa53aadeff9247769846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769847 .

_:807f36cf91fe4e8caa53aadeff9247769846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:807f36cf91fe4e8caa53aadeff9247769847 rdf:first _:807f36cf91fe4e8caa53aadeff9247769848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:807f36cf91fe4e8caa53aadeff9247769850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10695-1 a owl:Class;
  rdfs:label "CYCLOPHOSPHAMIDE <-> PENTOSTATINE"@fr;
  dct:identifier "IAM_10695";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769852;
  r:natureDuRisque "Majoration du risque de toxicité pulmonaire pouvant être fatale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769858, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769852 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769853 .

_:807f36cf91fe4e8caa53aadeff9247769853 rdf:first _:807f36cf91fe4e8caa53aadeff9247769854;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769855 .

_:807f36cf91fe4e8caa53aadeff9247769854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10235 .

_:807f36cf91fe4e8caa53aadeff9247769855 rdf:first _:807f36cf91fe4e8caa53aadeff9247769856;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10704 .

_:807f36cf91fe4e8caa53aadeff9247769858 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10696-1 a owl:Class;
  rdfs:label "CYPROHEPTADINE <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10696";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769860;
  r:natureDuRisque "Risque de diminution de l'efficacité de l'antidépresseur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769860 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769861 .

_:807f36cf91fe4e8caa53aadeff9247769861 rdf:first _:807f36cf91fe4e8caa53aadeff9247769862;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769863 .

_:807f36cf91fe4e8caa53aadeff9247769862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff9247769863 rdf:first _:807f36cf91fe4e8caa53aadeff9247769864;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10237 .

_:807f36cf91fe4e8caa53aadeff9247769866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10697-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10697";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769868;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Association déconseillée:
- dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant.

Précaution d'emploi
- dans se"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769869 .

_:807f36cf91fe4e8caa53aadeff9247769869 rdf:first _:807f36cf91fe4e8caa53aadeff9247769870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769871 .

_:807f36cf91fe4e8caa53aadeff9247769870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff9247769871 rdf:first _:807f36cf91fe4e8caa53aadeff9247769872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff9247769874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10698-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10698";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769876;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Association déconseillée
- dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant.

Précaution d'emploi
- dans ses"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769877 .

_:807f36cf91fe4e8caa53aadeff9247769877 rdf:first _:807f36cf91fe4e8caa53aadeff9247769878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769879 .

_:807f36cf91fe4e8caa53aadeff9247769878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff9247769879 rdf:first _:807f36cf91fe4e8caa53aadeff9247769880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff9247769882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10699-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10699";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769884;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone, par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769885 .

_:807f36cf91fe4e8caa53aadeff9247769885 rdf:first _:807f36cf91fe4e8caa53aadeff9247769886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769887 .

_:807f36cf91fe4e8caa53aadeff9247769886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff9247769887 rdf:first _:807f36cf91fe4e8caa53aadeff9247769888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff9247769890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10700-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> PÉRAMPANEL"@fr;
  dct:identifier "IAM_10700";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769892;
  r:natureDuRisque "Pour des doses de pérampanel > ou = à 12 mg/jour, risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir "Dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769898, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769892 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769893 .

_:807f36cf91fe4e8caa53aadeff9247769893 rdf:first _:807f36cf91fe4e8caa53aadeff9247769894;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769895 .

_:807f36cf91fe4e8caa53aadeff9247769894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff9247769895 rdf:first _:807f36cf91fe4e8caa53aadeff9247769896;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:807f36cf91fe4e8caa53aadeff9247769898 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10691-1 a owl:Class;
  rdfs:label "CYCLINES <-> RÉTINOÏDES"@fr;
  dct:identifier "IAM_10691";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769900;
  r:natureDuRisque "Risque d'hypertension intracrânienne."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769906, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769900 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769901 .

_:807f36cf91fe4e8caa53aadeff9247769901 rdf:first _:807f36cf91fe4e8caa53aadeff9247769902;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769903 .

_:807f36cf91fe4e8caa53aadeff9247769902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:807f36cf91fe4e8caa53aadeff9247769903 rdf:first _:807f36cf91fe4e8caa53aadeff9247769904;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff9247769906 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10702-1 a owl:Class;
  rdfs:label "CYTOTOXIQUES <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10702";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769908;
  r:natureDuRisque "Immunodépression excessive avec risque de syndrome lympho-prolifératif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769914, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769908 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769909 .

_:807f36cf91fe4e8caa53aadeff9247769909 rdf:first _:807f36cf91fe4e8caa53aadeff9247769910;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769911 .

_:807f36cf91fe4e8caa53aadeff9247769910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10060 .

_:807f36cf91fe4e8caa53aadeff9247769911 rdf:first _:807f36cf91fe4e8caa53aadeff9247769912;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff9247769914 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10690-1 a owl:Class;
  rdfs:label "CYCLINES <-> FER"@fr;
  dct:identifier "IAM_10690";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769916;
  r:natureDuRisque "Avec les cyclines utilisées par voie orale : diminution de l'absorption digestive des cyclines (formation de complexes)."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance des cyclines (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769922, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769916 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769917 .

_:807f36cf91fe4e8caa53aadeff9247769917 rdf:first _:807f36cf91fe4e8caa53aadeff9247769918;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769919 .

_:807f36cf91fe4e8caa53aadeff9247769918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:807f36cf91fe4e8caa53aadeff9247769919 rdf:first _:807f36cf91fe4e8caa53aadeff9247769920;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff9247769922 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10704-1 a owl:Class;
  rdfs:label "CYTOTOXIQUES <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10704";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769924;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir """- Et pendant les 6 mois suivant l'arrêt de la chimiothérapie.

- Et, à l'exception de l'hydroxycarbamide dans son indication chez le patient drépanocytaire."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769930, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769924 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769925 .

_:807f36cf91fe4e8caa53aadeff9247769925 rdf:first _:807f36cf91fe4e8caa53aadeff9247769926;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769927 .

_:807f36cf91fe4e8caa53aadeff9247769926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10060 .

_:807f36cf91fe4e8caa53aadeff9247769927 rdf:first _:807f36cf91fe4e8caa53aadeff9247769928;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff9247769930 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10705-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10705";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769932;
  r:natureDuRisque "Doublement des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769938, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769932 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769933 .

_:807f36cf91fe4e8caa53aadeff9247769933 rdf:first _:807f36cf91fe4e8caa53aadeff9247769934;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769935 .

_:807f36cf91fe4e8caa53aadeff9247769934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff9247769935 rdf:first _:807f36cf91fe4e8caa53aadeff9247769936;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff9247769938 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10706-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10706";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769940;
  r:natureDuRisque "Augmentation de plus du double des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769946, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769940 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769941 .

_:807f36cf91fe4e8caa53aadeff9247769941 rdf:first _:807f36cf91fe4e8caa53aadeff9247769942;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769943 .

_:807f36cf91fe4e8caa53aadeff9247769942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff9247769943 rdf:first _:807f36cf91fe4e8caa53aadeff9247769944;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff9247769946 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10707-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10707";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769948;
  r:natureDuRisque "Augmentation de plus du double des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769954, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769948 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769949 .

_:807f36cf91fe4e8caa53aadeff9247769949 rdf:first _:807f36cf91fe4e8caa53aadeff9247769950;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769951 .

_:807f36cf91fe4e8caa53aadeff9247769950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff9247769951 rdf:first _:807f36cf91fe4e8caa53aadeff9247769952;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff9247769954 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10708-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> QUINIDINE"@fr;
  dct:identifier "IAM_10708";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769956;
  r:natureDuRisque """Augmentation des concentrations plasmatiques de dabigatran,
avec majoration du risque de saignement."""@fr;
  r:conduiteATenir "Dans l'indication post-chirurgicale : surveillance clinique et adaptation de la posologie du dabigatran à 150 mg/j en une prise."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769962, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769956 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769957 .

_:807f36cf91fe4e8caa53aadeff9247769957 rdf:first _:807f36cf91fe4e8caa53aadeff9247769958;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769959 .

_:807f36cf91fe4e8caa53aadeff9247769958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff9247769959 rdf:first _:807f36cf91fe4e8caa53aadeff9247769960;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff9247769962 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10709-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10709";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769964;
  r:natureDuRisque "Diminution des concentrations plasmatiques de dabigatran, avec risque de diminution de l'effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769970, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769964 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769965 .

_:807f36cf91fe4e8caa53aadeff9247769965 rdf:first _:807f36cf91fe4e8caa53aadeff9247769966;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769967 .

_:807f36cf91fe4e8caa53aadeff9247769966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff9247769967 rdf:first _:807f36cf91fe4e8caa53aadeff9247769968;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff9247769970 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10710-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10710";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769972;
  r:natureDuRisque "Risque d'augmentation des concentrations plasmatiques de dabigatran."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769978, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769972 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769973 .

_:807f36cf91fe4e8caa53aadeff9247769973 rdf:first _:807f36cf91fe4e8caa53aadeff9247769974;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769975 .

_:807f36cf91fe4e8caa53aadeff9247769974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff9247769975 rdf:first _:807f36cf91fe4e8caa53aadeff9247769976;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff9247769978 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10711-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10711";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769980;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769986, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769980 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769981 .

_:807f36cf91fe4e8caa53aadeff9247769981 rdf:first _:807f36cf91fe4e8caa53aadeff9247769982;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769983 .

_:807f36cf91fe4e8caa53aadeff9247769982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff9247769983 rdf:first _:807f36cf91fe4e8caa53aadeff9247769984;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff9247769986 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10712-1 a owl:Class;
  rdfs:label "DABIGATRAN <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10712";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769988;
  r:natureDuRisque """Augmentation des concentrations plasmatiques de dabigatran,
avec majoration du risque de saignement."""@fr;
  r:conduiteATenir """Dans l'indication post-chirurgicale : surveillance clinique et adaptation de la posologie du dabigatran à 150 mg/j en une prise, voire 75 mg/j en cas d'insuffisance rénale modérée.

Dans l'indication fibrillation auriculaire : surveillance clinique et ada"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff9247769994, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769988 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769989 .

_:807f36cf91fe4e8caa53aadeff9247769989 rdf:first _:807f36cf91fe4e8caa53aadeff9247769990;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769991 .

_:807f36cf91fe4e8caa53aadeff9247769990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff9247769991 rdf:first _:807f36cf91fe4e8caa53aadeff9247769992;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff9247769992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff9247769994 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10001-1 a owl:Class;
  rdfs:label "ABATACEPT <-> ANTI-TNF ALPHA"@fr;
  dct:identifier "IAM_10001";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff9247769996;
  r:natureDuRisque "Majoration de l’immunodépression."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610002, r:Interaction .

_:807f36cf91fe4e8caa53aadeff9247769996 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff9247769997 .

_:807f36cf91fe4e8caa53aadeff9247769997 rdf:first _:807f36cf91fe4e8caa53aadeff9247769998;
  rdf:rest _:807f36cf91fe4e8caa53aadeff9247769999 .

_:807f36cf91fe4e8caa53aadeff9247769998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10021 .

_:807f36cf91fe4e8caa53aadeff9247769999 rdf:first _:807f36cf91fe4e8caa53aadeff92477610000;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477610002 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10701-1 a owl:Class;
  rdfs:label "CYPROTERONE <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10701";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610004;
  r:natureDuRisque """Dans l'indication contraception d'urgence de l'ulipristal :
Antagonisme des effets de l’ulipristal en cas de reprise d’un contraceptif hormonal moins de 5 jours après la prise de la contraception d’urgence.

Dans l’indication fibrome de l'ulipristal :
Ant"""@fr;
  r:conduiteATenir """Association déconseillée 
Dans l'utilisation à visée contraceptive de la cyprotérone

- Dans l'indication contraception d'urgence de l'ulipristal
Dans le cas où la (re)prise d’une contraception hormonale est envisagée, utiliser une contraception additionn"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610010, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610004 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610005 .

_:807f36cf91fe4e8caa53aadeff92477610005 rdf:first _:807f36cf91fe4e8caa53aadeff92477610006;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610007 .

_:807f36cf91fe4e8caa53aadeff92477610006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff92477610007 rdf:first _:807f36cf91fe4e8caa53aadeff92477610008;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477610010 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10666-1 a owl:Class;
  rdfs:label "CLOZAPINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10666";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610012;
  r:natureDuRisque "Risque d'inefficacité du traitement antipsychotique (diminution des concentrations plasmatiques de clozapine par augmentation de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Surveillance clinique et augmentation éventuelle de la posologie de la clozapine durant le traitement par la phénytoïne."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610018, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610012 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610013 .

_:807f36cf91fe4e8caa53aadeff92477610013 rdf:first _:807f36cf91fe4e8caa53aadeff92477610014;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610015 .

_:807f36cf91fe4e8caa53aadeff92477610014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477610015 rdf:first _:807f36cf91fe4e8caa53aadeff92477610016;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:807f36cf91fe4e8caa53aadeff92477610018 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10606-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> SULFINPYRAZONE"@fr;
  dct:identifier "IAM_10606";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610020;
  r:natureDuRisque "Diminution des concentrations sanguines de ciclosporine par augmentation de son métabolisme par la sulfinpyrazone."@fr;
  r:conduiteATenir "Contrôle des concentrations sanguines de ciclosporine et adaptation éventuelle de sa posologie pendant le traitement par sulfinpyrazone et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610026, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610020 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610021 .

_:807f36cf91fe4e8caa53aadeff92477610021 rdf:first _:807f36cf91fe4e8caa53aadeff92477610022;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610023 .

_:807f36cf91fe4e8caa53aadeff92477610022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610023 rdf:first _:807f36cf91fe4e8caa53aadeff92477610024;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10873 .

_:807f36cf91fe4e8caa53aadeff92477610026 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10655-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_10655";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610028;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610034, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610028 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610029 .

_:807f36cf91fe4e8caa53aadeff92477610029 rdf:first _:807f36cf91fe4e8caa53aadeff92477610030;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610031 .

_:807f36cf91fe4e8caa53aadeff92477610030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477610031 rdf:first _:807f36cf91fe4e8caa53aadeff92477610032;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477610034 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10657-1 a owl:Class;
  rdfs:label "CLINDAMYCINE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10657";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610036;
  r:natureDuRisque "Diminution des concentrations sanguines de l'immunosuppresseur, avec risque de perte de l'activité immunosuppressive."@fr;
  r:conduiteATenir "Contrôle renforcé des dosages sanguins de tacrolimus et augmentation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610042, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610036 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610037 .

_:807f36cf91fe4e8caa53aadeff92477610037 rdf:first _:807f36cf91fe4e8caa53aadeff92477610038;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610039 .

_:807f36cf91fe4e8caa53aadeff92477610038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10209 .

_:807f36cf91fe4e8caa53aadeff92477610039 rdf:first _:807f36cf91fe4e8caa53aadeff92477610040;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477610042 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10658-1 a owl:Class;
  rdfs:label "CLOBAZAM <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10658";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610044;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de ces anticonvulsivants, avec risque de surdosage, par inhibition de leur métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique, dosage plasmatique, lorsque cela est possible, de l'anticonvulsivant associé au stiripentol et éventuelle adaptation posologique de l'anticonvulsivant associé."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610050, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610044 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610045 .

_:807f36cf91fe4e8caa53aadeff92477610045 rdf:first _:807f36cf91fe4e8caa53aadeff92477610046;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610047 .

_:807f36cf91fe4e8caa53aadeff92477610046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10210 .

_:807f36cf91fe4e8caa53aadeff92477610047 rdf:first _:807f36cf91fe4e8caa53aadeff92477610048;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477610050 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10659-1 a owl:Class;
  rdfs:label "CLONIDINE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10659";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610052;
  r:natureDuRisque "Troubles de l'automatisme (troubles de la conduction auriculo-ventriculaire par addition des effets négatifs sur la conduction)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610058, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610052 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610053 .

_:807f36cf91fe4e8caa53aadeff92477610053 rdf:first _:807f36cf91fe4e8caa53aadeff92477610054;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610055 .

_:807f36cf91fe4e8caa53aadeff92477610054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10214 .

_:807f36cf91fe4e8caa53aadeff92477610055 rdf:first _:807f36cf91fe4e8caa53aadeff92477610056;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477610058 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10660-1 a owl:Class;
  rdfs:label "CLONIDINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10660";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610060;
  r:natureDuRisque "Troubles de l'automatisme (troubles de la conduction auriculo-ventriculaire par addition des effets négatifs sur la conduction)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610066, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610060 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610061 .

_:807f36cf91fe4e8caa53aadeff92477610061 rdf:first _:807f36cf91fe4e8caa53aadeff92477610062;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610063 .

_:807f36cf91fe4e8caa53aadeff92477610062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10214 .

_:807f36cf91fe4e8caa53aadeff92477610063 rdf:first _:807f36cf91fe4e8caa53aadeff92477610064;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477610066 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10661-1 a owl:Class;
  rdfs:label "CLONIDINE <-> YOHIMBINE"@fr;
  dct:identifier "IAM_10661";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610068;
  r:natureDuRisque "Inhibition possible de l’activité antihypertensive par antagonisme au niveau des récepteurs."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610074, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610068 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610069 .

_:807f36cf91fe4e8caa53aadeff92477610069 rdf:first _:807f36cf91fe4e8caa53aadeff92477610070;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610071 .

_:807f36cf91fe4e8caa53aadeff92477610070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10214 .

_:807f36cf91fe4e8caa53aadeff92477610071 rdf:first _:807f36cf91fe4e8caa53aadeff92477610072;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11001 .

_:807f36cf91fe4e8caa53aadeff92477610074 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10662-1 a owl:Class;
  rdfs:label "CLOPIDOGREL <-> PACLITAXEL"@fr;
  dct:identifier "IAM_10662";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610076;
  r:natureDuRisque "Augmentation des concentrations du paclitaxel par le clopidogrel, avec risque de majoration des effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610082, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610076 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610077 .

_:807f36cf91fe4e8caa53aadeff92477610077 rdf:first _:807f36cf91fe4e8caa53aadeff92477610078;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610079 .

_:807f36cf91fe4e8caa53aadeff92477610078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:807f36cf91fe4e8caa53aadeff92477610079 rdf:first _:807f36cf91fe4e8caa53aadeff92477610080;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10685 .

_:807f36cf91fe4e8caa53aadeff92477610082 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10663-1 a owl:Class;
  rdfs:label "CLOPIDOGREL <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10663";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610084;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec signes de surdosage (inhibition du métabolisme de la phénytoïne)."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénytoïne."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610084 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610085 .

_:807f36cf91fe4e8caa53aadeff92477610085 rdf:first _:807f36cf91fe4e8caa53aadeff92477610086;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610087 .

_:807f36cf91fe4e8caa53aadeff92477610086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477610087 rdf:first _:807f36cf91fe4e8caa53aadeff92477610088;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:807f36cf91fe4e8caa53aadeff92477610090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10692-1 a owl:Class;
  rdfs:label "CYCLINES <-> STRONTIUM"@fr;
  dct:identifier "IAM_10692";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610092;
  r:natureDuRisque "Diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des cyclines (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610093 .

_:807f36cf91fe4e8caa53aadeff92477610093 rdf:first _:807f36cf91fe4e8caa53aadeff92477610094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610095 .

_:807f36cf91fe4e8caa53aadeff92477610094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:807f36cf91fe4e8caa53aadeff92477610095 rdf:first _:807f36cf91fe4e8caa53aadeff92477610096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:807f36cf91fe4e8caa53aadeff92477610098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10665-1 a owl:Class;
  rdfs:label "CLOZAPINE <-> FLUVOXAMINE"@fr;
  dct:identifier "IAM_10665";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610100;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de clozapine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie de la clozapine pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610101 .

_:807f36cf91fe4e8caa53aadeff92477610101 rdf:first _:807f36cf91fe4e8caa53aadeff92477610102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610103 .

_:807f36cf91fe4e8caa53aadeff92477610102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:807f36cf91fe4e8caa53aadeff92477610103 rdf:first _:807f36cf91fe4e8caa53aadeff92477610104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477610106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10653-1 a owl:Class;
  rdfs:label "CLARITHROMYCINE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10653";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610108;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par la clarithromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610109 .

_:807f36cf91fe4e8caa53aadeff92477610109 rdf:first _:807f36cf91fe4e8caa53aadeff92477610110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610111 .

_:807f36cf91fe4e8caa53aadeff92477610110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477610111 rdf:first _:807f36cf91fe4e8caa53aadeff92477610112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477610114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10667-1 a owl:Class;
  rdfs:label "CLOZAPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10667";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610116;
  r:natureDuRisque "Risque d'inefficacité du traitement antipsychotique (diminution des concentrations plasmatiques de clozapine par augmentation de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Surveillance clinique et augmentation éventuelle de la posologie de la clozapine durant le traitement par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610122, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610116 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610117 .

_:807f36cf91fe4e8caa53aadeff92477610117 rdf:first _:807f36cf91fe4e8caa53aadeff92477610118;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610119 .

_:807f36cf91fe4e8caa53aadeff92477610118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:807f36cf91fe4e8caa53aadeff92477610119 rdf:first _:807f36cf91fe4e8caa53aadeff92477610120;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477610122 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10675-1 a owl:Class;
  rdfs:label "COBICISTAT <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_10675";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610124;
  r:natureDuRisque "Majoration de la neurotoxicité de l’antimitotique par diminution de son métabolisme hépatique par le cobicistat."@fr;
  r:conduiteATenir "Surveillance clinique étroite et adaptation éventuelle de la posologie de l’antimitotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610130, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610124 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610125 .

_:807f36cf91fe4e8caa53aadeff92477610125 rdf:first _:807f36cf91fe4e8caa53aadeff92477610126;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610127 .

_:807f36cf91fe4e8caa53aadeff92477610126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477610127 rdf:first _:807f36cf91fe4e8caa53aadeff92477610128;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477610130 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10668-1 a owl:Class;
  rdfs:label "COBICISTAT <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10668";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610132;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques du cobicistat ou de l’inhibiteur du CYP3A4."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque interaction, il convient de se reporter aux AMM specifiques à chaque spécialité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610138, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610132 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610133 .

_:807f36cf91fe4e8caa53aadeff92477610133 rdf:first _:807f36cf91fe4e8caa53aadeff92477610134;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610135 .

_:807f36cf91fe4e8caa53aadeff92477610134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477610135 rdf:first _:807f36cf91fe4e8caa53aadeff92477610136;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477610138 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10669-1 a owl:Class;
  rdfs:label "COBICISTAT <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10669";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610140;
  r:natureDuRisque "Risque d’augmentation des concentrations d’itraconazole par le cobicistat."@fr;
  r:conduiteATenir "Surveillance clinique lors de l’association. L’administration de doses élevées d’itraconazole (>200 mg par jour) n’est pas recommandée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610146, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610140 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610141 .

_:807f36cf91fe4e8caa53aadeff92477610141 rdf:first _:807f36cf91fe4e8caa53aadeff92477610142;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610143 .

_:807f36cf91fe4e8caa53aadeff92477610142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477610143 rdf:first _:807f36cf91fe4e8caa53aadeff92477610144;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477610146 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10670-1 a owl:Class;
  rdfs:label "COBICISTAT <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10670";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610148;
  r:natureDuRisque "Risque de diminution de l’efficacité du cobicistat par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610154, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610148 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610149 .

_:807f36cf91fe4e8caa53aadeff92477610149 rdf:first _:807f36cf91fe4e8caa53aadeff92477610150;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610151 .

_:807f36cf91fe4e8caa53aadeff92477610150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477610151 rdf:first _:807f36cf91fe4e8caa53aadeff92477610152;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477610154 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10671-1 a owl:Class;
  rdfs:label "COBICISTAT <-> QUINIDINE"@fr;
  dct:identifier "IAM_10671";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610156;
  r:natureDuRisque "Risque de majoration des effets indésirables de la quinidine par diminution de son métabolisme par le cobicistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610162, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610156 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610157 .

_:807f36cf91fe4e8caa53aadeff92477610157 rdf:first _:807f36cf91fe4e8caa53aadeff92477610158;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610159 .

_:807f36cf91fe4e8caa53aadeff92477610158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477610159 rdf:first _:807f36cf91fe4e8caa53aadeff92477610160;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477610162 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10672-1 a owl:Class;
  rdfs:label "COBICISTAT <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10672";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610164;
  r:natureDuRisque "Augmentation très importante du métabolite de la rifabutine, avec risque de majoration de sa toxicité (uvéites, neutropénies). Par ailleurs, possible diminution des concentrations de cobicistat."@fr;
  r:conduiteATenir "Adaptation de la posologie de la rifabutine (en principe, réduction des doses de moitié)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610170, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610164 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610165 .

_:807f36cf91fe4e8caa53aadeff92477610165 rdf:first _:807f36cf91fe4e8caa53aadeff92477610166;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610167 .

_:807f36cf91fe4e8caa53aadeff92477610166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477610167 rdf:first _:807f36cf91fe4e8caa53aadeff92477610168;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477610170 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10687-1 a owl:Class;
  rdfs:label "CURARES <-> LINCOSANIDES"@fr;
  dct:identifier "IAM_10687";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610172;
  r:chapeau """Certaines substances peuvent modifier l'intensité et/ou la durée de l'effet des curares non dépolarisants. 
Les médicaments susceptibles de potentialiser l'action des curares non dépolarisants sont :
- les anesthésiques volatils tels que isoflurane, enflu"""@fr;
  r:natureDuRisque "Potentialisation des curares lorque l'antibiotique est administré par voie parentérale et/ou péritonéale avant, pendant ou après l'agent curarisant."@fr;
  r:conduiteATenir "Surveiller le degré de curarisation en fin d'anesthésie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610178, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610172 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610173 .

_:807f36cf91fe4e8caa53aadeff92477610173 rdf:first _:807f36cf91fe4e8caa53aadeff92477610174;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610175 .

_:807f36cf91fe4e8caa53aadeff92477610174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10057 .

_:807f36cf91fe4e8caa53aadeff92477610175 rdf:first _:807f36cf91fe4e8caa53aadeff92477610176;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10106 .

_:807f36cf91fe4e8caa53aadeff92477610178 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10688-1 a owl:Class;
  rdfs:label "CURARES <-> POLYMYXINE B"@fr;
  dct:identifier "IAM_10688";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610180;
  r:natureDuRisque "Potentialisation des curares lorque l'antibiotique est administré par voie parentérale et/ou péritonéale avant, pendant ou après l'agent curarisant."@fr;
  r:conduiteATenir "Surveiller le degré de curarisation en fin d'anesthésie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610186, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610180 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610181 .

_:807f36cf91fe4e8caa53aadeff92477610181 rdf:first _:807f36cf91fe4e8caa53aadeff92477610182;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610183 .

_:807f36cf91fe4e8caa53aadeff92477610182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10057 .

_:807f36cf91fe4e8caa53aadeff92477610183 rdf:first _:807f36cf91fe4e8caa53aadeff92477610184;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10739 .

_:807f36cf91fe4e8caa53aadeff92477610186 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10689-1 a owl:Class;
  rdfs:label "CURARES NON DÉPOLARISANTS <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10689";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610188;
  r:natureDuRisque "Avec les glucocorticoïdes par voie IV : risque de myopathie sévère, réversible après un délai éventuellement long (plusieurs mois)."@fr;
  rdfs:comment """Une interaction entre l'hydrocortisone et les curares non dépolarisants a été retenue en raison de l’existence de plusieurs cas de myopathie aiguë avec l’utilisation de corticoïdes injectables.
La Myopathie Aiguë de Réanimation (MAR) est une atteinte musc"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610194, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610188 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610189 .

_:807f36cf91fe4e8caa53aadeff92477610189 rdf:first _:807f36cf91fe4e8caa53aadeff92477610190;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610191 .

_:807f36cf91fe4e8caa53aadeff92477610190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10058 .

_:807f36cf91fe4e8caa53aadeff92477610191 rdf:first _:807f36cf91fe4e8caa53aadeff92477610192;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477610194 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10664-1 a owl:Class;
  rdfs:label "CLOPIDOGREL <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10664";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610196;
  r:natureDuRisque "Augmentation des concentrations du répaglinide par le clopidogrel, avec risque de majoration des effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610202, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610196 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610197 .

_:807f36cf91fe4e8caa53aadeff92477610197 rdf:first _:807f36cf91fe4e8caa53aadeff92477610198;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610199 .

_:807f36cf91fe4e8caa53aadeff92477610198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:807f36cf91fe4e8caa53aadeff92477610199 rdf:first _:807f36cf91fe4e8caa53aadeff92477610200;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:807f36cf91fe4e8caa53aadeff92477610202 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10558-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> PAROXETINE"@fr;
  dct:identifier "IAM_10558";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610204;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de carbamazépine et réduction éventuelle de la posologie de la carbamazépine pendant le traitement par l'antidépresseur sérotoninergique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610210, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610204 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610205 .

_:807f36cf91fe4e8caa53aadeff92477610205 rdf:first _:807f36cf91fe4e8caa53aadeff92477610206;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610207 .

_:807f36cf91fe4e8caa53aadeff92477610206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610207 rdf:first _:807f36cf91fe4e8caa53aadeff92477610208;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477610210 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10547-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10547";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610212;
  r:natureDuRisque "Pour des doses de fluconazole >= 200 mg par jour : augmentation possible des effets indésirables de la carbamazépine."@fr;
  r:conduiteATenir "Adapter la posologie de carbamazépine, pendant et après l’arrêt du traitement antifongique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610218, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610212 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610213 .

_:807f36cf91fe4e8caa53aadeff92477610213 rdf:first _:807f36cf91fe4e8caa53aadeff92477610214;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610215 .

_:807f36cf91fe4e8caa53aadeff92477610214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610215 rdf:first _:807f36cf91fe4e8caa53aadeff92477610216;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477610218 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10548-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> FLUOXETINE"@fr;
  dct:identifier "IAM_10548";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610220;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de carbamazépine et réduction éventuelle de la posologie de la carbamazépine pendant le traitement par l'antidépresseur sérotoninergique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610226, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610220 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610221 .

_:807f36cf91fe4e8caa53aadeff92477610221 rdf:first _:807f36cf91fe4e8caa53aadeff92477610222;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610223 .

_:807f36cf91fe4e8caa53aadeff92477610222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610223 rdf:first _:807f36cf91fe4e8caa53aadeff92477610224;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477610226 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10549-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> FLUVOXAMINE"@fr;
  dct:identifier "IAM_10549";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610228;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de carbamazépine et réduction éventuelle de la posologie de la carbamazépine pendant le traitement par l'antidépresseur sérotoninergique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610234, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610228 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610229 .

_:807f36cf91fe4e8caa53aadeff92477610229 rdf:first _:807f36cf91fe4e8caa53aadeff92477610230;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610231 .

_:807f36cf91fe4e8caa53aadeff92477610230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610231 rdf:first _:807f36cf91fe4e8caa53aadeff92477610232;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477610234 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10550-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> ISONIAZIDE"@fr;
  dct:identifier "IAM_10550";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610236;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage par inhibition de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610242, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610236 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610237 .

_:807f36cf91fe4e8caa53aadeff92477610237 rdf:first _:807f36cf91fe4e8caa53aadeff92477610238;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610239 .

_:807f36cf91fe4e8caa53aadeff92477610238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610239 rdf:first _:807f36cf91fe4e8caa53aadeff92477610240;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477610242 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10551-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_10551";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610244;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage, par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, dosage plasmatique et réduction éventuelle de la posologie de la carbamazépine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610250, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610244 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610245 .

_:807f36cf91fe4e8caa53aadeff92477610245 rdf:first _:807f36cf91fe4e8caa53aadeff92477610246;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610247 .

_:807f36cf91fe4e8caa53aadeff92477610246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610247 rdf:first _:807f36cf91fe4e8caa53aadeff92477610248;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477610250 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10552-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_10552";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610252;
  r:natureDuRisque "Risque d'augmentation des effets neurologiques (vertiges, ataxie, diplopie) de la carbamazépine lors de l'introduction de la lamotrigine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la carbamazépine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610258, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610252 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610253 .

_:807f36cf91fe4e8caa53aadeff92477610253 rdf:first _:807f36cf91fe4e8caa53aadeff92477610254;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610255 .

_:807f36cf91fe4e8caa53aadeff92477610254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610255 rdf:first _:807f36cf91fe4e8caa53aadeff92477610256;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:807f36cf91fe4e8caa53aadeff92477610258 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10553-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> LITHIUM"@fr;
  dct:identifier "IAM_10553";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610260;
  r:natureDuRisque "Risque de neurotoxicité se manifestant par des troubles cérébelleux, confusion, somnolence, ataxie. Ces troubles sont réversibles à l'arrêt du traitement par le lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610266, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610260 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610261 .

_:807f36cf91fe4e8caa53aadeff92477610261 rdf:first _:807f36cf91fe4e8caa53aadeff92477610262;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610263 .

_:807f36cf91fe4e8caa53aadeff92477610262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610263 rdf:first _:807f36cf91fe4e8caa53aadeff92477610264;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477610266 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10554-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10554";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610268;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques et de l'efficacité de la carbamazepine."@fr;
  rdfs:comment "Bien qu'une étude d'interaction rigoureuse, menée sur des volontaires sains, n'ait pas mis en évidence de modification des paramètres pharmacocinétiques de la carbamazépine lorsque celle-ci était administrée conjointement au millepertuis, une association"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610274, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610268 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610269 .

_:807f36cf91fe4e8caa53aadeff92477610269 rdf:first _:807f36cf91fe4e8caa53aadeff92477610270;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610271 .

_:807f36cf91fe4e8caa53aadeff92477610270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610271 rdf:first _:807f36cf91fe4e8caa53aadeff92477610272;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477610274 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10555-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_10555";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610276;
  r:natureDuRisque "Diminution des concentrations plasmatiques du nintédanib par diminution de son absorption par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610282, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610276 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610277 .

_:807f36cf91fe4e8caa53aadeff92477610277 rdf:first _:807f36cf91fe4e8caa53aadeff92477610278;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610279 .

_:807f36cf91fe4e8caa53aadeff92477610278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610279 rdf:first _:807f36cf91fe4e8caa53aadeff92477610280;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477610282 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10608-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_10608";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610284;
  r:natureDuRisque "Diminution des concentrations sanguines de ciclosporine."@fr;
  r:conduiteATenir "Contrôle des concentrations sanguines de ciclosporine et adaptation éventuelle de sa posologie pendant le traitement par terbinafine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610290, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610284 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610285 .

_:807f36cf91fe4e8caa53aadeff92477610285 rdf:first _:807f36cf91fe4e8caa53aadeff92477610286;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610287 .

_:807f36cf91fe4e8caa53aadeff92477610286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610287 rdf:first _:807f36cf91fe4e8caa53aadeff92477610288;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477610290 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10557-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10557";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610292;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine, avec risque de surdosage, par inhibition de son métabolisme par le pamplemousse."@fr;
  rdfs:comment "Outre l’existence de 3 trois cas cliniques suggérant un risque de surdosage en carbamazépine lors de l’ingestion de jus de pamplemousse, une étude pharmacocinétique chez 10 patients a confirmé une augmentation des concentrations de carbamazépine après ing"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610298, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610292 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610293 .

_:807f36cf91fe4e8caa53aadeff92477610293 rdf:first _:807f36cf91fe4e8caa53aadeff92477610294;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610295 .

_:807f36cf91fe4e8caa53aadeff92477610294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477610295 rdf:first _:807f36cf91fe4e8caa53aadeff92477610296;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610298 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10544-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10544";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610300;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine, avec signes de surdosage, par inhibition de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610306, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610300 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610301 .

_:807f36cf91fe4e8caa53aadeff92477610301 rdf:first _:807f36cf91fe4e8caa53aadeff92477610302;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610303 .

_:807f36cf91fe4e8caa53aadeff92477610302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610303 rdf:first _:807f36cf91fe4e8caa53aadeff92477610304;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610304 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477610306 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10559-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_10559";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610308;
  r:natureDuRisque "Diminution progressive des concentrations plasmatiques de carbamazépine et de son métabolite actif sans modification apparente de l'efficacité anticomitiale."@fr;
  r:conduiteATenir "Prudence quant à l'interprétation des concentrations plasmatiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610314, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610308 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610309 .

_:807f36cf91fe4e8caa53aadeff92477610309 rdf:first _:807f36cf91fe4e8caa53aadeff92477610310;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610311 .

_:807f36cf91fe4e8caa53aadeff92477610310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477610311 rdf:first _:807f36cf91fe4e8caa53aadeff92477610312;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610312 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610314 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10560-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10560";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610316;
  r:natureDuRisque "Réduction réciproque des concentrations plasmatiques (augmentation du métabolisme sans modification apparente de l'efficacité anticomitiale)."@fr;
  r:conduiteATenir "Prudence dans l'interprétation des concentrations plasmatiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610322, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610316 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610317 .

_:807f36cf91fe4e8caa53aadeff92477610317 rdf:first _:807f36cf91fe4e8caa53aadeff92477610318;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610319 .

_:807f36cf91fe4e8caa53aadeff92477610318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477610319 rdf:first _:807f36cf91fe4e8caa53aadeff92477610320;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610322 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10561-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10561";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610324;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la carbamazépine par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques et adaptation de la posologie de la carbamazépine pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610330, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610324 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610325 .

_:807f36cf91fe4e8caa53aadeff92477610325 rdf:first _:807f36cf91fe4e8caa53aadeff92477610326;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610327 .

_:807f36cf91fe4e8caa53aadeff92477610326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610327 rdf:first _:807f36cf91fe4e8caa53aadeff92477610328;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610328 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477610330 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10562-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> RISPERIDONE"@fr;
  dct:identifier "IAM_10562";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610332;
  r:natureDuRisque "Risque de diminution de la fraction active de la rispéridone et de son efficacité thérapeutique par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, et si besoin, adaptation posologique de la rispéridone."@fr;
  rdfs:comment """La rispéridone est majoritairement métabolisée par le CYP2D6 en 9-OH-rispéridone, métabolite actif. La fraction pharmacologiquement active de la rispéridone est ainsi constituée par la molécule mère et son métabolite hydroxylé.
Dans un cas isolé non publi"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610338, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610332 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610333 .

_:807f36cf91fe4e8caa53aadeff92477610333 rdf:first _:807f36cf91fe4e8caa53aadeff92477610334;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610335 .

_:807f36cf91fe4e8caa53aadeff92477610334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610335 rdf:first _:807f36cf91fe4e8caa53aadeff92477610336;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10805 .

_:807f36cf91fe4e8caa53aadeff92477610338 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10563-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10563";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610340;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de simvastatine, par augmentation de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610346, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610340 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610341 .

_:807f36cf91fe4e8caa53aadeff92477610341 rdf:first _:807f36cf91fe4e8caa53aadeff92477610342;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610343 .

_:807f36cf91fe4e8caa53aadeff92477610342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610343 rdf:first _:807f36cf91fe4e8caa53aadeff92477610344;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477610346 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10564-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> TOPIRAMATE"@fr;
  dct:identifier "IAM_10564";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610348;
  r:natureDuRisque "Diminution des concentrations du topiramate avec risque de moindre efficacité, par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, et si besoin, adaptation posologique du topiramate pendant le traitement par la carbamazépine et après son arrêt."@fr;
  rdfs:comment "Les concentrations du topiramate ont diminué de moitié environ en association avec la carbamazépine, tant chez des patients que des volontaires sains. En revanche, le profil pharmacocinétique de la carbamazépine n’est pas modifié par le topiramate."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610354, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610348 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610349 .

_:807f36cf91fe4e8caa53aadeff92477610349 rdf:first _:807f36cf91fe4e8caa53aadeff92477610350;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610351 .

_:807f36cf91fe4e8caa53aadeff92477610350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610351 rdf:first _:807f36cf91fe4e8caa53aadeff92477610352;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610352 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:807f36cf91fe4e8caa53aadeff92477610354 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10565-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_10565";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610356;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du métabolite actif de la carbamazépine avec signes de surdosage. De plus, diminution des concentrations plasmatiques d'acide valproïque par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, dosages plasmatiques et adaptation de la posologie des deux anticonvulsivants."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610362, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610356 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610357 .

_:807f36cf91fe4e8caa53aadeff92477610357 rdf:first _:807f36cf91fe4e8caa53aadeff92477610358;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610359 .

_:807f36cf91fe4e8caa53aadeff92477610358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477610359 rdf:first _:807f36cf91fe4e8caa53aadeff92477610360;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610360 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610362 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10566-1 a owl:Class;
  rdfs:label "CARMUSTINE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10566";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610364;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : toxicité médullaire accrue (inhibition du métabolisme de la carmustine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610370, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610364 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610365 .

_:807f36cf91fe4e8caa53aadeff92477610365 rdf:first _:807f36cf91fe4e8caa53aadeff92477610366;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610367 .

_:807f36cf91fe4e8caa53aadeff92477610366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477610367 rdf:first _:807f36cf91fe4e8caa53aadeff92477610368;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610368 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477610370 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10567-1 a owl:Class;
  rdfs:label "CARVEDILOL <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10567";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610372;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations du carvédilol, pouvant être préjudiciables dans le cas du traitement de l'insuffisance cardiaque, par diminution de son métabolisme hépatique par la"@fr;
  r:conduiteATenir "Utiliser un autre antisécrétoire gastrique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610378, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610372 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610373 .

_:807f36cf91fe4e8caa53aadeff92477610373 rdf:first _:807f36cf91fe4e8caa53aadeff92477610374;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610375 .

_:807f36cf91fe4e8caa53aadeff92477610374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10163 .

_:807f36cf91fe4e8caa53aadeff92477610375 rdf:first _:807f36cf91fe4e8caa53aadeff92477610376;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610376 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477610378 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10556-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> OLANZAPINE"@fr;
  dct:identifier "IAM_10556";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610380;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'olanzapine et de son efficacité thérapeutique, par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, et si besoin, adaptation posologique de l'olanzapine."@fr;
  rdfs:comment """Plusieurs publications chez des volontaires sains ou des patients montrent que les concentrations plasmatiques de l’olanzapine sont diminuées de plus de la moitié lors de son association avec la carbamazépine, inducteur puissant des CYP3A4 et CYP1A2. 
L’o"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610386, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610380 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610381 .

_:807f36cf91fe4e8caa53aadeff92477610381 rdf:first _:807f36cf91fe4e8caa53aadeff92477610382;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610383 .

_:807f36cf91fe4e8caa53aadeff92477610382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610383 rdf:first _:807f36cf91fe4e8caa53aadeff92477610384;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10658 .

_:807f36cf91fe4e8caa53aadeff92477610386 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10534-1 a owl:Class;
  rdfs:label "CALCIUM <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10534";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610388;
  r:natureDuRisque "Diminution de l’absorption des hormones thyroïdiennes."@fr;
  r:conduiteATenir "Prendre les sels de calcium à distance des hormones thyroïdiennes (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610394, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610388 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610389 .

_:807f36cf91fe4e8caa53aadeff92477610389 rdf:first _:807f36cf91fe4e8caa53aadeff92477610390;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610391 .

_:807f36cf91fe4e8caa53aadeff92477610390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477610391 rdf:first _:807f36cf91fe4e8caa53aadeff92477610392;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477610394 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10523-1 a owl:Class;
  rdfs:label "CAFEINE <-> ENOXACINE"@fr;
  dct:identifier "IAM_10523";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610396;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de caféine, pouvant entraîner excitations et hallucinations, par diminution de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610402, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610396 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610397 .

_:807f36cf91fe4e8caa53aadeff92477610397 rdf:first _:807f36cf91fe4e8caa53aadeff92477610398;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610399 .

_:807f36cf91fe4e8caa53aadeff92477610398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477610399 rdf:first _:807f36cf91fe4e8caa53aadeff92477610400;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10323 .

_:807f36cf91fe4e8caa53aadeff92477610402 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10524-1 a owl:Class;
  rdfs:label "CAFEINE <-> LITHIUM"@fr;
  dct:identifier "IAM_10524";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610404;
  r:natureDuRisque "En cas d’arrêt brutal de la consommation de café ou de médicaments contenant de la caféine, risque d’augmentation de la lithémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610410, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610404 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610405 .

_:807f36cf91fe4e8caa53aadeff92477610405 rdf:first _:807f36cf91fe4e8caa53aadeff92477610406;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610407 .

_:807f36cf91fe4e8caa53aadeff92477610406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477610407 rdf:first _:807f36cf91fe4e8caa53aadeff92477610408;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610408 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477610410 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10525-1 a owl:Class;
  rdfs:label "CAFEINE <-> MEXILETINE"@fr;
  dct:identifier "IAM_10525";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610412;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de caféine, par inhibition de son métabolisme hépatique par la méxilétine."@fr;
  rdfs:comment "La caféine est métabolisée par le CYP1A2 et des cas d’intoxication par inhibition de son métabolisme ont été antérieurement décrits avec l’idrocilamide ou la ciprofloxacine. Pour cette dernière, déjà retenue au niveau \"à prendre en compte\", la diminution"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610418, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610412 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610413 .

_:807f36cf91fe4e8caa53aadeff92477610413 rdf:first _:807f36cf91fe4e8caa53aadeff92477610414;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610415 .

_:807f36cf91fe4e8caa53aadeff92477610414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477610415 rdf:first _:807f36cf91fe4e8caa53aadeff92477610416;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610416 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10582 .

_:807f36cf91fe4e8caa53aadeff92477610418 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10526-1 a owl:Class;
  rdfs:label "CAFEINE <-> NORFLOXACINE"@fr;
  dct:identifier "IAM_10526";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610420;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de caféine, par diminution du métabolisme hépatique de la caféine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610426, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610420 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610421 .

_:807f36cf91fe4e8caa53aadeff92477610421 rdf:first _:807f36cf91fe4e8caa53aadeff92477610422;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610423 .

_:807f36cf91fe4e8caa53aadeff92477610422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477610423 rdf:first _:807f36cf91fe4e8caa53aadeff92477610424;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610424 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10650 .

_:807f36cf91fe4e8caa53aadeff92477610426 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10527-1 a owl:Class;
  rdfs:label "CAFEINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10527";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610428;
  r:natureDuRisque "Augmentation possible des concentrations plasmatiques de la caféine, avec risque de surdosage, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de caféine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610434, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610428 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610429 .

_:807f36cf91fe4e8caa53aadeff92477610429 rdf:first _:807f36cf91fe4e8caa53aadeff92477610430;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610431 .

_:807f36cf91fe4e8caa53aadeff92477610430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477610431 rdf:first _:807f36cf91fe4e8caa53aadeff92477610432;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610432 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477610434 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10528-1 a owl:Class;
  rdfs:label "CALCITONINE <-> LITHIUM"@fr;
  dct:identifier "IAM_10528";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610436;
  r:natureDuRisque "Risque de baisse de l’efficacité du lithium par augmentation de son élimination rénale par la calcitonine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610442, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610436 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610437 .

_:807f36cf91fe4e8caa53aadeff92477610437 rdf:first _:807f36cf91fe4e8caa53aadeff92477610438;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610439 .

_:807f36cf91fe4e8caa53aadeff92477610438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10148 .

_:807f36cf91fe4e8caa53aadeff92477610439 rdf:first _:807f36cf91fe4e8caa53aadeff92477610440;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610440 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477610442 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10529-1 a owl:Class;
  rdfs:label "CALCIUM <-> CYCLINES"@fr;
  dct:identifier "IAM_10529";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610444;
  r:natureDuRisque "Diminution de l'absorption digestive des cyclines."@fr;
  r:conduiteATenir "Prendre les sels de calcium à distance des cyclines (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610450, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610444 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610445 .

_:807f36cf91fe4e8caa53aadeff92477610445 rdf:first _:807f36cf91fe4e8caa53aadeff92477610446;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610447 .

_:807f36cf91fe4e8caa53aadeff92477610446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10059 .

_:807f36cf91fe4e8caa53aadeff92477610447 rdf:first _:807f36cf91fe4e8caa53aadeff92477610448;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610448 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477610450 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10530-1 a owl:Class;
  rdfs:label "CALCIUM <-> DIGOXINE"@fr;
  dct:identifier "IAM_10530";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610452;
  r:natureDuRisque "Risque de troubles du rythme graves, voire mortels avec les sels de calcium administrés par voie IV."@fr;
  r:conduiteATenir """Contre-indication :
- avec les sels de calcium IV, hormis supplémentation parentérale.

Précaution d'emploi :
- avec les sels de calcium par voie orale.
Surveillance clinique et, s'il y a lieu, contrôle de l'ECG et de la calcémie."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610458, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610452 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610453 .

_:807f36cf91fe4e8caa53aadeff92477610453 rdf:first _:807f36cf91fe4e8caa53aadeff92477610454;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610455 .

_:807f36cf91fe4e8caa53aadeff92477610454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477610455 rdf:first _:807f36cf91fe4e8caa53aadeff92477610456;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610456 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477610458 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10531-1 a owl:Class;
  rdfs:label "CALCIUM <-> DIURÉTIQUES THIAZIDIQUES ET APPARENTÉS"@fr;
  dct:identifier "IAM_10531";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610460;
  r:natureDuRisque "Risque d'hypercalcémie par diminution de l'élimination urinaire du calcium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610466, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610460 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610461 .

_:807f36cf91fe4e8caa53aadeff92477610461 rdf:first _:807f36cf91fe4e8caa53aadeff92477610462;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610463 .

_:807f36cf91fe4e8caa53aadeff92477610462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477610463 rdf:first _:807f36cf91fe4e8caa53aadeff92477610464;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610464 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477610466 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10546-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> FELBAMATE"@fr;
  dct:identifier "IAM_10546";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610468;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du métabolite actif de la carbamazépine. De plus, diminution des concentrations plasmatiques de felbamate par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, dosages plasmatiques et adaptation éventuelle des posologies des deux anticonvulsivants."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610474, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610468 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610469 .

_:807f36cf91fe4e8caa53aadeff92477610469 rdf:first _:807f36cf91fe4e8caa53aadeff92477610470;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610471 .

_:807f36cf91fe4e8caa53aadeff92477610470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610471 rdf:first _:807f36cf91fe4e8caa53aadeff92477610472;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610472 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10369 .

_:807f36cf91fe4e8caa53aadeff92477610474 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10533-1 a owl:Class;
  rdfs:label "CALCIUM <-> FER"@fr;
  dct:identifier "IAM_10533";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610476;
  r:natureDuRisque "Avec les sels de fer par voie orale : diminution de l'absorption digestive des sels de fer."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance des repas et en l'absence de calcium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610482, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610476 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610477 .

_:807f36cf91fe4e8caa53aadeff92477610477 rdf:first _:807f36cf91fe4e8caa53aadeff92477610478;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610479 .

_:807f36cf91fe4e8caa53aadeff92477610478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477610479 rdf:first _:807f36cf91fe4e8caa53aadeff92477610480;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610480 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477610482 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10545-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> ETHOSUXIMIDE"@fr;
  dct:identifier "IAM_10545";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610484;
  r:natureDuRisque "Diminution des concentrations plasmatiques d'éthosuximide."@fr;
  r:conduiteATenir "Surveillance clinique, dosage plasmatique de l'éthosuximide et augmentation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610490, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610484 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610485 .

_:807f36cf91fe4e8caa53aadeff92477610485 rdf:first _:807f36cf91fe4e8caa53aadeff92477610486;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610487 .

_:807f36cf91fe4e8caa53aadeff92477610486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610487 rdf:first _:807f36cf91fe4e8caa53aadeff92477610488;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10352 .

_:807f36cf91fe4e8caa53aadeff92477610490 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10535-1 a owl:Class;
  rdfs:label "CALCIUM <-> STRONTIUM"@fr;
  dct:identifier "IAM_10535";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610492;
  r:natureDuRisque "Avec les sels de calcium administrés par voie orale : diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des sels de calcium (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610498, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610492 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610493 .

_:807f36cf91fe4e8caa53aadeff92477610493 rdf:first _:807f36cf91fe4e8caa53aadeff92477610494;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610495 .

_:807f36cf91fe4e8caa53aadeff92477610494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477610495 rdf:first _:807f36cf91fe4e8caa53aadeff92477610496;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:807f36cf91fe4e8caa53aadeff92477610498 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10536-1 a owl:Class;
  rdfs:label "CALCIUM <-> ZINC"@fr;
  dct:identifier "IAM_10536";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610500;
  r:natureDuRisque "Diminution de l’absorption digestive du zinc par le calcium."@fr;
  r:conduiteATenir "Prendre les sels de calcium à distance du zinc (plus de 2 heures si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610506, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610500 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610501 .

_:807f36cf91fe4e8caa53aadeff92477610501 rdf:first _:807f36cf91fe4e8caa53aadeff92477610502;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610503 .

_:807f36cf91fe4e8caa53aadeff92477610502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477610503 rdf:first _:807f36cf91fe4e8caa53aadeff92477610504;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:807f36cf91fe4e8caa53aadeff92477610506 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10537-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10537";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610508;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : en début de traitement, augmentation des concentrations plasmatiques de carbamazépine par inhibition de son métabolisme hépatique par la cimétidine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la carbamazépine, spécialement pendant les premiers jours de traitement par la cimétidine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610514, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610508 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610509 .

_:807f36cf91fe4e8caa53aadeff92477610509 rdf:first _:807f36cf91fe4e8caa53aadeff92477610510;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610511 .

_:807f36cf91fe4e8caa53aadeff92477610510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610511 rdf:first _:807f36cf91fe4e8caa53aadeff92477610512;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477610514 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10538-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> CLARITHROMYCINE"@fr;
  dct:identifier "IAM_10538";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610516;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la carbamazépine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610522, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610516 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610517 .

_:807f36cf91fe4e8caa53aadeff92477610517 rdf:first _:807f36cf91fe4e8caa53aadeff92477610518;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610519 .

_:807f36cf91fe4e8caa53aadeff92477610518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610519 rdf:first _:807f36cf91fe4e8caa53aadeff92477610520;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10206 .

_:807f36cf91fe4e8caa53aadeff92477610522 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10539-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> CLONAZEPAM"@fr;
  dct:identifier "IAM_10539";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610524;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du métabolite actif de la carbamazépine. De plus, diminution des concentrations plasmatiques du clonazépam par augmentation de son métabolisme hépatique par la carbamazépine."@fr;
  r:conduiteATenir "Surveillance clinique, dosages plasmatiques et adaptation éventuelle des posologies des deux anticonvulsivants."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610530, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610524 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610525 .

_:807f36cf91fe4e8caa53aadeff92477610525 rdf:first _:807f36cf91fe4e8caa53aadeff92477610526;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610527 .

_:807f36cf91fe4e8caa53aadeff92477610526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610527 rdf:first _:807f36cf91fe4e8caa53aadeff92477610528;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10213 .

_:807f36cf91fe4e8caa53aadeff92477610530 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10540-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> CLOZAPINE"@fr;
  dct:identifier "IAM_10540";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610532;
  r:natureDuRisque "Risque de majoration des effets hématologiques graves."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610538, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610532 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610533 .

_:807f36cf91fe4e8caa53aadeff92477610533 rdf:first _:807f36cf91fe4e8caa53aadeff92477610534;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610535 .

_:807f36cf91fe4e8caa53aadeff92477610534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610535 rdf:first _:807f36cf91fe4e8caa53aadeff92477610536;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10220 .

_:807f36cf91fe4e8caa53aadeff92477610538 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10541-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> DANAZOL"@fr;
  dct:identifier "IAM_10541";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610540;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine, avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la carbamazépine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610546, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610540 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610541 .

_:807f36cf91fe4e8caa53aadeff92477610541 rdf:first _:807f36cf91fe4e8caa53aadeff92477610542;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610543 .

_:807f36cf91fe4e8caa53aadeff92477610542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610543 rdf:first _:807f36cf91fe4e8caa53aadeff92477610544;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:807f36cf91fe4e8caa53aadeff92477610546 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10542-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10542";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610548;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine et diminution de la digoxinémie."@fr;
  r:conduiteATenir "Prudence dans l'interprétation des concentrations plasmatiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610554, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610548 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610549 .

_:807f36cf91fe4e8caa53aadeff92477610549 rdf:first _:807f36cf91fe4e8caa53aadeff92477610550;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610551 .

_:807f36cf91fe4e8caa53aadeff92477610550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610551 rdf:first _:807f36cf91fe4e8caa53aadeff92477610552;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477610554 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10543-1 a owl:Class;
  rdfs:label "CARBAMAZEPINE <-> DIURÉTIQUES HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10543";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610556;
  r:natureDuRisque "Risque d'hyponatrémie symptomatique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique. Si possible, utiliser une autre classe de diurétiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610562, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610556 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610557 .

_:807f36cf91fe4e8caa53aadeff92477610557 rdf:first _:807f36cf91fe4e8caa53aadeff92477610558;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610559 .

_:807f36cf91fe4e8caa53aadeff92477610558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:807f36cf91fe4e8caa53aadeff92477610559 rdf:first _:807f36cf91fe4e8caa53aadeff92477610560;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477610562 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10570-1 a owl:Class;
  rdfs:label "CATIORESINE SULFO SODIQUE <-> SORBITOL"@fr;
  dct:identifier "IAM_10570";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610564;
  r:natureDuRisque "Avec la résine administrée par voie orale et rectale : risque de nécrose colique, éventuellement fatale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610570, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610564 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610565 .

_:807f36cf91fe4e8caa53aadeff92477610565 rdf:first _:807f36cf91fe4e8caa53aadeff92477610566;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610567 .

_:807f36cf91fe4e8caa53aadeff92477610566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10167 .

_:807f36cf91fe4e8caa53aadeff92477610567 rdf:first _:807f36cf91fe4e8caa53aadeff92477610568;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10853 .

_:807f36cf91fe4e8caa53aadeff92477610570 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10532-1 a owl:Class;
  rdfs:label "CALCIUM <-> ESTRAMUSTINE"@fr;
  dct:identifier "IAM_10532";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610572;
  r:natureDuRisque "Diminution de l'absorption digestive de l'estramustine."@fr;
  r:conduiteATenir "Prendre les sels de calcium à distance de l'estramustine (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610578, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610572 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610573 .

_:807f36cf91fe4e8caa53aadeff92477610573 rdf:first _:807f36cf91fe4e8caa53aadeff92477610574;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610575 .

_:807f36cf91fe4e8caa53aadeff92477610574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477610575 rdf:first _:807f36cf91fe4e8caa53aadeff92477610576;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10345 .

_:807f36cf91fe4e8caa53aadeff92477610578 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10595-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> NIFEDIPINE"@fr;
  dct:identifier "IAM_10595";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610580;
  r:natureDuRisque "Risque d'addition d'effets indésirables à type de gingivopathies."@fr;
  r:conduiteATenir "Utiliser une autre dihydropyridine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610586, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610580 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610581 .

_:807f36cf91fe4e8caa53aadeff92477610581 rdf:first _:807f36cf91fe4e8caa53aadeff92477610582;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610583 .

_:807f36cf91fe4e8caa53aadeff92477610582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610583 rdf:first _:807f36cf91fe4e8caa53aadeff92477610584;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610584 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10633 .

_:807f36cf91fe4e8caa53aadeff92477610586 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10568-1 a owl:Class;
  rdfs:label "CARVEDILOL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10568";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610588;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques du carvédilol, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique régulière et adaptation de la posologie du carvédilol pendant le traitement par la rifampicine. A l'arrêt de la rifampicine, risque de remontée importante des concentrations plasmatiques de carvédilol imposant une réduction posologiq"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610594, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610588 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610589 .

_:807f36cf91fe4e8caa53aadeff92477610589 rdf:first _:807f36cf91fe4e8caa53aadeff92477610590;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610591 .

_:807f36cf91fe4e8caa53aadeff92477610590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10163 .

_:807f36cf91fe4e8caa53aadeff92477610591 rdf:first _:807f36cf91fe4e8caa53aadeff92477610592;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610592 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477610594 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11038-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> INHIBITEURS DE LA CATÉCHOL-O-MÉTHYLTRANSFÉRASE (COMT)"@fr;
  dct:identifier "IAM_11038";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610596;
  r:natureDuRisque "Potentialisation des effets pharmacologiques, et notamment vasopresseurs, des catécholamines par inhibition conjuguée de leur métabolisme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610602, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610596 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610597 .

_:807f36cf91fe4e8caa53aadeff92477610597 rdf:first _:807f36cf91fe4e8caa53aadeff92477610598;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610599 .

_:807f36cf91fe4e8caa53aadeff92477610598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477610599 rdf:first _:807f36cf91fe4e8caa53aadeff92477610600;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610600 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10097 .

_:807f36cf91fe4e8caa53aadeff92477610602 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11039-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_11039";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610604;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  r:conduiteATenir "Respecter un délai de deux semaines entre l'arrêt de l'IMAO et le début du traitement par l'antidépresseur sérotoninergique, et d'au moins une semaine entre l'arrêt de l'antidépresseur sérotoninergique (sauf pour la fluoxétine : cinq semaines) et le début"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610610, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610604 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610605 .

_:807f36cf91fe4e8caa53aadeff92477610605 rdf:first _:807f36cf91fe4e8caa53aadeff92477610606;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610607 .

_:807f36cf91fe4e8caa53aadeff92477610606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477610607 rdf:first _:807f36cf91fe4e8caa53aadeff92477610608;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610608 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477610610 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11040-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES"@fr;
  dct:identifier "IAM_11040";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610612;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  r:conduiteATenir "Respecter un délai de deux semaines entre l'arrêt de l'IMAO et le début de l'autre traitement, et d'au moins une semaine entre l'arrêt de l'autre traitement et le début de l'IMAO."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610618, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610612 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610613 .

_:807f36cf91fe4e8caa53aadeff92477610613 rdf:first _:807f36cf91fe4e8caa53aadeff92477610614;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610615 .

_:807f36cf91fe4e8caa53aadeff92477610614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477610615 rdf:first _:807f36cf91fe4e8caa53aadeff92477610616;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:807f36cf91fe4e8caa53aadeff92477610618 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11041-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> MIDODRINE"@fr;
  dct:identifier "IAM_11041";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610620;
  r:natureDuRisque "Crises hypertensives (inhibition du métabolisme des amines pressives). Du fait de la durée d'action des IMAO, cette interaction est encore possible 15 jours après l'arrêt de l'IMAO."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610626, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610620 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610621 .

_:807f36cf91fe4e8caa53aadeff92477610621 rdf:first _:807f36cf91fe4e8caa53aadeff92477610622;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610623 .

_:807f36cf91fe4e8caa53aadeff92477610622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477610623 rdf:first _:807f36cf91fe4e8caa53aadeff92477610624;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10587 .

_:807f36cf91fe4e8caa53aadeff92477610626 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10589-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_10589";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610628;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt du macrolide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610634, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610628 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610629 .

_:807f36cf91fe4e8caa53aadeff92477610629 rdf:first _:807f36cf91fe4e8caa53aadeff92477610630;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610631 .

_:807f36cf91fe4e8caa53aadeff92477610630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610631 rdf:first _:807f36cf91fe4e8caa53aadeff92477610632;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477610634 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10590-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> LERCANIDIPINE"@fr;
  dct:identifier "IAM_10590";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610636;
  r:natureDuRisque "Augmentation modérée des concentrations sanguines de l'immunosuppresseur et augmentation plus notable des concentrations de lercanidipine."@fr;
  r:conduiteATenir "Décaler les prises des deux médicaments. Dosage des concentrations sanguines de l'immunosuppresseur, et adaptation si nécessaire de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610642, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610636 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610637 .

_:807f36cf91fe4e8caa53aadeff92477610637 rdf:first _:807f36cf91fe4e8caa53aadeff92477610638;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610639 .

_:807f36cf91fe4e8caa53aadeff92477610638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610639 rdf:first _:807f36cf91fe4e8caa53aadeff92477610640;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10514 .

_:807f36cf91fe4e8caa53aadeff92477610642 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10591-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10591";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610644;
  r:natureDuRisque "Augmentation de la toxicité du méthotrexate et de la ciclosporine avec augmentation de la créatininémie : diminution réciproque des clairances des deux médicaments."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de ciclosporine et de méthotrexate. Adaptation posologique si nécessaire pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610650, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610644 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610645 .

_:807f36cf91fe4e8caa53aadeff92477610645 rdf:first _:807f36cf91fe4e8caa53aadeff92477610646;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610647 .

_:807f36cf91fe4e8caa53aadeff92477610646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610647 rdf:first _:807f36cf91fe4e8caa53aadeff92477610648;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477610650 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10592-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> METHYLPREDNISOLONE"@fr;
  dct:identifier "IAM_10592";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610652;
  r:natureDuRisque "Avec la méthylprednisolone administrée par voie IV : augmentation possible des concentrations sanguines de ciclosporine et de la créatininémie. Mécanisme invoqué : diminution de l'élimination hépatique de la ciclosporine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610658, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610652 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610653 .

_:807f36cf91fe4e8caa53aadeff92477610653 rdf:first _:807f36cf91fe4e8caa53aadeff92477610654;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610655 .

_:807f36cf91fe4e8caa53aadeff92477610654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610655 rdf:first _:807f36cf91fe4e8caa53aadeff92477610656;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10576 .

_:807f36cf91fe4e8caa53aadeff92477610658 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11037-1 a owl:Class;
  rdfs:label "IFOSFAMIDE <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_11037";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610660;
  r:natureDuRisque "Risque de diminution des concentrations de l'ifosfamide, avec augmentation de son métabolite actif et toxicité majorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610666, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610660 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610661 .

_:807f36cf91fe4e8caa53aadeff92477610661 rdf:first _:807f36cf91fe4e8caa53aadeff92477610662;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610663 .

_:807f36cf91fe4e8caa53aadeff92477610662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10445 .

_:807f36cf91fe4e8caa53aadeff92477610663 rdf:first _:807f36cf91fe4e8caa53aadeff92477610664;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:807f36cf91fe4e8caa53aadeff92477610666 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10594-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> MODAFINIL"@fr;
  dct:identifier "IAM_10594";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610668;
  r:natureDuRisque "Risque de diminution des concentrations sanguines et de l'efficacité de l'immunosuppresseur."@fr;
  rdfs:comment "L’existence d’un seul cas de baisse des concentrations plasmatiques de ciclosporine, lors de l’association à du modafinil, s’explique vraisemblablement par l'indication restreinte du modafinil et son usage limité. Dans la mesure où toute suspicion d’induc"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610674, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610668 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610669 .

_:807f36cf91fe4e8caa53aadeff92477610669 rdf:first _:807f36cf91fe4e8caa53aadeff92477610670;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610671 .

_:807f36cf91fe4e8caa53aadeff92477610670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610671 rdf:first _:807f36cf91fe4e8caa53aadeff92477610672;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10599 .

_:807f36cf91fe4e8caa53aadeff92477610674 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11036-1 a owl:Class;
  rdfs:label "IFOSFAMIDE <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_11036";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610676;
  r:natureDuRisque "Risque de majoration de la neurotoxicité de l'ifosfamide par augmentation de son métabolisme hépatique par le phénobarbital."@fr;
  rdfs:comment """L'association entre les cytotoxiques et la phénytoïne, qui faisait l'objet d'un double niveau de contrainte, a été harmonisée en une seule association déconseillée. 
Cette modification s'applique de la même façon à l'interaction entre le phénobarbital et"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610682, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610676 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610677 .

_:807f36cf91fe4e8caa53aadeff92477610677 rdf:first _:807f36cf91fe4e8caa53aadeff92477610678;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610679 .

_:807f36cf91fe4e8caa53aadeff92477610678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477610679 rdf:first _:807f36cf91fe4e8caa53aadeff92477610680;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10445 .

_:807f36cf91fe4e8caa53aadeff92477610682 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10596-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_10596";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610684;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par la ciclosporine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610690, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610684 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610685 .

_:807f36cf91fe4e8caa53aadeff92477610685 rdf:first _:807f36cf91fe4e8caa53aadeff92477610686;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610687 .

_:807f36cf91fe4e8caa53aadeff92477610686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610687 rdf:first _:807f36cf91fe4e8caa53aadeff92477610688;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477610690 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10597-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> ORLISTAT"@fr;
  dct:identifier "IAM_10597";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610692;
  r:natureDuRisque "Diminution des concentrations sanguines de ciclosporine par diminution de son absorption intestinale, avec risque de perte de l'activité immunosuppressive."@fr;
  r:conduiteATenir "Prendre l'orlistat à distance de la ciclosporine (au moins 3 heures). Contrôle renforcé des dosages sanguins de ciclosporine, notamment en début d’association, et lors d’augmentation éventuelle de la posologie de l’orlistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610698, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610692 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610693 .

_:807f36cf91fe4e8caa53aadeff92477610693 rdf:first _:807f36cf91fe4e8caa53aadeff92477610694;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610695 .

_:807f36cf91fe4e8caa53aadeff92477610694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610695 rdf:first _:807f36cf91fe4e8caa53aadeff92477610696;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477610698 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10598-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> PITAVASTATINE"@fr;
  dct:identifier "IAM_10598";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610700;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, ou de néphrotoxicité, par diminution du métabolisme de la pitavastatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610706, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610700 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610701 .

_:807f36cf91fe4e8caa53aadeff92477610701 rdf:first _:807f36cf91fe4e8caa53aadeff92477610702;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610703 .

_:807f36cf91fe4e8caa53aadeff92477610702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610703 rdf:first _:807f36cf91fe4e8caa53aadeff92477610704;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10735 .

_:807f36cf91fe4e8caa53aadeff92477610706 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10599-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> POTASSIUM"@fr;
  dct:identifier "IAM_10599";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610708;
  r:natureDuRisque "Hyperkaliémie essentiellement létale, surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Eviter cette association sauf s'il existe une hypokaliémie préalable."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610714, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610708 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610709 .

_:807f36cf91fe4e8caa53aadeff92477610709 rdf:first _:807f36cf91fe4e8caa53aadeff92477610710;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610711 .

_:807f36cf91fe4e8caa53aadeff92477610710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610711 rdf:first _:807f36cf91fe4e8caa53aadeff92477610712;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:807f36cf91fe4e8caa53aadeff92477610714 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10600-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> PREDNISOLONE"@fr;
  dct:identifier "IAM_10600";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610716;
  r:natureDuRisque "Augmentation des effets de la prednisolone : aspect cushingoïde, réduction de la tolérance aux glucides (diminution de la clairance de la prednisolone)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610722, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610716 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610717 .

_:807f36cf91fe4e8caa53aadeff92477610717 rdf:first _:807f36cf91fe4e8caa53aadeff92477610718;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610719 .

_:807f36cf91fe4e8caa53aadeff92477610718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610719 rdf:first _:807f36cf91fe4e8caa53aadeff92477610720;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10752 .

_:807f36cf91fe4e8caa53aadeff92477610722 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10601-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10601";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610724;
  r:natureDuRisque "Augmentation de plus du double des concentrations du répaglinide par augmentation de son absorption."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610730, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610724 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610725 .

_:807f36cf91fe4e8caa53aadeff92477610725 rdf:first _:807f36cf91fe4e8caa53aadeff92477610726;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610727 .

_:807f36cf91fe4e8caa53aadeff92477610726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610727 rdf:first _:807f36cf91fe4e8caa53aadeff92477610728;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:807f36cf91fe4e8caa53aadeff92477610730 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10602-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> ROSUVASTATINE"@fr;
  dct:identifier "IAM_10602";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610732;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, ou de néphrotoxicité, par diminution du métabolisme de la rosuvastatine."@fr;
  rdfs:comment "La ciclosporine entraîne un doublement des concentrations de l'hypolipémiant. La rosuvastatine ayant une marge thérapeutique étroite et exposant à un risque musculaire et rénal imprévisible, cette association est contre-indiquée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610738, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610732 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610733 .

_:807f36cf91fe4e8caa53aadeff92477610733 rdf:first _:807f36cf91fe4e8caa53aadeff92477610734;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610735 .

_:807f36cf91fe4e8caa53aadeff92477610734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610735 rdf:first _:807f36cf91fe4e8caa53aadeff92477610736;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10814 .

_:807f36cf91fe4e8caa53aadeff92477610738 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10603-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> ROXITHROMYCINE"@fr;
  dct:identifier "IAM_10603";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610740;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt du macrolide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610746, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610740 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610741 .

_:807f36cf91fe4e8caa53aadeff92477610741 rdf:first _:807f36cf91fe4e8caa53aadeff92477610742;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610743 .

_:807f36cf91fe4e8caa53aadeff92477610742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610743 rdf:first _:807f36cf91fe4e8caa53aadeff92477610744;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:807f36cf91fe4e8caa53aadeff92477610746 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10604-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10604";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610748;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par diminution du métabolisme de la simvastatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610754, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610748 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610749 .

_:807f36cf91fe4e8caa53aadeff92477610749 rdf:first _:807f36cf91fe4e8caa53aadeff92477610750;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610751 .

_:807f36cf91fe4e8caa53aadeff92477610750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610751 rdf:first _:807f36cf91fe4e8caa53aadeff92477610752;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477610754 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10605-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> SIROLIMUS"@fr;
  dct:identifier "IAM_10605";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610756;
  r:natureDuRisque "Augmentation des concentrations sanguines de sirolimus par la ciclosporine. La néphrotoxicité de la ciclosporine est également augmentée lors de l’association."@fr;
  r:conduiteATenir "Il est recommandé d’administrer le sirolimus 4 heures après la ciclosporine. Contrôle de la fonction rénale, pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610756 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610757 .

_:807f36cf91fe4e8caa53aadeff92477610757 rdf:first _:807f36cf91fe4e8caa53aadeff92477610758;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610759 .

_:807f36cf91fe4e8caa53aadeff92477610758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610759 rdf:first _:807f36cf91fe4e8caa53aadeff92477610760;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10839 .

_:807f36cf91fe4e8caa53aadeff92477610762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10593-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> MIDECAMYCINE"@fr;
  dct:identifier "IAM_10593";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610764;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de la ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt du macrolide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610765 .

_:807f36cf91fe4e8caa53aadeff92477610765 rdf:first _:807f36cf91fe4e8caa53aadeff92477610766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610767 .

_:807f36cf91fe4e8caa53aadeff92477610766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610767 rdf:first _:807f36cf91fe4e8caa53aadeff92477610768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10586 .

_:807f36cf91fe4e8caa53aadeff92477610770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11289-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_11289";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610772;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques d’éribuline par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610773 .

_:807f36cf91fe4e8caa53aadeff92477610773 rdf:first _:807f36cf91fe4e8caa53aadeff92477610774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610775 .

_:807f36cf91fe4e8caa53aadeff92477610774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:807f36cf91fe4e8caa53aadeff92477610775 rdf:first _:807f36cf91fe4e8caa53aadeff92477610776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477610778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10302-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_10302";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610780;
  r:natureDuRisque "Diminution des concentrations du lédipasvir en cas d’administration de l’inhibiteur de la pompe à protons avant le lédipasvir."@fr;
  r:conduiteATenir "Il est recommandé de prendre l'’inhibiteur de la pompe à protons et le lédipasvir simultanément."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610781 .

_:807f36cf91fe4e8caa53aadeff92477610781 rdf:first _:807f36cf91fe4e8caa53aadeff92477610782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610783 .

_:807f36cf91fe4e8caa53aadeff92477610782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477610783 rdf:first _:807f36cf91fe4e8caa53aadeff92477610784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477610786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10571-1 a owl:Class;
  rdfs:label "CHLORDIAZEPOXIDE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10571";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610788;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : risque accru de somnolence."@fr;
  r:conduiteATenir "Avertir les patients de l'augmentation du risque en cas de conduite automobile ou d'utilisation de machines."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610789 .

_:807f36cf91fe4e8caa53aadeff92477610789 rdf:first _:807f36cf91fe4e8caa53aadeff92477610790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610791 .

_:807f36cf91fe4e8caa53aadeff92477610790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10182 .

_:807f36cf91fe4e8caa53aadeff92477610791 rdf:first _:807f36cf91fe4e8caa53aadeff92477610792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477610794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10572-1 a owl:Class;
  rdfs:label "CHLOROQUINE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10572";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610796;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de ciclosporine et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après l'arrêt de la chloroquine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610797 .

_:807f36cf91fe4e8caa53aadeff92477610797 rdf:first _:807f36cf91fe4e8caa53aadeff92477610798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610799 .

_:807f36cf91fe4e8caa53aadeff92477610798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10184 .

_:807f36cf91fe4e8caa53aadeff92477610799 rdf:first _:807f36cf91fe4e8caa53aadeff92477610800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477610802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10573-1 a owl:Class;
  rdfs:label "CHLOROQUINE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10573";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610804;
  r:natureDuRisque "Ralentissement de l’élimination de la chloroquine et risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610805 .

_:807f36cf91fe4e8caa53aadeff92477610805 rdf:first _:807f36cf91fe4e8caa53aadeff92477610806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610807 .

_:807f36cf91fe4e8caa53aadeff92477610806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10184 .

_:807f36cf91fe4e8caa53aadeff92477610807 rdf:first _:807f36cf91fe4e8caa53aadeff92477610808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477610810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10574-1 a owl:Class;
  rdfs:label "CHLOROQUINE <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10574";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610812;
  r:natureDuRisque "Risque d’hypothyroïdie clinique chez les patients substitués par hormones thyroïdiennes."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie de l'hormone thyroïdienne pendant le traitement par l’antipaludique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610813 .

_:807f36cf91fe4e8caa53aadeff92477610813 rdf:first _:807f36cf91fe4e8caa53aadeff92477610814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610815 .

_:807f36cf91fe4e8caa53aadeff92477610814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477610815 rdf:first _:807f36cf91fe4e8caa53aadeff92477610816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10184 .

_:807f36cf91fe4e8caa53aadeff92477610818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10575-1 a owl:Class;
  rdfs:label "CHLORPROMAZINE <-> INSULINE"@fr;
  dct:identifier "IAM_10575";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610820;
  r:natureDuRisque "A fortes posologies (100 mg par jour de chlorpromazine) : élévation de la glycémie (diminution de la libération de l'insuline)."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer l'autosurveillance glycémique. Adapter éventuellement la posologie de l'insuline pendant le traitement par le neuroleptique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610821 .

_:807f36cf91fe4e8caa53aadeff92477610821 rdf:first _:807f36cf91fe4e8caa53aadeff92477610822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610823 .

_:807f36cf91fe4e8caa53aadeff92477610822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10186 .

_:807f36cf91fe4e8caa53aadeff92477610823 rdf:first _:807f36cf91fe4e8caa53aadeff92477610824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:807f36cf91fe4e8caa53aadeff92477610826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10576-1 a owl:Class;
  rdfs:label "CHLORPROMAZINE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10576";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610828;
  r:natureDuRisque "A fortes posologies (100 mg par jour de chlorpromazine) : élévation de la glycémie (diminution de la libération de l'insuline)."@fr;
  r:conduiteATenir "Prévenir le patient et renforcer l'autosurveillance glycémique. Adapter éventuellement la posologie du neuroleptique pendant le traitement et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610829 .

_:807f36cf91fe4e8caa53aadeff92477610829 rdf:first _:807f36cf91fe4e8caa53aadeff92477610830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610831 .

_:807f36cf91fe4e8caa53aadeff92477610830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477610831 rdf:first _:807f36cf91fe4e8caa53aadeff92477610832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10186 .

_:807f36cf91fe4e8caa53aadeff92477610834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10888-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> TRICLABENDAZOLE"@fr;
  dct:identifier "IAM_10888";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610836;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l’alcaloïde de l’ergot de seigle)."@fr;
  r:conduiteATenir "Respecter un délai de 24 heures entre l’arrêt du triclabendazole et l’ergotamine, et inversement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610837 .

_:807f36cf91fe4e8caa53aadeff92477610837 rdf:first _:807f36cf91fe4e8caa53aadeff92477610838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610839 .

_:807f36cf91fe4e8caa53aadeff92477610838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477610839 rdf:first _:807f36cf91fe4e8caa53aadeff92477610840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10953 .

_:807f36cf91fe4e8caa53aadeff92477610842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11461-1 a owl:Class;
  rdfs:label "VERAPAMIL <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_11461";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610844;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’éribuline par le vérapamil."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610845 .

_:807f36cf91fe4e8caa53aadeff92477610845 rdf:first _:807f36cf91fe4e8caa53aadeff92477610846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610847 .

_:807f36cf91fe4e8caa53aadeff92477610846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:807f36cf91fe4e8caa53aadeff92477610847 rdf:first _:807f36cf91fe4e8caa53aadeff92477610848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477610850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10077-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> IMAO IRRÉVERSIBLES"@fr;
  dct:identifier "IAM_10077";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610852;
  r:natureDuRisque "Majoration des effets hypertenseurs et/ou hyperthermiques de la tyramine présente dans certaines boissons alcoolisées (chianti, certaines bières, etc)."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610858, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610852 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610853 .

_:807f36cf91fe4e8caa53aadeff92477610853 rdf:first _:807f36cf91fe4e8caa53aadeff92477610854;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610855 .

_:807f36cf91fe4e8caa53aadeff92477610854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477610855 rdf:first _:807f36cf91fe4e8caa53aadeff92477610856;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477610858 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11124-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_11124";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610860;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’éribuline par le ritonavir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610860 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610861 .

_:807f36cf91fe4e8caa53aadeff92477610861 rdf:first _:807f36cf91fe4e8caa53aadeff92477610862;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610863 .

_:807f36cf91fe4e8caa53aadeff92477610862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477610863 rdf:first _:807f36cf91fe4e8caa53aadeff92477610864;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:807f36cf91fe4e8caa53aadeff92477610866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10569-1 a owl:Class;
  rdfs:label "CATIORESINE SULFO CALCIQUE <-> SORBITOL"@fr;
  dct:identifier "IAM_10569";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610868;
  r:natureDuRisque "Avec la résine administrée par voie orale et rectale : risque de nécrose colique, éventuellement fatale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610869 .

_:807f36cf91fe4e8caa53aadeff92477610869 rdf:first _:807f36cf91fe4e8caa53aadeff92477610870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610871 .

_:807f36cf91fe4e8caa53aadeff92477610870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10166 .

_:807f36cf91fe4e8caa53aadeff92477610871 rdf:first _:807f36cf91fe4e8caa53aadeff92477610872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10853 .

_:807f36cf91fe4e8caa53aadeff92477610874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10893-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_10893";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610876;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le torsadogène associé. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610877 .

_:807f36cf91fe4e8caa53aadeff92477610877 rdf:first _:807f36cf91fe4e8caa53aadeff92477610878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610879 .

_:807f36cf91fe4e8caa53aadeff92477610878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477610879 rdf:first _:807f36cf91fe4e8caa53aadeff92477610880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:807f36cf91fe4e8caa53aadeff92477610882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10901-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_10901";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610884;
  r:natureDuRisque "Risque de majoration de la toxicité de l'antimitotique par diminution de son métabolisme hépatique par l' érythromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique étroite. Eventuellement, utiliser un autre antibiotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610885 .

_:807f36cf91fe4e8caa53aadeff92477610885 rdf:first _:807f36cf91fe4e8caa53aadeff92477610886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610887 .

_:807f36cf91fe4e8caa53aadeff92477610886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477610887 rdf:first _:807f36cf91fe4e8caa53aadeff92477610888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477610890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10889-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10889";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610892;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610898, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610892 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610893 .

_:807f36cf91fe4e8caa53aadeff92477610893 rdf:first _:807f36cf91fe4e8caa53aadeff92477610894;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610895 .

_:807f36cf91fe4e8caa53aadeff92477610894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477610895 rdf:first _:807f36cf91fe4e8caa53aadeff92477610896;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:807f36cf91fe4e8caa53aadeff92477610898 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10890-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> GLIBENCLAMIDE"@fr;
  dct:identifier "IAM_10890";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610900;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation de l’absorption et des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par l’érythromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610906, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610900 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610901 .

_:807f36cf91fe4e8caa53aadeff92477610901 rdf:first _:807f36cf91fe4e8caa53aadeff92477610902;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610903 .

_:807f36cf91fe4e8caa53aadeff92477610902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477610903 rdf:first _:807f36cf91fe4e8caa53aadeff92477610904;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10414 .

_:807f36cf91fe4e8caa53aadeff92477610906 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10421-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS MÉDICAMENTS HYPONATRÉMIANTS <-> HYPONATRÉMIANTS"@fr;
  dct:identifier "IAM_10421";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610908;
  r:natureDuRisque "Majoration du risque d’hyponatrémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610910, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff92477610910 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11031-1 a owl:Class;
  rdfs:label "IBRUTINIB <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11031";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610912;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’ibrutinib par diminution de son métabolisme hépatique par le vérapamil."@fr;
  r:conduiteATenir "Surveiller clinique étroite et réduction de la dose d’ibrutinib à 140 mg par jour pendant la durée de l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610918, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610912 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610913 .

_:807f36cf91fe4e8caa53aadeff92477610913 rdf:first _:807f36cf91fe4e8caa53aadeff92477610914;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610915 .

_:807f36cf91fe4e8caa53aadeff92477610914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10441 .

_:807f36cf91fe4e8caa53aadeff92477610915 rdf:first _:807f36cf91fe4e8caa53aadeff92477610916;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477610918 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11032-1 a owl:Class;
  rdfs:label "IDÉLALISIB <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11032";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610920;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’idélalisib par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610926, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610920 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610921 .

_:807f36cf91fe4e8caa53aadeff92477610921 rdf:first _:807f36cf91fe4e8caa53aadeff92477610922;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610923 .

_:807f36cf91fe4e8caa53aadeff92477610922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477610923 rdf:first _:807f36cf91fe4e8caa53aadeff92477610924;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:807f36cf91fe4e8caa53aadeff92477610926 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11033-1 a owl:Class;
  rdfs:label "IDÉLALISIB <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11033";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610928;
  r:natureDuRisque "Risque de diminution importante des concentrations plasmatiques d’idélalisib par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610934, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610928 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610929 .

_:807f36cf91fe4e8caa53aadeff92477610929 rdf:first _:807f36cf91fe4e8caa53aadeff92477610930;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610931 .

_:807f36cf91fe4e8caa53aadeff92477610930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:807f36cf91fe4e8caa53aadeff92477610931 rdf:first _:807f36cf91fe4e8caa53aadeff92477610932;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477610934 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11034-1 a owl:Class;
  rdfs:label "IDÉLALISIB <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11034";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610936;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’idélalisib par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610942, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610936 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610937 .

_:807f36cf91fe4e8caa53aadeff92477610937 rdf:first _:807f36cf91fe4e8caa53aadeff92477610938;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610939 .

_:807f36cf91fe4e8caa53aadeff92477610938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:807f36cf91fe4e8caa53aadeff92477610939 rdf:first _:807f36cf91fe4e8caa53aadeff92477610940;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477610942 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11035-1 a owl:Class;
  rdfs:label "IDÉLALISIB <-> SUBSTRATS À RISQUE DU CYP3A4"@fr;
  dct:identifier "IAM_11035";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610944;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du substrat par diminution de son métabolisme hépatique par l’idelalisib."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610950, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610944 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610945 .

_:807f36cf91fe4e8caa53aadeff92477610945 rdf:first _:807f36cf91fe4e8caa53aadeff92477610946;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610947 .

_:807f36cf91fe4e8caa53aadeff92477610946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10145 .

_:807f36cf91fe4e8caa53aadeff92477610947 rdf:first _:807f36cf91fe4e8caa53aadeff92477610948;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:807f36cf91fe4e8caa53aadeff92477610950 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11087-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_11087";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610952;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques d’éribuline par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610958, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610952 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610953 .

_:807f36cf91fe4e8caa53aadeff92477610953 rdf:first _:807f36cf91fe4e8caa53aadeff92477610954;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610955 .

_:807f36cf91fe4e8caa53aadeff92477610954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477610955 rdf:first _:807f36cf91fe4e8caa53aadeff92477610956;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:807f36cf91fe4e8caa53aadeff92477610958 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10138-1 a owl:Class;
  rdfs:label "AMIODARONE <-> OLAPARIB"@fr;
  dct:identifier "IAM_10138";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610960;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par l' amiodarone"@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 200 mg 2 fois par jour avec l’amiodarone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610966, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610960 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610961 .

_:807f36cf91fe4e8caa53aadeff92477610961 rdf:first _:807f36cf91fe4e8caa53aadeff92477610962;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610963 .

_:807f36cf91fe4e8caa53aadeff92477610962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477610963 rdf:first _:807f36cf91fe4e8caa53aadeff92477610964;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:807f36cf91fe4e8caa53aadeff92477610966 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10127-1 a owl:Class;
  rdfs:label "AMIODARONE <-> DABIGATRAN"@fr;
  dct:identifier "IAM_10127";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610968;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  r:conduiteATenir "Dans l'indication post-chirurgicale : surveillance clinique et adaptation de la posologie du dabigatran si nécessaire, sans excéder 150 mg/j."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610974, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610968 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610969 .

_:807f36cf91fe4e8caa53aadeff92477610969 rdf:first _:807f36cf91fe4e8caa53aadeff92477610970;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610971 .

_:807f36cf91fe4e8caa53aadeff92477610970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477610971 rdf:first _:807f36cf91fe4e8caa53aadeff92477610972;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff92477610974 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10128-1 a owl:Class;
  rdfs:label "AMIODARONE <-> DACLATASVIR"@fr;
  dct:identifier "IAM_10128";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610976;
  r:natureDuRisque """Uniquement lors de la bithérapie daclatasvir/sofosbuvir :
Survenue de bradycardie éventuellement brutale, pouvant avoir des conséquences fatales."""@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et ECG étroite, en particulier pendant les premières semaines de traitement par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610982, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610976 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610977 .

_:807f36cf91fe4e8caa53aadeff92477610977 rdf:first _:807f36cf91fe4e8caa53aadeff92477610978;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610979 .

_:807f36cf91fe4e8caa53aadeff92477610978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477610979 rdf:first _:807f36cf91fe4e8caa53aadeff92477610980;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:807f36cf91fe4e8caa53aadeff92477610982 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10129-1 a owl:Class;
  rdfs:label "AMIODARONE <-> DIGOXINE"@fr;
  dct:identifier "IAM_10129";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610984;
  r:natureDuRisque "Dépression de l'automatisme (bradycardie excessive) et troubles de la conduction auriculo-ventriculaire. De plus, augmentation de la digoxinémie par diminution de la clairance de la digoxine."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et, s'il y a lieu, contrôle de la digoxinémie et adaptation de la posologie de la digoxine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610990, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610984 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610985 .

_:807f36cf91fe4e8caa53aadeff92477610985 rdf:first _:807f36cf91fe4e8caa53aadeff92477610986;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610987 .

_:807f36cf91fe4e8caa53aadeff92477610986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477610987 rdf:first _:807f36cf91fe4e8caa53aadeff92477610988;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610988 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477610990 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10130-1 a owl:Class;
  rdfs:label "AMIODARONE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10130";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477610992;
  r:natureDuRisque """Pour diltiazem voie injectable : risque de bradycardie et de bloc auriculo-ventriculaire

Pour diltiazem per os : risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez les personnes âgées."""@fr;
  r:conduiteATenir """Précaution d'emploi avec :
- le diltiazem per os
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477610998, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477610992 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477610993 .

_:807f36cf91fe4e8caa53aadeff92477610993 rdf:first _:807f36cf91fe4e8caa53aadeff92477610994;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477610995 .

_:807f36cf91fe4e8caa53aadeff92477610994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477610995 rdf:first _:807f36cf91fe4e8caa53aadeff92477610996;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477610996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477610998 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10131-1 a owl:Class;
  rdfs:label "AMIODARONE <-> ESMOLOL"@fr;
  dct:identifier "IAM_10131";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611000;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611006, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611000 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611001 .

_:807f36cf91fe4e8caa53aadeff92477611001 rdf:first _:807f36cf91fe4e8caa53aadeff92477611002;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611003 .

_:807f36cf91fe4e8caa53aadeff92477611002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611003 rdf:first _:807f36cf91fe4e8caa53aadeff92477611004;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:807f36cf91fe4e8caa53aadeff92477611006 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10132-1 a owl:Class;
  rdfs:label "AMIODARONE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10132";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611008;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611014, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611008 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611009 .

_:807f36cf91fe4e8caa53aadeff92477611009 rdf:first _:807f36cf91fe4e8caa53aadeff92477611010;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611011 .

_:807f36cf91fe4e8caa53aadeff92477611010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611011 rdf:first _:807f36cf91fe4e8caa53aadeff92477611012;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:807f36cf91fe4e8caa53aadeff92477611014 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10133-1 a owl:Class;
  rdfs:label "AMIODARONE <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10133";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611016;
  r:natureDuRisque "Risque d’allongement de l’intervalle QT."@fr;
  r:conduiteATenir "Surveillance clinique, particulièrement aux fortes doses de fluconazole (800 mg/j)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611022, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611016 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611017 .

_:807f36cf91fe4e8caa53aadeff92477611017 rdf:first _:807f36cf91fe4e8caa53aadeff92477611018;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611019 .

_:807f36cf91fe4e8caa53aadeff92477611018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611019 rdf:first _:807f36cf91fe4e8caa53aadeff92477611020;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477611022 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10134-1 a owl:Class;
  rdfs:label "AMIODARONE <-> IBRUTINIB"@fr;
  dct:identifier "IAM_10134";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611024;
  r:natureDuRisque "Risque d'augmentation des concentrations plasmatiques d’ibrutinib par diminution de son métabolisme hépatique par l’amiodarone."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique étroite et réduction de la dose d’ibrutinib à 140 mg par jour pendant la durée de l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611030, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611024 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611025 .

_:807f36cf91fe4e8caa53aadeff92477611025 rdf:first _:807f36cf91fe4e8caa53aadeff92477611026;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611027 .

_:807f36cf91fe4e8caa53aadeff92477611026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611027 rdf:first _:807f36cf91fe4e8caa53aadeff92477611028;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611028 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10441 .

_:807f36cf91fe4e8caa53aadeff92477611030 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10135-1 a owl:Class;
  rdfs:label "AMIODARONE <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_10135";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611032;
  r:natureDuRisque "Uniquement lors de la bithérapie lédipasvir/sofosbuvir, survenue de bradycardie, éventuellement brutale, pouvant avoir des conséquences fatales."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, il est recommandé de surveiller étroitement les patients, en particulier pendant les premières semaines de traitement par la bithérapie (surveillance clinique et ECG)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611038, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611032 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611033 .

_:807f36cf91fe4e8caa53aadeff92477611033 rdf:first _:807f36cf91fe4e8caa53aadeff92477611034;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611035 .

_:807f36cf91fe4e8caa53aadeff92477611034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611035 rdf:first _:807f36cf91fe4e8caa53aadeff92477611036;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611036 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477611038 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10059-1 a owl:Class;
  rdfs:label "ALBENDAZOLE <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10059";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611040;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de l’albendazole et de son métabolite actif par l’inducteur, avec risque de baisse de son efficacité."@fr;
  r:conduiteATenir "Surveillance clinique de la réponse thérapeutique et adaptation éventuelle de la posologie de l’albendazole pendant le traitement avec l’inducteur enzymatique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611046, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611040 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611041 .

_:807f36cf91fe4e8caa53aadeff92477611041 rdf:first _:807f36cf91fe4e8caa53aadeff92477611042;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611043 .

_:807f36cf91fe4e8caa53aadeff92477611042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477611043 rdf:first _:807f36cf91fe4e8caa53aadeff92477611044;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611044 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477611046 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10137-1 a owl:Class;
  rdfs:label "AMIODARONE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_10137";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611048;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par l'amiodarone."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611054, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611048 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611049 .

_:807f36cf91fe4e8caa53aadeff92477611049 rdf:first _:807f36cf91fe4e8caa53aadeff92477611050;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611051 .

_:807f36cf91fe4e8caa53aadeff92477611050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611051 rdf:first _:807f36cf91fe4e8caa53aadeff92477611052;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611052 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477611054 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10124-1 a owl:Class;
  rdfs:label "AMIODARONE <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10124";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611056;
  r:chapeau """A l’heure actuelle, 4 bêta-bloquants ont l'indication \"insuffisance cardiaque\" : le carvédilol, le bisoprolol, le métoprolol et le névibolol.
Les interactions médicamenteuses des bêta-bloquants, lorsqu’ils sont prescrits dans l’insuffisance cardiaque, pe"""@fr;
  r:natureDuRisque "Troubles de l'automatisme et de la conduction cardiaque avec risque de bradycardie excessive."@fr;
  r:conduiteATenir "Surveillance clinique et ECG régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611062, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611056 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611057 .

_:807f36cf91fe4e8caa53aadeff92477611057 rdf:first _:807f36cf91fe4e8caa53aadeff92477611058;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611059 .

_:807f36cf91fe4e8caa53aadeff92477611058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477611059 rdf:first _:807f36cf91fe4e8caa53aadeff92477611060;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611060 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611062 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10139-1 a owl:Class;
  rdfs:label "AMIODARONE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10139";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611064;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'amiodarone par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611070, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611064 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611065 .

_:807f36cf91fe4e8caa53aadeff92477611065 rdf:first _:807f36cf91fe4e8caa53aadeff92477611066;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611067 .

_:807f36cf91fe4e8caa53aadeff92477611066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477611067 rdf:first _:807f36cf91fe4e8caa53aadeff92477611068;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611068 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611070 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10140-1 a owl:Class;
  rdfs:label "AMIODARONE <-> ORLISTAT"@fr;
  dct:identifier "IAM_10140";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611072;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'amiodarone et de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611078, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611072 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611073 .

_:807f36cf91fe4e8caa53aadeff92477611073 rdf:first _:807f36cf91fe4e8caa53aadeff92477611074;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611075 .

_:807f36cf91fe4e8caa53aadeff92477611074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611075 rdf:first _:807f36cf91fe4e8caa53aadeff92477611076;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611076 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477611078 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10141-1 a owl:Class;
  rdfs:label "AMIODARONE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10141";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611080;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la phénytoïne avec signes de surdosage, en particulier neurologiques (diminution du métabolisme hépatique de la phénytoïne)."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de phénytoïne et adaptation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611086, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611080 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611081 .

_:807f36cf91fe4e8caa53aadeff92477611081 rdf:first _:807f36cf91fe4e8caa53aadeff92477611082;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611083 .

_:807f36cf91fe4e8caa53aadeff92477611082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477611083 rdf:first _:807f36cf91fe4e8caa53aadeff92477611084;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611084 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611086 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10142-1 a owl:Class;
  rdfs:label "AMIODARONE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10142";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611088;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/j de simvastatine ou utiliser une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611094, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611088 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611089 .

_:807f36cf91fe4e8caa53aadeff92477611089 rdf:first _:807f36cf91fe4e8caa53aadeff92477611090;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611091 .

_:807f36cf91fe4e8caa53aadeff92477611090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611091 rdf:first _:807f36cf91fe4e8caa53aadeff92477611092;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611092 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477611094 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10143-1 a owl:Class;
  rdfs:label "AMIODARONE <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_10143";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611096;
  r:natureDuRisque """Uniquement lors de la bithérapie daclatasvir/sofosbuvir ou lédipasvir/sofosbuvir :
Survenue de bradycardie éventuellement brutale, pouvant avoir des conséquences fatales."""@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et ECG étroite, en particulier pendant les premières semaines de traitement par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611102, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611096 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611097 .

_:807f36cf91fe4e8caa53aadeff92477611097 rdf:first _:807f36cf91fe4e8caa53aadeff92477611098;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611099 .

_:807f36cf91fe4e8caa53aadeff92477611098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611099 rdf:first _:807f36cf91fe4e8caa53aadeff92477611100;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611100 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:807f36cf91fe4e8caa53aadeff92477611102 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10144-1 a owl:Class;
  rdfs:label "AMIODARONE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10144";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611104;
  r:natureDuRisque "Augmentation des concentrations sanguines de tacrolimus par inhibition de son métabolisme par l’amiodarone."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de tacrolimus, contrôle de la fonction rénale et adaptation de la posologie de tacrolimus pendant l’association et à l’arrêt de l’amiodarone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611110, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611104 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611105 .

_:807f36cf91fe4e8caa53aadeff92477611105 rdf:first _:807f36cf91fe4e8caa53aadeff92477611106;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611107 .

_:807f36cf91fe4e8caa53aadeff92477611106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611107 rdf:first _:807f36cf91fe4e8caa53aadeff92477611108;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611108 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477611110 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10145-1 a owl:Class;
  rdfs:label "AMIODARONE <-> TAMSULOSINE"@fr;
  dct:identifier "IAM_10145";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611112;
  r:natureDuRisque "Risque de majoration des effets indésirables de la tamsulosine, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la tamsulosine pendant le traitement par l’inhibiteur enzymatique et après son arrêt, le cas échéant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611118, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611112 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611113 .

_:807f36cf91fe4e8caa53aadeff92477611113 rdf:first _:807f36cf91fe4e8caa53aadeff92477611114;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611115 .

_:807f36cf91fe4e8caa53aadeff92477611114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611115 rdf:first _:807f36cf91fe4e8caa53aadeff92477611116;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611116 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10883 .

_:807f36cf91fe4e8caa53aadeff92477611118 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10147-1 a owl:Class;
  rdfs:label "AMIODARONE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10147";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611120;
  r:natureDuRisque """Pour vérapamil voie injectable :
-risque de bradycardie ou de bloc auriculo-ventriculaire.

Pour vérapamil per os :
-risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez les personnes âgées."""@fr;
  r:conduiteATenir """Association déconseillée avec :
- le vérapamil IV
Si l'association ne peut être évitée, surveillance clinique et ECG continu.

Précaution d'emploi avec :
- le vérapamil per os
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611126, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611120 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611121 .

_:807f36cf91fe4e8caa53aadeff92477611121 rdf:first _:807f36cf91fe4e8caa53aadeff92477611122;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611123 .

_:807f36cf91fe4e8caa53aadeff92477611122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611123 rdf:first _:807f36cf91fe4e8caa53aadeff92477611124;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477611126 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10148-1 a owl:Class;
  rdfs:label "AMIODARONE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10148";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611128;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes, par possible diminution du métabolisme de l’amiodarone."@fr;
  r:conduiteATenir "Surveillance clinique et ECG, et adaptation éventuelle de la posologie de l’amiodarone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611134, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611128 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611129 .

_:807f36cf91fe4e8caa53aadeff92477611129 rdf:first _:807f36cf91fe4e8caa53aadeff92477611130;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611131 .

_:807f36cf91fe4e8caa53aadeff92477611130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611131 rdf:first _:807f36cf91fe4e8caa53aadeff92477611132;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477611134 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10136-1 a owl:Class;
  rdfs:label "AMIODARONE <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10136";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611136;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de lidocaïne, avec possibilité d’effets indésirables neurologiques et cardiaques, par diminution de son métabolisme hépatique par l’amiodarone."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations plasmatiques de lidocaïne. Si besoin, adaptation de la posologie de la lidocaïne pendant le traitement par amiodarone et après son arrêt."@fr;
  rdfs:comment "La littérature rapporte des cas d’augmentation des effets indésirables de la lidocaïne lorsqu'elle est associée à l’amiodarone. Il s’agit d’une interaction métabolique avec augmentation des concentrations plasmatiques de lidocaïne, l’amiodarone étant un i"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611142, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611136 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611137 .

_:807f36cf91fe4e8caa53aadeff92477611137 rdf:first _:807f36cf91fe4e8caa53aadeff92477611138;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611139 .

_:807f36cf91fe4e8caa53aadeff92477611138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611139 rdf:first _:807f36cf91fe4e8caa53aadeff92477611140;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:807f36cf91fe4e8caa53aadeff92477611142 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10115-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> CEFALOTINE"@fr;
  dct:identifier "IAM_10115";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611144;
  r:natureDuRisque "L'augmentation de la néphrotoxicité des aminosides par la céfalotine est discutée."@fr;
  r:conduiteATenir "Surveillance de la fonction rénale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611150, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611144 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611145 .

_:807f36cf91fe4e8caa53aadeff92477611145 rdf:first _:807f36cf91fe4e8caa53aadeff92477611146;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611147 .

_:807f36cf91fe4e8caa53aadeff92477611146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477611147 rdf:first _:807f36cf91fe4e8caa53aadeff92477611148;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10168 .

_:807f36cf91fe4e8caa53aadeff92477611150 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11079-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> RANOLAZINE"@fr;
  dct:identifier "IAM_11079";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611152;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme par la ranolazine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, et adaptation éventuelle de la posologie de l’immunosuppresseur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611158, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611152 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611153 .

_:807f36cf91fe4e8caa53aadeff92477611153 rdf:first _:807f36cf91fe4e8caa53aadeff92477611154;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611155 .

_:807f36cf91fe4e8caa53aadeff92477611154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477611155 rdf:first _:807f36cf91fe4e8caa53aadeff92477611156;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:807f36cf91fe4e8caa53aadeff92477611158 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10061-1 a owl:Class;
  rdfs:label "ALBENDAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10061";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611160;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de l’albendazole et de son métabolite actif par l’inducteur, avec risque de baisse de son efficacité."@fr;
  r:conduiteATenir "Surveillance clinique de la réponse thérapeutique et adaptation éventuelle de la posologie de l’albendazole pendant le traitement avec l’inducteur enzymatique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611166, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611160 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611161 .

_:807f36cf91fe4e8caa53aadeff92477611161 rdf:first _:807f36cf91fe4e8caa53aadeff92477611162;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611163 .

_:807f36cf91fe4e8caa53aadeff92477611162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477611163 rdf:first _:807f36cf91fe4e8caa53aadeff92477611164;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477611166 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10062-1 a owl:Class;
  rdfs:label "ALCALINISANTS URINAIRES <-> HYDROQUINIDINE"@fr;
  dct:identifier "IAM_10062";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611168;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'hydroquinidine et risque de surdosage (diminution de l'excrétion rénale de l'hydroquinidine par alcalinisation des urines)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations de l'hydroquinidine ; si besoin, adaptation de la posologie pendant le traitement alcalinisant et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611174, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611168 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611169 .

_:807f36cf91fe4e8caa53aadeff92477611169 rdf:first _:807f36cf91fe4e8caa53aadeff92477611170;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611171 .

_:807f36cf91fe4e8caa53aadeff92477611170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10006 .

_:807f36cf91fe4e8caa53aadeff92477611171 rdf:first _:807f36cf91fe4e8caa53aadeff92477611172;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10434 .

_:807f36cf91fe4e8caa53aadeff92477611174 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10063-1 a owl:Class;
  rdfs:label "ALCALINISANTS URINAIRES <-> QUINIDINE"@fr;
  dct:identifier "IAM_10063";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611176;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la quinidine et risque de surdosage (diminution de l'excrétion rénale de la quinidine par alcalinisation des urines)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle de la quinidinémie ; si besoin, adaptation de la posologie pendant le traitement alcalinisant et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611182, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611176 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611177 .

_:807f36cf91fe4e8caa53aadeff92477611177 rdf:first _:807f36cf91fe4e8caa53aadeff92477611178;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611179 .

_:807f36cf91fe4e8caa53aadeff92477611178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10006 .

_:807f36cf91fe4e8caa53aadeff92477611179 rdf:first _:807f36cf91fe4e8caa53aadeff92477611180;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477611182 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10064-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS"@fr;
  dct:identifier "IAM_10064";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611184;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:comment "Les propriétés pharmacologiques des dérivés de l'ergot exposent à un risque de vasoconstriction, qui peut être grave selon les antécédents du patient. Les risques vasculaires sont en effet communs à tous les dérivés de l'ergot et pourraient s'additionner"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611190, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611184 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611185 .

_:807f36cf91fe4e8caa53aadeff92477611185 rdf:first _:807f36cf91fe4e8caa53aadeff92477611186;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611187 .

_:807f36cf91fe4e8caa53aadeff92477611186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:807f36cf91fe4e8caa53aadeff92477611187 rdf:first _:807f36cf91fe4e8caa53aadeff92477611188;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477611190 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10065-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> ANTIPARKINSONIENS ANTICHOLINERGIQUES"@fr;
  dct:identifier "IAM_10065";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611192;
  r:natureDuRisque "Risque de majoration des troubles neuropsychiques."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611198, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611192 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611193 .

_:807f36cf91fe4e8caa53aadeff92477611193 rdf:first _:807f36cf91fe4e8caa53aadeff92477611194;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611195 .

_:807f36cf91fe4e8caa53aadeff92477611194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:807f36cf91fe4e8caa53aadeff92477611195 rdf:first _:807f36cf91fe4e8caa53aadeff92477611196;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10037 .

_:807f36cf91fe4e8caa53aadeff92477611198 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10066-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10066";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611200;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du dopaminergique avec accroissement possible de son activité ou apparition de signes de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611206, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611200 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611201 .

_:807f36cf91fe4e8caa53aadeff92477611201 rdf:first _:807f36cf91fe4e8caa53aadeff92477611202;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611203 .

_:807f36cf91fe4e8caa53aadeff92477611202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:807f36cf91fe4e8caa53aadeff92477611203 rdf:first _:807f36cf91fe4e8caa53aadeff92477611204;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:807f36cf91fe4e8caa53aadeff92477611206 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10067-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> SYMPATHOMIMÉTIQUES ALPHA (VOIES ORALE ET/OU NASALE)"@fr;
  dct:identifier "IAM_10067";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611208;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611214, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611208 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611209 .

_:807f36cf91fe4e8caa53aadeff92477611209 rdf:first _:807f36cf91fe4e8caa53aadeff92477611210;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611211 .

_:807f36cf91fe4e8caa53aadeff92477611210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:807f36cf91fe4e8caa53aadeff92477611211 rdf:first _:807f36cf91fe4e8caa53aadeff92477611212;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10148 .

_:807f36cf91fe4e8caa53aadeff92477611214 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10068-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE DOPAMINERGIQUES <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_10068";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611216;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:comment """Les décisions suivantes, émanant de trois instances de l'Afssaps, ont été prises en compte : 
- la Commission Nationale de Pharmacovigilance a pris acte d'une toxicité de la phénylpropanolamine supérieure à celle des autres sympathomimétiques indirects ("""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611222, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611216 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611217 .

_:807f36cf91fe4e8caa53aadeff92477611217 rdf:first _:807f36cf91fe4e8caa53aadeff92477611218;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611219 .

_:807f36cf91fe4e8caa53aadeff92477611218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10007 .

_:807f36cf91fe4e8caa53aadeff92477611219 rdf:first _:807f36cf91fe4e8caa53aadeff92477611220;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477611222 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10126-1 a owl:Class;
  rdfs:label "AMIODARONE <-> COBICISTAT"@fr;
  dct:identifier "IAM_10126";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611224;
  r:natureDuRisque "Risque de majoration des effets indésirables de l'amiodarone par diminution de son métabolisme par le cobicistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611230, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611224 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611225 .

_:807f36cf91fe4e8caa53aadeff92477611225 rdf:first _:807f36cf91fe4e8caa53aadeff92477611226;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611227 .

_:807f36cf91fe4e8caa53aadeff92477611226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611227 rdf:first _:807f36cf91fe4e8caa53aadeff92477611228;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477611230 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10070-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10070";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611232;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Risque de vasoconstriction coronaire ou des extrémités (ergotisme), ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611238, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611232 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611233 .

_:807f36cf91fe4e8caa53aadeff92477611233 rdf:first _:807f36cf91fe4e8caa53aadeff92477611234;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611235 .

_:807f36cf91fe4e8caa53aadeff92477611234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477611235 rdf:first _:807f36cf91fe4e8caa53aadeff92477611236;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477611238 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10125-1 a owl:Class;
  rdfs:label "AMIODARONE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10125";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611240;
  r:natureDuRisque "Augmentation des concentrations sanguines de ciclosporine, par diminution de son métabolisme hépatique, avec risque d'effets néphrotoxiques."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de ciclosporine, contrôle de la fonction rénale et adaptation de la posologie de la ciclosporine pendant le traitement par l'amiodarone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611246, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611240 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611241 .

_:807f36cf91fe4e8caa53aadeff92477611241 rdf:first _:807f36cf91fe4e8caa53aadeff92477611242;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611243 .

_:807f36cf91fe4e8caa53aadeff92477611242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611243 rdf:first _:807f36cf91fe4e8caa53aadeff92477611244;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477611246 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10116-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10116";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611248;
  r:natureDuRisque "Augmentation de la créatininémie plus importante que sous ciclosporine seule, avec majoration du risque néphrotoxique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611254, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611248 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611249 .

_:807f36cf91fe4e8caa53aadeff92477611249 rdf:first _:807f36cf91fe4e8caa53aadeff92477611250;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611251 .

_:807f36cf91fe4e8caa53aadeff92477611250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477611251 rdf:first _:807f36cf91fe4e8caa53aadeff92477611252;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477611254 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10117-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> CURARES"@fr;
  dct:identifier "IAM_10117";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611256;
  r:chapeau """Certaines substances peuvent modifier l'intensité et/ou la durée de l'effet des curares non dépolarisants. 
Les médicaments susceptibles de potentialiser l'action des curares non dépolarisants sont :
- les anesthésiques volatils tels que isoflurane, enflu"""@fr;
  r:natureDuRisque "Potentialisation des curares lorque l'antibiotique est administré par voie parentérale et/ou péritonéale avant, pendant ou après l'agent curarisant."@fr;
  r:conduiteATenir "Surveiller le degré de curarisation en fin d'anesthésie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611262, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611256 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611257 .

_:807f36cf91fe4e8caa53aadeff92477611257 rdf:first _:807f36cf91fe4e8caa53aadeff92477611258;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611259 .

_:807f36cf91fe4e8caa53aadeff92477611258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477611259 rdf:first _:807f36cf91fe4e8caa53aadeff92477611260;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10057 .

_:807f36cf91fe4e8caa53aadeff92477611262 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10118-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> DIURÉTIQUES DE L'ANSE"@fr;
  dct:identifier "IAM_10118";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611264;
  r:natureDuRisque "Augmentation des risques néphrotoxiques et ototoxiques de l'aminoside (insuffisance rénale fonctionnelle liée à la déshydratation entraînée par le diurétique)."@fr;
  r:conduiteATenir "Association possible sous contrôle de l'état d'hydratation, des fonctions rénale et cochléovestibulaire, et éventuellement, des concentrations plasmatiques de l'aminoside."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611270, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611264 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611265 .

_:807f36cf91fe4e8caa53aadeff92477611265 rdf:first _:807f36cf91fe4e8caa53aadeff92477611266;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611267 .

_:807f36cf91fe4e8caa53aadeff92477611266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477611267 rdf:first _:807f36cf91fe4e8caa53aadeff92477611268;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10064 .

_:807f36cf91fe4e8caa53aadeff92477611270 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10119-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> ORGANOPLATINES"@fr;
  dct:identifier "IAM_10119";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611272;
  r:natureDuRisque "Addition des effets néphrotoxiques et/ou ototoxiques, notamment en cas d'insuffisance rénale préalable."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611278, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611272 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611273 .

_:807f36cf91fe4e8caa53aadeff92477611273 rdf:first _:807f36cf91fe4e8caa53aadeff92477611274;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611275 .

_:807f36cf91fe4e8caa53aadeff92477611274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477611275 rdf:first _:807f36cf91fe4e8caa53aadeff92477611276;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477611278 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10120-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> POLYMYXINE B"@fr;
  dct:identifier "IAM_10120";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611280;
  r:natureDuRisque "Addition des effets néphrotoxiques."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance stricte avec une justification bactériologique indiscutable."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611286, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611280 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611281 .

_:807f36cf91fe4e8caa53aadeff92477611281 rdf:first _:807f36cf91fe4e8caa53aadeff92477611282;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611283 .

_:807f36cf91fe4e8caa53aadeff92477611282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477611283 rdf:first _:807f36cf91fe4e8caa53aadeff92477611284;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10739 .

_:807f36cf91fe4e8caa53aadeff92477611286 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10121-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10121";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611288;
  r:natureDuRisque "Augmentation de la créatininémie plus importante que sous tacrolimus seul (synergie des effets néphrotoxiques des deux substances)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611294, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611288 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611289 .

_:807f36cf91fe4e8caa53aadeff92477611289 rdf:first _:807f36cf91fe4e8caa53aadeff92477611290;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611291 .

_:807f36cf91fe4e8caa53aadeff92477611290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477611291 rdf:first _:807f36cf91fe4e8caa53aadeff92477611292;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477611294 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10146-1 a owl:Class;
  rdfs:label "AMIODARONE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10146";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611296;
  r:natureDuRisque "Troubles de l'automatisme et de la conduction cardiaque avec risque de bradycardie excessive."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611296 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611297 .

_:807f36cf91fe4e8caa53aadeff92477611297 rdf:first _:807f36cf91fe4e8caa53aadeff92477611298;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611299 .

_:807f36cf91fe4e8caa53aadeff92477611298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611299 rdf:first _:807f36cf91fe4e8caa53aadeff92477611300;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477611302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10122-1 a owl:Class;
  rdfs:label "AMIODARONE <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10122";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611304;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'amiodarone et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611305 .

_:807f36cf91fe4e8caa53aadeff92477611305 rdf:first _:807f36cf91fe4e8caa53aadeff92477611306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611307 .

_:807f36cf91fe4e8caa53aadeff92477611306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477611307 rdf:first _:807f36cf91fe4e8caa53aadeff92477611308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10123-1 a owl:Class;
  rdfs:label "AMIODARONE <-> BÊTA-BLOQUANTS (SAUF ESMOLOL ET SOTALOL)"@fr;
  dct:identifier "IAM_10123";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611312;
  r:natureDuRisque "Troubles de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:comment """L'amiodarone a longtemps été déconseillée avec les bêta-bloquants, en raison d’une majoration possible du risque de bradycardie et de torsades de pointes.
Cependant, considérant que :
- le risque de torsades de pointes est exceptionnel avec l’amiodarone,"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611313 .

_:807f36cf91fe4e8caa53aadeff92477611313 rdf:first _:807f36cf91fe4e8caa53aadeff92477611314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611315 .

_:807f36cf91fe4e8caa53aadeff92477611314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10053 .

_:807f36cf91fe4e8caa53aadeff92477611315 rdf:first _:807f36cf91fe4e8caa53aadeff92477611316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477611318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10151-1 a owl:Class;
  rdfs:label "AMPHOTERICINE B <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10151";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611320;
  r:natureDuRisque "Avec l'amphotéricine B administrée par voie IV : augmentation de la créatininémie plus importante que sous tacrolimus seul (synergie des effets néphrotoxiques des deux substances)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611320 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611321 .

_:807f36cf91fe4e8caa53aadeff92477611321 rdf:first _:807f36cf91fe4e8caa53aadeff92477611322;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611323 .

_:807f36cf91fe4e8caa53aadeff92477611322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477611323 rdf:first _:807f36cf91fe4e8caa53aadeff92477611324;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477611326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10069-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10069";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611328;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de vasoconstriction coronaire ou des extrémités (ergotisme), ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611329 .

_:807f36cf91fe4e8caa53aadeff92477611329 rdf:first _:807f36cf91fe4e8caa53aadeff92477611330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611331 .

_:807f36cf91fe4e8caa53aadeff92477611330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477611331 rdf:first _:807f36cf91fe4e8caa53aadeff92477611332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477611334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10185-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10185";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611336;
  r:natureDuRisque "Dans les indications où cette association est possible, risque accru de dégradation de la fonction rénale, voire insuffisance rénale aiguë, et majoration de l'hyperkaliémie, ainsi que de l'hypotension et des syncopes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611337 .

_:807f36cf91fe4e8caa53aadeff92477611337 rdf:first _:807f36cf91fe4e8caa53aadeff92477611338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611339 .

_:807f36cf91fe4e8caa53aadeff92477611338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477611339 rdf:first _:807f36cf91fe4e8caa53aadeff92477611340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477611342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10149-1 a owl:Class;
  rdfs:label "AMLODIPINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10149";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611344;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/j de simvastatine ou utiliser une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611345 .

_:807f36cf91fe4e8caa53aadeff92477611345 rdf:first _:807f36cf91fe4e8caa53aadeff92477611346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611347 .

_:807f36cf91fe4e8caa53aadeff92477611346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10069 .

_:807f36cf91fe4e8caa53aadeff92477611347 rdf:first _:807f36cf91fe4e8caa53aadeff92477611348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477611350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10176-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_10176";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611352;
  r:natureDuRisque "Poussée hypertensive peropératoire."@fr;
  r:conduiteATenir "En cas d'intervention programmée, il est préférable d'interrompre le traitement quelques jours avant l'intervention."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611353 .

_:807f36cf91fe4e8caa53aadeff92477611353 rdf:first _:807f36cf91fe4e8caa53aadeff92477611354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611355 .

_:807f36cf91fe4e8caa53aadeff92477611354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477611355 rdf:first _:807f36cf91fe4e8caa53aadeff92477611356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477611358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10075-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> ANTABUSE (RÉACTION)"@fr;
  dct:identifier "IAM_10075";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611360;
  r:natureDuRisque "Effet antabuse (chaleur, rougeurs, vomissements, tachycardie)."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool. Tenir compte de l’élimination complète des médicaments en se référant à leur demi-vie avant la reprise de boissons alcoolisées ou du médicament contenant de l’alcool."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611361 .

_:807f36cf91fe4e8caa53aadeff92477611361 rdf:first _:807f36cf91fe4e8caa53aadeff92477611362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611363 .

_:807f36cf91fe4e8caa53aadeff92477611362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10018 .

_:807f36cf91fe4e8caa53aadeff92477611363 rdf:first _:807f36cf91fe4e8caa53aadeff92477611364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477611366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10177-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10177";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611368;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir """Précaution d'emploi :
Surveillance clinique et adaptation éventuelle de la posologie de l'antagoniste du calcium pendant le traitement par l'anticonvulsivant et après son arrêt."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611369 .

_:807f36cf91fe4e8caa53aadeff92477611369 rdf:first _:807f36cf91fe4e8caa53aadeff92477611370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611371 .

_:807f36cf91fe4e8caa53aadeff92477611370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:807f36cf91fe4e8caa53aadeff92477611371 rdf:first _:807f36cf91fe4e8caa53aadeff92477611372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477611374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10178-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> IDÉLALISIB"@fr;
  dct:identifier "IAM_10178";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611376;
  r:natureDuRisque "Majoration des effets indésirables de l’antagoniste des canaux calciques, à type d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’antagoniste calcique pendant le traitement par l’idélalisib et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611377 .

_:807f36cf91fe4e8caa53aadeff92477611377 rdf:first _:807f36cf91fe4e8caa53aadeff92477611378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611379 .

_:807f36cf91fe4e8caa53aadeff92477611378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:807f36cf91fe4e8caa53aadeff92477611379 rdf:first _:807f36cf91fe4e8caa53aadeff92477611380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:807f36cf91fe4e8caa53aadeff92477611382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10179-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10179";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611384;
  r:natureDuRisque "Majoration des effets indésirables de l’antagoniste des canaux calciques, le plus souvent à type d'hypotension notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation posologique pendant le traitement par l’inhibiteur enzymatique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611390, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611384 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611385 .

_:807f36cf91fe4e8caa53aadeff92477611385 rdf:first _:807f36cf91fe4e8caa53aadeff92477611386;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611387 .

_:807f36cf91fe4e8caa53aadeff92477611386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:807f36cf91fe4e8caa53aadeff92477611387 rdf:first _:807f36cf91fe4e8caa53aadeff92477611388;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477611390 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10180-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10180";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611392;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir """Précaution d'emploi :
Surveillance clinique et adaptation éventuelle de la posologie de l'antagoniste du calcium pendant le traitement par la rifampicine et après son arrêt."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611398, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611392 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611393 .

_:807f36cf91fe4e8caa53aadeff92477611393 rdf:first _:807f36cf91fe4e8caa53aadeff92477611394;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611395 .

_:807f36cf91fe4e8caa53aadeff92477611394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:807f36cf91fe4e8caa53aadeff92477611395 rdf:first _:807f36cf91fe4e8caa53aadeff92477611396;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477611398 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10181-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> ANTI-INFLAMMATOIRES NON STÉROÏDIENS"@fr;
  dct:identifier "IAM_10181";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611400;
  r:natureDuRisque "Insuffisance rénale aiguë chez le patient à risque (sujet âgé, déshydratation, traitement associé avec diurétiques, altération de la fonction rénale), par diminution de la filtration glomérulaire (inhibition des prostaglandines vasodilatatrices due aux an"@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement et régulièrement pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611400 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611401 .

_:807f36cf91fe4e8caa53aadeff92477611401 rdf:first _:807f36cf91fe4e8caa53aadeff92477611402;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611403 .

_:807f36cf91fe4e8caa53aadeff92477611402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477611403 rdf:first _:807f36cf91fe4e8caa53aadeff92477611404;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477611406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10182-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10182";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611408;
  r:natureDuRisque "Risque d'hyperkaliémie (potentiellement létale) surtout en cas d'insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir """Précaution d'emploi :
- pour la spironolactone à des doses comprises entre 12,5 mg et 50 mg/jour, et pour l’éplérénone utilisées dans le traitement de l'insuffisance cardiaque, ainsi qu'en cas d'hypokaliémie : contrôle strict de la kaliémie et de la fonct"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611409 .

_:807f36cf91fe4e8caa53aadeff92477611409 rdf:first _:807f36cf91fe4e8caa53aadeff92477611410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611411 .

_:807f36cf91fe4e8caa53aadeff92477611410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477611411 rdf:first _:807f36cf91fe4e8caa53aadeff92477611412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477611414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10174-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> ISOPRENALINE"@fr;
  dct:identifier "IAM_10174";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611416;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611417 .

_:807f36cf91fe4e8caa53aadeff92477611417 rdf:first _:807f36cf91fe4e8caa53aadeff92477611418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611419 .

_:807f36cf91fe4e8caa53aadeff92477611418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477611419 rdf:first _:807f36cf91fe4e8caa53aadeff92477611420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10491 .

_:807f36cf91fe4e8caa53aadeff92477611422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10184-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> EPLERENONE"@fr;
  dct:identifier "IAM_10184";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611424;
  r:natureDuRisque "Majoration du risque d’hyperkaliémie, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Contrôle strict de la kaliémie et de la fonction rénale pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611425 .

_:807f36cf91fe4e8caa53aadeff92477611425 rdf:first _:807f36cf91fe4e8caa53aadeff92477611426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611427 .

_:807f36cf91fe4e8caa53aadeff92477611426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477611427 rdf:first _:807f36cf91fe4e8caa53aadeff92477611428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10329 .

_:807f36cf91fe4e8caa53aadeff92477611430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10173-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> ISONIAZIDE"@fr;
  dct:identifier "IAM_10173";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611432;
  r:natureDuRisque "Potentialisation de l'effet hépatotoxique de l'isonazide, avec formation accrue de métabolites toxiques de l'isoniazide."@fr;
  r:conduiteATenir "En cas d'intervention programmée, arrêter, par prudence, le traitement par l'isoniazide une semaine avant l'intervention et ne le reprendre que 15 jours après."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611433 .

_:807f36cf91fe4e8caa53aadeff92477611433 rdf:first _:807f36cf91fe4e8caa53aadeff92477611434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611435 .

_:807f36cf91fe4e8caa53aadeff92477611434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477611435 rdf:first _:807f36cf91fe4e8caa53aadeff92477611436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477611438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10186-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> LITHIUM"@fr;
  dct:identifier "IAM_10186";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611440;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques (diminution de l'excrétion rénale du lithium)."@fr;
  r:conduiteATenir "Si l'usage d'un antagoniste de l'angiotensine II est indispensable, surveillance stricte de la lithémie et adaptation de la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611441 .

_:807f36cf91fe4e8caa53aadeff92477611441 rdf:first _:807f36cf91fe4e8caa53aadeff92477611442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611443 .

_:807f36cf91fe4e8caa53aadeff92477611442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477611443 rdf:first _:807f36cf91fe4e8caa53aadeff92477611444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477611446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10187-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> POTASSIUM"@fr;
  dct:identifier "IAM_10187";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611448;
  r:natureDuRisque "Hyperkaliémie (potentiellement létale) surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Eviter cette association sauf s'il existe une hypokaliémie préalable."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611449 .

_:807f36cf91fe4e8caa53aadeff92477611449 rdf:first _:807f36cf91fe4e8caa53aadeff92477611450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611451 .

_:807f36cf91fe4e8caa53aadeff92477611450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477611451 rdf:first _:807f36cf91fe4e8caa53aadeff92477611452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:807f36cf91fe4e8caa53aadeff92477611454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10188-1 a owl:Class;
  rdfs:label "ANTIAGRÉGANTS PLAQUETTAIRES <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10188";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611456;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611457 .

_:807f36cf91fe4e8caa53aadeff92477611457 rdf:first _:807f36cf91fe4e8caa53aadeff92477611458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611459 .

_:807f36cf91fe4e8caa53aadeff92477611458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:807f36cf91fe4e8caa53aadeff92477611459 rdf:first _:807f36cf91fe4e8caa53aadeff92477611460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477611462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10189-1 a owl:Class;
  rdfs:label "ANTIAGRÉGANTS PLAQUETTAIRES <-> DÉFIBROTIDE"@fr;
  dct:identifier "IAM_10189";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611464;
  r:natureDuRisque "Risque hémorragique accru."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611465 .

_:807f36cf91fe4e8caa53aadeff92477611465 rdf:first _:807f36cf91fe4e8caa53aadeff92477611466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611467 .

_:807f36cf91fe4e8caa53aadeff92477611466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:807f36cf91fe4e8caa53aadeff92477611467 rdf:first _:807f36cf91fe4e8caa53aadeff92477611468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10262 .

_:807f36cf91fe4e8caa53aadeff92477611470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10190-1 a owl:Class;
  rdfs:label "ANTIAGRÉGANTS PLAQUETTAIRES <-> HÉPARINES"@fr;
  dct:identifier "IAM_10190";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611472;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611473 .

_:807f36cf91fe4e8caa53aadeff92477611473 rdf:first _:807f36cf91fe4e8caa53aadeff92477611474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611475 .

_:807f36cf91fe4e8caa53aadeff92477611474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:807f36cf91fe4e8caa53aadeff92477611475 rdf:first _:807f36cf91fe4e8caa53aadeff92477611476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10088 .

_:807f36cf91fe4e8caa53aadeff92477611478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10191-1 a owl:Class;
  rdfs:label "ANTIAGRÉGANTS PLAQUETTAIRES <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_10191";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611480;
  r:chapeau """Plusieurs substances sont impliquées dans des interactions, du fait de leurs propriétés antiagrégantes plaquettaires. 
L’utilisation de plusieurs antiagrégants plaquettaires majore le risque de saignement, de même que leur association à l’héparine et aux"""@fr;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611481 .

_:807f36cf91fe4e8caa53aadeff92477611481 rdf:first _:807f36cf91fe4e8caa53aadeff92477611482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611483 .

_:807f36cf91fe4e8caa53aadeff92477611482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:807f36cf91fe4e8caa53aadeff92477611483 rdf:first _:807f36cf91fe4e8caa53aadeff92477611484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:807f36cf91fe4e8caa53aadeff92477611486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10192-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES <-> AUTRES ANTIARYTHMIQUES"@fr;
  dct:identifier "IAM_10192";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611488;
  r:natureDuRisque "L'association de deux antiarythmiques est très délicate. Elle est dans la majorité des cas, contre-indiquée ou déconseillée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611490, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10024 .

_:807f36cf91fe4e8caa53aadeff92477611490 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10193-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE I (SAUF LIDOCAÏNE) <-> BÊTA-BLOQUANTS (SAUF ESMOLOL ET SOTALOL)"@fr;
  dct:identifier "IAM_10193";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611492;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611498, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611492 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611493 .

_:807f36cf91fe4e8caa53aadeff92477611493 rdf:first _:807f36cf91fe4e8caa53aadeff92477611494;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611495 .

_:807f36cf91fe4e8caa53aadeff92477611494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10025 .

_:807f36cf91fe4e8caa53aadeff92477611495 rdf:first _:807f36cf91fe4e8caa53aadeff92477611496;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10053 .

_:807f36cf91fe4e8caa53aadeff92477611498 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10194-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE I (SAUF LIDOCAÏNE) <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10194";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611500;
  r:chapeau """A l’heure actuelle, 4 bêta-bloquants ont l'indication \"insuffisance cardiaque\" : le carvédilol, le bisoprolol, le métoprolol et le névibolol.
Les interactions médicamenteuses des bêta-bloquants, lorsqu’ils sont prescrits dans l’insuffisance cardiaque, pe"""@fr;
  r:natureDuRisque "Effet inotrope négatif avec risque de décompensation cardiaque."@fr;
  rdfs:comment """Les études effectuées avec des antiarythmiques de classe I prescrits à des insuffisants cardiaques ont montré une surmortalité dans le groupe traité.
Ces études ont été faites avant l'utilisation des bêta-bloquants dans cette indication, mais qu'il s'agis"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611506, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611500 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611501 .

_:807f36cf91fe4e8caa53aadeff92477611501 rdf:first _:807f36cf91fe4e8caa53aadeff92477611502;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611503 .

_:807f36cf91fe4e8caa53aadeff92477611502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10025 .

_:807f36cf91fe4e8caa53aadeff92477611503 rdf:first _:807f36cf91fe4e8caa53aadeff92477611504;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477611506 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10195-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE IA <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10195";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611508;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de l'antiarythmique, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et contrôle des concentrations plasmatiques ; si besoin, adaptation de la posologie de l'antiarythmique pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611514, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611508 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611509 .

_:807f36cf91fe4e8caa53aadeff92477611509 rdf:first _:807f36cf91fe4e8caa53aadeff92477611510;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611511 .

_:807f36cf91fe4e8caa53aadeff92477611510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10026 .

_:807f36cf91fe4e8caa53aadeff92477611511 rdf:first _:807f36cf91fe4e8caa53aadeff92477611512;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477611514 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10183-1 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> DIURÉTIQUES HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10183";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611516;
  r:natureDuRisque "Risque d'hypotension artérielle brutale et/ou d'insuffisance rénale aiguë lors de l'instauration ou de l'augmentation de la posologie d'un traitement par un antagoniste de l'angiotensine II en cas de déplétion hydrosodée préexistante."@fr;
  r:conduiteATenir """Dans l'hypertension artérielle, lorsqu'un traitement diurétique préalable a pu entraîner une déplétion hydrosodée, il faut : 
- soit arrêter le diurétique avant de débuter le traitement par l'antagoniste de l'angiotensine II, et réintroduire un diurétique"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611522, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611516 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611517 .

_:807f36cf91fe4e8caa53aadeff92477611517 rdf:first _:807f36cf91fe4e8caa53aadeff92477611518;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611519 .

_:807f36cf91fe4e8caa53aadeff92477611518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477611519 rdf:first _:807f36cf91fe4e8caa53aadeff92477611520;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:807f36cf91fe4e8caa53aadeff92477611522 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10162-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES DE PALIER III <-> MORPHINIQUES AGONISTES-ANTAGONISTES"@fr;
  dct:identifier "IAM_10162";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611524;
  r:natureDuRisque "Diminution de l'effet antalgique par blocage compétitif des récepteurs, avec risque d'apparition d'un syndrome de sevrage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611530, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611524 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611525 .

_:807f36cf91fe4e8caa53aadeff92477611525 rdf:first _:807f36cf91fe4e8caa53aadeff92477611526;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611527 .

_:807f36cf91fe4e8caa53aadeff92477611526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10014 .

_:807f36cf91fe4e8caa53aadeff92477611527 rdf:first _:807f36cf91fe4e8caa53aadeff92477611528;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:807f36cf91fe4e8caa53aadeff92477611530 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10058-1 a owl:Class;
  rdfs:label "AGOMELATINE <-> FLUVOXAMINE"@fr;
  dct:identifier "IAM_10058";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611532;
  r:natureDuRisque "Augmentation des concentrations d'agomélatine, avec risque de majoration des effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611538, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611532 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611533 .

_:807f36cf91fe4e8caa53aadeff92477611533 rdf:first _:807f36cf91fe4e8caa53aadeff92477611534;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611535 .

_:807f36cf91fe4e8caa53aadeff92477611534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10041 .

_:807f36cf91fe4e8caa53aadeff92477611535 rdf:first _:807f36cf91fe4e8caa53aadeff92477611536;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477611538 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10152-1 a owl:Class;
  rdfs:label "AMPHOTERICINE B <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_10152";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611540;
  r:natureDuRisque "Avec l'amphotéricine B administrée par voie IV : augmentation de la toxicité hématologique (addition d'effets de toxicité médullaire)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'hémogramme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611546, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611540 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611541 .

_:807f36cf91fe4e8caa53aadeff92477611541 rdf:first _:807f36cf91fe4e8caa53aadeff92477611542;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611543 .

_:807f36cf91fe4e8caa53aadeff92477611542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477611543 rdf:first _:807f36cf91fe4e8caa53aadeff92477611544;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:807f36cf91fe4e8caa53aadeff92477611546 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10153-1 a owl:Class;
  rdfs:label "ANAGRELIDE <-> ANTIAGRÉGANTS PLAQUETTAIRES"@fr;
  dct:identifier "IAM_10153";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611548;
  r:natureDuRisque "Majoration des événements hémorragiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611554, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611548 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611549 .

_:807f36cf91fe4e8caa53aadeff92477611549 rdf:first _:807f36cf91fe4e8caa53aadeff92477611550;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611551 .

_:807f36cf91fe4e8caa53aadeff92477611550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10023 .

_:807f36cf91fe4e8caa53aadeff92477611551 rdf:first _:807f36cf91fe4e8caa53aadeff92477611552;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477611554 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10154-1 a owl:Class;
  rdfs:label "ANAGRELIDE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10154";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611556;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Surveillance clinique et électrocardiographique pendant
l'association."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611562, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611556 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611557 .

_:807f36cf91fe4e8caa53aadeff92477611557 rdf:first _:807f36cf91fe4e8caa53aadeff92477611558;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611559 .

_:807f36cf91fe4e8caa53aadeff92477611558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477611559 rdf:first _:807f36cf91fe4e8caa53aadeff92477611560;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477611562 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10155-1 a owl:Class;
  rdfs:label "ANAKINRA <-> ANTI-TNF ALPHA"@fr;
  dct:identifier "IAM_10155";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611564;
  r:natureDuRisque "Risque accru d'infections graves et de neutropénies."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611570, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611564 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611565 .

_:807f36cf91fe4e8caa53aadeff92477611565 rdf:first _:807f36cf91fe4e8caa53aadeff92477611566;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611567 .

_:807f36cf91fe4e8caa53aadeff92477611566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10021 .

_:807f36cf91fe4e8caa53aadeff92477611567 rdf:first _:807f36cf91fe4e8caa53aadeff92477611568;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10076 .

_:807f36cf91fe4e8caa53aadeff92477611570 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10156-1 a owl:Class;
  rdfs:label "ANAKINRA <-> ETANERCEPT"@fr;
  dct:identifier "IAM_10156";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611572;
  r:natureDuRisque "Risque accru d'infections graves et de neutropénies."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611578, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611572 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611573 .

_:807f36cf91fe4e8caa53aadeff92477611573 rdf:first _:807f36cf91fe4e8caa53aadeff92477611574;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611575 .

_:807f36cf91fe4e8caa53aadeff92477611574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10076 .

_:807f36cf91fe4e8caa53aadeff92477611575 rdf:first _:807f36cf91fe4e8caa53aadeff92477611576;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10349 .

_:807f36cf91fe4e8caa53aadeff92477611578 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10159-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES AGONISTES <-> AUTRES ANALGÉSIQUES MORPHINIQUES AGONISTES"@fr;
  dct:identifier "IAM_10159";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611580;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611582, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477611582 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10157-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES AGONISTES <-> ANTITUSSIFS MORPHINE-LIKE"@fr;
  dct:identifier "IAM_10157";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611584;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611590, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611584 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611585 .

_:807f36cf91fe4e8caa53aadeff92477611585 rdf:first _:807f36cf91fe4e8caa53aadeff92477611586;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611587 .

_:807f36cf91fe4e8caa53aadeff92477611586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477611587 rdf:first _:807f36cf91fe4e8caa53aadeff92477611588;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10044 .

_:807f36cf91fe4e8caa53aadeff92477611590 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10158-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES AGONISTES <-> ANTITUSSIFS MORPHINIQUES VRAIS"@fr;
  dct:identifier "IAM_10158";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611592;
  r:natureDuRisque "Risque majoré de dépression respiratoire, pouvant être fatale en cas de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611598, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611592 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611593 .

_:807f36cf91fe4e8caa53aadeff92477611593 rdf:first _:807f36cf91fe4e8caa53aadeff92477611594;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611595 .

_:807f36cf91fe4e8caa53aadeff92477611594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477611595 rdf:first _:807f36cf91fe4e8caa53aadeff92477611596;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff92477611598 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10175-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_10175";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611600;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611606, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611600 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611601 .

_:807f36cf91fe4e8caa53aadeff92477611601 rdf:first _:807f36cf91fe4e8caa53aadeff92477611602;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611603 .

_:807f36cf91fe4e8caa53aadeff92477611602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477611603 rdf:first _:807f36cf91fe4e8caa53aadeff92477611604;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:807f36cf91fe4e8caa53aadeff92477611606 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10161-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES DE PALIER II <-> MORPHINIQUES ANTAGONISTES PARTIELS"@fr;
  dct:identifier "IAM_10161";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611608;
  r:natureDuRisque "Risque de diminution de l’effet antalgique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611614, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611608 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611609 .

_:807f36cf91fe4e8caa53aadeff92477611609 rdf:first _:807f36cf91fe4e8caa53aadeff92477611610;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611611 .

_:807f36cf91fe4e8caa53aadeff92477611610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10013 .

_:807f36cf91fe4e8caa53aadeff92477611611 rdf:first _:807f36cf91fe4e8caa53aadeff92477611612;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10111 .

_:807f36cf91fe4e8caa53aadeff92477611614 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10150-1 a owl:Class;
  rdfs:label "AMPHOTERICINE B <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10150";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611616;
  r:natureDuRisque "Avec l'amphotéricine B administrée par voie IV : augmentation de la créatininémie plus importante que sous ciclosporine seule (synergie des effets néphrotoxiques des deux substances)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611622, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611616 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611617 .

_:807f36cf91fe4e8caa53aadeff92477611617 rdf:first _:807f36cf91fe4e8caa53aadeff92477611618;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611619 .

_:807f36cf91fe4e8caa53aadeff92477611618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477611619 rdf:first _:807f36cf91fe4e8caa53aadeff92477611620;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477611622 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10163-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES DE PALIER III <-> MORPHINIQUES ANTAGONISTES PARTIELS"@fr;
  dct:identifier "IAM_10163";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611624;
  r:natureDuRisque "Risque de diminution de l’effet antalgique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611630, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611624 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611625 .

_:807f36cf91fe4e8caa53aadeff92477611625 rdf:first _:807f36cf91fe4e8caa53aadeff92477611626;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611627 .

_:807f36cf91fe4e8caa53aadeff92477611626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10014 .

_:807f36cf91fe4e8caa53aadeff92477611627 rdf:first _:807f36cf91fe4e8caa53aadeff92477611628;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10111 .

_:807f36cf91fe4e8caa53aadeff92477611630 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10164-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10164";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611632;
  r:natureDuRisque "Avec la ciclosporine administrée par voie orale : baisse des concentrations sanguines de ciclosporine (diminution de son absorption intestinale)."@fr;
  r:conduiteATenir "Augmentation des doses de ciclosporine sous contrôle des concentrations plasmatiques et réduction de la posologie après l'arrêt du traitement par l'analogue de la somatostatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611638, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611632 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611633 .

_:807f36cf91fe4e8caa53aadeff92477611633 rdf:first _:807f36cf91fe4e8caa53aadeff92477611634;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611635 .

_:807f36cf91fe4e8caa53aadeff92477611634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:807f36cf91fe4e8caa53aadeff92477611635 rdf:first _:807f36cf91fe4e8caa53aadeff92477611636;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477611638 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10165-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> INSULINE"@fr;
  dct:identifier "IAM_10165";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611640;
  r:natureDuRisque "Risque d'hypoglycémie ou d'hyperglycémie : diminution ou augmentation des besoins en insuline, par diminution ou augmentation de la sécrétion de glucagon endogène."@fr;
  r:conduiteATenir "Prévenir le patient du risque d'hypoglycémie ou d'hyperglycémie, renforcer l'autosurveillance glycémique et adapter si besoin la posologie de l'insuline pendant le traitement par l'analogue de la somatostatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611646, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611640 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611641 .

_:807f36cf91fe4e8caa53aadeff92477611641 rdf:first _:807f36cf91fe4e8caa53aadeff92477611642;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611643 .

_:807f36cf91fe4e8caa53aadeff92477611642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:807f36cf91fe4e8caa53aadeff92477611643 rdf:first _:807f36cf91fe4e8caa53aadeff92477611644;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:807f36cf91fe4e8caa53aadeff92477611646 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10166-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> PIOGLITAZONE"@fr;
  dct:identifier "IAM_10166";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611648;
  r:natureDuRisque """Risque d’hypoglycémie ou d’hyperglycémie : diminution ou
augmentation des besoins en glitazone, par diminution ou
augmentation de la sécrétion de glucagon endogène."""@fr;
  r:conduiteATenir """Renforcer l’autosurveillance glycémique et adapter si besoin la
posologie de la glitazone pendant le traitement par l'analogue de la
somatostatine."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611654, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611648 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611649 .

_:807f36cf91fe4e8caa53aadeff92477611649 rdf:first _:807f36cf91fe4e8caa53aadeff92477611650;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611651 .

_:807f36cf91fe4e8caa53aadeff92477611650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:807f36cf91fe4e8caa53aadeff92477611651 rdf:first _:807f36cf91fe4e8caa53aadeff92477611652;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10723 .

_:807f36cf91fe4e8caa53aadeff92477611654 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10167-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10167";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611656;
  r:natureDuRisque "Risque d'hypoglycémie ou d'hyperglycémie : diminution ou augmentation des besoins en repaglidine, par diminution ou augmentation de la sécrétion de glucagon endogène."@fr;
  r:conduiteATenir "Renforcer l'autosurveillance glycémique et adapter si besoin la posologie de la repaglidine pendant le traitement par l'analogue de la somatostatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611662, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611656 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611657 .

_:807f36cf91fe4e8caa53aadeff92477611657 rdf:first _:807f36cf91fe4e8caa53aadeff92477611658;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611659 .

_:807f36cf91fe4e8caa53aadeff92477611658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:807f36cf91fe4e8caa53aadeff92477611659 rdf:first _:807f36cf91fe4e8caa53aadeff92477611660;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:807f36cf91fe4e8caa53aadeff92477611662 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10168-1 a owl:Class;
  rdfs:label "ANALOGUES DE LA SOMATOSTATINE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10168";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611664;
  r:natureDuRisque "Risque d'hypoglycémie ou d'hyperglycémie : diminution ou augmentation des besoins en sulfamide hypoglycemiant, par diminution ou augmentation de la sécrétion de glucagon endogène."@fr;
  r:conduiteATenir "Renforcer l'autosurveillance glycémique et adapter si besoin la posologie du sulfamide hypoglycemiant pendant le traitement par l'analogue de la somatostatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611670, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611664 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611665 .

_:807f36cf91fe4e8caa53aadeff92477611665 rdf:first _:807f36cf91fe4e8caa53aadeff92477611666;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611667 .

_:807f36cf91fe4e8caa53aadeff92477611666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10015 .

_:807f36cf91fe4e8caa53aadeff92477611667 rdf:first _:807f36cf91fe4e8caa53aadeff92477611668;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477611670 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10169-1 a owl:Class;
  rdfs:label "ANDROGÈNES <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10169";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611672;
  r:natureDuRisque "Augmentation du risque hémorragique par effet direct sur la coagulation et/ou les systèmes fibrinolytiques."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation de la posologie de l’antivitamine K pendant le traitement par l'androgène et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611678, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611672 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611673 .

_:807f36cf91fe4e8caa53aadeff92477611673 rdf:first _:807f36cf91fe4e8caa53aadeff92477611674;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611675 .

_:807f36cf91fe4e8caa53aadeff92477611674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10016 .

_:807f36cf91fe4e8caa53aadeff92477611675 rdf:first _:807f36cf91fe4e8caa53aadeff92477611676;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477611678 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10170-1 a owl:Class;
  rdfs:label "ANDROGÈNES <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10170";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611680;
  r:chapeau "Certains médicaments ont la propriété d'activer considérablement certaines voies métaboliques hépatiques par induction enzymatique. Associés à des médicaments fortement métabolisés au niveau du foie, ils sont, de ce fait, en mesure d'en modifier les conce"@fr;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'androgène et par conséquent de son efficacité, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et biologique pendant l’association et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611686, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611680 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611681 .

_:807f36cf91fe4e8caa53aadeff92477611681 rdf:first _:807f36cf91fe4e8caa53aadeff92477611682;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611683 .

_:807f36cf91fe4e8caa53aadeff92477611682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10016 .

_:807f36cf91fe4e8caa53aadeff92477611683 rdf:first _:807f36cf91fe4e8caa53aadeff92477611684;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477611686 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10171-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> BÊTA-BLOQUANTS (SAUF ESMOLOL)"@fr;
  dct:identifier "IAM_10171";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611688;
  r:natureDuRisque "Réduction des réactions cardiovasculaires de compensation par les bêta-bloquants. L'inhibition bêta-adrénergique peut être levée durant l'intervention par les bêta-mimétiques."@fr;
  r:conduiteATenir "En règle générale, ne pas arrêter le traitement bêta-bloquant et, de toute façon, éviter l'arrêt brutal. Informer l'anesthésiste de ce traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611694, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611688 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611689 .

_:807f36cf91fe4e8caa53aadeff92477611689 rdf:first _:807f36cf91fe4e8caa53aadeff92477611690;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611691 .

_:807f36cf91fe4e8caa53aadeff92477611690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477611691 rdf:first _:807f36cf91fe4e8caa53aadeff92477611692;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477611694 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10172-1 a owl:Class;
  rdfs:label "ANESTHÉSIQUES VOLATILS HALOGÉNÉS <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10172";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611696;
  r:natureDuRisque "Réduction des réactions cardiovasculaires de compensation par les bêta-bloquants. L'inhibition bêta-adrénergique peut être levée durant l'intervention par les bêta-stimulants."@fr;
  r:conduiteATenir "En règle générale, ne pas arrêter le traitement bêta-bloquant et, de toute façon, éviter l'arrêt brutal. Informer l'anesthésiste de ce traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611702, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611696 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611697 .

_:807f36cf91fe4e8caa53aadeff92477611697 rdf:first _:807f36cf91fe4e8caa53aadeff92477611698;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611699 .

_:807f36cf91fe4e8caa53aadeff92477611698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477611699 rdf:first _:807f36cf91fe4e8caa53aadeff92477611700;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477611702 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10160-1 a owl:Class;
  rdfs:label "ANALGÉSIQUES MORPHINIQUES DE PALIER II <-> MORPHINIQUES AGONISTES-ANTAGONISTES"@fr;
  dct:identifier "IAM_10160";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611704;
  r:natureDuRisque "Diminution de l'effet antalgique par blocage compétitif des récepteurs, avec risque d'apparition d'un syndrome de sevrage."@fr;
  rdfs:comment "L’association d’agonistes-antagonistes morphiniques (buprénorphine, nalbuphine, pentazocine) avec des analgésiques morphiniques agonistes a été contre-indiquée jusqu'à présent, et ce, quel que soit leur niveau (palier II ou III de la classification de l'O"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611710, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611704 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611705 .

_:807f36cf91fe4e8caa53aadeff92477611705 rdf:first _:807f36cf91fe4e8caa53aadeff92477611706;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611707 .

_:807f36cf91fe4e8caa53aadeff92477611706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10013 .

_:807f36cf91fe4e8caa53aadeff92477611707 rdf:first _:807f36cf91fe4e8caa53aadeff92477611708;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:807f36cf91fe4e8caa53aadeff92477611710 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10101-1 a owl:Class;
  rdfs:label "ALLOPURINOL <-> VIDARABINE"@fr;
  dct:identifier "IAM_10101";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611712;
  r:natureDuRisque "Risque accru de troubles neurologiques (tremblements, confusion) par inhibition partielle du métabolisme de l'antiviral."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611718, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611712 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611713 .

_:807f36cf91fe4e8caa53aadeff92477611713 rdf:first _:807f36cf91fe4e8caa53aadeff92477611714;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611715 .

_:807f36cf91fe4e8caa53aadeff92477611714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10051 .

_:807f36cf91fe4e8caa53aadeff92477611715 rdf:first _:807f36cf91fe4e8caa53aadeff92477611716;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10981 .

_:807f36cf91fe4e8caa53aadeff92477611718 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10090-1 a owl:Class;
  rdfs:label "ALISKIREN <-> ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II"@fr;
  dct:identifier "IAM_10090";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611720;
  r:natureDuRisque "Risque d’hyperkaliémie, d’insuffisance rénale, d’augmentation de la morbi-mortalité cardio-vasculaire."@fr;
  r:conduiteATenir """Contre-indication :
- chez le patient diabétique ou insuffisant rénal

Association déconseillée :
- dans les autres cas"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611726, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611720 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611721 .

_:807f36cf91fe4e8caa53aadeff92477611721 rdf:first _:807f36cf91fe4e8caa53aadeff92477611722;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611723 .

_:807f36cf91fe4e8caa53aadeff92477611722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477611723 rdf:first _:807f36cf91fe4e8caa53aadeff92477611724;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477611726 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10091-1 a owl:Class;
  rdfs:label "ALISKIREN <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10091";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611728;
  r:natureDuRisque "Augmentation de près de 5 fois des concentrations plasmatiques d’aliskiren et majoration du risque de ses effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611734, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611728 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611729 .

_:807f36cf91fe4e8caa53aadeff92477611729 rdf:first _:807f36cf91fe4e8caa53aadeff92477611730;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611731 .

_:807f36cf91fe4e8caa53aadeff92477611730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477611731 rdf:first _:807f36cf91fe4e8caa53aadeff92477611732;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477611734 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10092-1 a owl:Class;
  rdfs:label "ALISKIREN <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10092";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611736;
  r:natureDuRisque "Risque d’hyperkaliémie, d’insuffisance rénale, d’augmentation de la morbi-mortalité cardio-vasculaire."@fr;
  r:conduiteATenir """Contre-indication :
- chez le patient diabétique ou insuffisant rénal

Association déconseillée :
- dans les autres cas"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611742, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611736 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611737 .

_:807f36cf91fe4e8caa53aadeff92477611737 rdf:first _:807f36cf91fe4e8caa53aadeff92477611738;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611739 .

_:807f36cf91fe4e8caa53aadeff92477611738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477611739 rdf:first _:807f36cf91fe4e8caa53aadeff92477611740;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477611742 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10093-1 a owl:Class;
  rdfs:label "ALISKIREN <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10093";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611744;
  r:natureDuRisque "Augmentation de près de 6 fois des concentrations plasmatiques d’aliskiren et majoration du risque de ses effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611750, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611744 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611745 .

_:807f36cf91fe4e8caa53aadeff92477611745 rdf:first _:807f36cf91fe4e8caa53aadeff92477611746;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611747 .

_:807f36cf91fe4e8caa53aadeff92477611746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477611747 rdf:first _:807f36cf91fe4e8caa53aadeff92477611748;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477611750 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10094-1 a owl:Class;
  rdfs:label "ALISKIREN <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10094";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611752;
  r:natureDuRisque "Risque de diminution de l’efficacité de l’aliskiren en cas de consommation de pamplemousse."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611758, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611752 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611753 .

_:807f36cf91fe4e8caa53aadeff92477611753 rdf:first _:807f36cf91fe4e8caa53aadeff92477611754;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611755 .

_:807f36cf91fe4e8caa53aadeff92477611754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477611755 rdf:first _:807f36cf91fe4e8caa53aadeff92477611756;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477611758 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10095-1 a owl:Class;
  rdfs:label "ALISKIREN <-> QUINIDINE"@fr;
  dct:identifier "IAM_10095";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611760;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’aliskiren et majoration du risque de ses effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611766, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611760 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611761 .

_:807f36cf91fe4e8caa53aadeff92477611761 rdf:first _:807f36cf91fe4e8caa53aadeff92477611762;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611763 .

_:807f36cf91fe4e8caa53aadeff92477611762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477611763 rdf:first _:807f36cf91fe4e8caa53aadeff92477611764;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611764 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477611766 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10096-1 a owl:Class;
  rdfs:label "ALISKIREN <-> SACUBITRIL"@fr;
  dct:identifier "IAM_10096";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611768;
  r:natureDuRisque "Chez les patients diabétiques ou insuffisants rénaux, augmentation des effets indésirables tels que hypotension, hyperkaliémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611774, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611768 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611769 .

_:807f36cf91fe4e8caa53aadeff92477611769 rdf:first _:807f36cf91fe4e8caa53aadeff92477611770;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611771 .

_:807f36cf91fe4e8caa53aadeff92477611770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477611771 rdf:first _:807f36cf91fe4e8caa53aadeff92477611772;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611772 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10821 .

_:807f36cf91fe4e8caa53aadeff92477611774 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10097-1 a owl:Class;
  rdfs:label "ALISKIREN <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10097";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611776;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’aliskiren et majoration du risque de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611782, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611776 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611777 .

_:807f36cf91fe4e8caa53aadeff92477611777 rdf:first _:807f36cf91fe4e8caa53aadeff92477611778;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611779 .

_:807f36cf91fe4e8caa53aadeff92477611778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477611779 rdf:first _:807f36cf91fe4e8caa53aadeff92477611780;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611780 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477611782 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10098-1 a owl:Class;
  rdfs:label "ALLOPURINOL <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10098";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611784;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique (diminution de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'allopurinol et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611790, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611784 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611785 .

_:807f36cf91fe4e8caa53aadeff92477611785 rdf:first _:807f36cf91fe4e8caa53aadeff92477611786;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611787 .

_:807f36cf91fe4e8caa53aadeff92477611786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477611787 rdf:first _:807f36cf91fe4e8caa53aadeff92477611788;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611788 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10051 .

_:807f36cf91fe4e8caa53aadeff92477611790 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10060-1 a owl:Class;
  rdfs:label "ALBENDAZOLE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10060";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611792;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de l’albendazole et de son métabolite actif par le ritonavir, avec risque de baisse de son efficacité."@fr;
  r:conduiteATenir "Surveillance clinique de la réponse thérapeutique et adaptation éventuelle de la posologie de l’albendazole pendant le traitement avec l’inducteur enzymatique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611798, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611792 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611793 .

_:807f36cf91fe4e8caa53aadeff92477611793 rdf:first _:807f36cf91fe4e8caa53aadeff92477611794;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611795 .

_:807f36cf91fe4e8caa53aadeff92477611794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477611795 rdf:first _:807f36cf91fe4e8caa53aadeff92477611796;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477611798 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10100-1 a owl:Class;
  rdfs:label "ALLOPURINOL <-> PÉNICILLINES A"@fr;
  dct:identifier "IAM_10100";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611800;
  r:natureDuRisque "Risque accru de réactions cutanées."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611806, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611800 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611801 .

_:807f36cf91fe4e8caa53aadeff92477611801 rdf:first _:807f36cf91fe4e8caa53aadeff92477611802;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611803 .

_:807f36cf91fe4e8caa53aadeff92477611802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff92477611803 rdf:first _:807f36cf91fe4e8caa53aadeff92477611804;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10051 .

_:807f36cf91fe4e8caa53aadeff92477611806 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10087-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10087";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611808;
  r:natureDuRisque "Augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’analgésique opiacé en cas de traitement par un inhibiteur puissant du CYP3A4."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611814, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611808 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611809 .

_:807f36cf91fe4e8caa53aadeff92477611809 rdf:first _:807f36cf91fe4e8caa53aadeff92477611810;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611811 .

_:807f36cf91fe4e8caa53aadeff92477611810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477611811 rdf:first _:807f36cf91fe4e8caa53aadeff92477611812;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611812 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff92477611814 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10103-1 a owl:Class;
  rdfs:label "ALPHABLOQUANTS À VISÉE UROLOGIQUE <-> ANTIHYPERTENSEURS SAUF ALPHA-BLOQUANTS"@fr;
  dct:identifier "IAM_10103";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611816;
  r:natureDuRisque "Majoration de l'effet hypotenseur. Risque d'hypotension orthostatique majoré."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611822, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611816 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611817 .

_:807f36cf91fe4e8caa53aadeff92477611817 rdf:first _:807f36cf91fe4e8caa53aadeff92477611818;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611819 .

_:807f36cf91fe4e8caa53aadeff92477611818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10009 .

_:807f36cf91fe4e8caa53aadeff92477611819 rdf:first _:807f36cf91fe4e8caa53aadeff92477611820;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611820 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10035 .

_:807f36cf91fe4e8caa53aadeff92477611822 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10102-1 a owl:Class;
  rdfs:label "ALPHABLOQUANTS À VISÉE UROLOGIQUE <-> ANTIHYPERTENSEURS ALPHA-BLOQUANTS"@fr;
  dct:identifier "IAM_10102";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611824;
  r:natureDuRisque "Majoration de l'effet hypotenseur. Risque d'hypotension orthostatique sévère."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611830, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611824 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611825 .

_:807f36cf91fe4e8caa53aadeff92477611825 rdf:first _:807f36cf91fe4e8caa53aadeff92477611826;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611827 .

_:807f36cf91fe4e8caa53aadeff92477611826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10009 .

_:807f36cf91fe4e8caa53aadeff92477611827 rdf:first _:807f36cf91fe4e8caa53aadeff92477611828;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611828 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10033 .

_:807f36cf91fe4e8caa53aadeff92477611830 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10104-1 a owl:Class;
  rdfs:label "ALPHABLOQUANTS À VISÉE UROLOGIQUE <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10104";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611832;
  r:natureDuRisque "Risque d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir """Association déconseillée :
- avec la doxazosine

Précaution d'emploi :
- avec les autres alpha-bloquants
Débuter le traitement aux posologies minimales recommandées et adapter progressivement les doses si besoin."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611838, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611832 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611833 .

_:807f36cf91fe4e8caa53aadeff92477611833 rdf:first _:807f36cf91fe4e8caa53aadeff92477611834;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611835 .

_:807f36cf91fe4e8caa53aadeff92477611834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10009 .

_:807f36cf91fe4e8caa53aadeff92477611835 rdf:first _:807f36cf91fe4e8caa53aadeff92477611836;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611836 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477611838 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10105-1 a owl:Class;
  rdfs:label "ALPHA-TOCOPHEROL <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10105";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611840;
  r:natureDuRisque "Avec la vitamine E utilisée à des doses supérieures ou égales à 500 mg/j : augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par vitamine E et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611846, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611840 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611841 .

_:807f36cf91fe4e8caa53aadeff92477611841 rdf:first _:807f36cf91fe4e8caa53aadeff92477611842;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611843 .

_:807f36cf91fe4e8caa53aadeff92477611842 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477611843 rdf:first _:807f36cf91fe4e8caa53aadeff92477611844;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477611846 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10106-1 a owl:Class;
  rdfs:label "ALPRAZOLAM <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10106";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611848;
  r:natureDuRisque "Possible augmentation de l'effet sédatif de l'alprazolam."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611854, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611848 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611849 .

_:807f36cf91fe4e8caa53aadeff92477611849 rdf:first _:807f36cf91fe4e8caa53aadeff92477611850;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611851 .

_:807f36cf91fe4e8caa53aadeff92477611850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477611851 rdf:first _:807f36cf91fe4e8caa53aadeff92477611852;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477611854 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10107-1 a owl:Class;
  rdfs:label "ALUMINIUM (SELS) <-> CITRATES"@fr;
  dct:identifier "IAM_10107";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611856;
  r:natureDuRisque "Risque de facilitation du passage systémique de l’aluminium, notamment en cas de fonction rénale altérée."@fr;
  r:conduiteATenir "Prendre les topiques gastro-intestinaux à base d'aluminium à distance des citrates (plus de 2 heures si possible), y compris les citrates naturels (jus d'agrumes)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611862, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611856 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611857 .

_:807f36cf91fe4e8caa53aadeff92477611857 rdf:first _:807f36cf91fe4e8caa53aadeff92477611858;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611859 .

_:807f36cf91fe4e8caa53aadeff92477611858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10010 .

_:807f36cf91fe4e8caa53aadeff92477611859 rdf:first _:807f36cf91fe4e8caa53aadeff92477611860;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10056 .

_:807f36cf91fe4e8caa53aadeff92477611862 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10108-1 a owl:Class;
  rdfs:label "AMBRISENTAN <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10108";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611864;
  r:natureDuRisque "Doublement des concentrations d’ambrisentan, avec majoration de l’effet vasodilatateur (céphalées)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611870, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611864 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611865 .

_:807f36cf91fe4e8caa53aadeff92477611865 rdf:first _:807f36cf91fe4e8caa53aadeff92477611866;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611867 .

_:807f36cf91fe4e8caa53aadeff92477611866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10061 .

_:807f36cf91fe4e8caa53aadeff92477611867 rdf:first _:807f36cf91fe4e8caa53aadeff92477611868;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611868 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477611870 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10109-1 a owl:Class;
  rdfs:label "AMINOGLUTETHIMIDE <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10109";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611872;
  r:natureDuRisque "Décrit pour warfarine et acénocoumarol. Diminution de l'effet de l'antivitamine K, par augmentation de son métabolisme hépatique par l'aminogluthétimide."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par aminogluthétimide et deux semaines après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611878, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611872 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611873 .

_:807f36cf91fe4e8caa53aadeff92477611873 rdf:first _:807f36cf91fe4e8caa53aadeff92477611874;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611875 .

_:807f36cf91fe4e8caa53aadeff92477611874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477611875 rdf:first _:807f36cf91fe4e8caa53aadeff92477611876;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611876 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10064 .

_:807f36cf91fe4e8caa53aadeff92477611878 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10110-1 a owl:Class;
  rdfs:label "AMINOGLUTETHIMIDE <-> DEXAMETHASONE"@fr;
  dct:identifier "IAM_10110";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611880;
  r:natureDuRisque "Diminution de l'efficacité de la dexaméthasone, par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adaptation de la posologie de la dexaméthasone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611886, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611880 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611881 .

_:807f36cf91fe4e8caa53aadeff92477611881 rdf:first _:807f36cf91fe4e8caa53aadeff92477611882;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611883 .

_:807f36cf91fe4e8caa53aadeff92477611882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10064 .

_:807f36cf91fe4e8caa53aadeff92477611883 rdf:first _:807f36cf91fe4e8caa53aadeff92477611884;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611884 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477611886 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10099-1 a owl:Class;
  rdfs:label "ALLOPURINOL <-> DIDANOSINE"@fr;
  dct:identifier "IAM_10099";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611888;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de didanosine et de ses effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611894, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611888 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611889 .

_:807f36cf91fe4e8caa53aadeff92477611889 rdf:first _:807f36cf91fe4e8caa53aadeff92477611890;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611891 .

_:807f36cf91fe4e8caa53aadeff92477611890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10051 .

_:807f36cf91fe4e8caa53aadeff92477611891 rdf:first _:807f36cf91fe4e8caa53aadeff92477611892;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:807f36cf91fe4e8caa53aadeff92477611894 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10013-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANAGRELIDE"@fr;
  dct:identifier "IAM_10013";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611896;
  r:natureDuRisque "Majoration des événements hémorragiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611902, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611896 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611897 .

_:807f36cf91fe4e8caa53aadeff92477611897 rdf:first _:807f36cf91fe4e8caa53aadeff92477611898;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611899 .

_:807f36cf91fe4e8caa53aadeff92477611898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477611899 rdf:first _:807f36cf91fe4e8caa53aadeff92477611900;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477611902 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10002-1 a owl:Class;
  rdfs:label "ABATACEPT <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10002";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611904;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  r:conduiteATenir "ainsi que pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611910, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611904 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611905 .

_:807f36cf91fe4e8caa53aadeff92477611905 rdf:first _:807f36cf91fe4e8caa53aadeff92477611906;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611907 .

_:807f36cf91fe4e8caa53aadeff92477611906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477611907 rdf:first _:807f36cf91fe4e8caa53aadeff92477611908;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477611910 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10003-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10003";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611912;
  r:natureDuRisque "Diminution notable des concentrations plasmatiques de l’abiratérone, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611918, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611912 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611913 .

_:807f36cf91fe4e8caa53aadeff92477611913 rdf:first _:807f36cf91fe4e8caa53aadeff92477611914;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611915 .

_:807f36cf91fe4e8caa53aadeff92477611914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477611915 rdf:first _:807f36cf91fe4e8caa53aadeff92477611916;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477611918 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10004-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10004";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611920;
  r:natureDuRisque "Risque d'augmentation des effets indésirables du flecaïnide, par diminution de son métabolisme hépatique par l'abiratérone."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du flécaïnide pendant le traitement par l'abiratérone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611926, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611920 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611921 .

_:807f36cf91fe4e8caa53aadeff92477611921 rdf:first _:807f36cf91fe4e8caa53aadeff92477611922;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611923 .

_:807f36cf91fe4e8caa53aadeff92477611922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477611923 rdf:first _:807f36cf91fe4e8caa53aadeff92477611924;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:807f36cf91fe4e8caa53aadeff92477611926 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10005-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10005";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611928;
  r:natureDuRisque "Chez l'insuffisant cardiaque, risque d'augmentation des effets indésirables du métoprolol, par diminution de son métabolisme hépatique par l'abiratérone."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par l'abiratérone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611934, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611928 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611929 .

_:807f36cf91fe4e8caa53aadeff92477611929 rdf:first _:807f36cf91fe4e8caa53aadeff92477611930;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611931 .

_:807f36cf91fe4e8caa53aadeff92477611930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477611931 rdf:first _:807f36cf91fe4e8caa53aadeff92477611932;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477611934 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10006-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10006";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611936;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la propafénone, par diminution de son métabolisme hépatique par l'abiratérone."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la propafénone pendant le traitement par l'abiratérone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611942, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611936 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611937 .

_:807f36cf91fe4e8caa53aadeff92477611937 rdf:first _:807f36cf91fe4e8caa53aadeff92477611938;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611939 .

_:807f36cf91fe4e8caa53aadeff92477611938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477611939 rdf:first _:807f36cf91fe4e8caa53aadeff92477611940;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477611942 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10007-1 a owl:Class;
  rdfs:label "ABIRATERONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10007";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611944;
  r:natureDuRisque "Diminution notable des concentrations plasmatiques de l’abiratérone, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611950, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611944 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611945 .

_:807f36cf91fe4e8caa53aadeff92477611945 rdf:first _:807f36cf91fe4e8caa53aadeff92477611946;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611947 .

_:807f36cf91fe4e8caa53aadeff92477611946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477611947 rdf:first _:807f36cf91fe4e8caa53aadeff92477611948;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477611950 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10008-1 a owl:Class;
  rdfs:label "ACETAZOLAMIDE <-> ACIDE ACETYLSALICYLIQUE"@fr;
  dct:identifier "IAM_10008";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611952;
  r:natureDuRisque "Majoration des effets indésirables, et notamment de l'acidose métabolique, de l'acide acétylsalicylique à doses élevées et de l'acétazolamide, par diminution de l'élimination de l'acide acétylsalicylique par l'acétazolamide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611958, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611952 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611953 .

_:807f36cf91fe4e8caa53aadeff92477611953 rdf:first _:807f36cf91fe4e8caa53aadeff92477611954;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611955 .

_:807f36cf91fe4e8caa53aadeff92477611954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477611955 rdf:first _:807f36cf91fe4e8caa53aadeff92477611956;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477611958 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10009-1 a owl:Class;
  rdfs:label "ACETAZOLAMIDE <-> CARBAMAZEPINE"@fr;
  dct:identifier "IAM_10009";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611960;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de carbamazépine avec signes de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, contrôle des concentrations plasmatiques de carbamazépine et réduction éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611966, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611960 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611961 .

_:807f36cf91fe4e8caa53aadeff92477611961 rdf:first _:807f36cf91fe4e8caa53aadeff92477611962;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611963 .

_:807f36cf91fe4e8caa53aadeff92477611962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477611963 rdf:first _:807f36cf91fe4e8caa53aadeff92477611964;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477611966 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10010-1 a owl:Class;
  rdfs:label "ACETAZOLAMIDE <-> LITHIUM"@fr;
  dct:identifier "IAM_10010";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611968;
  r:natureDuRisque "Diminution de la lithémie avec risque de baisse de l’efficacité thérapeutique."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611974, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611968 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611969 .

_:807f36cf91fe4e8caa53aadeff92477611969 rdf:first _:807f36cf91fe4e8caa53aadeff92477611970;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611971 .

_:807f36cf91fe4e8caa53aadeff92477611970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477611971 rdf:first _:807f36cf91fe4e8caa53aadeff92477611972;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477611974 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10089-1 a owl:Class;
  rdfs:label "ALFUZOSINE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10089";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611976;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'afuzosine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611982, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611976 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611977 .

_:807f36cf91fe4e8caa53aadeff92477611977 rdf:first _:807f36cf91fe4e8caa53aadeff92477611978;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611979 .

_:807f36cf91fe4e8caa53aadeff92477611978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477611979 rdf:first _:807f36cf91fe4e8caa53aadeff92477611980;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477611982 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10012-1 a owl:Class;
  rdfs:label "ACIDE ACETOHYDROXAMIQUE <-> FER"@fr;
  dct:identifier "IAM_10012";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611984;
  r:natureDuRisque "Diminution de l'absorption digestive de ces deux médicaments par chélation du fer."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611990, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611984 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611985 .

_:807f36cf91fe4e8caa53aadeff92477611985 rdf:first _:807f36cf91fe4e8caa53aadeff92477611986;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611987 .

_:807f36cf91fe4e8caa53aadeff92477611986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477611987 rdf:first _:807f36cf91fe4e8caa53aadeff92477611988;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611988 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477611990 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10088-1 a owl:Class;
  rdfs:label "ALFUZOSINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10088";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477611992;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de l’alfuzosine et de ses effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477611998, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477611992 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477611993 .

_:807f36cf91fe4e8caa53aadeff92477611993 rdf:first _:807f36cf91fe4e8caa53aadeff92477611994;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477611995 .

_:807f36cf91fe4e8caa53aadeff92477611994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477611995 rdf:first _:807f36cf91fe4e8caa53aadeff92477611996;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477611996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477611998 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10071-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10071";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612000;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'alcaloïde de l'ergot de seigle vasoconstricteur par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612006, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612000 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612001 .

_:807f36cf91fe4e8caa53aadeff92477612001 rdf:first _:807f36cf91fe4e8caa53aadeff92477612002;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612003 .

_:807f36cf91fe4e8caa53aadeff92477612002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477612003 rdf:first _:807f36cf91fe4e8caa53aadeff92477612004;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477612006 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10072-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> SYMPATHOMIMÉTIQUES ALPHA (VOIES ORALE ET/OU NASALE)"@fr;
  dct:identifier "IAM_10072";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612008;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612014, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612008 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612009 .

_:807f36cf91fe4e8caa53aadeff92477612009 rdf:first _:807f36cf91fe4e8caa53aadeff92477612010;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612011 .

_:807f36cf91fe4e8caa53aadeff92477612010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477612011 rdf:first _:807f36cf91fe4e8caa53aadeff92477612012;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10148 .

_:807f36cf91fe4e8caa53aadeff92477612014 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10073-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_10073";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612016;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:comment """Les décisions suivantes, émanant de trois instances de l'Afssaps, ont été prises en compte : 
- la Commission Nationale de Pharmacovigilance a pris acte d'une toxicité de la phénylpropanolamine supérieure à celle des autres sympathomimétiques indirects ("""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612022, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612016 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612017 .

_:807f36cf91fe4e8caa53aadeff92477612017 rdf:first _:807f36cf91fe4e8caa53aadeff92477612018;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612019 .

_:807f36cf91fe4e8caa53aadeff92477612018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477612019 rdf:first _:807f36cf91fe4e8caa53aadeff92477612020;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477612022 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10074-1 a owl:Class;
  rdfs:label "ALCALOÏDES DE L'ERGOT DE SEIGLE VASOCONSTRICTEURS <-> TRIPTANS"@fr;
  dct:identifier "IAM_10074";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612024;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  r:conduiteATenir "Respecter un délai de 6 à 24 heures, selon le triptan, entre la prise de celui-ci et celle de l'alcaloïde ergoté"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612030, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612024 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612025 .

_:807f36cf91fe4e8caa53aadeff92477612025 rdf:first _:807f36cf91fe4e8caa53aadeff92477612026;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612027 .

_:807f36cf91fe4e8caa53aadeff92477612026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477612027 rdf:first _:807f36cf91fe4e8caa53aadeff92477612028;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612028 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10156 .

_:807f36cf91fe4e8caa53aadeff92477612030 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10082-1 a owl:Class;
  rdfs:label "ALDESLEUKINE <-> PRODUITS DE CONTRASTE IODÉS"@fr;
  dct:identifier "IAM_10082";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612032;
  r:natureDuRisque "Majoration du risque de réaction aux produits de contraste en cas de traitement antérieur par interleukine 2 : éruption cutanée ou plus rarement hypotension, oligurie voire insuffisance rénale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612038, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612032 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612033 .

_:807f36cf91fe4e8caa53aadeff92477612033 rdf:first _:807f36cf91fe4e8caa53aadeff92477612034;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612035 .

_:807f36cf91fe4e8caa53aadeff92477612034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10133 .

_:807f36cf91fe4e8caa53aadeff92477612035 rdf:first _:807f36cf91fe4e8caa53aadeff92477612036;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612036 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477612038 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10083-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10083";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612040;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adapter la posologie de l'alfentanil en cas de traitement par la cimétidine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612046, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612040 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612041 .

_:807f36cf91fe4e8caa53aadeff92477612041 rdf:first _:807f36cf91fe4e8caa53aadeff92477612042;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612043 .

_:807f36cf91fe4e8caa53aadeff92477612042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff92477612043 rdf:first _:807f36cf91fe4e8caa53aadeff92477612044;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612044 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477612046 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10084-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10084";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612048;
  r:natureDuRisque "Augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adapter la posologie de l'alfentanil en cas de traitement par le diltiazem."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612054, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612048 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612049 .

_:807f36cf91fe4e8caa53aadeff92477612049 rdf:first _:807f36cf91fe4e8caa53aadeff92477612050;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612051 .

_:807f36cf91fe4e8caa53aadeff92477612050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff92477612051 rdf:first _:807f36cf91fe4e8caa53aadeff92477612052;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612052 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477612054 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10085-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10085";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612056;
  r:natureDuRisque "Augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adapter la posologie de l'alfentanil en cas de traitement par l'érythromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612062, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612056 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612057 .

_:807f36cf91fe4e8caa53aadeff92477612057 rdf:first _:807f36cf91fe4e8caa53aadeff92477612058;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612059 .

_:807f36cf91fe4e8caa53aadeff92477612058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff92477612059 rdf:first _:807f36cf91fe4e8caa53aadeff92477612060;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612060 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477612062 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10086-1 a owl:Class;
  rdfs:label "ALFENTANIL <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10086";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612064;
  r:natureDuRisque "Augmentation de l'effet dépresseur respiratoire de l'analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Adapter la posologie de l'alfentanil en cas de traitement par le fluconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612070, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612064 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612065 .

_:807f36cf91fe4e8caa53aadeff92477612065 rdf:first _:807f36cf91fe4e8caa53aadeff92477612066;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612067 .

_:807f36cf91fe4e8caa53aadeff92477612066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10045 .

_:807f36cf91fe4e8caa53aadeff92477612067 rdf:first _:807f36cf91fe4e8caa53aadeff92477612068;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612068 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477612070 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10112-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> ATALUREN"@fr;
  dct:identifier "IAM_10112";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612072;
  r:natureDuRisque "Risque de potentialisation de la toxicité rénale de l’aminoside."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612078, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612072 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612073 .

_:807f36cf91fe4e8caa53aadeff92477612073 rdf:first _:807f36cf91fe4e8caa53aadeff92477612074;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612075 .

_:807f36cf91fe4e8caa53aadeff92477612074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477612075 rdf:first _:807f36cf91fe4e8caa53aadeff92477612076;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612076 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10086 .

_:807f36cf91fe4e8caa53aadeff92477612078 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10011-1 a owl:Class;
  rdfs:label "ACETAZOLAMIDE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_10011";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612080;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612086, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612080 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612081 .

_:807f36cf91fe4e8caa53aadeff92477612081 rdf:first _:807f36cf91fe4e8caa53aadeff92477612082;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612083 .

_:807f36cf91fe4e8caa53aadeff92477612082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477612083 rdf:first _:807f36cf91fe4e8caa53aadeff92477612084;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612084 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10008 .

_:807f36cf91fe4e8caa53aadeff92477612086 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10047-1 a owl:Class;
  rdfs:label "AFATINIB <-> AMIODARONE"@fr;
  dct:identifier "IAM_10047";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612088;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’afatinib par augmentation de son absorption par l'amiodarone."@fr;
  r:conduiteATenir """Il est recommandé d’administrer l'amiodarone le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612094, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612088 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612089 .

_:807f36cf91fe4e8caa53aadeff92477612089 rdf:first _:807f36cf91fe4e8caa53aadeff92477612090;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612091 .

_:807f36cf91fe4e8caa53aadeff92477612090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477612091 rdf:first _:807f36cf91fe4e8caa53aadeff92477612092;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612092 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477612094 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10113-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> AUTRES AMINOSIDES"@fr;
  dct:identifier "IAM_10113";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612096;
  r:natureDuRisque "Risque accru de néphrotoxicité et d'ototoxicité (l'ototoxicité est cumulative en cas d'administrations successives)."@fr;
  r:conduiteATenir """A prendre en compte :
- en cas d'administrations successives"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477612098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10037-1 a owl:Class;
  rdfs:label "ACIDE FUSIDIQUE <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10037";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612100;
  r:natureDuRisque """Risque majoré d'effets indésirables (concentration-dépendants) à
type de rhabdomyolyse."""@fr;
  r:conduiteATenir """Arrêter le traitement par l'inhibiteur de l'HMG Co-A
réductase avant d'initier un traitement par acide fusidique ou utiliser un autre antibiotique."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612101 .

_:807f36cf91fe4e8caa53aadeff92477612101 rdf:first _:807f36cf91fe4e8caa53aadeff92477612102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612103 .

_:807f36cf91fe4e8caa53aadeff92477612102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477612103 rdf:first _:807f36cf91fe4e8caa53aadeff92477612104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10021 .

_:807f36cf91fe4e8caa53aadeff92477612106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10038-1 a owl:Class;
  rdfs:label "ACIDE FUSIDIQUE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10038";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612108;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'acide fusidique par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612109 .

_:807f36cf91fe4e8caa53aadeff92477612109 rdf:first _:807f36cf91fe4e8caa53aadeff92477612110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612111 .

_:807f36cf91fe4e8caa53aadeff92477612110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477612111 rdf:first _:807f36cf91fe4e8caa53aadeff92477612112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10021 .

_:807f36cf91fe4e8caa53aadeff92477612114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10039-1 a owl:Class;
  rdfs:label "ACIDE NICOTINIQUE <-> ALCOOL (BOISSON OU EXCIPIENT)"@fr;
  dct:identifier "IAM_10039";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612116;
  r:natureDuRisque "Risque de prurit, de rougeur et de chaleur, lié à une potentialisation de l'effet vasodilatateur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612122, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612116 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612117 .

_:807f36cf91fe4e8caa53aadeff92477612117 rdf:first _:807f36cf91fe4e8caa53aadeff92477612118;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612119 .

_:807f36cf91fe4e8caa53aadeff92477612118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10026 .

_:807f36cf91fe4e8caa53aadeff92477612119 rdf:first _:807f36cf91fe4e8caa53aadeff92477612120;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477612122 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10040-1 a owl:Class;
  rdfs:label "ACIDE URSODESOXYCHOLIQUE <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10040";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612124;
  r:natureDuRisque "Risque de variation des concentrations sanguines de ciclosporine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612130, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612124 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612125 .

_:807f36cf91fe4e8caa53aadeff92477612125 rdf:first _:807f36cf91fe4e8caa53aadeff92477612126;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612127 .

_:807f36cf91fe4e8caa53aadeff92477612126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10033 .

_:807f36cf91fe4e8caa53aadeff92477612127 rdf:first _:807f36cf91fe4e8caa53aadeff92477612128;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477612130 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10041-1 a owl:Class;
  rdfs:label "ACITRETINE <-> ALCOOL (BOISSON OU EXCIPIENT)"@fr;
  dct:identifier "IAM_10041";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612132;
  r:natureDuRisque "Chez la femme en âge de procréer, risque de transformation de l’acitrétine en étrétinate, puissant tératogène dont la demi-vie très prolongée (120 jours) expose à un risque tératogène majeur en cas de grossesse, pendant le traitement et les 2 mois suivan"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612138, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612132 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612133 .

_:807f36cf91fe4e8caa53aadeff92477612133 rdf:first _:807f36cf91fe4e8caa53aadeff92477612134;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612135 .

_:807f36cf91fe4e8caa53aadeff92477612134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10036 .

_:807f36cf91fe4e8caa53aadeff92477612135 rdf:first _:807f36cf91fe4e8caa53aadeff92477612136;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477612138 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10042-1 a owl:Class;
  rdfs:label "ACITRETINE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10042";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612140;
  r:natureDuRisque "Risque de majoration de l’hépatotoxicité du méthotrexate."@fr;
  r:conduiteATenir "Si l’association est jugée nécessaire, renforcer la surveillance du bilan hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612146, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612140 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612141 .

_:807f36cf91fe4e8caa53aadeff92477612141 rdf:first _:807f36cf91fe4e8caa53aadeff92477612142;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612143 .

_:807f36cf91fe4e8caa53aadeff92477612142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10036 .

_:807f36cf91fe4e8caa53aadeff92477612143 rdf:first _:807f36cf91fe4e8caa53aadeff92477612144;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477612146 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10045-1 a owl:Class;
  rdfs:label "ADRÉNALINE (VOIE BUCCO-DENTAIRE OU SOUS-CUTANÉE) <-> IMAO IRRÉVERSIBLES"@fr;
  dct:identifier "IAM_10045";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612148;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  r:conduiteATenir "Limiter l'apport, par exemple : moins de 0,1 mg d'adrénaline en 10 minutes ou 0,3 mg en 1 heure chez l'adulte."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612154, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612148 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612149 .

_:807f36cf91fe4e8caa53aadeff92477612149 rdf:first _:807f36cf91fe4e8caa53aadeff92477612150;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612151 .

_:807f36cf91fe4e8caa53aadeff92477612150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477612151 rdf:first _:807f36cf91fe4e8caa53aadeff92477612152;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10005 .

_:807f36cf91fe4e8caa53aadeff92477612154 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10043-1 a owl:Class;
  rdfs:label "ADRÉNALINE (VOIE BUCCO-DENTAIRE OU SOUS-CUTANÉE) <-> ANESTHÉSIQUES VOLATILS HALOGÉNÉS"@fr;
  dct:identifier "IAM_10043";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612156;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  r:conduiteATenir "Limiter l'apport, par exemple : moins de 0,1 mg d'adrénaline en 10 minutes ou 0,3 mg en 1 heure chez l'adulte."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612162, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612156 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612157 .

_:807f36cf91fe4e8caa53aadeff92477612157 rdf:first _:807f36cf91fe4e8caa53aadeff92477612158;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612159 .

_:807f36cf91fe4e8caa53aadeff92477612158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10005 .

_:807f36cf91fe4e8caa53aadeff92477612159 rdf:first _:807f36cf91fe4e8caa53aadeff92477612160;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477612162 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10035-1 a owl:Class;
  rdfs:label "ACIDE CLODRONIQUE <-> ESTRAMUSTINE"@fr;
  dct:identifier "IAM_10035";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612164;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques d’estramustine par le clodronate."@fr;
  r:conduiteATenir "Surveillance clinique au cours de l’association."@fr;
  rdfs:comment "Une étude effectuée chez 12 patients ne montre pas de modification significative des paramètres pharmacocinétiques (Cmax, AUC) ou de l’excrétion diurne du clodronate, lorsqu’il est associé à l’estramustine. En revanche, une augmentation de 77% de la Cmax"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612170, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612164 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612165 .

_:807f36cf91fe4e8caa53aadeff92477612165 rdf:first _:807f36cf91fe4e8caa53aadeff92477612166;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612167 .

_:807f36cf91fe4e8caa53aadeff92477612166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10017 .

_:807f36cf91fe4e8caa53aadeff92477612167 rdf:first _:807f36cf91fe4e8caa53aadeff92477612168;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10345 .

_:807f36cf91fe4e8caa53aadeff92477612170 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10046-1 a owl:Class;
  rdfs:label "ADRÉNALINE (VOIE BUCCO-DENTAIRE OU SOUS-CUTANÉE) <-> MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES"@fr;
  dct:identifier "IAM_10046";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612172;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  r:conduiteATenir "Limiter l'apport, par exemple : moins de 0,1 mg d'adrénaline en 10 minutes ou 0,3 mg en 1 heure chez l'adulte."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612178, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612172 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612173 .

_:807f36cf91fe4e8caa53aadeff92477612173 rdf:first _:807f36cf91fe4e8caa53aadeff92477612174;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612175 .

_:807f36cf91fe4e8caa53aadeff92477612174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10005 .

_:807f36cf91fe4e8caa53aadeff92477612175 rdf:first _:807f36cf91fe4e8caa53aadeff92477612176;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:807f36cf91fe4e8caa53aadeff92477612178 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10034-1 a owl:Class;
  rdfs:label "ACIDE CHOLIQUE <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_10034";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612180;
  r:natureDuRisque "Effet antagoniste du barbiturique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612186, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612180 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612181 .

_:807f36cf91fe4e8caa53aadeff92477612181 rdf:first _:807f36cf91fe4e8caa53aadeff92477612182;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612183 .

_:807f36cf91fe4e8caa53aadeff92477612182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477612183 rdf:first _:807f36cf91fe4e8caa53aadeff92477612184;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10016 .

_:807f36cf91fe4e8caa53aadeff92477612186 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10048-1 a owl:Class;
  rdfs:label "AFATINIB <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10048";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612188;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’afatinib par augmentation de son métabolisme par ces substances."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association et 1 à 2 semaines après leur arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612194, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612188 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612189 .

_:807f36cf91fe4e8caa53aadeff92477612189 rdf:first _:807f36cf91fe4e8caa53aadeff92477612190;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612191 .

_:807f36cf91fe4e8caa53aadeff92477612190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612191 rdf:first _:807f36cf91fe4e8caa53aadeff92477612192;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477612194 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10049-1 a owl:Class;
  rdfs:label "AFATINIB <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10049";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612196;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par la ciclosporine."@fr;
  r:conduiteATenir """Il est recommandé d’administrer la ciclosporine le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
 de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612202, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612196 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612197 .

_:807f36cf91fe4e8caa53aadeff92477612197 rdf:first _:807f36cf91fe4e8caa53aadeff92477612198;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612199 .

_:807f36cf91fe4e8caa53aadeff92477612198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477612199 rdf:first _:807f36cf91fe4e8caa53aadeff92477612200;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477612202 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10050-1 a owl:Class;
  rdfs:label "AFATINIB <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10050";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612204;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par l'érythromycine."@fr;
  r:conduiteATenir """Il est recommandé d’administrer l'érythromycine le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
 de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612210, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612204 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612205 .

_:807f36cf91fe4e8caa53aadeff92477612205 rdf:first _:807f36cf91fe4e8caa53aadeff92477612206;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612207 .

_:807f36cf91fe4e8caa53aadeff92477612206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477612207 rdf:first _:807f36cf91fe4e8caa53aadeff92477612208;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477612210 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10051-1 a owl:Class;
  rdfs:label "AFATINIB <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10051";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612212;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par l'inhibiteur de protéases."@fr;
  r:conduiteATenir "Il est recommandé d’administrer l'inhibiteur de protéases le plus à distance possible de l’afatinib, en respectant de préférence un intervalle de 6 heures ou de 12 heures par rapport à la prise d’afatinib."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612218, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612212 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612213 .

_:807f36cf91fe4e8caa53aadeff92477612213 rdf:first _:807f36cf91fe4e8caa53aadeff92477612214;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612215 .

_:807f36cf91fe4e8caa53aadeff92477612214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477612215 rdf:first _:807f36cf91fe4e8caa53aadeff92477612216;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477612218 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10052-1 a owl:Class;
  rdfs:label "AFATINIB <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10052";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612220;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par l'itraconazole."@fr;
  r:conduiteATenir """Il est recommandé d’administrer l'itraconazole le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612226, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612220 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612221 .

_:807f36cf91fe4e8caa53aadeff92477612221 rdf:first _:807f36cf91fe4e8caa53aadeff92477612222;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612223 .

_:807f36cf91fe4e8caa53aadeff92477612222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477612223 rdf:first _:807f36cf91fe4e8caa53aadeff92477612224;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477612226 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10053-1 a owl:Class;
  rdfs:label "AFATINIB <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10053";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612228;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par le kétoconazole."@fr;
  r:conduiteATenir """Il est recommandé d’administrer le kétoconazole le plus à distance possible de l’afatinib, en respectant de préférence un intervalle 
de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612234, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612228 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612229 .

_:807f36cf91fe4e8caa53aadeff92477612229 rdf:first _:807f36cf91fe4e8caa53aadeff92477612230;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612231 .

_:807f36cf91fe4e8caa53aadeff92477612230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477612231 rdf:first _:807f36cf91fe4e8caa53aadeff92477612232;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477612234 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10054-1 a owl:Class;
  rdfs:label "AFATINIB <-> PRIMIDONE"@fr;
  dct:identifier "IAM_10054";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612236;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’afatinib par augmentation de son métabolisme par la primidone."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association et 1 à 2 semaines après leur arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612242, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612236 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612237 .

_:807f36cf91fe4e8caa53aadeff92477612237 rdf:first _:807f36cf91fe4e8caa53aadeff92477612238;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612239 .

_:807f36cf91fe4e8caa53aadeff92477612238 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477612239 rdf:first _:807f36cf91fe4e8caa53aadeff92477612240;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612240 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10756 .

_:807f36cf91fe4e8caa53aadeff92477612242 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10055-1 a owl:Class;
  rdfs:label "AFATINIB <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10055";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612244;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’afatinib par augmentation de son métabolisme par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association et 1 à 2 semaines après leur arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612250, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612244 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612245 .

_:807f36cf91fe4e8caa53aadeff92477612245 rdf:first _:807f36cf91fe4e8caa53aadeff92477612246;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612247 .

_:807f36cf91fe4e8caa53aadeff92477612246 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477612247 rdf:first _:807f36cf91fe4e8caa53aadeff92477612248;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612248 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477612250 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10056-1 a owl:Class;
  rdfs:label "AFATINIB <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10056";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612252;
  r:natureDuRisque "Augmentation des concentrations plasmatique d’afatinib par augmentation de son absorption par le vérapamil."@fr;
  r:conduiteATenir """Il est recommandé d’administrer le vérapamil le plus à distance possible de l’afatinib, en respectant de préférence un intervalle
de 6 heures ou de 12 heures par rapport à la prise d’afatinib."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612258, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612252 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612253 .

_:807f36cf91fe4e8caa53aadeff92477612253 rdf:first _:807f36cf91fe4e8caa53aadeff92477612254;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612255 .

_:807f36cf91fe4e8caa53aadeff92477612254 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10040 .

_:807f36cf91fe4e8caa53aadeff92477612255 rdf:first _:807f36cf91fe4e8caa53aadeff92477612256;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612256 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477612258 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10057-1 a owl:Class;
  rdfs:label "AGOMELATINE <-> CIPROFLOXACINE"@fr;
  dct:identifier "IAM_10057";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612260;
  r:natureDuRisque """Augmentation des concentrations d'agomélatine, avec risque de 
majoration des effets indésirables."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612266, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612260 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612261 .

_:807f36cf91fe4e8caa53aadeff92477612261 rdf:first _:807f36cf91fe4e8caa53aadeff92477612262;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612263 .

_:807f36cf91fe4e8caa53aadeff92477612262 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10041 .

_:807f36cf91fe4e8caa53aadeff92477612263 rdf:first _:807f36cf91fe4e8caa53aadeff92477612264;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612264 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10200 .

_:807f36cf91fe4e8caa53aadeff92477612266 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10044-1 a owl:Class;
  rdfs:label "ADRÉNALINE (VOIE BUCCO-DENTAIRE OU SOUS-CUTANÉE) <-> ANTIDÉPRESSEURS IMIPRAMINIQUES"@fr;
  dct:identifier "IAM_10044";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612268;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  r:conduiteATenir "Limiter l'apport, par exemple : moins de 0,1 mg d'adrénaline en 10 minutes ou 0,3 mg en 1 heure chez l'adulte."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612274, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612268 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612269 .

_:807f36cf91fe4e8caa53aadeff92477612269 rdf:first _:807f36cf91fe4e8caa53aadeff92477612270;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612271 .

_:807f36cf91fe4e8caa53aadeff92477612270 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10005 .

_:807f36cf91fe4e8caa53aadeff92477612271 rdf:first _:807f36cf91fe4e8caa53aadeff92477612272;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612272 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:807f36cf91fe4e8caa53aadeff92477612274 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10023-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10023";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612276;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire et agression de la muqueuse gastroduodénale par l’acide acétylsalicylique)."@fr;
  r:conduiteATenir """A prendre en compte avec :
- des doses antiagrégantes (de 50 mg à 375 mg par jour)."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612282, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612276 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612277 .

_:807f36cf91fe4e8caa53aadeff92477612277 rdf:first _:807f36cf91fe4e8caa53aadeff92477612278;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612279 .

_:807f36cf91fe4e8caa53aadeff92477612278 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:807f36cf91fe4e8caa53aadeff92477612279 rdf:first _:807f36cf91fe4e8caa53aadeff92477612280;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612280 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612282 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10205-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10205";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612284;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Surveillance clinique et, le cas échéant, contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'anticoagulant oral pendant la durée de l'association et à son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612290, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612284 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612285 .

_:807f36cf91fe4e8caa53aadeff92477612285 rdf:first _:807f36cf91fe4e8caa53aadeff92477612286;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612287 .

_:807f36cf91fe4e8caa53aadeff92477612286 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477612287 rdf:first _:807f36cf91fe4e8caa53aadeff92477612288;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612288 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477612290 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10114-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> BOTULIQUE (TOXINE)"@fr;
  dct:identifier "IAM_10114";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612292;
  r:natureDuRisque "Risque d'augmentation des effets de la toxine botulique avec les aminosides (par extrapolation à partir des effets observés au cours du botulisme)."@fr;
  r:conduiteATenir "Utiliser un autre antibiotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612298, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612292 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612293 .

_:807f36cf91fe4e8caa53aadeff92477612293 rdf:first _:807f36cf91fe4e8caa53aadeff92477612294;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612295 .

_:807f36cf91fe4e8caa53aadeff92477612294 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477612295 rdf:first _:807f36cf91fe4e8caa53aadeff92477612296;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612296 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477612298 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10014-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II"@fr;
  dct:identifier "IAM_10014";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612300;
  r:natureDuRisque """Pour des doses anti-inflammatoires d'acide acétylsalicylique (>= 1g par prise et/ou >= 3g par jour) ou pour des doses antalgiques ou antipyrétiques (>= 500 mg par prise et/ou < 3g par jour) : 

Insuffisance rénale aiguë chez le malade déshydraté, par dimi"""@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612306, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612300 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612301 .

_:807f36cf91fe4e8caa53aadeff92477612301 rdf:first _:807f36cf91fe4e8caa53aadeff92477612302;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612303 .

_:807f36cf91fe4e8caa53aadeff92477612302 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477612303 rdf:first _:807f36cf91fe4e8caa53aadeff92477612304;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612304 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612306 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10015-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10015";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612308;
  r:natureDuRisque "Majoration du risque hémorragique, notamment en cas d’antécédent d’ulcère gastro-duodénal."@fr;
  r:conduiteATenir """A prendre en compte avec :
- des doses antiagrégantes (de 50 mg à 375 mg par jour)"""@fr;
  rdfs:comment "Jusqu'à présent, cette interaction se présentait selon deux niveaux distincts : une contre-indication avec l'acide acétylsalicylique administré à doses anti-inflammatoires et une association déconseillée avec l'aspirine donnée à doses antalgiques ou anti"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612314, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612308 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612309 .

_:807f36cf91fe4e8caa53aadeff92477612309 rdf:first _:807f36cf91fe4e8caa53aadeff92477612310;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612311 .

_:807f36cf91fe4e8caa53aadeff92477612310 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477612311 rdf:first _:807f36cf91fe4e8caa53aadeff92477612312;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612312 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612314 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10016-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTI-INFLAMMATOIRES NON STÉROÏDIENS"@fr;
  dct:identifier "IAM_10016";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612316;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  r:conduiteATenir """A prendre en compte avec :
- des doses antiagrégantes (de 50 mg à 375 mg par jour en 1 ou plusieurs prises)"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612322, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612316 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612317 .

_:807f36cf91fe4e8caa53aadeff92477612317 rdf:first _:807f36cf91fe4e8caa53aadeff92477612318;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612319 .

_:807f36cf91fe4e8caa53aadeff92477612318 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477612319 rdf:first _:807f36cf91fe4e8caa53aadeff92477612320;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612320 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612322 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10017-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> CLOPIDOGREL"@fr;
  dct:identifier "IAM_10017";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612324;
  r:natureDuRisque "Majoration du risque hémorragique par addition des activités antiagrégantes plaquettaires."@fr;
  r:conduiteATenir """Association déconseillée :
- en dehors des indications validées pour cette association dans les syndromes coronariens aigus.

Précaution d'emploi :
- dans les indications validées pour cette association dans les syndromes coronariens aigus. Surveillance c"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612330, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612324 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612325 .

_:807f36cf91fe4e8caa53aadeff92477612325 rdf:first _:807f36cf91fe4e8caa53aadeff92477612326;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612327 .

_:807f36cf91fe4e8caa53aadeff92477612326 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612327 rdf:first _:807f36cf91fe4e8caa53aadeff92477612328;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612328 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:807f36cf91fe4e8caa53aadeff92477612330 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10018-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10018";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612332;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  r:conduiteATenir """A prendre en compte :
- Pour des doses anti-inflammatoires d'acide acétylsalicylique (1g par prise et/ou 3g par jour)
- Pour des doses antalgiques ou antipyrétiques d'acide acétylsalicylique (500 mg par prise et/ou <3g par jour) et (500 mg par prise e"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612338, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612332 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612333 .

_:807f36cf91fe4e8caa53aadeff92477612333 rdf:first _:807f36cf91fe4e8caa53aadeff92477612334;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612335 .

_:807f36cf91fe4e8caa53aadeff92477612334 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612335 rdf:first _:807f36cf91fe4e8caa53aadeff92477612336;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612336 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477612338 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10019-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> DIURÉTIQUES"@fr;
  dct:identifier "IAM_10019";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612340;
  r:natureDuRisque """Pour des doses anti-inflammatoires d'acide acétylsalicylique (>= 1g par prise et/ou >= 3g par jour) ou pour des doses antalgiques ou antipyrétiques (>= 500 mg par prise et/ou < 3g par jour) : 

Insuffisance rénale aiguë chez le malade déshydraté, par dimi"""@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612346, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612340 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612341 .

_:807f36cf91fe4e8caa53aadeff92477612341 rdf:first _:807f36cf91fe4e8caa53aadeff92477612342;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612343 .

_:807f36cf91fe4e8caa53aadeff92477612342 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10063 .

_:807f36cf91fe4e8caa53aadeff92477612343 rdf:first _:807f36cf91fe4e8caa53aadeff92477612344;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612344 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612346 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10020-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10020";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612348;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour)

A prendre en compte avec :
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612354, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612348 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612349 .

_:807f36cf91fe4e8caa53aadeff92477612349 rdf:first _:807f36cf91fe4e8caa53aadeff92477612350;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612351 .

_:807f36cf91fe4e8caa53aadeff92477612350 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477612351 rdf:first _:807f36cf91fe4e8caa53aadeff92477612352;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612352 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612354 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10036-1 a owl:Class;
  rdfs:label "ACIDE FOLINIQUE <-> FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES)"@fr;
  dct:identifier "IAM_10036";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612356;
  r:natureDuRisque "Potentialisation des effets, à la fois cytostatiques et indésirables, du fluoro-uracile."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612362, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612356 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612357 .

_:807f36cf91fe4e8caa53aadeff92477612357 rdf:first _:807f36cf91fe4e8caa53aadeff92477612358;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612359 .

_:807f36cf91fe4e8caa53aadeff92477612358 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:807f36cf91fe4e8caa53aadeff92477612359 rdf:first _:807f36cf91fe4e8caa53aadeff92477612360;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612360 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10019 .

_:807f36cf91fe4e8caa53aadeff92477612362 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10022-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES PRÉVENTIVES)"@fr;
  dct:identifier "IAM_10022";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612364;
  r:natureDuRisque "L’utilisation conjointe de médicaments agissant à divers niveaux de l’hémostase majore le risque de saignement. Ainsi, chez le sujet de moins de 65 ans, l’association de l'héparine à doses préventives, ou de substances apparentées, à l’acide acétylsalicyl"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612370, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612364 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612365 .

_:807f36cf91fe4e8caa53aadeff92477612365 rdf:first _:807f36cf91fe4e8caa53aadeff92477612366;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612367 .

_:807f36cf91fe4e8caa53aadeff92477612366 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10090 .

_:807f36cf91fe4e8caa53aadeff92477612367 rdf:first _:807f36cf91fe4e8caa53aadeff92477612368;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612368 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612370 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10111-1 a owl:Class;
  rdfs:label "AMINOSIDES <-> AMPHOTERICINE B"@fr;
  dct:identifier "IAM_10111";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612372;
  r:natureDuRisque "Avec l'amphotéricine B administrée par voie IV : risque accru de néphrotoxicité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612378, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612372 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612373 .

_:807f36cf91fe4e8caa53aadeff92477612373 rdf:first _:807f36cf91fe4e8caa53aadeff92477612374;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612375 .

_:807f36cf91fe4e8caa53aadeff92477612374 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477612375 rdf:first _:807f36cf91fe4e8caa53aadeff92477612376;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612376 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477612378 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10024-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES NON FRACTIONNÉES (DOSES PRÉVENTIVES)"@fr;
  dct:identifier "IAM_10024";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612380;
  r:natureDuRisque "L’utilisation conjointe de médicaments agissant à divers niveaux de l’hémostase majore le risque de saignement. Ainsi, chez le sujet de moins de 65 ans, l’association des héparines à doses préventives à l’acide acétylsalicylique, quelle que soit la dose,"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612386, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612380 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612381 .

_:807f36cf91fe4e8caa53aadeff92477612381 rdf:first _:807f36cf91fe4e8caa53aadeff92477612382;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612383 .

_:807f36cf91fe4e8caa53aadeff92477612382 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10092 .

_:807f36cf91fe4e8caa53aadeff92477612383 rdf:first _:807f36cf91fe4e8caa53aadeff92477612384;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612384 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612386 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10025-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10025";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612388;
  r:natureDuRisque """Pour des doses anti-inflammatoires d'acide acétylsalicylique (>= 1g par prise et/ou >= 3g par jour) ou pour des doses antalgiques ou antipyrétiques (>= 500 mg par prise et/ou < 3g par jour) : 

Insuffisance rénale aiguë chez le malade déshydraté, par dim"""@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612394, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612388 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612389 .

_:807f36cf91fe4e8caa53aadeff92477612389 rdf:first _:807f36cf91fe4e8caa53aadeff92477612390;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612391 .

_:807f36cf91fe4e8caa53aadeff92477612390 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477612391 rdf:first _:807f36cf91fe4e8caa53aadeff92477612392;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612392 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612394 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10026-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10026";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612396;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612402, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612396 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612397 .

_:807f36cf91fe4e8caa53aadeff92477612397 rdf:first _:807f36cf91fe4e8caa53aadeff92477612398;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612399 .

_:807f36cf91fe4e8caa53aadeff92477612398 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477612399 rdf:first _:807f36cf91fe4e8caa53aadeff92477612400;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612400 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612402 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10027-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10027";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612404;
  r:natureDuRisque "Majoration de la toxicité, notamment hématologique, du méthotrexate (diminution de sa clairance rénale par l'acide acétylsalicylique)."@fr;
  r:conduiteATenir """Avec le méthotrexate utilisé à des doses > 20 mg/semaine : 
- contre-indication avec l'acide acétylsalicylique utilisé à doses antalgiques, antipyrétiques ou anti-inflammatoires
- précaution d'emploi avec des doses antiagrégantes plaquettaires d'acide acé"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612410, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612404 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612405 .

_:807f36cf91fe4e8caa53aadeff92477612405 rdf:first _:807f36cf91fe4e8caa53aadeff92477612406;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612407 .

_:807f36cf91fe4e8caa53aadeff92477612406 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612407 rdf:first _:807f36cf91fe4e8caa53aadeff92477612408;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612408 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477612410 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10028-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> PEMETREXED"@fr;
  dct:identifier "IAM_10028";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612412;
  r:natureDuRisque "Risque de majoration de la toxicité du pemetrexed (diminution de sa clairance rénale par l’acide acétylsalicylique à doses anti-inflammatoires)."@fr;
  r:conduiteATenir """Association déconseillée : 
- en cas de fonction rénale faible à modérée .

Précaution d'emploi :
- en cas de fonction rénale normale. Surveillance biologique de la fonction rénale."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612418, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612412 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612413 .

_:807f36cf91fe4e8caa53aadeff92477612413 rdf:first _:807f36cf91fe4e8caa53aadeff92477612414;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612415 .

_:807f36cf91fe4e8caa53aadeff92477612414 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612415 rdf:first _:807f36cf91fe4e8caa53aadeff92477612416;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612416 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10700 .

_:807f36cf91fe4e8caa53aadeff92477612418 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10029-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> PROBENECIDE"@fr;
  dct:identifier "IAM_10029";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612420;
  r:natureDuRisque "Diminution de l’effet uricosurique par compétition de l’élimination de l’acide urique au niveau des tubules rénaux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612426, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612420 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612421 .

_:807f36cf91fe4e8caa53aadeff92477612421 rdf:first _:807f36cf91fe4e8caa53aadeff92477612422;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612423 .

_:807f36cf91fe4e8caa53aadeff92477612422 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612423 rdf:first _:807f36cf91fe4e8caa53aadeff92477612424;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612424 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10758 .

_:807f36cf91fe4e8caa53aadeff92477612426 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10030-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_10030";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612428;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612434, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612428 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612429 .

_:807f36cf91fe4e8caa53aadeff92477612429 rdf:first _:807f36cf91fe4e8caa53aadeff92477612430;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612431 .

_:807f36cf91fe4e8caa53aadeff92477612430 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:807f36cf91fe4e8caa53aadeff92477612431 rdf:first _:807f36cf91fe4e8caa53aadeff92477612432;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612432 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612434 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10031-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10031";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612436;
  r:natureDuRisque """Majoration du risque hémorragique par addition des activités
antiagrégantes plaquettaires."""@fr;
  r:conduiteATenir """Association déconseillée :
- en dehors des indications validées pour cette association dans les syndromes coronariens aigus.

Précaution d'emploi :
- dans les indications validées pour cette association dans les syndromes coronariens aigus. Surveillance c"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612442, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612436 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612437 .

_:807f36cf91fe4e8caa53aadeff92477612437 rdf:first _:807f36cf91fe4e8caa53aadeff92477612438;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612439 .

_:807f36cf91fe4e8caa53aadeff92477612438 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612439 rdf:first _:807f36cf91fe4e8caa53aadeff92477612440;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612440 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477612442 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10032-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> TICLOPIDINE"@fr;
  dct:identifier "IAM_10032";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612444;
  r:natureDuRisque "Majoration du risque hémorragique par addition des activités antiagrégantes plaquettaires."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612450, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612444 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612445 .

_:807f36cf91fe4e8caa53aadeff92477612445 rdf:first _:807f36cf91fe4e8caa53aadeff92477612446;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612447 .

_:807f36cf91fe4e8caa53aadeff92477612446 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612447 rdf:first _:807f36cf91fe4e8caa53aadeff92477612448;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612448 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10928 .

_:807f36cf91fe4e8caa53aadeff92477612450 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10033-1 a owl:Class;
  rdfs:label "ACIDE ASCORBIQUE <-> DÉFÉROXAMINE"@fr;
  dct:identifier "IAM_10033";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612452;
  r:natureDuRisque "Avec l'acide ascorbique à fortes doses et par voie IV : anomalies de la fonction cardiaque, voire insuffisance cardiaque aiguë (en général réversible à l'arrêt de la vitamine C)."@fr;
  r:conduiteATenir "En cas d'hémochromatose, ne donner de la vitamine C qu'après avoir commencé le traitement par la déféroxamine. Surveiller la fonction cardiaque en cas d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612458, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612452 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612453 .

_:807f36cf91fe4e8caa53aadeff92477612453 rdf:first _:807f36cf91fe4e8caa53aadeff92477612454;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612455 .

_:807f36cf91fe4e8caa53aadeff92477612454 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10015 .

_:807f36cf91fe4e8caa53aadeff92477612455 rdf:first _:807f36cf91fe4e8caa53aadeff92477612456;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612456 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10261 .

_:807f36cf91fe4e8caa53aadeff92477612458 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10021-1 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10021";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612460;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire et agression de la muqueuse gastroduodénale par l’acide acétylsalicylique."@fr;
  r:conduiteATenir """A prendre en compte avec :
- des doses antiagrégantes (de 50 mg à 375 mg par jour)."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612466, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612460 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612461 .

_:807f36cf91fe4e8caa53aadeff92477612461 rdf:first _:807f36cf91fe4e8caa53aadeff92477612462;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612463 .

_:807f36cf91fe4e8caa53aadeff92477612462 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477612463 rdf:first _:807f36cf91fe4e8caa53aadeff92477612464;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612464 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477612466 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10245-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_10245";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612468;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la télithromycine, avec risque d'échec du traitement anti-infectieux, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  rdfs:comment "Compte tenu de la baisse très importante (80%) des concentrations de télithromycine en présence de rifampicine, l'interaction a été extrapolée aux autres inducteurs enzymatiques puissants, le phénobarbital, la primidone, la phénytoïne et la carbamazépine,"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612474, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612468 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612469 .

_:807f36cf91fe4e8caa53aadeff92477612469 rdf:first _:807f36cf91fe4e8caa53aadeff92477612470;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612471 .

_:807f36cf91fe4e8caa53aadeff92477612470 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612471 rdf:first _:807f36cf91fe4e8caa53aadeff92477612472;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612472 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477612474 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10232-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> MONTELUKAST"@fr;
  dct:identifier "IAM_10232";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612476;
  r:natureDuRisque "Risque de baisse de l'efficacité du montélukast par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l'anti-asthmatique pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612482, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612476 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612477 .

_:807f36cf91fe4e8caa53aadeff92477612477 rdf:first _:807f36cf91fe4e8caa53aadeff92477612478;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612479 .

_:807f36cf91fe4e8caa53aadeff92477612478 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612479 rdf:first _:807f36cf91fe4e8caa53aadeff92477612480;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612480 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10604 .

_:807f36cf91fe4e8caa53aadeff92477612482 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10233-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> NIMODIPINE"@fr;
  dct:identifier "IAM_10233";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612484;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l'antagoniste du calcium pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612490, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612484 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612485 .

_:807f36cf91fe4e8caa53aadeff92477612485 rdf:first _:807f36cf91fe4e8caa53aadeff92477612486;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612487 .

_:807f36cf91fe4e8caa53aadeff92477612486 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612487 rdf:first _:807f36cf91fe4e8caa53aadeff92477612488;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612488 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10636 .

_:807f36cf91fe4e8caa53aadeff92477612490 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10234-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> PÉRAMPANEL"@fr;
  dct:identifier "IAM_10234";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612492;
  r:natureDuRisque "Diminution importante (jusqu’aux deux-tiers) des concentrations de pérampanel."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612498, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612492 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612493 .

_:807f36cf91fe4e8caa53aadeff92477612493 rdf:first _:807f36cf91fe4e8caa53aadeff92477612494;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612495 .

_:807f36cf91fe4e8caa53aadeff92477612494 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612495 rdf:first _:807f36cf91fe4e8caa53aadeff92477612496;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:807f36cf91fe4e8caa53aadeff92477612498 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10235-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10235";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612500;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du posaconazole."@fr;
  r:conduiteATenir "Surveillance clinique. Si possible, dosages plasmatiques du posaconazole et adaptation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612506, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612500 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612501 .

_:807f36cf91fe4e8caa53aadeff92477612501 rdf:first _:807f36cf91fe4e8caa53aadeff92477612502;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612503 .

_:807f36cf91fe4e8caa53aadeff92477612502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612503 rdf:first _:807f36cf91fe4e8caa53aadeff92477612504;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477612506 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10236-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> PRAZIQUANTEL"@fr;
  dct:identifier "IAM_10236";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612508;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques du praziquantel, avec risque d'échec du traitement, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  rdfs:comment "La mesure des concentrations du praziquantel chez des patients traités par anticonvulsivants inducteurs enzymatiques, suggère que l'effet inducteur du phénobarbital, de la phénytoine ou de la carbamazépine retentit de façon importante sur le métabolisme d"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612514, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612508 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612509 .

_:807f36cf91fe4e8caa53aadeff92477612509 rdf:first _:807f36cf91fe4e8caa53aadeff92477612510;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612511 .

_:807f36cf91fe4e8caa53aadeff92477612510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612511 rdf:first _:807f36cf91fe4e8caa53aadeff92477612512;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10750 .

_:807f36cf91fe4e8caa53aadeff92477612514 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10238-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10238";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612516;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la propafénone par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. S'il y a lieu, adaptation de la posologie de la propafénone pendant l'association et après l'arrêt de l'inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612522, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612516 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612517 .

_:807f36cf91fe4e8caa53aadeff92477612517 rdf:first _:807f36cf91fe4e8caa53aadeff92477612518;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612519 .

_:807f36cf91fe4e8caa53aadeff92477612518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612519 rdf:first _:807f36cf91fe4e8caa53aadeff92477612520;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477612522 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10239-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> QUETIAPINE"@fr;
  dct:identifier "IAM_10239";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612524;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de quétiapine par augmentation de son métabolisme hépatique par l'inducteur, avec risque d’inefficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612530, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612524 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612525 .

_:807f36cf91fe4e8caa53aadeff92477612525 rdf:first _:807f36cf91fe4e8caa53aadeff92477612526;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612527 .

_:807f36cf91fe4e8caa53aadeff92477612526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612527 rdf:first _:807f36cf91fe4e8caa53aadeff92477612528;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:807f36cf91fe4e8caa53aadeff92477612530 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10240-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> QUININE"@fr;
  dct:identifier "IAM_10240";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612532;
  r:natureDuRisque "Risque de perte de l’efficacité de la quinine par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la quinine pendant le traitement par l’inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612538, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612532 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612533 .

_:807f36cf91fe4e8caa53aadeff92477612533 rdf:first _:807f36cf91fe4e8caa53aadeff92477612534;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612535 .

_:807f36cf91fe4e8caa53aadeff92477612534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612535 rdf:first _:807f36cf91fe4e8caa53aadeff92477612536;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:807f36cf91fe4e8caa53aadeff92477612538 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10241-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> RANOLAZINE"@fr;
  dct:identifier "IAM_10241";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612540;
  r:natureDuRisque "Risque de diminution importante des concentrations de ranolazine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612546, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612540 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612541 .

_:807f36cf91fe4e8caa53aadeff92477612541 rdf:first _:807f36cf91fe4e8caa53aadeff92477612542;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612543 .

_:807f36cf91fe4e8caa53aadeff92477612542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612543 rdf:first _:807f36cf91fe4e8caa53aadeff92477612544;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:807f36cf91fe4e8caa53aadeff92477612546 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10196-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE IA <-> ESMOLOL"@fr;
  dct:identifier "IAM_10196";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612548;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612554, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612548 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612549 .

_:807f36cf91fe4e8caa53aadeff92477612549 rdf:first _:807f36cf91fe4e8caa53aadeff92477612550;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612551 .

_:807f36cf91fe4e8caa53aadeff92477612550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10026 .

_:807f36cf91fe4e8caa53aadeff92477612551 rdf:first _:807f36cf91fe4e8caa53aadeff92477612552;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:807f36cf91fe4e8caa53aadeff92477612554 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10243-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10243";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612556;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'anticonvulsivant, avec risque de surdosage, par inhibition de son métabolisme hépatique par le stiripentol."@fr;
  r:conduiteATenir "Surveillance clinique et dosage plasmatique, lorsque cela est possible, de l'anticonvulsivant associé au stiripentol et adaptation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612562, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612556 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612557 .

_:807f36cf91fe4e8caa53aadeff92477612557 rdf:first _:807f36cf91fe4e8caa53aadeff92477612558;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612559 .

_:807f36cf91fe4e8caa53aadeff92477612558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612559 rdf:first _:807f36cf91fe4e8caa53aadeff92477612560;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477612562 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11010-1 a owl:Class;
  rdfs:label "HALOPERIDOL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11010";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612564;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'halopéridol et de son efficacité thérapeutique, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, adaptation posologique pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612570, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612564 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612565 .

_:807f36cf91fe4e8caa53aadeff92477612565 rdf:first _:807f36cf91fe4e8caa53aadeff92477612566;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612567 .

_:807f36cf91fe4e8caa53aadeff92477612566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10426 .

_:807f36cf91fe4e8caa53aadeff92477612567 rdf:first _:807f36cf91fe4e8caa53aadeff92477612568;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477612570 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10246-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10246";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612572;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la théophylline par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, de la théophyllinémie. Adaptation éventuelle de la posologie de la théophylline pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612578, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612572 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612573 .

_:807f36cf91fe4e8caa53aadeff92477612573 rdf:first _:807f36cf91fe4e8caa53aadeff92477612574;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612575 .

_:807f36cf91fe4e8caa53aadeff92477612574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612575 rdf:first _:807f36cf91fe4e8caa53aadeff92477612576;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477612578 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10247-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> TIAGABINE"@fr;
  dct:identifier "IAM_10247";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612580;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la tiagabine par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Une augmentation de la posologie de tiagabine peut s'avérer nécessaire en cas d'association à un anticonvulsivant inducteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612586, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612580 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612581 .

_:807f36cf91fe4e8caa53aadeff92477612581 rdf:first _:807f36cf91fe4e8caa53aadeff92477612582;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612583 .

_:807f36cf91fe4e8caa53aadeff92477612582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612583 rdf:first _:807f36cf91fe4e8caa53aadeff92477612584;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612584 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10922 .

_:807f36cf91fe4e8caa53aadeff92477612586 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10248-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10248";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612588;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de ticagrelor par augmentation de son métabolisme hépatique par l'anticonvulsivant inducteur enzymatique, avec risque de diminution de l’effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612594, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612588 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612589 .

_:807f36cf91fe4e8caa53aadeff92477612589 rdf:first _:807f36cf91fe4e8caa53aadeff92477612590;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612591 .

_:807f36cf91fe4e8caa53aadeff92477612590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612591 rdf:first _:807f36cf91fe4e8caa53aadeff92477612592;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612592 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477612594 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10249-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10249";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612596;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Préférer une alternative thérapeutique peu ou pas métabolisée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612602, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612596 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612597 .

_:807f36cf91fe4e8caa53aadeff92477612597 rdf:first _:807f36cf91fe4e8caa53aadeff92477612598;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612599 .

_:807f36cf91fe4e8caa53aadeff92477612598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612599 rdf:first _:807f36cf91fe4e8caa53aadeff92477612600;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612600 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477612602 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10250-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> VITAMINE D"@fr;
  dct:identifier "IAM_10250";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612604;
  r:natureDuRisque "Diminution des concentrations de vitamine D plus marquée qu’en l’absence d'inducteur."@fr;
  r:conduiteATenir "Dosage des concentrations de vitamine D et supplémentation si nécessaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612610, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612604 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612605 .

_:807f36cf91fe4e8caa53aadeff92477612605 rdf:first _:807f36cf91fe4e8caa53aadeff92477612606;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612607 .

_:807f36cf91fe4e8caa53aadeff92477612606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612607 rdf:first _:807f36cf91fe4e8caa53aadeff92477612608;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612608 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10162 .

_:807f36cf91fe4e8caa53aadeff92477612610 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10251-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10251";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612612;
  r:natureDuRisque """- pour carbamazépine, phénobarbital, primidone : Risque de baisse de l'efficacité du voriconazole par augmentation de son métabolisme hépatique par l'inducteur.

- pour phénytoïne, fosphénytoïne : 
Diminution importante des concentrations plasmatiques du"""@fr;
  r:conduiteATenir """Contre-indication :
- pour carbamazépine, phénobarbital, primidone

Association déconseillée :
- pour phénytoïne, fosphénytoïne
Si l'association ne peut être évitée, surveillance clinique étroite, dosage des concentrations plasmatiques de phénytoïne et ad"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612618, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612612 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612613 .

_:807f36cf91fe4e8caa53aadeff92477612613 rdf:first _:807f36cf91fe4e8caa53aadeff92477612614;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612615 .

_:807f36cf91fe4e8caa53aadeff92477612614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612615 rdf:first _:807f36cf91fe4e8caa53aadeff92477612616;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477612618 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10237-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> PROCARBAZINE"@fr;
  dct:identifier "IAM_10237";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612620;
  r:natureDuRisque "Augmentation des réactions d'hypersensibilité (hyperéosinophilie, rash), par augmentation du métabolisme de la procarbazine par l'inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612626, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612620 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612621 .

_:807f36cf91fe4e8caa53aadeff92477612621 rdf:first _:807f36cf91fe4e8caa53aadeff92477612622;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612623 .

_:807f36cf91fe4e8caa53aadeff92477612622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612623 rdf:first _:807f36cf91fe4e8caa53aadeff92477612624;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10759 .

_:807f36cf91fe4e8caa53aadeff92477612626 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10252-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS MÉTABOLISÉS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10252";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612628;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques et de l'efficacité de l'anticonvulsivant."@fr;
  rdfs:comment "Une contre-indication a été retenue entre la quasi totalité des médicaments anticonvulsivants et le millepertuis. Cette plante médicinale est un inducteur enzymatique puissant qui expose à une baisse des concentrations plasmatiques de nombreux médicaments"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612634, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612628 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612629 .

_:807f36cf91fe4e8caa53aadeff92477612629 rdf:first _:807f36cf91fe4e8caa53aadeff92477612630;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612631 .

_:807f36cf91fe4e8caa53aadeff92477612630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10030 .

_:807f36cf91fe4e8caa53aadeff92477612631 rdf:first _:807f36cf91fe4e8caa53aadeff92477612632;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477612634 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10253-1 a owl:Class;
  rdfs:label "ANTICORPS MONOCLONAUX (HORS ANTI-TNF ALPHA) <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10253";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612636;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  r:conduiteATenir """Association déconseillée avec :
- bélimumab, blinatumomab, canakinumab, obinutuzumab, ofatumumab, rituximab, tocilizumab, ustékinumab 

A prendre en compte avec :
- alemtuzumab, bevacizumab, brentuximab, cetuximab, daratumumab, dénosumab, ibritumomab, ipi"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612642, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612636 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612637 .

_:807f36cf91fe4e8caa53aadeff92477612637 rdf:first _:807f36cf91fe4e8caa53aadeff92477612638;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612639 .

_:807f36cf91fe4e8caa53aadeff92477612638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10031 .

_:807f36cf91fe4e8caa53aadeff92477612639 rdf:first _:807f36cf91fe4e8caa53aadeff92477612640;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477612642 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10242-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> RIVAROXABAN"@fr;
  dct:identifier "IAM_10242";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612644;
  r:natureDuRisque "Diminution des concentrations plasmatiques de rivaroxaban, avec risque de diminution de l'effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612650, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612644 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612645 .

_:807f36cf91fe4e8caa53aadeff92477612645 rdf:first _:807f36cf91fe4e8caa53aadeff92477612646;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612647 .

_:807f36cf91fe4e8caa53aadeff92477612646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612647 rdf:first _:807f36cf91fe4e8caa53aadeff92477612648;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10808 .

_:807f36cf91fe4e8caa53aadeff92477612650 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11000-1 a owl:Class;
  rdfs:label "GLUCOCORTICOÏDES (SAUF HYDROCORTISONE) <-> ISONIAZIDE"@fr;
  dct:identifier "IAM_11000";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612652;
  r:natureDuRisque "Décrit pour la prednisolone. Diminution des concentrations plasmatiques de l'isoniazide. Mécanisme invoqué : augmentation du métabolisme hépatique de l'isoniazide et diminution de celui des glucocorticoïdes."@fr;
  r:conduiteATenir "Surveillance clinique et biologique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612658, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612652 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612653 .

_:807f36cf91fe4e8caa53aadeff92477612653 rdf:first _:807f36cf91fe4e8caa53aadeff92477612654;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612655 .

_:807f36cf91fe4e8caa53aadeff92477612654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477612655 rdf:first _:807f36cf91fe4e8caa53aadeff92477612656;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477612658 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10343-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10343";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612660;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'itraconazole et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612666, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612660 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612661 .

_:807f36cf91fe4e8caa53aadeff92477612661 rdf:first _:807f36cf91fe4e8caa53aadeff92477612662;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612663 .

_:807f36cf91fe4e8caa53aadeff92477612662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477612663 rdf:first _:807f36cf91fe4e8caa53aadeff92477612664;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477612666 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10344-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> LEVOCARNITINE"@fr;
  dct:identifier "IAM_10344";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612668;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique"@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la lévocarnitine et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612674, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612668 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612669 .

_:807f36cf91fe4e8caa53aadeff92477612669 rdf:first _:807f36cf91fe4e8caa53aadeff92477612670;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612671 .

_:807f36cf91fe4e8caa53aadeff92477612670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477612671 rdf:first _:807f36cf91fe4e8caa53aadeff92477612672;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10516 .

_:807f36cf91fe4e8caa53aadeff92477612674 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10345-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10345";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612676;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par le macrolide et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612682, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612676 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612677 .

_:807f36cf91fe4e8caa53aadeff92477612677 rdf:first _:807f36cf91fe4e8caa53aadeff92477612678;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612679 .

_:807f36cf91fe4e8caa53aadeff92477612678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477612679 rdf:first _:807f36cf91fe4e8caa53aadeff92477612680;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:807f36cf91fe4e8caa53aadeff92477612682 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10346-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> METHYLPREDNISOLONE"@fr;
  dct:identifier "IAM_10346";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612684;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Pour des doses de 0,5 à 1g de méthylprednisolone administrées en bolus : augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle de l'INR 2 à 4 jours après le bolus de méthylprednisolone ou en présence de tous signes hémorragiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612690, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612684 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612685 .

_:807f36cf91fe4e8caa53aadeff92477612685 rdf:first _:807f36cf91fe4e8caa53aadeff92477612686;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612687 .

_:807f36cf91fe4e8caa53aadeff92477612686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477612687 rdf:first _:807f36cf91fe4e8caa53aadeff92477612688;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10576 .

_:807f36cf91fe4e8caa53aadeff92477612690 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10347-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> MICONAZOLE"@fr;
  dct:identifier "IAM_10347";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612692;
  r:natureDuRisque "Hémorragies imprévisibles, éventuellement graves."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612698, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612692 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612693 .

_:807f36cf91fe4e8caa53aadeff92477612693 rdf:first _:807f36cf91fe4e8caa53aadeff92477612694;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612695 .

_:807f36cf91fe4e8caa53aadeff92477612694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477612695 rdf:first _:807f36cf91fe4e8caa53aadeff92477612696;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10584 .

_:807f36cf91fe4e8caa53aadeff92477612698 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10348-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10348";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612700;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antivitamine K, en raison de son effet inducteur enzymatique, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (évènement thrombotique"@fr;
  r:conduiteATenir "En cas d'association fortuite, ne pas interrompre brutalement la prise de millepertuis mais contrôler l'INR avant puis après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612706, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612700 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612701 .

_:807f36cf91fe4e8caa53aadeff92477612701 rdf:first _:807f36cf91fe4e8caa53aadeff92477612702;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612703 .

_:807f36cf91fe4e8caa53aadeff92477612702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477612703 rdf:first _:807f36cf91fe4e8caa53aadeff92477612704;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477612706 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10349-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_10349";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612708;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612714, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612708 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612709 .

_:807f36cf91fe4e8caa53aadeff92477612709 rdf:first _:807f36cf91fe4e8caa53aadeff92477612710;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612711 .

_:807f36cf91fe4e8caa53aadeff92477612710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477612711 rdf:first _:807f36cf91fe4e8caa53aadeff92477612712;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477612714 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10350-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> NOSCAPINE"@fr;
  dct:identifier "IAM_10350";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612716;
  r:natureDuRisque "Augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612722, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612716 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612717 .

_:807f36cf91fe4e8caa53aadeff92477612717 rdf:first _:807f36cf91fe4e8caa53aadeff92477612718;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612719 .

_:807f36cf91fe4e8caa53aadeff92477612718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477612719 rdf:first _:807f36cf91fe4e8caa53aadeff92477612720;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10653 .

_:807f36cf91fe4e8caa53aadeff92477612722 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10351-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> ORLISTAT"@fr;
  dct:identifier "IAM_10351";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612724;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'orlistat et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612730, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612724 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612725 .

_:807f36cf91fe4e8caa53aadeff92477612725 rdf:first _:807f36cf91fe4e8caa53aadeff92477612726;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612727 .

_:807f36cf91fe4e8caa53aadeff92477612726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477612727 rdf:first _:807f36cf91fe4e8caa53aadeff92477612728;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477612730 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10231-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> MINÉRALOCORTICOÏDES"@fr;
  dct:identifier "IAM_10231";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612732;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des corticoïdes par augmentation de leur métabolisme hépatique par l'inducteur : les conséquences sont particulièrement importantes chez les addisoniens traités par l'hydrocortisone et en cas d"@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie des corticoïdes pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612738, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612732 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612733 .

_:807f36cf91fe4e8caa53aadeff92477612733 rdf:first _:807f36cf91fe4e8caa53aadeff92477612734;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612735 .

_:807f36cf91fe4e8caa53aadeff92477612734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612735 rdf:first _:807f36cf91fe4e8caa53aadeff92477612736;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10108 .

_:807f36cf91fe4e8caa53aadeff92477612738 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10999-1 a owl:Class;
  rdfs:label "GLOBULINES ANTILYMPHOCYTAIRES <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10999";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612740;
  r:natureDuRisque "Risque de maladie généralisée éventuellement mortelle. Ce risque est majoré chez les sujets âgés déjà immunodéprimés par la maladie sous-jacente."@fr;
  r:conduiteATenir "En particulier, utiliser un vaccin inactivé lorsqu'il existe (poliomyélite)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612746, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612740 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612741 .

_:807f36cf91fe4e8caa53aadeff92477612741 rdf:first _:807f36cf91fe4e8caa53aadeff92477612742;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612743 .

_:807f36cf91fe4e8caa53aadeff92477612742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff92477612743 rdf:first _:807f36cf91fe4e8caa53aadeff92477612744;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477612746 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10230-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_10230";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612748;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du midazolam par l'anticonvulsivant."@fr;
  rdfs:comment """L’administration de carbamazépine ou de phénytoïne diminue significativement les concentrations plasmatiques et la demi-vie d’une dose orale de 15 mg de midazolam.
Le midazolam administré par voie orale subit un effet de premier passage hépatique importan"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612754, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612748 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612749 .

_:807f36cf91fe4e8caa53aadeff92477612749 rdf:first _:807f36cf91fe4e8caa53aadeff92477612750;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612751 .

_:807f36cf91fe4e8caa53aadeff92477612750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477612751 rdf:first _:807f36cf91fe4e8caa53aadeff92477612752;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477612754 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11001-1 a owl:Class;
  rdfs:label "GLUCOCORTICOÏDES (SAUF HYDROCORTISONE) <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11001";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612756;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des corticoïdes par augmentation de leur métabolisme hépatique par la rifampicine ; les conséquences sont particulièrement importantes chez les addisoniens traités par l'hydrocortisone et en ca"@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie des corticoïdes pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612756 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612757 .

_:807f36cf91fe4e8caa53aadeff92477612757 rdf:first _:807f36cf91fe4e8caa53aadeff92477612758;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612759 .

_:807f36cf91fe4e8caa53aadeff92477612758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477612759 rdf:first _:807f36cf91fe4e8caa53aadeff92477612760;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477612762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11002-1 a owl:Class;
  rdfs:label "GLUCOCORTICOÏDES (SAUF HYDROCORTISONE) <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11002";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612764;
  r:natureDuRisque "A l'exception des voies inhalées et locales, et pour des posologies supérieures à 10 mg/j d’équivalent-prednisone (ou > 2 mg/kg/j chez l’enfant ou > 20 mg/j chez l’enfant de plus de 10 kg) pendant plus de deux semaines et pour les « bolus » de corticoïdes"@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt de la corticothérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612765 .

_:807f36cf91fe4e8caa53aadeff92477612765 rdf:first _:807f36cf91fe4e8caa53aadeff92477612766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612767 .

_:807f36cf91fe4e8caa53aadeff92477612766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477612767 rdf:first _:807f36cf91fe4e8caa53aadeff92477612768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477612770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11003-1 a owl:Class;
  rdfs:label "GLYCEROL <-> LITHIUM"@fr;
  dct:identifier "IAM_11003";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612772;
  r:natureDuRisque "Diminution de la lithémie avec risque de baisse de l’efficacité thérapeutique."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612773 .

_:807f36cf91fe4e8caa53aadeff92477612773 rdf:first _:807f36cf91fe4e8caa53aadeff92477612774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612775 .

_:807f36cf91fe4e8caa53aadeff92477612774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10419 .

_:807f36cf91fe4e8caa53aadeff92477612775 rdf:first _:807f36cf91fe4e8caa53aadeff92477612776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477612778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11004-1 a owl:Class;
  rdfs:label "GRISEOFULVINE <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_11004";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612780;
  r:natureDuRisque "Risque de diminution de l'efficacité du contraceptif hormonal par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612781 .

_:807f36cf91fe4e8caa53aadeff92477612781 rdf:first _:807f36cf91fe4e8caa53aadeff92477612782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612783 .

_:807f36cf91fe4e8caa53aadeff92477612782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477612783 rdf:first _:807f36cf91fe4e8caa53aadeff92477612784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10422 .

_:807f36cf91fe4e8caa53aadeff92477612786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11005-1 a owl:Class;
  rdfs:label "GUANETHIDINE <-> IMAO IRRÉVERSIBLES"@fr;
  dct:identifier "IAM_11005";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612788;
  r:natureDuRisque "Avec la guanéthidine utilisée par voie IV : risque de réactions vasculaires imprévisibles, notamment d'hypotension."@fr;
  r:conduiteATenir "Interrompre le traitement par IMAO 15 jours avant le traitement par guanéthidine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612789 .

_:807f36cf91fe4e8caa53aadeff92477612789 rdf:first _:807f36cf91fe4e8caa53aadeff92477612790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612791 .

_:807f36cf91fe4e8caa53aadeff92477612790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477612791 rdf:first _:807f36cf91fe4e8caa53aadeff92477612792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10423 .

_:807f36cf91fe4e8caa53aadeff92477612794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11006-1 a owl:Class;
  rdfs:label "HALOFANTRINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11006";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612796;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaires, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre l'inhibiteur. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612797 .

_:807f36cf91fe4e8caa53aadeff92477612797 rdf:first _:807f36cf91fe4e8caa53aadeff92477612798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612799 .

_:807f36cf91fe4e8caa53aadeff92477612798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477612799 rdf:first _:807f36cf91fe4e8caa53aadeff92477612800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:807f36cf91fe4e8caa53aadeff92477612802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11007-1 a owl:Class;
  rdfs:label "HALOFANTRINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_11007";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612804;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le macrolide. Si l’association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612805 .

_:807f36cf91fe4e8caa53aadeff92477612805 rdf:first _:807f36cf91fe4e8caa53aadeff92477612806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612807 .

_:807f36cf91fe4e8caa53aadeff92477612806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:807f36cf91fe4e8caa53aadeff92477612807 rdf:first _:807f36cf91fe4e8caa53aadeff92477612808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477612810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11008-1 a owl:Class;
  rdfs:label "HALOFANTRINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11008";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612812;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612813 .

_:807f36cf91fe4e8caa53aadeff92477612813 rdf:first _:807f36cf91fe4e8caa53aadeff92477612814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612815 .

_:807f36cf91fe4e8caa53aadeff92477612814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477612815 rdf:first _:807f36cf91fe4e8caa53aadeff92477612816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:807f36cf91fe4e8caa53aadeff92477612818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11009-1 a owl:Class;
  rdfs:label "HALOFANTRINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11009";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612820;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612821 .

_:807f36cf91fe4e8caa53aadeff92477612821 rdf:first _:807f36cf91fe4e8caa53aadeff92477612822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612823 .

_:807f36cf91fe4e8caa53aadeff92477612822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:807f36cf91fe4e8caa53aadeff92477612823 rdf:first _:807f36cf91fe4e8caa53aadeff92477612824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477612826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10256-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> CLONIDINE"@fr;
  dct:identifier "IAM_10256";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612828;
  r:natureDuRisque "Décrit pour désipramine, imipramine : inhibition de l'effet antihypertenseur de la clonidine (antagonisme au niveau des récepteurs adrénergiques)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612829 .

_:807f36cf91fe4e8caa53aadeff92477612829 rdf:first _:807f36cf91fe4e8caa53aadeff92477612830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612831 .

_:807f36cf91fe4e8caa53aadeff92477612830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:807f36cf91fe4e8caa53aadeff92477612831 rdf:first _:807f36cf91fe4e8caa53aadeff92477612832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10214 .

_:807f36cf91fe4e8caa53aadeff92477612834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10352-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PARACETAMOL"@fr;
  dct:identifier "IAM_10352";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612836;
  r:natureDuRisque "Risque d’augmentation de l’effet de l’antivitamine K et du risque hémorragique en cas de prise de paracétamol aux doses maximales (4 g/j) pendant au moins 4 jours."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par le paracétamol et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612837 .

_:807f36cf91fe4e8caa53aadeff92477612837 rdf:first _:807f36cf91fe4e8caa53aadeff92477612838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612839 .

_:807f36cf91fe4e8caa53aadeff92477612838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477612839 rdf:first _:807f36cf91fe4e8caa53aadeff92477612840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10690 .

_:807f36cf91fe4e8caa53aadeff92477612842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10292-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10292";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612844;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612845 .

_:807f36cf91fe4e8caa53aadeff92477612845 rdf:first _:807f36cf91fe4e8caa53aadeff92477612846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612847 .

_:807f36cf91fe4e8caa53aadeff92477612846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477612847 rdf:first _:807f36cf91fe4e8caa53aadeff92477612848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477612850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10254-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> BACLOFENE"@fr;
  dct:identifier "IAM_10254";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612852;
  r:natureDuRisque "Risque d'augmentation de l'hypotonie musculaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612858, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612852 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612853 .

_:807f36cf91fe4e8caa53aadeff92477612853 rdf:first _:807f36cf91fe4e8caa53aadeff92477612854;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612855 .

_:807f36cf91fe4e8caa53aadeff92477612854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:807f36cf91fe4e8caa53aadeff92477612855 rdf:first _:807f36cf91fe4e8caa53aadeff92477612856;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10102 .

_:807f36cf91fe4e8caa53aadeff92477612858 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10282-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> TENOFOVIR DISOPROXIL"@fr;
  dct:identifier "IAM_10282";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612860;
  r:natureDuRisque "Risque de majoration de la néphrotoxicité du ténofovir, notamment avec des doses élevées de l'anti-inflammatoire ou en présence de facteurs de risque d'insuffisance rénale."@fr;
  r:conduiteATenir "En cas d’association, surveiller la fonction rénale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612860 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612861 .

_:807f36cf91fe4e8caa53aadeff92477612861 rdf:first _:807f36cf91fe4e8caa53aadeff92477612862;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612863 .

_:807f36cf91fe4e8caa53aadeff92477612862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477612863 rdf:first _:807f36cf91fe4e8caa53aadeff92477612864;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10896 .

_:807f36cf91fe4e8caa53aadeff92477612866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10283-1 a owl:Class;
  rdfs:label "ANTIPARASITAIRES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10283";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612868;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication:
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine
et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes.
Si cela est possible, interrompre l'un des d"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612869 .

_:807f36cf91fe4e8caa53aadeff92477612869 rdf:first _:807f36cf91fe4e8caa53aadeff92477612870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612871 .

_:807f36cf91fe4e8caa53aadeff92477612870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10036 .

_:807f36cf91fe4e8caa53aadeff92477612871 rdf:first _:807f36cf91fe4e8caa53aadeff92477612872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477612874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10284-1 a owl:Class;
  rdfs:label "ANTIPARKINSONIENS DOPAMINERGIQUES <-> NEUROLEPTIQUES ANTIPSYCHOTIQUES (SAUF CLOZAPINE)"@fr;
  dct:identifier "IAM_10284";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612876;
  r:natureDuRisque "Antagonisme réciproque du dopaminergique et des neuroleptiques. Le dopaminergique peut provoquer ou aggraver les troubles psychotiques. En cas de nécessité d'un traitement par neuroleptiques chez le patient parkinsonien traité par dopaminergique, ces dern"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612877 .

_:807f36cf91fe4e8caa53aadeff92477612877 rdf:first _:807f36cf91fe4e8caa53aadeff92477612878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612879 .

_:807f36cf91fe4e8caa53aadeff92477612878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10038 .

_:807f36cf91fe4e8caa53aadeff92477612879 rdf:first _:807f36cf91fe4e8caa53aadeff92477612880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10125 .

_:807f36cf91fe4e8caa53aadeff92477612882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10285-1 a owl:Class;
  rdfs:label "ANTIPURINES <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10285";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612884;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Diminution de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K à la mise en route du traitement par l'immunomodulateur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612885 .

_:807f36cf91fe4e8caa53aadeff92477612885 rdf:first _:807f36cf91fe4e8caa53aadeff92477612886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612887 .

_:807f36cf91fe4e8caa53aadeff92477612886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10039 .

_:807f36cf91fe4e8caa53aadeff92477612887 rdf:first _:807f36cf91fe4e8caa53aadeff92477612888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477612890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10286-1 a owl:Class;
  rdfs:label "ANTIPURINES <-> DÉRIVÉS DE L'ACIDE AMINOSALICYLIQUE (ASA)"@fr;
  dct:identifier "IAM_10286";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612892;
  r:natureDuRisque "Risque de majoration de l'effet myélosuppresseur de l'immunomodulateur par inhibition de son métabolisme hépatique par le dérivé de l'ASA, notamment chez les sujets présentant un déficit partiel en thiopurine méthyltransférase (TPMT)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612898, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612892 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612893 .

_:807f36cf91fe4e8caa53aadeff92477612893 rdf:first _:807f36cf91fe4e8caa53aadeff92477612894;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612895 .

_:807f36cf91fe4e8caa53aadeff92477612894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10039 .

_:807f36cf91fe4e8caa53aadeff92477612895 rdf:first _:807f36cf91fe4e8caa53aadeff92477612896;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10070 .

_:807f36cf91fe4e8caa53aadeff92477612898 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10287-1 a owl:Class;
  rdfs:label "ANTIPURINES <-> INHIBITEURS DE LA XANTHINE OXYDASE"@fr;
  dct:identifier "IAM_10287";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612900;
  r:natureDuRisque "Insuffisance médullaire éventuellement grave."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612906, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612900 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612901 .

_:807f36cf91fe4e8caa53aadeff92477612901 rdf:first _:807f36cf91fe4e8caa53aadeff92477612902;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612903 .

_:807f36cf91fe4e8caa53aadeff92477612902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10039 .

_:807f36cf91fe4e8caa53aadeff92477612903 rdf:first _:807f36cf91fe4e8caa53aadeff92477612904;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10099 .

_:807f36cf91fe4e8caa53aadeff92477612906 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10288-1 a owl:Class;
  rdfs:label "ANTIPURINES <-> RIBAVIRINE"@fr;
  dct:identifier "IAM_10288";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612908;
  r:natureDuRisque "Risque majoré d'effets indésirables graves, par inhibition du métabolisme de l'immunomodulateur par la ribavirine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612914, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612908 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612909 .

_:807f36cf91fe4e8caa53aadeff92477612909 rdf:first _:807f36cf91fe4e8caa53aadeff92477612910;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612911 .

_:807f36cf91fe4e8caa53aadeff92477612910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10039 .

_:807f36cf91fe4e8caa53aadeff92477612911 rdf:first _:807f36cf91fe4e8caa53aadeff92477612912;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10797 .

_:807f36cf91fe4e8caa53aadeff92477612914 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10289-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> ATAZANAVIR"@fr;
  dct:identifier "IAM_10289";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612916;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de l'atazanavir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612922, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612916 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612917 .

_:807f36cf91fe4e8caa53aadeff92477612917 rdf:first _:807f36cf91fe4e8caa53aadeff92477612918;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612919 .

_:807f36cf91fe4e8caa53aadeff92477612918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477612919 rdf:first _:807f36cf91fe4e8caa53aadeff92477612920;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff92477612922 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10280-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> PENTOXIFYLLINE"@fr;
  dct:identifier "IAM_10280";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612924;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612930, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612924 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612925 .

_:807f36cf91fe4e8caa53aadeff92477612925 rdf:first _:807f36cf91fe4e8caa53aadeff92477612926;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612927 .

_:807f36cf91fe4e8caa53aadeff92477612926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477612927 rdf:first _:807f36cf91fe4e8caa53aadeff92477612928;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10705 .

_:807f36cf91fe4e8caa53aadeff92477612930 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10291-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS"@fr;
  dct:identifier "IAM_10291";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612932;
  r:natureDuRisque "Risque de diminution de la biodisponibilité de l’inhibiteur de tyrosine kinases, en raison de son absorption pH-dépendante."@fr;
  r:conduiteATenir "- sauf avec le vandétanib."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612938, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612932 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612933 .

_:807f36cf91fe4e8caa53aadeff92477612933 rdf:first _:807f36cf91fe4e8caa53aadeff92477612934;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612935 .

_:807f36cf91fe4e8caa53aadeff92477612934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477612935 rdf:first _:807f36cf91fe4e8caa53aadeff92477612936;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477612938 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10279-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> PEMETREXED"@fr;
  dct:identifier "IAM_10279";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612940;
  r:natureDuRisque "Risque de majoration de la toxicité du pemetrexed (diminution de sa clairance rénale par les AINS)."@fr;
  r:conduiteATenir """Association déconseillée : 
- en cas de fonction rénale faible à modérée.

Précaution d'emploi :
- en cas de fonction rénale normale. Surveillance biologique de la fonction rénale."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612946, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612940 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612941 .

_:807f36cf91fe4e8caa53aadeff92477612941 rdf:first _:807f36cf91fe4e8caa53aadeff92477612942;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612943 .

_:807f36cf91fe4e8caa53aadeff92477612942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477612943 rdf:first _:807f36cf91fe4e8caa53aadeff92477612944;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10700 .

_:807f36cf91fe4e8caa53aadeff92477612946 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10293-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10293";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612948;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612954, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612948 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612949 .

_:807f36cf91fe4e8caa53aadeff92477612949 rdf:first _:807f36cf91fe4e8caa53aadeff92477612950;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612951 .

_:807f36cf91fe4e8caa53aadeff92477612950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477612951 rdf:first _:807f36cf91fe4e8caa53aadeff92477612952;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477612954 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10294-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10294";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612956;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  r:conduiteATenir """Association déconseillée:
- uniquement avec la forme suspension buvable de posaconazole."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612962, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612956 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612957 .

_:807f36cf91fe4e8caa53aadeff92477612957 rdf:first _:807f36cf91fe4e8caa53aadeff92477612958;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612959 .

_:807f36cf91fe4e8caa53aadeff92477612958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477612959 rdf:first _:807f36cf91fe4e8caa53aadeff92477612960;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477612962 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10295-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_10295";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612964;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de la rilpivirine."@fr;
  r:conduiteATenir "Si nécessaire, utiliser un antihistaminique H2 actif en une prise par jour, à prendre au moins 12 heures avant, ou au moins 4 heures après."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612970, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612964 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612965 .

_:807f36cf91fe4e8caa53aadeff92477612965 rdf:first _:807f36cf91fe4e8caa53aadeff92477612966;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612967 .

_:807f36cf91fe4e8caa53aadeff92477612966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477612967 rdf:first _:807f36cf91fe4e8caa53aadeff92477612968;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:807f36cf91fe4e8caa53aadeff92477612970 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10296-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10296";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612972;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par diminution de son absorption."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612978, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612972 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612973 .

_:807f36cf91fe4e8caa53aadeff92477612973 rdf:first _:807f36cf91fe4e8caa53aadeff92477612974;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612975 .

_:807f36cf91fe4e8caa53aadeff92477612974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477612975 rdf:first _:807f36cf91fe4e8caa53aadeff92477612976;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477612978 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10297-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> ATAZANAVIR"@fr;
  dct:identifier "IAM_10297";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612980;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de l'atazanavir, avec risque d'échec thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612986, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612980 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612981 .

_:807f36cf91fe4e8caa53aadeff92477612981 rdf:first _:807f36cf91fe4e8caa53aadeff92477612982;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612983 .

_:807f36cf91fe4e8caa53aadeff92477612982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477612983 rdf:first _:807f36cf91fe4e8caa53aadeff92477612984;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10087 .

_:807f36cf91fe4e8caa53aadeff92477612986 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10298-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> CYANOCOBALAMINE"@fr;
  dct:identifier "IAM_10298";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612988;
  r:natureDuRisque "Risque de carence en cyanocobalamine après traitement prolongé (quelques années), la réduction de l’acidité gastrique par ces médicaments pouvant diminuer l’absorption digestive de la vitamine B12."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477612994, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612988 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612989 .

_:807f36cf91fe4e8caa53aadeff92477612989 rdf:first _:807f36cf91fe4e8caa53aadeff92477612990;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612991 .

_:807f36cf91fe4e8caa53aadeff92477612990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477612991 rdf:first _:807f36cf91fe4e8caa53aadeff92477612992;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477612992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10233 .

_:807f36cf91fe4e8caa53aadeff92477612994 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10299-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS"@fr;
  dct:identifier "IAM_10299";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477612996;
  r:natureDuRisque "Risque de diminution de la biodisponibilité de l’inhibiteur de tyrosine kinases, en raison de son absorption pH-dépendante."@fr;
  r:conduiteATenir "- sauf avec l'imatinib et le vandétanib"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613002, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477612996 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477612997 .

_:807f36cf91fe4e8caa53aadeff92477612997 rdf:first _:807f36cf91fe4e8caa53aadeff92477612998;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477612999 .

_:807f36cf91fe4e8caa53aadeff92477612998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477612999 rdf:first _:807f36cf91fe4e8caa53aadeff92477613000;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477613002 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10300-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10300";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613004;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613010, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613004 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613005 .

_:807f36cf91fe4e8caa53aadeff92477613005 rdf:first _:807f36cf91fe4e8caa53aadeff92477613006;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613007 .

_:807f36cf91fe4e8caa53aadeff92477613006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477613007 rdf:first _:807f36cf91fe4e8caa53aadeff92477613008;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477613010 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10301-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10301";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613012;
  r:natureDuRisque "Diminution de l'absorption de l'azolé antifongique, par augmentation du pH intragastrique par l'antisécrétoire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613018, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613012 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613013 .

_:807f36cf91fe4e8caa53aadeff92477613013 rdf:first _:807f36cf91fe4e8caa53aadeff92477613014;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613015 .

_:807f36cf91fe4e8caa53aadeff92477613014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477613015 rdf:first _:807f36cf91fe4e8caa53aadeff92477613016;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477613018 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10715-1 a owl:Class;
  rdfs:label "DACLATASVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10715";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613020;
  r:natureDuRisque "Diminution des concentrations plasmatiques de daclatasvir par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir """Contre-indication:
- avec la rifampicine
- avec les anticonvulsivants inducteurs enzymatiques
- avec l'oxcarbazépine

Précaution d'emploi:
- avec les autres inducteurs, la dose recommandée est de 90 mg/jour de daclatasvir"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613026, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613020 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613021 .

_:807f36cf91fe4e8caa53aadeff92477613021 rdf:first _:807f36cf91fe4e8caa53aadeff92477613022;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613023 .

_:807f36cf91fe4e8caa53aadeff92477613022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477613023 rdf:first _:807f36cf91fe4e8caa53aadeff92477613024;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:807f36cf91fe4e8caa53aadeff92477613026 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10290-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES ANTIHISTAMINIQUES H2 <-> CYANOCOBALAMINE"@fr;
  dct:identifier "IAM_10290";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613028;
  r:natureDuRisque "Risque de carence en cyanocobalamine après traitement prolongé (quelques années), la réduction de l’acidité gastrique par ces médicaments pouvant diminuer l’absorption digestive de la vitamine B12."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613034, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613028 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613029 .

_:807f36cf91fe4e8caa53aadeff92477613029 rdf:first _:807f36cf91fe4e8caa53aadeff92477613030;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613031 .

_:807f36cf91fe4e8caa53aadeff92477613030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10042 .

_:807f36cf91fe4e8caa53aadeff92477613031 rdf:first _:807f36cf91fe4e8caa53aadeff92477613032;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10233 .

_:807f36cf91fe4e8caa53aadeff92477613034 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10268-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10268";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613036;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613042, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613036 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613037 .

_:807f36cf91fe4e8caa53aadeff92477613037 rdf:first _:807f36cf91fe4e8caa53aadeff92477613038;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613039 .

_:807f36cf91fe4e8caa53aadeff92477613038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613039 rdf:first _:807f36cf91fe4e8caa53aadeff92477613040;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477613042 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10227-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> IVABRADINE"@fr;
  dct:identifier "IAM_10227";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613044;
  r:natureDuRisque "Risque de diminution de l'efficacité de l’ivabradine, par augmentation de son métabolisme par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’ivabradine pendant l’association et après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613050, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613044 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613045 .

_:807f36cf91fe4e8caa53aadeff92477613045 rdf:first _:807f36cf91fe4e8caa53aadeff92477613046;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613047 .

_:807f36cf91fe4e8caa53aadeff92477613046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613047 rdf:first _:807f36cf91fe4e8caa53aadeff92477613048;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477613050 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10257-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10257";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613052;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'antidépresseur imipraminique avec risque de convulsions et augmentation des effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique accrue et, si nécessaire, adaptation posologique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613058, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613052 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613053 .

_:807f36cf91fe4e8caa53aadeff92477613053 rdf:first _:807f36cf91fe4e8caa53aadeff92477613054;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613055 .

_:807f36cf91fe4e8caa53aadeff92477613054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:807f36cf91fe4e8caa53aadeff92477613055 rdf:first _:807f36cf91fe4e8caa53aadeff92477613056;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477613058 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10258-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> ORLISTAT"@fr;
  dct:identifier "IAM_10258";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613060;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613066, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613060 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613061 .

_:807f36cf91fe4e8caa53aadeff92477613061 rdf:first _:807f36cf91fe4e8caa53aadeff92477613062;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613063 .

_:807f36cf91fe4e8caa53aadeff92477613062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:807f36cf91fe4e8caa53aadeff92477613063 rdf:first _:807f36cf91fe4e8caa53aadeff92477613064;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477613066 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10259-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_10259";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613068;
  r:natureDuRisque "Hypertension paroxystique avec possibilité de troubles du rythme (inhibition de l'entrée du sympathomimétique dans la fibre sympathique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613074, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613068 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613069 .

_:807f36cf91fe4e8caa53aadeff92477613069 rdf:first _:807f36cf91fe4e8caa53aadeff92477613070;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613071 .

_:807f36cf91fe4e8caa53aadeff92477613070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:807f36cf91fe4e8caa53aadeff92477613071 rdf:first _:807f36cf91fe4e8caa53aadeff92477613072;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:807f36cf91fe4e8caa53aadeff92477613074 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10260-1 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS ALPHA-BLOQUANTS <-> ANTIHYPERTENSEURS SAUF ALPHA-BLOQUANTS"@fr;
  dct:identifier "IAM_10260";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613076;
  r:natureDuRisque "Majoration de l'effet hypotenseur. Risque majoré d'hypotension orthostatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613082, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613076 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613077 .

_:807f36cf91fe4e8caa53aadeff92477613077 rdf:first _:807f36cf91fe4e8caa53aadeff92477613078;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613079 .

_:807f36cf91fe4e8caa53aadeff92477613078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10033 .

_:807f36cf91fe4e8caa53aadeff92477613079 rdf:first _:807f36cf91fe4e8caa53aadeff92477613080;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10035 .

_:807f36cf91fe4e8caa53aadeff92477613082 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10261-1 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS ALPHA-BLOQUANTS <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10261";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613084;
  r:natureDuRisque "Risque d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir """Association déconseillée :
- avec la doxazosine 

Précaution d'emploi :
- avec les autres alpha-bloquants
Débuter le traitement aux posologies minimales recommandées et adapter progressivement les doses si besoin."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613084 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613085 .

_:807f36cf91fe4e8caa53aadeff92477613085 rdf:first _:807f36cf91fe4e8caa53aadeff92477613086;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613087 .

_:807f36cf91fe4e8caa53aadeff92477613086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10033 .

_:807f36cf91fe4e8caa53aadeff92477613087 rdf:first _:807f36cf91fe4e8caa53aadeff92477613088;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477613090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10262-1 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS CENTRAUX <-> BÊTA-BLOQUANTS (SAUF ESMOLOL)"@fr;
  dct:identifier "IAM_10262";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613092;
  r:natureDuRisque "Augmentation importante de la pression artérielle en cas d'arrêt brutal du traitement par l'antihypertenseur central."@fr;
  r:conduiteATenir "Eviter l'arrêt brutal du traitement par l'antihypertenseur central. Surveillance clinique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613093 .

_:807f36cf91fe4e8caa53aadeff92477613093 rdf:first _:807f36cf91fe4e8caa53aadeff92477613094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613095 .

_:807f36cf91fe4e8caa53aadeff92477613094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10034 .

_:807f36cf91fe4e8caa53aadeff92477613095 rdf:first _:807f36cf91fe4e8caa53aadeff92477613096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477613098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10263-1 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS CENTRAUX <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10263";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613100;
  r:natureDuRisque "Diminution centrale du tonus sympathique et effet vasodilatateur des antihypertenseurs centraux, préjudiciables en cas d'insuffisance cardiaque traitée par bêta-bloquant et vasodilatateur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613101 .

_:807f36cf91fe4e8caa53aadeff92477613101 rdf:first _:807f36cf91fe4e8caa53aadeff92477613102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613103 .

_:807f36cf91fe4e8caa53aadeff92477613102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10034 .

_:807f36cf91fe4e8caa53aadeff92477613103 rdf:first _:807f36cf91fe4e8caa53aadeff92477613104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477613106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10265-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> AUTRES ANTI-INFLAMMATOIRES NON STÉROÏDIENS"@fr;
  dct:identifier "IAM_10265";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613108;
  r:natureDuRisque "Avec les autres anti-inflammatoires non stéroïdiens : majoration du risque ulcérogène et hémorragique digestif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613110, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613108 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613110 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10281-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10281";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613112;
  r:natureDuRisque "Risque d’addition des effets néphrotoxiques, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveiller la fonction rénale en début de traitement par l’AINS."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613118, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613112 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613113 .

_:807f36cf91fe4e8caa53aadeff92477613113 rdf:first _:807f36cf91fe4e8caa53aadeff92477613114;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613115 .

_:807f36cf91fe4e8caa53aadeff92477613114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613115 rdf:first _:807f36cf91fe4e8caa53aadeff92477613116;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613116 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477613118 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10267-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> CICLOSPORINE"@fr;
  dct:identifier "IAM_10267";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613120;
  r:natureDuRisque "Risque d’addition des effets néphrotoxiques, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveiller la fonction rénale en début de traitement par l’AINS."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613126, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613120 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613121 .

_:807f36cf91fe4e8caa53aadeff92477613121 rdf:first _:807f36cf91fe4e8caa53aadeff92477613122;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613123 .

_:807f36cf91fe4e8caa53aadeff92477613122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613123 rdf:first _:807f36cf91fe4e8caa53aadeff92477613124;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477613126 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10255-1 a owl:Class;
  rdfs:label "ANTIDÉPRESSEURS IMIPRAMINIQUES <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10255";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613128;
  r:natureDuRisque "Effet vasodilatateur et risque d'hypotension, notamment orthostatique (effet additif)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613134, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613128 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613129 .

_:807f36cf91fe4e8caa53aadeff92477613129 rdf:first _:807f36cf91fe4e8caa53aadeff92477613130;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613131 .

_:807f36cf91fe4e8caa53aadeff92477613130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10032 .

_:807f36cf91fe4e8caa53aadeff92477613131 rdf:first _:807f36cf91fe4e8caa53aadeff92477613132;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477613134 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10269-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> DIURÉTIQUES"@fr;
  dct:identifier "IAM_10269";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613136;
  r:natureDuRisque "Insuffisance rénale aiguë chez le malade à risque (sujet âgé et/ou déshydraté) par diminution de la filtration glomérulaire (inhibition des prostaglandines vasodilatatrices due aux anti-inflammatoires non stéroïdiens). Par ailleurs, réduction de l'effet a"@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613142, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613136 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613137 .

_:807f36cf91fe4e8caa53aadeff92477613137 rdf:first _:807f36cf91fe4e8caa53aadeff92477613138;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613139 .

_:807f36cf91fe4e8caa53aadeff92477613138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613139 rdf:first _:807f36cf91fe4e8caa53aadeff92477613140;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10063 .

_:807f36cf91fe4e8caa53aadeff92477613142 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10270-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10270";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613144;
  r:natureDuRisque "Augmentation du risque d’ulcération et d’hémorragie gastro-intestinale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613150, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613144 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613145 .

_:807f36cf91fe4e8caa53aadeff92477613145 rdf:first _:807f36cf91fe4e8caa53aadeff92477613146;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613147 .

_:807f36cf91fe4e8caa53aadeff92477613146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613147 rdf:first _:807f36cf91fe4e8caa53aadeff92477613148;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477613150 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10271-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10271";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613152;
  r:natureDuRisque "Augmentation du risque hémorragique (agression de la muqueuse gastroduodénale par les anti-inflammatoires non stéroïdiens)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613158, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613152 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613153 .

_:807f36cf91fe4e8caa53aadeff92477613153 rdf:first _:807f36cf91fe4e8caa53aadeff92477613154;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613155 .

_:807f36cf91fe4e8caa53aadeff92477613154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613155 rdf:first _:807f36cf91fe4e8caa53aadeff92477613156;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477613158 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10272-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES PRÉVENTIVES)"@fr;
  dct:identifier "IAM_10272";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613160;
  r:chapeau """Dans le cas de leur utilisation à doses prophylactiques (en dehors du sujet âgé), l'utilisation de médicaments agissant à divers niveaux de l'hémostase majore le risque de saignement. 
Ainsi, chez le sujet non âgé, l'association de l'héparine ou de molécu"""@fr;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613166, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613160 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613161 .

_:807f36cf91fe4e8caa53aadeff92477613161 rdf:first _:807f36cf91fe4e8caa53aadeff92477613162;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613163 .

_:807f36cf91fe4e8caa53aadeff92477613162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613163 rdf:first _:807f36cf91fe4e8caa53aadeff92477613164;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10090 .

_:807f36cf91fe4e8caa53aadeff92477613166 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10274-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> HÉPARINES NON FRACTIONNÉES (DOSES PRÉVENTIVES)"@fr;
  dct:identifier "IAM_10274";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613168;
  r:chapeau """Dans le cas de leur utilisation à doses prophylactiques (en dehors du sujet âgé), l'utilisation de médicaments agissant à divers niveaux de l'hémostase majore le risque de saignement. 
Ainsi, chez le sujet non âgé, l'association de l'héparine ou de molécu"""@fr;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613174, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613168 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613169 .

_:807f36cf91fe4e8caa53aadeff92477613169 rdf:first _:807f36cf91fe4e8caa53aadeff92477613170;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613171 .

_:807f36cf91fe4e8caa53aadeff92477613170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613171 rdf:first _:807f36cf91fe4e8caa53aadeff92477613172;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10092 .

_:807f36cf91fe4e8caa53aadeff92477613174 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10273-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10273";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613176;
  r:natureDuRisque "Augmentation du risque hémorragique (agression de la muqueuse gastroduodénale par les anti-inflammatoires non stéroïdiens)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613182, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613176 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613177 .

_:807f36cf91fe4e8caa53aadeff92477613177 rdf:first _:807f36cf91fe4e8caa53aadeff92477613178;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613179 .

_:807f36cf91fe4e8caa53aadeff92477613178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613179 rdf:first _:807f36cf91fe4e8caa53aadeff92477613180;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:807f36cf91fe4e8caa53aadeff92477613182 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10275-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10275";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613184;
  r:natureDuRisque "Insuffisance rénale aiguë chez le patient à risque (âgé, déshydraté, sous diurétiques, avec une fonction rénale altérée), par diminution de la filtration glomérulaire (inhibition des prostaglandines vasodilatatrices due aux anti-inflammatoires non stéroïd"@fr;
  r:conduiteATenir "Hydrater le malade et surveiller la fonction rénale en début de traitement et régulièrement pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613190, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613184 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613185 .

_:807f36cf91fe4e8caa53aadeff92477613185 rdf:first _:807f36cf91fe4e8caa53aadeff92477613186;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613187 .

_:807f36cf91fe4e8caa53aadeff92477613186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613187 rdf:first _:807f36cf91fe4e8caa53aadeff92477613188;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477613190 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10276-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_10276";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613192;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613198, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613192 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613193 .

_:807f36cf91fe4e8caa53aadeff92477613193 rdf:first _:807f36cf91fe4e8caa53aadeff92477613194;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613195 .

_:807f36cf91fe4e8caa53aadeff92477613194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613195 rdf:first _:807f36cf91fe4e8caa53aadeff92477613196;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477613198 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10277-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> LITHIUM"@fr;
  dct:identifier "IAM_10277";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613200;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques (diminution de l'excrétion rénale du lithium)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveiller étroitement la lithémie et adapter la posologie du lithium pendant l'association et après l'arrêt de l'anti-inflammatoire non stéroïdien."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613206, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613200 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613201 .

_:807f36cf91fe4e8caa53aadeff92477613201 rdf:first _:807f36cf91fe4e8caa53aadeff92477613202;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613203 .

_:807f36cf91fe4e8caa53aadeff92477613202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613203 rdf:first _:807f36cf91fe4e8caa53aadeff92477613204;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477613206 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10278-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10278";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613208;
  r:natureDuRisque "Augmentation de la toxicité hématologique du méthotrexate (diminution de la clairance rénale du méthotrexate par les anti-inflammatoires)."@fr;
  r:conduiteATenir """Association déconseillée:
- pour des doses de méthotrexate supérieures à 20 mg par semaine.
- avec le kétoprofène et le méthotrexate à des doses supérieures à 20 mg par semaines, respecter un intervalle d'au moins 12 heures entre l'arrêt ou le début d'un"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613214, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613208 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613209 .

_:807f36cf91fe4e8caa53aadeff92477613209 rdf:first _:807f36cf91fe4e8caa53aadeff92477613210;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613211 .

_:807f36cf91fe4e8caa53aadeff92477613210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613211 rdf:first _:807f36cf91fe4e8caa53aadeff92477613212;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477613214 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10266-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> BÊTA-BLOQUANTS (SAUF ESMOLOL)"@fr;
  dct:identifier "IAM_10266";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613216;
  r:natureDuRisque "Réduction de l'effet antihypertenseur (inhibition des prostaglandines vasodilatatrices par les anti-inflammatoires non stéroïdiens)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613222, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613216 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613217 .

_:807f36cf91fe4e8caa53aadeff92477613217 rdf:first _:807f36cf91fe4e8caa53aadeff92477613218;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613219 .

_:807f36cf91fe4e8caa53aadeff92477613218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613219 rdf:first _:807f36cf91fe4e8caa53aadeff92477613220;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10054 .

_:807f36cf91fe4e8caa53aadeff92477613222 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10677-1 a owl:Class;
  rdfs:label "COLCHICINE <-> FIBRATES"@fr;
  dct:identifier "IAM_10677";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613224;
  r:natureDuRisque "Risque de majoration des effets indésirables musculaires de ces substances, et notamment de rhabdomyolyse."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, particulièrement au début de l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613230, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613224 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613225 .

_:807f36cf91fe4e8caa53aadeff92477613225 rdf:first _:807f36cf91fe4e8caa53aadeff92477613226;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613227 .

_:807f36cf91fe4e8caa53aadeff92477613226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:807f36cf91fe4e8caa53aadeff92477613227 rdf:first _:807f36cf91fe4e8caa53aadeff92477613228;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477613230 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11229-1 a owl:Class;
  rdfs:label "LÉDIPASVIR <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11229";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613232;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques du lédipasvir par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613238, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613232 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613233 .

_:807f36cf91fe4e8caa53aadeff92477613233 rdf:first _:807f36cf91fe4e8caa53aadeff92477613234;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613235 .

_:807f36cf91fe4e8caa53aadeff92477613234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477613235 rdf:first _:807f36cf91fe4e8caa53aadeff92477613236;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477613238 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10264-1 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10264";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613240;
  r:natureDuRisque "Augmentation du risque hémorragique de l'anticoagulant oral (agression de la muqueuse gastroduodénale par les anti-inflammatoires non stéroïdiens)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite, voire biologique ."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613246, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613240 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613241 .

_:807f36cf91fe4e8caa53aadeff92477613241 rdf:first _:807f36cf91fe4e8caa53aadeff92477613242;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613243 .

_:807f36cf91fe4e8caa53aadeff92477613242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477613243 rdf:first _:807f36cf91fe4e8caa53aadeff92477613244;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477613246 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10202-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> DÉFIBROTIDE"@fr;
  dct:identifier "IAM_10202";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613248;
  r:natureDuRisque "Risque hémorragique accru."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613254, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613248 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613249 .

_:807f36cf91fe4e8caa53aadeff92477613249 rdf:first _:807f36cf91fe4e8caa53aadeff92477613250;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613251 .

_:807f36cf91fe4e8caa53aadeff92477613250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477613251 rdf:first _:807f36cf91fe4e8caa53aadeff92477613252;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10262 .

_:807f36cf91fe4e8caa53aadeff92477613254 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10203-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10203";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613256;
  r:natureDuRisque "Glucocorticoïdes (voies générale et rectale) : impact éventuel de la corticothérapie sur le métabolisme de l'antivitamine K et sur celui des facteurs de la coagulation. Risque hémorragique propre à la corticothérapie (muqueuse digestive, fragilité vascula"@fr;
  r:conduiteATenir "Lorsque l'association est justifiée, renforcer la surveillance : le cas échéant, avec les antivitamines K, contrôle biologique au 8e jour, puis tous les 15 jours pendant la corticothérapie et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613262, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613256 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613257 .

_:807f36cf91fe4e8caa53aadeff92477613257 rdf:first _:807f36cf91fe4e8caa53aadeff92477613258;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613259 .

_:807f36cf91fe4e8caa53aadeff92477613258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477613259 rdf:first _:807f36cf91fe4e8caa53aadeff92477613260;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477613262 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10353-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PENTOXIFYLLINE"@fr;
  dct:identifier "IAM_10353";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613264;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la pentoxifylline et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613270, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613264 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613265 .

_:807f36cf91fe4e8caa53aadeff92477613265 rdf:first _:807f36cf91fe4e8caa53aadeff92477613266;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613267 .

_:807f36cf91fe4e8caa53aadeff92477613266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477613267 rdf:first _:807f36cf91fe4e8caa53aadeff92477613268;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10705 .

_:807f36cf91fe4e8caa53aadeff92477613270 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10354-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PRISTINAMYCINE"@fr;
  dct:identifier "IAM_10354";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613272;
  r:natureDuRisque "Augmentation de l'effet de l'antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la pristinamycine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613278, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613272 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613273 .

_:807f36cf91fe4e8caa53aadeff92477613273 rdf:first _:807f36cf91fe4e8caa53aadeff92477613274;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613275 .

_:807f36cf91fe4e8caa53aadeff92477613274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477613275 rdf:first _:807f36cf91fe4e8caa53aadeff92477613276;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10757 .

_:807f36cf91fe4e8caa53aadeff92477613278 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10355-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PROGUANIL"@fr;
  dct:identifier "IAM_10355";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613280;
  r:natureDuRisque "Risque d’augmentation de l’effet de l’antivitamine K et du risque hémorragique."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l’INR. Adaptation éventuelle de la posologie de l’antivitamine K pendant le traitement par le proguanil et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613286, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613280 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613281 .

_:807f36cf91fe4e8caa53aadeff92477613281 rdf:first _:807f36cf91fe4e8caa53aadeff92477613282;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613283 .

_:807f36cf91fe4e8caa53aadeff92477613282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477613283 rdf:first _:807f36cf91fe4e8caa53aadeff92477613284;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10761 .

_:807f36cf91fe4e8caa53aadeff92477613286 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10356-1 a owl:Class;
  rdfs:label "ANTIVITAMINES K <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10356";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613288;
  r:natureDuRisque "Augmentation de l'effet anticoagulant et du risque hémorragique. Mécanisme invoqué : inhibition du métabolisme de l'antivitamine K."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par la propafénone et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613294, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613288 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613289 .

_:807f36cf91fe4e8caa53aadeff92477613289 rdf:first _:807f36cf91fe4e8caa53aadeff92477613290;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613291 .

_:807f36cf91fe4e8caa53aadeff92477613290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477613291 rdf:first _:807f36cf91fe4e8caa53aadeff92477613292;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477613294 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10673-1 a owl:Class;
  rdfs:label "COBICISTAT <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10673";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613296;
  r:natureDuRisque "Risque de diminution de l’efficacité du cobicistat par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613296 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613297 .

_:807f36cf91fe4e8caa53aadeff92477613297 rdf:first _:807f36cf91fe4e8caa53aadeff92477613298;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613299 .

_:807f36cf91fe4e8caa53aadeff92477613298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477613299 rdf:first _:807f36cf91fe4e8caa53aadeff92477613300;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477613302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10200-1 a owl:Class;
  rdfs:label "ANTICHOLINESTÉRASIQUES <-> SUXAMETHONIUM"@fr;
  dct:identifier "IAM_10200";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613304;
  r:chapeau """(voir aussi \"bradycardisants\")

+ MEDICAMENTS ATROPINIQUES
Il convient de prendre en compte le risque lié à l'association d'un médicament à action atropinique (imipraminiques, neuroleptiques phénothiaziniques, antispasmodiques, certains antihistaminiques"""@fr;
  r:natureDuRisque "Risque d'allongement du bloc moteur, majoré en cas de déficit partiel en pseudocholinestérase."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613305 .

_:807f36cf91fe4e8caa53aadeff92477613305 rdf:first _:807f36cf91fe4e8caa53aadeff92477613306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613307 .

_:807f36cf91fe4e8caa53aadeff92477613306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10027 .

_:807f36cf91fe4e8caa53aadeff92477613307 rdf:first _:807f36cf91fe4e8caa53aadeff92477613308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10878 .

_:807f36cf91fe4e8caa53aadeff92477613310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10676-1 a owl:Class;
  rdfs:label "COCAINE <-> DISULFIRAME"@fr;
  dct:identifier "IAM_10676";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613312;
  r:natureDuRisque "Augmentation des concentrations de cocaïne par diminution de son métabolisme par le disulfirame, avec risque majoré de survenue de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613313 .

_:807f36cf91fe4e8caa53aadeff92477613313 rdf:first _:807f36cf91fe4e8caa53aadeff92477613314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613315 .

_:807f36cf91fe4e8caa53aadeff92477613314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10223 .

_:807f36cf91fe4e8caa53aadeff92477613315 rdf:first _:807f36cf91fe4e8caa53aadeff92477613316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:807f36cf91fe4e8caa53aadeff92477613318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10199-1 a owl:Class;
  rdfs:label "ANTICHOLINESTÉRASIQUES <-> PILOCARPINE"@fr;
  dct:identifier "IAM_10199";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613320;
  r:natureDuRisque "Risque d'addition des effets indésirables cholinergiques, notamment digestifs."@fr;
  rdfs:comment "La pilocarpine est un parasympathomimétique direct utilisé dans le traitement du glaucome sous forme de collyre. Il existe aussi une AMM par voie orale dont l’indication est l’hyposialie et la xérostomie après radiothérapie chez l’adulte, ainsi que les sé"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613320 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613321 .

_:807f36cf91fe4e8caa53aadeff92477613321 rdf:first _:807f36cf91fe4e8caa53aadeff92477613322;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613323 .

_:807f36cf91fe4e8caa53aadeff92477613322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10027 .

_:807f36cf91fe4e8caa53aadeff92477613323 rdf:first _:807f36cf91fe4e8caa53aadeff92477613324;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10719 .

_:807f36cf91fe4e8caa53aadeff92477613326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10678-1 a owl:Class;
  rdfs:label "COLCHICINE <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10678";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613328;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine, aux conséquences potentiellement fatales."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613329 .

_:807f36cf91fe4e8caa53aadeff92477613329 rdf:first _:807f36cf91fe4e8caa53aadeff92477613330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613331 .

_:807f36cf91fe4e8caa53aadeff92477613330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477613331 rdf:first _:807f36cf91fe4e8caa53aadeff92477613332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477613334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10679-1 a owl:Class;
  rdfs:label "COLCHICINE <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10679";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613336;
  r:natureDuRisque "Risque de majoration des effets indésirables musculaires de ces substances, et notamment de rhabdomyolyse."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, notamment au début de l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613337 .

_:807f36cf91fe4e8caa53aadeff92477613337 rdf:first _:807f36cf91fe4e8caa53aadeff92477613338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613339 .

_:807f36cf91fe4e8caa53aadeff92477613338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477613339 rdf:first _:807f36cf91fe4e8caa53aadeff92477613340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477613342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10680-1 a owl:Class;
  rdfs:label "COLCHICINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10680";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613344;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine, aux conséquences potentiellement fatales."@fr;
  r:conduiteATenir """Contre-indication :
- avec les macrolides

Association déconseillée :
- avec les antifongiques azolés, les inhibiteurs de protéases boostés par ritonavir et le cobicistat"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613345 .

_:807f36cf91fe4e8caa53aadeff92477613345 rdf:first _:807f36cf91fe4e8caa53aadeff92477613346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613347 .

_:807f36cf91fe4e8caa53aadeff92477613346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477613347 rdf:first _:807f36cf91fe4e8caa53aadeff92477613348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477613350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10681-1 a owl:Class;
  rdfs:label "COLCHICINE <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10681";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613352;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine, aux conséquences potentiellement fatales."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613353 .

_:807f36cf91fe4e8caa53aadeff92477613353 rdf:first _:807f36cf91fe4e8caa53aadeff92477613354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613355 .

_:807f36cf91fe4e8caa53aadeff92477613354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:807f36cf91fe4e8caa53aadeff92477613355 rdf:first _:807f36cf91fe4e8caa53aadeff92477613356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477613358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10682-1 a owl:Class;
  rdfs:label "COLCHICINE <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10682";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613360;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la colchicine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  r:conduiteATenir """Contre-indication:
- chez les patients insuffisants rénaux et/ou hépatiques."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613361 .

_:807f36cf91fe4e8caa53aadeff92477613361 rdf:first _:807f36cf91fe4e8caa53aadeff92477613362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613363 .

_:807f36cf91fe4e8caa53aadeff92477613362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477613363 rdf:first _:807f36cf91fe4e8caa53aadeff92477613364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477613366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10683-1 a owl:Class;
  rdfs:label "COLCHICINE <-> PRISTINAMYCINE"@fr;
  dct:identifier "IAM_10683";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613368;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine aux conséquences potentiellement fatales."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613369 .

_:807f36cf91fe4e8caa53aadeff92477613369 rdf:first _:807f36cf91fe4e8caa53aadeff92477613370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613371 .

_:807f36cf91fe4e8caa53aadeff92477613370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477613371 rdf:first _:807f36cf91fe4e8caa53aadeff92477613372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10757 .

_:807f36cf91fe4e8caa53aadeff92477613374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10684-1 a owl:Class;
  rdfs:label "COLCHICINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10684";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613376;
  r:natureDuRisque "Risque de majoration des effets indésirables de la colchicine, par augmentation de ses concentrations plasmatiques par le vérapamil."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613377 .

_:807f36cf91fe4e8caa53aadeff92477613377 rdf:first _:807f36cf91fe4e8caa53aadeff92477613378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613379 .

_:807f36cf91fe4e8caa53aadeff92477613378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477613379 rdf:first _:807f36cf91fe4e8caa53aadeff92477613380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477613382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10685-1 a owl:Class;
  rdfs:label "COLISTINE <-> CURARES"@fr;
  dct:identifier "IAM_10685";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613384;
  r:natureDuRisque "Potentialisation des curares lorque l'antibiotique est administré par voie parentérale et/ou péritonéale avant, pendant ou après l'agent curarisant."@fr;
  r:conduiteATenir "Surveiller le degré de curarisation en fin d'anesthésie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613390, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613384 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613385 .

_:807f36cf91fe4e8caa53aadeff92477613385 rdf:first _:807f36cf91fe4e8caa53aadeff92477613386;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613387 .

_:807f36cf91fe4e8caa53aadeff92477613386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10057 .

_:807f36cf91fe4e8caa53aadeff92477613387 rdf:first _:807f36cf91fe4e8caa53aadeff92477613388;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10228 .

_:807f36cf91fe4e8caa53aadeff92477613390 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10686-1 a owl:Class;
  rdfs:label "CRIZOTINIB <-> SUBSTRATS À RISQUE DU CYP3A4"@fr;
  dct:identifier "IAM_10686";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613392;
  r:natureDuRisque "Risque de majoration de la toxicité de ces molécules par diminution de leur métabolisme et/ou augmentation de leur biodisponibilité par le crizotinib."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613398, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613392 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613393 .

_:807f36cf91fe4e8caa53aadeff92477613393 rdf:first _:807f36cf91fe4e8caa53aadeff92477613394;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613395 .

_:807f36cf91fe4e8caa53aadeff92477613394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10145 .

_:807f36cf91fe4e8caa53aadeff92477613395 rdf:first _:807f36cf91fe4e8caa53aadeff92477613396;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10231 .

_:807f36cf91fe4e8caa53aadeff92477613398 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10229-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_10229";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613400;
  r:natureDuRisque "Diminution des concentrations plasmatiques du métronidazole par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de métronidazole pendant le traitement par l’inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613400 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613401 .

_:807f36cf91fe4e8caa53aadeff92477613401 rdf:first _:807f36cf91fe4e8caa53aadeff92477613402;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613403 .

_:807f36cf91fe4e8caa53aadeff92477613402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613403 rdf:first _:807f36cf91fe4e8caa53aadeff92477613404;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:807f36cf91fe4e8caa53aadeff92477613406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10674-1 a owl:Class;
  rdfs:label "COBICISTAT <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_10674";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613408;
  r:natureDuRisque "Avec l'atazanavir, le darunavir ou le lopinavir boostés par cobicistat, augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour. L’association avec les autres inhibiteurs de protéases du VIH n’a pas été étudiée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613409 .

_:807f36cf91fe4e8caa53aadeff92477613409 rdf:first _:807f36cf91fe4e8caa53aadeff92477613410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613411 .

_:807f36cf91fe4e8caa53aadeff92477613410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477613411 rdf:first _:807f36cf91fe4e8caa53aadeff92477613412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477613414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10215-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DEFERASIROX"@fr;
  dct:identifier "IAM_10215";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613416;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de déférasirox."@fr;
  r:conduiteATenir "Surveiller la ferritinémie pendant et après le traitement par l’inducteur enzymatique. Si besoin, adaptation de la posologie de déférasirox."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613417 .

_:807f36cf91fe4e8caa53aadeff92477613417 rdf:first _:807f36cf91fe4e8caa53aadeff92477613418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613419 .

_:807f36cf91fe4e8caa53aadeff92477613418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613419 rdf:first _:807f36cf91fe4e8caa53aadeff92477613420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477613422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11078-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> QUINUPRISTINE"@fr;
  dct:identifier "IAM_11078";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613424;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613425 .

_:807f36cf91fe4e8caa53aadeff92477613425 rdf:first _:807f36cf91fe4e8caa53aadeff92477613426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613427 .

_:807f36cf91fe4e8caa53aadeff92477613426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477613427 rdf:first _:807f36cf91fe4e8caa53aadeff92477613428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10778 .

_:807f36cf91fe4e8caa53aadeff92477613430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10206-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> IPILIMUMAB"@fr;
  dct:identifier "IAM_10206";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613432;
  r:natureDuRisque "Augmentation du risque d'hémorragies digestives."@fr;
  r:conduiteATenir "Surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613433 .

_:807f36cf91fe4e8caa53aadeff92477613433 rdf:first _:807f36cf91fe4e8caa53aadeff92477613434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613435 .

_:807f36cf91fe4e8caa53aadeff92477613434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477613435 rdf:first _:807f36cf91fe4e8caa53aadeff92477613436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10482 .

_:807f36cf91fe4e8caa53aadeff92477613438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10207-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES"@fr;
  dct:identifier "IAM_10207";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613440;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Surveillance clinique et, le cas échéant, contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'anticoagulant oral pendant la durée de l'association et à son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613441 .

_:807f36cf91fe4e8caa53aadeff92477613441 rdf:first _:807f36cf91fe4e8caa53aadeff92477613442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613443 .

_:807f36cf91fe4e8caa53aadeff92477613442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477613443 rdf:first _:807f36cf91fe4e8caa53aadeff92477613444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:807f36cf91fe4e8caa53aadeff92477613446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10244-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10244";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613448;
  r:natureDuRisque "Risque de diminution très importante des concentrations de télaprévir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613449 .

_:807f36cf91fe4e8caa53aadeff92477613449 rdf:first _:807f36cf91fe4e8caa53aadeff92477613450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613451 .

_:807f36cf91fe4e8caa53aadeff92477613450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613451 rdf:first _:807f36cf91fe4e8caa53aadeff92477613452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477613454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10208-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> ANTIVITAMINES K"@fr;
  dct:identifier "IAM_10208";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613456;
  r:chapeau """ANTI-INFECTIEUX ET INR
De nombreux cas d’augmentation de l’activité des antivitamines K ont été rapportés chez des patients recevant des antibiotiques. Le contexte infectieux ou inflammatoire marqué, l’âge et l’état général du patient apparaissent comme d"""@fr;
  r:natureDuRisque "Diminution (ou, rarement, augmentation avec la phénytoïne) de l'effet de l'antivitamine K par augmentation de son métabolisme hépatique par l'anticonvulsivant inducteur."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'INR. Adaptation éventuelle de la posologie de l'antivitamine K pendant le traitement par l'anticonvulsivant inducteur et 8 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613457 .

_:807f36cf91fe4e8caa53aadeff92477613457 rdf:first _:807f36cf91fe4e8caa53aadeff92477613458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613459 .

_:807f36cf91fe4e8caa53aadeff92477613458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613459 rdf:first _:807f36cf91fe4e8caa53aadeff92477613460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10046 .

_:807f36cf91fe4e8caa53aadeff92477613462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10209-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> APIXABAN"@fr;
  dct:identifier "IAM_10209";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613464;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’apixaban par l' anticonvulsivant inducteur enzymatique, avec risque de diminution de l’effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613465 .

_:807f36cf91fe4e8caa53aadeff92477613465 rdf:first _:807f36cf91fe4e8caa53aadeff92477613466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613467 .

_:807f36cf91fe4e8caa53aadeff92477613466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613467 rdf:first _:807f36cf91fe4e8caa53aadeff92477613468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10078 .

_:807f36cf91fe4e8caa53aadeff92477613470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10210-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> APREPITANT"@fr;
  dct:identifier "IAM_10210";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613472;
  r:natureDuRisque "Risque de diminution très importante des concentrations d'aprépitant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613473 .

_:807f36cf91fe4e8caa53aadeff92477613473 rdf:first _:807f36cf91fe4e8caa53aadeff92477613474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613475 .

_:807f36cf91fe4e8caa53aadeff92477613474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613475 rdf:first _:807f36cf91fe4e8caa53aadeff92477613476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff92477613478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10211-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> BOCEPREVIR"@fr;
  dct:identifier "IAM_10211";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613480;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de bocéprévir."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613481 .

_:807f36cf91fe4e8caa53aadeff92477613481 rdf:first _:807f36cf91fe4e8caa53aadeff92477613482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613483 .

_:807f36cf91fe4e8caa53aadeff92477613482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613483 rdf:first _:807f36cf91fe4e8caa53aadeff92477613484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477613486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10212-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> BOSENTAN"@fr;
  dct:identifier "IAM_10212";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613488;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de bosentan."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613494, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613488 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613489 .

_:807f36cf91fe4e8caa53aadeff92477613489 rdf:first _:807f36cf91fe4e8caa53aadeff92477613490;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613491 .

_:807f36cf91fe4e8caa53aadeff92477613490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613491 rdf:first _:807f36cf91fe4e8caa53aadeff92477613492;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477613494 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10201-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> AUTRES ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10201";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613496;
  r:natureDuRisque "Risque de majoration des événements hémorragiques lors du relais d'un anticoagulant oral par un autre."@fr;
  r:conduiteATenir "Tenir compte de la demi-vie de l'anticoagulant oral et observer, le cas échéant, un délai de carence avant le début du traitement par l'autre. Penser à informer le patient."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613498, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613496 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477613498 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10214-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DABIGATRAN"@fr;
  dct:identifier "IAM_10214";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613500;
  r:natureDuRisque "Diminution des concentrations plasmatiques de dabigatran, avec risque de diminution de l'effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613506, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613500 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613501 .

_:807f36cf91fe4e8caa53aadeff92477613501 rdf:first _:807f36cf91fe4e8caa53aadeff92477613502;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613503 .

_:807f36cf91fe4e8caa53aadeff92477613502 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613503 rdf:first _:807f36cf91fe4e8caa53aadeff92477613504;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613504 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff92477613506 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11230-1 a owl:Class;
  rdfs:label "LÉDIPASVIR <-> TENOFOVIR DISOPROXIL"@fr;
  dct:identifier "IAM_11230";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613508;
  r:natureDuRisque "Lors de sa co-administration avec un inhibiteur de protéase, augmentation des concentrations plasmatiques du ténofovir par le lédipasvir."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, notamment de la fonction rénale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613514, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613508 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613509 .

_:807f36cf91fe4e8caa53aadeff92477613509 rdf:first _:807f36cf91fe4e8caa53aadeff92477613510;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613511 .

_:807f36cf91fe4e8caa53aadeff92477613510 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477613511 rdf:first _:807f36cf91fe4e8caa53aadeff92477613512;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613512 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10896 .

_:807f36cf91fe4e8caa53aadeff92477613514 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10216-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DÉLAMANID"@fr;
  dct:identifier "IAM_10216";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613516;
  r:natureDuRisque "Diminution des concentrations plasmatiques de delamanid par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613522, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613516 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613517 .

_:807f36cf91fe4e8caa53aadeff92477613517 rdf:first _:807f36cf91fe4e8caa53aadeff92477613518;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613519 .

_:807f36cf91fe4e8caa53aadeff92477613518 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613519 rdf:first _:807f36cf91fe4e8caa53aadeff92477613520;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10263 .

_:807f36cf91fe4e8caa53aadeff92477613522 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10217-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DOXYCYCLINE"@fr;
  dct:identifier "IAM_10217";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613524;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la doxycycline par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la doxycycline."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613530, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613524 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613525 .

_:807f36cf91fe4e8caa53aadeff92477613525 rdf:first _:807f36cf91fe4e8caa53aadeff92477613526;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613527 .

_:807f36cf91fe4e8caa53aadeff92477613526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613527 rdf:first _:807f36cf91fe4e8caa53aadeff92477613528;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10309 .

_:807f36cf91fe4e8caa53aadeff92477613530 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10218-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10218";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613532;
  r:natureDuRisque "Diminution importante des concentrations de dronédarone par augmentation de son métabolisme, sans modification notable du métabolite actif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613538, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613532 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613533 .

_:807f36cf91fe4e8caa53aadeff92477613533 rdf:first _:807f36cf91fe4e8caa53aadeff92477613534;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613535 .

_:807f36cf91fe4e8caa53aadeff92477613534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613535 rdf:first _:807f36cf91fe4e8caa53aadeff92477613536;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477613538 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10219-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> ESTROGÈNES NON CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10219";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613540;
  r:natureDuRisque "Diminution de l'efficacité de l'estrogène."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l'administration de l'anticonvulsivant inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613546, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613540 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613541 .

_:807f36cf91fe4e8caa53aadeff92477613541 rdf:first _:807f36cf91fe4e8caa53aadeff92477613542;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613543 .

_:807f36cf91fe4e8caa53aadeff92477613542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613543 rdf:first _:807f36cf91fe4e8caa53aadeff92477613544;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477613546 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10220-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> FENTANYL"@fr;
  dct:identifier "IAM_10220";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613548;
  r:natureDuRisque "Diminution des concentrations plasmatiques de fentanyl par augmentation de son métabolisme hépatique par l'anticonvulsivant."@fr;
  r:conduiteATenir "Préférer un autre morphinique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613554, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613548 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613549 .

_:807f36cf91fe4e8caa53aadeff92477613549 rdf:first _:807f36cf91fe4e8caa53aadeff92477613550;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613551 .

_:807f36cf91fe4e8caa53aadeff92477613550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613551 rdf:first _:807f36cf91fe4e8caa53aadeff92477613552;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10374 .

_:807f36cf91fe4e8caa53aadeff92477613554 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10221-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10221";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613556;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des corticoïdes par augmentation de leur métabolisme hépatique par l'inducteur : les conséquences sont particulièrement importantes chez les addisoniens traités par l'hydrocortisone et en cas d"@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie des corticoïdes pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613562, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613556 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613557 .

_:807f36cf91fe4e8caa53aadeff92477613557 rdf:first _:807f36cf91fe4e8caa53aadeff92477613558;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613559 .

_:807f36cf91fe4e8caa53aadeff92477613558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613559 rdf:first _:807f36cf91fe4e8caa53aadeff92477613560;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477613562 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10222-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> HALOPERIDOL"@fr;
  dct:identifier "IAM_10222";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613564;
  r:natureDuRisque "Surveillance clinique et, si besoin, adaptation posologique pendant le traitement par la carbamazépine et après son arrêt."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, adaptation posologique pendant le traitement par la carbamazépine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613570, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613564 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613565 .

_:807f36cf91fe4e8caa53aadeff92477613565 rdf:first _:807f36cf91fe4e8caa53aadeff92477613566;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613567 .

_:807f36cf91fe4e8caa53aadeff92477613566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613567 rdf:first _:807f36cf91fe4e8caa53aadeff92477613568;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10426 .

_:807f36cf91fe4e8caa53aadeff92477613570 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10223-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10223";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613572;
  r:natureDuRisque "Risque d'hypothyroïdie clinique chez les patients hypothyroïdiens, par augmentation du métabolisme de la T3 et de la T4."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie des hormones thyroïdiennes pendant le traitement par l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613578, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613572 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613573 .

_:807f36cf91fe4e8caa53aadeff92477613573 rdf:first _:807f36cf91fe4e8caa53aadeff92477613574;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613575 .

_:807f36cf91fe4e8caa53aadeff92477613574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613575 rdf:first _:807f36cf91fe4e8caa53aadeff92477613576;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477613578 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10197-1 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES CLASSE IA <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10197";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613580;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de l'antiarythmique (augmentation de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement de la concentration plasmatique de l'antiarythmique. Si besoin, adaptation de la posologie de l'antiarythmique pendant le traitement par la rifampicine et après son arrêt (risque de surdosage en antiarythmique)"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613586, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613580 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613581 .

_:807f36cf91fe4e8caa53aadeff92477613581 rdf:first _:807f36cf91fe4e8caa53aadeff92477613582;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613583 .

_:807f36cf91fe4e8caa53aadeff92477613582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10026 .

_:807f36cf91fe4e8caa53aadeff92477613583 rdf:first _:807f36cf91fe4e8caa53aadeff92477613584;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613584 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477613586 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10198-1 a owl:Class;
  rdfs:label "ANTICHOLINESTÉRASIQUES <-> BÊTA-BLOQUANTS DANS L'INSUFFISANCE CARDIAQUE"@fr;
  dct:identifier "IAM_10198";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613588;
  r:chapeau """(voir aussi \"bradycardisants\")

+ MEDICAMENTS ATROPINIQUES
Il convient de prendre en compte le risque lié à l'association d'un médicament à action atropinique (imipraminiques, neuroleptiques phénothiaziniques, antispasmodiques, certains antihistaminiques"""@fr;
  r:natureDuRisque "Risque de bradycardie excessive (addition des effets bradycardisants)."@fr;
  r:conduiteATenir "Surveillance clinique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613594, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613588 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613589 .

_:807f36cf91fe4e8caa53aadeff92477613589 rdf:first _:807f36cf91fe4e8caa53aadeff92477613590;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613591 .

_:807f36cf91fe4e8caa53aadeff92477613590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10027 .

_:807f36cf91fe4e8caa53aadeff92477613591 rdf:first _:807f36cf91fe4e8caa53aadeff92477613592;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613592 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10055 .

_:807f36cf91fe4e8caa53aadeff92477613594 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10213-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> COBICISTAT"@fr;
  dct:identifier "IAM_10213";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613596;
  r:natureDuRisque "Risque de diminution de l’efficacité du cobicistat par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613602, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613596 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613597 .

_:807f36cf91fe4e8caa53aadeff92477613597 rdf:first _:807f36cf91fe4e8caa53aadeff92477613598;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613599 .

_:807f36cf91fe4e8caa53aadeff92477613598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613599 rdf:first _:807f36cf91fe4e8caa53aadeff92477613600;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613600 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10221 .

_:807f36cf91fe4e8caa53aadeff92477613602 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10588-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10588";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613604;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613610, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613604 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613605 .

_:807f36cf91fe4e8caa53aadeff92477613605 rdf:first _:807f36cf91fe4e8caa53aadeff92477613606;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613607 .

_:807f36cf91fe4e8caa53aadeff92477613606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477613607 rdf:first _:807f36cf91fe4e8caa53aadeff92477613608;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613608 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:807f36cf91fe4e8caa53aadeff92477613610 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10998-1 a owl:Class;
  rdfs:label "GLOBULINES ANTILYMPHOCYTAIRES <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10998";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613612;
  r:natureDuRisque "Immunodépression excessive avec risque de lymphoprolifération."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613618, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613612 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613613 .

_:807f36cf91fe4e8caa53aadeff92477613613 rdf:first _:807f36cf91fe4e8caa53aadeff92477613614;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613615 .

_:807f36cf91fe4e8caa53aadeff92477613614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10080 .

_:807f36cf91fe4e8caa53aadeff92477613615 rdf:first _:807f36cf91fe4e8caa53aadeff92477613616;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477613618 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10578-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> CLINDAMYCINE"@fr;
  dct:identifier "IAM_10578";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613620;
  r:natureDuRisque "Diminution des concentrations sanguines de l'immunosuppresseur avec risque de perte de l'activité immunosuppressive."@fr;
  r:conduiteATenir "Contrôle renforcé des dosages sanguins de ciclosporine et augmentation éventuelle de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613626, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613620 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613621 .

_:807f36cf91fe4e8caa53aadeff92477613621 rdf:first _:807f36cf91fe4e8caa53aadeff92477613622;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613623 .

_:807f36cf91fe4e8caa53aadeff92477613622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477613623 rdf:first _:807f36cf91fe4e8caa53aadeff92477613624;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10209 .

_:807f36cf91fe4e8caa53aadeff92477613626 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10579-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> COLCHICINE"@fr;
  dct:identifier "IAM_10579";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613628;
  r:natureDuRisque "Risque d’addition des effets indésirables neuromusculaires et augmentation de la toxicité de la colchicine avec risque de surdosage par inhibition de son élimination par la ciclosporine, notamment en cas d’insuffisance rénale préexistante."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613634, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613628 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613629 .

_:807f36cf91fe4e8caa53aadeff92477613629 rdf:first _:807f36cf91fe4e8caa53aadeff92477613630;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613631 .

_:807f36cf91fe4e8caa53aadeff92477613630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477613631 rdf:first _:807f36cf91fe4e8caa53aadeff92477613632;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477613634 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10580-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> DABIGATRAN"@fr;
  dct:identifier "IAM_10580";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613636;
  r:natureDuRisque "Augmentation de plus du double des concentrations plasmatiques de dabigatran, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613642, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613636 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613637 .

_:807f36cf91fe4e8caa53aadeff92477613637 rdf:first _:807f36cf91fe4e8caa53aadeff92477613638;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613639 .

_:807f36cf91fe4e8caa53aadeff92477613638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477613639 rdf:first _:807f36cf91fe4e8caa53aadeff92477613640;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10240 .

_:807f36cf91fe4e8caa53aadeff92477613642 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10581-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> DANAZOL"@fr;
  dct:identifier "IAM_10581";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613644;
  r:natureDuRisque "Augmentation des concentrations sanguines de ciclosporine par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de ciclosporine, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613650, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613644 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613645 .

_:807f36cf91fe4e8caa53aadeff92477613645 rdf:first _:807f36cf91fe4e8caa53aadeff92477613646;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613647 .

_:807f36cf91fe4e8caa53aadeff92477613646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477613647 rdf:first _:807f36cf91fe4e8caa53aadeff92477613648;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:807f36cf91fe4e8caa53aadeff92477613650 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10582-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10582";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613652;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613658, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613652 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613653 .

_:807f36cf91fe4e8caa53aadeff92477613653 rdf:first _:807f36cf91fe4e8caa53aadeff92477613654;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613655 .

_:807f36cf91fe4e8caa53aadeff92477613654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477613655 rdf:first _:807f36cf91fe4e8caa53aadeff92477613656;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477613658 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10583-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> DIURÉTIQUES HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10583";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613660;
  r:natureDuRisque "Risque d'augmentation de la créatininémie sans modification des concentrations sanguines de ciclosporine, même en l'absence de déplétion hydrosodée. Egalement, risque d'hyperuricémie et de complications comme la goutte."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613666, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613660 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613661 .

_:807f36cf91fe4e8caa53aadeff92477613661 rdf:first _:807f36cf91fe4e8caa53aadeff92477613662;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613663 .

_:807f36cf91fe4e8caa53aadeff92477613662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:807f36cf91fe4e8caa53aadeff92477613663 rdf:first _:807f36cf91fe4e8caa53aadeff92477613664;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477613666 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10584-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> ÉRIBULINE"@fr;
  dct:identifier "IAM_10584";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613668;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’éribuline par la ciclosporine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613674, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613668 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613669 .

_:807f36cf91fe4e8caa53aadeff92477613669 rdf:first _:807f36cf91fe4e8caa53aadeff92477613670;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613671 .

_:807f36cf91fe4e8caa53aadeff92477613670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477613671 rdf:first _:807f36cf91fe4e8caa53aadeff92477613672;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10335 .

_:807f36cf91fe4e8caa53aadeff92477613674 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10585-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> EVEROLIMUS"@fr;
  dct:identifier "IAM_10585";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613676;
  r:natureDuRisque "Augmentation des concentrations sanguines de l’évérolimus par la ciclosporine. La néphrotoxicité de la ciclosporine est également augmentée lors de l’association."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines d’évérolimus, éventuellement adaptation de la posologie et contrôle de la fonction rénale, pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613682, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613676 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613677 .

_:807f36cf91fe4e8caa53aadeff92477613677 rdf:first _:807f36cf91fe4e8caa53aadeff92477613678;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613679 .

_:807f36cf91fe4e8caa53aadeff92477613678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477613679 rdf:first _:807f36cf91fe4e8caa53aadeff92477613680;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10363 .

_:807f36cf91fe4e8caa53aadeff92477613682 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10510-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10510";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613684;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la buspirone par diminution de son métabolisme hépatique par le diltiazem, avec augmentation de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la buspirone si nécessaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613690, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613684 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613685 .

_:807f36cf91fe4e8caa53aadeff92477613685 rdf:first _:807f36cf91fe4e8caa53aadeff92477613686;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613687 .

_:807f36cf91fe4e8caa53aadeff92477613686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff92477613687 rdf:first _:807f36cf91fe4e8caa53aadeff92477613688;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477613690 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10587-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> FENOFIBRATE"@fr;
  dct:identifier "IAM_10587";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613692;
  r:natureDuRisque "Risque d'augmentation de la néphrotoxicité de la ciclosporine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique de la fonction rénale, pendant et après l'association."@fr;
  rdfs:comment "Des augmentations réversibles de la créatininémie ont été rapportées parmi les évènements indésirables rares du fénofibrate. De plus, diverses données bibliographiques indiquent une potentialisation du risque de néphrotoxicité chez des patients transplant"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613698, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613692 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613693 .

_:807f36cf91fe4e8caa53aadeff92477613693 rdf:first _:807f36cf91fe4e8caa53aadeff92477613694;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613695 .

_:807f36cf91fe4e8caa53aadeff92477613694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477613695 rdf:first _:807f36cf91fe4e8caa53aadeff92477613696;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10371 .

_:807f36cf91fe4e8caa53aadeff92477613698 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10509-1 a owl:Class;
  rdfs:label "BUSPIRONE <-> DIAZEPAM"@fr;
  dct:identifier "IAM_10509";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613700;
  r:natureDuRisque "Risque de majoration des effets indésirables de la buspirone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613706, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613700 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613701 .

_:807f36cf91fe4e8caa53aadeff92477613701 rdf:first _:807f36cf91fe4e8caa53aadeff92477613702;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613703 .

_:807f36cf91fe4e8caa53aadeff92477613702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff92477613703 rdf:first _:807f36cf91fe4e8caa53aadeff92477613704;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10280 .

_:807f36cf91fe4e8caa53aadeff92477613706 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10882-1 a owl:Class;
  rdfs:label "EPLERENONE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10882";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613708;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de l’éplérénone par l'inhibiteur et de ses effets indésirables, notamment l’hyperkaliémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613714, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613708 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613709 .

_:807f36cf91fe4e8caa53aadeff92477613709 rdf:first _:807f36cf91fe4e8caa53aadeff92477613710;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613711 .

_:807f36cf91fe4e8caa53aadeff92477613710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477613711 rdf:first _:807f36cf91fe4e8caa53aadeff92477613712;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10329 .

_:807f36cf91fe4e8caa53aadeff92477613714 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10883-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10883";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613716;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (diminution de l'élimination hépatique de l'ergotamine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613722, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613716 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613717 .

_:807f36cf91fe4e8caa53aadeff92477613717 rdf:first _:807f36cf91fe4e8caa53aadeff92477613718;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613719 .

_:807f36cf91fe4e8caa53aadeff92477613718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:807f36cf91fe4e8caa53aadeff92477613719 rdf:first _:807f36cf91fe4e8caa53aadeff92477613720;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477613722 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10884-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> OXPRENOLOL"@fr;
  dct:identifier "IAM_10884";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613724;
  r:natureDuRisque "Ergotisme : quelques cas de spasme artériel avec ischémie des extrémités ont été observés (addition d'effets vasculaires)."@fr;
  r:conduiteATenir "Surveillance clinique renforcée, en particulier pendant les premières semaines de l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613730, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613724 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613725 .

_:807f36cf91fe4e8caa53aadeff92477613725 rdf:first _:807f36cf91fe4e8caa53aadeff92477613726;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613727 .

_:807f36cf91fe4e8caa53aadeff92477613726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477613727 rdf:first _:807f36cf91fe4e8caa53aadeff92477613728;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10678 .

_:807f36cf91fe4e8caa53aadeff92477613730 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10885-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> PROPRANOLOL"@fr;
  dct:identifier "IAM_10885";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613732;
  r:natureDuRisque "Ergotisme : quelques cas de spasme artériel avec ischémie des extrémités ont été observés (addition d'effets vasculaires)."@fr;
  r:conduiteATenir "Surveillance clinique renforcée, en particulier pendant les premières semaines de l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613738, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613732 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613733 .

_:807f36cf91fe4e8caa53aadeff92477613733 rdf:first _:807f36cf91fe4e8caa53aadeff92477613734;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613735 .

_:807f36cf91fe4e8caa53aadeff92477613734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477613735 rdf:first _:807f36cf91fe4e8caa53aadeff92477613736;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10767 .

_:807f36cf91fe4e8caa53aadeff92477613738 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10886-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> QUINUPRISTINE"@fr;
  dct:identifier "IAM_10886";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613740;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613746, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613740 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613741 .

_:807f36cf91fe4e8caa53aadeff92477613741 rdf:first _:807f36cf91fe4e8caa53aadeff92477613742;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613743 .

_:807f36cf91fe4e8caa53aadeff92477613742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477613743 rdf:first _:807f36cf91fe4e8caa53aadeff92477613744;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10778 .

_:807f36cf91fe4e8caa53aadeff92477613746 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10887-1 a owl:Class;
  rdfs:label "ERGOTAMINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10887";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613748;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition de l’élimination hépatique de l'alcaloïde de l’ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613754, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613748 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613749 .

_:807f36cf91fe4e8caa53aadeff92477613749 rdf:first _:807f36cf91fe4e8caa53aadeff92477613750;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613751 .

_:807f36cf91fe4e8caa53aadeff92477613750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477613751 rdf:first _:807f36cf91fe4e8caa53aadeff92477613752;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477613754 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10224-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> IDÉLALISIB"@fr;
  dct:identifier "IAM_10224";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613756;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’idélalisib par augmentation de son métabolisme hépatique par l'anticonvulsivant inducteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613756 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613757 .

_:807f36cf91fe4e8caa53aadeff92477613757 rdf:first _:807f36cf91fe4e8caa53aadeff92477613758;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613759 .

_:807f36cf91fe4e8caa53aadeff92477613758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613759 rdf:first _:807f36cf91fe4e8caa53aadeff92477613760;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10444 .

_:807f36cf91fe4e8caa53aadeff92477613762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10225-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10225";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613764;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'inhibiteur de protéases par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613765 .

_:807f36cf91fe4e8caa53aadeff92477613765 rdf:first _:807f36cf91fe4e8caa53aadeff92477613766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613767 .

_:807f36cf91fe4e8caa53aadeff92477613766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613767 rdf:first _:807f36cf91fe4e8caa53aadeff92477613768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477613770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10226-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS"@fr;
  dct:identifier "IAM_10226";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613772;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l’efficacité de l’inhibiteur de tyrosine kinase, par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613773 .

_:807f36cf91fe4e8caa53aadeff92477613773 rdf:first _:807f36cf91fe4e8caa53aadeff92477613774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613775 .

_:807f36cf91fe4e8caa53aadeff92477613774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613775 rdf:first _:807f36cf91fe4e8caa53aadeff92477613776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477613778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10204-1 a owl:Class;
  rdfs:label "ANTICOAGULANTS ORAUX <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10204";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613780;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, renforcer la surveillance clinique et, le cas échéant, biologique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613781 .

_:807f36cf91fe4e8caa53aadeff92477613781 rdf:first _:807f36cf91fe4e8caa53aadeff92477613782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613783 .

_:807f36cf91fe4e8caa53aadeff92477613782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477613783 rdf:first _:807f36cf91fe4e8caa53aadeff92477613784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477613786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10586-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> EZETIMIBE"@fr;
  dct:identifier "IAM_10586";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613788;
  r:natureDuRisque "D’une part, risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par augmentation des concentrations d’ézétimibe ; d’autre part, possible augmentation des concentrations de ciclosporine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613789 .

_:807f36cf91fe4e8caa53aadeff92477613789 rdf:first _:807f36cf91fe4e8caa53aadeff92477613790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613791 .

_:807f36cf91fe4e8caa53aadeff92477613790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477613791 rdf:first _:807f36cf91fe4e8caa53aadeff92477613792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10365 .

_:807f36cf91fe4e8caa53aadeff92477613794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10409-1 a owl:Class;
  rdfs:label "AUTRES CORTICOÏDES, NOTAMMENT INHALÉS <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10409";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613796;
  r:natureDuRisque "En cas d’utilisation prolongée par voie orale ou inhalée : augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par l’inhibiteur de protéases, avec risque d’apparition d’un syndrome cushingoïde voire d’une"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613797 .

_:807f36cf91fe4e8caa53aadeff92477613797 rdf:first _:807f36cf91fe4e8caa53aadeff92477613798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613799 .

_:807f36cf91fe4e8caa53aadeff92477613798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10047 .

_:807f36cf91fe4e8caa53aadeff92477613799 rdf:first _:807f36cf91fe4e8caa53aadeff92477613800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477613802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11231-1 a owl:Class;
  rdfs:label "LERCANIDIPINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11231";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613804;
  r:natureDuRisque "Risque majoré d'effets indésirables, notamment d'oedèmes, par diminution du métabolisme intestinal de la dihydropyridine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613805 .

_:807f36cf91fe4e8caa53aadeff92477613805 rdf:first _:807f36cf91fe4e8caa53aadeff92477613806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613807 .

_:807f36cf91fe4e8caa53aadeff92477613806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477613807 rdf:first _:807f36cf91fe4e8caa53aadeff92477613808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10514 .

_:807f36cf91fe4e8caa53aadeff92477613810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11232-1 a owl:Class;
  rdfs:label "LEVODOPA <-> METHYLDOPA"@fr;
  dct:identifier "IAM_11232";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613812;
  r:natureDuRisque "Augmentation des effets de la lévodopa mais également de ses effets indésirables. Majoration de l'effet antihypertenseur de la méthyldopa."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement diminution des doses de lévodopa."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613813 .

_:807f36cf91fe4e8caa53aadeff92477613813 rdf:first _:807f36cf91fe4e8caa53aadeff92477613814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613815 .

_:807f36cf91fe4e8caa53aadeff92477613814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477613815 rdf:first _:807f36cf91fe4e8caa53aadeff92477613816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10572 .

_:807f36cf91fe4e8caa53aadeff92477613818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11233-1 a owl:Class;
  rdfs:label "LEVODOPA <-> NEUROLEPTIQUES ANTIÉMÉTIQUES"@fr;
  dct:identifier "IAM_11233";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613820;
  r:natureDuRisque "Antagonisme réciproque entre la lévodopa et le neuroleptique."@fr;
  r:conduiteATenir "Utiliser un antiémétique dénué d'effets extrapyramidaux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613821 .

_:807f36cf91fe4e8caa53aadeff92477613821 rdf:first _:807f36cf91fe4e8caa53aadeff92477613822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613823 .

_:807f36cf91fe4e8caa53aadeff92477613822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477613823 rdf:first _:807f36cf91fe4e8caa53aadeff92477613824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477613826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11234-1 a owl:Class;
  rdfs:label "LEVODOPA <-> NEUROLEPTIQUES ANTIPSYCHOTIQUES (SAUF CLOZAPINE)"@fr;
  dct:identifier "IAM_11234";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613828;
  r:natureDuRisque "Antagonisme réciproque de la lévodopa et des neuroleptiques."@fr;
  r:conduiteATenir "Chez le patient parkinsonien, utiliser les doses minimales efficaces de chacun des deux médicaments."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613829 .

_:807f36cf91fe4e8caa53aadeff92477613829 rdf:first _:807f36cf91fe4e8caa53aadeff92477613830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613831 .

_:807f36cf91fe4e8caa53aadeff92477613830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10125 .

_:807f36cf91fe4e8caa53aadeff92477613831 rdf:first _:807f36cf91fe4e8caa53aadeff92477613832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477613834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11235-1 a owl:Class;
  rdfs:label "LEVODOPA <-> RESERPINE"@fr;
  dct:identifier "IAM_11235";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613836;
  r:natureDuRisque "Inhibition des effets de la lévodopa."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613837 .

_:807f36cf91fe4e8caa53aadeff92477613837 rdf:first _:807f36cf91fe4e8caa53aadeff92477613838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613839 .

_:807f36cf91fe4e8caa53aadeff92477613838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477613839 rdf:first _:807f36cf91fe4e8caa53aadeff92477613840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10792 .

_:807f36cf91fe4e8caa53aadeff92477613842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10303-1 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10303";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613844;
  r:natureDuRisque "Risque d’augmentation de la toxicité du méthotrexate par diminution de son élimination."@fr;
  r:conduiteATenir """Association déconseillée :
- avec le méthotrexate aux doses > 20 mg / semaine

A prendre en compte :
- pour des doses inférieures"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613845 .

_:807f36cf91fe4e8caa53aadeff92477613845 rdf:first _:807f36cf91fe4e8caa53aadeff92477613846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613847 .

_:807f36cf91fe4e8caa53aadeff92477613846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477613847 rdf:first _:807f36cf91fe4e8caa53aadeff92477613848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477613850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10403-1 a owl:Class;
  rdfs:label "ATORVASTATINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10403";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613852;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d'hypocholestérolémiant. Si l'objectif thérapeutique n'est pas atteint, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613858, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613852 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613853 .

_:807f36cf91fe4e8caa53aadeff92477613853 rdf:first _:807f36cf91fe4e8caa53aadeff92477613854;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613855 .

_:807f36cf91fe4e8caa53aadeff92477613854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477613855 rdf:first _:807f36cf91fe4e8caa53aadeff92477613856;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477613858 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10404-1 a owl:Class;
  rdfs:label "ATOVAQUONE <-> EFAVIRENZ"@fr;
  dct:identifier "IAM_10404";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613860;
  r:natureDuRisque "Diminution des concentrations plasmatiques d'atovaquone par l'inducteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613860 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613861 .

_:807f36cf91fe4e8caa53aadeff92477613861 rdf:first _:807f36cf91fe4e8caa53aadeff92477613862;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613863 .

_:807f36cf91fe4e8caa53aadeff92477613862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10090 .

_:807f36cf91fe4e8caa53aadeff92477613863 rdf:first _:807f36cf91fe4e8caa53aadeff92477613864;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477613866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10405-1 a owl:Class;
  rdfs:label "ATOVAQUONE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10405";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613868;
  r:natureDuRisque "Diminution, éventuellement très importante, des concentrations plasmatiques de l’atovaquone par augmentation de son métabolisme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613869 .

_:807f36cf91fe4e8caa53aadeff92477613869 rdf:first _:807f36cf91fe4e8caa53aadeff92477613870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613871 .

_:807f36cf91fe4e8caa53aadeff92477613870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477613871 rdf:first _:807f36cf91fe4e8caa53aadeff92477613872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10090 .

_:807f36cf91fe4e8caa53aadeff92477613874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10577-1 a owl:Class;
  rdfs:label "CICLOSPORINE <-> CIMETIDINE"@fr;
  dct:identifier "IAM_10577";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613876;
  r:natureDuRisque "Avec la cimétidine utilisée à des doses supérieures ou égales à 800 mg/j : augmentation des concentrations sanguines de ciclosporine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613877 .

_:807f36cf91fe4e8caa53aadeff92477613877 rdf:first _:807f36cf91fe4e8caa53aadeff92477613878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613879 .

_:807f36cf91fe4e8caa53aadeff92477613878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10193 .

_:807f36cf91fe4e8caa53aadeff92477613879 rdf:first _:807f36cf91fe4e8caa53aadeff92477613880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10196 .

_:807f36cf91fe4e8caa53aadeff92477613882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10407-1 a owl:Class;
  rdfs:label "ATOVAQUONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10407";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613884;
  r:natureDuRisque "Diminution des concentrations plasmatiques d'atovaquone par l'inducteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613885 .

_:807f36cf91fe4e8caa53aadeff92477613885 rdf:first _:807f36cf91fe4e8caa53aadeff92477613886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613887 .

_:807f36cf91fe4e8caa53aadeff92477613886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10090 .

_:807f36cf91fe4e8caa53aadeff92477613887 rdf:first _:807f36cf91fe4e8caa53aadeff92477613888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477613890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10228-1 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_10228";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613892;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques du lédipasvir par augmentation de son métabolisme hépatique par l'anticonvulsivant inducteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613898, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613892 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613893 .

_:807f36cf91fe4e8caa53aadeff92477613893 rdf:first _:807f36cf91fe4e8caa53aadeff92477613894;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613895 .

_:807f36cf91fe4e8caa53aadeff92477613894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477613895 rdf:first _:807f36cf91fe4e8caa53aadeff92477613896;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477613898 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10410-1 a owl:Class;
  rdfs:label "AUTRES CORTICOÏDES, NOTAMMENT INHALÉS <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10410";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613900;
  r:natureDuRisque "En cas d’utilisation prolongée par voie orale ou inhalée : augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par l’itraconazole, avec risque d’apparition d’un syndrome cushingoïde voire d’une insuffisan"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613906, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613900 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613901 .

_:807f36cf91fe4e8caa53aadeff92477613901 rdf:first _:807f36cf91fe4e8caa53aadeff92477613902;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613903 .

_:807f36cf91fe4e8caa53aadeff92477613902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10047 .

_:807f36cf91fe4e8caa53aadeff92477613903 rdf:first _:807f36cf91fe4e8caa53aadeff92477613904;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477613906 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10411-1 a owl:Class;
  rdfs:label "AUTRES CORTICOÏDES, NOTAMMENT INHALÉS <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10411";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613908;
  r:natureDuRisque "En cas d’utilisation prolongée par voie orale ou inhalée : augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par le kétoconazole, avec risque d’apparition d’un syndrome cushingoïde voire d’une insuffisa"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613914, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613908 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613909 .

_:807f36cf91fe4e8caa53aadeff92477613909 rdf:first _:807f36cf91fe4e8caa53aadeff92477613910;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613911 .

_:807f36cf91fe4e8caa53aadeff92477613910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10047 .

_:807f36cf91fe4e8caa53aadeff92477613911 rdf:first _:807f36cf91fe4e8caa53aadeff92477613912;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477613914 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10500-1 a owl:Class;
  rdfs:label "BUPROPION <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10500";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613916;
  r:natureDuRisque "Risque d'augmentation des effets indésirables du flécaïnide par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du flécaïnide pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613922, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613916 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613917 .

_:807f36cf91fe4e8caa53aadeff92477613917 rdf:first _:807f36cf91fe4e8caa53aadeff92477613918;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613919 .

_:807f36cf91fe4e8caa53aadeff92477613918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477613919 rdf:first _:807f36cf91fe4e8caa53aadeff92477613920;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:807f36cf91fe4e8caa53aadeff92477613922 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10503-1 a owl:Class;
  rdfs:label "BUPROPION <-> METOPROLOL"@fr;
  dct:identifier "IAM_10503";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613924;
  r:natureDuRisque "Avec le métoprolol utilisé dans l'insuffisance cardiaque : risque d'augmentation des effets indésirables du métoprolol par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613930, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613924 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613925 .

_:807f36cf91fe4e8caa53aadeff92477613925 rdf:first _:807f36cf91fe4e8caa53aadeff92477613926;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613927 .

_:807f36cf91fe4e8caa53aadeff92477613926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477613927 rdf:first _:807f36cf91fe4e8caa53aadeff92477613928;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477613930 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10504-1 a owl:Class;
  rdfs:label "BUPROPION <-> NORTRIPTYLINE"@fr;
  dct:identifier "IAM_10504";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613932;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la nortriptyline par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la nortriptyline pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613938, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613932 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613933 .

_:807f36cf91fe4e8caa53aadeff92477613933 rdf:first _:807f36cf91fe4e8caa53aadeff92477613934;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613935 .

_:807f36cf91fe4e8caa53aadeff92477613934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477613935 rdf:first _:807f36cf91fe4e8caa53aadeff92477613936;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10652 .

_:807f36cf91fe4e8caa53aadeff92477613938 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10502-1 a owl:Class;
  rdfs:label "BUPROPION <-> MEQUITAZINE"@fr;
  dct:identifier "IAM_10502";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613940;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613946, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613940 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613941 .

_:807f36cf91fe4e8caa53aadeff92477613941 rdf:first _:807f36cf91fe4e8caa53aadeff92477613942;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613943 .

_:807f36cf91fe4e8caa53aadeff92477613942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477613943 rdf:first _:807f36cf91fe4e8caa53aadeff92477613944;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:807f36cf91fe4e8caa53aadeff92477613946 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10505-1 a owl:Class;
  rdfs:label "BUPROPION <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10505";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613948;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la propafénone par diminution de son métabolisme hépatique par le bupropion."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la propafénone pendant le traitement par le bupropion."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613954, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613948 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613949 .

_:807f36cf91fe4e8caa53aadeff92477613949 rdf:first _:807f36cf91fe4e8caa53aadeff92477613950;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613951 .

_:807f36cf91fe4e8caa53aadeff92477613950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477613951 rdf:first _:807f36cf91fe4e8caa53aadeff92477613952;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477613954 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10506-1 a owl:Class;
  rdfs:label "BUPROPION <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_10506";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613956;
  r:natureDuRisque "Risque de baisse de l'efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la terbinafine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613962, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613956 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613957 .

_:807f36cf91fe4e8caa53aadeff92477613957 rdf:first _:807f36cf91fe4e8caa53aadeff92477613958;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613959 .

_:807f36cf91fe4e8caa53aadeff92477613958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477613959 rdf:first _:807f36cf91fe4e8caa53aadeff92477613960;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:807f36cf91fe4e8caa53aadeff92477613962 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10507-1 a owl:Class;
  rdfs:label "BUPROPION <-> TRAMADOL"@fr;
  dct:identifier "IAM_10507";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613964;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du tramadol par diminution de son métabolisme hépatique par le bupropion. De plus, risque de convulsions par addition des effets des deux médicaments."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613970, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613964 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613965 .

_:807f36cf91fe4e8caa53aadeff92477613965 rdf:first _:807f36cf91fe4e8caa53aadeff92477613966;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613967 .

_:807f36cf91fe4e8caa53aadeff92477613966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477613967 rdf:first _:807f36cf91fe4e8caa53aadeff92477613968;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477613970 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10508-1 a owl:Class;
  rdfs:label "BUPROPION <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_10508";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613972;
  r:natureDuRisque "Risque de diminution des concentrations du bupropion, avec augmentation de son métabolite actif et toxicité majorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613978, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613972 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613973 .

_:807f36cf91fe4e8caa53aadeff92477613973 rdf:first _:807f36cf91fe4e8caa53aadeff92477613974;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613975 .

_:807f36cf91fe4e8caa53aadeff92477613974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477613975 rdf:first _:807f36cf91fe4e8caa53aadeff92477613976;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:807f36cf91fe4e8caa53aadeff92477613978 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10406-1 a owl:Class;
  rdfs:label "ATOVAQUONE <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10406";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613980;
  r:natureDuRisque "Diminution modérée des concentrations plasmatiques d'atovaquone par l'inducteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613986, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613980 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613981 .

_:807f36cf91fe4e8caa53aadeff92477613981 rdf:first _:807f36cf91fe4e8caa53aadeff92477613982;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613983 .

_:807f36cf91fe4e8caa53aadeff92477613982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10090 .

_:807f36cf91fe4e8caa53aadeff92477613983 rdf:first _:807f36cf91fe4e8caa53aadeff92477613984;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477613986 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11263-1 a owl:Class;
  rdfs:label "MEQUITAZINE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11263";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613988;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613994, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613988 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477613989 .

_:807f36cf91fe4e8caa53aadeff92477613989 rdf:first _:807f36cf91fe4e8caa53aadeff92477613990;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477613991 .

_:807f36cf91fe4e8caa53aadeff92477613990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:807f36cf91fe4e8caa53aadeff92477613991 rdf:first _:807f36cf91fe4e8caa53aadeff92477613992;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477613992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477613994 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10418-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS ABAISSANT LE SEUIL ÉPILEPTOGÈNE <-> MÉDICAMENTS ABAISSANT LE SEUIL ÉPILEPTOGÈNE"@fr;
  dct:identifier "IAM_10418";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477613996;
  r:chapeau "L'utilisation conjointe de médicaments proconvulsivants, ou abaissant le seuil épileptogène, devra être soigneusement pesée, en raison de la sévérité du risque encouru. Ces médicaments sont représentés notamment par la plupart des antidépresseurs (imipram"@fr;
  r:natureDuRisque "Risque accru de convulsions."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477613998, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477613996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10114 .

_:807f36cf91fe4e8caa53aadeff92477613998 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10420-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS ATROPINIQUES <-> MÉDICAMENTS ATROPINIQUES"@fr;
  dct:identifier "IAM_10420";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614000;
  r:natureDuRisque "Addition des effets indésirables atropiniques à type de rétention urinaire, constipation, sécheresse de la bouche…."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614002, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10115 .

_:807f36cf91fe4e8caa53aadeff92477614002 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10422-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS MÉTHÉMOGLOBINISANTS <-> MÉDICAMENTS MÉTHÉMOGLOBINISANTS"@fr;
  dct:identifier "IAM_10422";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614004;
  r:natureDuRisque "Risque d'addition des effets méthémoglobinisants."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614006, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10117 .

_:807f36cf91fe4e8caa53aadeff92477614006 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11258-1 a owl:Class;
  rdfs:label "MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES <-> ORLISTAT"@fr;
  dct:identifier "IAM_11258";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614008;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614014, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614008 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614009 .

_:807f36cf91fe4e8caa53aadeff92477614009 rdf:first _:807f36cf91fe4e8caa53aadeff92477614010;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614011 .

_:807f36cf91fe4e8caa53aadeff92477614010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:807f36cf91fe4e8caa53aadeff92477614011 rdf:first _:807f36cf91fe4e8caa53aadeff92477614012;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477614014 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11259-1 a owl:Class;
  rdfs:label "MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_11259";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614016;
  r:natureDuRisque "Hypertension paroxystique avec possibilité de troubles du rythme (inhibition de l'entrée du sympathomimétique dans la fibre sympathique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614022, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614016 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614017 .

_:807f36cf91fe4e8caa53aadeff92477614017 rdf:first _:807f36cf91fe4e8caa53aadeff92477614018;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614019 .

_:807f36cf91fe4e8caa53aadeff92477614018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:807f36cf91fe4e8caa53aadeff92477614019 rdf:first _:807f36cf91fe4e8caa53aadeff92477614020;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:807f36cf91fe4e8caa53aadeff92477614022 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10423-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS NÉPHROTOXIQUES <-> MÉDICAMENTS NÉPHROTOXIQUES"@fr;
  dct:identifier "IAM_10423";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614024;
  r:chapeau """L'utilisation conjointe de médicaments ayant une toxicité rénale propre augmente le risque de néphrotoxicité. Si une telle association est nécessaire, il faut renforcer la surveillance biologique rénale.
Les médicaments concernés sont représentés notammen"""@fr;
  r:natureDuRisque "Risque de majoration de la néphrotoxicité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614026, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10118 .

_:807f36cf91fe4e8caa53aadeff92477614026 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10424-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS OTOTOXIQUES <-> MÉDICAMENTS OTOTOXIQUES"@fr;
  dct:identifier "IAM_10424";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614028;
  r:natureDuRisque "Majoration de l'ototoxicité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614030, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614028 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10119 .

_:807f36cf91fe4e8caa53aadeff92477614030 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10079-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> MÉDICAMENTS SÉDATIFS"@fr;
  dct:identifier "IAM_10079";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614032;
  r:natureDuRisque "Majoration par l'alcool de l'effet sédatif de ces substances. L'altération de la vigilance peut rendre dangereuses la conduite de véhicules et l'utilisation de machines."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614038, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614032 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614033 .

_:807f36cf91fe4e8caa53aadeff92477614033 rdf:first _:807f36cf91fe4e8caa53aadeff92477614034;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614035 .

_:807f36cf91fe4e8caa53aadeff92477614034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10120 .

_:807f36cf91fe4e8caa53aadeff92477614035 rdf:first _:807f36cf91fe4e8caa53aadeff92477614036;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614036 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477614038 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10425-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS SÉDATIFS <-> MÉDICAMENTS SÉDATIFS"@fr;
  dct:identifier "IAM_10425";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614040;
  r:natureDuRisque """Majoration de la dépression centrale.
L'altération de la vigilance peut rendre dangereuses la conduite de véhicules et l'utilisation de machines."""@fr;
  r:conduiteATenir """Association déconseillée:
- avec l'oxybate de sodium.

A prendre en compte:
- avec les autres médicaments sédatifs."""@fr;
  rdfs:comment "A"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614042, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10120 .

_:807f36cf91fe4e8caa53aadeff92477614042 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11218-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11218";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614044;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des deux anti-infectieux (induction enzymatique par la rifampicine et diminution de l'absorption intestinale par l’azolé antifongique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614050, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614044 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614045 .

_:807f36cf91fe4e8caa53aadeff92477614045 rdf:first _:807f36cf91fe4e8caa53aadeff92477614046;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614047 .

_:807f36cf91fe4e8caa53aadeff92477614046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477614047 rdf:first _:807f36cf91fe4e8caa53aadeff92477614048;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477614050 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11262-1 a owl:Class;
  rdfs:label "MEQUITAZINE <-> PAROXETINE"@fr;
  dct:identifier "IAM_11262";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614052;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614058, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614052 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614053 .

_:807f36cf91fe4e8caa53aadeff92477614053 rdf:first _:807f36cf91fe4e8caa53aadeff92477614054;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614055 .

_:807f36cf91fe4e8caa53aadeff92477614054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:807f36cf91fe4e8caa53aadeff92477614055 rdf:first _:807f36cf91fe4e8caa53aadeff92477614056;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477614058 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10417-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS À L'ORIGINE D'UN SYNDROME SÉROTONINERGIQUE <-> MÉDICAMENTS À L'ORIGINE D'UN SYNDROME SÉROTONINERGIQUE"@fr;
  dct:identifier "IAM_10417";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614060;
  r:natureDuRisque "Risque d'apparition ou de majoration d'un syndrome sérotoninergique en cas d'association de ces médicaments."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614062, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614060 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10121 .

_:807f36cf91fe4e8caa53aadeff92477614062 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10080-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> METFORMINE"@fr;
  dct:identifier "IAM_10080";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614064;
  r:natureDuRisque "Risque majoré d'acidose lactique lors d'intoxication alcoolique aiguë, particulièrement en cas de jeûne ou dénutrition, ou bien d'insuffisance hépatocellulaire."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614070, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614064 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614065 .

_:807f36cf91fe4e8caa53aadeff92477614065 rdf:first _:807f36cf91fe4e8caa53aadeff92477614066;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614067 .

_:807f36cf91fe4e8caa53aadeff92477614066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10566 .

_:807f36cf91fe4e8caa53aadeff92477614067 rdf:first _:807f36cf91fe4e8caa53aadeff92477614068;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614068 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477614070 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11264-1 a owl:Class;
  rdfs:label "METFORMINE <-> PRODUITS DE CONTRASTE IODÉS"@fr;
  dct:identifier "IAM_11264";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614072;
  r:natureDuRisque "Acidose lactique liée aux concentrations élevées de metformine en rapport avec l'insuffisance rénale fonctionnelle induite par l'examen radiologique."@fr;
  r:conduiteATenir "Le traitement par la metformine doit être suspendu au moment de l'examen radiologique pour n'être repris que 2 jours après."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614078, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614072 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614073 .

_:807f36cf91fe4e8caa53aadeff92477614073 rdf:first _:807f36cf91fe4e8caa53aadeff92477614074;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614075 .

_:807f36cf91fe4e8caa53aadeff92477614074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10133 .

_:807f36cf91fe4e8caa53aadeff92477614075 rdf:first _:807f36cf91fe4e8caa53aadeff92477614076;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614076 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10566 .

_:807f36cf91fe4e8caa53aadeff92477614078 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11265-1 a owl:Class;
  rdfs:label "METHADONE <-> MORPHINIQUES AGONISTES-ANTAGONISTES"@fr;
  dct:identifier "IAM_11265";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614080;
  r:natureDuRisque "Diminution de l'effet de la méthadone par blocage compétitif des récepteurs."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614086, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614080 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614081 .

_:807f36cf91fe4e8caa53aadeff92477614081 rdf:first _:807f36cf91fe4e8caa53aadeff92477614082;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614083 .

_:807f36cf91fe4e8caa53aadeff92477614082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:807f36cf91fe4e8caa53aadeff92477614083 rdf:first _:807f36cf91fe4e8caa53aadeff92477614084;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614084 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477614086 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11266-1 a owl:Class;
  rdfs:label "METHADONE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11266";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614088;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine
et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614094, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614088 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614089 .

_:807f36cf91fe4e8caa53aadeff92477614089 rdf:first _:807f36cf91fe4e8caa53aadeff92477614090;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614091 .

_:807f36cf91fe4e8caa53aadeff92477614090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477614091 rdf:first _:807f36cf91fe4e8caa53aadeff92477614092;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614092 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477614094 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11267-1 a owl:Class;
  rdfs:label "METHENAMINE <-> SULFAMETHIZOL"@fr;
  dct:identifier "IAM_11267";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614096;
  r:natureDuRisque "Précipitation cristalline dans les voies urinaires (favorisée par l'acidification des urines)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614102, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614096 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614097 .

_:807f36cf91fe4e8caa53aadeff92477614097 rdf:first _:807f36cf91fe4e8caa53aadeff92477614098;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614099 .

_:807f36cf91fe4e8caa53aadeff92477614098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10568 .

_:807f36cf91fe4e8caa53aadeff92477614099 rdf:first _:807f36cf91fe4e8caa53aadeff92477614100;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614100 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10870 .

_:807f36cf91fe4e8caa53aadeff92477614102 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11268-1 a owl:Class;
  rdfs:label "METHOTREXATE <-> PÉNICILLINES"@fr;
  dct:identifier "IAM_11268";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614104;
  r:natureDuRisque "Augmentation des effets et de la toxicité hématologique du méthotrexate : inhibition de la sécrétion tubulaire rénale du méthotrexate par les pénicillines."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614110, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614104 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614105 .

_:807f36cf91fe4e8caa53aadeff92477614105 rdf:first _:807f36cf91fe4e8caa53aadeff92477614106;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614107 .

_:807f36cf91fe4e8caa53aadeff92477614106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10138 .

_:807f36cf91fe4e8caa53aadeff92477614107 rdf:first _:807f36cf91fe4e8caa53aadeff92477614108;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614108 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477614110 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11269-1 a owl:Class;
  rdfs:label "METHOTREXATE <-> PROBENECIDE"@fr;
  dct:identifier "IAM_11269";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614112;
  r:natureDuRisque "Augmentation de la toxicité du méthotrexate : inhibition de la sécrétion tubulaire rénale du méthotrexate par le probénécide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614118, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614112 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614113 .

_:807f36cf91fe4e8caa53aadeff92477614113 rdf:first _:807f36cf91fe4e8caa53aadeff92477614114;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614115 .

_:807f36cf91fe4e8caa53aadeff92477614114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477614115 rdf:first _:807f36cf91fe4e8caa53aadeff92477614116;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614116 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10758 .

_:807f36cf91fe4e8caa53aadeff92477614118 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11270-1 a owl:Class;
  rdfs:label "METHOTREXATE <-> SULFAMIDES ANTIBACTÉRIENS"@fr;
  dct:identifier "IAM_11270";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614120;
  r:natureDuRisque "Augmentation de la toxicité hématologique du méthotrexate."@fr;
  r:conduiteATenir "Dosage des concentrations de méthotrexate. Adapatation posologique si nécessaire pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614126, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614120 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614121 .

_:807f36cf91fe4e8caa53aadeff92477614121 rdf:first _:807f36cf91fe4e8caa53aadeff92477614122;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614123 .

_:807f36cf91fe4e8caa53aadeff92477614122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10146 .

_:807f36cf91fe4e8caa53aadeff92477614123 rdf:first _:807f36cf91fe4e8caa53aadeff92477614124;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477614126 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11271-1 a owl:Class;
  rdfs:label "METHOTREXATE <-> TRIMETHOPRIME"@fr;
  dct:identifier "IAM_11271";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614128;
  r:natureDuRisque "Augmentation de la toxicité hématologique du méthotrexate (diminution de son excrétion rénale ainsi qu'inhibition de la dihydrofolate réductase)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614134, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614128 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614129 .

_:807f36cf91fe4e8caa53aadeff92477614129 rdf:first _:807f36cf91fe4e8caa53aadeff92477614130;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614131 .

_:807f36cf91fe4e8caa53aadeff92477614130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477614131 rdf:first _:807f36cf91fe4e8caa53aadeff92477614132;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10955 .

_:807f36cf91fe4e8caa53aadeff92477614134 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11261-1 a owl:Class;
  rdfs:label "MEFLOQUINE <-> QUININE"@fr;
  dct:identifier "IAM_11261";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614136;
  r:natureDuRisque "Pour la quinine administrée par voie IV : risque majoré de survenue de crises épileptiques par addition des effets proconvulsivants."@fr;
  r:conduiteATenir "Respecter un délai minimum de 12 heures entre la fin de l'administration IV de quinine et le début de l'administration de méfloquine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614142, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614136 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614137 .

_:807f36cf91fe4e8caa53aadeff92477614137 rdf:first _:807f36cf91fe4e8caa53aadeff92477614138;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614139 .

_:807f36cf91fe4e8caa53aadeff92477614138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10555 .

_:807f36cf91fe4e8caa53aadeff92477614139 rdf:first _:807f36cf91fe4e8caa53aadeff92477614140;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:807f36cf91fe4e8caa53aadeff92477614142 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11244-1 a owl:Class;
  rdfs:label "LITHIUM <-> ORLISTAT"@fr;
  dct:identifier "IAM_11244";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614144;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614150, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614144 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614145 .

_:807f36cf91fe4e8caa53aadeff92477614145 rdf:first _:807f36cf91fe4e8caa53aadeff92477614146;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614147 .

_:807f36cf91fe4e8caa53aadeff92477614146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477614147 rdf:first _:807f36cf91fe4e8caa53aadeff92477614148;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477614150 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11321-1 a owl:Class;
  rdfs:label "MYCOPHENOLATE SODIQUE <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11321";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614152;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614158, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614152 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614153 .

_:807f36cf91fe4e8caa53aadeff92477614153 rdf:first _:807f36cf91fe4e8caa53aadeff92477614154;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614155 .

_:807f36cf91fe4e8caa53aadeff92477614154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477614155 rdf:first _:807f36cf91fe4e8caa53aadeff92477614156;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10610 .

_:807f36cf91fe4e8caa53aadeff92477614158 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11220-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11220";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614160;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'hypocholestérolémiant)."@fr;
  r:conduiteATenir "Utiliser une statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614166, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614160 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614161 .

_:807f36cf91fe4e8caa53aadeff92477614161 rdf:first _:807f36cf91fe4e8caa53aadeff92477614162;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614163 .

_:807f36cf91fe4e8caa53aadeff92477614162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477614163 rdf:first _:807f36cf91fe4e8caa53aadeff92477614164;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477614166 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11221-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11221";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614168;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration avec le kétoconazole, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614174, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614168 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614169 .

_:807f36cf91fe4e8caa53aadeff92477614169 rdf:first _:807f36cf91fe4e8caa53aadeff92477614170;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614171 .

_:807f36cf91fe4e8caa53aadeff92477614170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477614171 rdf:first _:807f36cf91fe4e8caa53aadeff92477614172;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477614174 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11236-1 a owl:Class;
  rdfs:label "LEVODOPA <-> SPIRAMYCINE"@fr;
  dct:identifier "IAM_11236";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614176;
  r:natureDuRisque "En cas d'association avec la carbidopa : inhibition de l'absorption de la carbidopa avec diminution des concentrations plasmatiques de la lévodopa."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la lévodopa."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614182, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614176 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614177 .

_:807f36cf91fe4e8caa53aadeff92477614177 rdf:first _:807f36cf91fe4e8caa53aadeff92477614178;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614179 .

_:807f36cf91fe4e8caa53aadeff92477614178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477614179 rdf:first _:807f36cf91fe4e8caa53aadeff92477614180;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10856 .

_:807f36cf91fe4e8caa53aadeff92477614182 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11237-1 a owl:Class;
  rdfs:label "LEVODOPA <-> TETRABENAZINE"@fr;
  dct:identifier "IAM_11237";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614184;
  r:natureDuRisque "Antagonisme réciproque entre la lévodopa et la tétrabénazine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614190, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614184 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614185 .

_:807f36cf91fe4e8caa53aadeff92477614185 rdf:first _:807f36cf91fe4e8caa53aadeff92477614186;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614187 .

_:807f36cf91fe4e8caa53aadeff92477614186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477614187 rdf:first _:807f36cf91fe4e8caa53aadeff92477614188;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10908 .

_:807f36cf91fe4e8caa53aadeff92477614190 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11238-1 a owl:Class;
  rdfs:label "LEVOFLOXACINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11238";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614192;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Surveillance clinique et électrocardiographique pendant
l'association."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614198, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614192 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614193 .

_:807f36cf91fe4e8caa53aadeff92477614193 rdf:first _:807f36cf91fe4e8caa53aadeff92477614194;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614195 .

_:807f36cf91fe4e8caa53aadeff92477614194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477614195 rdf:first _:807f36cf91fe4e8caa53aadeff92477614196;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10518 .

_:807f36cf91fe4e8caa53aadeff92477614198 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11239-1 a owl:Class;
  rdfs:label "LINEZOLIDE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11239";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614200;
  r:natureDuRisque "Risque de diminution de l'efficacité du linézolide par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et augmentation éventuelle de la posologie du linézolide pendant le traitement par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614206, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614200 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614201 .

_:807f36cf91fe4e8caa53aadeff92477614201 rdf:first _:807f36cf91fe4e8caa53aadeff92477614202;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614203 .

_:807f36cf91fe4e8caa53aadeff92477614202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10526 .

_:807f36cf91fe4e8caa53aadeff92477614203 rdf:first _:807f36cf91fe4e8caa53aadeff92477614204;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477614206 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11240-1 a owl:Class;
  rdfs:label "LITHIUM <-> MANNITOL"@fr;
  dct:identifier "IAM_11240";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614208;
  r:natureDuRisque "Diminution de la lithémie avec risque de baisse de l’efficacité thérapeutique."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614214, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614208 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614209 .

_:807f36cf91fe4e8caa53aadeff92477614209 rdf:first _:807f36cf91fe4e8caa53aadeff92477614210;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614211 .

_:807f36cf91fe4e8caa53aadeff92477614210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477614211 rdf:first _:807f36cf91fe4e8caa53aadeff92477614212;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10549 .

_:807f36cf91fe4e8caa53aadeff92477614214 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11241-1 a owl:Class;
  rdfs:label "LITHIUM <-> METHYLDOPA"@fr;
  dct:identifier "IAM_11241";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614216;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques, avec signes de surdosage en lithium."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614222, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614216 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614217 .

_:807f36cf91fe4e8caa53aadeff92477614217 rdf:first _:807f36cf91fe4e8caa53aadeff92477614218;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614219 .

_:807f36cf91fe4e8caa53aadeff92477614218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477614219 rdf:first _:807f36cf91fe4e8caa53aadeff92477614220;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10572 .

_:807f36cf91fe4e8caa53aadeff92477614222 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11254-1 a owl:Class;
  rdfs:label "MÉDICAMENTS À RISQUE LORS DU SEVRAGE TABAGIQUE <-> TRAITEMENTS DE SUBSTITUTION NICOTINIQUE"@fr;
  dct:identifier "IAM_11254";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614224;
  r:natureDuRisque "Risque de surdosage lors du remplacement du tabac par le traitement substitutif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614230, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614224 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614225 .

_:807f36cf91fe4e8caa53aadeff92477614225 rdf:first _:807f36cf91fe4e8caa53aadeff92477614226;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614227 .

_:807f36cf91fe4e8caa53aadeff92477614226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10123 .

_:807f36cf91fe4e8caa53aadeff92477614227 rdf:first _:807f36cf91fe4e8caa53aadeff92477614228;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10155 .

_:807f36cf91fe4e8caa53aadeff92477614230 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11243-1 a owl:Class;
  rdfs:label "LITHIUM <-> NEUROLEPTIQUES"@fr;
  dct:identifier "IAM_11243";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614232;
  r:natureDuRisque "Risque d’apparition de signes neuropsychiques évocateurs d’un syndrome malin des neuroleptiques ou d’une intoxication au lithium."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614238, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614232 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614233 .

_:807f36cf91fe4e8caa53aadeff92477614233 rdf:first _:807f36cf91fe4e8caa53aadeff92477614234;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614235 .

_:807f36cf91fe4e8caa53aadeff92477614234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10124 .

_:807f36cf91fe4e8caa53aadeff92477614235 rdf:first _:807f36cf91fe4e8caa53aadeff92477614236;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477614238 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11255-1 a owl:Class;
  rdfs:label "MÉDICAMENTS ABAISSANT LA PRESSION ARTÉRIELLE <-> MÉDICAMENTS À L'ORIGINE D'UNE HYPOTENSION ORTHOSTATIQUE"@fr;
  dct:identifier "IAM_11255";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614240;
  r:natureDuRisque "Risque de majoration d’une hypotension, notamment orthostatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614246, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614240 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614241 .

_:807f36cf91fe4e8caa53aadeff92477614241 rdf:first _:807f36cf91fe4e8caa53aadeff92477614242;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614243 .

_:807f36cf91fe4e8caa53aadeff92477614242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10113 .

_:807f36cf91fe4e8caa53aadeff92477614243 rdf:first _:807f36cf91fe4e8caa53aadeff92477614244;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10122 .

_:807f36cf91fe4e8caa53aadeff92477614246 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11245-1 a owl:Class;
  rdfs:label "LITHIUM <-> SODIUM (BICARBONATE DE)"@fr;
  dct:identifier "IAM_11245";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614248;
  r:natureDuRisque "Risque de baisse de l’efficacité du lithium par augmentation de son élimination rénale par les sels de sodium."@fr;
  r:conduiteATenir "Eviter les surcharges sodées et tenir compte de la présence de sodium dans certains médicaments comme les antiacides."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614254, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614248 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614249 .

_:807f36cf91fe4e8caa53aadeff92477614249 rdf:first _:807f36cf91fe4e8caa53aadeff92477614250;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614251 .

_:807f36cf91fe4e8caa53aadeff92477614250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477614251 rdf:first _:807f36cf91fe4e8caa53aadeff92477614252;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10841 .

_:807f36cf91fe4e8caa53aadeff92477614254 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11246-1 a owl:Class;
  rdfs:label "LITHIUM <-> SODIUM (CHLORURE DE)"@fr;
  dct:identifier "IAM_11246";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614256;
  r:natureDuRisque "Risque de baisse de l’efficacité du lithium par augmentation de son élimination rénale par les sels de sodium."@fr;
  r:conduiteATenir "Eviter les surcharges sodées et tenir compte de la présence de sodium dans certains médicaments comme les antiacides."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614262, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614256 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614257 .

_:807f36cf91fe4e8caa53aadeff92477614257 rdf:first _:807f36cf91fe4e8caa53aadeff92477614258;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614259 .

_:807f36cf91fe4e8caa53aadeff92477614258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477614259 rdf:first _:807f36cf91fe4e8caa53aadeff92477614260;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10842 .

_:807f36cf91fe4e8caa53aadeff92477614262 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11247-1 a owl:Class;
  rdfs:label "LITHIUM <-> THEOPHYLLINE"@fr;
  dct:identifier "IAM_11247";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614264;
  r:natureDuRisque "Diminution de la lithémie avec risque de baisse de l’efficacité thérapeutique."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614270, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614264 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614265 .

_:807f36cf91fe4e8caa53aadeff92477614265 rdf:first _:807f36cf91fe4e8caa53aadeff92477614266;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614267 .

_:807f36cf91fe4e8caa53aadeff92477614266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477614267 rdf:first _:807f36cf91fe4e8caa53aadeff92477614268;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10915 .

_:807f36cf91fe4e8caa53aadeff92477614270 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11248-1 a owl:Class;
  rdfs:label "LITHIUM <-> TOPIRAMATE"@fr;
  dct:identifier "IAM_11248";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614272;
  r:natureDuRisque "Pour des doses de topiramate >= 200 mg par jour : augmentation de la lithémie pouvant atteindre des valeurs toxiques, avec signes de surdosage en lithium."@fr;
  r:conduiteATenir "Surveillance clinique et biologique. Adaptation de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614278, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614272 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614273 .

_:807f36cf91fe4e8caa53aadeff92477614273 rdf:first _:807f36cf91fe4e8caa53aadeff92477614274;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614275 .

_:807f36cf91fe4e8caa53aadeff92477614274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477614275 rdf:first _:807f36cf91fe4e8caa53aadeff92477614276;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:807f36cf91fe4e8caa53aadeff92477614278 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11249-1 a owl:Class;
  rdfs:label "LOMITAPIDE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11249";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614280;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du lomitapide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614286, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614280 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614281 .

_:807f36cf91fe4e8caa53aadeff92477614281 rdf:first _:807f36cf91fe4e8caa53aadeff92477614282;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614283 .

_:807f36cf91fe4e8caa53aadeff92477614282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10533 .

_:807f36cf91fe4e8caa53aadeff92477614283 rdf:first _:807f36cf91fe4e8caa53aadeff92477614284;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614286 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11250-1 a owl:Class;
  rdfs:label "LURASIDONE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11250";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614288;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la lurasidone par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614294, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614288 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614289 .

_:807f36cf91fe4e8caa53aadeff92477614289 rdf:first _:807f36cf91fe4e8caa53aadeff92477614290;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614291 .

_:807f36cf91fe4e8caa53aadeff92477614290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10542 .

_:807f36cf91fe4e8caa53aadeff92477614291 rdf:first _:807f36cf91fe4e8caa53aadeff92477614292;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614294 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11251-1 a owl:Class;
  rdfs:label "LURASIDONE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11251";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614296;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la lurasidone par diminution de son métabolisme par le pamplemousse."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614296 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614297 .

_:807f36cf91fe4e8caa53aadeff92477614297 rdf:first _:807f36cf91fe4e8caa53aadeff92477614298;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614299 .

_:807f36cf91fe4e8caa53aadeff92477614298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477614299 rdf:first _:807f36cf91fe4e8caa53aadeff92477614300;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10542 .

_:807f36cf91fe4e8caa53aadeff92477614302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11252-1 a owl:Class;
  rdfs:label "MACITENTAN <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11252";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614304;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de macitentan par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614305 .

_:807f36cf91fe4e8caa53aadeff92477614305 rdf:first _:807f36cf91fe4e8caa53aadeff92477614306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614307 .

_:807f36cf91fe4e8caa53aadeff92477614306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10544 .

_:807f36cf91fe4e8caa53aadeff92477614307 rdf:first _:807f36cf91fe4e8caa53aadeff92477614308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11253-1 a owl:Class;
  rdfs:label "MARAVIROC <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11253";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614312;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de maraviroc pouvant conduire à une perte de la réponse virologique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614313 .

_:807f36cf91fe4e8caa53aadeff92477614313 rdf:first _:807f36cf91fe4e8caa53aadeff92477614314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614315 .

_:807f36cf91fe4e8caa53aadeff92477614314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10551 .

_:807f36cf91fe4e8caa53aadeff92477614315 rdf:first _:807f36cf91fe4e8caa53aadeff92477614316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11274-1 a owl:Class;
  rdfs:label "METOPROLOL <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_11274";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614320;
  r:natureDuRisque "Diminution des concentrations plasmatiques du métoprolol avec réduction de ses effets cliniques (augmentation de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614320 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614321 .

_:807f36cf91fe4e8caa53aadeff92477614321 rdf:first _:807f36cf91fe4e8caa53aadeff92477614322;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614323 .

_:807f36cf91fe4e8caa53aadeff92477614322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477614323 rdf:first _:807f36cf91fe4e8caa53aadeff92477614324;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477614326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11242-1 a owl:Class;
  rdfs:label "LITHIUM <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_11242";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614328;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques, avec signes de surdosage en lithium."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614329 .

_:807f36cf91fe4e8caa53aadeff92477614329 rdf:first _:807f36cf91fe4e8caa53aadeff92477614330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614331 .

_:807f36cf91fe4e8caa53aadeff92477614330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477614331 rdf:first _:807f36cf91fe4e8caa53aadeff92477614332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:807f36cf91fe4e8caa53aadeff92477614334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11310-1 a owl:Class;
  rdfs:label "MIRABÉGRON <-> PROPAFENONE"@fr;
  dct:identifier "IAM_11310";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614336;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la propafénone par diminution de son métabolisme par le mirabégron."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de la propafénone pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614337 .

_:807f36cf91fe4e8caa53aadeff92477614337 rdf:first _:807f36cf91fe4e8caa53aadeff92477614338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614339 .

_:807f36cf91fe4e8caa53aadeff92477614338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10591 .

_:807f36cf91fe4e8caa53aadeff92477614339 rdf:first _:807f36cf91fe4e8caa53aadeff92477614340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477614342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11272-1 a owl:Class;
  rdfs:label "METOPROLOL <-> MIRABÉGRON"@fr;
  dct:identifier "IAM_11272";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614344;
  r:natureDuRisque "Avec le métoprolol utilisé dans l'insuffisance cardiaque, augmentation des concentrations plasmatiques du métoprolol par diminution de son métabolisme par le mirabégron."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie du métoprolol pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614345 .

_:807f36cf91fe4e8caa53aadeff92477614345 rdf:first _:807f36cf91fe4e8caa53aadeff92477614346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614347 .

_:807f36cf91fe4e8caa53aadeff92477614346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477614347 rdf:first _:807f36cf91fe4e8caa53aadeff92477614348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10591 .

_:807f36cf91fe4e8caa53aadeff92477614350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11300-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_11300";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614352;
  r:natureDuRisque """Risque de diminution des concentrations plasmatiques de 
sofosbuvir par diminution de son absorption intestinale par
le millepertuis."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614353 .

_:807f36cf91fe4e8caa53aadeff92477614353 rdf:first _:807f36cf91fe4e8caa53aadeff92477614354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614355 .

_:807f36cf91fe4e8caa53aadeff92477614354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614355 rdf:first _:807f36cf91fe4e8caa53aadeff92477614356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:807f36cf91fe4e8caa53aadeff92477614358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11301-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11301";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614360;
  r:natureDuRisque "Risque de diminution très importante des concentrations de télaprévir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614361 .

_:807f36cf91fe4e8caa53aadeff92477614361 rdf:first _:807f36cf91fe4e8caa53aadeff92477614362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614363 .

_:807f36cf91fe4e8caa53aadeff92477614362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614363 rdf:first _:807f36cf91fe4e8caa53aadeff92477614364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477614366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11302-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11302";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614368;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la télithromycine, avec risque d'échec du traitement anti-infectieux, par augmentation du métabolisme hépatique de la télithromycine par le millepertuis."@fr;
  rdfs:comment "Le millepertuis a des propriétés d'induction enzymatique importantes. En raison du risque d'échec de l'antibiothérapie, une contre-indication a été retenue entre la télithromycine et le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614369 .

_:807f36cf91fe4e8caa53aadeff92477614369 rdf:first _:807f36cf91fe4e8caa53aadeff92477614370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614371 .

_:807f36cf91fe4e8caa53aadeff92477614370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614371 rdf:first _:807f36cf91fe4e8caa53aadeff92477614372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477614374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11303-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11303";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614376;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la théophylline, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (survenue"@fr;
  r:conduiteATenir "En cas d'association fortuite, ne pas interrompre brutalement la prise de millepertuis mais contrôler les concentrations plasmatiques (ou l'efficacité) du médicament associé avant puis après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614377 .

_:807f36cf91fe4e8caa53aadeff92477614377 rdf:first _:807f36cf91fe4e8caa53aadeff92477614378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614379 .

_:807f36cf91fe4e8caa53aadeff92477614378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477614379 rdf:first _:807f36cf91fe4e8caa53aadeff92477614380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11304-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11304";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614384;
  r:natureDuRisque "Risque de diminution importante des concentrations plasmatiques de ticagrelor par augmentation de son métabolisme hépatique par le millepertuis, avec diminution de son effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614390, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614384 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614385 .

_:807f36cf91fe4e8caa53aadeff92477614385 rdf:first _:807f36cf91fe4e8caa53aadeff92477614386;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614387 .

_:807f36cf91fe4e8caa53aadeff92477614386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614387 rdf:first _:807f36cf91fe4e8caa53aadeff92477614388;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477614390 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11305-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11305";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614392;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Préférer une alternative thérapeutique peu ou pas métabolisée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614398, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614392 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614393 .

_:807f36cf91fe4e8caa53aadeff92477614393 rdf:first _:807f36cf91fe4e8caa53aadeff92477614394;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614395 .

_:807f36cf91fe4e8caa53aadeff92477614394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614395 rdf:first _:807f36cf91fe4e8caa53aadeff92477614396;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477614398 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11306-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11306";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614400;
  r:natureDuRisque "Réduction importante des concentrations de vérapamil, avec risque de perte de son effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614400 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614401 .

_:807f36cf91fe4e8caa53aadeff92477614401 rdf:first _:807f36cf91fe4e8caa53aadeff92477614402;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614403 .

_:807f36cf91fe4e8caa53aadeff92477614402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614403 rdf:first _:807f36cf91fe4e8caa53aadeff92477614404;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477614406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11307-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> VISMODÉGIB"@fr;
  dct:identifier "IAM_11307";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614408;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de vismodégib."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614409 .

_:807f36cf91fe4e8caa53aadeff92477614409 rdf:first _:807f36cf91fe4e8caa53aadeff92477614410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614411 .

_:807f36cf91fe4e8caa53aadeff92477614410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614411 rdf:first _:807f36cf91fe4e8caa53aadeff92477614412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10996 .

_:807f36cf91fe4e8caa53aadeff92477614414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11298-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> SIMÉPRÉVIR"@fr;
  dct:identifier "IAM_11298";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614416;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de simeprévir par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614417 .

_:807f36cf91fe4e8caa53aadeff92477614417 rdf:first _:807f36cf91fe4e8caa53aadeff92477614418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614419 .

_:807f36cf91fe4e8caa53aadeff92477614418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614419 rdf:first _:807f36cf91fe4e8caa53aadeff92477614420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10837 .

_:807f36cf91fe4e8caa53aadeff92477614422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11309-1 a owl:Class;
  rdfs:label "MINÉRALOCORTICOÏDES <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11309";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614424;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des corticoïdes par augmentation de leur métabolisme hépatique par la rifampicine ; les conséquences sont particulièrement importantes chez les addisoniens traités par l'hydrocortisone et en ca"@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie des corticoïdes pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614425 .

_:807f36cf91fe4e8caa53aadeff92477614425 rdf:first _:807f36cf91fe4e8caa53aadeff92477614426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614427 .

_:807f36cf91fe4e8caa53aadeff92477614426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10108 .

_:807f36cf91fe4e8caa53aadeff92477614427 rdf:first _:807f36cf91fe4e8caa53aadeff92477614428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477614430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11297-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_11297";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614432;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de rilpivirine par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614433 .

_:807f36cf91fe4e8caa53aadeff92477614433 rdf:first _:807f36cf91fe4e8caa53aadeff92477614434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614435 .

_:807f36cf91fe4e8caa53aadeff92477614434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614435 rdf:first _:807f36cf91fe4e8caa53aadeff92477614436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:807f36cf91fe4e8caa53aadeff92477614438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11311-1 a owl:Class;
  rdfs:label "MITOMYCINE C <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11311";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614440;
  r:natureDuRisque "Risque de majoration de la toxicité pulmonaire de la mitomycine et des vinca-alcaloïdes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614441 .

_:807f36cf91fe4e8caa53aadeff92477614441 rdf:first _:807f36cf91fe4e8caa53aadeff92477614442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614443 .

_:807f36cf91fe4e8caa53aadeff92477614442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477614443 rdf:first _:807f36cf91fe4e8caa53aadeff92477614444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10593 .

_:807f36cf91fe4e8caa53aadeff92477614446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11312-1 a owl:Class;
  rdfs:label "MITOTANE <-> SPIRONOLACTONE"@fr;
  dct:identifier "IAM_11312";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614448;
  r:natureDuRisque "Risque de blocage de l’action du mitotane par la spironolactone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614449 .

_:807f36cf91fe4e8caa53aadeff92477614449 rdf:first _:807f36cf91fe4e8caa53aadeff92477614450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614451 .

_:807f36cf91fe4e8caa53aadeff92477614450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10594 .

_:807f36cf91fe4e8caa53aadeff92477614451 rdf:first _:807f36cf91fe4e8caa53aadeff92477614452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10857 .

_:807f36cf91fe4e8caa53aadeff92477614454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11313-1 a owl:Class;
  rdfs:label "MIZOLASTINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11313";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614456;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614457 .

_:807f36cf91fe4e8caa53aadeff92477614457 rdf:first _:807f36cf91fe4e8caa53aadeff92477614458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614459 .

_:807f36cf91fe4e8caa53aadeff92477614458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:807f36cf91fe4e8caa53aadeff92477614459 rdf:first _:807f36cf91fe4e8caa53aadeff92477614460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477614462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11314-1 a owl:Class;
  rdfs:label "MODAFINIL <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_11314";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614464;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de sofosbuvir par diminution de son absorption intestinale par le modafinil."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614465 .

_:807f36cf91fe4e8caa53aadeff92477614465 rdf:first _:807f36cf91fe4e8caa53aadeff92477614466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614467 .

_:807f36cf91fe4e8caa53aadeff92477614466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10599 .

_:807f36cf91fe4e8caa53aadeff92477614467 rdf:first _:807f36cf91fe4e8caa53aadeff92477614468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:807f36cf91fe4e8caa53aadeff92477614470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11315-1 a owl:Class;
  rdfs:label "MONTELUKAST <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11315";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614472;
  r:natureDuRisque "Risque de baisse de l'efficacité du montélukast par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l'antiasthmatique pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614473 .

_:807f36cf91fe4e8caa53aadeff92477614473 rdf:first _:807f36cf91fe4e8caa53aadeff92477614474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614475 .

_:807f36cf91fe4e8caa53aadeff92477614474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10604 .

_:807f36cf91fe4e8caa53aadeff92477614475 rdf:first _:807f36cf91fe4e8caa53aadeff92477614476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477614478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11316-1 a owl:Class;
  rdfs:label "MORPHINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11316";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614480;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la morphine et de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la morphine pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614481 .

_:807f36cf91fe4e8caa53aadeff92477614481 rdf:first _:807f36cf91fe4e8caa53aadeff92477614482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614483 .

_:807f36cf91fe4e8caa53aadeff92477614482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10606 .

_:807f36cf91fe4e8caa53aadeff92477614483 rdf:first _:807f36cf91fe4e8caa53aadeff92477614484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477614486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11317-1 a owl:Class;
  rdfs:label "MORPHINIQUES AGONISTES-ANTAGONISTES <-> MORPHINIQUES ANTAGONISTES PARTIELS"@fr;
  dct:identifier "IAM_11317";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614488;
  r:natureDuRisque "Risque de diminution de l’effet antalgique et/ou d’apparition d’un syndrome de sevrage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614494, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614488 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614489 .

_:807f36cf91fe4e8caa53aadeff92477614489 rdf:first _:807f36cf91fe4e8caa53aadeff92477614490;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614491 .

_:807f36cf91fe4e8caa53aadeff92477614490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10110 .

_:807f36cf91fe4e8caa53aadeff92477614491 rdf:first _:807f36cf91fe4e8caa53aadeff92477614492;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10111 .

_:807f36cf91fe4e8caa53aadeff92477614494 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11318-1 a owl:Class;
  rdfs:label "MORPHINIQUES ANTAGONISTES PARTIELS <-> MORPHINIQUES EN TRAITEMENT DE SUBSTITUTION"@fr;
  dct:identifier "IAM_11318";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614496;
  r:natureDuRisque "Risque d’apparition d’un syndrome de sevrage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614502, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614496 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614497 .

_:807f36cf91fe4e8caa53aadeff92477614497 rdf:first _:807f36cf91fe4e8caa53aadeff92477614498;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614499 .

_:807f36cf91fe4e8caa53aadeff92477614498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10111 .

_:807f36cf91fe4e8caa53aadeff92477614499 rdf:first _:807f36cf91fe4e8caa53aadeff92477614500;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10112 .

_:807f36cf91fe4e8caa53aadeff92477614502 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11319-1 a owl:Class;
  rdfs:label "MYCOPHENOLATE MOFETIL <-> PÉNICILLINES A"@fr;
  dct:identifier "IAM_11319";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614504;
  r:natureDuRisque "Diminution des concentrations de l’acide mycophénolique d’environ un tiers, avec risque potentiel de baisse d’efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614510, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614504 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614505 .

_:807f36cf91fe4e8caa53aadeff92477614505 rdf:first _:807f36cf91fe4e8caa53aadeff92477614506;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614507 .

_:807f36cf91fe4e8caa53aadeff92477614506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10139 .

_:807f36cf91fe4e8caa53aadeff92477614507 rdf:first _:807f36cf91fe4e8caa53aadeff92477614508;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10609 .

_:807f36cf91fe4e8caa53aadeff92477614510 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10713-1 a owl:Class;
  rdfs:label "DACARBAZINE <-> FOTEMUSTINE"@fr;
  dct:identifier "IAM_10713";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614512;
  r:natureDuRisque "Avec la dacarbazine à doses élevées : risque de toxicité pulmonaire (syndrome de détresse respiratoire aiguë de l'adulte)."@fr;
  r:conduiteATenir "Ne pas utiliser simultanément mais respecter un délai d'une semaine entre la dernière administration de fotémustine et le premier jour de la cure de dacarbazine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614518, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614512 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614513 .

_:807f36cf91fe4e8caa53aadeff92477614513 rdf:first _:807f36cf91fe4e8caa53aadeff92477614514;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614515 .

_:807f36cf91fe4e8caa53aadeff92477614514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10242 .

_:807f36cf91fe4e8caa53aadeff92477614515 rdf:first _:807f36cf91fe4e8caa53aadeff92477614516;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10404 .

_:807f36cf91fe4e8caa53aadeff92477614518 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11308-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11308";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614520;
  r:natureDuRisque "Réduction importante des concentrations de voriconazole, avec risque de perte de son effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614526, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614520 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614521 .

_:807f36cf91fe4e8caa53aadeff92477614521 rdf:first _:807f36cf91fe4e8caa53aadeff92477614522;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614523 .

_:807f36cf91fe4e8caa53aadeff92477614522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614523 rdf:first _:807f36cf91fe4e8caa53aadeff92477614524;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477614526 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11285-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11285";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614528;
  r:natureDuRisque "Risque d'absence d'effet du midazolam, avec diminution très importante de ses concentrations plasmatiques, par augmentation de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614534, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614528 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614529 .

_:807f36cf91fe4e8caa53aadeff92477614529 rdf:first _:807f36cf91fe4e8caa53aadeff92477614530;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614531 .

_:807f36cf91fe4e8caa53aadeff92477614530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477614531 rdf:first _:807f36cf91fe4e8caa53aadeff92477614532;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477614534 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11217-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_11217";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614536;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par le kétoconazole."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614542, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614536 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614537 .

_:807f36cf91fe4e8caa53aadeff92477614537 rdf:first _:807f36cf91fe4e8caa53aadeff92477614538;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614539 .

_:807f36cf91fe4e8caa53aadeff92477614538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477614539 rdf:first _:807f36cf91fe4e8caa53aadeff92477614540;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477614542 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11275-1 a owl:Class;
  rdfs:label "METOPROLOL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11275";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614544;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du bêta-bloquant (augmentation de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614550, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614544 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614545 .

_:807f36cf91fe4e8caa53aadeff92477614545 rdf:first _:807f36cf91fe4e8caa53aadeff92477614546;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614547 .

_:807f36cf91fe4e8caa53aadeff92477614546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477614547 rdf:first _:807f36cf91fe4e8caa53aadeff92477614548;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477614550 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11276-1 a owl:Class;
  rdfs:label "METOPROLOL <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11276";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614552;
  r:natureDuRisque "Chez l'insuffisant cardiaque, risque d'augmentation des effets indésirables du métoprolol, par diminution de son métabolisme hépatique par la terbinafine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par la terbinafine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614558, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614552 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614553 .

_:807f36cf91fe4e8caa53aadeff92477614553 rdf:first _:807f36cf91fe4e8caa53aadeff92477614554;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614555 .

_:807f36cf91fe4e8caa53aadeff92477614554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477614555 rdf:first _:807f36cf91fe4e8caa53aadeff92477614556;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477614558 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11277-1 a owl:Class;
  rdfs:label "METRONIDAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11277";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614560;
  r:natureDuRisque "Diminution des concentrations plasmatiques du métronidazole par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de métronidazole pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614566, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614560 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614561 .

_:807f36cf91fe4e8caa53aadeff92477614561 rdf:first _:807f36cf91fe4e8caa53aadeff92477614562;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614563 .

_:807f36cf91fe4e8caa53aadeff92477614562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:807f36cf91fe4e8caa53aadeff92477614563 rdf:first _:807f36cf91fe4e8caa53aadeff92477614564;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477614566 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11278-1 a owl:Class;
  rdfs:label "METYRAPONE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11278";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614568;
  r:natureDuRisque "Risque de faux négatif du test à la métyrapone, dû à une diminution de ses concentrations plasmatiques, par augmentation de son métabolisme hépatique par la phénytoïne."@fr;
  r:conduiteATenir "Doubler la posologie de métyrapone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614574, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614568 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614569 .

_:807f36cf91fe4e8caa53aadeff92477614569 rdf:first _:807f36cf91fe4e8caa53aadeff92477614570;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614571 .

_:807f36cf91fe4e8caa53aadeff92477614570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477614571 rdf:first _:807f36cf91fe4e8caa53aadeff92477614572;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10581 .

_:807f36cf91fe4e8caa53aadeff92477614574 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11279-1 a owl:Class;
  rdfs:label "MEXILETINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11279";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614576;
  r:natureDuRisque "Diminution de l'activité antiarythmique, des concentrations plasmatiques et de la demi-vie de la méxilétine (augmentation de son métabolisme hépatique)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement des concentrations plasmatiques de la mexilétine ; s'il y a lieu, adaptation de la posologie de la mexilétine pendant le traitement par la phénytoïne et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614582, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614576 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614577 .

_:807f36cf91fe4e8caa53aadeff92477614577 rdf:first _:807f36cf91fe4e8caa53aadeff92477614578;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614579 .

_:807f36cf91fe4e8caa53aadeff92477614578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477614579 rdf:first _:807f36cf91fe4e8caa53aadeff92477614580;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10582 .

_:807f36cf91fe4e8caa53aadeff92477614582 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11280-1 a owl:Class;
  rdfs:label "MEXILETINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11280";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614584;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution du métabolisme hépatique de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par la mexilétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614590, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614584 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614585 .

_:807f36cf91fe4e8caa53aadeff92477614585 rdf:first _:807f36cf91fe4e8caa53aadeff92477614586;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614587 .

_:807f36cf91fe4e8caa53aadeff92477614586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477614587 rdf:first _:807f36cf91fe4e8caa53aadeff92477614588;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10582 .

_:807f36cf91fe4e8caa53aadeff92477614590 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11281-1 a owl:Class;
  rdfs:label "MICONAZOLE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11281";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614592;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne pouvant atteindre des valeurs toxiques. Mécanisme invoqué : inhibition du métabolisme hépatique de la phénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614598, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614592 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614593 .

_:807f36cf91fe4e8caa53aadeff92477614593 rdf:first _:807f36cf91fe4e8caa53aadeff92477614594;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614595 .

_:807f36cf91fe4e8caa53aadeff92477614594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477614595 rdf:first _:807f36cf91fe4e8caa53aadeff92477614596;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10584 .

_:807f36cf91fe4e8caa53aadeff92477614598 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11282-1 a owl:Class;
  rdfs:label "MICONAZOLE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_11282";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614600;
  r:natureDuRisque "Avec le miconazole par voie générale et gel buccal : augmentation de l'effet hypoglycémiant avec survenue possible de manifestations hypoglycémiques, voire de coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614606, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614600 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614601 .

_:807f36cf91fe4e8caa53aadeff92477614601 rdf:first _:807f36cf91fe4e8caa53aadeff92477614602;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614603 .

_:807f36cf91fe4e8caa53aadeff92477614602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477614603 rdf:first _:807f36cf91fe4e8caa53aadeff92477614604;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10584 .

_:807f36cf91fe4e8caa53aadeff92477614606 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11299-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11299";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614608;
  r:natureDuRisque "Diminution de l’efficacité de l’hypocholestérolémiant par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614614, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614608 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614609 .

_:807f36cf91fe4e8caa53aadeff92477614609 rdf:first _:807f36cf91fe4e8caa53aadeff92477614610;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614611 .

_:807f36cf91fe4e8caa53aadeff92477614610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614611 rdf:first _:807f36cf91fe4e8caa53aadeff92477614612;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477614614 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11284-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_11284";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614616;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du midazolam par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614622, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614616 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614617 .

_:807f36cf91fe4e8caa53aadeff92477614617 rdf:first _:807f36cf91fe4e8caa53aadeff92477614618;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614619 .

_:807f36cf91fe4e8caa53aadeff92477614618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477614619 rdf:first _:807f36cf91fe4e8caa53aadeff92477614620;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477614622 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11273-1 a owl:Class;
  rdfs:label "METOPROLOL <-> PAROXETINE"@fr;
  dct:identifier "IAM_11273";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614624;
  r:natureDuRisque "Risque de majoration des effets indésirables du métoprolol, avec notamment bradycardie excessive, par inhibition de son métabolisme par la paroxétine."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie du métoprolol pendant la durée du traitement par la paroxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614630, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614624 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614625 .

_:807f36cf91fe4e8caa53aadeff92477614625 rdf:first _:807f36cf91fe4e8caa53aadeff92477614626;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614627 .

_:807f36cf91fe4e8caa53aadeff92477614626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477614627 rdf:first _:807f36cf91fe4e8caa53aadeff92477614628;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477614630 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11286-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> ROXITHROMYCINE"@fr;
  dct:identifier "IAM_11286";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614632;
  r:natureDuRisque "Majoration légère de la sédation."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614638, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614632 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614633 .

_:807f36cf91fe4e8caa53aadeff92477614633 rdf:first _:807f36cf91fe4e8caa53aadeff92477614634;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614635 .

_:807f36cf91fe4e8caa53aadeff92477614634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477614635 rdf:first _:807f36cf91fe4e8caa53aadeff92477614636;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:807f36cf91fe4e8caa53aadeff92477614638 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11287-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11287";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614640;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du midazolam par diminution de son métabolisme hépatique avec majoration de la sédation."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie pendant le traitement par le stiripentol."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614646, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614640 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614641 .

_:807f36cf91fe4e8caa53aadeff92477614641 rdf:first _:807f36cf91fe4e8caa53aadeff92477614642;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614643 .

_:807f36cf91fe4e8caa53aadeff92477614642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477614643 rdf:first _:807f36cf91fe4e8caa53aadeff92477614644;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477614646 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11288-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11288";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614648;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam (diminution de son métabolisme hépatique avec majoration de la sédation)."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de midazolam pendant le traitement par le vérapamil."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614654, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614648 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614649 .

_:807f36cf91fe4e8caa53aadeff92477614649 rdf:first _:807f36cf91fe4e8caa53aadeff92477614650;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614651 .

_:807f36cf91fe4e8caa53aadeff92477614650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477614651 rdf:first _:807f36cf91fe4e8caa53aadeff92477614652;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477614654 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11290-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_11290";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614656;
  r:natureDuRisque "Risque de diminution significative des concentrations plasmatiques de la névirapine par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614662, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614656 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614657 .

_:807f36cf91fe4e8caa53aadeff92477614657 rdf:first _:807f36cf91fe4e8caa53aadeff92477614658;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614659 .

_:807f36cf91fe4e8caa53aadeff92477614658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614659 rdf:first _:807f36cf91fe4e8caa53aadeff92477614660;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477614662 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11291-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_11291";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614664;
  r:natureDuRisque "Diminution des concentrations plasmatiques du nintédanib par diminution de son absorption par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614670, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614664 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614665 .

_:807f36cf91fe4e8caa53aadeff92477614665 rdf:first _:807f36cf91fe4e8caa53aadeff92477614666;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614667 .

_:807f36cf91fe4e8caa53aadeff92477614666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614667 rdf:first _:807f36cf91fe4e8caa53aadeff92477614668;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477614670 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11292-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> OXYCODONE"@fr;
  dct:identifier "IAM_11292";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614672;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’oxycodone par augmentation de son métabolisme par le millepertuis."@fr;
  r:conduiteATenir "Adaptation éventuelle de la posologie de l’oxycodone ."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614678, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614672 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614673 .

_:807f36cf91fe4e8caa53aadeff92477614673 rdf:first _:807f36cf91fe4e8caa53aadeff92477614674;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614675 .

_:807f36cf91fe4e8caa53aadeff92477614674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614675 rdf:first _:807f36cf91fe4e8caa53aadeff92477614676;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10681 .

_:807f36cf91fe4e8caa53aadeff92477614678 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11293-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_11293";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614680;
  r:natureDuRisque "Diminution des concentrations plasmatiques du contraceptif hormonal, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (sur"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614686, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614680 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614681 .

_:807f36cf91fe4e8caa53aadeff92477614681 rdf:first _:807f36cf91fe4e8caa53aadeff92477614682;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614683 .

_:807f36cf91fe4e8caa53aadeff92477614682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477614683 rdf:first _:807f36cf91fe4e8caa53aadeff92477614684;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614686 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11294-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> PROPAFENONE"@fr;
  dct:identifier "IAM_11294";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614688;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la propafénone par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. S'il y a lieu, adaptation de la posologie de la propafénone pendant l'association et après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614694, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614688 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614689 .

_:807f36cf91fe4e8caa53aadeff92477614689 rdf:first _:807f36cf91fe4e8caa53aadeff92477614690;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614691 .

_:807f36cf91fe4e8caa53aadeff92477614690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614691 rdf:first _:807f36cf91fe4e8caa53aadeff92477614692;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477614694 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11295-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> QUETIAPINE"@fr;
  dct:identifier "IAM_11295";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614696;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de quétiapine par augmentation de son métabolisme hépatique par l'inducteur, avec risque d’inefficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614702, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614696 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614697 .

_:807f36cf91fe4e8caa53aadeff92477614697 rdf:first _:807f36cf91fe4e8caa53aadeff92477614698;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614699 .

_:807f36cf91fe4e8caa53aadeff92477614698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614699 rdf:first _:807f36cf91fe4e8caa53aadeff92477614700;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:807f36cf91fe4e8caa53aadeff92477614702 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11296-1 a owl:Class;
  rdfs:label "MILLEPERTUIS <-> RÉGORAFÉNIB"@fr;
  dct:identifier "IAM_11296";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614704;
  r:natureDuRisque "Diminution des concentrations plasmatiques de régorafenib par augmentation de son métabolisme par le millepertuis"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614710, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614704 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614705 .

_:807f36cf91fe4e8caa53aadeff92477614705 rdf:first _:807f36cf91fe4e8caa53aadeff92477614706;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614707 .

_:807f36cf91fe4e8caa53aadeff92477614706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614707 rdf:first _:807f36cf91fe4e8caa53aadeff92477614708;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10789 .

_:807f36cf91fe4e8caa53aadeff92477614710 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11283-1 a owl:Class;
  rdfs:label "MIDAZOLAM <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11283";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614712;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de midazolam par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614718, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614712 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614713 .

_:807f36cf91fe4e8caa53aadeff92477614713 rdf:first _:807f36cf91fe4e8caa53aadeff92477614714;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614715 .

_:807f36cf91fe4e8caa53aadeff92477614714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477614715 rdf:first _:807f36cf91fe4e8caa53aadeff92477614716;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614718 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11147-1 a owl:Class;
  rdfs:label "INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11147";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614720;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l’efficacité de l’inhibiteur de tyrosine kinase, par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614726, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614720 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614721 .

_:807f36cf91fe4e8caa53aadeff92477614721 rdf:first _:807f36cf91fe4e8caa53aadeff92477614722;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614723 .

_:807f36cf91fe4e8caa53aadeff92477614722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477614723 rdf:first _:807f36cf91fe4e8caa53aadeff92477614724;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477614726 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11135-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> RIFABUTINE"@fr;
  dct:identifier "IAM_11135";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614728;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'inhibiteur de protéases (ce d'autant que la posologie de la rifabutine est importante) d'une part, et risque d'augmentation des effets indésirables (uvéites) de la rifabutine, d'autre part."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614734, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614728 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614729 .

_:807f36cf91fe4e8caa53aadeff92477614729 rdf:first _:807f36cf91fe4e8caa53aadeff92477614730;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614731 .

_:807f36cf91fe4e8caa53aadeff92477614730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477614731 rdf:first _:807f36cf91fe4e8caa53aadeff92477614732;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477614734 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11136-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11136";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614736;
  r:natureDuRisque """Diminution très importante des concentrations plasmatiques de l'inhibiteur de protéases, par augmentation de son métabolisme hépatique par la rifampicine.

Pour l'association (saquinavir + ritonavir) :
risque de toxicité hépatocellulaire sévère."""@fr;
  r:conduiteATenir "Dans l'attente de données complémentaires avec les inhibiteurs de protéases \"boostés\"."@fr;
  rdfs:comment "La rifampicine est un inducteur enzymatique puissant des CYP450 et diminue fortement la concentration des inhibiteurs de protéases avec un risque de perte d’efficacité du traitement antirétroviral. Une contre-indication entre la majorité des inhibiteurs d"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614742, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614736 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614737 .

_:807f36cf91fe4e8caa53aadeff92477614737 rdf:first _:807f36cf91fe4e8caa53aadeff92477614738;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614739 .

_:807f36cf91fe4e8caa53aadeff92477614738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477614739 rdf:first _:807f36cf91fe4e8caa53aadeff92477614740;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477614742 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11137-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> ROSUVASTATINE"@fr;
  dct:identifier "IAM_11137";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614744;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la rosuvastatine par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et biologique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614750, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614744 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614745 .

_:807f36cf91fe4e8caa53aadeff92477614745 rdf:first _:807f36cf91fe4e8caa53aadeff92477614746;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614747 .

_:807f36cf91fe4e8caa53aadeff92477614746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477614747 rdf:first _:807f36cf91fe4e8caa53aadeff92477614748;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10814 .

_:807f36cf91fe4e8caa53aadeff92477614750 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11138-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11138";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614752;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  rdfs:comment "Le groupe de travail européen de pharmacovigilance a émis des recommandations s'appliquant à tous les inhibiteurs de protéases (IPs), inhibiteurs puissants du CYP3A4. Celles-ci modulent les niveaux de contrainte existants entre les IPs et les statines mét"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614758, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614752 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614753 .

_:807f36cf91fe4e8caa53aadeff92477614753 rdf:first _:807f36cf91fe4e8caa53aadeff92477614754;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614755 .

_:807f36cf91fe4e8caa53aadeff92477614754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477614755 rdf:first _:807f36cf91fe4e8caa53aadeff92477614756;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477614758 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11140-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11140";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614760;
  r:natureDuRisque "Avec l'atazanavir, le darunavir ou le lopinavir, augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour. L’association avec les autres inhibiteurs de protéases du VIH n’a pas été étudiée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614766, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614760 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614761 .

_:807f36cf91fe4e8caa53aadeff92477614761 rdf:first _:807f36cf91fe4e8caa53aadeff92477614762;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614763 .

_:807f36cf91fe4e8caa53aadeff92477614762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477614763 rdf:first _:807f36cf91fe4e8caa53aadeff92477614764;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614764 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477614766 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11141-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11141";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614768;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la théophylline, par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par l'inhibiteur de protéases et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614774, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614768 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614769 .

_:807f36cf91fe4e8caa53aadeff92477614769 rdf:first _:807f36cf91fe4e8caa53aadeff92477614770;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614771 .

_:807f36cf91fe4e8caa53aadeff92477614770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477614771 rdf:first _:807f36cf91fe4e8caa53aadeff92477614772;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614772 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477614774 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11142-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11142";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614776;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Préférer une alternative thérapeutique peu ou pas métabolisée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614782, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614776 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614777 .

_:807f36cf91fe4e8caa53aadeff92477614777 rdf:first _:807f36cf91fe4e8caa53aadeff92477614778;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614779 .

_:807f36cf91fe4e8caa53aadeff92477614778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477614779 rdf:first _:807f36cf91fe4e8caa53aadeff92477614780;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614780 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477614782 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11143-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11143";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614784;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614790, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614784 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614785 .

_:807f36cf91fe4e8caa53aadeff92477614785 rdf:first _:807f36cf91fe4e8caa53aadeff92477614786;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614787 .

_:807f36cf91fe4e8caa53aadeff92477614786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477614787 rdf:first _:807f36cf91fe4e8caa53aadeff92477614788;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614788 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477614790 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11145-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11145";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614792;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Baisse très importante des concentrations de l’antifongique par augmentation de son métabolisme par le ritonavir, avec risque d’échec du traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614798, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614792 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614793 .

_:807f36cf91fe4e8caa53aadeff92477614793 rdf:first _:807f36cf91fe4e8caa53aadeff92477614794;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614795 .

_:807f36cf91fe4e8caa53aadeff92477614794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477614795 rdf:first _:807f36cf91fe4e8caa53aadeff92477614796;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477614798 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11219-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> SALMETEROL"@fr;
  dct:identifier "IAM_11219";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614800;
  r:natureDuRisque "Augmentation importante des concentrations de salmétérol par diminution de son métabolisme hépatique par le kétoconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614806, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614800 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614801 .

_:807f36cf91fe4e8caa53aadeff92477614801 rdf:first _:807f36cf91fe4e8caa53aadeff92477614802;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614803 .

_:807f36cf91fe4e8caa53aadeff92477614802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477614803 rdf:first _:807f36cf91fe4e8caa53aadeff92477614804;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10823 .

_:807f36cf91fe4e8caa53aadeff92477614806 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11149-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> IRINOTECAN"@fr;
  dct:identifier "IAM_11149";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614808;
  r:natureDuRisque "Risque de majoration des effets indésirables de l’irinotécan par augmentation des concentrations plasmatiques de son métabolite actif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614814, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614808 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614809 .

_:807f36cf91fe4e8caa53aadeff92477614809 rdf:first _:807f36cf91fe4e8caa53aadeff92477614810;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614811 .

_:807f36cf91fe4e8caa53aadeff92477614810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477614811 rdf:first _:807f36cf91fe4e8caa53aadeff92477614812;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614812 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10486 .

_:807f36cf91fe4e8caa53aadeff92477614814 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11119-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> SACUBITRIL"@fr;
  dct:identifier "IAM_11119";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614816;
  r:natureDuRisque "Augmentation du risque d'angioedème."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614822, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614816 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614817 .

_:807f36cf91fe4e8caa53aadeff92477614817 rdf:first _:807f36cf91fe4e8caa53aadeff92477614818;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614819 .

_:807f36cf91fe4e8caa53aadeff92477614818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477614819 rdf:first _:807f36cf91fe4e8caa53aadeff92477614820;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614820 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10821 .

_:807f36cf91fe4e8caa53aadeff92477614822 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11148-1 a owl:Class;
  rdfs:label "INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11148";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614824;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l’efficacité de l’inhibiteur de tyrosine kinase, par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614830, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614824 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614825 .

_:807f36cf91fe4e8caa53aadeff92477614825 rdf:first _:807f36cf91fe4e8caa53aadeff92477614826;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614827 .

_:807f36cf91fe4e8caa53aadeff92477614826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477614827 rdf:first _:807f36cf91fe4e8caa53aadeff92477614828;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614828 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477614830 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10419-1 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS AGISSANT SUR L'HÉMOSTASE <-> INHIBITEURS DIRECTS DE LA THROMBINE À INDICATION SPÉCIFIQUE"@fr;
  dct:identifier "IAM_10419";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614832;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614838, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614832 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614833 .

_:807f36cf91fe4e8caa53aadeff92477614833 rdf:first _:807f36cf91fe4e8caa53aadeff92477614834;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614835 .

_:807f36cf91fe4e8caa53aadeff92477614834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10102 .

_:807f36cf91fe4e8caa53aadeff92477614835 rdf:first _:807f36cf91fe4e8caa53aadeff92477614836;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614836 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10163 .

_:807f36cf91fe4e8caa53aadeff92477614838 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11150-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> ISAVUCONAZOLE"@fr;
  dct:identifier "IAM_11150";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614840;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’isavuconazole par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  r:conduiteATenir """Contre-indication:
- avec le kétoconazole


Précaution d'emploi:
- avec les autres inhibiteurs puissants du CYP3A4"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614846, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614840 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614841 .

_:807f36cf91fe4e8caa53aadeff92477614841 rdf:first _:807f36cf91fe4e8caa53aadeff92477614842;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614843 .

_:807f36cf91fe4e8caa53aadeff92477614842 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477614843 rdf:first _:807f36cf91fe4e8caa53aadeff92477614844;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10487 .

_:807f36cf91fe4e8caa53aadeff92477614846 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11151-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> IVABRADINE"@fr;
  dct:identifier "IAM_11151";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614848;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’ivabradine et par conséquent de ses effets indésirables (inhibition de son métabolisme hépatique par l’inhibiteur)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614854, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614848 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614849 .

_:807f36cf91fe4e8caa53aadeff92477614849 rdf:first _:807f36cf91fe4e8caa53aadeff92477614850;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614851 .

_:807f36cf91fe4e8caa53aadeff92477614850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477614851 rdf:first _:807f36cf91fe4e8caa53aadeff92477614852;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477614854 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11152-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> IVACAFTOR"@fr;
  dct:identifier "IAM_11152";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614856;
  r:natureDuRisque "Augmentation importante des concentrations d’ivacaftor, avec risques de majoration des effets indésirables."@fr;
  r:conduiteATenir "Réduire la dose du quart, soit 150 mg 1 jour sur 2."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614862, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614856 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614857 .

_:807f36cf91fe4e8caa53aadeff92477614857 rdf:first _:807f36cf91fe4e8caa53aadeff92477614858;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614859 .

_:807f36cf91fe4e8caa53aadeff92477614858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477614859 rdf:first _:807f36cf91fe4e8caa53aadeff92477614860;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10498 .

_:807f36cf91fe4e8caa53aadeff92477614862 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11153-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> LOMITAPIDE"@fr;
  dct:identifier "IAM_11153";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614864;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du lomitapide par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614870, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614864 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614865 .

_:807f36cf91fe4e8caa53aadeff92477614865 rdf:first _:807f36cf91fe4e8caa53aadeff92477614866;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614867 .

_:807f36cf91fe4e8caa53aadeff92477614866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477614867 rdf:first _:807f36cf91fe4e8caa53aadeff92477614868;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614868 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10533 .

_:807f36cf91fe4e8caa53aadeff92477614870 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11154-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> LURASIDONE"@fr;
  dct:identifier "IAM_11154";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614872;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la lurasidone par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614878, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614872 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614873 .

_:807f36cf91fe4e8caa53aadeff92477614873 rdf:first _:807f36cf91fe4e8caa53aadeff92477614874;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614875 .

_:807f36cf91fe4e8caa53aadeff92477614874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477614875 rdf:first _:807f36cf91fe4e8caa53aadeff92477614876;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614876 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10542 .

_:807f36cf91fe4e8caa53aadeff92477614878 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11155-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> MARAVIROC"@fr;
  dct:identifier "IAM_11155";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614880;
  r:natureDuRisque "Augmentation des concentrations de maraviroc par l’inhibiteur."@fr;
  r:conduiteATenir """La dose de maraviroc doit être diminuée à 150 mg deux fois par jour en cas de co-administration avec cet inhibiteur.
A l'exception du tipranavir boosté par ritonavir où la dose de maraviroc doit être de 300 mg deux fois par jour."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614886, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614880 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614881 .

_:807f36cf91fe4e8caa53aadeff92477614881 rdf:first _:807f36cf91fe4e8caa53aadeff92477614882;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614883 .

_:807f36cf91fe4e8caa53aadeff92477614882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477614883 rdf:first _:807f36cf91fe4e8caa53aadeff92477614884;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614884 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10551 .

_:807f36cf91fe4e8caa53aadeff92477614886 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11156-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> METHYLPREDNISOLONE"@fr;
  dct:identifier "IAM_11156";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614888;
  r:natureDuRisque "En cas d’utilisation prolongée, augmentation des concentrations plasmatiques du corticoïde par diminution de son métabolisme hépatique par l’inhibiteur, avec risque d'apparition d'un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614894, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614888 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614889 .

_:807f36cf91fe4e8caa53aadeff92477614889 rdf:first _:807f36cf91fe4e8caa53aadeff92477614890;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614891 .

_:807f36cf91fe4e8caa53aadeff92477614890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477614891 rdf:first _:807f36cf91fe4e8caa53aadeff92477614892;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10576 .

_:807f36cf91fe4e8caa53aadeff92477614894 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11146-1 a owl:Class;
  rdfs:label "INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11146";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614896;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque """Risque de majoration des effets indésirables de l’inhibiteur de
tyrosine kinase par diminution de son métabolisme."""@fr;
  r:conduiteATenir """Association déconseillée :
- avec l'axitinib, le bosutinib, le céritinib, le cobimétinib, le dabrafenib, le dasatinib, le nilotinib, le sunitinib
- avec l'ibrutinib, si l’association ne peut être évitée ,surveillance clinique étroite et réduction de la do"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614902, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614896 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614897 .

_:807f36cf91fe4e8caa53aadeff92477614897 rdf:first _:807f36cf91fe4e8caa53aadeff92477614898;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614899 .

_:807f36cf91fe4e8caa53aadeff92477614898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477614899 rdf:first _:807f36cf91fe4e8caa53aadeff92477614900;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477614902 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11109-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> VISMODÉGIB"@fr;
  dct:identifier "IAM_11109";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614904;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de vismodegib par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614910, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614904 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614905 .

_:807f36cf91fe4e8caa53aadeff92477614905 rdf:first _:807f36cf91fe4e8caa53aadeff92477614906;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614907 .

_:807f36cf91fe4e8caa53aadeff92477614906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477614907 rdf:first _:807f36cf91fe4e8caa53aadeff92477614908;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10996 .

_:807f36cf91fe4e8caa53aadeff92477614910 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11098-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_11098";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614912;
  r:chapeau "Certains médicaments ont la propriété d'activer considérablement certaines voies métaboliques hépatiques par induction enzymatique. Associés à des médicaments fortement métabolisés au niveau du foie, ils sont, de ce fait, en mesure d'en modifier les conce"@fr;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la bithérapie par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614918, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614912 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614913 .

_:807f36cf91fe4e8caa53aadeff92477614913 rdf:first _:807f36cf91fe4e8caa53aadeff92477614914;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614915 .

_:807f36cf91fe4e8caa53aadeff92477614914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477614915 rdf:first _:807f36cf91fe4e8caa53aadeff92477614916;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477614918 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11099-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> OXYCODONE"@fr;
  dct:identifier "IAM_11099";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614920;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l’oxycodone par augmentation de son métabolisme par l’inducteur."@fr;
  r:conduiteATenir "Adaptation éventuelle de la posologie d’oxycodone ."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614926, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614920 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614921 .

_:807f36cf91fe4e8caa53aadeff92477614921 rdf:first _:807f36cf91fe4e8caa53aadeff92477614922;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614923 .

_:807f36cf91fe4e8caa53aadeff92477614922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477614923 rdf:first _:807f36cf91fe4e8caa53aadeff92477614924;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10681 .

_:807f36cf91fe4e8caa53aadeff92477614926 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11100-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_11100";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614928;
  r:natureDuRisque "Diminution de l'efficacité contraceptive du contraceptif hormonal, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614934, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614928 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614929 .

_:807f36cf91fe4e8caa53aadeff92477614929 rdf:first _:807f36cf91fe4e8caa53aadeff92477614930;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614931 .

_:807f36cf91fe4e8caa53aadeff92477614930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477614931 rdf:first _:807f36cf91fe4e8caa53aadeff92477614932;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477614934 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11101-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> PROGESTATIFS NON CONTRACEPTIFS, ASSOCIÉS OU NON À UN ESTROGÈNE"@fr;
  dct:identifier "IAM_11101";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614936;
  r:chapeau "Certains médicaments ont la propriété d'activer considérablement certaines voies métaboliques hépatiques par induction enzymatique. Associés à des médicaments fortement métabolisés au niveau du foie, ils sont, de ce fait, en mesure d'en modifier les conce"@fr;
  r:natureDuRisque "Diminution de l'efficacité du progestatif."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l'administration de l'inducteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614942, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614936 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614937 .

_:807f36cf91fe4e8caa53aadeff92477614937 rdf:first _:807f36cf91fe4e8caa53aadeff92477614938;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614939 .

_:807f36cf91fe4e8caa53aadeff92477614938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477614939 rdf:first _:807f36cf91fe4e8caa53aadeff92477614940;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10135 .

_:807f36cf91fe4e8caa53aadeff92477614942 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11102-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> RÉGORAFÉNIB"@fr;
  dct:identifier "IAM_11102";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614944;
  r:natureDuRisque "Diminution des concentrations plasmatiques de régorafenib par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614950, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614944 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614945 .

_:807f36cf91fe4e8caa53aadeff92477614945 rdf:first _:807f36cf91fe4e8caa53aadeff92477614946;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614947 .

_:807f36cf91fe4e8caa53aadeff92477614946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477614947 rdf:first _:807f36cf91fe4e8caa53aadeff92477614948;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10789 .

_:807f36cf91fe4e8caa53aadeff92477614950 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11103-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_11103";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614952;
  r:natureDuRisque "Diminution significative des concentrations plasmatiques de rilpivirine par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614958, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614952 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614953 .

_:807f36cf91fe4e8caa53aadeff92477614953 rdf:first _:807f36cf91fe4e8caa53aadeff92477614954;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614955 .

_:807f36cf91fe4e8caa53aadeff92477614954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477614955 rdf:first _:807f36cf91fe4e8caa53aadeff92477614956;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:807f36cf91fe4e8caa53aadeff92477614958 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11104-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> SERTRALINE"@fr;
  dct:identifier "IAM_11104";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614960;
  r:natureDuRisque "Risque d’inefficacité du traitement antidépresseur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614966, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614960 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614961 .

_:807f36cf91fe4e8caa53aadeff92477614961 rdf:first _:807f36cf91fe4e8caa53aadeff92477614962;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614963 .

_:807f36cf91fe4e8caa53aadeff92477614962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477614963 rdf:first _:807f36cf91fe4e8caa53aadeff92477614964;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10831 .

_:807f36cf91fe4e8caa53aadeff92477614966 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11105-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> SIMÉPRÉVIR"@fr;
  dct:identifier "IAM_11105";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614968;
  r:natureDuRisque "Diminution des concentrations plasmatiques de simeprévir par augmentation de son métabolisme hépatique par l’inducteur"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614974, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614968 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614969 .

_:807f36cf91fe4e8caa53aadeff92477614969 rdf:first _:807f36cf91fe4e8caa53aadeff92477614970;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614971 .

_:807f36cf91fe4e8caa53aadeff92477614970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477614971 rdf:first _:807f36cf91fe4e8caa53aadeff92477614972;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10837 .

_:807f36cf91fe4e8caa53aadeff92477614974 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11106-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_11106";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614976;
  r:natureDuRisque """Risque de diminution des concentrations plasmatiques de 
sofosbuvir par diminution de son absorption intestinale par
l’inducteur."""@fr;
  r:conduiteATenir """Contre-indication :
- avec la rifampicine
- avec les anticonvulsivants inducteurs enzymatiques

Association déconseillée:
- avec les autres inducteurs."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614982, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614976 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614977 .

_:807f36cf91fe4e8caa53aadeff92477614977 rdf:first _:807f36cf91fe4e8caa53aadeff92477614978;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614979 .

_:807f36cf91fe4e8caa53aadeff92477614978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477614979 rdf:first _:807f36cf91fe4e8caa53aadeff92477614980;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:807f36cf91fe4e8caa53aadeff92477614982 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11134-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> QUINIDINE"@fr;
  dct:identifier "IAM_11134";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614984;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614990, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614984 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614985 .

_:807f36cf91fe4e8caa53aadeff92477614985 rdf:first _:807f36cf91fe4e8caa53aadeff92477614986;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614987 .

_:807f36cf91fe4e8caa53aadeff92477614986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477614987 rdf:first _:807f36cf91fe4e8caa53aadeff92477614988;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614988 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477614990 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11108-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_11108";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477614992;
  r:natureDuRisque "Risque de diminution des concentrations du vémurafénib, avec moindre efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477614998, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477614992 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477614993 .

_:807f36cf91fe4e8caa53aadeff92477614993 rdf:first _:807f36cf91fe4e8caa53aadeff92477614994;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477614995 .

_:807f36cf91fe4e8caa53aadeff92477614994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477614995 rdf:first _:807f36cf91fe4e8caa53aadeff92477614996;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477614996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:807f36cf91fe4e8caa53aadeff92477614998 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11133-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> PROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_11133";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615000;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par diminution des concentrations en contraceptif hormonal, dûe à l'augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique (préservatif ou stérilet), pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615006, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615000 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615001 .

_:807f36cf91fe4e8caa53aadeff92477615001 rdf:first _:807f36cf91fe4e8caa53aadeff92477615002;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615003 .

_:807f36cf91fe4e8caa53aadeff92477615002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477615003 rdf:first _:807f36cf91fe4e8caa53aadeff92477615004;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477615006 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11110-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_11110";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615008;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la vortioxétine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant l'association et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615014, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615008 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615009 .

_:807f36cf91fe4e8caa53aadeff92477615009 rdf:first _:807f36cf91fe4e8caa53aadeff92477615010;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615011 .

_:807f36cf91fe4e8caa53aadeff92477615010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477615011 rdf:first _:807f36cf91fe4e8caa53aadeff92477615012;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:807f36cf91fe4e8caa53aadeff92477615014 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11111-1 a owl:Class;
  rdfs:label "INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5 <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11111";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615016;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Augmentation (très importante pour l'avanafil et le vardénafil) des concentrations plasmatiques de l'IPDE5, avec risque d'hypotension (sévère avec le vardénafil)."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque IPDE5 avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux AMM specifiques à chacun d'eux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615022, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615016 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615017 .

_:807f36cf91fe4e8caa53aadeff92477615017 rdf:first _:807f36cf91fe4e8caa53aadeff92477615018;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615019 .

_:807f36cf91fe4e8caa53aadeff92477615018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477615019 rdf:first _:807f36cf91fe4e8caa53aadeff92477615020;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615022 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11112-1 a owl:Class;
  rdfs:label "INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5 <-> RIOCIGUAT"@fr;
  dct:identifier "IAM_11112";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615024;
  r:natureDuRisque "Risque d'hypotension importante (effet synergique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615030, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615024 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615025 .

_:807f36cf91fe4e8caa53aadeff92477615025 rdf:first _:807f36cf91fe4e8caa53aadeff92477615026;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615027 .

_:807f36cf91fe4e8caa53aadeff92477615026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477615027 rdf:first _:807f36cf91fe4e8caa53aadeff92477615028;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615028 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10804 .

_:807f36cf91fe4e8caa53aadeff92477615030 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11113-1 a owl:Class;
  rdfs:label "INHIBITEURS DE LA XANTHINE OXYDASE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11113";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615032;
  r:natureDuRisque "En cas de posologies élevées de l'inhibiteur, augmentation des concentrations plasmatiques de théophylline par inhibition de son métabolisme."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle de la théophyllinémie jusqu'à deux à trois semaines après la mise en route du traitement par l'inhibiteur ; s'il y a lieu, adaptation de la posologie pendant le traitement par l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615038, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615032 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615033 .

_:807f36cf91fe4e8caa53aadeff92477615033 rdf:first _:807f36cf91fe4e8caa53aadeff92477615034;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615035 .

_:807f36cf91fe4e8caa53aadeff92477615034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10099 .

_:807f36cf91fe4e8caa53aadeff92477615035 rdf:first _:807f36cf91fe4e8caa53aadeff92477615036;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615036 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477615038 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11114-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> INSULINE"@fr;
  dct:identifier "IAM_11114";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615040;
  r:natureDuRisque "L'utilisation des IEC peut entraîner une majoration de l'effet hypoglycémiant chez le diabétique traité par insuline. La survenue de malaises hypoglycémiques semble exceptionnelle (amélioration de la tolérance au glucose qui aurait pour conséquence une ré"@fr;
  r:conduiteATenir "Renforcer l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615046, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615040 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615041 .

_:807f36cf91fe4e8caa53aadeff92477615041 rdf:first _:807f36cf91fe4e8caa53aadeff92477615042;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615043 .

_:807f36cf91fe4e8caa53aadeff92477615042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477615043 rdf:first _:807f36cf91fe4e8caa53aadeff92477615044;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615044 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:807f36cf91fe4e8caa53aadeff92477615046 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11115-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> LITHIUM"@fr;
  dct:identifier "IAM_11115";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615048;
  r:natureDuRisque "Augmentation de la lithémie pouvant atteindre des valeurs toxiques (diminution de l'excrétion rénale du lithium)."@fr;
  r:conduiteATenir "Si l'usage d'un IEC est indispensable, surveillance stricte de la lithémie et adaptation de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615054, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615048 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615049 .

_:807f36cf91fe4e8caa53aadeff92477615049 rdf:first _:807f36cf91fe4e8caa53aadeff92477615050;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615051 .

_:807f36cf91fe4e8caa53aadeff92477615050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477615051 rdf:first _:807f36cf91fe4e8caa53aadeff92477615052;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615052 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477615054 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11116-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> OR"@fr;
  dct:identifier "IAM_11116";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615056;
  r:natureDuRisque "Avec les sels d'or administrés par voie IV : risque de réaction «nitritoïde» à l’introduction de l’IEC (nausées, vomissements, effets vasomoteurs à type de flush, hypotension, éventuellement collapsus)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615062, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615056 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615057 .

_:807f36cf91fe4e8caa53aadeff92477615057 rdf:first _:807f36cf91fe4e8caa53aadeff92477615058;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615059 .

_:807f36cf91fe4e8caa53aadeff92477615058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477615059 rdf:first _:807f36cf91fe4e8caa53aadeff92477615060;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615060 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10666 .

_:807f36cf91fe4e8caa53aadeff92477615062 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11117-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> POTASSIUM"@fr;
  dct:identifier "IAM_11117";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615064;
  r:natureDuRisque "Hyperkaliémie (potentiellement létale) surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Sauf s'il existe une hypokaliémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615070, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615064 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615065 .

_:807f36cf91fe4e8caa53aadeff92477615065 rdf:first _:807f36cf91fe4e8caa53aadeff92477615066;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615067 .

_:807f36cf91fe4e8caa53aadeff92477615066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477615067 rdf:first _:807f36cf91fe4e8caa53aadeff92477615068;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615068 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:807f36cf91fe4e8caa53aadeff92477615070 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11118-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> RACECADOTRIL"@fr;
  dct:identifier "IAM_11118";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615072;
  r:natureDuRisque "Risque de majoration des effets indésirables à type d'œdème angio-neurotique (angio-œdème)."@fr;
  r:conduiteATenir """Contre-indication:
- en cas d'antécédents d'angio-oedème sous IEC.

Association déconseillée:
- en l'absence d’antécédents d'angio-oedème sous IEC."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615078, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615072 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615073 .

_:807f36cf91fe4e8caa53aadeff92477615073 rdf:first _:807f36cf91fe4e8caa53aadeff92477615074;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615075 .

_:807f36cf91fe4e8caa53aadeff92477615074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477615075 rdf:first _:807f36cf91fe4e8caa53aadeff92477615076;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615076 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10780 .

_:807f36cf91fe4e8caa53aadeff92477615078 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11159-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_11159";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615080;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la bithérapie par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  r:conduiteATenir """Contre-indication: 
- sauf avec le ritonavir."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615086, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615080 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615081 .

_:807f36cf91fe4e8caa53aadeff92477615081 rdf:first _:807f36cf91fe4e8caa53aadeff92477615082;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615083 .

_:807f36cf91fe4e8caa53aadeff92477615082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615083 rdf:first _:807f36cf91fe4e8caa53aadeff92477615084;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615084 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477615086 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11107-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11107";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615088;
  r:natureDuRisque "Diminution des concentrations plasmatiques du ténofovir alafénamide par diminution de son absorption par l’inducteur."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique pendant l’association et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615094, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615088 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615089 .

_:807f36cf91fe4e8caa53aadeff92477615089 rdf:first _:807f36cf91fe4e8caa53aadeff92477615090;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615091 .

_:807f36cf91fe4e8caa53aadeff92477615090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477615091 rdf:first _:807f36cf91fe4e8caa53aadeff92477615092;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615092 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477615094 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11203-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11203";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615096;
  r:natureDuRisque "Majoration de la neurotoxicité de l'antimitotique, par diminution de son métabolisme hépatique par l'itraconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615102, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615096 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615097 .

_:807f36cf91fe4e8caa53aadeff92477615097 rdf:first _:807f36cf91fe4e8caa53aadeff92477615098;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615099 .

_:807f36cf91fe4e8caa53aadeff92477615098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477615099 rdf:first _:807f36cf91fe4e8caa53aadeff92477615100;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615100 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477615102 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11157-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_11157";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615104;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam par diminution de son métabolisme hépatique, avec majoration de la sédation."@fr;
  r:conduiteATenir """Association déconseillée:
- avec le midazolam per os

Précaution d'emploi avec :
- avec le midazolam IV et sublingual
Surveillance clinique et réduction de la posologie de midazolam en cas de traitement par l'inhibiteur."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615110, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615104 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615105 .

_:807f36cf91fe4e8caa53aadeff92477615105 rdf:first _:807f36cf91fe4e8caa53aadeff92477615106;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615107 .

_:807f36cf91fe4e8caa53aadeff92477615106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615107 rdf:first _:807f36cf91fe4e8caa53aadeff92477615108;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615108 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477615110 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10078-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> INSULINE"@fr;
  dct:identifier "IAM_10078";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615112;
  r:natureDuRisque "Augmentation de la réaction hypoglycémique (inhibition des réactions de compensation pouvant faciliter la survenue de coma hypoglycémique)."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615118, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615112 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615113 .

_:807f36cf91fe4e8caa53aadeff92477615113 rdf:first _:807f36cf91fe4e8caa53aadeff92477615114;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615115 .

_:807f36cf91fe4e8caa53aadeff92477615114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:807f36cf91fe4e8caa53aadeff92477615115 rdf:first _:807f36cf91fe4e8caa53aadeff92477615116;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615116 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477615118 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11184-1 a owl:Class;
  rdfs:label "IRINOTECAN <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11184";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615120;
  r:natureDuRisque "Diminution des concentrations plasmatiques du métabolite actif de l'irinotécan, avec risque d'échec du traitement cytotoxique."@fr;
  rdfs:comment "Une étude randomisée, chez 5 patients traités par irinotécan, a mis en évidence une diminution de 42 % des concentrations de son métabolite actif, le SN-38, qui est un substrat de l'isoenzyme CYP3A4. En cas d'association de l'irinotécan avec le millepertu"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615126, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615120 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615121 .

_:807f36cf91fe4e8caa53aadeff92477615121 rdf:first _:807f36cf91fe4e8caa53aadeff92477615122;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615123 .

_:807f36cf91fe4e8caa53aadeff92477615122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10486 .

_:807f36cf91fe4e8caa53aadeff92477615123 rdf:first _:807f36cf91fe4e8caa53aadeff92477615124;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477615126 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11185-1 a owl:Class;
  rdfs:label "ISAVUCONAZOLE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11185";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615128;
  r:natureDuRisque "Diminution des concentrations plasmatiques d’isavuconazole par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615134, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615128 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615129 .

_:807f36cf91fe4e8caa53aadeff92477615129 rdf:first _:807f36cf91fe4e8caa53aadeff92477615130;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615131 .

_:807f36cf91fe4e8caa53aadeff92477615130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10487 .

_:807f36cf91fe4e8caa53aadeff92477615131 rdf:first _:807f36cf91fe4e8caa53aadeff92477615132;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477615134 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11186-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_11186";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615136;
  r:natureDuRisque "Diminution des concentrations plasmatiques de kétoconazole."@fr;
  r:conduiteATenir "Espacer les prises des deux anti-infectieux d'au moins 12 heures. Surveiller les concentrations plasmatiques du kétoconazole et adapter éventuellement sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615142, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615136 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615137 .

_:807f36cf91fe4e8caa53aadeff92477615137 rdf:first _:807f36cf91fe4e8caa53aadeff92477615138;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615139 .

_:807f36cf91fe4e8caa53aadeff92477615138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477615139 rdf:first _:807f36cf91fe4e8caa53aadeff92477615140;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477615142 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11187-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11187";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615144;
  r:natureDuRisque "Surdosage en phénytoïne (diminution de son métabolisme)."@fr;
  r:conduiteATenir "Surveillance clinique étroite, dosage des concentrations plasmatiques de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par l'isoniazide et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615150, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615144 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615145 .

_:807f36cf91fe4e8caa53aadeff92477615145 rdf:first _:807f36cf91fe4e8caa53aadeff92477615146;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615147 .

_:807f36cf91fe4e8caa53aadeff92477615146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477615147 rdf:first _:807f36cf91fe4e8caa53aadeff92477615148;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477615150 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11188-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> PYRAZINAMIDE"@fr;
  dct:identifier "IAM_11188";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615152;
  r:natureDuRisque "Addition des effets hépatotoxiques."@fr;
  r:conduiteATenir "Surveillance clinique et biologique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615158, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615152 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615153 .

_:807f36cf91fe4e8caa53aadeff92477615153 rdf:first _:807f36cf91fe4e8caa53aadeff92477615154;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615155 .

_:807f36cf91fe4e8caa53aadeff92477615154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477615155 rdf:first _:807f36cf91fe4e8caa53aadeff92477615156;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10770 .

_:807f36cf91fe4e8caa53aadeff92477615158 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11189-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11189";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615160;
  r:natureDuRisque "Augmentation de l'hépatotoxicité de l'isoniazide (augmentation de la formation de métabolites toxiques de l'isoniazide)."@fr;
  r:conduiteATenir "Surveillance clinique et biologique de cette association classique. En cas d'hépatite, arrêter l'isoniazide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615166, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615160 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615161 .

_:807f36cf91fe4e8caa53aadeff92477615161 rdf:first _:807f36cf91fe4e8caa53aadeff92477615162;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615163 .

_:807f36cf91fe4e8caa53aadeff92477615162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477615163 rdf:first _:807f36cf91fe4e8caa53aadeff92477615164;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477615166 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11190-1 a owl:Class;
  rdfs:label "ISONIAZIDE <-> STAVUDINE"@fr;
  dct:identifier "IAM_11190";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615168;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615174, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615168 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615169 .

_:807f36cf91fe4e8caa53aadeff92477615169 rdf:first _:807f36cf91fe4e8caa53aadeff92477615170;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615171 .

_:807f36cf91fe4e8caa53aadeff92477615170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477615171 rdf:first _:807f36cf91fe4e8caa53aadeff92477615172;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:807f36cf91fe4e8caa53aadeff92477615174 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11182-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> TRAMADOL"@fr;
  dct:identifier "IAM_11182";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615176;
  r:natureDuRisque "Risque d'apparition de convulsions et/ou d'un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615182, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615176 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615177 .

_:807f36cf91fe4e8caa53aadeff92477615177 rdf:first _:807f36cf91fe4e8caa53aadeff92477615178;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615179 .

_:807f36cf91fe4e8caa53aadeff92477615178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477615179 rdf:first _:807f36cf91fe4e8caa53aadeff92477615180;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477615182 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11192-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_11192";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615184;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le torsadogène associé. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615190, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615184 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615185 .

_:807f36cf91fe4e8caa53aadeff92477615185 rdf:first _:807f36cf91fe4e8caa53aadeff92477615186;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615187 .

_:807f36cf91fe4e8caa53aadeff92477615186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477615187 rdf:first _:807f36cf91fe4e8caa53aadeff92477615188;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:807f36cf91fe4e8caa53aadeff92477615190 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11181-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> ORLISTAT"@fr;
  dct:identifier "IAM_11181";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615192;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615198, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615192 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615193 .

_:807f36cf91fe4e8caa53aadeff92477615193 rdf:first _:807f36cf91fe4e8caa53aadeff92477615194;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615195 .

_:807f36cf91fe4e8caa53aadeff92477615194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477615195 rdf:first _:807f36cf91fe4e8caa53aadeff92477615196;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477615198 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11191-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> LERCANIDIPINE"@fr;
  dct:identifier "IAM_11191";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615200;
  r:natureDuRisque "Risque majoré d'effets indesirables, notamment d'oedèmes, par diminution du métabolisme hépatique de la dihydropyridine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615206, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615200 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615201 .

_:807f36cf91fe4e8caa53aadeff92477615201 rdf:first _:807f36cf91fe4e8caa53aadeff92477615202;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615203 .

_:807f36cf91fe4e8caa53aadeff92477615202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477615203 rdf:first _:807f36cf91fe4e8caa53aadeff92477615204;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10514 .

_:807f36cf91fe4e8caa53aadeff92477615206 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11193-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11193";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615208;
  r:natureDuRisque "Risque de diminution importante des concentrations plasmatiques d’itraconazole, avec risque de perte d’efficacité, par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615214, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615208 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615209 .

_:807f36cf91fe4e8caa53aadeff92477615209 rdf:first _:807f36cf91fe4e8caa53aadeff92477615210;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615211 .

_:807f36cf91fe4e8caa53aadeff92477615210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477615211 rdf:first _:807f36cf91fe4e8caa53aadeff92477615212;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477615214 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11210-1 a owl:Class;
  rdfs:label "JOSAMYCINE <-> SILDENAFIL"@fr;
  dct:identifier "IAM_11210";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615216;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de sildénafil, avec risque d'hypotension."@fr;
  r:conduiteATenir "Débuter le traitement par sildénafil à la dose minimale en cas d'association avec la josamycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615222, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615216 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615217 .

_:807f36cf91fe4e8caa53aadeff92477615217 rdf:first _:807f36cf91fe4e8caa53aadeff92477615218;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615219 .

_:807f36cf91fe4e8caa53aadeff92477615218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477615219 rdf:first _:807f36cf91fe4e8caa53aadeff92477615220;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10834 .

_:807f36cf91fe4e8caa53aadeff92477615222 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11211-1 a owl:Class;
  rdfs:label "JOSAMYCINE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_11211";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615224;
  r:natureDuRisque "Augmentation des concentrations sanguines de tacrolimus et de la créatininémie, par inhibition du métabolisme hépatique du tacrolimus par la josamycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615230, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615224 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615225 .

_:807f36cf91fe4e8caa53aadeff92477615225 rdf:first _:807f36cf91fe4e8caa53aadeff92477615226;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615227 .

_:807f36cf91fe4e8caa53aadeff92477615226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477615227 rdf:first _:807f36cf91fe4e8caa53aadeff92477615228;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477615230 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11212-1 a owl:Class;
  rdfs:label "JOSAMYCINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11212";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615232;
  r:natureDuRisque "Risque d'augmentation de la théophyllinémie, particulièrement chez l'enfant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615238, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615232 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615233 .

_:807f36cf91fe4e8caa53aadeff92477615233 rdf:first _:807f36cf91fe4e8caa53aadeff92477615234;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615235 .

_:807f36cf91fe4e8caa53aadeff92477615234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477615235 rdf:first _:807f36cf91fe4e8caa53aadeff92477615236;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477615238 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11223-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11223";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615240;
  r:natureDuRisque "Majoration de la neurotoxicité de l'antimitotique, par diminution de son métabolisme hépatique par le kétoconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615246, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615240 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615241 .

_:807f36cf91fe4e8caa53aadeff92477615241 rdf:first _:807f36cf91fe4e8caa53aadeff92477615242;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615243 .

_:807f36cf91fe4e8caa53aadeff92477615242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477615243 rdf:first _:807f36cf91fe4e8caa53aadeff92477615244;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477615246 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11214-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_11214";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615248;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le torsadogène associé. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615254, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615248 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615249 .

_:807f36cf91fe4e8caa53aadeff92477615249 rdf:first _:807f36cf91fe4e8caa53aadeff92477615250;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615251 .

_:807f36cf91fe4e8caa53aadeff92477615250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477615251 rdf:first _:807f36cf91fe4e8caa53aadeff92477615252;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:807f36cf91fe4e8caa53aadeff92477615254 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11213-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> LERCANIDIPINE"@fr;
  dct:identifier "IAM_11213";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615256;
  r:natureDuRisque "Risque majoré d'effets indesirables, notamment d'oedèmes, par diminution du métabolisme hépatique de la dihydropyridine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615262, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615256 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615257 .

_:807f36cf91fe4e8caa53aadeff92477615257 rdf:first _:807f36cf91fe4e8caa53aadeff92477615258;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615259 .

_:807f36cf91fe4e8caa53aadeff92477615258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477615259 rdf:first _:807f36cf91fe4e8caa53aadeff92477615260;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10514 .

_:807f36cf91fe4e8caa53aadeff92477615262 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11215-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_11215";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615264;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615270, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615264 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615265 .

_:807f36cf91fe4e8caa53aadeff92477615265 rdf:first _:807f36cf91fe4e8caa53aadeff92477615266;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615267 .

_:807f36cf91fe4e8caa53aadeff92477615266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477615267 rdf:first _:807f36cf91fe4e8caa53aadeff92477615268;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:807f36cf91fe4e8caa53aadeff92477615270 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11216-1 a owl:Class;
  rdfs:label "KETOCONAZOLE <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_11216";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615272;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de névirapine par diminution de son métabolisme hépatique par le kétoconazole, d'une part, et diminution des concentrations plasmatiques du kétoconazole par augmentation de son métabolisme hépatique par la névi"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615278, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615272 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615273 .

_:807f36cf91fe4e8caa53aadeff92477615273 rdf:first _:807f36cf91fe4e8caa53aadeff92477615274;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615275 .

_:807f36cf91fe4e8caa53aadeff92477615274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477615275 rdf:first _:807f36cf91fe4e8caa53aadeff92477615276;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477615278 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11199-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11199";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615280;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de télaprévir et de l’itraconazole."@fr;
  r:conduiteATenir "Surveillance clinique. Eviter des doses élevées d’itraconazole (> 200 mg par jour)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615286, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615280 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615281 .

_:807f36cf91fe4e8caa53aadeff92477615281 rdf:first _:807f36cf91fe4e8caa53aadeff92477615282;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615283 .

_:807f36cf91fe4e8caa53aadeff92477615282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477615283 rdf:first _:807f36cf91fe4e8caa53aadeff92477615284;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477615286 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11170-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> SUBSTRATS À RISQUE DU CYP3A4"@fr;
  dct:identifier "IAM_11170";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615288;
  r:chapeau "Pour connaître les risques et les niveaux de contrainte de chacun de ces substrats avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux interactions spécifiques de chaque substrat."@fr;
  r:natureDuRisque "Majoration des effets indésirables propres à chaque substrat, avec conséquences souvent sévères."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615294, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615288 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615289 .

_:807f36cf91fe4e8caa53aadeff92477615289 rdf:first _:807f36cf91fe4e8caa53aadeff92477615290;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615291 .

_:807f36cf91fe4e8caa53aadeff92477615290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615291 rdf:first _:807f36cf91fe4e8caa53aadeff92477615292;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10145 .

_:807f36cf91fe4e8caa53aadeff92477615294 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11322-1 a owl:Class;
  rdfs:label "NEBIVOLOL <-> PAROXETINE"@fr;
  dct:identifier "IAM_11322";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615296;
  r:natureDuRisque "Risque de majoration des effets indésirables du nébivolol avec notamment bradycardie excessive, par inhibition de son métabolisme par l’antidépresseur."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie du nébivolol pendant la durée du traitement par l’antidépresseur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615296 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615297 .

_:807f36cf91fe4e8caa53aadeff92477615297 rdf:first _:807f36cf91fe4e8caa53aadeff92477615298;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615299 .

_:807f36cf91fe4e8caa53aadeff92477615298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10623 .

_:807f36cf91fe4e8caa53aadeff92477615299 rdf:first _:807f36cf91fe4e8caa53aadeff92477615300;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477615302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11160-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> OXYCODONE"@fr;
  dct:identifier "IAM_11160";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615304;
  r:natureDuRisque "Majoration des effets indésirables, notamment respiratoires, de l’oxycodone par diminution de son métabolisme par l'inhibiteur."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l’oxycodone pendant le traitement par l'inhibiteur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615305 .

_:807f36cf91fe4e8caa53aadeff92477615305 rdf:first _:807f36cf91fe4e8caa53aadeff92477615306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615307 .

_:807f36cf91fe4e8caa53aadeff92477615306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615307 rdf:first _:807f36cf91fe4e8caa53aadeff92477615308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10681 .

_:807f36cf91fe4e8caa53aadeff92477615310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11161-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> PANOBINOSTAT"@fr;
  dct:identifier "IAM_11161";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615312;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment cardiaques, du panobinostat par diminution de son métabolisme par l’inhibiteur."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. Débuter le traitement à dose réduite de moitié (10 mg)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615313 .

_:807f36cf91fe4e8caa53aadeff92477615313 rdf:first _:807f36cf91fe4e8caa53aadeff92477615314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615315 .

_:807f36cf91fe4e8caa53aadeff92477615314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615315 rdf:first _:807f36cf91fe4e8caa53aadeff92477615316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10688 .

_:807f36cf91fe4e8caa53aadeff92477615318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11162-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> PIMOZIDE"@fr;
  dct:identifier "IAM_11162";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615320;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615320 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615321 .

_:807f36cf91fe4e8caa53aadeff92477615321 rdf:first _:807f36cf91fe4e8caa53aadeff92477615322;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615323 .

_:807f36cf91fe4e8caa53aadeff92477615322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615323 rdf:first _:807f36cf91fe4e8caa53aadeff92477615324;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477615326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11163-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> QUETIAPINE"@fr;
  dct:identifier "IAM_11163";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615328;
  r:natureDuRisque "Augmentation importante des concentrations de quétiapine, avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615329 .

_:807f36cf91fe4e8caa53aadeff92477615329 rdf:first _:807f36cf91fe4e8caa53aadeff92477615330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615331 .

_:807f36cf91fe4e8caa53aadeff92477615330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615331 rdf:first _:807f36cf91fe4e8caa53aadeff92477615332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:807f36cf91fe4e8caa53aadeff92477615334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11164-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> QUININE"@fr;
  dct:identifier "IAM_11164";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615336;
  r:natureDuRisque "Risque de majoration des effets indésirables de la quinine, notamment troubles du rythme ventriculaire et troubles neurosensoriels (cinchonisme)."@fr;
  r:conduiteATenir """Association déconseillée : 
- avec les inhibiteurs de protéases

Précaution d’emploi : 
- avec les azolés antifongiques et certains macrolides.
Surveillance clinique et ECG. Adaptation éventuelle de la posologie de la quinine pendant le traitement par l’i"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615337 .

_:807f36cf91fe4e8caa53aadeff92477615337 rdf:first _:807f36cf91fe4e8caa53aadeff92477615338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615339 .

_:807f36cf91fe4e8caa53aadeff92477615338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615339 rdf:first _:807f36cf91fe4e8caa53aadeff92477615340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:807f36cf91fe4e8caa53aadeff92477615342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11165-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> RANOLAZINE"@fr;
  dct:identifier "IAM_11165";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615344;
  r:natureDuRisque "Augmentation des concentrations de ranolazine par diminution de son métabolisme par l'inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615345 .

_:807f36cf91fe4e8caa53aadeff92477615345 rdf:first _:807f36cf91fe4e8caa53aadeff92477615346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615347 .

_:807f36cf91fe4e8caa53aadeff92477615346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615347 rdf:first _:807f36cf91fe4e8caa53aadeff92477615348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:807f36cf91fe4e8caa53aadeff92477615350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11166-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> RÉGORAFÉNIB"@fr;
  dct:identifier "IAM_11166";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615352;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de régorafenib par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615353 .

_:807f36cf91fe4e8caa53aadeff92477615353 rdf:first _:807f36cf91fe4e8caa53aadeff92477615354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615355 .

_:807f36cf91fe4e8caa53aadeff92477615354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615355 rdf:first _:807f36cf91fe4e8caa53aadeff92477615356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10789 .

_:807f36cf91fe4e8caa53aadeff92477615358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11167-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> RIOCIGUAT"@fr;
  dct:identifier "IAM_11167";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615360;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de riociguat par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615361 .

_:807f36cf91fe4e8caa53aadeff92477615361 rdf:first _:807f36cf91fe4e8caa53aadeff92477615362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615363 .

_:807f36cf91fe4e8caa53aadeff92477615362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615363 rdf:first _:807f36cf91fe4e8caa53aadeff92477615364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10804 .

_:807f36cf91fe4e8caa53aadeff92477615366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11183-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> TRIPTANS"@fr;
  dct:identifier "IAM_11183";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615368;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615369 .

_:807f36cf91fe4e8caa53aadeff92477615369 rdf:first _:807f36cf91fe4e8caa53aadeff92477615370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615371 .

_:807f36cf91fe4e8caa53aadeff92477615370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477615371 rdf:first _:807f36cf91fe4e8caa53aadeff92477615372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10156 .

_:807f36cf91fe4e8caa53aadeff92477615374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11169-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> SIMÉPRÉVIR"@fr;
  dct:identifier "IAM_11169";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615376;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de siméprévir par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615377 .

_:807f36cf91fe4e8caa53aadeff92477615377 rdf:first _:807f36cf91fe4e8caa53aadeff92477615378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615379 .

_:807f36cf91fe4e8caa53aadeff92477615378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615379 rdf:first _:807f36cf91fe4e8caa53aadeff92477615380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10837 .

_:807f36cf91fe4e8caa53aadeff92477615382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11158-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> OLAPARIB"@fr;
  dct:identifier "IAM_11158";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615384;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par l’inhibiteur."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 150 mg deux fois par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615390, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615384 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615385 .

_:807f36cf91fe4e8caa53aadeff92477615385 rdf:first _:807f36cf91fe4e8caa53aadeff92477615386;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615387 .

_:807f36cf91fe4e8caa53aadeff92477615386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615387 rdf:first _:807f36cf91fe4e8caa53aadeff92477615388;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:807f36cf91fe4e8caa53aadeff92477615390 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11171-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> SUFENTANIL"@fr;
  dct:identifier "IAM_11171";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615392;
  r:natureDuRisque "Augmentation de l’effet dépresseur respiratoire de l’analgésique opiacé par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’analgésique opiacé en cas de traitement par un inhibiteur puissant du CYP3A4."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615398, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615392 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615393 .

_:807f36cf91fe4e8caa53aadeff92477615393 rdf:first _:807f36cf91fe4e8caa53aadeff92477615394;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615395 .

_:807f36cf91fe4e8caa53aadeff92477615394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615395 rdf:first _:807f36cf91fe4e8caa53aadeff92477615396;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10865 .

_:807f36cf91fe4e8caa53aadeff92477615398 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11172-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> TAMSULOSINE"@fr;
  dct:identifier "IAM_11172";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615400;
  r:natureDuRisque "Risque de majoration des effets indésirables de la tamsulosine, par inhibition de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615400 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615401 .

_:807f36cf91fe4e8caa53aadeff92477615401 rdf:first _:807f36cf91fe4e8caa53aadeff92477615402;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615403 .

_:807f36cf91fe4e8caa53aadeff92477615402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615403 rdf:first _:807f36cf91fe4e8caa53aadeff92477615404;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10883 .

_:807f36cf91fe4e8caa53aadeff92477615406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11173-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11173";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615408;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment à type de troubles du rythme cardiaque."@fr;
  r:conduiteATenir "chez le patient insuffisant rénal ou hépatique sévère."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615409 .

_:807f36cf91fe4e8caa53aadeff92477615409 rdf:first _:807f36cf91fe4e8caa53aadeff92477615410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615411 .

_:807f36cf91fe4e8caa53aadeff92477615410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615411 rdf:first _:807f36cf91fe4e8caa53aadeff92477615412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477615414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11174-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11174";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615416;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de ticagrelor par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615417 .

_:807f36cf91fe4e8caa53aadeff92477615417 rdf:first _:807f36cf91fe4e8caa53aadeff92477615418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615419 .

_:807f36cf91fe4e8caa53aadeff92477615418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615419 rdf:first _:807f36cf91fe4e8caa53aadeff92477615420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477615422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11175-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> TRASTUZUMAB EMTANSINE"@fr;
  dct:identifier "IAM_11175";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615424;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du DM1, un composant du trastuzumab emtansine, par inhibition de son métabolisme par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615425 .

_:807f36cf91fe4e8caa53aadeff92477615425 rdf:first _:807f36cf91fe4e8caa53aadeff92477615426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615427 .

_:807f36cf91fe4e8caa53aadeff92477615426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615427 rdf:first _:807f36cf91fe4e8caa53aadeff92477615428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10948 .

_:807f36cf91fe4e8caa53aadeff92477615430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11176-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11176";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615432;
  r:natureDuRisque "Bradycardie et/ou troubles de la conduction auriculo-ventriculaire, par diminution du métabolisme hépatique du vérapamil par l’inhibiteur."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. S’il y a lieu, adaptation de la posologie du vérapamil pendant le traitement par l’inhibiteur, et après son arrêt, le cas échéant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615433 .

_:807f36cf91fe4e8caa53aadeff92477615433 rdf:first _:807f36cf91fe4e8caa53aadeff92477615434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615435 .

_:807f36cf91fe4e8caa53aadeff92477615434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615435 rdf:first _:807f36cf91fe4e8caa53aadeff92477615436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477615438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11177-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> ZOLPIDEM"@fr;
  dct:identifier "IAM_11177";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615440;
  r:natureDuRisque "Légère augmentation de l'effet sédatif du zolpidem."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615441 .

_:807f36cf91fe4e8caa53aadeff92477615441 rdf:first _:807f36cf91fe4e8caa53aadeff92477615442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615443 .

_:807f36cf91fe4e8caa53aadeff92477615442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615443 rdf:first _:807f36cf91fe4e8caa53aadeff92477615444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11008 .

_:807f36cf91fe4e8caa53aadeff92477615446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11178-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> ZOPICLONE"@fr;
  dct:identifier "IAM_11178";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615448;
  r:natureDuRisque "Légère augmentation de l'effet sédatif de la zopiclone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615449 .

_:807f36cf91fe4e8caa53aadeff92477615449 rdf:first _:807f36cf91fe4e8caa53aadeff92477615450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615451 .

_:807f36cf91fe4e8caa53aadeff92477615450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615451 rdf:first _:807f36cf91fe4e8caa53aadeff92477615452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11010 .

_:807f36cf91fe4e8caa53aadeff92477615454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11179-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> LITHIUM"@fr;
  dct:identifier "IAM_11179";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615456;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615457 .

_:807f36cf91fe4e8caa53aadeff92477615457 rdf:first _:807f36cf91fe4e8caa53aadeff92477615458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615459 .

_:807f36cf91fe4e8caa53aadeff92477615458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477615459 rdf:first _:807f36cf91fe4e8caa53aadeff92477615460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477615462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11180-1 a owl:Class;
  rdfs:label "INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11180";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615464;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615465 .

_:807f36cf91fe4e8caa53aadeff92477615465 rdf:first _:807f36cf91fe4e8caa53aadeff92477615466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615467 .

_:807f36cf91fe4e8caa53aadeff92477615466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477615467 rdf:first _:807f36cf91fe4e8caa53aadeff92477615468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477615470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11168-1 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> RIVAROXABAN"@fr;
  dct:identifier "IAM_11168";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615472;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de rivaroxaban, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615473 .

_:807f36cf91fe4e8caa53aadeff92477615473 rdf:first _:807f36cf91fe4e8caa53aadeff92477615474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615475 .

_:807f36cf91fe4e8caa53aadeff92477615474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615475 rdf:first _:807f36cf91fe4e8caa53aadeff92477615476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10808 .

_:807f36cf91fe4e8caa53aadeff92477615478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11448-1 a owl:Class;
  rdfs:label "TÉNOFOVIR ALAFÉNAMIDE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11448";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615480;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration avec le vérapamil, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615481 .

_:807f36cf91fe4e8caa53aadeff92477615481 rdf:first _:807f36cf91fe4e8caa53aadeff92477615482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615483 .

_:807f36cf91fe4e8caa53aadeff92477615482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477615483 rdf:first _:807f36cf91fe4e8caa53aadeff92477615484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477615486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11439-1 a owl:Class;
  rdfs:label "SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> TORSADOGÈNES (SAUF ANTIPARASITAIRES, NEUROLEPTIQUES, MÉTHADONE)"@fr;
  dct:identifier "IAM_11439";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615488;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication:
- Pour l'érythromycine et la vincamine, seules les formes administrées par voie intraveineuse sont concernées par cette interaction.
- Pour la spiramycine, la voie IV et la voie orale sont concernées.

Association déconseillée:
- avec l"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615494, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615488 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615489 .

_:807f36cf91fe4e8caa53aadeff92477615489 rdf:first _:807f36cf91fe4e8caa53aadeff92477615490;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615491 .

_:807f36cf91fe4e8caa53aadeff92477615490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477615491 rdf:first _:807f36cf91fe4e8caa53aadeff92477615492;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10154 .

_:807f36cf91fe4e8caa53aadeff92477615494 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11440-1 a owl:Class;
  rdfs:label "SUCRALFATE <-> SULPIRIDE"@fr;
  dct:identifier "IAM_11440";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615496;
  r:natureDuRisque "Diminution de l'absorption digestive du sulpiride."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance du sulpiride (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615502, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615496 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615497 .

_:807f36cf91fe4e8caa53aadeff92477615497 rdf:first _:807f36cf91fe4e8caa53aadeff92477615498;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615499 .

_:807f36cf91fe4e8caa53aadeff92477615498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:807f36cf91fe4e8caa53aadeff92477615499 rdf:first _:807f36cf91fe4e8caa53aadeff92477615500;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10875 .

_:807f36cf91fe4e8caa53aadeff92477615502 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10081-1 a owl:Class;
  rdfs:label "ALCOOL (BOISSON OU EXCIPIENT) <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10081";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615504;
  r:natureDuRisque "Effet antabuse, notamment pour glibenclamide, glipizide, tolbutamide. Augmentation de la réaction hypoglycémique (inhibition des réactions de compensation) pouvant faciliter la survenue de coma hypoglycémique."@fr;
  r:conduiteATenir "Eviter la prise de boissons alcoolisées et de médicaments contenant de l'alcool."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615510, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615504 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615505 .

_:807f36cf91fe4e8caa53aadeff92477615505 rdf:first _:807f36cf91fe4e8caa53aadeff92477615506;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615507 .

_:807f36cf91fe4e8caa53aadeff92477615506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477615507 rdf:first _:807f36cf91fe4e8caa53aadeff92477615508;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11013 .

_:807f36cf91fe4e8caa53aadeff92477615510 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11441-1 a owl:Class;
  rdfs:label "SYMPATHOMIMÉTIQUES ALPHA (VOIES ORALE ET/OU NASALE) <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_11441";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615512;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615518, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615512 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615513 .

_:807f36cf91fe4e8caa53aadeff92477615513 rdf:first _:807f36cf91fe4e8caa53aadeff92477615514;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615515 .

_:807f36cf91fe4e8caa53aadeff92477615514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10148 .

_:807f36cf91fe4e8caa53aadeff92477615515 rdf:first _:807f36cf91fe4e8caa53aadeff92477615516;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477615518 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10427-1 a owl:Class;
  rdfs:label "AUTRES SYMPATHOMIMETIQUES INDIRECTS <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_10427";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615520;
  r:natureDuRisque "Risque de vasoconstriction et/ou de crises hypertensives."@fr;
  rdfs:comment """Les décisions suivantes, émanant de trois instances de l'Afssaps, ont été prises en compte : 
- la Commission Nationale de Pharmacovigilance a pris acte d'une toxicité de la phénylpropanolamine supérieure à celle des autres sympathomimétiques indirects ("""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615522, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615520 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477615522 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11442-1 a owl:Class;
  rdfs:label "TACROLIMUS <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11442";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615524;
  r:natureDuRisque "Augmentation des concentrations sanguines du tacrolimus (diminution de son métabolisme hépatique par le verapamil)."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l’immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615530, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615524 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615525 .

_:807f36cf91fe4e8caa53aadeff92477615525 rdf:first _:807f36cf91fe4e8caa53aadeff92477615526;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615527 .

_:807f36cf91fe4e8caa53aadeff92477615526 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477615527 rdf:first _:807f36cf91fe4e8caa53aadeff92477615528;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615528 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477615530 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11443-1 a owl:Class;
  rdfs:label "TAMOXIFENE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11443";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615532;
  r:natureDuRisque "Risque de baisse de l'efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la terbinafine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615538, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615532 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615533 .

_:807f36cf91fe4e8caa53aadeff92477615533 rdf:first _:807f36cf91fe4e8caa53aadeff92477615534;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615535 .

_:807f36cf91fe4e8caa53aadeff92477615534 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:807f36cf91fe4e8caa53aadeff92477615535 rdf:first _:807f36cf91fe4e8caa53aadeff92477615536;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615536 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477615538 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11444-1 a owl:Class;
  rdfs:label "TAMSULOSINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11444";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615540;
  r:natureDuRisque "Risque de majoration des effets indésirables de la tamsulosine, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la tamsulosine pensant le traitement par l’inhibiteur enzymatique et après son arrêt, le cas échéant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615546, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615540 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615541 .

_:807f36cf91fe4e8caa53aadeff92477615541 rdf:first _:807f36cf91fe4e8caa53aadeff92477615542;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615543 .

_:807f36cf91fe4e8caa53aadeff92477615542 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10883 .

_:807f36cf91fe4e8caa53aadeff92477615543 rdf:first _:807f36cf91fe4e8caa53aadeff92477615544;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615544 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477615546 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11445-1 a owl:Class;
  rdfs:label "TELAPREVIR <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11445";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615548;
  r:natureDuRisque "Risque de diminution de l'efficacité du ténofovir alafénamide par diminution de son activité intracellulaire par le télaprévir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615554, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615548 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615549 .

_:807f36cf91fe4e8caa53aadeff92477615549 rdf:first _:807f36cf91fe4e8caa53aadeff92477615550;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615551 .

_:807f36cf91fe4e8caa53aadeff92477615550 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477615551 rdf:first _:807f36cf91fe4e8caa53aadeff92477615552;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615552 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477615554 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11415-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TIAGABINE"@fr;
  dct:identifier "IAM_11415";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615556;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la tiagabine par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Une augmentation de la posologie de la tiagabine peut s’avérer nécessaire en cas d’association à la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615562, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615556 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615557 .

_:807f36cf91fe4e8caa53aadeff92477615557 rdf:first _:807f36cf91fe4e8caa53aadeff92477615558;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615559 .

_:807f36cf91fe4e8caa53aadeff92477615558 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477615559 rdf:first _:807f36cf91fe4e8caa53aadeff92477615560;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615560 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10922 .

_:807f36cf91fe4e8caa53aadeff92477615562 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11446-1 a owl:Class;
  rdfs:label "TELITHROMYCINE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11446";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615564;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615570, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615564 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615565 .

_:807f36cf91fe4e8caa53aadeff92477615565 rdf:first _:807f36cf91fe4e8caa53aadeff92477615566;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615567 .

_:807f36cf91fe4e8caa53aadeff92477615566 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477615567 rdf:first _:807f36cf91fe4e8caa53aadeff92477615568;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615568 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477615570 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11436-1 a owl:Class;
  rdfs:label "STIRIPENTOL <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11436";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615572;
  r:natureDuRisque "Augmentation possible de la théophyllinémie, avec risque de surdosage, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique, dosage plasmatique et adaptation éventuelle de la posologie de théophylline."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615578, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615572 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615573 .

_:807f36cf91fe4e8caa53aadeff92477615573 rdf:first _:807f36cf91fe4e8caa53aadeff92477615574;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615575 .

_:807f36cf91fe4e8caa53aadeff92477615574 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477615575 rdf:first _:807f36cf91fe4e8caa53aadeff92477615576;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615576 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477615578 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11449-1 a owl:Class;
  rdfs:label "TERBINAFINE <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_11449";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615580;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution importante de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par la terbinafine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615586, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615580 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615581 .

_:807f36cf91fe4e8caa53aadeff92477615581 rdf:first _:807f36cf91fe4e8caa53aadeff92477615582;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615583 .

_:807f36cf91fe4e8caa53aadeff92477615582 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477615583 rdf:first _:807f36cf91fe4e8caa53aadeff92477615584;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615584 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:807f36cf91fe4e8caa53aadeff92477615586 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11450-1 a owl:Class;
  rdfs:label "TÉRIFLUNOMIDE <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11450";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615588;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615594, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615588 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615589 .

_:807f36cf91fe4e8caa53aadeff92477615589 rdf:first _:807f36cf91fe4e8caa53aadeff92477615590;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615591 .

_:807f36cf91fe4e8caa53aadeff92477615590 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477615591 rdf:first _:807f36cf91fe4e8caa53aadeff92477615592;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615592 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10902 .

_:807f36cf91fe4e8caa53aadeff92477615594 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11451-1 a owl:Class;
  rdfs:label "THALIDOMIDE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_11451";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615596;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615602, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615596 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615597 .

_:807f36cf91fe4e8caa53aadeff92477615597 rdf:first _:807f36cf91fe4e8caa53aadeff92477615598;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615599 .

_:807f36cf91fe4e8caa53aadeff92477615598 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10913 .

_:807f36cf91fe4e8caa53aadeff92477615599 rdf:first _:807f36cf91fe4e8caa53aadeff92477615600;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615600 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:807f36cf91fe4e8caa53aadeff92477615602 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11454-1 a owl:Class;
  rdfs:label "THEOPHYLLINE <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_11454";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615604;
  r:natureDuRisque "Augmentation importante des concentrations de théophylline, avec risques de majoration de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la théophylline pendant le traitement par vémurafénib et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615610, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615604 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615605 .

_:807f36cf91fe4e8caa53aadeff92477615605 rdf:first _:807f36cf91fe4e8caa53aadeff92477615606;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615607 .

_:807f36cf91fe4e8caa53aadeff92477615606 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10915 .

_:807f36cf91fe4e8caa53aadeff92477615607 rdf:first _:807f36cf91fe4e8caa53aadeff92477615608;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615608 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:807f36cf91fe4e8caa53aadeff92477615610 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11452-1 a owl:Class;
  rdfs:label "THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE) <-> TIABENDAZOLE"@fr;
  dct:identifier "IAM_11452";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615612;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage, par diminution du métabolisme hépatique de la théophylline."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement (et après son arrêt, dans le cas où l'anthelminthique est prescrit pour une durée excédant 48 heures)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615618, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615612 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615613 .

_:807f36cf91fe4e8caa53aadeff92477615613 rdf:first _:807f36cf91fe4e8caa53aadeff92477615614;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615615 .

_:807f36cf91fe4e8caa53aadeff92477615614 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477615615 rdf:first _:807f36cf91fe4e8caa53aadeff92477615616;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10921 .

_:807f36cf91fe4e8caa53aadeff92477615618 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11453-1 a owl:Class;
  rdfs:label "THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE) <-> TICLOPIDINE"@fr;
  dct:identifier "IAM_11453";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615620;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution de la clairance plasmatique de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par la ticlopidine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615626, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615620 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615621 .

_:807f36cf91fe4e8caa53aadeff92477615621 rdf:first _:807f36cf91fe4e8caa53aadeff92477615622;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615623 .

_:807f36cf91fe4e8caa53aadeff92477615622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477615623 rdf:first _:807f36cf91fe4e8caa53aadeff92477615624;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10928 .

_:807f36cf91fe4e8caa53aadeff92477615626 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11455-1 a owl:Class;
  rdfs:label "TICAGRELOR <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11455";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615628;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de ticagrelor par diminution de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615634, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615628 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615629 .

_:807f36cf91fe4e8caa53aadeff92477615629 rdf:first _:807f36cf91fe4e8caa53aadeff92477615630;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615631 .

_:807f36cf91fe4e8caa53aadeff92477615630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477615631 rdf:first _:807f36cf91fe4e8caa53aadeff92477615632;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477615634 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11257-1 a owl:Class;
  rdfs:label "MÉDICAMENTS ADMINISTRÉS PAR VOIE ORALE <-> TOPIQUES GASTRO-INTESTINAUX, ANTIACIDES ET ADSORBANTS"@fr;
  dct:identifier "IAM_11257";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615636;
  r:natureDuRisque "Diminution de l'absorption de certains autres médicaments ingérés simultanément."@fr;
  r:conduiteATenir "Par mesure de précaution, il convient de prendre ces topiques ou antiacides à distance de tout autre médicament (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615642, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615636 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615637 .

_:807f36cf91fe4e8caa53aadeff92477615637 rdf:first _:807f36cf91fe4e8caa53aadeff92477615638;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615639 .

_:807f36cf91fe4e8caa53aadeff92477615638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10153 .

_:807f36cf91fe4e8caa53aadeff92477615639 rdf:first _:807f36cf91fe4e8caa53aadeff92477615640;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10166 .

_:807f36cf91fe4e8caa53aadeff92477615642 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11456-1 a owl:Class;
  rdfs:label "TOPIRAMATE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11456";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615644;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615650, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615644 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615645 .

_:807f36cf91fe4e8caa53aadeff92477615645 rdf:first _:807f36cf91fe4e8caa53aadeff92477615646;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615647 .

_:807f36cf91fe4e8caa53aadeff92477615646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477615647 rdf:first _:807f36cf91fe4e8caa53aadeff92477615648;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:807f36cf91fe4e8caa53aadeff92477615650 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11447-1 a owl:Class;
  rdfs:label "TELITHROMYCINE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11447";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615652;
  r:natureDuRisque "Risque de majoration de la toxicité de l'antimitotique par diminution de son métabolisme hépatique par la télithromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique étroite. Eventuellement, utiliser un autre antibiotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615658, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615652 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615653 .

_:807f36cf91fe4e8caa53aadeff92477615653 rdf:first _:807f36cf91fe4e8caa53aadeff92477615654;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615655 .

_:807f36cf91fe4e8caa53aadeff92477615654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477615655 rdf:first _:807f36cf91fe4e8caa53aadeff92477615656;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477615658 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11427-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11427";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615660;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615666, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615660 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615661 .

_:807f36cf91fe4e8caa53aadeff92477615661 rdf:first _:807f36cf91fe4e8caa53aadeff92477615662;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615663 .

_:807f36cf91fe4e8caa53aadeff92477615662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477615663 rdf:first _:807f36cf91fe4e8caa53aadeff92477615664;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477615666 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11320-1 a owl:Class;
  rdfs:label "MYCOPHENOLATE MOFETIL <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11320";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615668;
  r:natureDuRisque "Risque de maladie vaccinale généralisée éventuellement mortelle."@fr;
  r:conduiteATenir "Et pendant les 3 mois suivant l'arrêt du traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615674, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615668 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615669 .

_:807f36cf91fe4e8caa53aadeff92477615669 rdf:first _:807f36cf91fe4e8caa53aadeff92477615670;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615671 .

_:807f36cf91fe4e8caa53aadeff92477615670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477615671 rdf:first _:807f36cf91fe4e8caa53aadeff92477615672;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10609 .

_:807f36cf91fe4e8caa53aadeff92477615674 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11417-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11417";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615676;
  r:natureDuRisque "Risque de diminution de l’effet de l’ulipristal, par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  r:conduiteATenir "Préférer une alternative thérapeutique peu ou pas métabolisée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615682, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615676 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615677 .

_:807f36cf91fe4e8caa53aadeff92477615677 rdf:first _:807f36cf91fe4e8caa53aadeff92477615678;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615679 .

_:807f36cf91fe4e8caa53aadeff92477615678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477615679 rdf:first _:807f36cf91fe4e8caa53aadeff92477615680;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477615682 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11418-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11418";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615684;
  r:natureDuRisque "Risque de survenue de crises convulsives, par augmentation du métabolisme hépatique du valproate par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique, et adaptation éventuelle de la posologie de l'anticonvulsivant pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615690, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615684 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615685 .

_:807f36cf91fe4e8caa53aadeff92477615685 rdf:first _:807f36cf91fe4e8caa53aadeff92477615686;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615687 .

_:807f36cf91fe4e8caa53aadeff92477615686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477615687 rdf:first _:807f36cf91fe4e8caa53aadeff92477615688;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477615690 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11419-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> VITAMINE D"@fr;
  dct:identifier "IAM_11419";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615692;
  r:natureDuRisque "Diminution des concentrations de vitamine D plus marquée qu’en l’absence de traitement par la rifampicine"@fr;
  r:conduiteATenir "Dosage des concentrations de vitamine D et supplémentation si nécessaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615698, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615692 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615693 .

_:807f36cf91fe4e8caa53aadeff92477615693 rdf:first _:807f36cf91fe4e8caa53aadeff92477615694;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615695 .

_:807f36cf91fe4e8caa53aadeff92477615694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10162 .

_:807f36cf91fe4e8caa53aadeff92477615695 rdf:first _:807f36cf91fe4e8caa53aadeff92477615696;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477615698 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11420-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11420";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615700;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques du voriconazole avec risque de perte d'efficacité, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615706, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615700 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615701 .

_:807f36cf91fe4e8caa53aadeff92477615701 rdf:first _:807f36cf91fe4e8caa53aadeff92477615702;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615703 .

_:807f36cf91fe4e8caa53aadeff92477615702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477615703 rdf:first _:807f36cf91fe4e8caa53aadeff92477615704;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477615706 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11421-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> ZOLPIDEM"@fr;
  dct:identifier "IAM_11421";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615708;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du zolpidem par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique. Utiliser éventuellement un autre hypnotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615714, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615708 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615709 .

_:807f36cf91fe4e8caa53aadeff92477615709 rdf:first _:807f36cf91fe4e8caa53aadeff92477615710;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615711 .

_:807f36cf91fe4e8caa53aadeff92477615710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477615711 rdf:first _:807f36cf91fe4e8caa53aadeff92477615712;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11008 .

_:807f36cf91fe4e8caa53aadeff92477615714 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11422-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> ZOPICLONE"@fr;
  dct:identifier "IAM_11422";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615716;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la zopiclone par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique. Utiliser éventuellement un autre hypnotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615722, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615716 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615717 .

_:807f36cf91fe4e8caa53aadeff92477615717 rdf:first _:807f36cf91fe4e8caa53aadeff92477615718;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615719 .

_:807f36cf91fe4e8caa53aadeff92477615718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477615719 rdf:first _:807f36cf91fe4e8caa53aadeff92477615720;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11010 .

_:807f36cf91fe4e8caa53aadeff92477615722 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11423-1 a owl:Class;
  rdfs:label "ROXITHROMYCINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11423";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615724;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse."@fr;
  r:conduiteATenir "Utiliser des doses plus faibles d’hypocholestérolémiant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615730, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615724 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615725 .

_:807f36cf91fe4e8caa53aadeff92477615725 rdf:first _:807f36cf91fe4e8caa53aadeff92477615726;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615727 .

_:807f36cf91fe4e8caa53aadeff92477615726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:807f36cf91fe4e8caa53aadeff92477615727 rdf:first _:807f36cf91fe4e8caa53aadeff92477615728;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477615730 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11424-1 a owl:Class;
  rdfs:label "ROXITHROMYCINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11424";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615732;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes."""@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615738, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615732 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615733 .

_:807f36cf91fe4e8caa53aadeff92477615733 rdf:first _:807f36cf91fe4e8caa53aadeff92477615734;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615735 .

_:807f36cf91fe4e8caa53aadeff92477615734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477615735 rdf:first _:807f36cf91fe4e8caa53aadeff92477615736;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:807f36cf91fe4e8caa53aadeff92477615738 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11438-1 a owl:Class;
  rdfs:label "SUBSTANCES À ABSORPTION RÉDUITE PAR LES TOPIQUES GASTRO-INTESTINAUX, ANTIACIDES ET ADSORBANTS <-> TOPIQUES GASTRO-INTESTINAUX, ANTIACIDES ET ADSORBANTS"@fr;
  dct:identifier "IAM_11438";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615740;
  r:natureDuRisque "Diminution de l'absorption de ces substances."@fr;
  r:conduiteATenir "Prendre les topiques ou antiacides, adsorbants à distance de ces substances (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615746, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615740 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615741 .

_:807f36cf91fe4e8caa53aadeff92477615741 rdf:first _:807f36cf91fe4e8caa53aadeff92477615742;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615743 .

_:807f36cf91fe4e8caa53aadeff92477615742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10144 .

_:807f36cf91fe4e8caa53aadeff92477615743 rdf:first _:807f36cf91fe4e8caa53aadeff92477615744;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10153 .

_:807f36cf91fe4e8caa53aadeff92477615746 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11426-1 a owl:Class;
  rdfs:label "RUFINAMIDE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11426";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615748;
  r:natureDuRisque "Possible augmentation des concentrations de rufinamide, notamment chez l’enfant de moins de 30 kg."@fr;
  r:conduiteATenir """Chez l’enfant de moins de 30 kg :
ne pas dépasser la dose totale de 600 mg/j après la période de titration."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615754, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615748 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615749 .

_:807f36cf91fe4e8caa53aadeff92477615749 rdf:first _:807f36cf91fe4e8caa53aadeff92477615750;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615751 .

_:807f36cf91fe4e8caa53aadeff92477615750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477615751 rdf:first _:807f36cf91fe4e8caa53aadeff92477615752;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10818 .

_:807f36cf91fe4e8caa53aadeff92477615754 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11437-1 a owl:Class;
  rdfs:label "STRONTIUM <-> ZINC"@fr;
  dct:identifier "IAM_11437";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615756;
  r:natureDuRisque "Diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des sels de zinc (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615756 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615757 .

_:807f36cf91fe4e8caa53aadeff92477615757 rdf:first _:807f36cf91fe4e8caa53aadeff92477615758;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615759 .

_:807f36cf91fe4e8caa53aadeff92477615758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:807f36cf91fe4e8caa53aadeff92477615759 rdf:first _:807f36cf91fe4e8caa53aadeff92477615760;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:807f36cf91fe4e8caa53aadeff92477615762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11428-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11428";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615764;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615765 .

_:807f36cf91fe4e8caa53aadeff92477615765 rdf:first _:807f36cf91fe4e8caa53aadeff92477615766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615767 .

_:807f36cf91fe4e8caa53aadeff92477615766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477615767 rdf:first _:807f36cf91fe4e8caa53aadeff92477615768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477615770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11429-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11429";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615772;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  rdfs:comment """La télithromycine est un inhibiteur du CYP3A4. Par conséquent, son administration peut inhiber le métabolisme des médicaments qui sont métabolisés par ce cytochrome, dont la simvastatine. 
L’association de la télithromycine avec la simvastatine augmente d"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615773 .

_:807f36cf91fe4e8caa53aadeff92477615773 rdf:first _:807f36cf91fe4e8caa53aadeff92477615774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615775 .

_:807f36cf91fe4e8caa53aadeff92477615774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477615775 rdf:first _:807f36cf91fe4e8caa53aadeff92477615776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477615778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11430-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11430";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615780;
  r:natureDuRisque "Risque majoré d’effets indésirables (dose-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’hypocholestérolémiant)."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/j de simvastatine ou utiliser une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615781 .

_:807f36cf91fe4e8caa53aadeff92477615781 rdf:first _:807f36cf91fe4e8caa53aadeff92477615782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615783 .

_:807f36cf91fe4e8caa53aadeff92477615782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477615783 rdf:first _:807f36cf91fe4e8caa53aadeff92477615784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477615786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11431-1 a owl:Class;
  rdfs:label "SIMVASTATINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11431";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615788;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par diminution du métabolisme hépatique de la simvastatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615789 .

_:807f36cf91fe4e8caa53aadeff92477615789 rdf:first _:807f36cf91fe4e8caa53aadeff92477615790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615791 .

_:807f36cf91fe4e8caa53aadeff92477615790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477615791 rdf:first _:807f36cf91fe4e8caa53aadeff92477615792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477615794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11432-1 a owl:Class;
  rdfs:label "SIROLIMUS <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11432";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615796;
  r:natureDuRisque "Augmentation des concentrations sanguines du sirolimus (diminution de son métabolisme hépatique par le vérapamil)."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l’immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615797 .

_:807f36cf91fe4e8caa53aadeff92477615797 rdf:first _:807f36cf91fe4e8caa53aadeff92477615798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615799 .

_:807f36cf91fe4e8caa53aadeff92477615798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10839 .

_:807f36cf91fe4e8caa53aadeff92477615799 rdf:first _:807f36cf91fe4e8caa53aadeff92477615800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477615802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11260-1 a owl:Class;
  rdfs:label "MÉDICAMENTS UTILISÉS PAR VOIE VAGINALE <-> SPERMICIDES"@fr;
  dct:identifier "IAM_11260";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615804;
  r:natureDuRisque "Tout traitement local vaginal est susceptible d'inactiver une contraception locale spermicide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615805 .

_:807f36cf91fe4e8caa53aadeff92477615805 rdf:first _:807f36cf91fe4e8caa53aadeff92477615806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615807 .

_:807f36cf91fe4e8caa53aadeff92477615806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10142 .

_:807f36cf91fe4e8caa53aadeff92477615807 rdf:first _:807f36cf91fe4e8caa53aadeff92477615808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10165 .

_:807f36cf91fe4e8caa53aadeff92477615810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11434-1 a owl:Class;
  rdfs:label "STAVUDINE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_11434";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615812;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral, par antagonisme compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615813 .

_:807f36cf91fe4e8caa53aadeff92477615813 rdf:first _:807f36cf91fe4e8caa53aadeff92477615814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615815 .

_:807f36cf91fe4e8caa53aadeff92477615814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:807f36cf91fe4e8caa53aadeff92477615815 rdf:first _:807f36cf91fe4e8caa53aadeff92477615816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:807f36cf91fe4e8caa53aadeff92477615818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11433-1 a owl:Class;
  rdfs:label "STAVUDINE <-> THALIDOMIDE"@fr;
  dct:identifier "IAM_11433";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615820;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615821 .

_:807f36cf91fe4e8caa53aadeff92477615821 rdf:first _:807f36cf91fe4e8caa53aadeff92477615822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615823 .

_:807f36cf91fe4e8caa53aadeff92477615822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:807f36cf91fe4e8caa53aadeff92477615823 rdf:first _:807f36cf91fe4e8caa53aadeff92477615824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10913 .

_:807f36cf91fe4e8caa53aadeff92477615826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11435-1 a owl:Class;
  rdfs:label "STAVUDINE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_11435";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615828;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral par antagoniste compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615829 .

_:807f36cf91fe4e8caa53aadeff92477615829 rdf:first _:807f36cf91fe4e8caa53aadeff92477615830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615831 .

_:807f36cf91fe4e8caa53aadeff92477615830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:807f36cf91fe4e8caa53aadeff92477615831 rdf:first _:807f36cf91fe4e8caa53aadeff92477615832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:807f36cf91fe4e8caa53aadeff92477615834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11459-1 a owl:Class;
  rdfs:label "VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE <-> ZONISAMIDE"@fr;
  dct:identifier "IAM_11459";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615836;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615837 .

_:807f36cf91fe4e8caa53aadeff92477615837 rdf:first _:807f36cf91fe4e8caa53aadeff92477615838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615839 .

_:807f36cf91fe4e8caa53aadeff92477615838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477615839 rdf:first _:807f36cf91fe4e8caa53aadeff92477615840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11009 .

_:807f36cf91fe4e8caa53aadeff92477615842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11425-1 a owl:Class;
  rdfs:label "ROXITHROMYCINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11425";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615844;
  r:natureDuRisque "Risque d'augmentation de la théophyllinémie, particulièrement chez l'enfant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615845 .

_:807f36cf91fe4e8caa53aadeff92477615845 rdf:first _:807f36cf91fe4e8caa53aadeff92477615846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615847 .

_:807f36cf91fe4e8caa53aadeff92477615846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477615847 rdf:first _:807f36cf91fe4e8caa53aadeff92477615848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10817 .

_:807f36cf91fe4e8caa53aadeff92477615850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10104-2 a owl:Class;
  rdfs:label "ALPHABLOQUANTS À VISÉE UROLOGIQUE <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10104";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615852;
  r:natureDuRisque "Risque d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir """Association déconseillée :
- avec la doxazosine

Précaution d'emploi :
- avec les autres alpha-bloquants
Débuter le traitement aux posologies minimales recommandées et adapter progressivement les doses si besoin."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615858, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615852 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615853 .

_:807f36cf91fe4e8caa53aadeff92477615853 rdf:first _:807f36cf91fe4e8caa53aadeff92477615854;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615855 .

_:807f36cf91fe4e8caa53aadeff92477615854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10009 .

_:807f36cf91fe4e8caa53aadeff92477615855 rdf:first _:807f36cf91fe4e8caa53aadeff92477615856;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477615858 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11457-1 a owl:Class;
  rdfs:label "TRAMADOL <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11457";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615860;
  r:natureDuRisque "Risque d'apparition de convulsions et/ou d'un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615860 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615861 .

_:807f36cf91fe4e8caa53aadeff92477615861 rdf:first _:807f36cf91fe4e8caa53aadeff92477615862;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615863 .

_:807f36cf91fe4e8caa53aadeff92477615862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477615863 rdf:first _:807f36cf91fe4e8caa53aadeff92477615864;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477615866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10092-2 a owl:Class;
  rdfs:label "ALISKIREN <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10092";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615868;
  r:natureDuRisque "Risque d’hyperkaliémie, d’insuffisance rénale, d’augmentation de la morbi-mortalité cardio-vasculaire."@fr;
  r:conduiteATenir """Contre-indication :
- chez le patient diabétique ou insuffisant rénal

Association déconseillée :
- dans les autres cas"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615869 .

_:807f36cf91fe4e8caa53aadeff92477615869 rdf:first _:807f36cf91fe4e8caa53aadeff92477615870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615871 .

_:807f36cf91fe4e8caa53aadeff92477615870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477615871 rdf:first _:807f36cf91fe4e8caa53aadeff92477615872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477615874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10680-2 a owl:Class;
  rdfs:label "COLCHICINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10680";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615876;
  r:natureDuRisque "Augmentation des effets indésirables de la colchicine, aux conséquences potentiellement fatales."@fr;
  r:conduiteATenir """Contre-indication :
- avec les macrolides

Association déconseillée :
- avec les antifongiques azolés, les inhibiteurs de protéases boostés par ritonavir et le cobicistat"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615877 .

_:807f36cf91fe4e8caa53aadeff92477615877 rdf:first _:807f36cf91fe4e8caa53aadeff92477615878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615879 .

_:807f36cf91fe4e8caa53aadeff92477615878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615879 rdf:first _:807f36cf91fe4e8caa53aadeff92477615880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10225 .

_:807f36cf91fe4e8caa53aadeff92477615882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11324-2 a owl:Class;
  rdfs:label "NEUROLEPTIQUES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11324";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615884;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615885 .

_:807f36cf91fe4e8caa53aadeff92477615885 rdf:first _:807f36cf91fe4e8caa53aadeff92477615886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615887 .

_:807f36cf91fe4e8caa53aadeff92477615886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10127 .

_:807f36cf91fe4e8caa53aadeff92477615887 rdf:first _:807f36cf91fe4e8caa53aadeff92477615888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477615890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10283-2 a owl:Class;
  rdfs:label "ANTIPARASITAIRES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_10283";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615892;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication:
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine
et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes.
Si cela est possible, interrompre l'un des d"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615898, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615892 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615893 .

_:807f36cf91fe4e8caa53aadeff92477615893 rdf:first _:807f36cf91fe4e8caa53aadeff92477615894;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615895 .

_:807f36cf91fe4e8caa53aadeff92477615894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10036 .

_:807f36cf91fe4e8caa53aadeff92477615895 rdf:first _:807f36cf91fe4e8caa53aadeff92477615896;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477615898 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10113-2 a owl:Class;
  rdfs:label "AMINOSIDES <-> AUTRES AMINOSIDES"@fr;
  dct:identifier "IAM_10113";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615900;
  r:natureDuRisque "Risque accru de néphrotoxicité et d'ototoxicité (l'ototoxicité est cumulative en cas d'administrations successives)."@fr;
  r:conduiteATenir """Contre-indication :
- en cas d'administration simultanée"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615902, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10011 .

_:807f36cf91fe4e8caa53aadeff92477615902 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10182-2 a owl:Class;
  rdfs:label "ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10182";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615904;
  r:natureDuRisque "Risque d'hyperkaliémie (potentiellement létale) surtout en cas d'insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir """Association déconseillée :
- si l'association est justifiée, contrôle strict de la kaliémie et de la fonctioénale"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615910, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615904 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615905 .

_:807f36cf91fe4e8caa53aadeff92477615905 rdf:first _:807f36cf91fe4e8caa53aadeff92477615906;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615907 .

_:807f36cf91fe4e8caa53aadeff92477615906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477615907 rdf:first _:807f36cf91fe4e8caa53aadeff92477615908;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477615910 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11085-2 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11085";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615912;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique par le voriconazole."@fr;
  r:conduiteATenir """Association déconseillée
- avec l'évérolimus, le sirolimus, et le temsirolimus.

Précaution d'emploi
- avec la ciclosporine et le tacrolimus :
dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la p"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615918, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615912 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615913 .

_:807f36cf91fe4e8caa53aadeff92477615913 rdf:first _:807f36cf91fe4e8caa53aadeff92477615914;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615915 .

_:807f36cf91fe4e8caa53aadeff92477615914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477615915 rdf:first _:807f36cf91fe4e8caa53aadeff92477615916;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477615918 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10826-2 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10826";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615920;
  r:natureDuRisque "Risque d'hyperkaliémie (potentiellement létale) surtout en cas d'insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir """Association déconseillée :
- si l'association est justifiée, contrôle strict de la kaliémie et de la fonction rénale"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615926, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615920 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615921 .

_:807f36cf91fe4e8caa53aadeff92477615921 rdf:first _:807f36cf91fe4e8caa53aadeff92477615922;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615923 .

_:807f36cf91fe4e8caa53aadeff92477615922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477615923 rdf:first _:807f36cf91fe4e8caa53aadeff92477615924;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477615926 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11106-2 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> SOFOSBUVIR"@fr;
  dct:identifier "IAM_11106";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615928;
  r:natureDuRisque """Risque de diminution des concentrations plasmatiques de 
sofosbuvir par diminution de son absorption intestinale par
l’inducteur."""@fr;
  r:conduiteATenir """Contre-indication :
- avec la rifampicine
- avec les anticonvulsivants inducteurs enzymatiques

Association déconseillée:
- avec les autres inducteurs."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615934, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615928 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615929 .

_:807f36cf91fe4e8caa53aadeff92477615929 rdf:first _:807f36cf91fe4e8caa53aadeff92477615930;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615931 .

_:807f36cf91fe4e8caa53aadeff92477615930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477615931 rdf:first _:807f36cf91fe4e8caa53aadeff92477615932;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10850 .

_:807f36cf91fe4e8caa53aadeff92477615934 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10278-2 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10278";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615936;
  r:natureDuRisque "Augmentation de la toxicité hématologique du méthotrexate (diminution de la clairance rénale du méthotrexate par les anti-inflammatoires)."@fr;
  r:conduiteATenir """Association déconseillée:
- pour des doses de méthotrexate supérieures à 20 mg par semaine.
- avec le kétoprofène et le méthotrexate à des doses supérieures à 20 mg par semaines, respecter un intervalle d'au moins 12 heures entre l'arrêt ou le début d'un"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615942, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615936 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615937 .

_:807f36cf91fe4e8caa53aadeff92477615937 rdf:first _:807f36cf91fe4e8caa53aadeff92477615938;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615939 .

_:807f36cf91fe4e8caa53aadeff92477615938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477615939 rdf:first _:807f36cf91fe4e8caa53aadeff92477615940;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477615942 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10251-2 a owl:Class;
  rdfs:label "ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10251";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615944;
  r:natureDuRisque """- pour carbamazépine, phénobarbital, primidone : Risque de baisse de l'efficacité du voriconazole par augmentation de son métabolisme hépatique par l'inducteur.

- pour phénytoïne, fosphénytoïne : 
Diminution importante des concentrations plasmatiques du"""@fr;
  r:conduiteATenir """Contre-indication :
- pour carbamazépine, phénobarbital, primidone

Association déconseillée :
- pour phénytoïne, fosphénytoïne
Si l'association ne peut être évitée, surveillance clinique étroite, dosage des concentrations plasmatiques de phénytoïne et ad"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615950, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615944 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615945 .

_:807f36cf91fe4e8caa53aadeff92477615945 rdf:first _:807f36cf91fe4e8caa53aadeff92477615946;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615947 .

_:807f36cf91fe4e8caa53aadeff92477615946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477615947 rdf:first _:807f36cf91fe4e8caa53aadeff92477615948;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477615950 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11127-2 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_11127";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615952;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de diminution des concentrations et de l’efficacité de la lamotrigine par augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir """Association déconseillée 
- Eviter de mettre en route le traitement par ritonavir pendant la période d’ajustement posologique de la lamotrigine.

Précaution d'emploi
- Surveillance clinique et adaptation de la posologie de la lamotrigine lors de la mise e"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615958, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615952 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615953 .

_:807f36cf91fe4e8caa53aadeff92477615953 rdf:first _:807f36cf91fe4e8caa53aadeff92477615954;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615955 .

_:807f36cf91fe4e8caa53aadeff92477615954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477615955 rdf:first _:807f36cf91fe4e8caa53aadeff92477615956;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:807f36cf91fe4e8caa53aadeff92477615958 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11146-2 a owl:Class;
  rdfs:label "INHIBITEURS DES TYROSINE KINASES MÉTABOLISÉS <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11146";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615960;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque """Risque de majoration des effets indésirables de l’inhibiteur de
tyrosine kinase par diminution de son métabolisme."""@fr;
  r:conduiteATenir """Association déconseillée :
- avec l'axitinib, le bosutinib, le céritinib, le cobimétinib, le dabrafenib, le dasatinib, le nilotinib, le sunitinib
- avec l'ibrutinib, si l’association ne peut être évitée ,surveillance clinique étroite et réduction de la do"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615966, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615960 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615961 .

_:807f36cf91fe4e8caa53aadeff92477615961 rdf:first _:807f36cf91fe4e8caa53aadeff92477615962;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615963 .

_:807f36cf91fe4e8caa53aadeff92477615962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10101 .

_:807f36cf91fe4e8caa53aadeff92477615963 rdf:first _:807f36cf91fe4e8caa53aadeff92477615964;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477615966 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10903-2 a owl:Class;
  rdfs:label "ESMOLOL <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10903";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615968;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir """Association déconseillée :
- en cas d'altération de la fonction ventriculaire gauche."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615974, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615968 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615969 .

_:807f36cf91fe4e8caa53aadeff92477615969 rdf:first _:807f36cf91fe4e8caa53aadeff92477615970;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615971 .

_:807f36cf91fe4e8caa53aadeff92477615970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:807f36cf91fe4e8caa53aadeff92477615971 rdf:first _:807f36cf91fe4e8caa53aadeff92477615972;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477615974 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10180-2 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10180";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615976;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Association déconseillée avec la nimodipine"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615982, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615976 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615977 .

_:807f36cf91fe4e8caa53aadeff92477615977 rdf:first _:807f36cf91fe4e8caa53aadeff92477615978;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615979 .

_:807f36cf91fe4e8caa53aadeff92477615978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:807f36cf91fe4e8caa53aadeff92477615979 rdf:first _:807f36cf91fe4e8caa53aadeff92477615980;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477615982 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10697-2 a owl:Class;
  rdfs:label "CYPROTERONE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10697";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615984;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Association déconseillée:
- dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant.

Précaution d'emploi
- dans se"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615990, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615984 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615985 .

_:807f36cf91fe4e8caa53aadeff92477615985 rdf:first _:807f36cf91fe4e8caa53aadeff92477615986;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615987 .

_:807f36cf91fe4e8caa53aadeff92477615986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477615987 rdf:first _:807f36cf91fe4e8caa53aadeff92477615988;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615988 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff92477615990 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10261-2 a owl:Class;
  rdfs:label "ANTIHYPERTENSEURS ALPHA-BLOQUANTS <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10261";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477615992;
  r:natureDuRisque "Risque d’hypotension orthostatique, notamment chez le sujet âgé."@fr;
  r:conduiteATenir """Association déconseillée :
- avec la doxazosine 

Précaution d'emploi :
- avec les autres alpha-bloquants
Débuter le traitement aux posologies minimales recommandées et adapter progressivement les doses si besoin."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477615998, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477615992 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477615993 .

_:807f36cf91fe4e8caa53aadeff92477615993 rdf:first _:807f36cf91fe4e8caa53aadeff92477615994;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477615995 .

_:807f36cf91fe4e8caa53aadeff92477615994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10033 .

_:807f36cf91fe4e8caa53aadeff92477615995 rdf:first _:807f36cf91fe4e8caa53aadeff92477615996;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477615996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477615998 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10023-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10023";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616000;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire et agression de la muqueuse gastroduodénale par l’acide acétylsalicylique)."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour) 
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)
Utiliser un autre anti-inflammatoire ou un au"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616006, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616000 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616001 .

_:807f36cf91fe4e8caa53aadeff92477616001 rdf:first _:807f36cf91fe4e8caa53aadeff92477616002;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616003 .

_:807f36cf91fe4e8caa53aadeff92477616002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:807f36cf91fe4e8caa53aadeff92477616003 rdf:first _:807f36cf91fe4e8caa53aadeff92477616004;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477616006 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10020-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10020";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616008;
  r:natureDuRisque "Majoration du risque hémorragique."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour)

A prendre en compte avec :
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616014, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616008 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616009 .

_:807f36cf91fe4e8caa53aadeff92477616009 rdf:first _:807f36cf91fe4e8caa53aadeff92477616010;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616011 .

_:807f36cf91fe4e8caa53aadeff92477616010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477616011 rdf:first _:807f36cf91fe4e8caa53aadeff92477616012;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477616014 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10021-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10021";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616016;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire et agression de la muqueuse gastroduodénale par l’acide acétylsalicylique."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour) 
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)
Utiliser un autre anti-inflammatoire ou un au"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616022, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616016 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616017 .

_:807f36cf91fe4e8caa53aadeff92477616017 rdf:first _:807f36cf91fe4e8caa53aadeff92477616018;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616019 .

_:807f36cf91fe4e8caa53aadeff92477616018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477616019 rdf:first _:807f36cf91fe4e8caa53aadeff92477616020;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477616022 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10303-2 a owl:Class;
  rdfs:label "ANTISÉCRÉTOIRES INHIBITEURS DE LA POMPE À PROTONS <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10303";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616024;
  r:natureDuRisque "Risque d’augmentation de la toxicité du méthotrexate par diminution de son élimination."@fr;
  r:conduiteATenir """Association déconseillée :
- avec le méthotrexate aux doses > 20 mg / semaine

A prendre en compte :
- pour des doses inférieures"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616030, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616024 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616025 .

_:807f36cf91fe4e8caa53aadeff92477616025 rdf:first _:807f36cf91fe4e8caa53aadeff92477616026;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616027 .

_:807f36cf91fe4e8caa53aadeff92477616026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10043 .

_:807f36cf91fe4e8caa53aadeff92477616027 rdf:first _:807f36cf91fe4e8caa53aadeff92477616028;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616028 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477616030 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11157-2 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_11157";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616032;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam par diminution de son métabolisme hépatique, avec majoration de la sédation."@fr;
  r:conduiteATenir """Association déconseillée:
- avec le midazolam per os

Précaution d'emploi avec :
- avec le midazolam IV et sublingual
Surveillance clinique et réduction de la posologie de midazolam en cas de traitement par l'inhibiteur."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616038, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616032 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616033 .

_:807f36cf91fe4e8caa53aadeff92477616033 rdf:first _:807f36cf91fe4e8caa53aadeff92477616034;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616035 .

_:807f36cf91fe4e8caa53aadeff92477616034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477616035 rdf:first _:807f36cf91fe4e8caa53aadeff92477616036;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616036 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477616038 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11150-2 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> ISAVUCONAZOLE"@fr;
  dct:identifier "IAM_11150";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616040;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’isavuconazole par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  r:conduiteATenir """Contre-indication:
- avec le kétoconazole


Précaution d'emploi:
- avec les autres inhibiteurs puissants du CYP3A4"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616046, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616040 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616041 .

_:807f36cf91fe4e8caa53aadeff92477616041 rdf:first _:807f36cf91fe4e8caa53aadeff92477616042;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616043 .

_:807f36cf91fe4e8caa53aadeff92477616042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477616043 rdf:first _:807f36cf91fe4e8caa53aadeff92477616044;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616044 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10487 .

_:807f36cf91fe4e8caa53aadeff92477616046 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11414-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11414";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616048;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la théophylline (augmentation de son métabolisme par induction enzymatique)."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, de la théophyllinémie. Adapter, s'il y a lieu, la posologie de la théophylline pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616054, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616048 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616049 .

_:807f36cf91fe4e8caa53aadeff92477616049 rdf:first _:807f36cf91fe4e8caa53aadeff92477616050;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616051 .

_:807f36cf91fe4e8caa53aadeff92477616050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477616051 rdf:first _:807f36cf91fe4e8caa53aadeff92477616052;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616052 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616054 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11460-1 a owl:Class;
  rdfs:label "VENLAFAXINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11460";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616056;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616062, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616056 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616057 .

_:807f36cf91fe4e8caa53aadeff92477616057 rdf:first _:807f36cf91fe4e8caa53aadeff92477616058;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616059 .

_:807f36cf91fe4e8caa53aadeff92477616058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477616059 rdf:first _:807f36cf91fe4e8caa53aadeff92477616060;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616060 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477616062 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10310-2 a owl:Class;
  rdfs:label "ANTISPASMODIQUES URINAIRES <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10310";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616064;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Risque de majoration des effets indésirables."@fr;
  r:conduiteATenir """Contre-indication :
- avec la darifénacine
- avec la fésotérodine et la solifénacine, en cas d'insuffisance rénale ou hépatique, modérée à sévère.

Association déconseillée : 
- avec la toltérodine

Précaution d'emploi:
- avec la fésotérodine ou la solifé"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616070, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616064 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616065 .

_:807f36cf91fe4e8caa53aadeff92477616065 rdf:first _:807f36cf91fe4e8caa53aadeff92477616066;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616067 .

_:807f36cf91fe4e8caa53aadeff92477616066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10041 .

_:807f36cf91fe4e8caa53aadeff92477616067 rdf:first _:807f36cf91fe4e8caa53aadeff92477616068;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616068 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477616070 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11111-2 a owl:Class;
  rdfs:label "INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5 <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11111";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616072;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Augmentation (très importante pour l'avanafil et le vardénafil) des concentrations plasmatiques de l'IPDE5, avec risque d'hypotension (sévère avec le vardénafil)."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque IPDE5 avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux AMM specifiques à chacun d'eux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616078, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616072 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616073 .

_:807f36cf91fe4e8caa53aadeff92477616073 rdf:first _:807f36cf91fe4e8caa53aadeff92477616074;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616075 .

_:807f36cf91fe4e8caa53aadeff92477616074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477616075 rdf:first _:807f36cf91fe4e8caa53aadeff92477616076;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616076 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477616078 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10015-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10015";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616080;
  r:natureDuRisque "Majoration du risque hémorragique, notamment en cas d’antécédent d’ulcère gastro-duodénal."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour) en l'absence d’antécédent d’ulcère gastro-duodénal
- des doses antiagrégantes (de 50 mg à 375 mg par jour) et en cas d’antécédent d’ulcère ga"""@fr;
  rdfs:comment "Jusqu'à présent, cette interaction se présentait selon deux niveaux distincts : une contre-indication avec l'acide acétylsalicylique administré à doses anti-inflammatoires et une association déconseillée avec l'aspirine donnée à doses antalgiques ou anti"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616086, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616080 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616081 .

_:807f36cf91fe4e8caa53aadeff92477616081 rdf:first _:807f36cf91fe4e8caa53aadeff92477616082;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616083 .

_:807f36cf91fe4e8caa53aadeff92477616082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477616083 rdf:first _:807f36cf91fe4e8caa53aadeff92477616084;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616084 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477616086 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10192-2 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES <-> AUTRES ANTIARYTHMIQUES"@fr;
  dct:identifier "IAM_10192";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616088;
  r:natureDuRisque "L'association de deux antiarythmiques est très délicate. Elle est dans la majorité des cas, contre-indiquée ou déconseillée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10024 .

_:807f36cf91fe4e8caa53aadeff92477616090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10310-3 a owl:Class;
  rdfs:label "ANTISPASMODIQUES URINAIRES <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10310";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616092;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Risque de majoration des effets indésirables."@fr;
  r:conduiteATenir """Contre-indication :
- avec la darifénacine
- avec la fésotérodine et la solifénacine, en cas d'insuffisance rénale ou hépatique, modérée à sévère.

Association déconseillée : 
- avec la toltérodine

Précaution d'emploi:
- avec la fésotérodine ou la solifé"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616093 .

_:807f36cf91fe4e8caa53aadeff92477616093 rdf:first _:807f36cf91fe4e8caa53aadeff92477616094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616095 .

_:807f36cf91fe4e8caa53aadeff92477616094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10041 .

_:807f36cf91fe4e8caa53aadeff92477616095 rdf:first _:807f36cf91fe4e8caa53aadeff92477616096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477616098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11111-3 a owl:Class;
  rdfs:label "INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5 <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11111";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616100;
  r:chapeau "Certains médicaments possèdent la capacité d’inhiber fortement le CYP3A4, une enzyme qui intervient dans le métabolisme de nombreux médicaments. Lorsque l’activité de cette enzyme est inhibée, elle n’est plus en mesure de métaboliser le médicament qui va"@fr;
  r:natureDuRisque "Augmentation (très importante pour l'avanafil et le vardénafil) des concentrations plasmatiques de l'IPDE5, avec risque d'hypotension (sévère avec le vardénafil)."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque IPDE5 avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux AMM specifiques à chacun d'eux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616101 .

_:807f36cf91fe4e8caa53aadeff92477616101 rdf:first _:807f36cf91fe4e8caa53aadeff92477616102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616103 .

_:807f36cf91fe4e8caa53aadeff92477616102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477616103 rdf:first _:807f36cf91fe4e8caa53aadeff92477616104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477616106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10015-3 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTICOAGULANTS ORAUX"@fr;
  dct:identifier "IAM_10015";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616108;
  r:natureDuRisque "Majoration du risque hémorragique, notamment en cas d’antécédent d’ulcère gastro-duodénal."@fr;
  r:conduiteATenir """Contre-indication avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour)
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour) et en cas d’antécédent d’ulcère gastro-duodénal"""@fr;
  rdfs:comment "Jusqu'à présent, cette interaction se présentait selon deux niveaux distincts : une contre-indication avec l'acide acétylsalicylique administré à doses anti-inflammatoires et une association déconseillée avec l'aspirine donnée à doses antalgiques ou anti"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616109 .

_:807f36cf91fe4e8caa53aadeff92477616109 rdf:first _:807f36cf91fe4e8caa53aadeff92477616110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616111 .

_:807f36cf91fe4e8caa53aadeff92477616110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10028 .

_:807f36cf91fe4e8caa53aadeff92477616111 rdf:first _:807f36cf91fe4e8caa53aadeff92477616112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477616114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11118-2 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> RACECADOTRIL"@fr;
  dct:identifier "IAM_11118";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616116;
  r:natureDuRisque "Risque de majoration des effets indésirables à type d'œdème angio-neurotique (angio-œdème)."@fr;
  r:conduiteATenir """Contre-indication:
- en cas d'antécédents d'angio-oedème sous IEC.

Association déconseillée:
- en l'absence d’antécédents d'angio-oedème sous IEC."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616122, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616116 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616117 .

_:807f36cf91fe4e8caa53aadeff92477616117 rdf:first _:807f36cf91fe4e8caa53aadeff92477616118;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616119 .

_:807f36cf91fe4e8caa53aadeff92477616118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477616119 rdf:first _:807f36cf91fe4e8caa53aadeff92477616120;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10780 .

_:807f36cf91fe4e8caa53aadeff92477616122 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10530-2 a owl:Class;
  rdfs:label "CALCIUM <-> DIGOXINE"@fr;
  dct:identifier "IAM_10530";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616124;
  r:natureDuRisque "Risque de troubles du rythme graves, voire mortels avec les sels de calcium administrés par voie IV."@fr;
  r:conduiteATenir """Contre-indication :
- avec les sels de calcium IV, hormis supplémentation parentérale.

Précaution d'emploi :
- avec les sels de calcium par voie orale.
Surveillance clinique et, s'il y a lieu, contrôle de l'ECG et de la calcémie."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616130, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616124 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616125 .

_:807f36cf91fe4e8caa53aadeff92477616125 rdf:first _:807f36cf91fe4e8caa53aadeff92477616126;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616127 .

_:807f36cf91fe4e8caa53aadeff92477616126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477616127 rdf:first _:807f36cf91fe4e8caa53aadeff92477616128;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477616130 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11458-1 a owl:Class;
  rdfs:label "VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_11458";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616132;
  r:natureDuRisque "Risque d’augmentation des effets indésirables, notamment hématologiques, de la zidovudine par diminution de son métabolisme par l’acide valproïque."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière. Un hémogramme à la recherche d’une anémie devrait être réalisé au cours des deux premiers mois de l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616138, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616132 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616133 .

_:807f36cf91fe4e8caa53aadeff92477616133 rdf:first _:807f36cf91fe4e8caa53aadeff92477616134;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616135 .

_:807f36cf91fe4e8caa53aadeff92477616134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477616135 rdf:first _:807f36cf91fe4e8caa53aadeff92477616136;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:807f36cf91fe4e8caa53aadeff92477616138 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10715-2 a owl:Class;
  rdfs:label "DACLATASVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10715";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616140;
  r:natureDuRisque "Diminution des concentrations plasmatiques de daclatasvir par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir """Contre-indication:
- avec la rifampicine
- avec les anticonvulsivants inducteurs enzymatiques
- avec l'oxcarbazépine

Précaution d'emploi:
- avec les autres inducteurs, la dose recommandée est de 90 mg/jour de daclatasvir"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616146, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616140 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616141 .

_:807f36cf91fe4e8caa53aadeff92477616141 rdf:first _:807f36cf91fe4e8caa53aadeff92477616142;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616143 .

_:807f36cf91fe4e8caa53aadeff92477616142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477616143 rdf:first _:807f36cf91fe4e8caa53aadeff92477616144;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:807f36cf91fe4e8caa53aadeff92477616146 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10027-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> METHOTREXATE"@fr;
  dct:identifier "IAM_10027";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616148;
  r:natureDuRisque "Majoration de la toxicité, notamment hématologique, du méthotrexate (diminution de sa clairance rénale par l'acide acétylsalicylique)."@fr;
  r:conduiteATenir """Avec le méthotrexate utilisé à des doses > 20 mg/semaine : 
- contre-indication avec l'acide acétylsalicylique utilisé à doses antalgiques, antipyrétiques ou anti-inflammatoires
- précaution d'emploi avec des doses antiagrégantes plaquettaires d'acide acé"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616154, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616148 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616149 .

_:807f36cf91fe4e8caa53aadeff92477616149 rdf:first _:807f36cf91fe4e8caa53aadeff92477616150;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616151 .

_:807f36cf91fe4e8caa53aadeff92477616150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477616151 rdf:first _:807f36cf91fe4e8caa53aadeff92477616152;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10569 .

_:807f36cf91fe4e8caa53aadeff92477616154 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11122-2 a owl:Class;
  rdfs:label "INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES) <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_11122";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616156;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de la statine et de ses effets indésirables à type de rhabdomyolyse."@fr;
  r:conduiteATenir """Contre-indication :
- avec la rosuvastatine.

Précaution d'emploi :
- avec les autres inhibiteurs de l'HMG Co-A réductase.
Surveillance clinique et biologique. Adaptation éventuelle de la posologie de la statine."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616162, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616156 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616157 .

_:807f36cf91fe4e8caa53aadeff92477616157 rdf:first _:807f36cf91fe4e8caa53aadeff92477616158;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616159 .

_:807f36cf91fe4e8caa53aadeff92477616158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477616159 rdf:first _:807f36cf91fe4e8caa53aadeff92477616160;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477616162 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11266-2 a owl:Class;
  rdfs:label "METHADONE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11266";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616164;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine
et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616170, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616164 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616165 .

_:807f36cf91fe4e8caa53aadeff92477616165 rdf:first _:807f36cf91fe4e8caa53aadeff92477616166;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616167 .

_:807f36cf91fe4e8caa53aadeff92477616166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477616167 rdf:first _:807f36cf91fe4e8caa53aadeff92477616168;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477616170 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11059-2 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_11059";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616172;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  r:conduiteATenir """Contre-indication :
avec le bupropion

Association déconseillée :
avec les autres sympathomimétiques indirects"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616178, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616172 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616173 .

_:807f36cf91fe4e8caa53aadeff92477616173 rdf:first _:807f36cf91fe4e8caa53aadeff92477616174;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616175 .

_:807f36cf91fe4e8caa53aadeff92477616174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477616175 rdf:first _:807f36cf91fe4e8caa53aadeff92477616176;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477616178 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11439-2 a owl:Class;
  rdfs:label "SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> TORSADOGÈNES (SAUF ANTIPARASITAIRES, NEUROLEPTIQUES, MÉTHADONE)"@fr;
  dct:identifier "IAM_11439";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616180;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication:
- Pour l'érythromycine et la vincamine, seules les formes administrées par voie intraveineuse sont concernées par cette interaction.
- Pour la spiramycine, la voie IV et la voie orale sont concernées.

Association déconseillée:
- avec l"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616186, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616180 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616181 .

_:807f36cf91fe4e8caa53aadeff92477616181 rdf:first _:807f36cf91fe4e8caa53aadeff92477616182;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616183 .

_:807f36cf91fe4e8caa53aadeff92477616182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477616183 rdf:first _:807f36cf91fe4e8caa53aadeff92477616184;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10154 .

_:807f36cf91fe4e8caa53aadeff92477616186 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10939-2 a owl:Class;
  rdfs:label "FIBRATES <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10939";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616188;
  r:natureDuRisque "Risque d'addition d'effets indésirables (dose-dépendants) à type de rhabdomyolyse. En outre, avec le gemfibrozil, diminution du métabolisme de la simvastatine et de la rosuvastatine, ce qui majore le risque musculaire, ainsi que la néphrotoxicité de la ro"@fr;
  r:conduiteATenir """Contre-indication 
- entre le gemfibrozil et la simvastatine
- pour des doses de rosuvastatine de 40 mg

Association déconseillée 
- entre les autres fibrates et les autres statines 
- ne pas dépasser 10 mg de simvastatine (cette restriction de doses ne"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616194, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616188 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616189 .

_:807f36cf91fe4e8caa53aadeff92477616189 rdf:first _:807f36cf91fe4e8caa53aadeff92477616190;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616191 .

_:807f36cf91fe4e8caa53aadeff92477616190 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:807f36cf91fe4e8caa53aadeff92477616191 rdf:first _:807f36cf91fe4e8caa53aadeff92477616192;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477616194 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10939-3 a owl:Class;
  rdfs:label "GEMFIBROZIL <-> SIVASTATINE"@fr;
  dct:identifier "IAM_10939";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616196;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616202, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616196 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616197 .

_:807f36cf91fe4e8caa53aadeff92477616197 rdf:first _:807f36cf91fe4e8caa53aadeff92477616198;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616199 .

_:807f36cf91fe4e8caa53aadeff92477616198 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GEMFIBROZIL .

_:807f36cf91fe4e8caa53aadeff92477616199 rdf:first _:807f36cf91fe4e8caa53aadeff92477616200;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616200 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_SIMVASTATINE .

_:807f36cf91fe4e8caa53aadeff92477616202 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10939-4 a owl:Class;
  rdfs:label "FIBRATES <-> ROSUVASTATINE + de 40 mg"@fr;
  dct:identifier "IAM_10939";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616204;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616210, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616204 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616205 .

_:807f36cf91fe4e8caa53aadeff92477616205 rdf:first _:807f36cf91fe4e8caa53aadeff92477616206;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616207 .

_:807f36cf91fe4e8caa53aadeff92477616206 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:807f36cf91fe4e8caa53aadeff92477616207 rdf:first _:807f36cf91fe4e8caa53aadeff92477616208;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616208 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_ROSUVASTATINE_40mg .

_:807f36cf91fe4e8caa53aadeff92477616210 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10828-2 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> POTASSIUM"@fr;
  dct:identifier "IAM_10828";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616212;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, notamment chez l'insuffisant rénal (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Contre-indication:-en dehors d'une hypokaliémie ou en cas d'utilisation parentérale des sels de potassium"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616218, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616212 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616213 .

_:807f36cf91fe4e8caa53aadeff92477616213 rdf:first _:807f36cf91fe4e8caa53aadeff92477616214;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616215 .

_:807f36cf91fe4e8caa53aadeff92477616214 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477616215 rdf:first _:807f36cf91fe4e8caa53aadeff92477616216;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616216 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:807f36cf91fe4e8caa53aadeff92477616218 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10090-2 a owl:Class;
  rdfs:label "ALISKIREN <-> ANTAGONISTES DES RÉCEPTEURS DE L'ANGIOTENSINE II"@fr;
  dct:identifier "IAM_10090";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616220;
  r:natureDuRisque "Risque d’hyperkaliémie, d’insuffisance rénale, d’augmentation de la morbi-mortalité cardio-vasculaire."@fr;
  r:conduiteATenir """Contre-indication :
- chez le patient diabétique ou insuffisant rénal

Association déconseillée :
- dans les autres cas"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616226, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616220 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616221 .

_:807f36cf91fe4e8caa53aadeff92477616221 rdf:first _:807f36cf91fe4e8caa53aadeff92477616222;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616223 .

_:807f36cf91fe4e8caa53aadeff92477616222 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10020 .

_:807f36cf91fe4e8caa53aadeff92477616223 rdf:first _:807f36cf91fe4e8caa53aadeff92477616224;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616224 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10048 .

_:807f36cf91fe4e8caa53aadeff92477616226 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11029-2 a owl:Class;
  rdfs:label "HYDROXYCHLOROQUINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11029";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616228;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616234, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616228 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616229 .

_:807f36cf91fe4e8caa53aadeff92477616229 rdf:first _:807f36cf91fe4e8caa53aadeff92477616230;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616231 .

_:807f36cf91fe4e8caa53aadeff92477616230 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477616231 rdf:first _:807f36cf91fe4e8caa53aadeff92477616232;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616232 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10437 .

_:807f36cf91fe4e8caa53aadeff92477616234 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10192-3 a owl:Class;
  rdfs:label "ANTIARYTHMIQUES <-> AUTRES ANTIARYTHMIQUES"@fr;
  dct:identifier "IAM_10192";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616236;
  r:natureDuRisque "L'association de deux antiarythmiques est très délicate. Elle est dans la majorité des cas, contre-indiquée ou déconseillée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616238, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10024 .

_:807f36cf91fe4e8caa53aadeff92477616238 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11358-1 a owl:Class;
  rdfs:label "PEG-INTERFERON ALFA-2A <-> TELBIVUDINE"@fr;
  dct:identifier "IAM_11358";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616240;
  r:natureDuRisque "Risque majoré de neuropathies périphériques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616246, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616240 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616241 .

_:807f36cf91fe4e8caa53aadeff92477616241 rdf:first _:807f36cf91fe4e8caa53aadeff92477616242;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616243 .

_:807f36cf91fe4e8caa53aadeff92477616242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10698 .

_:807f36cf91fe4e8caa53aadeff92477616243 rdf:first _:807f36cf91fe4e8caa53aadeff92477616244;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10888 .

_:807f36cf91fe4e8caa53aadeff92477616246 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11347-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> RÉGORAFÉNIB"@fr;
  dct:identifier "IAM_11347";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616248;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de régorafenib par diminution de son métabolisme hépatique par le pamplemousse."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616254, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616248 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616249 .

_:807f36cf91fe4e8caa53aadeff92477616249 rdf:first _:807f36cf91fe4e8caa53aadeff92477616250;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616251 .

_:807f36cf91fe4e8caa53aadeff92477616250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477616251 rdf:first _:807f36cf91fe4e8caa53aadeff92477616252;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10789 .

_:807f36cf91fe4e8caa53aadeff92477616254 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11348-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> SERTRALINE"@fr;
  dct:identifier "IAM_11348";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616256;
  r:natureDuRisque "Augmentation parfois importante des concentrations de l’antidépresseur chez certains patients par diminution de son métabolisme intestinal."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616262, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616256 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616257 .

_:807f36cf91fe4e8caa53aadeff92477616257 rdf:first _:807f36cf91fe4e8caa53aadeff92477616258;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616259 .

_:807f36cf91fe4e8caa53aadeff92477616258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477616259 rdf:first _:807f36cf91fe4e8caa53aadeff92477616260;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10831 .

_:807f36cf91fe4e8caa53aadeff92477616262 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11349-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11349";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616264;
  r:natureDuRisque "Augmentation considérable des concentrations plasmatiques de l'hypolipémiant, avec risque de survenue d'effets indésirables, notamment musculaires."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616270, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616264 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616265 .

_:807f36cf91fe4e8caa53aadeff92477616265 rdf:first _:807f36cf91fe4e8caa53aadeff92477616266;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616267 .

_:807f36cf91fe4e8caa53aadeff92477616266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477616267 rdf:first _:807f36cf91fe4e8caa53aadeff92477616268;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477616270 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11350-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11350";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616272;
  r:natureDuRisque "Doublement des concentrations plasmatiques de l'antiagrégant, avec risque de majoration des effets indésirables, notamment hémorragiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616278, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616272 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616273 .

_:807f36cf91fe4e8caa53aadeff92477616273 rdf:first _:807f36cf91fe4e8caa53aadeff92477616274;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616275 .

_:807f36cf91fe4e8caa53aadeff92477616274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477616275 rdf:first _:807f36cf91fe4e8caa53aadeff92477616276;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477616278 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11351-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> VARDENAFIL"@fr;
  dct:identifier "IAM_11351";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616280;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du vardénafil, avec risque d’hypotension."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616286, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616280 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616281 .

_:807f36cf91fe4e8caa53aadeff92477616281 rdf:first _:807f36cf91fe4e8caa53aadeff92477616282;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616283 .

_:807f36cf91fe4e8caa53aadeff92477616282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477616283 rdf:first _:807f36cf91fe4e8caa53aadeff92477616284;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10975 .

_:807f36cf91fe4e8caa53aadeff92477616286 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11352-1 a owl:Class;
  rdfs:label "PAMPLEMOUSSE (JUS ET FRUIT) <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11352";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616288;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de vérapamil, avec risque de survenue d’effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616294, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616288 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616289 .

_:807f36cf91fe4e8caa53aadeff92477616289 rdf:first _:807f36cf91fe4e8caa53aadeff92477616290;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616291 .

_:807f36cf91fe4e8caa53aadeff92477616290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477616291 rdf:first _:807f36cf91fe4e8caa53aadeff92477616292;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477616294 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11353-1 a owl:Class;
  rdfs:label "PAROXETINE <-> PIMOZIDE"@fr;
  dct:identifier "IAM_11353";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616296;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616296 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616297 .

_:807f36cf91fe4e8caa53aadeff92477616297 rdf:first _:807f36cf91fe4e8caa53aadeff92477616298;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616299 .

_:807f36cf91fe4e8caa53aadeff92477616298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477616299 rdf:first _:807f36cf91fe4e8caa53aadeff92477616300;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477616302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11354-1 a owl:Class;
  rdfs:label "PAROXETINE <-> RISPERIDONE"@fr;
  dct:identifier "IAM_11354";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616304;
  r:natureDuRisque "Augmentation de la fraction active de la rispéridone par diminution de son métabolisme hépatique par la paroxétine, avec risque de majoration des effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, adaptation posologique de la rispéridone."@fr;
  rdfs:comment "La rispéridone est majoritairement métabolisée par le CYP2D6 en 9-OH-rispéridone, métabolite actif. La fraction pharmacologiquement active de la rispéridone est ainsi constituée par la molécule mère et son métabolite hydroxylé. La paroxétine est un inhibi"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616305 .

_:807f36cf91fe4e8caa53aadeff92477616305 rdf:first _:807f36cf91fe4e8caa53aadeff92477616306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616307 .

_:807f36cf91fe4e8caa53aadeff92477616306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477616307 rdf:first _:807f36cf91fe4e8caa53aadeff92477616308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10805 .

_:807f36cf91fe4e8caa53aadeff92477616310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11355-1 a owl:Class;
  rdfs:label "PAROXETINE <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_11355";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616312;
  r:natureDuRisque "Baisse de l’efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la paroxétine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616313 .

_:807f36cf91fe4e8caa53aadeff92477616313 rdf:first _:807f36cf91fe4e8caa53aadeff92477616314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616315 .

_:807f36cf91fe4e8caa53aadeff92477616314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477616315 rdf:first _:807f36cf91fe4e8caa53aadeff92477616316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:807f36cf91fe4e8caa53aadeff92477616318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11416-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11416";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616320;
  r:natureDuRisque "Diminution importante des concentrations plasmatiques de ticagrelor par augmentation de son métabolisme hépatique par la rifampicine, avec risque de diminution de l’effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616320 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616321 .

_:807f36cf91fe4e8caa53aadeff92477616321 rdf:first _:807f36cf91fe4e8caa53aadeff92477616322;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616323 .

_:807f36cf91fe4e8caa53aadeff92477616322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616323 rdf:first _:807f36cf91fe4e8caa53aadeff92477616324;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477616326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11357-1 a owl:Class;
  rdfs:label "PEFLOXACINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11357";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616328;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution du métabolisme de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616329 .

_:807f36cf91fe4e8caa53aadeff92477616329 rdf:first _:807f36cf91fe4e8caa53aadeff92477616330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616331 .

_:807f36cf91fe4e8caa53aadeff92477616330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477616331 rdf:first _:807f36cf91fe4e8caa53aadeff92477616332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10697 .

_:807f36cf91fe4e8caa53aadeff92477616334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11344-1 a owl:Class;
  rdfs:label "ORLISTAT <-> VITAMINE D"@fr;
  dct:identifier "IAM_11344";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616336;
  r:natureDuRisque "Diminution de l'absorption de la vitamine D."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616337 .

_:807f36cf91fe4e8caa53aadeff92477616337 rdf:first _:807f36cf91fe4e8caa53aadeff92477616338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616339 .

_:807f36cf91fe4e8caa53aadeff92477616338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10162 .

_:807f36cf91fe4e8caa53aadeff92477616339 rdf:first _:807f36cf91fe4e8caa53aadeff92477616340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477616342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11359-1 a owl:Class;
  rdfs:label "PÉNEMS <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11359";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616344;
  r:natureDuRisque "Risque de survenue de crises convulsives, par diminution rapide des concentrations plasmatiques de l’acide valproïque, pouvant devenir indétectables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616345 .

_:807f36cf91fe4e8caa53aadeff92477616345 rdf:first _:807f36cf91fe4e8caa53aadeff92477616346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616347 .

_:807f36cf91fe4e8caa53aadeff92477616346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10137 .

_:807f36cf91fe4e8caa53aadeff92477616347 rdf:first _:807f36cf91fe4e8caa53aadeff92477616348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477616350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11361-1 a owl:Class;
  rdfs:label "PENTAMIDINE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_11361";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616352;
  r:natureDuRisque "Risque accru de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616353 .

_:807f36cf91fe4e8caa53aadeff92477616353 rdf:first _:807f36cf91fe4e8caa53aadeff92477616354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616355 .

_:807f36cf91fe4e8caa53aadeff92477616354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10703 .

_:807f36cf91fe4e8caa53aadeff92477616355 rdf:first _:807f36cf91fe4e8caa53aadeff92477616356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:807f36cf91fe4e8caa53aadeff92477616358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11360-1 a owl:Class;
  rdfs:label "PENTAMIDINE <-> STAVUDINE"@fr;
  dct:identifier "IAM_11360";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616360;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616361 .

_:807f36cf91fe4e8caa53aadeff92477616361 rdf:first _:807f36cf91fe4e8caa53aadeff92477616362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616363 .

_:807f36cf91fe4e8caa53aadeff92477616362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10703 .

_:807f36cf91fe4e8caa53aadeff92477616363 rdf:first _:807f36cf91fe4e8caa53aadeff92477616364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:807f36cf91fe4e8caa53aadeff92477616366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11362-1 a owl:Class;
  rdfs:label "PENTOXIFYLLINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11362";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616368;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (compétition au niveau du métabolisme hépatique de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par la pentoxifylline et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616369 .

_:807f36cf91fe4e8caa53aadeff92477616369 rdf:first _:807f36cf91fe4e8caa53aadeff92477616370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616371 .

_:807f36cf91fe4e8caa53aadeff92477616370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477616371 rdf:first _:807f36cf91fe4e8caa53aadeff92477616372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10705 .

_:807f36cf91fe4e8caa53aadeff92477616374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11384-1 a owl:Class;
  rdfs:label "PROGESTATIFS CONTRACEPTIFS <-> PÉRAMPANEL"@fr;
  dct:identifier "IAM_11384";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616376;
  r:natureDuRisque "Pour des doses de pérampanel >= 12 mg/jour : Risque de diminution de l’efficacité contraceptive."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616377 .

_:807f36cf91fe4e8caa53aadeff92477616377 rdf:first _:807f36cf91fe4e8caa53aadeff92477616378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616379 .

_:807f36cf91fe4e8caa53aadeff92477616378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477616379 rdf:first _:807f36cf91fe4e8caa53aadeff92477616380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:807f36cf91fe4e8caa53aadeff92477616382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11363-1 a owl:Class;
  rdfs:label "PÉRAMPANEL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11363";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616384;
  r:natureDuRisque "Diminution importante (jusqu’aux deux-tiers) des concentrations de pérampanel."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616390, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616384 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616385 .

_:807f36cf91fe4e8caa53aadeff92477616385 rdf:first _:807f36cf91fe4e8caa53aadeff92477616386;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616387 .

_:807f36cf91fe4e8caa53aadeff92477616386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:807f36cf91fe4e8caa53aadeff92477616387 rdf:first _:807f36cf91fe4e8caa53aadeff92477616388;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616390 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11364-1 a owl:Class;
  rdfs:label "PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE) <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11364";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616392;
  r:natureDuRisque """En cas de traitement antérieur par le phénobarbital ou la primidone, et adjonction de phénytoïne, augmentation des concentrations plasmatiques de phénobarbital pouvant entraîner des signes toxiques (inhibition du métabolisme par compétition).

En cas de t"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616398, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616392 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616393 .

_:807f36cf91fe4e8caa53aadeff92477616393 rdf:first _:807f36cf91fe4e8caa53aadeff92477616394;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616395 .

_:807f36cf91fe4e8caa53aadeff92477616394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477616395 rdf:first _:807f36cf91fe4e8caa53aadeff92477616396;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477616398 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11365-1 a owl:Class;
  rdfs:label "PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE) <-> PROPRANOLOL"@fr;
  dct:identifier "IAM_11365";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616400;
  r:natureDuRisque "Diminution des concentrations plasmatiques du propranolol avec réduction de ses effets cliniques (augmentation de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616400 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616401 .

_:807f36cf91fe4e8caa53aadeff92477616401 rdf:first _:807f36cf91fe4e8caa53aadeff92477616402;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616403 .

_:807f36cf91fe4e8caa53aadeff92477616402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477616403 rdf:first _:807f36cf91fe4e8caa53aadeff92477616404;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10767 .

_:807f36cf91fe4e8caa53aadeff92477616406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11366-1 a owl:Class;
  rdfs:label "PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE) <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11366";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616408;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616409 .

_:807f36cf91fe4e8caa53aadeff92477616409 rdf:first _:807f36cf91fe4e8caa53aadeff92477616410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616411 .

_:807f36cf91fe4e8caa53aadeff92477616410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477616411 rdf:first _:807f36cf91fe4e8caa53aadeff92477616412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477616414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11356-1 a owl:Class;
  rdfs:label "PAROXETINE <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_11356";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616416;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution importante de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par la paroxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616417 .

_:807f36cf91fe4e8caa53aadeff92477616417 rdf:first _:807f36cf91fe4e8caa53aadeff92477616418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616419 .

_:807f36cf91fe4e8caa53aadeff92477616418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10694 .

_:807f36cf91fe4e8caa53aadeff92477616419 rdf:first _:807f36cf91fe4e8caa53aadeff92477616420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:807f36cf91fe4e8caa53aadeff92477616422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11334-1 a owl:Class;
  rdfs:label "OLAPARIB <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11334";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616424;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par le vérapamil."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 200 mg deux fois par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616425 .

_:807f36cf91fe4e8caa53aadeff92477616425 rdf:first _:807f36cf91fe4e8caa53aadeff92477616426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616427 .

_:807f36cf91fe4e8caa53aadeff92477616426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:807f36cf91fe4e8caa53aadeff92477616427 rdf:first _:807f36cf91fe4e8caa53aadeff92477616428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477616430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11323-1 a owl:Class;
  rdfs:label "NEUROLEPTIQUES <-> ORLISTAT"@fr;
  dct:identifier "IAM_11323";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616432;
  r:natureDuRisque "Risque d'échec thérapeutique en cas de traitement concomitant par orlistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616433 .

_:807f36cf91fe4e8caa53aadeff92477616433 rdf:first _:807f36cf91fe4e8caa53aadeff92477616434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616435 .

_:807f36cf91fe4e8caa53aadeff92477616434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10124 .

_:807f36cf91fe4e8caa53aadeff92477616435 rdf:first _:807f36cf91fe4e8caa53aadeff92477616436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477616438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11324-1 a owl:Class;
  rdfs:label "NEUROLEPTIQUES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11324";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616440;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616441 .

_:807f36cf91fe4e8caa53aadeff92477616441 rdf:first _:807f36cf91fe4e8caa53aadeff92477616442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616443 .

_:807f36cf91fe4e8caa53aadeff92477616442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10127 .

_:807f36cf91fe4e8caa53aadeff92477616443 rdf:first _:807f36cf91fe4e8caa53aadeff92477616444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477616446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11325-1 a owl:Class;
  rdfs:label "NEVIRAPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11325";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616448;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la névirapine par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616449 .

_:807f36cf91fe4e8caa53aadeff92477616449 rdf:first _:807f36cf91fe4e8caa53aadeff92477616450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616451 .

_:807f36cf91fe4e8caa53aadeff92477616450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477616451 rdf:first _:807f36cf91fe4e8caa53aadeff92477616452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11326-1 a owl:Class;
  rdfs:label "NEVIRAPINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11326";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616456;
  r:natureDuRisque "Risque de baisse de l'efficacité du voriconazole par augmentation de son métabolisme hépatique par la névirapine."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite et adaptation éventuelle de la posologie du voriconazole pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616457 .

_:807f36cf91fe4e8caa53aadeff92477616457 rdf:first _:807f36cf91fe4e8caa53aadeff92477616458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616459 .

_:807f36cf91fe4e8caa53aadeff92477616458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477616459 rdf:first _:807f36cf91fe4e8caa53aadeff92477616460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477616462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11327-1 a owl:Class;
  rdfs:label "NIMODIPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11327";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616464;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l'antagoniste du calcium pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616465 .

_:807f36cf91fe4e8caa53aadeff92477616465 rdf:first _:807f36cf91fe4e8caa53aadeff92477616466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616467 .

_:807f36cf91fe4e8caa53aadeff92477616466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10636 .

_:807f36cf91fe4e8caa53aadeff92477616467 rdf:first _:807f36cf91fe4e8caa53aadeff92477616468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11328-1 a owl:Class;
  rdfs:label "NIMODIPINE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11328";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616472;
  r:natureDuRisque "Avec la nimodipine par voie orale, et par extrapolation, par voie injectable : risque de majoration de l'effet hypotenseur de la nimodipine par augmentation de ses concentrations plasmatiques (diminution de son métabolisme par l'acide valproïque)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616473 .

_:807f36cf91fe4e8caa53aadeff92477616473 rdf:first _:807f36cf91fe4e8caa53aadeff92477616474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616475 .

_:807f36cf91fe4e8caa53aadeff92477616474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477616475 rdf:first _:807f36cf91fe4e8caa53aadeff92477616476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10636 .

_:807f36cf91fe4e8caa53aadeff92477616478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11329-1 a owl:Class;
  rdfs:label "NINTÉDANIB <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_11329";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616480;
  r:natureDuRisque "Diminution des concentrations plasmatiques du nintédanib par diminution de son absorption par la phénytoïne ou la fosphénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616481 .

_:807f36cf91fe4e8caa53aadeff92477616481 rdf:first _:807f36cf91fe4e8caa53aadeff92477616482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616483 .

_:807f36cf91fe4e8caa53aadeff92477616482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477616483 rdf:first _:807f36cf91fe4e8caa53aadeff92477616484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477616486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11330-1 a owl:Class;
  rdfs:label "NINTÉDANIB <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11330";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616488;
  r:natureDuRisque "Diminution des concentrations plasmatiques du nintédanib par diminution de son absorption par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616494, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616488 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616489 .

_:807f36cf91fe4e8caa53aadeff92477616489 rdf:first _:807f36cf91fe4e8caa53aadeff92477616490;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616491 .

_:807f36cf91fe4e8caa53aadeff92477616490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477616491 rdf:first _:807f36cf91fe4e8caa53aadeff92477616492;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616494 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11331-1 a owl:Class;
  rdfs:label "NINTÉDANIB <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11331";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616496;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par le vérapamil."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616502, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616496 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616497 .

_:807f36cf91fe4e8caa53aadeff92477616497 rdf:first _:807f36cf91fe4e8caa53aadeff92477616498;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616499 .

_:807f36cf91fe4e8caa53aadeff92477616498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477616499 rdf:first _:807f36cf91fe4e8caa53aadeff92477616500;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477616502 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11346-1 a owl:Class;
  rdfs:label "OXCARBAZEPINE <-> TOPIRAMATE"@fr;
  dct:identifier "IAM_11346";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616504;
  r:natureDuRisque "Risque de diminution des concentrations du topiramate avec risque de moindre efficacité, par augmentation de son métabolisme hépatique par l'oxcarbazépine."@fr;
  r:conduiteATenir "Surveillance clinique, et si besoin, adaptation posologique du topiramate pendant le traitement par l'oxcarbazépine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616510, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616504 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616505 .

_:807f36cf91fe4e8caa53aadeff92477616505 rdf:first _:807f36cf91fe4e8caa53aadeff92477616506;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616507 .

_:807f36cf91fe4e8caa53aadeff92477616506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10674 .

_:807f36cf91fe4e8caa53aadeff92477616507 rdf:first _:807f36cf91fe4e8caa53aadeff92477616508;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:807f36cf91fe4e8caa53aadeff92477616510 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11333-1 a owl:Class;
  rdfs:label "NORFLOXACINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11333";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616512;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution du métabolisme de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616518, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616512 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616513 .

_:807f36cf91fe4e8caa53aadeff92477616513 rdf:first _:807f36cf91fe4e8caa53aadeff92477616514;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616515 .

_:807f36cf91fe4e8caa53aadeff92477616514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477616515 rdf:first _:807f36cf91fe4e8caa53aadeff92477616516;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10650 .

_:807f36cf91fe4e8caa53aadeff92477616518 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11345-1 a owl:Class;
  rdfs:label "OXCARBAZEPINE <-> PÉRAMPANEL"@fr;
  dct:identifier "IAM_11345";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616520;
  r:natureDuRisque "Diminution de moitié des concentrations de pérampanel et légère augmentation de celles de l’oxcarbazépine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616526, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616520 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616521 .

_:807f36cf91fe4e8caa53aadeff92477616521 rdf:first _:807f36cf91fe4e8caa53aadeff92477616522;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616523 .

_:807f36cf91fe4e8caa53aadeff92477616522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10674 .

_:807f36cf91fe4e8caa53aadeff92477616523 rdf:first _:807f36cf91fe4e8caa53aadeff92477616524;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10706 .

_:807f36cf91fe4e8caa53aadeff92477616526 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11335-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> PIMOZIDE"@fr;
  dct:identifier "IAM_11335";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616528;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du pimozide par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616534, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616528 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616529 .

_:807f36cf91fe4e8caa53aadeff92477616529 rdf:first _:807f36cf91fe4e8caa53aadeff92477616530;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616531 .

_:807f36cf91fe4e8caa53aadeff92477616530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477616531 rdf:first _:807f36cf91fe4e8caa53aadeff92477616532;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477616534 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11336-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> QUETIAPINE"@fr;
  dct:identifier "IAM_11336";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616536;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la quétiapine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616542, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616536 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616537 .

_:807f36cf91fe4e8caa53aadeff92477616537 rdf:first _:807f36cf91fe4e8caa53aadeff92477616538;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616539 .

_:807f36cf91fe4e8caa53aadeff92477616538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477616539 rdf:first _:807f36cf91fe4e8caa53aadeff92477616540;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:807f36cf91fe4e8caa53aadeff92477616542 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11337-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> QUINIDINE"@fr;
  dct:identifier "IAM_11337";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616544;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la quinidine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616550, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616544 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616545 .

_:807f36cf91fe4e8caa53aadeff92477616545 rdf:first _:807f36cf91fe4e8caa53aadeff92477616546;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616547 .

_:807f36cf91fe4e8caa53aadeff92477616546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477616547 rdf:first _:807f36cf91fe4e8caa53aadeff92477616548;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477616550 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11338-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> SILDENAFIL"@fr;
  dct:identifier "IAM_11338";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616552;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du sildénafil par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616558, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616552 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616553 .

_:807f36cf91fe4e8caa53aadeff92477616553 rdf:first _:807f36cf91fe4e8caa53aadeff92477616554;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616555 .

_:807f36cf91fe4e8caa53aadeff92477616554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477616555 rdf:first _:807f36cf91fe4e8caa53aadeff92477616556;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10834 .

_:807f36cf91fe4e8caa53aadeff92477616558 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11339-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11339";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616560;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la simvastatine par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616566, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616560 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616561 .

_:807f36cf91fe4e8caa53aadeff92477616561 rdf:first _:807f36cf91fe4e8caa53aadeff92477616562;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616563 .

_:807f36cf91fe4e8caa53aadeff92477616562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477616563 rdf:first _:807f36cf91fe4e8caa53aadeff92477616564;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477616566 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11340-1 a owl:Class;
  rdfs:label "OMBITASVIR + PARITAPRÉVIR <-> TICAGRELOR"@fr;
  dct:identifier "IAM_11340";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616568;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ticagrélor par diminution de son métabolisme hépatique par la bithérapie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616574, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616568 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616569 .

_:807f36cf91fe4e8caa53aadeff92477616569 rdf:first _:807f36cf91fe4e8caa53aadeff92477616570;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616571 .

_:807f36cf91fe4e8caa53aadeff92477616570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477616571 rdf:first _:807f36cf91fe4e8caa53aadeff92477616572;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477616574 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11341-1 a owl:Class;
  rdfs:label "OMEPRAZOLE <-> TACROLIMUS"@fr;
  dct:identifier "IAM_11341";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616576;
  r:natureDuRisque "Augmentation des concentrations sanguines du tacrolimus."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines du tacrolimus, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616582, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616576 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616577 .

_:807f36cf91fe4e8caa53aadeff92477616577 rdf:first _:807f36cf91fe4e8caa53aadeff92477616578;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616579 .

_:807f36cf91fe4e8caa53aadeff92477616578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10664 .

_:807f36cf91fe4e8caa53aadeff92477616579 rdf:first _:807f36cf91fe4e8caa53aadeff92477616580;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477616582 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11342-1 a owl:Class;
  rdfs:label "ONDANSETRON <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11342";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616584;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes."""@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616590, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616584 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616585 .

_:807f36cf91fe4e8caa53aadeff92477616585 rdf:first _:807f36cf91fe4e8caa53aadeff92477616586;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616587 .

_:807f36cf91fe4e8caa53aadeff92477616586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477616587 rdf:first _:807f36cf91fe4e8caa53aadeff92477616588;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10665 .

_:807f36cf91fe4e8caa53aadeff92477616590 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11343-1 a owl:Class;
  rdfs:label "ONDANSETRON <-> TRAMADOL"@fr;
  dct:identifier "IAM_11343";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616592;
  r:natureDuRisque "Diminution de l’intensité et de la durée de l’effet analgésique du tramadol et risque de diminution de l’effet antiémétique de l’ondansétron."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616598, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616592 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616593 .

_:807f36cf91fe4e8caa53aadeff92477616593 rdf:first _:807f36cf91fe4e8caa53aadeff92477616594;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616595 .

_:807f36cf91fe4e8caa53aadeff92477616594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10665 .

_:807f36cf91fe4e8caa53aadeff92477616595 rdf:first _:807f36cf91fe4e8caa53aadeff92477616596;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477616598 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11369-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> SULFAMETHIZOL"@fr;
  dct:identifier "IAM_11369";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616600;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne jusqu'à des valeurs toxiques (inhibition de son métabolisme)."@fr;
  r:conduiteATenir "Utiliser de préférence une autre classe d'anti-infectieux, sinon surveillance clinique étroite, dosage des concentrations de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par le sulfamide anti-infectieux et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616606, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616600 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616601 .

_:807f36cf91fe4e8caa53aadeff92477616601 rdf:first _:807f36cf91fe4e8caa53aadeff92477616602;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616603 .

_:807f36cf91fe4e8caa53aadeff92477616602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477616603 rdf:first _:807f36cf91fe4e8caa53aadeff92477616604;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10870 .

_:807f36cf91fe4e8caa53aadeff92477616606 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11332-1 a owl:Class;
  rdfs:label "NORFLOXACINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11332";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616608;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Surveillance clinique et électrocardiographique pendant
l'association."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616614, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616608 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616609 .

_:807f36cf91fe4e8caa53aadeff92477616609 rdf:first _:807f36cf91fe4e8caa53aadeff92477616610;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616611 .

_:807f36cf91fe4e8caa53aadeff92477616610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477616611 rdf:first _:807f36cf91fe4e8caa53aadeff92477616612;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10650 .

_:807f36cf91fe4e8caa53aadeff92477616614 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10426-1 a owl:Class;
  rdfs:label "AUTRES RÉTINOÏDES <-> RÉTINOÏDES"@fr;
  dct:identifier "IAM_10426";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616616;
  r:natureDuRisque "Risque de symptômes évocateurs d’une hypervitaminose A."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616618, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616616 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff92477616618 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11367-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> SUCRALFATE"@fr;
  dct:identifier "IAM_11367";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616620;
  r:natureDuRisque "Diminution de l'absorption digestive de la phénytoïne."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance de la phénytoïne (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616626, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616620 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616621 .

_:807f36cf91fe4e8caa53aadeff92477616621 rdf:first _:807f36cf91fe4e8caa53aadeff92477616622;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616623 .

_:807f36cf91fe4e8caa53aadeff92477616622 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477616623 rdf:first _:807f36cf91fe4e8caa53aadeff92477616624;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616624 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:807f36cf91fe4e8caa53aadeff92477616626 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11395-1 a owl:Class;
  rdfs:label "QUINIDINE <-> TRICLABENDAZOLE"@fr;
  dct:identifier "IAM_11395";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616628;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes (inhibition du métabolisme hépatique du médicament torsadogène)."@fr;
  r:conduiteATenir "Respecter un délai de 24 heures entre l’arrêt du triclabendazole et la prise du médicament torsadogène, et inversement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616634, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616628 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616629 .

_:807f36cf91fe4e8caa53aadeff92477616629 rdf:first _:807f36cf91fe4e8caa53aadeff92477616630;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616631 .

_:807f36cf91fe4e8caa53aadeff92477616630 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477616631 rdf:first _:807f36cf91fe4e8caa53aadeff92477616632;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616632 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10953 .

_:807f36cf91fe4e8caa53aadeff92477616634 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11396-1 a owl:Class;
  rdfs:label "QUINIDINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11396";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616636;
  r:natureDuRisque "Risque de majoration importante des effets hémodynamiques du vérapamil, avec hypotension et bradycardie sévères."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616642, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616636 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616637 .

_:807f36cf91fe4e8caa53aadeff92477616637 rdf:first _:807f36cf91fe4e8caa53aadeff92477616638;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616639 .

_:807f36cf91fe4e8caa53aadeff92477616638 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477616639 rdf:first _:807f36cf91fe4e8caa53aadeff92477616640;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616640 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477616642 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11397-1 a owl:Class;
  rdfs:label "QUINIDINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11397";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616644;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616650, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616644 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616645 .

_:807f36cf91fe4e8caa53aadeff92477616645 rdf:first _:807f36cf91fe4e8caa53aadeff92477616646;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616647 .

_:807f36cf91fe4e8caa53aadeff92477616646 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477616647 rdf:first _:807f36cf91fe4e8caa53aadeff92477616648;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616648 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477616650 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11398-1 a owl:Class;
  rdfs:label "QUINIDINE <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_11398";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616652;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution importante de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par la quinidine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616658, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616652 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616653 .

_:807f36cf91fe4e8caa53aadeff92477616653 rdf:first _:807f36cf91fe4e8caa53aadeff92477616654;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616655 .

_:807f36cf91fe4e8caa53aadeff92477616654 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477616655 rdf:first _:807f36cf91fe4e8caa53aadeff92477616656;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616656 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:807f36cf91fe4e8caa53aadeff92477616658 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11399-1 a owl:Class;
  rdfs:label "QUININE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11399";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616660;
  r:natureDuRisque "Risque de perte de l’efficacité de la quinine par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616666, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616660 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616661 .

_:807f36cf91fe4e8caa53aadeff92477616661 rdf:first _:807f36cf91fe4e8caa53aadeff92477616662;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616663 .

_:807f36cf91fe4e8caa53aadeff92477616662 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:807f36cf91fe4e8caa53aadeff92477616663 rdf:first _:807f36cf91fe4e8caa53aadeff92477616664;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616664 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616666 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11400-1 a owl:Class;
  rdfs:label "RALTÉGRAVIR <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11400";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616668;
  r:natureDuRisque "Diminution des concentrations du raltégravir par la rifampicine."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, un doublement de la dose de raltégravir peut être envisagé."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616674, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616668 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616669 .

_:807f36cf91fe4e8caa53aadeff92477616669 rdf:first _:807f36cf91fe4e8caa53aadeff92477616670;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616671 .

_:807f36cf91fe4e8caa53aadeff92477616670 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10781 .

_:807f36cf91fe4e8caa53aadeff92477616671 rdf:first _:807f36cf91fe4e8caa53aadeff92477616672;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616672 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616674 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11401-1 a owl:Class;
  rdfs:label "RANOLAZINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11401";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616676;
  r:natureDuRisque "Diminution très importante des concentrations de ranolazine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616682, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616676 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616677 .

_:807f36cf91fe4e8caa53aadeff92477616677 rdf:first _:807f36cf91fe4e8caa53aadeff92477616678;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616679 .

_:807f36cf91fe4e8caa53aadeff92477616678 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:807f36cf91fe4e8caa53aadeff92477616679 rdf:first _:807f36cf91fe4e8caa53aadeff92477616680;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616680 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616682 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11402-1 a owl:Class;
  rdfs:label "RANOLAZINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11402";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616684;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par inhibition du métabolisme de la simvastatine par la ranolazine."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/j de simvastatine ou utiliser une autre statine non concernée par ce type d’interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616690, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616684 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616685 .

_:807f36cf91fe4e8caa53aadeff92477616685 rdf:first _:807f36cf91fe4e8caa53aadeff92477616686;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616687 .

_:807f36cf91fe4e8caa53aadeff92477616686 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:807f36cf91fe4e8caa53aadeff92477616687 rdf:first _:807f36cf91fe4e8caa53aadeff92477616688;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616688 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477616690 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11393-1 a owl:Class;
  rdfs:label "QUINIDINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11393";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616692;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616698, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616692 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616693 .

_:807f36cf91fe4e8caa53aadeff92477616693 rdf:first _:807f36cf91fe4e8caa53aadeff92477616694;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616695 .

_:807f36cf91fe4e8caa53aadeff92477616694 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477616695 rdf:first _:807f36cf91fe4e8caa53aadeff92477616696;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616696 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477616698 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11256-1 a owl:Class;
  rdfs:label "MÉDICAMENTS ADMINISTRÉS PAR VOIE ORALE <-> RÉSINES CHÉLATRICES"@fr;
  dct:identifier "IAM_11256";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616700;
  r:natureDuRisque "La prise de résine chélatrice peut diminuer l’absorption intestinale et, potentiellement, l’efficacité d’autres médicaments pris simultanément."@fr;
  r:conduiteATenir "D’une façon générale, la prise de la résine doit se faire à distance de celle des autres médicaments, en respectant un intervalle de plus de 2 heures, si possible."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616706, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616700 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616701 .

_:807f36cf91fe4e8caa53aadeff92477616701 rdf:first _:807f36cf91fe4e8caa53aadeff92477616702;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616703 .

_:807f36cf91fe4e8caa53aadeff92477616702 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477616703 rdf:first _:807f36cf91fe4e8caa53aadeff92477616704;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616704 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10166 .

_:807f36cf91fe4e8caa53aadeff92477616706 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11392-1 a owl:Class;
  rdfs:label "QUETIAPINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11392";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616708;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de quétiapine par augmentation de son métabolisme hépatique par l'inducteur, avec risque d’inefficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616714, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616708 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616709 .

_:807f36cf91fe4e8caa53aadeff92477616709 rdf:first _:807f36cf91fe4e8caa53aadeff92477616710;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616711 .

_:807f36cf91fe4e8caa53aadeff92477616710 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10773 .

_:807f36cf91fe4e8caa53aadeff92477616711 rdf:first _:807f36cf91fe4e8caa53aadeff92477616712;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616712 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616714 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11404-1 a owl:Class;
  rdfs:label "RÉTINOÏDES <-> VITAMINE A"@fr;
  dct:identifier "IAM_11404";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616716;
  r:natureDuRisque "Risque de symptômes évocateurs d’une hypervitaminose A."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616722, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616716 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616717 .

_:807f36cf91fe4e8caa53aadeff92477616717 rdf:first _:807f36cf91fe4e8caa53aadeff92477616718;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616719 .

_:807f36cf91fe4e8caa53aadeff92477616718 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10141 .

_:807f36cf91fe4e8caa53aadeff92477616719 rdf:first _:807f36cf91fe4e8caa53aadeff92477616720;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616720 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10997 .

_:807f36cf91fe4e8caa53aadeff92477616722 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11405-1 a owl:Class;
  rdfs:label "RIBAVIRINE <-> STAVUDINE"@fr;
  dct:identifier "IAM_11405";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616724;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral, par antagonisme compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616730, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616724 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616725 .

_:807f36cf91fe4e8caa53aadeff92477616725 rdf:first _:807f36cf91fe4e8caa53aadeff92477616726;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616727 .

_:807f36cf91fe4e8caa53aadeff92477616726 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10797 .

_:807f36cf91fe4e8caa53aadeff92477616727 rdf:first _:807f36cf91fe4e8caa53aadeff92477616728;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616728 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10858 .

_:807f36cf91fe4e8caa53aadeff92477616730 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11406-1 a owl:Class;
  rdfs:label "RIBAVIRINE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_11406";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616732;
  r:natureDuRisque "Risque de diminution de l'efficacité de chaque antiviral, par antagonisme compétitif de la réaction de phosphorylation à l'origine des métabolites actifs."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616738, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616732 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616733 .

_:807f36cf91fe4e8caa53aadeff92477616733 rdf:first _:807f36cf91fe4e8caa53aadeff92477616734;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616735 .

_:807f36cf91fe4e8caa53aadeff92477616734 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10797 .

_:807f36cf91fe4e8caa53aadeff92477616735 rdf:first _:807f36cf91fe4e8caa53aadeff92477616736;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616736 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:807f36cf91fe4e8caa53aadeff92477616738 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11407-1 a owl:Class;
  rdfs:label "RIFABUTINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_11407";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616740;
  r:natureDuRisque "Diminution des concentrations plasmatiques du voriconazole avec risque de perte d'efficacité, par augmentation de son métabolisme hépatique par la rifabutine d'une part, et risque d'augmentation des effets indésirables (uvéites) de la rifabutine d'autre p"@fr;
  r:conduiteATenir "Si l'association est jugée néccessaire, surveillance clinique et adaptation de la posologie du voriconazole (en général doublée) pendant le traitement par la rifabutine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616746, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616740 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616741 .

_:807f36cf91fe4e8caa53aadeff92477616741 rdf:first _:807f36cf91fe4e8caa53aadeff92477616742;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616743 .

_:807f36cf91fe4e8caa53aadeff92477616742 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477616743 rdf:first _:807f36cf91fe4e8caa53aadeff92477616744;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616744 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477616746 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11408-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> RIVAROXABAN"@fr;
  dct:identifier "IAM_11408";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616748;
  r:natureDuRisque "Diminution des concentrations plasmatiques de rivaroxaban, avec risque de diminution de l'effet thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616754, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616748 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616749 .

_:807f36cf91fe4e8caa53aadeff92477616749 rdf:first _:807f36cf91fe4e8caa53aadeff92477616750;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616751 .

_:807f36cf91fe4e8caa53aadeff92477616750 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616751 rdf:first _:807f36cf91fe4e8caa53aadeff92477616752;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616752 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10808 .

_:807f36cf91fe4e8caa53aadeff92477616754 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11409-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11409";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616756;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de simvastatine, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616756 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616757 .

_:807f36cf91fe4e8caa53aadeff92477616757 rdf:first _:807f36cf91fe4e8caa53aadeff92477616758;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616759 .

_:807f36cf91fe4e8caa53aadeff92477616758 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616759 rdf:first _:807f36cf91fe4e8caa53aadeff92477616760;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477616762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11410-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11410";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616764;
  r:natureDuRisque "Diminution très importante des concentrations de télaprévir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616765 .

_:807f36cf91fe4e8caa53aadeff92477616765 rdf:first _:807f36cf91fe4e8caa53aadeff92477616766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616767 .

_:807f36cf91fe4e8caa53aadeff92477616766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616767 rdf:first _:807f36cf91fe4e8caa53aadeff92477616768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477616770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11411-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_11411";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616772;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques de la télithromycine, avec risque d'échec du traitement anti-infectieux, par augmentation du métabolisme hépatique de la télithromycine par la rifampicine."@fr;
  rdfs:comment """La rifampicine est l'un des inducteurs enzymatiques les plus puissants. Administrée avec la télithromycine, elle diminue ses concentrations de 80%.
Le risque important d'échec de l'antibiothérapie justifie une association déconseillée."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616773 .

_:807f36cf91fe4e8caa53aadeff92477616773 rdf:first _:807f36cf91fe4e8caa53aadeff92477616774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616775 .

_:807f36cf91fe4e8caa53aadeff92477616774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616775 rdf:first _:807f36cf91fe4e8caa53aadeff92477616776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477616778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11412-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11412";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616780;
  r:natureDuRisque "Diminution des concentrations plasmatiques du ténofovir alafénamide par diminution de son absorption par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association et 1 à 2 semaines après l’arrêt de la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616781 .

_:807f36cf91fe4e8caa53aadeff92477616781 rdf:first _:807f36cf91fe4e8caa53aadeff92477616782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616783 .

_:807f36cf91fe4e8caa53aadeff92477616782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616783 rdf:first _:807f36cf91fe4e8caa53aadeff92477616784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477616786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11413-1 a owl:Class;
  rdfs:label "RIFAMPICINE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11413";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616788;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de la terbinafine, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la terbinafine pendant le traitement par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616789 .

_:807f36cf91fe4e8caa53aadeff92477616789 rdf:first _:807f36cf91fe4e8caa53aadeff92477616790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616791 .

_:807f36cf91fe4e8caa53aadeff92477616790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616791 rdf:first _:807f36cf91fe4e8caa53aadeff92477616792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477616794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11403-1 a owl:Class;
  rdfs:label "REPAGLINIDE <-> TRIMETHOPRIME"@fr;
  dct:identifier "IAM_11403";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616796;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de répaglinide par inhibition de son métabolisme hépatique par le triméthoprime."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et biologique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616797 .

_:807f36cf91fe4e8caa53aadeff92477616797 rdf:first _:807f36cf91fe4e8caa53aadeff92477616798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616799 .

_:807f36cf91fe4e8caa53aadeff92477616798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:807f36cf91fe4e8caa53aadeff92477616799 rdf:first _:807f36cf91fe4e8caa53aadeff92477616800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10955 .

_:807f36cf91fe4e8caa53aadeff92477616802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11379-1 a owl:Class;
  rdfs:label "POSACONAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11379";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616804;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité des deux anti-infectieux (induction enzymatique par la rifampicine et diminution de l'absorption intestinale par l’azolé antifongique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616805 .

_:807f36cf91fe4e8caa53aadeff92477616805 rdf:first _:807f36cf91fe4e8caa53aadeff92477616806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616807 .

_:807f36cf91fe4e8caa53aadeff92477616806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477616807 rdf:first _:807f36cf91fe4e8caa53aadeff92477616808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11095-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> METHADONE"@fr;
  dct:identifier "IAM_11095";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616812;
  r:natureDuRisque "Diminution des concentrations plasmatiques de méthadone avec risque d'apparition d'un syndrome de sevrage, par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Augmenter la fréquence des prises de méthadone (2 à 3 fois par jour au lieu d'une fois par jour)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616813 .

_:807f36cf91fe4e8caa53aadeff92477616813 rdf:first _:807f36cf91fe4e8caa53aadeff92477616814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616815 .

_:807f36cf91fe4e8caa53aadeff92477616814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477616815 rdf:first _:807f36cf91fe4e8caa53aadeff92477616816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477616818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11370-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> SULFAMETHOXAZOLE"@fr;
  dct:identifier "IAM_11370";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616820;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne jusqu'à des valeurs toxiques (inhibition de son métabolisme)."@fr;
  r:conduiteATenir "Utiliser de préférence une autre classe d'anti-infectieux, sinon surveillance clinique étroite, dosage des concentrations de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par le sulfamide anti-infectieux et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616821 .

_:807f36cf91fe4e8caa53aadeff92477616821 rdf:first _:807f36cf91fe4e8caa53aadeff92477616822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616823 .

_:807f36cf91fe4e8caa53aadeff92477616822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477616823 rdf:first _:807f36cf91fe4e8caa53aadeff92477616824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10871 .

_:807f36cf91fe4e8caa53aadeff92477616826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11371-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> TICLOPIDINE"@fr;
  dct:identifier "IAM_11371";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616828;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec signes de surdosage (inhibition du métabolisme de la phénytoïne)."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénytoïne."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616829 .

_:807f36cf91fe4e8caa53aadeff92477616829 rdf:first _:807f36cf91fe4e8caa53aadeff92477616830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616831 .

_:807f36cf91fe4e8caa53aadeff92477616830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477616831 rdf:first _:807f36cf91fe4e8caa53aadeff92477616832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10928 .

_:807f36cf91fe4e8caa53aadeff92477616834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11372-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_11372";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616836;
  r:natureDuRisque "Augmentation de l'hyperammoniémie, avec risque accru d'encéphalopathie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616837 .

_:807f36cf91fe4e8caa53aadeff92477616837 rdf:first _:807f36cf91fe4e8caa53aadeff92477616838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616839 .

_:807f36cf91fe4e8caa53aadeff92477616838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477616839 rdf:first _:807f36cf91fe4e8caa53aadeff92477616840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477616842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11373-1 a owl:Class;
  rdfs:label "PIMOZIDE <-> QUINUPRISTINE"@fr;
  dct:identifier "IAM_11373";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616844;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616845 .

_:807f36cf91fe4e8caa53aadeff92477616845 rdf:first _:807f36cf91fe4e8caa53aadeff92477616846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616847 .

_:807f36cf91fe4e8caa53aadeff92477616846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477616847 rdf:first _:807f36cf91fe4e8caa53aadeff92477616848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10778 .

_:807f36cf91fe4e8caa53aadeff92477616850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11374-1 a owl:Class;
  rdfs:label "PIMOZIDE <-> SERTRALINE"@fr;
  dct:identifier "IAM_11374";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616852;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:comment """Le pimozide est un neuroleptique métabolisé par le CYP3A4 et à marge thérapeutique étroite. Il peut entraîner des torsades de pointes en cas de surdosage.
Une étude d’interaction pharmacocinétique entre la sertraline et le pimozide a été réalisée chez 15"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616858, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616852 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616853 .

_:807f36cf91fe4e8caa53aadeff92477616853 rdf:first _:807f36cf91fe4e8caa53aadeff92477616854;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616855 .

_:807f36cf91fe4e8caa53aadeff92477616854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477616855 rdf:first _:807f36cf91fe4e8caa53aadeff92477616856;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10831 .

_:807f36cf91fe4e8caa53aadeff92477616858 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11375-1 a owl:Class;
  rdfs:label "PIMOZIDE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_11375";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616860;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616860 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616861 .

_:807f36cf91fe4e8caa53aadeff92477616861 rdf:first _:807f36cf91fe4e8caa53aadeff92477616862;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616863 .

_:807f36cf91fe4e8caa53aadeff92477616862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477616863 rdf:first _:807f36cf91fe4e8caa53aadeff92477616864;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477616866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11376-1 a owl:Class;
  rdfs:label "PIMOZIDE <-> TRICLABENDAZOLE"@fr;
  dct:identifier "IAM_11376";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616868;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes (inhibition du métabolisme hépatique du médicament torsadogène)."@fr;
  r:conduiteATenir "Respecter un délai de 24 heures entre l’arrêt du triclabendazole et la prise du médicament torsadogène, et inversement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616869 .

_:807f36cf91fe4e8caa53aadeff92477616869 rdf:first _:807f36cf91fe4e8caa53aadeff92477616870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616871 .

_:807f36cf91fe4e8caa53aadeff92477616870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477616871 rdf:first _:807f36cf91fe4e8caa53aadeff92477616872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10953 .

_:807f36cf91fe4e8caa53aadeff92477616874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11377-1 a owl:Class;
  rdfs:label "PIOGLITAZONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11377";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616876;
  r:natureDuRisque """Diminution des concentrations plasmatiques de la glitazone par
augmentation de son métabolisme par la rifampicine."""@fr;
  r:conduiteATenir """Surveillance clinique et biologique ; adaptation de la posologie de la
glitazone pendant le traitement par la rifampicine et après son arrêt."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616877 .

_:807f36cf91fe4e8caa53aadeff92477616877 rdf:first _:807f36cf91fe4e8caa53aadeff92477616878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616879 .

_:807f36cf91fe4e8caa53aadeff92477616878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10723 .

_:807f36cf91fe4e8caa53aadeff92477616879 rdf:first _:807f36cf91fe4e8caa53aadeff92477616880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11394-1 a owl:Class;
  rdfs:label "QUINIDINE <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_11394";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616884;
  r:natureDuRisque "Risque de baisse de l'efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la quinidine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616885 .

_:807f36cf91fe4e8caa53aadeff92477616885 rdf:first _:807f36cf91fe4e8caa53aadeff92477616886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616887 .

_:807f36cf91fe4e8caa53aadeff92477616886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477616887 rdf:first _:807f36cf91fe4e8caa53aadeff92477616888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:807f36cf91fe4e8caa53aadeff92477616890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11378-1 a owl:Class;
  rdfs:label "POSACONAZOLE <-> RIFABUTINE"@fr;
  dct:identifier "IAM_11378";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616892;
  r:natureDuRisque "Risque d'accroissement des effets indésirables de la rifabutine (uvéites), par augmentation de ses concentrations et de celles de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616898, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616892 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616893 .

_:807f36cf91fe4e8caa53aadeff92477616893 rdf:first _:807f36cf91fe4e8caa53aadeff92477616894;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616895 .

_:807f36cf91fe4e8caa53aadeff92477616894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477616895 rdf:first _:807f36cf91fe4e8caa53aadeff92477616896;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477616898 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11368-1 a owl:Class;
  rdfs:label "PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE) <-> SULFAFURAZOL"@fr;
  dct:identifier "IAM_11368";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616900;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne jusqu'à des valeurs toxiques (inhibition de son métabolisme)."@fr;
  r:conduiteATenir "Utiliser de préférence une autre classe d'anti-infectieux, sinon surveillance clinique étroite, dosage des concentrations de phénytoïne et adaptation éventuelle de sa posologie pendant le traitement par le sulfamide anti-infectieux et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616906, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616900 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616901 .

_:807f36cf91fe4e8caa53aadeff92477616901 rdf:first _:807f36cf91fe4e8caa53aadeff92477616902;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616903 .

_:807f36cf91fe4e8caa53aadeff92477616902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477616903 rdf:first _:807f36cf91fe4e8caa53aadeff92477616904;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10868 .

_:807f36cf91fe4e8caa53aadeff92477616906 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11380-1 a owl:Class;
  rdfs:label "POSACONAZOLE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11380";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616908;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l’inhibiteur de l’HMG-CoA reductase)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616914, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616908 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616909 .

_:807f36cf91fe4e8caa53aadeff92477616909 rdf:first _:807f36cf91fe4e8caa53aadeff92477616910;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616911 .

_:807f36cf91fe4e8caa53aadeff92477616910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477616911 rdf:first _:807f36cf91fe4e8caa53aadeff92477616912;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477616914 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11382-1 a owl:Class;
  rdfs:label "POTASSIUM <-> TACROLIMUS"@fr;
  dct:identifier "IAM_11382";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616916;
  r:natureDuRisque "Hyperkaliémie essentiellement létale, surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Eviter cette association sauf s'il existe une hypokaliémie préalable."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616922, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616916 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616917 .

_:807f36cf91fe4e8caa53aadeff92477616917 rdf:first _:807f36cf91fe4e8caa53aadeff92477616918;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616919 .

_:807f36cf91fe4e8caa53aadeff92477616918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:807f36cf91fe4e8caa53aadeff92477616919 rdf:first _:807f36cf91fe4e8caa53aadeff92477616920;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477616922 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11383-1 a owl:Class;
  rdfs:label "PRAZIQUANTEL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11383";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616924;
  r:natureDuRisque "Diminution très importante des concentrations plasmatiques du praziquantel, avec risque d'échec du traitement, par augmentation du métabolisme hépatique du praziquantel par la rifampicine."@fr;
  rdfs:comment """Une étude montre que l'effet inducteur puissant de la rifampicine retentit de façon majeure sur le métabolisme du praziquantel, avec une diminution de l'AUC de 90%.
Bien que la durée du traitement antiparasitaire soit brève, une association déconseillée s"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616930, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616924 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616925 .

_:807f36cf91fe4e8caa53aadeff92477616925 rdf:first _:807f36cf91fe4e8caa53aadeff92477616926;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616927 .

_:807f36cf91fe4e8caa53aadeff92477616926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10750 .

_:807f36cf91fe4e8caa53aadeff92477616927 rdf:first _:807f36cf91fe4e8caa53aadeff92477616928;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616930 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11385-1 a owl:Class;
  rdfs:label "PROGESTATIFS CONTRACEPTIFS <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11385";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616932;
  r:natureDuRisque "Risque d'antagonisme des effets du progestatif."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive additionnelle de type mécanique pendant quelques jours après l’arrêt de l’ulipristal."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616938, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616932 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616933 .

_:807f36cf91fe4e8caa53aadeff92477616933 rdf:first _:807f36cf91fe4e8caa53aadeff92477616934;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616935 .

_:807f36cf91fe4e8caa53aadeff92477616934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10134 .

_:807f36cf91fe4e8caa53aadeff92477616935 rdf:first _:807f36cf91fe4e8caa53aadeff92477616936;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477616938 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11386-1 a owl:Class;
  rdfs:label "PROGESTATIFS NON CONTRACEPTIFS, ASSOCIÉS OU NON À UN ESTROGÈNE <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_11386";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616940;
  r:natureDuRisque "Risque d'antagonisme des effets du progestatif."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive additionnelle de type mécanique pendant quelques jours après l’arrêt de l’ulipristal."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616946, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616940 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616941 .

_:807f36cf91fe4e8caa53aadeff92477616941 rdf:first _:807f36cf91fe4e8caa53aadeff92477616942;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616943 .

_:807f36cf91fe4e8caa53aadeff92477616942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10135 .

_:807f36cf91fe4e8caa53aadeff92477616943 rdf:first _:807f36cf91fe4e8caa53aadeff92477616944;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477616946 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11387-1 a owl:Class;
  rdfs:label "PROPAFENONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11387";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616948;
  r:natureDuRisque "Diminution des concentrations plasmatiques de la propafénone, par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. S'il y a lieu, adaptation de la posologie de la propafénone pendant l'association et après l'arrêt de la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616954, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616948 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616949 .

_:807f36cf91fe4e8caa53aadeff92477616949 rdf:first _:807f36cf91fe4e8caa53aadeff92477616950;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616951 .

_:807f36cf91fe4e8caa53aadeff92477616950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477616951 rdf:first _:807f36cf91fe4e8caa53aadeff92477616952;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616954 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11388-1 a owl:Class;
  rdfs:label "PROPAFENONE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_11388";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616956;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la propafénone, par diminution de son métabolisme hépatique par la terbinafine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie de la propafénone pendant le traitement par la terbinafine."@fr;
  rdfs:comment """L’effet inhibiteur enzymatique de la terbinafine sur le CYP2D6 a été suggéré sur l’observation chez 12 volontaires sains d’une diminution du métabolisme hépatique de la désipramine, marqueur de l’activité de ce cytochrome.
Afin de prendre acte de cet effe"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616962, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616956 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616957 .

_:807f36cf91fe4e8caa53aadeff92477616957 rdf:first _:807f36cf91fe4e8caa53aadeff92477616958;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616959 .

_:807f36cf91fe4e8caa53aadeff92477616958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477616959 rdf:first _:807f36cf91fe4e8caa53aadeff92477616960;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477616962 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11389-1 a owl:Class;
  rdfs:label "PROPAFENONE <-> THEOPHYLLINE"@fr;
  dct:identifier "IAM_11389";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616964;
  r:natureDuRisque "Risque d’augmentation de la théophyllinémie par diminution de son métabolisme hépatique par la propafénone."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616970, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616964 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616965 .

_:807f36cf91fe4e8caa53aadeff92477616965 rdf:first _:807f36cf91fe4e8caa53aadeff92477616966;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616967 .

_:807f36cf91fe4e8caa53aadeff92477616966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477616967 rdf:first _:807f36cf91fe4e8caa53aadeff92477616968;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10915 .

_:807f36cf91fe4e8caa53aadeff92477616970 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11390-1 a owl:Class;
  rdfs:label "PROPRANOLOL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11390";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616972;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du bêta-bloquant (augmentation de son métabolisme hépatique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616978, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616972 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616973 .

_:807f36cf91fe4e8caa53aadeff92477616973 rdf:first _:807f36cf91fe4e8caa53aadeff92477616974;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616975 .

_:807f36cf91fe4e8caa53aadeff92477616974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10767 .

_:807f36cf91fe4e8caa53aadeff92477616975 rdf:first _:807f36cf91fe4e8caa53aadeff92477616976;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477616978 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11391-1 a owl:Class;
  rdfs:label "PYRIMETHAMINE <-> TRIMETHOPRIME"@fr;
  dct:identifier "IAM_11391";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616980;
  r:natureDuRisque "Anémie mégaloblastique, plus particulièrement à fortes doses des deux produits (déficit en acide folique par l'association de deux 2-4 diaminopyrimidines)."@fr;
  r:conduiteATenir "Contrôle régulier de l'hémogramme et association d'un traitement par l'acide folique (injections IM régulières)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616986, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616980 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616981 .

_:807f36cf91fe4e8caa53aadeff92477616981 rdf:first _:807f36cf91fe4e8caa53aadeff92477616982;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616983 .

_:807f36cf91fe4e8caa53aadeff92477616982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10772 .

_:807f36cf91fe4e8caa53aadeff92477616983 rdf:first _:807f36cf91fe4e8caa53aadeff92477616984;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10955 .

_:807f36cf91fe4e8caa53aadeff92477616986 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11381-1 a owl:Class;
  rdfs:label "POSACONAZOLE <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11381";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616988;
  r:natureDuRisque "Majoration de la neurotoxicité de l'antimitotique, par diminution de son métabolisme hépatique par le posaconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477616994, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616988 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616989 .

_:807f36cf91fe4e8caa53aadeff92477616989 rdf:first _:807f36cf91fe4e8caa53aadeff92477616990;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616991 .

_:807f36cf91fe4e8caa53aadeff92477616990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477616991 rdf:first _:807f36cf91fe4e8caa53aadeff92477616992;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477616992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477616994 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10823-1 a owl:Class;
  rdfs:label "DIURÉTIQUES DE L'ANSE <-> LITHIUM"@fr;
  dct:identifier "IAM_10823";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477616996;
  r:natureDuRisque "Augmentation de la lithémie avec signes de surdosage en lithium, comme lors d’un régime désodé (diminution de l’excrétion urinaire du lithium)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance stricte de la lithémie et adaptation de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617002, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477616996 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477616997 .

_:807f36cf91fe4e8caa53aadeff92477616997 rdf:first _:807f36cf91fe4e8caa53aadeff92477616998;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477616999 .

_:807f36cf91fe4e8caa53aadeff92477616998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10064 .

_:807f36cf91fe4e8caa53aadeff92477616999 rdf:first _:807f36cf91fe4e8caa53aadeff92477617000;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477617002 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10812-1 a owl:Class;
  rdfs:label "DIMÉTHYLE ( FUMARATE DE) <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10812";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617004;
  r:natureDuRisque "Possible augmentation du risque infectieux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617010, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617004 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617005 .

_:807f36cf91fe4e8caa53aadeff92477617005 rdf:first _:807f36cf91fe4e8caa53aadeff92477617006;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617007 .

_:807f36cf91fe4e8caa53aadeff92477617006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477617007 rdf:first _:807f36cf91fe4e8caa53aadeff92477617008;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10292 .

_:807f36cf91fe4e8caa53aadeff92477617010 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10813-1 a owl:Class;
  rdfs:label "DIPROPHYLLINE <-> PROBENECIDE"@fr;
  dct:identifier "IAM_10813";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617012;
  r:natureDuRisque "Risque de surdosage par augmentation des concentrations plasmatiques de diprophylline (inhibition de sa sécrétion tubulaire rénale)."@fr;
  r:conduiteATenir "Réduire la posologie de diprophylline pendant le traitement par le probénécide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617018, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617012 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617013 .

_:807f36cf91fe4e8caa53aadeff92477617013 rdf:first _:807f36cf91fe4e8caa53aadeff92477617014;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617015 .

_:807f36cf91fe4e8caa53aadeff92477617014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10296 .

_:807f36cf91fe4e8caa53aadeff92477617015 rdf:first _:807f36cf91fe4e8caa53aadeff92477617016;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10758 .

_:807f36cf91fe4e8caa53aadeff92477617018 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10814-1 a owl:Class;
  rdfs:label "DIPYRIDAMOLE <-> THÉINE"@fr;
  dct:identifier "IAM_10814";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617020;
  r:natureDuRisque "Avec le dipyridamole par voie injectable : réduction de l’effet vasodilatateur du dipyridamole par la théine."@fr;
  r:conduiteATenir "Eviter la consommation de produits à base de théine dans les 24 heures qui précèdent une imagerie myocardique avec le dipyridamole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617026, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617020 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617021 .

_:807f36cf91fe4e8caa53aadeff92477617021 rdf:first _:807f36cf91fe4e8caa53aadeff92477617022;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617023 .

_:807f36cf91fe4e8caa53aadeff92477617022 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10297 .

_:807f36cf91fe4e8caa53aadeff92477617023 rdf:first _:807f36cf91fe4e8caa53aadeff92477617024;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617024 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11014 .

_:807f36cf91fe4e8caa53aadeff92477617026 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10815-1 a owl:Class;
  rdfs:label "DIPYRIDAMOLE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10815";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617028;
  r:natureDuRisque "Avec le dipyridamole par voie injectable : réduction de l’effet vasodilatateur du dipyridamole par la théophylline."@fr;
  r:conduiteATenir "Interrompre un traitement par théophylline au moins 5 jours avant une imagerie myocardique avec le dipyridamole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617034, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617028 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617029 .

_:807f36cf91fe4e8caa53aadeff92477617029 rdf:first _:807f36cf91fe4e8caa53aadeff92477617030;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617031 .

_:807f36cf91fe4e8caa53aadeff92477617030 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477617031 rdf:first _:807f36cf91fe4e8caa53aadeff92477617032;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617032 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10297 .

_:807f36cf91fe4e8caa53aadeff92477617034 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10816-1 a owl:Class;
  rdfs:label "DISOPYRAMIDE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10816";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617036;
  r:natureDuRisque "Risque de diminution des concentrations du disopyramide par l’inducteur."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement adaptation de la posologie du disopyramide pendant l’associaiton et 1 à 2 semaines après l’arrêt de l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617042, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617036 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617037 .

_:807f36cf91fe4e8caa53aadeff92477617037 rdf:first _:807f36cf91fe4e8caa53aadeff92477617038;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617039 .

_:807f36cf91fe4e8caa53aadeff92477617038 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477617039 rdf:first _:807f36cf91fe4e8caa53aadeff92477617040;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617040 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10298 .

_:807f36cf91fe4e8caa53aadeff92477617042 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10817-1 a owl:Class;
  rdfs:label "DISOPYRAMIDE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10817";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617044;
  r:natureDuRisque "Risque d’augmentation des effets indésirables du disopyramide par diminution de son métabolisme."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du disopyramide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617050, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617044 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617045 .

_:807f36cf91fe4e8caa53aadeff92477617045 rdf:first _:807f36cf91fe4e8caa53aadeff92477617046;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617047 .

_:807f36cf91fe4e8caa53aadeff92477617046 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477617047 rdf:first _:807f36cf91fe4e8caa53aadeff92477617048;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617048 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10298 .

_:807f36cf91fe4e8caa53aadeff92477617050 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10818-1 a owl:Class;
  rdfs:label "DISOPYRAMIDE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_10818";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617052;
  r:natureDuRisque "Risque de majoration des effets indésirables du disopyramide : hypoglycémies sévères, allongement de l’intervalle QT et troubles du rythme ventriculaire graves, notamment à type de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique, biologique et électrocardiographique régulière."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617058, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617052 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617053 .

_:807f36cf91fe4e8caa53aadeff92477617053 rdf:first _:807f36cf91fe4e8caa53aadeff92477617054;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617055 .

_:807f36cf91fe4e8caa53aadeff92477617054 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10298 .

_:807f36cf91fe4e8caa53aadeff92477617055 rdf:first _:807f36cf91fe4e8caa53aadeff92477617056;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617056 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477617058 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10819-1 a owl:Class;
  rdfs:label "DISULFIRAME <-> ISONIAZIDE"@fr;
  dct:identifier "IAM_10819";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617060;
  r:natureDuRisque "Troubles du comportement et de la coordination."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617066, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617060 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617061 .

_:807f36cf91fe4e8caa53aadeff92477617061 rdf:first _:807f36cf91fe4e8caa53aadeff92477617062;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617063 .

_:807f36cf91fe4e8caa53aadeff92477617062 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:807f36cf91fe4e8caa53aadeff92477617063 rdf:first _:807f36cf91fe4e8caa53aadeff92477617064;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10490 .

_:807f36cf91fe4e8caa53aadeff92477617066 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10820-1 a owl:Class;
  rdfs:label "DISULFIRAME <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_10820";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617068;
  r:natureDuRisque "Risque d’épisodes de psychose aiguë ou d’état confusionnel, réversibles à l’arrêt de l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617074, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617068 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617069 .

_:807f36cf91fe4e8caa53aadeff92477617069 rdf:first _:807f36cf91fe4e8caa53aadeff92477617070;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617071 .

_:807f36cf91fe4e8caa53aadeff92477617070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:807f36cf91fe4e8caa53aadeff92477617071 rdf:first _:807f36cf91fe4e8caa53aadeff92477617072;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:807f36cf91fe4e8caa53aadeff92477617074 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10786-1 a owl:Class;
  rdfs:label "DIGOXINE <-> RANOLAZINE"@fr;
  dct:identifier "IAM_10786";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617076;
  r:natureDuRisque "Augmentation de la digoxinémie."@fr;
  r:conduiteATenir "Surveillance clinique, biologique et éventuellement ECG. Adaptation de la posologie de la digoxine, si besoin."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617082, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617076 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617077 .

_:807f36cf91fe4e8caa53aadeff92477617077 rdf:first _:807f36cf91fe4e8caa53aadeff92477617078;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617079 .

_:807f36cf91fe4e8caa53aadeff92477617078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477617079 rdf:first _:807f36cf91fe4e8caa53aadeff92477617080;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10786 .

_:807f36cf91fe4e8caa53aadeff92477617082 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10822-1 a owl:Class;
  rdfs:label "DIURÉTIQUES <-> PRODUITS DE CONTRASTE IODÉS"@fr;
  dct:identifier "IAM_10822";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617084;
  r:natureDuRisque "En cas de déshydratation provoquée par les diurétiques, risque majoré d'insuffisance rénale fonctionnelle aiguë, en particulier lors d'utilisation de doses importantes de produits de contraste iodés."@fr;
  r:conduiteATenir "Réhydratation avant administration du produit iodé."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617084 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617085 .

_:807f36cf91fe4e8caa53aadeff92477617085 rdf:first _:807f36cf91fe4e8caa53aadeff92477617086;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617087 .

_:807f36cf91fe4e8caa53aadeff92477617086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10063 .

_:807f36cf91fe4e8caa53aadeff92477617087 rdf:first _:807f36cf91fe4e8caa53aadeff92477617088;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10133 .

_:807f36cf91fe4e8caa53aadeff92477617090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10809-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10809";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617092;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse, par diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  r:conduiteATenir "Ne pas dépasser la posologie de 20 mg/jour de simvastatine. Si l'objectif thérapeutique n'est pas atteint à cette posologie, utiliser une autre statine non concernée par ce type d'interaction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617093 .

_:807f36cf91fe4e8caa53aadeff92477617093 rdf:first _:807f36cf91fe4e8caa53aadeff92477617094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617095 .

_:807f36cf91fe4e8caa53aadeff92477617094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617095 rdf:first _:807f36cf91fe4e8caa53aadeff92477617096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477617098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10824-1 a owl:Class;
  rdfs:label "DIURÉTIQUES DE L'ANSE <-> METFORMINE"@fr;
  dct:identifier "IAM_10824";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617100;
  r:natureDuRisque "Acidose lactique due à la metformine, déclenchée par une éventuelle insuffisance rénale fonctionnelle, liée aux diurétiques de l'anse."@fr;
  r:conduiteATenir "Ne pas utiliser la metformine lorsque la créatininémie dépasse 15 mg/l (135 µmol/l) chez l'homme, et 12 mg/l (110 µmol/l) chez la femme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617101 .

_:807f36cf91fe4e8caa53aadeff92477617101 rdf:first _:807f36cf91fe4e8caa53aadeff92477617102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617103 .

_:807f36cf91fe4e8caa53aadeff92477617102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10064 .

_:807f36cf91fe4e8caa53aadeff92477617103 rdf:first _:807f36cf91fe4e8caa53aadeff92477617104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10566 .

_:807f36cf91fe4e8caa53aadeff92477617106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10825-1 a owl:Class;
  rdfs:label "DIURÉTIQUES DE L'ANSE <-> ORGANOPLATINES"@fr;
  dct:identifier "IAM_10825";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617108;
  r:natureDuRisque "Risque d’addition des effets ototoxiques et/ou néphrotoxiques."@fr;
  rdfs:comment """La néphrotoxicité et l’ototoxicité des organoplatines, cytotoxiques majoritairement éliminés par voie rénale, sont bien documentées. L’administration concomitante avec un médicament diminuant leur élimination rénale peut majorer ce risque.
En favorisant l"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617109 .

_:807f36cf91fe4e8caa53aadeff92477617109 rdf:first _:807f36cf91fe4e8caa53aadeff92477617110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617111 .

_:807f36cf91fe4e8caa53aadeff92477617110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10064 .

_:807f36cf91fe4e8caa53aadeff92477617111 rdf:first _:807f36cf91fe4e8caa53aadeff92477617112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10129 .

_:807f36cf91fe4e8caa53aadeff92477617114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10413-1 a owl:Class;
  rdfs:label "AUTRES DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10413";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617116;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, notamment chez l'insuffisant rénal (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Contre-indiqué sauf s'il existe une hypokaliémie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617118, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617116 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477617118 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10830-1 a owl:Class;
  rdfs:label "DIURÉTIQUES HYPOKALIÉMIANTS <-> DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS)"@fr;
  dct:identifier "IAM_10830";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617120;
  r:natureDuRisque "L'association rationnelle, utile pour certains patients, n'exclut pas la survenue d'hypokaliémie ou, en particulier chez l'insuffisant rénal et le diabétique, d'hyperkaliémie."@fr;
  r:conduiteATenir "Surveiller la kaliémie, éventuellement l'ECG et, s'il y a lieu, reconsidérer le traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617126, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617120 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617121 .

_:807f36cf91fe4e8caa53aadeff92477617121 rdf:first _:807f36cf91fe4e8caa53aadeff92477617122;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617123 .

_:807f36cf91fe4e8caa53aadeff92477617122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:807f36cf91fe4e8caa53aadeff92477617123 rdf:first _:807f36cf91fe4e8caa53aadeff92477617124;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477617126 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10826-1 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10826";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617128;
  r:natureDuRisque "Risque d'hyperkaliémie (potentiellement létale) surtout en cas d'insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir """Précaution d'emploi :
- pour la spironolactone à des doses comprises entre 12,5 mg et 50 mg/jour, et pour l’éplérénone utilisées dans le traitement de l'insuffisance cardiaque, ainsi qu'en cas d'hypokaliémie : contrôle strict de la kaliémie et de la fonct"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617134, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617128 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617129 .

_:807f36cf91fe4e8caa53aadeff92477617129 rdf:first _:807f36cf91fe4e8caa53aadeff92477617130;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617131 .

_:807f36cf91fe4e8caa53aadeff92477617130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477617131 rdf:first _:807f36cf91fe4e8caa53aadeff92477617132;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477617134 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10827-1 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> LITHIUM"@fr;
  dct:identifier "IAM_10827";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617136;
  r:natureDuRisque "Augmentation de la lithémie avec signes de surdosage en lithium, comme lors d’un régime désodé (diminution de l’excrétion urinaire du lithium)."@fr;
  r:conduiteATenir "Surveillance stricte de la lithémie et adaptation éventuelle de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617142, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617136 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617137 .

_:807f36cf91fe4e8caa53aadeff92477617137 rdf:first _:807f36cf91fe4e8caa53aadeff92477617138;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617139 .

_:807f36cf91fe4e8caa53aadeff92477617138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477617139 rdf:first _:807f36cf91fe4e8caa53aadeff92477617140;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477617142 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10828-1 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> POTASSIUM"@fr;
  dct:identifier "IAM_10828";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617144;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, notamment chez l'insuffisant rénal (addition des effets hyperkaliémiants)."@fr;
  r:conduiteATenir "Association déconseillée:-en cas d'hypokaliémie ou d'utilisation parentérale des sels de potassium"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617150, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617144 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617145 .

_:807f36cf91fe4e8caa53aadeff92477617145 rdf:first _:807f36cf91fe4e8caa53aadeff92477617146;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617147 .

_:807f36cf91fe4e8caa53aadeff92477617146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477617147 rdf:first _:807f36cf91fe4e8caa53aadeff92477617148;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10742 .

_:807f36cf91fe4e8caa53aadeff92477617150 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10829-1 a owl:Class;
  rdfs:label "DIURÉTIQUES ÉPARGNEURS DE POTASSIUM (SEULS OU ASSOCIÉS) <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10829";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617152;
  r:natureDuRisque "Hyperkaliémie potentiellement létale, surtout lors d'une insuffisance rénale (addition des effets hyperkaliémiants)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617158, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617152 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617153 .

_:807f36cf91fe4e8caa53aadeff92477617153 rdf:first _:807f36cf91fe4e8caa53aadeff92477617154;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617155 .

_:807f36cf91fe4e8caa53aadeff92477617154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10067 .

_:807f36cf91fe4e8caa53aadeff92477617155 rdf:first _:807f36cf91fe4e8caa53aadeff92477617156;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477617158 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10831-1 a owl:Class;
  rdfs:label "DIURÉTIQUES HYPOKALIÉMIANTS <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10831";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617160;
  r:natureDuRisque "Risque d'hypotension artérielle brutale et/ou d'insuffisance rénale aiguë lors de l'instauration ou de l'augmentation de la posologie d'un traitement par un inhibiteur de l'enzyme de conversion en cas de déplétion hydrosodée préexistante."@fr;
  r:conduiteATenir """Dans l'hypertension artérielle, lorsqu'un traitement diurétique préalable a pu entraîner une déplétion hydrosodée, il faut : 
- soit arrêter le diurétique avant de débuter le traitement par l'IEC, et réintroduire un diurétique hypokaliémiant si nécessaire"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617166, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617160 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617161 .

_:807f36cf91fe4e8caa53aadeff92477617161 rdf:first _:807f36cf91fe4e8caa53aadeff92477617162;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617163 .

_:807f36cf91fe4e8caa53aadeff92477617162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10065 .

_:807f36cf91fe4e8caa53aadeff92477617163 rdf:first _:807f36cf91fe4e8caa53aadeff92477617164;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477617166 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10821-1 a owl:Class;
  rdfs:label "DISULFIRAME <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10821";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617168;
  r:natureDuRisque "Augmentation importante et rapide des concentrations plasmatiques de phénytoïne avec signes toxiques (inhibition de son métabolisme)."@fr;
  r:conduiteATenir "Si elle ne peut être évitée, contrôle clinique et des concentrations plasmatiques de phénytoïne pendant le traitement par le disulfirame et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617174, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617168 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617169 .

_:807f36cf91fe4e8caa53aadeff92477617169 rdf:first _:807f36cf91fe4e8caa53aadeff92477617170;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617171 .

_:807f36cf91fe4e8caa53aadeff92477617170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477617171 rdf:first _:807f36cf91fe4e8caa53aadeff92477617172;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10299 .

_:807f36cf91fe4e8caa53aadeff92477617174 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10799-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10799";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617176;
  r:natureDuRisque "Risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez le sujet âgé. Par ailleurs, légère augmentation des concentrations de dronédarone par diminution de son métabolisme par l’antagoniste des canaux calciques."@fr;
  r:conduiteATenir "Débuter le traitement par l’antagoniste calcique aux posologies minimales recommandées, et ajuster les doses en fonction de l’ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617182, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617176 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617177 .

_:807f36cf91fe4e8caa53aadeff92477617177 rdf:first _:807f36cf91fe4e8caa53aadeff92477617178;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617179 .

_:807f36cf91fe4e8caa53aadeff92477617178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617179 rdf:first _:807f36cf91fe4e8caa53aadeff92477617180;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477617182 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11097-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> OLAPARIB"@fr;
  dct:identifier "IAM_11097";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617184;
  r:natureDuRisque "Diminution, éventuellement très importante selon l’inducteur, des concentrations plasmatiques de l’olaparib par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617190, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617184 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617185 .

_:807f36cf91fe4e8caa53aadeff92477617185 rdf:first _:807f36cf91fe4e8caa53aadeff92477617186;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617187 .

_:807f36cf91fe4e8caa53aadeff92477617186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477617187 rdf:first _:807f36cf91fe4e8caa53aadeff92477617188;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:807f36cf91fe4e8caa53aadeff92477617190 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10788-1 a owl:Class;
  rdfs:label "DIGOXINE <-> SULFASALAZINE"@fr;
  dct:identifier "IAM_10788";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617192;
  r:natureDuRisque "Diminution de la digoxinémie pouvant atteindre 50 %."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et, éventuellement, de la digoxinémie. S'il y a lieu, adaptation de la posologie de la digoxine pendant le traitement par la sulfasalazine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617198, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617192 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617193 .

_:807f36cf91fe4e8caa53aadeff92477617193 rdf:first _:807f36cf91fe4e8caa53aadeff92477617194;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617195 .

_:807f36cf91fe4e8caa53aadeff92477617194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477617195 rdf:first _:807f36cf91fe4e8caa53aadeff92477617196;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10872 .

_:807f36cf91fe4e8caa53aadeff92477617198 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10790-1 a owl:Class;
  rdfs:label "DIGOXINE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_10790";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617200;
  r:natureDuRisque "Augmentation de la digoxinémie par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par la télithromycine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617206, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617200 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617201 .

_:807f36cf91fe4e8caa53aadeff92477617201 rdf:first _:807f36cf91fe4e8caa53aadeff92477617202;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617203 .

_:807f36cf91fe4e8caa53aadeff92477617202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477617203 rdf:first _:807f36cf91fe4e8caa53aadeff92477617204;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477617206 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10791-1 a owl:Class;
  rdfs:label "DIGOXINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10791";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617208;
  r:natureDuRisque "Bradycardie excessive et bloc auriculo-ventriculaire par majoration des effets de la digoxine sur l'automatisme et la conduction et par diminution de l'élimination rénale et extrarénale de la digoxine."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et, éventuellement, contrôle de la digoxinémie. S'il y a lieu, adaptation de la posologie de la digoxine pendant le traitement par le vérapamil et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617214, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617208 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617209 .

_:807f36cf91fe4e8caa53aadeff92477617209 rdf:first _:807f36cf91fe4e8caa53aadeff92477617210;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617211 .

_:807f36cf91fe4e8caa53aadeff92477617210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477617211 rdf:first _:807f36cf91fe4e8caa53aadeff92477617212;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477617214 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10792-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10792";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617216;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:comment "Le diltiazem est un un inhibiteur du CYP3A4. Même si elle est modeste, son activité inhibitrice doit être prise en compte, notamment lorsqu'il est associé à des médicaments à marge thérapeutique étroite comme la dihydroergotamine. Une faible augmentation"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617222, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617216 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617217 .

_:807f36cf91fe4e8caa53aadeff92477617217 rdf:first _:807f36cf91fe4e8caa53aadeff92477617218;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617219 .

_:807f36cf91fe4e8caa53aadeff92477617218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477617219 rdf:first _:807f36cf91fe4e8caa53aadeff92477617220;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617222 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10793-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> EFAVIRENZ"@fr;
  dct:identifier "IAM_10793";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617224;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617230, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617224 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617225 .

_:807f36cf91fe4e8caa53aadeff92477617225 rdf:first _:807f36cf91fe4e8caa53aadeff92477617226;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617227 .

_:807f36cf91fe4e8caa53aadeff92477617226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477617227 rdf:first _:807f36cf91fe4e8caa53aadeff92477617228;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477617230 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10794-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> MACROLIDES (SAUF SPIRAMYCINE)"@fr;
  dct:identifier "IAM_10794";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617232;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition de l’élimination hépatique de l'alcaloïde de l’ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617238, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617232 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617233 .

_:807f36cf91fe4e8caa53aadeff92477617233 rdf:first _:807f36cf91fe4e8caa53aadeff92477617234;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617235 .

_:807f36cf91fe4e8caa53aadeff92477617234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10107 .

_:807f36cf91fe4e8caa53aadeff92477617235 rdf:first _:807f36cf91fe4e8caa53aadeff92477617236;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477617238 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10795-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> QUINUPRISTINE"@fr;
  dct:identifier "IAM_10795";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617240;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617246, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617240 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617241 .

_:807f36cf91fe4e8caa53aadeff92477617241 rdf:first _:807f36cf91fe4e8caa53aadeff92477617242;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617243 .

_:807f36cf91fe4e8caa53aadeff92477617242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477617243 rdf:first _:807f36cf91fe4e8caa53aadeff92477617244;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10778 .

_:807f36cf91fe4e8caa53aadeff92477617246 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10796-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10796";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617248;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition de l’élimination hépatique de l'alcaloïde de l’ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617254, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617248 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617249 .

_:807f36cf91fe4e8caa53aadeff92477617249 rdf:first _:807f36cf91fe4e8caa53aadeff92477617250;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617251 .

_:807f36cf91fe4e8caa53aadeff92477617250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477617251 rdf:first _:807f36cf91fe4e8caa53aadeff92477617252;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477617254 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10811-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10811";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617256;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de ticagrelor par diminution de son métabolisme hépatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617262, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617256 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617257 .

_:807f36cf91fe4e8caa53aadeff92477617257 rdf:first _:807f36cf91fe4e8caa53aadeff92477617258;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617259 .

_:807f36cf91fe4e8caa53aadeff92477617258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617259 rdf:first _:807f36cf91fe4e8caa53aadeff92477617260;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477617262 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10798-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10798";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617264;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l’ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617270, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617264 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617265 .

_:807f36cf91fe4e8caa53aadeff92477617265 rdf:first _:807f36cf91fe4e8caa53aadeff92477617266;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617267 .

_:807f36cf91fe4e8caa53aadeff92477617266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477617267 rdf:first _:807f36cf91fe4e8caa53aadeff92477617268;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477617270 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10810-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> TAMSULOSINE"@fr;
  dct:identifier "IAM_10810";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617272;
  r:natureDuRisque "Risque de majoration des effets indésirables de la tamsulosine, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de la tamsulosine pensant le traitement par l’inhibiteur enzymatique et après son arrêt, le cas échéant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617278, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617272 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617273 .

_:807f36cf91fe4e8caa53aadeff92477617273 rdf:first _:807f36cf91fe4e8caa53aadeff92477617274;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617275 .

_:807f36cf91fe4e8caa53aadeff92477617274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617275 rdf:first _:807f36cf91fe4e8caa53aadeff92477617276;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10883 .

_:807f36cf91fe4e8caa53aadeff92477617278 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10800-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> ERGOTAMINE"@fr;
  dct:identifier "IAM_10800";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617280;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:comment "Le diltiazem est un inhibiteur du CYP3A4. Même si elle est modeste, son activité inhibitrice doit être prise en compte, notamment lorsqu'il est associé à des médicaments à marge thérapeutique étroite comme l'ergotamine. Une faible augmentation des concent"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617286, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617280 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617281 .

_:807f36cf91fe4e8caa53aadeff92477617281 rdf:first _:807f36cf91fe4e8caa53aadeff92477617282;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617283 .

_:807f36cf91fe4e8caa53aadeff92477617282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617283 rdf:first _:807f36cf91fe4e8caa53aadeff92477617284;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477617286 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10801-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> ESMOLOL"@fr;
  dct:identifier "IAM_10801";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617288;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir """Précaution d'emploi :
- si la fonction ventriculaire gauche est normale.
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617294, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617288 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617289 .

_:807f36cf91fe4e8caa53aadeff92477617289 rdf:first _:807f36cf91fe4e8caa53aadeff92477617290;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617291 .

_:807f36cf91fe4e8caa53aadeff92477617290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617291 rdf:first _:807f36cf91fe4e8caa53aadeff92477617292;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:807f36cf91fe4e8caa53aadeff92477617294 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10802-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> IBRUTINIB"@fr;
  dct:identifier "IAM_10802";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617296;
  r:natureDuRisque "Risque d'augmentation des concentrations plasmatiques d’ibrutinib par diminution de son métabolisme hépatique par le diltiazem."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique étroite et réduction de la dose d’ibrutinib à 140 mg par jour pendant la durée de l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617296 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617297 .

_:807f36cf91fe4e8caa53aadeff92477617297 rdf:first _:807f36cf91fe4e8caa53aadeff92477617298;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617299 .

_:807f36cf91fe4e8caa53aadeff92477617298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617299 rdf:first _:807f36cf91fe4e8caa53aadeff92477617300;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10441 .

_:807f36cf91fe4e8caa53aadeff92477617302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10803-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10803";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617304;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par diminution de son métabolisme."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617305 .

_:807f36cf91fe4e8caa53aadeff92477617305 rdf:first _:807f36cf91fe4e8caa53aadeff92477617306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617307 .

_:807f36cf91fe4e8caa53aadeff92477617306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477617307 rdf:first _:807f36cf91fe4e8caa53aadeff92477617308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10804-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> IVABRADINE"@fr;
  dct:identifier "IAM_10804";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617312;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’ivabradine et de ses effets indésirables, notamment cardiaques (inhibition de son métabolisme hépatique par le diltiazem), qui s’ajoutent aux effets bradycardisants de ces molécules."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617313 .

_:807f36cf91fe4e8caa53aadeff92477617313 rdf:first _:807f36cf91fe4e8caa53aadeff92477617314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617315 .

_:807f36cf91fe4e8caa53aadeff92477617314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617315 rdf:first _:807f36cf91fe4e8caa53aadeff92477617316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477617318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10805-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_10805";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617320;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam par diminution de son métabolisme hépatique, avec majoration de la sédation."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie pendant le traitement par le diltiazem."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617320 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617321 .

_:807f36cf91fe4e8caa53aadeff92477617321 rdf:first _:807f36cf91fe4e8caa53aadeff92477617322;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617323 .

_:807f36cf91fe4e8caa53aadeff92477617322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617323 rdf:first _:807f36cf91fe4e8caa53aadeff92477617324;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477617326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10806-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> NIFEDIPINE"@fr;
  dct:identifier "IAM_10806";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617328;
  r:natureDuRisque "Augmentation importantes des concentrations de nifédipine par diminution de son métabolisme hépatique par le diltiazem, avec risque d'hypotension sévère."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617329 .

_:807f36cf91fe4e8caa53aadeff92477617329 rdf:first _:807f36cf91fe4e8caa53aadeff92477617330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617331 .

_:807f36cf91fe4e8caa53aadeff92477617330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617331 rdf:first _:807f36cf91fe4e8caa53aadeff92477617332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10633 .

_:807f36cf91fe4e8caa53aadeff92477617334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10807-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> OLAPARIB"@fr;
  dct:identifier "IAM_10807";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617336;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par le diltiazem."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 200 mg deux fois par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617337 .

_:807f36cf91fe4e8caa53aadeff92477617337 rdf:first _:807f36cf91fe4e8caa53aadeff92477617338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617339 .

_:807f36cf91fe4e8caa53aadeff92477617338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617339 rdf:first _:807f36cf91fe4e8caa53aadeff92477617340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:807f36cf91fe4e8caa53aadeff92477617342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10808-1 a owl:Class;
  rdfs:label "DILTIAZEM <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10808";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617344;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:comment "Le diltiazem est un inhibiteur du CYP3A4. Même si elle est modeste, son activité inhibitrice doit être prise en compte, notamment lorsqu'il est associé à des médicaments à marge thérapeutique étroite comme le pimozide. Une faible augmentation des concentr"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617345 .

_:807f36cf91fe4e8caa53aadeff92477617345 rdf:first _:807f36cf91fe4e8caa53aadeff92477617346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617347 .

_:807f36cf91fe4e8caa53aadeff92477617346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617347 rdf:first _:807f36cf91fe4e8caa53aadeff92477617348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477617350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10834-1 a owl:Class;
  rdfs:label "DOCETAXEL <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10834";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617352;
  r:natureDuRisque "Diminution des concentrations du cytotoxique par augmentation de son métabolisme par l’inducteur, avec risque de moindre efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617353 .

_:807f36cf91fe4e8caa53aadeff92477617353 rdf:first _:807f36cf91fe4e8caa53aadeff92477617354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617355 .

_:807f36cf91fe4e8caa53aadeff92477617354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477617355 rdf:first _:807f36cf91fe4e8caa53aadeff92477617356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10300 .

_:807f36cf91fe4e8caa53aadeff92477617358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10797-1 a owl:Class;
  rdfs:label "DIHYDROERGOTAMINE <-> TRICLABENDAZOLE"@fr;
  dct:identifier "IAM_10797";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617360;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l’alcaloïde de l’ergot de seigle)."@fr;
  r:conduiteATenir "Respecter un délai de 24 heures entre l’arrêt du triclabendazole et la prise du médicament dérivé de l’ergot, et inversement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617361 .

_:807f36cf91fe4e8caa53aadeff92477617361 rdf:first _:807f36cf91fe4e8caa53aadeff92477617362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617363 .

_:807f36cf91fe4e8caa53aadeff92477617362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477617363 rdf:first _:807f36cf91fe4e8caa53aadeff92477617364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10953 .

_:807f36cf91fe4e8caa53aadeff92477617366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11054-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_11054";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617368;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique très étroite. Débuter l'association aux posologies minimales recommandées."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617369 .

_:807f36cf91fe4e8caa53aadeff92477617369 rdf:first _:807f36cf91fe4e8caa53aadeff92477617370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617371 .

_:807f36cf91fe4e8caa53aadeff92477617370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477617371 rdf:first _:807f36cf91fe4e8caa53aadeff92477617372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477617374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10832-1 a owl:Class;
  rdfs:label "DIURÉTIQUES THIAZIDIQUES ET APPARENTÉS <-> LITHIUM"@fr;
  dct:identifier "IAM_10832";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617376;
  r:natureDuRisque "Augmentation de la lithémie avec signes de surdosage en lithium, comme lors d’un régime désodé (diminution de l’excrétion urinaire du lithium)."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance stricte de la lithémie et adaptation de la posologie du lithium."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617377 .

_:807f36cf91fe4e8caa53aadeff92477617377 rdf:first _:807f36cf91fe4e8caa53aadeff92477617378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617379 .

_:807f36cf91fe4e8caa53aadeff92477617378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477617379 rdf:first _:807f36cf91fe4e8caa53aadeff92477617380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10530 .

_:807f36cf91fe4e8caa53aadeff92477617382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10859-1 a owl:Class;
  rdfs:label "DULOXETINE <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10859";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617384;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de propafénone avec risque de surdosage, par diminution de son métabolisme hépatique par la duloxétine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de la propafénone pendant le traitement par la duloxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617390, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617384 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617385 .

_:807f36cf91fe4e8caa53aadeff92477617385 rdf:first _:807f36cf91fe4e8caa53aadeff92477617386;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617387 .

_:807f36cf91fe4e8caa53aadeff92477617386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:807f36cf91fe4e8caa53aadeff92477617387 rdf:first _:807f36cf91fe4e8caa53aadeff92477617388;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477617390 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11046-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_11046";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617392;
  r:natureDuRisque "Augmentation de l'action pressive du sympathomimétique, le plus souvent modérée."@fr;
  r:conduiteATenir "A n'utiliser que sous contrôle médical strict."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617398, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617392 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617393 .

_:807f36cf91fe4e8caa53aadeff92477617393 rdf:first _:807f36cf91fe4e8caa53aadeff92477617394;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617395 .

_:807f36cf91fe4e8caa53aadeff92477617394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477617395 rdf:first _:807f36cf91fe4e8caa53aadeff92477617396;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:807f36cf91fe4e8caa53aadeff92477617398 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11045-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> SYMPATHOMIMÉTIQUES ALPHA (VOIES ORALE ET/OU NASALE)"@fr;
  dct:identifier "IAM_11045";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617400;
  r:natureDuRisque "Crises hypertensives (inhibition du métabolisme des amines pressives). Du fait de la durée d'action de l'IMAO, cette interaction est encore possible 15 jours après l'arrêt de l'IMAO."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617400 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617401 .

_:807f36cf91fe4e8caa53aadeff92477617401 rdf:first _:807f36cf91fe4e8caa53aadeff92477617402;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617403 .

_:807f36cf91fe4e8caa53aadeff92477617402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477617403 rdf:first _:807f36cf91fe4e8caa53aadeff92477617404;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10148 .

_:807f36cf91fe4e8caa53aadeff92477617406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11047-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_11047";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617408;
  r:natureDuRisque "Hypertension paroxystique, hyperthermie pouvant être fatale. Du fait de la durée d'action de l'IMAO, cette interaction est encore possible 15 jours après l'arrêt de l'IMAO."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617409 .

_:807f36cf91fe4e8caa53aadeff92477617409 rdf:first _:807f36cf91fe4e8caa53aadeff92477617410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617411 .

_:807f36cf91fe4e8caa53aadeff92477617410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477617411 rdf:first _:807f36cf91fe4e8caa53aadeff92477617412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477617414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11048-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TETRABENAZINE"@fr;
  dct:identifier "IAM_11048";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617416;
  r:natureDuRisque "Risque de crises hypertensives. Du fait de la durée d'action de l'IMAO, cette interaction est encore théoriquement possible 15 jours après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617417 .

_:807f36cf91fe4e8caa53aadeff92477617417 rdf:first _:807f36cf91fe4e8caa53aadeff92477617418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617419 .

_:807f36cf91fe4e8caa53aadeff92477617418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477617419 rdf:first _:807f36cf91fe4e8caa53aadeff92477617420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10908 .

_:807f36cf91fe4e8caa53aadeff92477617422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11049-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TIANEPTINE"@fr;
  dct:identifier "IAM_11049";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617424;
  r:natureDuRisque "Risque de collapsus, hypertension paroxystique, hyperthermie, convulsions, décès."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617425 .

_:807f36cf91fe4e8caa53aadeff92477617425 rdf:first _:807f36cf91fe4e8caa53aadeff92477617426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617427 .

_:807f36cf91fe4e8caa53aadeff92477617426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477617427 rdf:first _:807f36cf91fe4e8caa53aadeff92477617428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10923 .

_:807f36cf91fe4e8caa53aadeff92477617430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11050-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TRAMADOL"@fr;
  dct:identifier "IAM_11050";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617432;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, sueurs, tremblements, confusion, voire coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617433 .

_:807f36cf91fe4e8caa53aadeff92477617433 rdf:first _:807f36cf91fe4e8caa53aadeff92477617434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617435 .

_:807f36cf91fe4e8caa53aadeff92477617434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477617435 rdf:first _:807f36cf91fe4e8caa53aadeff92477617436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477617438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11052-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TRIPTANS NON MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11052";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617440;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617441 .

_:807f36cf91fe4e8caa53aadeff92477617441 rdf:first _:807f36cf91fe4e8caa53aadeff92477617442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617443 .

_:807f36cf91fe4e8caa53aadeff92477617442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477617443 rdf:first _:807f36cf91fe4e8caa53aadeff92477617444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477617446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10858-1 a owl:Class;
  rdfs:label "DULOXETINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10858";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617448;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de métoprolol avec risque de surdosage, par diminution de son métabolisme hépatique par la duloxétine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du métoprolol pendant le traitement par la duloxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617449 .

_:807f36cf91fe4e8caa53aadeff92477617449 rdf:first _:807f36cf91fe4e8caa53aadeff92477617450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617451 .

_:807f36cf91fe4e8caa53aadeff92477617450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:807f36cf91fe4e8caa53aadeff92477617451 rdf:first _:807f36cf91fe4e8caa53aadeff92477617452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477617454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11053-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> IMAO-B"@fr;
  dct:identifier "IAM_11053";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617456;
  r:natureDuRisque "Risque de poussée hypertensive, par perte de sélectivité sur la monoamine oxydase, notamment en cas d’alimentation riche en tyramine (fromage, bière,…)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617457 .

_:807f36cf91fe4e8caa53aadeff92477617457 rdf:first _:807f36cf91fe4e8caa53aadeff92477617458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617459 .

_:807f36cf91fe4e8caa53aadeff92477617458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477617459 rdf:first _:807f36cf91fe4e8caa53aadeff92477617460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477617462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10856-1 a owl:Class;
  rdfs:label "DULOXETINE <-> FLUVOXAMINE"@fr;
  dct:identifier "IAM_10856";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617464;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la duloxétine par diminution de son métabolisme hépatique par la fluvoxamine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617465 .

_:807f36cf91fe4e8caa53aadeff92477617465 rdf:first _:807f36cf91fe4e8caa53aadeff92477617466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617467 .

_:807f36cf91fe4e8caa53aadeff92477617466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:807f36cf91fe4e8caa53aadeff92477617467 rdf:first _:807f36cf91fe4e8caa53aadeff92477617468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477617470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11055-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> MÉDICAMENTS MIXTES ADRÉNERGIQUES-SÉROTONINERGIQUES"@fr;
  dct:identifier "IAM_11055";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617472;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueur, confusion voire coma."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique très étroite. Débuter l'association aux posologies minimales recommandées."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617473 .

_:807f36cf91fe4e8caa53aadeff92477617473 rdf:first _:807f36cf91fe4e8caa53aadeff92477617474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617475 .

_:807f36cf91fe4e8caa53aadeff92477617474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477617475 rdf:first _:807f36cf91fe4e8caa53aadeff92477617476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10116 .

_:807f36cf91fe4e8caa53aadeff92477617478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11194-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_11194";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617480;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617481 .

_:807f36cf91fe4e8caa53aadeff92477617481 rdf:first _:807f36cf91fe4e8caa53aadeff92477617482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617483 .

_:807f36cf91fe4e8caa53aadeff92477617482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477617483 rdf:first _:807f36cf91fe4e8caa53aadeff92477617484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:807f36cf91fe4e8caa53aadeff92477617486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11195-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_11195";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617488;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par l'itraconazole."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617494, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617488 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617489 .

_:807f36cf91fe4e8caa53aadeff92477617489 rdf:first _:807f36cf91fe4e8caa53aadeff92477617490;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617491 .

_:807f36cf91fe4e8caa53aadeff92477617490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477617491 rdf:first _:807f36cf91fe4e8caa53aadeff92477617492;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477617494 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11196-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> QUINIDINE"@fr;
  dct:identifier "IAM_11196";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617496;
  r:natureDuRisque """Risque majoré de troubles du rythme ventriculaire, notamment de
torsades de pointes, ainsi que d'acouphènes et/ou de diminution de l'acuité auditive (cinchonisme), par diminution du métabolisme
hépatique de la quinidine."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617502, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617496 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617497 .

_:807f36cf91fe4e8caa53aadeff92477617497 rdf:first _:807f36cf91fe4e8caa53aadeff92477617498;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617499 .

_:807f36cf91fe4e8caa53aadeff92477617498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477617499 rdf:first _:807f36cf91fe4e8caa53aadeff92477617500;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477617502 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11197-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> SALMETEROL"@fr;
  dct:identifier "IAM_11197";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617504;
  r:natureDuRisque "Augmentation importante des concentrations de salmétérol par diminution de son métabolisme hépatique par l'itraconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617510, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617504 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617505 .

_:807f36cf91fe4e8caa53aadeff92477617505 rdf:first _:807f36cf91fe4e8caa53aadeff92477617506;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617507 .

_:807f36cf91fe4e8caa53aadeff92477617506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477617507 rdf:first _:807f36cf91fe4e8caa53aadeff92477617508;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10823 .

_:807f36cf91fe4e8caa53aadeff92477617510 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11198-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_11198";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617512;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617518, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617512 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617513 .

_:807f36cf91fe4e8caa53aadeff92477617513 rdf:first _:807f36cf91fe4e8caa53aadeff92477617514;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617515 .

_:807f36cf91fe4e8caa53aadeff92477617514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477617515 rdf:first _:807f36cf91fe4e8caa53aadeff92477617516;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477617518 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11200-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> TÉNOFOVIR ALAFÉNAMIDE"@fr;
  dct:identifier "IAM_11200";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617520;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du ténofovir alafénamide par augmentation de son absorption."@fr;
  r:conduiteATenir "En cas de co-administration avec l’itraconazole, la dose de ténofovir alafénamide doit être limitée à 10 mg par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617526, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617520 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617521 .

_:807f36cf91fe4e8caa53aadeff92477617521 rdf:first _:807f36cf91fe4e8caa53aadeff92477617522;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617523 .

_:807f36cf91fe4e8caa53aadeff92477617522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477617523 rdf:first _:807f36cf91fe4e8caa53aadeff92477617524;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10895 .

_:807f36cf91fe4e8caa53aadeff92477617526 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11201-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> TRABECTÉDINE"@fr;
  dct:identifier "IAM_11201";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617528;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de la trabectedine par l’itraconazole."@fr;
  r:conduiteATenir "Si l’association est nécessaire, surveillance clinique et adaptation éventuelle de la posologie de la trabectedine pendant la durée du traitement par l’itraconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617534, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617528 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617529 .

_:807f36cf91fe4e8caa53aadeff92477617529 rdf:first _:807f36cf91fe4e8caa53aadeff92477617530;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617531 .

_:807f36cf91fe4e8caa53aadeff92477617530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477617531 rdf:first _:807f36cf91fe4e8caa53aadeff92477617532;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10944 .

_:807f36cf91fe4e8caa53aadeff92477617534 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11202-1 a owl:Class;
  rdfs:label "ITRACONAZOLE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_11202";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617536;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617542, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617536 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617537 .

_:807f36cf91fe4e8caa53aadeff92477617537 rdf:first _:807f36cf91fe4e8caa53aadeff92477617538;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617539 .

_:807f36cf91fe4e8caa53aadeff92477617538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477617539 rdf:first _:807f36cf91fe4e8caa53aadeff92477617540;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477617542 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11204-1 a owl:Class;
  rdfs:label "IVABRADINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_11204";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617544;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'ivabradine et par conséquent de ses effets indésirables (inhibition de son métabolisme hépatique par la josamycine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617550, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617544 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617545 .

_:807f36cf91fe4e8caa53aadeff92477617545 rdf:first _:807f36cf91fe4e8caa53aadeff92477617546;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617547 .

_:807f36cf91fe4e8caa53aadeff92477617546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477617547 rdf:first _:807f36cf91fe4e8caa53aadeff92477617548;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477617550 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11051-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> TRIPTANS MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11051";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617552;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617558, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617552 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617553 .

_:807f36cf91fe4e8caa53aadeff92477617553 rdf:first _:807f36cf91fe4e8caa53aadeff92477617554;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617555 .

_:807f36cf91fe4e8caa53aadeff92477617554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477617555 rdf:first _:807f36cf91fe4e8caa53aadeff92477617556;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10157 .

_:807f36cf91fe4e8caa53aadeff92477617558 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10845-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> FIDAXOMICINE"@fr;
  dct:identifier "IAM_10845";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617560;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617566, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617560 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617561 .

_:807f36cf91fe4e8caa53aadeff92477617561 rdf:first _:807f36cf91fe4e8caa53aadeff92477617562;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617563 .

_:807f36cf91fe4e8caa53aadeff92477617562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477617563 rdf:first _:807f36cf91fe4e8caa53aadeff92477617564;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:807f36cf91fe4e8caa53aadeff92477617566 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10785-1 a owl:Class;
  rdfs:label "DIGOXINE <-> QUININE"@fr;
  dct:identifier "IAM_10785";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617568;
  r:natureDuRisque "Augmentation modérée de la digoxinémie."@fr;
  r:conduiteATenir "Surveillance clinique et ECG, si besoin, avec adaptation éventuelle des doses de digoxine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617574, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617568 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617569 .

_:807f36cf91fe4e8caa53aadeff92477617569 rdf:first _:807f36cf91fe4e8caa53aadeff92477617570;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617571 .

_:807f36cf91fe4e8caa53aadeff92477617570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477617571 rdf:first _:807f36cf91fe4e8caa53aadeff92477617572;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:807f36cf91fe4e8caa53aadeff92477617574 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10835-1 a owl:Class;
  rdfs:label "DOCETAXEL <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10835";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617576;
  r:natureDuRisque "Risque de majoration des effets indésirables dose-dépendants du docétaxel par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du docétaxel pendant le traitement par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617582, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617576 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617577 .

_:807f36cf91fe4e8caa53aadeff92477617577 rdf:first _:807f36cf91fe4e8caa53aadeff92477617578;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617579 .

_:807f36cf91fe4e8caa53aadeff92477617578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477617579 rdf:first _:807f36cf91fe4e8caa53aadeff92477617580;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10300 .

_:807f36cf91fe4e8caa53aadeff92477617582 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10836-1 a owl:Class;
  rdfs:label "DOLUTÉGRAVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10836";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617584;
  r:natureDuRisque "Diminution des concentrations plasmatiques de dolutégravir par augmentation de son métabolisme par l’inducteur."@fr;
  r:conduiteATenir """Association déconseillée :
- en cas de résistance à la classe des inhibiteurs d'intégrase

Précaution d'emploi :
- en l'absence de résistance à la classe des inhibiteurs d'intégrase
Adaptation de la posologie de dolutégravir à 50 mg 2 fois par jour penda"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617590, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617584 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617585 .

_:807f36cf91fe4e8caa53aadeff92477617585 rdf:first _:807f36cf91fe4e8caa53aadeff92477617586;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617587 .

_:807f36cf91fe4e8caa53aadeff92477617586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477617587 rdf:first _:807f36cf91fe4e8caa53aadeff92477617588;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10301 .

_:807f36cf91fe4e8caa53aadeff92477617590 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10837-1 a owl:Class;
  rdfs:label "DOLUTÉGRAVIR <-> METFORMINE"@fr;
  dct:identifier "IAM_10837";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617592;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de metformine par le dolutegravir et de ses effets indésirables à type d’acidose lactique."@fr;
  r:conduiteATenir "Chez le patient avec une insuffisance rénale modérée (stade 3a, clairance de la créatinine comprise entre 45 et 59 ml/min), surveillance clinique et biologique, et adaptation éventuelle de la posologie de metformine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617598, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617592 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617593 .

_:807f36cf91fe4e8caa53aadeff92477617593 rdf:first _:807f36cf91fe4e8caa53aadeff92477617594;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617595 .

_:807f36cf91fe4e8caa53aadeff92477617594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10301 .

_:807f36cf91fe4e8caa53aadeff92477617595 rdf:first _:807f36cf91fe4e8caa53aadeff92477617596;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10566 .

_:807f36cf91fe4e8caa53aadeff92477617598 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10838-1 a owl:Class;
  rdfs:label "DOLUTÉGRAVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10838";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617600;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de dolutégravir par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617606, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617600 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617601 .

_:807f36cf91fe4e8caa53aadeff92477617601 rdf:first _:807f36cf91fe4e8caa53aadeff92477617602;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617603 .

_:807f36cf91fe4e8caa53aadeff92477617602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10301 .

_:807f36cf91fe4e8caa53aadeff92477617603 rdf:first _:807f36cf91fe4e8caa53aadeff92477617604;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477617606 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10839-1 a owl:Class;
  rdfs:label "DOMPERIDONE <-> FLUCONAZOLE"@fr;
  dct:identifier "IAM_10839";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617608;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617614, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617608 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617609 .

_:807f36cf91fe4e8caa53aadeff92477617609 rdf:first _:807f36cf91fe4e8caa53aadeff92477617610;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617611 .

_:807f36cf91fe4e8caa53aadeff92477617610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10302 .

_:807f36cf91fe4e8caa53aadeff92477617611 rdf:first _:807f36cf91fe4e8caa53aadeff92477617612;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477617614 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10840-1 a owl:Class;
  rdfs:label "DOMPERIDONE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10840";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617616;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de dompéridone par diminution de son métabolisme hépatique par l’inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617622, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617616 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617617 .

_:807f36cf91fe4e8caa53aadeff92477617617 rdf:first _:807f36cf91fe4e8caa53aadeff92477617618;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617619 .

_:807f36cf91fe4e8caa53aadeff92477617618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477617619 rdf:first _:807f36cf91fe4e8caa53aadeff92477617620;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10302 .

_:807f36cf91fe4e8caa53aadeff92477617622 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10841-1 a owl:Class;
  rdfs:label "DOPAMINERGIQUES <-> NEUROLEPTIQUES ANTIÉMÉTIQUES"@fr;
  dct:identifier "IAM_10841";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617624;
  r:natureDuRisque "Antagonisme réciproque entre le dopaminergique et le neuroleptique."@fr;
  r:conduiteATenir "Utiliser un antiémétique dénué d'effets extrapyramidaux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617630, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617624 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617625 .

_:807f36cf91fe4e8caa53aadeff92477617625 rdf:first _:807f36cf91fe4e8caa53aadeff92477617626;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617627 .

_:807f36cf91fe4e8caa53aadeff92477617626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10068 .

_:807f36cf91fe4e8caa53aadeff92477617627 rdf:first _:807f36cf91fe4e8caa53aadeff92477617628;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10126 .

_:807f36cf91fe4e8caa53aadeff92477617630 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10842-1 a owl:Class;
  rdfs:label "DOPAMINERGIQUES <-> TETRABENAZINE"@fr;
  dct:identifier "IAM_10842";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617632;
  r:natureDuRisque "Antagonisme réciproque entre le dopaminergique et la tétrabénazine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617638, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617632 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617633 .

_:807f36cf91fe4e8caa53aadeff92477617633 rdf:first _:807f36cf91fe4e8caa53aadeff92477617634;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617635 .

_:807f36cf91fe4e8caa53aadeff92477617634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10068 .

_:807f36cf91fe4e8caa53aadeff92477617635 rdf:first _:807f36cf91fe4e8caa53aadeff92477617636;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10908 .

_:807f36cf91fe4e8caa53aadeff92477617638 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10857-1 a owl:Class;
  rdfs:label "DULOXETINE <-> MEQUITAZINE"@fr;
  dct:identifier "IAM_10857";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617640;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617646, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617640 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617641 .

_:807f36cf91fe4e8caa53aadeff92477617641 rdf:first _:807f36cf91fe4e8caa53aadeff92477617642;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617643 .

_:807f36cf91fe4e8caa53aadeff92477617642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:807f36cf91fe4e8caa53aadeff92477617643 rdf:first _:807f36cf91fe4e8caa53aadeff92477617644;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:807f36cf91fe4e8caa53aadeff92477617646 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10844-1 a owl:Class;
  rdfs:label "DOXORUBICINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10844";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617648;
  r:natureDuRisque "Risque de majoration de la toxicité de la doxorubicine par augmentation de ses concentrations plasmatiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617654, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617648 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617649 .

_:807f36cf91fe4e8caa53aadeff92477617649 rdf:first _:807f36cf91fe4e8caa53aadeff92477617650;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617651 .

_:807f36cf91fe4e8caa53aadeff92477617650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10308 .

_:807f36cf91fe4e8caa53aadeff92477617651 rdf:first _:807f36cf91fe4e8caa53aadeff92477617652;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477617654 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10833-1 a owl:Class;
  rdfs:label "DOCETAXEL <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10833";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617656;
  r:natureDuRisque "Risque de majoration de la toxicité du docétaxel par diminution de son métabolisme."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du docétaxel pendant le traitement par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617662, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617656 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617657 .

_:807f36cf91fe4e8caa53aadeff92477617657 rdf:first _:807f36cf91fe4e8caa53aadeff92477617658;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617659 .

_:807f36cf91fe4e8caa53aadeff92477617658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10300 .

_:807f36cf91fe4e8caa53aadeff92477617659 rdf:first _:807f36cf91fe4e8caa53aadeff92477617660;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477617662 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10846-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10846";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617664;
  r:natureDuRisque "Augmentation importante des concentrations sanguines de l’immunosuppresseur par diminution de son métabolisme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617670, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617664 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617665 .

_:807f36cf91fe4e8caa53aadeff92477617665 rdf:first _:807f36cf91fe4e8caa53aadeff92477617666;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617667 .

_:807f36cf91fe4e8caa53aadeff92477617666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477617667 rdf:first _:807f36cf91fe4e8caa53aadeff92477617668;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477617670 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10847-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10847";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617672;
  r:natureDuRisque "Augmentation importante des concentrations de dronédarone par diminution de son métabolisme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617678, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617672 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617673 .

_:807f36cf91fe4e8caa53aadeff92477617673 rdf:first _:807f36cf91fe4e8caa53aadeff92477617674;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617675 .

_:807f36cf91fe4e8caa53aadeff92477617674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477617675 rdf:first _:807f36cf91fe4e8caa53aadeff92477617676;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477617678 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10848-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10848";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617680;
  r:natureDuRisque "Diminution importante des concentrations de dronédarone par augmentation de son métabolisme, sans modification notable du métabolite actif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617686, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617680 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617681 .

_:807f36cf91fe4e8caa53aadeff92477617681 rdf:first _:807f36cf91fe4e8caa53aadeff92477617682;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617683 .

_:807f36cf91fe4e8caa53aadeff92477617682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477617683 rdf:first _:807f36cf91fe4e8caa53aadeff92477617684;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477617686 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10849-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_10849";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617688;
  r:natureDuRisque "Augmentation des concentrations de dronédarone par inhibition de son métabolisme par le pamplemousse."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617694, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617688 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617689 .

_:807f36cf91fe4e8caa53aadeff92477617689 rdf:first _:807f36cf91fe4e8caa53aadeff92477617690;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617691 .

_:807f36cf91fe4e8caa53aadeff92477617690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477617691 rdf:first _:807f36cf91fe4e8caa53aadeff92477617692;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477617694 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10850-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> QUINIDINE"@fr;
  dct:identifier "IAM_10850";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617696;
  r:natureDuRisque "Risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez le sujet âgé. Par ailleurs, légère augmentation des concentrations de dronédarone par diminution de son métabolisme par la quinidine."@fr;
  r:conduiteATenir "Débuter le traitement par la quinidine aux posologies minimales recommandées, et ajuster les doses en fonction de l’ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617702, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617696 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617697 .

_:807f36cf91fe4e8caa53aadeff92477617697 rdf:first _:807f36cf91fe4e8caa53aadeff92477617698;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617699 .

_:807f36cf91fe4e8caa53aadeff92477617698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477617699 rdf:first _:807f36cf91fe4e8caa53aadeff92477617700;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477617702 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10851-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10851";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617704;
  r:natureDuRisque "Diminution importante des concentrations de dronédarone par augmentation de son métabolisme, sans modification notable du métabolite actif."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617710, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617704 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617705 .

_:807f36cf91fe4e8caa53aadeff92477617705 rdf:first _:807f36cf91fe4e8caa53aadeff92477617706;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617707 .

_:807f36cf91fe4e8caa53aadeff92477617706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477617707 rdf:first _:807f36cf91fe4e8caa53aadeff92477617708;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477617710 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10852-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10852";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617712;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de la simvastatine)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617718, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617712 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617713 .

_:807f36cf91fe4e8caa53aadeff92477617713 rdf:first _:807f36cf91fe4e8caa53aadeff92477617714;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617715 .

_:807f36cf91fe4e8caa53aadeff92477617714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477617715 rdf:first _:807f36cf91fe4e8caa53aadeff92477617716;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477617718 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10853-1 a owl:Class;
  rdfs:label "DRONEDARONE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10853";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617720;
  r:natureDuRisque "Risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez le sujet âgé. Par ailleurs, légère augmentation des concentrations de dronédarone par diminution de son métabolisme par l’antagoniste des canaux calciques."@fr;
  r:conduiteATenir "Débuter le traitement par l’antagoniste calcique aux posologies minimales recommandées, et ajuster les doses en fonction de l’ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617726, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617720 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617721 .

_:807f36cf91fe4e8caa53aadeff92477617721 rdf:first _:807f36cf91fe4e8caa53aadeff92477617722;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617723 .

_:807f36cf91fe4e8caa53aadeff92477617722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477617723 rdf:first _:807f36cf91fe4e8caa53aadeff92477617724;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477617726 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10854-1 a owl:Class;
  rdfs:label "DULOXETINE <-> ENOXACINE"@fr;
  dct:identifier "IAM_10854";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617728;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la duloxétine par diminution de son métabolisme hépatique par l'énoxacine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617734, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617728 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617729 .

_:807f36cf91fe4e8caa53aadeff92477617729 rdf:first _:807f36cf91fe4e8caa53aadeff92477617730;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617731 .

_:807f36cf91fe4e8caa53aadeff92477617730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:807f36cf91fe4e8caa53aadeff92477617731 rdf:first _:807f36cf91fe4e8caa53aadeff92477617732;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10323 .

_:807f36cf91fe4e8caa53aadeff92477617734 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10855-1 a owl:Class;
  rdfs:label "DULOXETINE <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10855";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617736;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de flecainide avec risque de surdosage, par diminution de son métabolisme hépatique par la duloxétine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du flecainide pendant le traitement par la duloxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617742, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617736 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617737 .

_:807f36cf91fe4e8caa53aadeff92477617737 rdf:first _:807f36cf91fe4e8caa53aadeff92477617738;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617739 .

_:807f36cf91fe4e8caa53aadeff92477617738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:807f36cf91fe4e8caa53aadeff92477617739 rdf:first _:807f36cf91fe4e8caa53aadeff92477617740;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:807f36cf91fe4e8caa53aadeff92477617742 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10843-1 a owl:Class;
  rdfs:label "DOPAMINERGIQUES, HORS PARKINSON <-> NEUROLEPTIQUES ANTIPSYCHOTIQUES (SAUF CLOZAPINE)"@fr;
  dct:identifier "IAM_10843";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617744;
  r:natureDuRisque "Antagonisme réciproque de l'agoniste dopaminergique et des neuroleptiques."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617750, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617744 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617745 .

_:807f36cf91fe4e8caa53aadeff92477617745 rdf:first _:807f36cf91fe4e8caa53aadeff92477617746;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617747 .

_:807f36cf91fe4e8caa53aadeff92477617746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10069 .

_:807f36cf91fe4e8caa53aadeff92477617747 rdf:first _:807f36cf91fe4e8caa53aadeff92477617748;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10125 .

_:807f36cf91fe4e8caa53aadeff92477617750 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10751-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10751";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617752;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617758, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617752 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617753 .

_:807f36cf91fe4e8caa53aadeff92477617753 rdf:first _:807f36cf91fe4e8caa53aadeff92477617754;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617755 .

_:807f36cf91fe4e8caa53aadeff92477617754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477617755 rdf:first _:807f36cf91fe4e8caa53aadeff92477617756;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477617758 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10740-1 a owl:Class;
  rdfs:label "DASABUVIR <-> MITOTANE"@fr;
  dct:identifier "IAM_10740";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617760;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du dasabuvir par le mitotane."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617766, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617760 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617761 .

_:807f36cf91fe4e8caa53aadeff92477617761 rdf:first _:807f36cf91fe4e8caa53aadeff92477617762;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617763 .

_:807f36cf91fe4e8caa53aadeff92477617762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:807f36cf91fe4e8caa53aadeff92477617763 rdf:first _:807f36cf91fe4e8caa53aadeff92477617764;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617764 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10594 .

_:807f36cf91fe4e8caa53aadeff92477617766 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10741-1 a owl:Class;
  rdfs:label "DEFERASIROX <-> DÉFÉRIPRONE"@fr;
  dct:identifier "IAM_10741";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617768;
  r:natureDuRisque "Risque d'hyperchélation."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617774, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617768 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617769 .

_:807f36cf91fe4e8caa53aadeff92477617769 rdf:first _:807f36cf91fe4e8caa53aadeff92477617770;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617771 .

_:807f36cf91fe4e8caa53aadeff92477617770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477617771 rdf:first _:807f36cf91fe4e8caa53aadeff92477617772;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617772 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10260 .

_:807f36cf91fe4e8caa53aadeff92477617774 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10742-1 a owl:Class;
  rdfs:label "DEFERASIROX <-> DÉFÉROXAMINE"@fr;
  dct:identifier "IAM_10742";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617776;
  r:natureDuRisque "Risque d'hyperchélation."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617782, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617776 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617777 .

_:807f36cf91fe4e8caa53aadeff92477617777 rdf:first _:807f36cf91fe4e8caa53aadeff92477617778;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617779 .

_:807f36cf91fe4e8caa53aadeff92477617778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477617779 rdf:first _:807f36cf91fe4e8caa53aadeff92477617780;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617780 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10261 .

_:807f36cf91fe4e8caa53aadeff92477617782 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10743-1 a owl:Class;
  rdfs:label "DEFERASIROX <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10743";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617784;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatique de répaglinide, par inhibition de son métabolisme hépatique par le deferasirox."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique et biologique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617790, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617784 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617785 .

_:807f36cf91fe4e8caa53aadeff92477617785 rdf:first _:807f36cf91fe4e8caa53aadeff92477617786;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617787 .

_:807f36cf91fe4e8caa53aadeff92477617786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477617787 rdf:first _:807f36cf91fe4e8caa53aadeff92477617788;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617788 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:807f36cf91fe4e8caa53aadeff92477617790 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10744-1 a owl:Class;
  rdfs:label "DEFERASIROX <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10744";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617792;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques de déférasirox."@fr;
  r:conduiteATenir "Surveiller la ferritinémie pendant et après le traitement par l’inducteur enzymatique. Si besoin, adaptation de la posologie de déférasirox."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617798, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617792 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617793 .

_:807f36cf91fe4e8caa53aadeff92477617793 rdf:first _:807f36cf91fe4e8caa53aadeff92477617794;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617795 .

_:807f36cf91fe4e8caa53aadeff92477617794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10259 .

_:807f36cf91fe4e8caa53aadeff92477617795 rdf:first _:807f36cf91fe4e8caa53aadeff92477617796;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477617798 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10745-1 a owl:Class;
  rdfs:label "DÉFIBROTIDE <-> HÉPARINES"@fr;
  dct:identifier "IAM_10745";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617800;
  r:natureDuRisque "Risque hémorragique accru."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617806, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617800 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617801 .

_:807f36cf91fe4e8caa53aadeff92477617801 rdf:first _:807f36cf91fe4e8caa53aadeff92477617802;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617803 .

_:807f36cf91fe4e8caa53aadeff92477617802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10088 .

_:807f36cf91fe4e8caa53aadeff92477617803 rdf:first _:807f36cf91fe4e8caa53aadeff92477617804;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10262 .

_:807f36cf91fe4e8caa53aadeff92477617806 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10746-1 a owl:Class;
  rdfs:label "DÉFIBROTIDE <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_10746";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617808;
  r:natureDuRisque "Risque hémorragique accru."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617814, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617808 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617809 .

_:807f36cf91fe4e8caa53aadeff92477617809 rdf:first _:807f36cf91fe4e8caa53aadeff92477617810;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617811 .

_:807f36cf91fe4e8caa53aadeff92477617810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:807f36cf91fe4e8caa53aadeff92477617811 rdf:first _:807f36cf91fe4e8caa53aadeff92477617812;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617812 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10262 .

_:807f36cf91fe4e8caa53aadeff92477617814 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10747-1 a owl:Class;
  rdfs:label "DÉLAMANID <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10747";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617816;
  r:natureDuRisque "Diminution des concentrations plasmatiques de delamanid par augmentation de son métabolisme hépatique par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617822, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617816 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617817 .

_:807f36cf91fe4e8caa53aadeff92477617817 rdf:first _:807f36cf91fe4e8caa53aadeff92477617818;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617819 .

_:807f36cf91fe4e8caa53aadeff92477617818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10263 .

_:807f36cf91fe4e8caa53aadeff92477617819 rdf:first _:807f36cf91fe4e8caa53aadeff92477617820;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617820 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477617822 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10748-1 a owl:Class;
  rdfs:label "DÉRIVÉS NITRÉS ET APPARENTÉS <-> INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE 5"@fr;
  dct:identifier "IAM_10748";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617824;
  r:natureDuRisque "Risque d'hypotension importante (effet synergique) pouvant aggraver l'état d'ischémie myocardique et provoquer notamment un accident coronarien aigu."@fr;
  rdfs:comment "Les dérivés nitrés sont des donneurs de monoxyde d'azote (NO). A ce titre, ils sont contre-indiqués avec le sildénafil, le vardénafil et le tadalafil, en raison du risque de vasodilatation majeure, pouvant être à l'origine d'un collapsus."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617830, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617824 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617825 .

_:807f36cf91fe4e8caa53aadeff92477617825 rdf:first _:807f36cf91fe4e8caa53aadeff92477617826;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617827 .

_:807f36cf91fe4e8caa53aadeff92477617826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10071 .

_:807f36cf91fe4e8caa53aadeff92477617827 rdf:first _:807f36cf91fe4e8caa53aadeff92477617828;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617828 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10098 .

_:807f36cf91fe4e8caa53aadeff92477617830 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10787-1 a owl:Class;
  rdfs:label "DIGOXINE <-> SUCRALFATE"@fr;
  dct:identifier "IAM_10787";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617832;
  r:natureDuRisque "Diminution de l'absorption digestive de la digoxine."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance de la digoxine (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617838, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617832 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617833 .

_:807f36cf91fe4e8caa53aadeff92477617833 rdf:first _:807f36cf91fe4e8caa53aadeff92477617834;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617835 .

_:807f36cf91fe4e8caa53aadeff92477617834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477617835 rdf:first _:807f36cf91fe4e8caa53aadeff92477617836;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617836 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:807f36cf91fe4e8caa53aadeff92477617838 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10750-1 a owl:Class;
  rdfs:label "DÉRIVÉS NITRÉS ET APPARENTÉS <-> RIOCIGUAT"@fr;
  dct:identifier "IAM_10750";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617840;
  r:natureDuRisque "Risque d'hypotension importante (effet synergique)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617846, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617840 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617841 .

_:807f36cf91fe4e8caa53aadeff92477617841 rdf:first _:807f36cf91fe4e8caa53aadeff92477617842;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617843 .

_:807f36cf91fe4e8caa53aadeff92477617842 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10071 .

_:807f36cf91fe4e8caa53aadeff92477617843 rdf:first _:807f36cf91fe4e8caa53aadeff92477617844;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10804 .

_:807f36cf91fe4e8caa53aadeff92477617846 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10737-1 a owl:Class;
  rdfs:label "DASABUVIR <-> GEMFIBROZIL"@fr;
  dct:identifier "IAM_10737";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617848;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques du dasabuvir par le gemfibrozil."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617854, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617848 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617849 .

_:807f36cf91fe4e8caa53aadeff92477617849 rdf:first _:807f36cf91fe4e8caa53aadeff92477617850;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617851 .

_:807f36cf91fe4e8caa53aadeff92477617850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:807f36cf91fe4e8caa53aadeff92477617851 rdf:first _:807f36cf91fe4e8caa53aadeff92477617852;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10411 .

_:807f36cf91fe4e8caa53aadeff92477617854 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10752-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10752";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617856;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur de protéases, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617862, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617856 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617857 .

_:807f36cf91fe4e8caa53aadeff92477617857 rdf:first _:807f36cf91fe4e8caa53aadeff92477617858;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617859 .

_:807f36cf91fe4e8caa53aadeff92477617858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477617859 rdf:first _:807f36cf91fe4e8caa53aadeff92477617860;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477617862 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10753-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10753";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617864;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617870, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617864 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617865 .

_:807f36cf91fe4e8caa53aadeff92477617865 rdf:first _:807f36cf91fe4e8caa53aadeff92477617866;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617867 .

_:807f36cf91fe4e8caa53aadeff92477617866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477617867 rdf:first _:807f36cf91fe4e8caa53aadeff92477617868;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617868 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477617870 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10754-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10754";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617872;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617878, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617872 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617873 .

_:807f36cf91fe4e8caa53aadeff92477617873 rdf:first _:807f36cf91fe4e8caa53aadeff92477617874;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617875 .

_:807f36cf91fe4e8caa53aadeff92477617874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477617875 rdf:first _:807f36cf91fe4e8caa53aadeff92477617876;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617876 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477617878 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10755-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10755";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617880;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617886, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617880 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617881 .

_:807f36cf91fe4e8caa53aadeff92477617881 rdf:first _:807f36cf91fe4e8caa53aadeff92477617882;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617883 .

_:807f36cf91fe4e8caa53aadeff92477617882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477617883 rdf:first _:807f36cf91fe4e8caa53aadeff92477617884;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617884 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477617886 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10756-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> PRAZIQUANTEL"@fr;
  dct:identifier "IAM_10756";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617888;
  r:natureDuRisque "Diminution des concentrations plasmatiques du praziquantel, avec risque d'échec du traitement, par augmentation du métabolisme hépatique du praziquantel par la dexaméthasone."@fr;
  r:conduiteATenir "Décaler l'administration des deux médicaments d'au moins une semaine."@fr;
  rdfs:comment "La dexamethasone diminue les concentrations de praziquantel en cas d'administration simultanée. Compte tenu du mode d'utilisation du praziquantel, sur une période courte, il est préférable de différer l'administration de la dexaméthasone, utilisée dans ce"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617894, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617888 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617889 .

_:807f36cf91fe4e8caa53aadeff92477617889 rdf:first _:807f36cf91fe4e8caa53aadeff92477617890;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617891 .

_:807f36cf91fe4e8caa53aadeff92477617890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477617891 rdf:first _:807f36cf91fe4e8caa53aadeff92477617892;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10750 .

_:807f36cf91fe4e8caa53aadeff92477617894 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10757-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> RILPIVIRINE"@fr;
  dct:identifier "IAM_10757";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617896;
  r:natureDuRisque "Avec la dexaméthasone par voie systémique (sauf en cas de prise unique), risque de diminution des concentrations plasmatiques de rilpivirine par augmentation de son métabolisme hépatique par la dexamethasone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617902, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617896 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617897 .

_:807f36cf91fe4e8caa53aadeff92477617897 rdf:first _:807f36cf91fe4e8caa53aadeff92477617898;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617899 .

_:807f36cf91fe4e8caa53aadeff92477617898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477617899 rdf:first _:807f36cf91fe4e8caa53aadeff92477617900;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10803 .

_:807f36cf91fe4e8caa53aadeff92477617902 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10945-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10945";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617904;
  r:natureDuRisque "Risque d'augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme et de la créatininémie."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617910, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617904 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617905 .

_:807f36cf91fe4e8caa53aadeff92477617905 rdf:first _:807f36cf91fe4e8caa53aadeff92477617906;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617907 .

_:807f36cf91fe4e8caa53aadeff92477617906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477617907 rdf:first _:807f36cf91fe4e8caa53aadeff92477617908;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477617910 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10946-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> IVACAFTOR"@fr;
  dct:identifier "IAM_10946";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617912;
  r:natureDuRisque "Augmentation des concentrations d’ivacaftor, avec risques de majoration des effets indésirables."@fr;
  r:conduiteATenir "Réduire la dose de moitié, soit 150 mg/j."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617918, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617912 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617913 .

_:807f36cf91fe4e8caa53aadeff92477617913 rdf:first _:807f36cf91fe4e8caa53aadeff92477617914;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617915 .

_:807f36cf91fe4e8caa53aadeff92477617914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477617915 rdf:first _:807f36cf91fe4e8caa53aadeff92477617916;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10498 .

_:807f36cf91fe4e8caa53aadeff92477617918 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10947-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> LOSARTAN"@fr;
  dct:identifier "IAM_10947";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617920;
  r:natureDuRisque "Risque de diminution de l’efficacité du losartan, par inhibition de la formation de son métabolite actif par le fluconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617926, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617920 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617921 .

_:807f36cf91fe4e8caa53aadeff92477617921 rdf:first _:807f36cf91fe4e8caa53aadeff92477617922;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617923 .

_:807f36cf91fe4e8caa53aadeff92477617922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477617923 rdf:first _:807f36cf91fe4e8caa53aadeff92477617924;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10539 .

_:807f36cf91fe4e8caa53aadeff92477617926 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10749-1 a owl:Class;
  rdfs:label "DÉRIVÉS NITRÉS ET APPARENTÉS <-> MÉDICAMENTS ABAISSANT LA PRESSION ARTÉRIELLE"@fr;
  dct:identifier "IAM_10749";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617928;
  r:natureDuRisque "Majoration du risque d’hypotension, notamment orthostatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617934, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617928 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617929 .

_:807f36cf91fe4e8caa53aadeff92477617929 rdf:first _:807f36cf91fe4e8caa53aadeff92477617930;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617931 .

_:807f36cf91fe4e8caa53aadeff92477617930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10071 .

_:807f36cf91fe4e8caa53aadeff92477617931 rdf:first _:807f36cf91fe4e8caa53aadeff92477617932;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10113 .

_:807f36cf91fe4e8caa53aadeff92477617934 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10727-1 a owl:Class;
  rdfs:label "DANTROLENE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10727";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617936;
  r:natureDuRisque "Avec le dantrolène administré par perfusion : chez l'animal, des cas de fibrillations ventriculaires mortelles sont constamment observés lors de l'administration de vérapamil et de dantrolène par voie IV. L'association d'un antagoniste du calcium et de da"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617942, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617936 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617937 .

_:807f36cf91fe4e8caa53aadeff92477617937 rdf:first _:807f36cf91fe4e8caa53aadeff92477617938;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617939 .

_:807f36cf91fe4e8caa53aadeff92477617938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10249 .

_:807f36cf91fe4e8caa53aadeff92477617939 rdf:first _:807f36cf91fe4e8caa53aadeff92477617940;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477617942 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10716-1 a owl:Class;
  rdfs:label "DACLATASVIR <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10716";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617944;
  r:natureDuRisque "Augmentation des concentrations de daclatasvir par l’inhibiteur."@fr;
  r:conduiteATenir "La dose de daclatasvir doit être diminuée à 30 mg 1 fois par jour en cas de co-administration avec l'inhibiteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617950, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617944 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617945 .

_:807f36cf91fe4e8caa53aadeff92477617945 rdf:first _:807f36cf91fe4e8caa53aadeff92477617946;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617947 .

_:807f36cf91fe4e8caa53aadeff92477617946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477617947 rdf:first _:807f36cf91fe4e8caa53aadeff92477617948;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:807f36cf91fe4e8caa53aadeff92477617950 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10717-1 a owl:Class;
  rdfs:label "DACLATASVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10717";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617952;
  r:natureDuRisque "Risque de diminution significative des concentrations plasmatiques de daclatasvir par augmentation de son métabolisme hépatique par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617958, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617952 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617953 .

_:807f36cf91fe4e8caa53aadeff92477617953 rdf:first _:807f36cf91fe4e8caa53aadeff92477617954;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617955 .

_:807f36cf91fe4e8caa53aadeff92477617954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10243 .

_:807f36cf91fe4e8caa53aadeff92477617955 rdf:first _:807f36cf91fe4e8caa53aadeff92477617956;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477617958 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10718-1 a owl:Class;
  rdfs:label "DALFOPRISTINE <-> DIHYDROERGOTAMINE"@fr;
  dct:identifier "IAM_10718";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617960;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617966, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617960 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617961 .

_:807f36cf91fe4e8caa53aadeff92477617961 rdf:first _:807f36cf91fe4e8caa53aadeff92477617962;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617963 .

_:807f36cf91fe4e8caa53aadeff92477617962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10245 .

_:807f36cf91fe4e8caa53aadeff92477617963 rdf:first _:807f36cf91fe4e8caa53aadeff92477617964;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10289 .

_:807f36cf91fe4e8caa53aadeff92477617966 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10719-1 a owl:Class;
  rdfs:label "DALFOPRISTINE <-> ERGOTAMINE"@fr;
  dct:identifier "IAM_10719";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617968;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617974, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617968 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617969 .

_:807f36cf91fe4e8caa53aadeff92477617969 rdf:first _:807f36cf91fe4e8caa53aadeff92477617970;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617971 .

_:807f36cf91fe4e8caa53aadeff92477617970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10245 .

_:807f36cf91fe4e8caa53aadeff92477617971 rdf:first _:807f36cf91fe4e8caa53aadeff92477617972;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477617974 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10720-1 a owl:Class;
  rdfs:label "DALFOPRISTINE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10720";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617976;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617982, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617976 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617977 .

_:807f36cf91fe4e8caa53aadeff92477617977 rdf:first _:807f36cf91fe4e8caa53aadeff92477617978;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617979 .

_:807f36cf91fe4e8caa53aadeff92477617978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477617979 rdf:first _:807f36cf91fe4e8caa53aadeff92477617980;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10245 .

_:807f36cf91fe4e8caa53aadeff92477617982 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10721-1 a owl:Class;
  rdfs:label "DALFOPRISTINE <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10721";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617984;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617990, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617984 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617985 .

_:807f36cf91fe4e8caa53aadeff92477617985 rdf:first _:807f36cf91fe4e8caa53aadeff92477617986;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617987 .

_:807f36cf91fe4e8caa53aadeff92477617986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10245 .

_:807f36cf91fe4e8caa53aadeff92477617987 rdf:first _:807f36cf91fe4e8caa53aadeff92477617988;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617988 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477617990 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10722-1 a owl:Class;
  rdfs:label "DANAZOL <-> INSULINE"@fr;
  dct:identifier "IAM_10722";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477617992;
  r:natureDuRisque "Effet diabétogène du danazol."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, prévenir le patient et renforcer l'autosurveillance glycémique. Adapter éventuellement la posologie de l'insuline pendant le traitement par le danazol et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477617998, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477617992 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477617993 .

_:807f36cf91fe4e8caa53aadeff92477617993 rdf:first _:807f36cf91fe4e8caa53aadeff92477617994;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477617995 .

_:807f36cf91fe4e8caa53aadeff92477617994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:807f36cf91fe4e8caa53aadeff92477617995 rdf:first _:807f36cf91fe4e8caa53aadeff92477617996;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477617996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10458 .

_:807f36cf91fe4e8caa53aadeff92477617998 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10723-1 a owl:Class;
  rdfs:label "DANAZOL <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10723";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618000;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse par diminution du métabolisme de la simvastatine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618006, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618000 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618001 .

_:807f36cf91fe4e8caa53aadeff92477618001 rdf:first _:807f36cf91fe4e8caa53aadeff92477618002;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618003 .

_:807f36cf91fe4e8caa53aadeff92477618002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:807f36cf91fe4e8caa53aadeff92477618003 rdf:first _:807f36cf91fe4e8caa53aadeff92477618004;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477618006 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10724-1 a owl:Class;
  rdfs:label "DANAZOL <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10724";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618008;
  r:natureDuRisque "Effet diabétogène du danazol."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, prévenir le patient et renforcer l'autosurveillance glycémique. Adapter éventuellement la posologie de l'antidiabétique pendant le traitement par le danazol et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618014, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618008 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618009 .

_:807f36cf91fe4e8caa53aadeff92477618009 rdf:first _:807f36cf91fe4e8caa53aadeff92477618010;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618011 .

_:807f36cf91fe4e8caa53aadeff92477618010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477618011 rdf:first _:807f36cf91fe4e8caa53aadeff92477618012;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:807f36cf91fe4e8caa53aadeff92477618014 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10739-1 a owl:Class;
  rdfs:label "DASABUVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10739";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618016;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du dasabuvir par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618022, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618016 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618017 .

_:807f36cf91fe4e8caa53aadeff92477618017 rdf:first _:807f36cf91fe4e8caa53aadeff92477618018;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618019 .

_:807f36cf91fe4e8caa53aadeff92477618018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:807f36cf91fe4e8caa53aadeff92477618019 rdf:first _:807f36cf91fe4e8caa53aadeff92477618020;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477618022 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10726-1 a owl:Class;
  rdfs:label "DANTROLENE <-> DIHYDROPYRIDINES"@fr;
  dct:identifier "IAM_10726";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618024;
  r:natureDuRisque "Avec le dantrolène administré par perfusion : chez l'animal des cas de fibrillations ventriculaires mortelles sont constamment observés lors de l'administration de vérapamil et de dantrolène IV. L'association d'un antagoniste du calcium et de dantrolène e"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618030, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618024 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618025 .

_:807f36cf91fe4e8caa53aadeff92477618025 rdf:first _:807f36cf91fe4e8caa53aadeff92477618026;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618027 .

_:807f36cf91fe4e8caa53aadeff92477618026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10062 .

_:807f36cf91fe4e8caa53aadeff92477618027 rdf:first _:807f36cf91fe4e8caa53aadeff92477618028;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618028 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10249 .

_:807f36cf91fe4e8caa53aadeff92477618030 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10738-1 a owl:Class;
  rdfs:label "DASABUVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10738";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618032;
  r:natureDuRisque "Risque de diminution des concentrations plasmatiques du dasabuvir par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618038, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618032 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618033 .

_:807f36cf91fe4e8caa53aadeff92477618033 rdf:first _:807f36cf91fe4e8caa53aadeff92477618034;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618035 .

_:807f36cf91fe4e8caa53aadeff92477618034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477618035 rdf:first _:807f36cf91fe4e8caa53aadeff92477618036;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618036 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:807f36cf91fe4e8caa53aadeff92477618038 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10728-1 a owl:Class;
  rdfs:label "DANTROLENE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10728";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618040;
  r:natureDuRisque "Avec le dantrolène administré par perfusion : chez l'animal, des cas de fibrillations ventriculaires mortelles sont constamment observés lors de l'administration de vérapamil et de dantrolène par voie IV. L'association d'un antagoniste du calcium et de da"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618046, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618040 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618041 .

_:807f36cf91fe4e8caa53aadeff92477618041 rdf:first _:807f36cf91fe4e8caa53aadeff92477618042;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618043 .

_:807f36cf91fe4e8caa53aadeff92477618042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10249 .

_:807f36cf91fe4e8caa53aadeff92477618043 rdf:first _:807f36cf91fe4e8caa53aadeff92477618044;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618044 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477618046 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10729-1 a owl:Class;
  rdfs:label "DAPOXÉTINE <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10729";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618048;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment à type de vertiges ou de syncopes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618054, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618048 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618049 .

_:807f36cf91fe4e8caa53aadeff92477618049 rdf:first _:807f36cf91fe4e8caa53aadeff92477618050;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618051 .

_:807f36cf91fe4e8caa53aadeff92477618050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477618051 rdf:first _:807f36cf91fe4e8caa53aadeff92477618052;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618052 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10250 .

_:807f36cf91fe4e8caa53aadeff92477618054 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10730-1 a owl:Class;
  rdfs:label "DAPOXÉTINE <-> MÉDICAMENTS À L'ORIGINE D'UNE HYPOTENSION ORTHOSTATIQUE"@fr;
  dct:identifier "IAM_10730";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618056;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment à type de vertiges ou de syncopes."@fr;
  r:conduiteATenir """Association déconseillée
- avec les inhibiteurs de la phosphodiestérase de type 5

A prendre en compte 
- avec les autres classes thérapeutiques"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618062, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618056 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618057 .

_:807f36cf91fe4e8caa53aadeff92477618057 rdf:first _:807f36cf91fe4e8caa53aadeff92477618058;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618059 .

_:807f36cf91fe4e8caa53aadeff92477618058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10122 .

_:807f36cf91fe4e8caa53aadeff92477618059 rdf:first _:807f36cf91fe4e8caa53aadeff92477618060;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618060 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10250 .

_:807f36cf91fe4e8caa53aadeff92477618062 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10731-1 a owl:Class;
  rdfs:label "DAPSONE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_10731";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618064;
  r:natureDuRisque "Augmentation de la toxicité hématologique (addition d'effets de toxicité médullaire)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'hémogramme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618070, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618064 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618065 .

_:807f36cf91fe4e8caa53aadeff92477618065 rdf:first _:807f36cf91fe4e8caa53aadeff92477618066;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618067 .

_:807f36cf91fe4e8caa53aadeff92477618066 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10251 .

_:807f36cf91fe4e8caa53aadeff92477618067 rdf:first _:807f36cf91fe4e8caa53aadeff92477618068;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618068 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:807f36cf91fe4e8caa53aadeff92477618070 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10732-1 a owl:Class;
  rdfs:label "DAPTOMYCINE <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10732";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618072;
  r:natureDuRisque "Risque d’addition des effets indésirables (dose-dépendant) à type de rhabdomyolyse."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, renforcer la surveillance biologique (dosage des CPK plus d’une fois par semaine) et surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618078, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618072 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618073 .

_:807f36cf91fe4e8caa53aadeff92477618073 rdf:first _:807f36cf91fe4e8caa53aadeff92477618074;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618075 .

_:807f36cf91fe4e8caa53aadeff92477618074 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477618075 rdf:first _:807f36cf91fe4e8caa53aadeff92477618076;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618076 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10252 .

_:807f36cf91fe4e8caa53aadeff92477618078 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10733-1 a owl:Class;
  rdfs:label "DARIFENACINE <-> FLECAINIDE"@fr;
  dct:identifier "IAM_10733";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618080;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de flécaïnide, avec risque de surdosage, par diminution de son métabolisme hépatique par la darifénacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du flécaïnide pendant le traitement par darifénacine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618086, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618080 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618081 .

_:807f36cf91fe4e8caa53aadeff92477618081 rdf:first _:807f36cf91fe4e8caa53aadeff92477618082;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618083 .

_:807f36cf91fe4e8caa53aadeff92477618082 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10253 .

_:807f36cf91fe4e8caa53aadeff92477618083 rdf:first _:807f36cf91fe4e8caa53aadeff92477618084;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618084 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:807f36cf91fe4e8caa53aadeff92477618086 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10734-1 a owl:Class;
  rdfs:label "DARIFENACINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10734";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618088;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du métoprolol, avec risque de surdosage, par diminution de son métabolisme hépatique par la darifénacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du métoprolol pendant le traitement par darifénacine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618094, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618088 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618089 .

_:807f36cf91fe4e8caa53aadeff92477618089 rdf:first _:807f36cf91fe4e8caa53aadeff92477618090;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618091 .

_:807f36cf91fe4e8caa53aadeff92477618090 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10253 .

_:807f36cf91fe4e8caa53aadeff92477618091 rdf:first _:807f36cf91fe4e8caa53aadeff92477618092;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618092 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477618094 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10735-1 a owl:Class;
  rdfs:label "DARIFENACINE <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10735";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618096;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de propafénone, avec risque de surdosage, par diminution de son métabolisme hépatique par la darifénacine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de la propafénone pendant le traitement par darifénacine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618102, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618096 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618097 .

_:807f36cf91fe4e8caa53aadeff92477618097 rdf:first _:807f36cf91fe4e8caa53aadeff92477618098;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618099 .

_:807f36cf91fe4e8caa53aadeff92477618098 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10253 .

_:807f36cf91fe4e8caa53aadeff92477618099 rdf:first _:807f36cf91fe4e8caa53aadeff92477618100;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618100 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477618102 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10736-1 a owl:Class;
  rdfs:label "DASABUVIR <-> ETHINYLESTRADIOL"@fr;
  dct:identifier "IAM_10736";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618104;
  r:natureDuRisque "Augmentation de l’hépatotoxicité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618110, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618104 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618105 .

_:807f36cf91fe4e8caa53aadeff92477618105 rdf:first _:807f36cf91fe4e8caa53aadeff92477618106;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618107 .

_:807f36cf91fe4e8caa53aadeff92477618106 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10255 .

_:807f36cf91fe4e8caa53aadeff92477618107 rdf:first _:807f36cf91fe4e8caa53aadeff92477618108;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618108 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10351 .

_:807f36cf91fe4e8caa53aadeff92477618110 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10950-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> OLAPARIB"@fr;
  dct:identifier "IAM_10950";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618112;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’olaparib par le fluconazole."@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, limiter la dose d’olaparib à 200 mg deux fois par jour."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618118, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618112 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618113 .

_:807f36cf91fe4e8caa53aadeff92477618113 rdf:first _:807f36cf91fe4e8caa53aadeff92477618114;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618115 .

_:807f36cf91fe4e8caa53aadeff92477618114 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477618115 rdf:first _:807f36cf91fe4e8caa53aadeff92477618116;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618116 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10659 .

_:807f36cf91fe4e8caa53aadeff92477618118 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10725-1 a owl:Class;
  rdfs:label "DANAZOL <-> TACROLIMUS"@fr;
  dct:identifier "IAM_10725";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618120;
  r:natureDuRisque "Augmentation des concentrations sanguines du tacrolimus par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines du tacrolimus et adaptation de sa posologie pendant l'association et après son arrêt, avec contrôle de la fonction rénale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618126, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618120 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618121 .

_:807f36cf91fe4e8caa53aadeff92477618121 rdf:first _:807f36cf91fe4e8caa53aadeff92477618122;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618123 .

_:807f36cf91fe4e8caa53aadeff92477618122 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10248 .

_:807f36cf91fe4e8caa53aadeff92477618123 rdf:first _:807f36cf91fe4e8caa53aadeff92477618124;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618124 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10880 .

_:807f36cf91fe4e8caa53aadeff92477618126 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10774-1 a owl:Class;
  rdfs:label "DIGOXINE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10774";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618128;
  r:natureDuRisque "Augmentation de la digoxinémie par augmentation de son absorption."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par l'érythromycine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618134, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618128 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618129 .

_:807f36cf91fe4e8caa53aadeff92477618129 rdf:first _:807f36cf91fe4e8caa53aadeff92477618130;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618131 .

_:807f36cf91fe4e8caa53aadeff92477618130 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477618131 rdf:first _:807f36cf91fe4e8caa53aadeff92477618132;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618132 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477618134 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10948-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> MIDAZOLAM"@fr;
  dct:identifier "IAM_10948";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618136;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de midazolam par diminution de son métabolisme hépatique, avec majoration de la sédation."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie de midazolam en cas de traitement par le fluconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618142, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618136 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618137 .

_:807f36cf91fe4e8caa53aadeff92477618137 rdf:first _:807f36cf91fe4e8caa53aadeff92477618138;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618139 .

_:807f36cf91fe4e8caa53aadeff92477618138 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477618139 rdf:first _:807f36cf91fe4e8caa53aadeff92477618140;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618140 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10585 .

_:807f36cf91fe4e8caa53aadeff92477618142 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10765-1 a owl:Class;
  rdfs:label "DIAZEPAM <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10765";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618144;
  r:natureDuRisque "Variations imprévisibles : les concentrations plasmatiques de phénytoïne peuvent augmenter, avec signes de surdosage, mais aussi diminuer ou rester stables."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénytoïne."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618150, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618144 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618145 .

_:807f36cf91fe4e8caa53aadeff92477618145 rdf:first _:807f36cf91fe4e8caa53aadeff92477618146;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618147 .

_:807f36cf91fe4e8caa53aadeff92477618146 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477618147 rdf:first _:807f36cf91fe4e8caa53aadeff92477618148;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618148 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10280 .

_:807f36cf91fe4e8caa53aadeff92477618150 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10766-1 a owl:Class;
  rdfs:label "DIAZEPAM <-> STIRIPENTOL"@fr;
  dct:identifier "IAM_10766";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618152;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du diazépam, avec risque de surdosage, par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et dosage plasmatique, lorsque cela est possible, de l'anticonvulsivant associé au stiripentol et éventuelle adaptation posologique de l'anticonvulsivant associé."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618158, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618152 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618153 .

_:807f36cf91fe4e8caa53aadeff92477618153 rdf:first _:807f36cf91fe4e8caa53aadeff92477618154;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618155 .

_:807f36cf91fe4e8caa53aadeff92477618154 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10280 .

_:807f36cf91fe4e8caa53aadeff92477618155 rdf:first _:807f36cf91fe4e8caa53aadeff92477618156;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618156 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10859 .

_:807f36cf91fe4e8caa53aadeff92477618158 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10772-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> ZALCITABINE"@fr;
  dct:identifier "IAM_10772";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618160;
  r:natureDuRisque "Risque majoré de survenue de pancréatite et de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique régulière et surveillance de l'amylasémie. Ne pas associer si l'amylasémie est à la limite supérieure de la normale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618166, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618160 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618161 .

_:807f36cf91fe4e8caa53aadeff92477618161 rdf:first _:807f36cf91fe4e8caa53aadeff92477618162;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618163 .

_:807f36cf91fe4e8caa53aadeff92477618162 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:807f36cf91fe4e8caa53aadeff92477618163 rdf:first _:807f36cf91fe4e8caa53aadeff92477618164;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618164 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:807f36cf91fe4e8caa53aadeff92477618166 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10767-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> GANCICLOVIR"@fr;
  dct:identifier "IAM_10767";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618168;
  r:natureDuRisque "Risque d'augmentation des effets indésirables de la didanosine, et notamment la toxicité mitochondriale, par augmentation importante de ses concentrations. De plus risque de diminution de l'efficacité du ganciclovir par diminution de ses concentrations, s"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618174, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618168 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618169 .

_:807f36cf91fe4e8caa53aadeff92477618169 rdf:first _:807f36cf91fe4e8caa53aadeff92477618170;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618171 .

_:807f36cf91fe4e8caa53aadeff92477618170 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:807f36cf91fe4e8caa53aadeff92477618171 rdf:first _:807f36cf91fe4e8caa53aadeff92477618172;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618172 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10408 .

_:807f36cf91fe4e8caa53aadeff92477618174 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10768-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> PENTAMIDINE"@fr;
  dct:identifier "IAM_10768";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618176;
  r:natureDuRisque "Risque majoré de survenue de pancréatite par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance de l'amylasémie. Ne pas associer si l'amylasémie est à la limite supérieure de la normale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618182, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618176 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618177 .

_:807f36cf91fe4e8caa53aadeff92477618177 rdf:first _:807f36cf91fe4e8caa53aadeff92477618178;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618179 .

_:807f36cf91fe4e8caa53aadeff92477618178 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:807f36cf91fe4e8caa53aadeff92477618179 rdf:first _:807f36cf91fe4e8caa53aadeff92477618180;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618180 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10703 .

_:807f36cf91fe4e8caa53aadeff92477618182 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10769-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> RIBAVIRINE"@fr;
  dct:identifier "IAM_10769";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618184;
  r:natureDuRisque "Risque de majoration de la toxicité mitochondriale de la didanosine par augmentation de son métabolite actif."@fr;
  rdfs:comment "La ribavirine, antiviral inhibant la synthèse des acides nucléiques du virus de l’hépatite C, augmente la concentration intra-cellulaire en inosine 5’ monophosphate (IMP) en inhibant l’IMP déhydrogénase. Cette augmentation entraîne une élévation de la con"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618190, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618184 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618185 .

_:807f36cf91fe4e8caa53aadeff92477618185 rdf:first _:807f36cf91fe4e8caa53aadeff92477618186;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618187 .

_:807f36cf91fe4e8caa53aadeff92477618186 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:807f36cf91fe4e8caa53aadeff92477618187 rdf:first _:807f36cf91fe4e8caa53aadeff92477618188;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10797 .

_:807f36cf91fe4e8caa53aadeff92477618190 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10770-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> TENOFOVIR DISOPROXIL"@fr;
  dct:identifier "IAM_10770";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618192;
  r:natureDuRisque "Risque d'échec du traitement antirétroviral, voire émergence de résistances. De plus, majoration du risque de la toxicité mitochondriale de la didanosine."@fr;
  rdfs:comment "Il existe une augmentation de 60% de l'AUC de la didanosine (DDI), administrée sous forme de comprimé tamponné, lorsqu’elle est associée avec le ténofovir. Si un ajustement posologique n'est pas toujours justifié, compte tenu d'une sensibilité individuell"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618198, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618192 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618193 .

_:807f36cf91fe4e8caa53aadeff92477618193 rdf:first _:807f36cf91fe4e8caa53aadeff92477618194;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618195 .

_:807f36cf91fe4e8caa53aadeff92477618194 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:807f36cf91fe4e8caa53aadeff92477618195 rdf:first _:807f36cf91fe4e8caa53aadeff92477618196;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10896 .

_:807f36cf91fe4e8caa53aadeff92477618198 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10771-1 a owl:Class;
  rdfs:label "DIDANOSINE <-> THALIDOMIDE"@fr;
  dct:identifier "IAM_10771";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618200;
  r:natureDuRisque "Risque majoré de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618206, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618200 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618201 .

_:807f36cf91fe4e8caa53aadeff92477618201 rdf:first _:807f36cf91fe4e8caa53aadeff92477618202;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618203 .

_:807f36cf91fe4e8caa53aadeff92477618202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10283 .

_:807f36cf91fe4e8caa53aadeff92477618203 rdf:first _:807f36cf91fe4e8caa53aadeff92477618204;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10913 .

_:807f36cf91fe4e8caa53aadeff92477618206 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10763-1 a owl:Class;
  rdfs:label "DEXTROMETHORPHANE <-> IMAO IRRÉVERSIBLES"@fr;
  dct:identifier "IAM_10763";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618208;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618214, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618208 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618209 .

_:807f36cf91fe4e8caa53aadeff92477618209 rdf:first _:807f36cf91fe4e8caa53aadeff92477618210;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618211 .

_:807f36cf91fe4e8caa53aadeff92477618210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477618211 rdf:first _:807f36cf91fe4e8caa53aadeff92477618212;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10278 .

_:807f36cf91fe4e8caa53aadeff92477618214 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10773-1 a owl:Class;
  rdfs:label "DIGOXINE <-> DRONEDARONE"@fr;
  dct:identifier "IAM_10773";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618216;
  r:natureDuRisque "Dépression de l'automatisme (bradycardie excessive) et troubles de la conduction auriculo-ventriculaire. En outre, augmentation de la digoxinémie par diminution du métabolisme de la digoxine. Surveillance clinique et ECG."@fr;
  r:conduiteATenir "Réduire de moitié les doses de digoxine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618222, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618216 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618217 .

_:807f36cf91fe4e8caa53aadeff92477618217 rdf:first _:807f36cf91fe4e8caa53aadeff92477618218;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618219 .

_:807f36cf91fe4e8caa53aadeff92477618218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477618219 rdf:first _:807f36cf91fe4e8caa53aadeff92477618220;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10311 .

_:807f36cf91fe4e8caa53aadeff92477618222 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10762-1 a owl:Class;
  rdfs:label "DEXTRAN 40 <-> HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10762";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618224;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire par le dextran 40)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618230, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618224 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618225 .

_:807f36cf91fe4e8caa53aadeff92477618225 rdf:first _:807f36cf91fe4e8caa53aadeff92477618226;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618227 .

_:807f36cf91fe4e8caa53aadeff92477618226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10061 .

_:807f36cf91fe4e8caa53aadeff92477618227 rdf:first _:807f36cf91fe4e8caa53aadeff92477618228;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:807f36cf91fe4e8caa53aadeff92477618230 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10775-1 a owl:Class;
  rdfs:label "DIGOXINE <-> HYDROQUINIDINE"@fr;
  dct:identifier "IAM_10775";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618232;
  r:natureDuRisque "Augmentation de la digoxinémie par diminution de la clairance rénale de la digoxine. De plus, troubles de l'automatisme (bradycardie excessive et troubles de la conduction auriculo-ventriculaire)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. En cas de réponse inattendue, contrôler la digoxinémie et adapter la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618238, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618232 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618233 .

_:807f36cf91fe4e8caa53aadeff92477618233 rdf:first _:807f36cf91fe4e8caa53aadeff92477618234;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618235 .

_:807f36cf91fe4e8caa53aadeff92477618234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477618235 rdf:first _:807f36cf91fe4e8caa53aadeff92477618236;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10434 .

_:807f36cf91fe4e8caa53aadeff92477618238 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10776-1 a owl:Class;
  rdfs:label "DIGOXINE <-> HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10776";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618240;
  r:natureDuRisque "Hypokaliémie favorisant les effets toxiques des digitaliques."@fr;
  r:conduiteATenir "Corriger auparavant toute hypokaliémie et réaliser une surveillance clinique, électrolytique et électrocardiographique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618246, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618240 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618241 .

_:807f36cf91fe4e8caa53aadeff92477618241 rdf:first _:807f36cf91fe4e8caa53aadeff92477618242;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618243 .

_:807f36cf91fe4e8caa53aadeff92477618242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10086 .

_:807f36cf91fe4e8caa53aadeff92477618243 rdf:first _:807f36cf91fe4e8caa53aadeff92477618244;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477618246 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10777-1 a owl:Class;
  rdfs:label "DIGOXINE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10777";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618248;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Augmentation de la digoxinémie, plus marquée pour la voie intraveineuse, par augmentation de l’absorption de la digoxine ou diminution de sa clairance rénale."@fr;
  r:conduiteATenir "Surveillance clinique et, s’il y a lieu, de l’ECG et de la digoxinémie, avec adaptation éventuelle de la posologie de digoxine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618254, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618248 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618249 .

_:807f36cf91fe4e8caa53aadeff92477618249 rdf:first _:807f36cf91fe4e8caa53aadeff92477618250;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618251 .

_:807f36cf91fe4e8caa53aadeff92477618250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477618251 rdf:first _:807f36cf91fe4e8caa53aadeff92477618252;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477618254 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10778-1 a owl:Class;
  rdfs:label "DIGOXINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10778";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618256;
  r:natureDuRisque "Augmentation de la digoxinémie avec nausées, vomissements, troubles du rythme."@fr;
  r:conduiteATenir "Surveillance clinique et, s'il y a lieu, de l'ECG et de la digoxinémie avec adaptation de la posologie de la digoxine pendant le traitement par l'itraconazole et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618262, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618256 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618257 .

_:807f36cf91fe4e8caa53aadeff92477618257 rdf:first _:807f36cf91fe4e8caa53aadeff92477618258;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618259 .

_:807f36cf91fe4e8caa53aadeff92477618258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477618259 rdf:first _:807f36cf91fe4e8caa53aadeff92477618260;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477618262 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10779-1 a owl:Class;
  rdfs:label "DIGOXINE <-> MIDODRINE"@fr;
  dct:identifier "IAM_10779";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618264;
  r:natureDuRisque "Troubles de l'automatisme (majoration de l'effet bradycardisant de la midodrine) et troubles de la conduction auriculo-ventriculaire."@fr;
  r:conduiteATenir "Si cette association ne peut être évitée, renforcer la surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618270, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618264 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618265 .

_:807f36cf91fe4e8caa53aadeff92477618265 rdf:first _:807f36cf91fe4e8caa53aadeff92477618266;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618267 .

_:807f36cf91fe4e8caa53aadeff92477618266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477618267 rdf:first _:807f36cf91fe4e8caa53aadeff92477618268;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10587 .

_:807f36cf91fe4e8caa53aadeff92477618270 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10780-1 a owl:Class;
  rdfs:label "DIGOXINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10780";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618272;
  r:natureDuRisque "Diminution de la digoxinémie, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet, dont les conséquences peuvent être éventuellement graves (décompensation d'une insuffisance cardiaq"@fr;
  r:conduiteATenir "En cas d'association fortuite, ne pas interrompre brutalement la prise de millepertuis mais contrôler les concentrations plasmatiques (ou l'efficacité) de la digoxine avant puis après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618278, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618272 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618273 .

_:807f36cf91fe4e8caa53aadeff92477618273 rdf:first _:807f36cf91fe4e8caa53aadeff92477618274;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618275 .

_:807f36cf91fe4e8caa53aadeff92477618274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477618275 rdf:first _:807f36cf91fe4e8caa53aadeff92477618276;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477618278 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10781-1 a owl:Class;
  rdfs:label "DIGOXINE <-> OMEPRAZOLE"@fr;
  dct:identifier "IAM_10781";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618280;
  r:natureDuRisque "Augmentation modérée de la digoxinémie par majoration de son absorption par l'oméprazole."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et de la digoxinémie, particulièrement chez le sujet âgé."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618286, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618280 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618281 .

_:807f36cf91fe4e8caa53aadeff92477618281 rdf:first _:807f36cf91fe4e8caa53aadeff92477618282;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618283 .

_:807f36cf91fe4e8caa53aadeff92477618282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477618283 rdf:first _:807f36cf91fe4e8caa53aadeff92477618284;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10664 .

_:807f36cf91fe4e8caa53aadeff92477618286 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10782-1 a owl:Class;
  rdfs:label "DIGOXINE <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_10782";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618288;
  r:natureDuRisque "Augmentation de la digoxinémie avec nausées, vomissements, troubles du rythme."@fr;
  r:conduiteATenir "Surveillance clinique et, s'il y a lieu, de l'ECG et de la digoxinémie, avec adaptation de la posologie de la digoxine pendant le traitement par le posaconazole et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618294, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618288 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618289 .

_:807f36cf91fe4e8caa53aadeff92477618289 rdf:first _:807f36cf91fe4e8caa53aadeff92477618290;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618291 .

_:807f36cf91fe4e8caa53aadeff92477618290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477618291 rdf:first _:807f36cf91fe4e8caa53aadeff92477618292;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477618294 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10783-1 a owl:Class;
  rdfs:label "DIGOXINE <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10783";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618296;
  r:natureDuRisque "Risque d’augmentation de la digoxinémie, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la digoxinémie pendant le traitement par propafénone et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618296 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618297 .

_:807f36cf91fe4e8caa53aadeff92477618297 rdf:first _:807f36cf91fe4e8caa53aadeff92477618298;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618299 .

_:807f36cf91fe4e8caa53aadeff92477618298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477618299 rdf:first _:807f36cf91fe4e8caa53aadeff92477618300;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477618302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10784-1 a owl:Class;
  rdfs:label "DIGOXINE <-> QUINIDINE"@fr;
  dct:identifier "IAM_10784";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618304;
  r:natureDuRisque "Augmentation de la digoxinémie par diminution de la clairance rénale de la digoxine. De plus, troubles de l'automatisme (bradycardie excessive et troubles de la conduction auriculo-ventriculaire)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. En cas de réponse inattendue, contrôler la digoxinémie et adapter la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618305 .

_:807f36cf91fe4e8caa53aadeff92477618305 rdf:first _:807f36cf91fe4e8caa53aadeff92477618306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618307 .

_:807f36cf91fe4e8caa53aadeff92477618306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477618307 rdf:first _:807f36cf91fe4e8caa53aadeff92477618308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10776 .

_:807f36cf91fe4e8caa53aadeff92477618310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10789-1 a owl:Class;
  rdfs:label "DIGOXINE <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10789";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618312;
  r:natureDuRisque "Augmentation de la digoxinémie."@fr;
  r:conduiteATenir "Surveillance clinique et biologique et adaptation, si besoin, de la posologie de la digoxine pendant le traitement par le télaprévir et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618313 .

_:807f36cf91fe4e8caa53aadeff92477618313 rdf:first _:807f36cf91fe4e8caa53aadeff92477618314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618315 .

_:807f36cf91fe4e8caa53aadeff92477618314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10286 .

_:807f36cf91fe4e8caa53aadeff92477618315 rdf:first _:807f36cf91fe4e8caa53aadeff92477618316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477618318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11125-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_11125";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618320;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de l’inhibiteur de protéase boosté par le ritonavir ou de l’inhibiteur du CYP3A4."@fr;
  r:conduiteATenir "Pour connaître les risques et les niveaux de contrainte de chaque inhibiteur de protéase boosté par le ritonavir avec les inhibiteurs puissants du CYP3A4, il convient de se reporter aux AMM spécifiques à chacun d'eux."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618320 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618321 .

_:807f36cf91fe4e8caa53aadeff92477618321 rdf:first _:807f36cf91fe4e8caa53aadeff92477618322;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618323 .

_:807f36cf91fe4e8caa53aadeff92477618322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477618323 rdf:first _:807f36cf91fe4e8caa53aadeff92477618324;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477618326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11207-1 a owl:Class;
  rdfs:label "IVABRADINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11207";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618328;
  r:natureDuRisque "Risque de diminution de l'efficacité de l’ivabradine, par augmentation de son métabolisme par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation de la posologie de l’ivabradine pendant l’association et après l’arrêt de la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618329 .

_:807f36cf91fe4e8caa53aadeff92477618329 rdf:first _:807f36cf91fe4e8caa53aadeff92477618330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618331 .

_:807f36cf91fe4e8caa53aadeff92477618330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477618331 rdf:first _:807f36cf91fe4e8caa53aadeff92477618332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477618334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10951-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> OXYCODONE"@fr;
  dct:identifier "IAM_10951";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618336;
  r:natureDuRisque "Majoration des effets indésirables, notamment respiratoires, de l’oxycodone par diminution de son métabolisme hépatique par le fluconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618337 .

_:807f36cf91fe4e8caa53aadeff92477618337 rdf:first _:807f36cf91fe4e8caa53aadeff92477618338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618339 .

_:807f36cf91fe4e8caa53aadeff92477618338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477618339 rdf:first _:807f36cf91fe4e8caa53aadeff92477618340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10681 .

_:807f36cf91fe4e8caa53aadeff92477618342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10952-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10952";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618344;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne pouvant atteindre des valeurs toxiques. Mécanisme invoqué : inhibition du métabolisme hépatique de la phénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique et biologique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618345 .

_:807f36cf91fe4e8caa53aadeff92477618345 rdf:first _:807f36cf91fe4e8caa53aadeff92477618346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618347 .

_:807f36cf91fe4e8caa53aadeff92477618346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477618347 rdf:first _:807f36cf91fe4e8caa53aadeff92477618348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477618350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10953-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10953";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618352;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618353 .

_:807f36cf91fe4e8caa53aadeff92477618353 rdf:first _:807f36cf91fe4e8caa53aadeff92477618354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618355 .

_:807f36cf91fe4e8caa53aadeff92477618354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477618355 rdf:first _:807f36cf91fe4e8caa53aadeff92477618356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477618358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11120-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> SPIRONOLACTONE"@fr;
  dct:identifier "IAM_11120";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618360;
  r:natureDuRisque """Avec la spironolactone à la posologie de 12,5 à 50 mg par jour, et avec des doses faibles d’IEC.

Dans le traitement de l’insuffisance cardiaque de classe III ou IV (NYHA) avec fraction d’éjection <35 % et préalablement traitée par l’association inhibiteu"""@fr;
  r:conduiteATenir "Vérifier au préalable l’absence d’hyperkaliémie et d’insuffisance rénale. Surveillance biologique étroite de la kaliémie et de la créatininémie (1 fois par semaine pendant le premier mois, puis une fois par mois ensuite)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618361 .

_:807f36cf91fe4e8caa53aadeff92477618361 rdf:first _:807f36cf91fe4e8caa53aadeff92477618362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618363 .

_:807f36cf91fe4e8caa53aadeff92477618362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477618363 rdf:first _:807f36cf91fe4e8caa53aadeff92477618364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10857 .

_:807f36cf91fe4e8caa53aadeff92477618366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11121-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'ENZYME DE CONVERSION <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_11121";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618368;
  r:natureDuRisque "L'utilisation des IEC peut entraîner une majoration de l'effet hypoglycémiant chez le diabétique traité par sulfamides hypoglycémiants. La survenue de malaises hypoglycémiques semble exceptionnelle (amélioration de la tolérance au glucose qui aurait pour"@fr;
  r:conduiteATenir "Renforcer l'autosurveillance glycémique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618369 .

_:807f36cf91fe4e8caa53aadeff92477618369 rdf:first _:807f36cf91fe4e8caa53aadeff92477618370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618371 .

_:807f36cf91fe4e8caa53aadeff92477618370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477618371 rdf:first _:807f36cf91fe4e8caa53aadeff92477618372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477618374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11122-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES) <-> LÉDIPASVIR"@fr;
  dct:identifier "IAM_11122";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618376;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques de la statine et de ses effets indésirables à type de rhabdomyolyse."@fr;
  r:conduiteATenir """Contre-indication :
- avec la rosuvastatine.

Précaution d'emploi :
- avec les autres inhibiteurs de l'HMG Co-A réductase.
Surveillance clinique et biologique. Adaptation éventuelle de la posologie de la statine."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618377 .

_:807f36cf91fe4e8caa53aadeff92477618377 rdf:first _:807f36cf91fe4e8caa53aadeff92477618378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618379 .

_:807f36cf91fe4e8caa53aadeff92477618378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477618379 rdf:first _:807f36cf91fe4e8caa53aadeff92477618380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10512 .

_:807f36cf91fe4e8caa53aadeff92477618382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11123-1 a owl:Class;
  rdfs:label "INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES) <-> LENALIDOMIDE"@fr;
  dct:identifier "IAM_11123";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618384;
  r:natureDuRisque "Risque majoré de survenue de rhabdomyolyses."@fr;
  r:conduiteATenir "Renforcer le contrôle clinique et biologique, notamment durant les premières semaines de traitement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618390, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618384 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618385 .

_:807f36cf91fe4e8caa53aadeff92477618385 rdf:first _:807f36cf91fe4e8caa53aadeff92477618386;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618387 .

_:807f36cf91fe4e8caa53aadeff92477618386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477618387 rdf:first _:807f36cf91fe4e8caa53aadeff92477618388;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10513 .

_:807f36cf91fe4e8caa53aadeff92477618390 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11128-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> LUMEFANTRINE"@fr;
  dct:identifier "IAM_11128";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618392;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618398, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618392 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618393 .

_:807f36cf91fe4e8caa53aadeff92477618393 rdf:first _:807f36cf91fe4e8caa53aadeff92477618394;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618395 .

_:807f36cf91fe4e8caa53aadeff92477618394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477618395 rdf:first _:807f36cf91fe4e8caa53aadeff92477618396;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10541 .

_:807f36cf91fe4e8caa53aadeff92477618398 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10764-1 a owl:Class;
  rdfs:label "DEXTROMETHORPHANE <-> IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE"@fr;
  dct:identifier "IAM_10764";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618400;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618400 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618401 .

_:807f36cf91fe4e8caa53aadeff92477618401 rdf:first _:807f36cf91fe4e8caa53aadeff92477618402;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618403 .

_:807f36cf91fe4e8caa53aadeff92477618402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477618403 rdf:first _:807f36cf91fe4e8caa53aadeff92477618404;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10278 .

_:807f36cf91fe4e8caa53aadeff92477618406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11144-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> VINCA-ALCALOÏDES CYTOTOXIQUES"@fr;
  dct:identifier "IAM_11144";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618408;
  r:natureDuRisque "Majoration de la toxicité de l’antimitotique, par diminution de son métabolisme hépatique par l’inhibiteur de protéases."@fr;
  r:conduiteATenir "Surveillance clinique étroite et adaptation éventuelle de la posologie de l’antimitotique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618409 .

_:807f36cf91fe4e8caa53aadeff92477618409 rdf:first _:807f36cf91fe4e8caa53aadeff92477618410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618411 .

_:807f36cf91fe4e8caa53aadeff92477618410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477618411 rdf:first _:807f36cf91fe4e8caa53aadeff92477618412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10161 .

_:807f36cf91fe4e8caa53aadeff92477618414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10949-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_10949";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618416;
  r:natureDuRisque "Doublement des concentrations de névirapine avec risque d'augmentation de ses effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la névirapine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618417 .

_:807f36cf91fe4e8caa53aadeff92477618417 rdf:first _:807f36cf91fe4e8caa53aadeff92477618418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618419 .

_:807f36cf91fe4e8caa53aadeff92477618418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477618419 rdf:first _:807f36cf91fe4e8caa53aadeff92477618420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477618422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11126-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_11126";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618424;
  r:natureDuRisque "Risque d’augmentation des concentrations d’itraconazole par l’inhibiteur de protéases."@fr;
  r:conduiteATenir "Surveillance clinique lors de l’association. L’administration de doses élevées d’itraconazole (>200 mg par jour) n’est pas recommandée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618425 .

_:807f36cf91fe4e8caa53aadeff92477618425 rdf:first _:807f36cf91fe4e8caa53aadeff92477618426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618427 .

_:807f36cf91fe4e8caa53aadeff92477618426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477618427 rdf:first _:807f36cf91fe4e8caa53aadeff92477618428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477618430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11127-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_11127";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618432;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de diminution des concentrations et de l’efficacité de la lamotrigine par augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir """Association déconseillée 
- Eviter de mettre en route le traitement par ritonavir pendant la période d’ajustement posologique de la lamotrigine.

Précaution d'emploi
- Surveillance clinique et adaptation de la posologie de la lamotrigine lors de la mise e"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618433 .

_:807f36cf91fe4e8caa53aadeff92477618433 rdf:first _:807f36cf91fe4e8caa53aadeff92477618434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618435 .

_:807f36cf91fe4e8caa53aadeff92477618434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477618435 rdf:first _:807f36cf91fe4e8caa53aadeff92477618436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:807f36cf91fe4e8caa53aadeff92477618438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11129-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> METHADONE"@fr;
  dct:identifier "IAM_11129";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618440;
  r:natureDuRisque "Diminution des concentrations plasmatiques de méthadone avec risque d'apparition d'un syndrome de sevrage par augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Surveillance clinique régulière et adaptation éventuelle de la posologie de méthadone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618441 .

_:807f36cf91fe4e8caa53aadeff92477618441 rdf:first _:807f36cf91fe4e8caa53aadeff92477618442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618443 .

_:807f36cf91fe4e8caa53aadeff92477618442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477618443 rdf:first _:807f36cf91fe4e8caa53aadeff92477618444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477618446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11130-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11130";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618448;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'inhibiteur de protéases, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves"@fr;
  r:conduiteATenir "En cas d'association fortuite, ne pas interrompre brutalement la prise de millepertuis mais contrôler les concentrations plasmatiques (ou l'efficacité) de l'inhibiteur de protéases avant puis après l'arrêt du millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618449 .

_:807f36cf91fe4e8caa53aadeff92477618449 rdf:first _:807f36cf91fe4e8caa53aadeff92477618450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618451 .

_:807f36cf91fe4e8caa53aadeff92477618450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477618451 rdf:first _:807f36cf91fe4e8caa53aadeff92477618452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477618454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11131-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_11131";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618456;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618457 .

_:807f36cf91fe4e8caa53aadeff92477618457 rdf:first _:807f36cf91fe4e8caa53aadeff92477618458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618459 .

_:807f36cf91fe4e8caa53aadeff92477618458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477618459 rdf:first _:807f36cf91fe4e8caa53aadeff92477618460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:807f36cf91fe4e8caa53aadeff92477618462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11132-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_11132";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618464;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par l'inhibiteur de protéases boosté par ritonavir."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618465 .

_:807f36cf91fe4e8caa53aadeff92477618465 rdf:first _:807f36cf91fe4e8caa53aadeff92477618466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618467 .

_:807f36cf91fe4e8caa53aadeff92477618466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477618467 rdf:first _:807f36cf91fe4e8caa53aadeff92477618468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477618470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10758-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> SIMÉPRÉVIR"@fr;
  dct:identifier "IAM_10758";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618472;
  r:natureDuRisque "Avec la dexaméthasone à usage systémique, risque de diminution des concentrations plasmatiques de simeprevir par augmentation de son métabolisme hépatique par la dexamethasone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618473 .

_:807f36cf91fe4e8caa53aadeff92477618473 rdf:first _:807f36cf91fe4e8caa53aadeff92477618474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618475 .

_:807f36cf91fe4e8caa53aadeff92477618474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477618475 rdf:first _:807f36cf91fe4e8caa53aadeff92477618476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10837 .

_:807f36cf91fe4e8caa53aadeff92477618478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10759-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> TELITHROMYCINE"@fr;
  dct:identifier "IAM_10759";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618480;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618481 .

_:807f36cf91fe4e8caa53aadeff92477618481 rdf:first _:807f36cf91fe4e8caa53aadeff92477618482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618483 .

_:807f36cf91fe4e8caa53aadeff92477618482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477618483 rdf:first _:807f36cf91fe4e8caa53aadeff92477618484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10889 .

_:807f36cf91fe4e8caa53aadeff92477618486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10760-1 a owl:Class;
  rdfs:label "DEXAMETHASONE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10760";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618488;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la dexaméthasone par diminution de son métabolisme hépatique par l'inhibiteur enzymatique, avec risque d’apparition d’un syndrome cushingoïde."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618494, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618488 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618489 .

_:807f36cf91fe4e8caa53aadeff92477618489 rdf:first _:807f36cf91fe4e8caa53aadeff92477618490;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618491 .

_:807f36cf91fe4e8caa53aadeff92477618490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10272 .

_:807f36cf91fe4e8caa53aadeff92477618491 rdf:first _:807f36cf91fe4e8caa53aadeff92477618492;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477618494 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10761-1 a owl:Class;
  rdfs:label "DEXTRAN 40 <-> HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ)"@fr;
  dct:identifier "IAM_10761";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618496;
  r:natureDuRisque "Augmentation du risque hémorragique (inhibition de la fonction plaquettaire par le dextran 40)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618502, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618496 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618497 .

_:807f36cf91fe4e8caa53aadeff92477618497 rdf:first _:807f36cf91fe4e8caa53aadeff92477618498;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618499 .

_:807f36cf91fe4e8caa53aadeff92477618498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10061 .

_:807f36cf91fe4e8caa53aadeff92477618499 rdf:first _:807f36cf91fe4e8caa53aadeff92477618500;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477618502 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11139-1 a owl:Class;
  rdfs:label "INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11139";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618504;
  r:natureDuRisque "Diminution des concentrations du télaprévir et du darunavir ou du fosamprénavir, avec risque d’échec thérapeutique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618510, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618504 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618505 .

_:807f36cf91fe4e8caa53aadeff92477618505 rdf:first _:807f36cf91fe4e8caa53aadeff92477618506;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618507 .

_:807f36cf91fe4e8caa53aadeff92477618506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477618507 rdf:first _:807f36cf91fe4e8caa53aadeff92477618508;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477618510 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10992-1 a owl:Class;
  rdfs:label "GANCICLOVIR <-> ZALCITABINE"@fr;
  dct:identifier "IAM_10992";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618512;
  r:natureDuRisque "Risque accru de survenue de neuropathies périphériques par addition d'effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618518, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618512 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618513 .

_:807f36cf91fe4e8caa53aadeff92477618513 rdf:first _:807f36cf91fe4e8caa53aadeff92477618514;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618515 .

_:807f36cf91fe4e8caa53aadeff92477618514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10408 .

_:807f36cf91fe4e8caa53aadeff92477618515 rdf:first _:807f36cf91fe4e8caa53aadeff92477618516;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11002 .

_:807f36cf91fe4e8caa53aadeff92477618518 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10981-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> PIRFENIDONE"@fr;
  dct:identifier "IAM_10981";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618520;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de pirfenidone avec signes de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618526, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618520 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618521 .

_:807f36cf91fe4e8caa53aadeff92477618521 rdf:first _:807f36cf91fe4e8caa53aadeff92477618522;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618523 .

_:807f36cf91fe4e8caa53aadeff92477618522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477618523 rdf:first _:807f36cf91fe4e8caa53aadeff92477618524;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10731 .

_:807f36cf91fe4e8caa53aadeff92477618526 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10982-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> PROPRANOLOL"@fr;
  dct:identifier "IAM_10982";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618528;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de propranolol par inhibition de son métabolisme hépatique, avec majoration de l'activité et des effets indésirables, par exemple : bradycardie importante."@fr;
  r:conduiteATenir "Surveillance clinique accrue et, si besoin, adaptation de la posologie du propranolol pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618534, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618528 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618529 .

_:807f36cf91fe4e8caa53aadeff92477618529 rdf:first _:807f36cf91fe4e8caa53aadeff92477618530;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618531 .

_:807f36cf91fe4e8caa53aadeff92477618530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477618531 rdf:first _:807f36cf91fe4e8caa53aadeff92477618532;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10767 .

_:807f36cf91fe4e8caa53aadeff92477618534 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10983-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> ROPINIROLE"@fr;
  dct:identifier "IAM_10983";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618536;
  r:natureDuRisque "Augmentation des concentrations de ropinirole, avec risque de surdosage, par diminution de son métabolisme hépatique par la fluvoxamine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du ropinirole pendant le traitement par fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618542, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618536 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618537 .

_:807f36cf91fe4e8caa53aadeff92477618537 rdf:first _:807f36cf91fe4e8caa53aadeff92477618538;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618539 .

_:807f36cf91fe4e8caa53aadeff92477618538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477618539 rdf:first _:807f36cf91fe4e8caa53aadeff92477618540;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10813 .

_:807f36cf91fe4e8caa53aadeff92477618542 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10984-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10984";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618544;
  r:natureDuRisque "Augmentation de la théophyllinémie avec signes de surdosage (diminution du métabolisme hépatique de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; si besoin, adaptation de la posologie de la théophylline pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618550, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618544 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618545 .

_:807f36cf91fe4e8caa53aadeff92477618545 rdf:first _:807f36cf91fe4e8caa53aadeff92477618546;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618547 .

_:807f36cf91fe4e8caa53aadeff92477618546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477618547 rdf:first _:807f36cf91fe4e8caa53aadeff92477618548;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477618550 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10985-1 a owl:Class;
  rdfs:label "FOLATES <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_10985";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618552;
  r:natureDuRisque "Diminution des concentrations plasmatiques du phénobarbital, par augmentation de son métabolisme dont les folates représentent un des cofacteurs."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques, et adaptation, s'il y a lieu, de la posologie du phénobarbital pendant la supplémentation folique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618558, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618552 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618553 .

_:807f36cf91fe4e8caa53aadeff92477618553 rdf:first _:807f36cf91fe4e8caa53aadeff92477618554;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618555 .

_:807f36cf91fe4e8caa53aadeff92477618554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10077 .

_:807f36cf91fe4e8caa53aadeff92477618555 rdf:first _:807f36cf91fe4e8caa53aadeff92477618556;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477618558 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10986-1 a owl:Class;
  rdfs:label "FOLATES <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10986";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618560;
  r:natureDuRisque "Diminution des concentrations plasmatiques de phénytoïne par augmentation de son métabolisme dont les folates représentent un des cofacteurs."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénytoïne. Adaptation éventuelle de la posologie de la phénytoïne pendant la supplémentation folique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618566, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618560 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618561 .

_:807f36cf91fe4e8caa53aadeff92477618561 rdf:first _:807f36cf91fe4e8caa53aadeff92477618562;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618563 .

_:807f36cf91fe4e8caa53aadeff92477618562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10077 .

_:807f36cf91fe4e8caa53aadeff92477618563 rdf:first _:807f36cf91fe4e8caa53aadeff92477618564;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477618566 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10987-1 a owl:Class;
  rdfs:label "FOSAMPRENAVIR <-> MARAVIROC"@fr;
  dct:identifier "IAM_10987";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618568;
  r:natureDuRisque "Diminution significative des concentrations d’amprénavir pouvant conduire à une perte de la réponse virologique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618574, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618568 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618569 .

_:807f36cf91fe4e8caa53aadeff92477618569 rdf:first _:807f36cf91fe4e8caa53aadeff92477618570;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618571 .

_:807f36cf91fe4e8caa53aadeff92477618570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:807f36cf91fe4e8caa53aadeff92477618571 rdf:first _:807f36cf91fe4e8caa53aadeff92477618572;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10551 .

_:807f36cf91fe4e8caa53aadeff92477618574 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10988-1 a owl:Class;
  rdfs:label "FOSAMPRENAVIR <-> METHADONE"@fr;
  dct:identifier "IAM_10988";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618576;
  r:natureDuRisque """Diminution des concentrations plasmatiques de méthadone avec
risque d'apparition d'un syndrome de sevrage par augmentation de son métabolisme hépatique par l'amprénavir."""@fr;
  r:conduiteATenir "Surveillance clinique régulière et adaptation éventuelle de la posologie de méthadone."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618582, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618576 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618577 .

_:807f36cf91fe4e8caa53aadeff92477618577 rdf:first _:807f36cf91fe4e8caa53aadeff92477618578;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618579 .

_:807f36cf91fe4e8caa53aadeff92477618578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:807f36cf91fe4e8caa53aadeff92477618579 rdf:first _:807f36cf91fe4e8caa53aadeff92477618580;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477618582 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10989-1 a owl:Class;
  rdfs:label "FOSAMPRENAVIR <-> NEVIRAPINE"@fr;
  dct:identifier "IAM_10989";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618584;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'amprénavir."@fr;
  r:conduiteATenir """Surveillance clinique et biologique régulière, notamment en début
d'association."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618590, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618584 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618585 .

_:807f36cf91fe4e8caa53aadeff92477618585 rdf:first _:807f36cf91fe4e8caa53aadeff92477618586;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618587 .

_:807f36cf91fe4e8caa53aadeff92477618586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:807f36cf91fe4e8caa53aadeff92477618587 rdf:first _:807f36cf91fe4e8caa53aadeff92477618588;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10628 .

_:807f36cf91fe4e8caa53aadeff92477618590 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11205-1 a owl:Class;
  rdfs:label "IVABRADINE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11205";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618592;
  r:natureDuRisque "Risque de diminution de l'efficacité de l’ivabradine, par augmentation de son métabolisme par le millepertuis."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618598, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618592 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618593 .

_:807f36cf91fe4e8caa53aadeff92477618593 rdf:first _:807f36cf91fe4e8caa53aadeff92477618594;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618595 .

_:807f36cf91fe4e8caa53aadeff92477618594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477618595 rdf:first _:807f36cf91fe4e8caa53aadeff92477618596;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477618598 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10991-1 a owl:Class;
  rdfs:label "FUROSEMIDE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10991";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618600;
  r:natureDuRisque "Diminution de l'effet diurétique pouvant atteindre 50 %."@fr;
  r:conduiteATenir "Utiliser éventuellement des doses plus élevées de furosémide."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618606, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618600 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618601 .

_:807f36cf91fe4e8caa53aadeff92477618601 rdf:first _:807f36cf91fe4e8caa53aadeff92477618602;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618603 .

_:807f36cf91fe4e8caa53aadeff92477618602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477618603 rdf:first _:807f36cf91fe4e8caa53aadeff92477618604;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10406 .

_:807f36cf91fe4e8caa53aadeff92477618606 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10978-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> MEXILETINE"@fr;
  dct:identifier "IAM_10978";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618608;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méxilétine, par inhibition de son métabolisme par la fluvoxamine."@fr;
  r:conduiteATenir "Surveillance clinique et ECG. Adaptation de la posologie de la méxilétine pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:comment "La méxilétine est un anti-arythmique de la classe Ib de la classification de Vaughan-Williams, indiquée dans le traitement et la prévention des arythmies ventriculaires mettant en jeu le pronostic vital. Son métabolisme dépend principalement du CYP2D6, et"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618614, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618608 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618609 .

_:807f36cf91fe4e8caa53aadeff92477618609 rdf:first _:807f36cf91fe4e8caa53aadeff92477618610;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618611 .

_:807f36cf91fe4e8caa53aadeff92477618610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477618611 rdf:first _:807f36cf91fe4e8caa53aadeff92477618612;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10582 .

_:807f36cf91fe4e8caa53aadeff92477618614 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10993-1 a owl:Class;
  rdfs:label "GANCICLOVIR <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_10993";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618616;
  r:natureDuRisque "Augmentation de la toxicité hématologique (addition d'effets de toxicité médullaire)."@fr;
  r:conduiteATenir "Arrêter de façon transitoire la zidovudine ; contrôler la NFS et réintroduire, si possible, la zidovudine à doses faibles."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618622, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618616 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618617 .

_:807f36cf91fe4e8caa53aadeff92477618617 rdf:first _:807f36cf91fe4e8caa53aadeff92477618618;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618619 .

_:807f36cf91fe4e8caa53aadeff92477618618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10408 .

_:807f36cf91fe4e8caa53aadeff92477618619 rdf:first _:807f36cf91fe4e8caa53aadeff92477618620;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:807f36cf91fe4e8caa53aadeff92477618622 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10994-1 a owl:Class;
  rdfs:label "GEMFIBROZIL <-> PIOGLITAZONE"@fr;
  dct:identifier "IAM_10994";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618624;
  r:natureDuRisque """Risque d’augmentation des effets indésirables de la glitazone par
diminution de son métabolisme hépatique par le gemfibrozil."""@fr;
  r:conduiteATenir "Si l’association ne peut être évitée, surveillance clinique étroite."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618630, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618624 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618625 .

_:807f36cf91fe4e8caa53aadeff92477618625 rdf:first _:807f36cf91fe4e8caa53aadeff92477618626;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618627 .

_:807f36cf91fe4e8caa53aadeff92477618626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10411 .

_:807f36cf91fe4e8caa53aadeff92477618627 rdf:first _:807f36cf91fe4e8caa53aadeff92477618628;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10723 .

_:807f36cf91fe4e8caa53aadeff92477618630 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10995-1 a owl:Class;
  rdfs:label "GEMFIBROZIL <-> REPAGLINIDE"@fr;
  dct:identifier "IAM_10995";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618632;
  r:natureDuRisque "Risque d'hypoglycémie sévère voire de coma, par augmentation importante des concentrations plasmatiques de repaglinide par le gemfibrozil."@fr;
  rdfs:comment "Une publication montre que le gemfibrozil augmente d'environ huit fois les concentrations plasmatiques du répaglinide. Les auteurs attribuent cet effet à une inhibition du CYP2C8 par le gemfibrozil. Cette isoenzyme est en effet largement impliquée dans le"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618638, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618632 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618633 .

_:807f36cf91fe4e8caa53aadeff92477618633 rdf:first _:807f36cf91fe4e8caa53aadeff92477618634;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618635 .

_:807f36cf91fe4e8caa53aadeff92477618634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10411 .

_:807f36cf91fe4e8caa53aadeff92477618635 rdf:first _:807f36cf91fe4e8caa53aadeff92477618636;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10791 .

_:807f36cf91fe4e8caa53aadeff92477618638 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10996-1 a owl:Class;
  rdfs:label "GLIPIZIDE <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10996";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618640;
  r:natureDuRisque "Risque d’augmentation des concentrations plasmatiques du glipizide à l’origine d’hypoglycémies potentiellement sévères."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide pendant et après le traitement par voriconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618646, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618640 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618641 .

_:807f36cf91fe4e8caa53aadeff92477618641 rdf:first _:807f36cf91fe4e8caa53aadeff92477618642;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618643 .

_:807f36cf91fe4e8caa53aadeff92477618642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10417 .

_:807f36cf91fe4e8caa53aadeff92477618643 rdf:first _:807f36cf91fe4e8caa53aadeff92477618644;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477618646 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10997-1 a owl:Class;
  rdfs:label "GLIPTINES <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10997";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618648;
  r:natureDuRisque "Majoration du risque de la survenue d’angio-oedèmes, par réduction de l’activité de l’enzyme dipeptidyl peptidase IV (DPP-IV) par la gliptine, chez les patients traités par inhibiteur de l’enzyme de conversion."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618654, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618648 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618649 .

_:807f36cf91fe4e8caa53aadeff92477618649 rdf:first _:807f36cf91fe4e8caa53aadeff92477618650;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618651 .

_:807f36cf91fe4e8caa53aadeff92477618650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10079 .

_:807f36cf91fe4e8caa53aadeff92477618651 rdf:first _:807f36cf91fe4e8caa53aadeff92477618652;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477618654 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11011-1 a owl:Class;
  rdfs:label "HALOTHANE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_11011";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618656;
  r:natureDuRisque "Troubles du rythme ventriculaire graves par augmentation de l'excitabilité cardiaque."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618662, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618656 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618657 .

_:807f36cf91fe4e8caa53aadeff92477618657 rdf:first _:807f36cf91fe4e8caa53aadeff92477618658;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618659 .

_:807f36cf91fe4e8caa53aadeff92477618658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477618659 rdf:first _:807f36cf91fe4e8caa53aadeff92477618660;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10427 .

_:807f36cf91fe4e8caa53aadeff92477618662 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11012-1 a owl:Class;
  rdfs:label "HÉPARINES DE BAS POIDS MOLÉCULAIRE ET APPARENTÉS (DOSES CURATIVES ET/OU SUJET ÂGÉ) <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_11012";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618664;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618670, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618664 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618665 .

_:807f36cf91fe4e8caa53aadeff92477618665 rdf:first _:807f36cf91fe4e8caa53aadeff92477618666;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618667 .

_:807f36cf91fe4e8caa53aadeff92477618666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10089 .

_:807f36cf91fe4e8caa53aadeff92477618667 rdf:first _:807f36cf91fe4e8caa53aadeff92477618668;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:807f36cf91fe4e8caa53aadeff92477618670 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11013-1 a owl:Class;
  rdfs:label "HÉPARINES NON FRACTIONNÉES (DOSES CURATIVES ET/OU SUJET ÂGÉ) <-> THROMBOLYTIQUES"@fr;
  dct:identifier "IAM_11013";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618672;
  r:natureDuRisque "Augmentation du risque hémorragique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618678, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618672 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618673 .

_:807f36cf91fe4e8caa53aadeff92477618673 rdf:first _:807f36cf91fe4e8caa53aadeff92477618674;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618675 .

_:807f36cf91fe4e8caa53aadeff92477618674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10091 .

_:807f36cf91fe4e8caa53aadeff92477618675 rdf:first _:807f36cf91fe4e8caa53aadeff92477618676;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10151 .

_:807f36cf91fe4e8caa53aadeff92477618678 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11014-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> IMATINIB"@fr;
  dct:identifier "IAM_11014";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618680;
  r:natureDuRisque "Risque de baisse de l’efficacité des hormones thyroïdiennes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618686, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618680 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618681 .

_:807f36cf91fe4e8caa53aadeff92477618681 rdf:first _:807f36cf91fe4e8caa53aadeff92477618682;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618683 .

_:807f36cf91fe4e8caa53aadeff92477618682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477618683 rdf:first _:807f36cf91fe4e8caa53aadeff92477618684;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10448 .

_:807f36cf91fe4e8caa53aadeff92477618686 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10990-1 a owl:Class;
  rdfs:label "FOSCARNET <-> PENTAMIDINE"@fr;
  dct:identifier "IAM_10990";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618688;
  r:natureDuRisque "Risque d'hypocalcémie sévère."@fr;
  r:conduiteATenir "Surveillance de la calcémie et supplémentation si nécessaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618694, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618688 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618689 .

_:807f36cf91fe4e8caa53aadeff92477618689 rdf:first _:807f36cf91fe4e8caa53aadeff92477618690;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618691 .

_:807f36cf91fe4e8caa53aadeff92477618690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10401 .

_:807f36cf91fe4e8caa53aadeff92477618691 rdf:first _:807f36cf91fe4e8caa53aadeff92477618692;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10703 .

_:807f36cf91fe4e8caa53aadeff92477618694 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10968-1 a owl:Class;
  rdfs:label "FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES) <-> ORNIDAZOLE"@fr;
  dct:identifier "IAM_10968";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618696;
  r:natureDuRisque "Augmentation de la toxicité du fluoro-uracile par diminution de sa clairance."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618702, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618696 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618697 .

_:807f36cf91fe4e8caa53aadeff92477618697 rdf:first _:807f36cf91fe4e8caa53aadeff92477618698;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618699 .

_:807f36cf91fe4e8caa53aadeff92477618698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:807f36cf91fe4e8caa53aadeff92477618699 rdf:first _:807f36cf91fe4e8caa53aadeff92477618700;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10668 .

_:807f36cf91fe4e8caa53aadeff92477618702 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10957-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> SULFAMIDES HYPOGLYCÉMIANTS"@fr;
  dct:identifier "IAM_10957";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618704;
  r:natureDuRisque "Augmentation du temps de demi-vie du sulfamide avec survenue possible de manifestations d'hypoglycémie."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide pendant le traitement par le fluconazole."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618710, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618704 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618705 .

_:807f36cf91fe4e8caa53aadeff92477618705 rdf:first _:807f36cf91fe4e8caa53aadeff92477618706;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618707 .

_:807f36cf91fe4e8caa53aadeff92477618706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10147 .

_:807f36cf91fe4e8caa53aadeff92477618707 rdf:first _:807f36cf91fe4e8caa53aadeff92477618708;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477618710 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10958-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10958";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618712;
  r:natureDuRisque "Augmentation de la théophyllinémie avec risque de surdosage (diminution de la clairance de la théophylline)."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement de la théophyllinémie ; s'il y a lieu, adaptation de la posologie de la théophylline pendant le traitement par le fluconazole et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618718, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618712 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618713 .

_:807f36cf91fe4e8caa53aadeff92477618713 rdf:first _:807f36cf91fe4e8caa53aadeff92477618714;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618715 .

_:807f36cf91fe4e8caa53aadeff92477618714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477618715 rdf:first _:807f36cf91fe4e8caa53aadeff92477618716;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477618718 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10959-1 a owl:Class;
  rdfs:label "FLUCYTOSINE <-> ZIDOVUDINE"@fr;
  dct:identifier "IAM_10959";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618720;
  r:natureDuRisque "Augmentation de la toxicité hématologique (addition d'effets de toxicité médullaire)."@fr;
  r:conduiteATenir "Contrôle plus fréquent de l'hémogramme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618726, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618720 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618721 .

_:807f36cf91fe4e8caa53aadeff92477618721 rdf:first _:807f36cf91fe4e8caa53aadeff92477618722;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618723 .

_:807f36cf91fe4e8caa53aadeff92477618722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10382 .

_:807f36cf91fe4e8caa53aadeff92477618723 rdf:first _:807f36cf91fe4e8caa53aadeff92477618724;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11004 .

_:807f36cf91fe4e8caa53aadeff92477618726 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10960-1 a owl:Class;
  rdfs:label "FLUDARABINE <-> PENTOSTATINE"@fr;
  dct:identifier "IAM_10960";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618728;
  r:natureDuRisque "Majoration du risque de toxicité pulmonaire pouvant être fatale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618734, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618728 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618729 .

_:807f36cf91fe4e8caa53aadeff92477618729 rdf:first _:807f36cf91fe4e8caa53aadeff92477618730;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618731 .

_:807f36cf91fe4e8caa53aadeff92477618730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10383 .

_:807f36cf91fe4e8caa53aadeff92477618731 rdf:first _:807f36cf91fe4e8caa53aadeff92477618732;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10704 .

_:807f36cf91fe4e8caa53aadeff92477618734 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10961-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> GLUCOCORTICOÏDES (SAUF HYDROCORTISONE)"@fr;
  dct:identifier "IAM_10961";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618736;
  r:natureDuRisque "Possible majoration du risque de tendinopathie, voire de rupture tendineuse (exceptionnelle), particulièrement chez les patients recevant une corticothérapie prolongée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618742, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618736 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618737 .

_:807f36cf91fe4e8caa53aadeff92477618737 rdf:first _:807f36cf91fe4e8caa53aadeff92477618738;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618739 .

_:807f36cf91fe4e8caa53aadeff92477618738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477618739 rdf:first _:807f36cf91fe4e8caa53aadeff92477618740;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10081 .

_:807f36cf91fe4e8caa53aadeff92477618742 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10962-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> MYCOPHENOLATE MOFETIL"@fr;
  dct:identifier "IAM_10962";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618744;
  r:natureDuRisque "Diminution des concentrations de l’acide mycophénolique d’environ un tiers, avec risque potentiel de baisse d’efficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618750, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618744 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618745 .

_:807f36cf91fe4e8caa53aadeff92477618745 rdf:first _:807f36cf91fe4e8caa53aadeff92477618746;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618747 .

_:807f36cf91fe4e8caa53aadeff92477618746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477618747 rdf:first _:807f36cf91fe4e8caa53aadeff92477618748;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10609 .

_:807f36cf91fe4e8caa53aadeff92477618750 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10963-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> STRONTIUM"@fr;
  dct:identifier "IAM_10963";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618752;
  r:natureDuRisque "Diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des fluoroquinolones (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618758, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618752 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618753 .

_:807f36cf91fe4e8caa53aadeff92477618753 rdf:first _:807f36cf91fe4e8caa53aadeff92477618754;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618755 .

_:807f36cf91fe4e8caa53aadeff92477618754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477618755 rdf:first _:807f36cf91fe4e8caa53aadeff92477618756;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:807f36cf91fe4e8caa53aadeff92477618758 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10964-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> SUCRALFATE"@fr;
  dct:identifier "IAM_10964";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618760;
  r:natureDuRisque "Diminution de l'absorption digestive des fluoroquinolones."@fr;
  r:conduiteATenir "Prendre le sucralfate à distance des fluoroquinolones (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618766, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618760 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618761 .

_:807f36cf91fe4e8caa53aadeff92477618761 rdf:first _:807f36cf91fe4e8caa53aadeff92477618762;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618763 .

_:807f36cf91fe4e8caa53aadeff92477618762 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477618763 rdf:first _:807f36cf91fe4e8caa53aadeff92477618764;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618764 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:807f36cf91fe4e8caa53aadeff92477618766 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10965-1 a owl:Class;
  rdfs:label "FLUOROQUINOLONES <-> ZINC"@fr;
  dct:identifier "IAM_10965";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618768;
  r:natureDuRisque "Diminution de l'absorption digestives des fluoroquinolones."@fr;
  r:conduiteATenir "Prendre les sels de zinc à distance des fluoroquinolones (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618774, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618768 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618769 .

_:807f36cf91fe4e8caa53aadeff92477618769 rdf:first _:807f36cf91fe4e8caa53aadeff92477618770;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618771 .

_:807f36cf91fe4e8caa53aadeff92477618770 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477618771 rdf:first _:807f36cf91fe4e8caa53aadeff92477618772;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618772 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:807f36cf91fe4e8caa53aadeff92477618774 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10980-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10980";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618776;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec signes de surdosage, par inhibition du métabolisme hépatique de la phénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement contröle des concentrations plamatiques de phénytoïne. Si besoin, adaptation posologique de la phénytoïne pendant le traitement par la fluvoxamine et après son arrët."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618782, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618776 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618777 .

_:807f36cf91fe4e8caa53aadeff92477618777 rdf:first _:807f36cf91fe4e8caa53aadeff92477618778;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618779 .

_:807f36cf91fe4e8caa53aadeff92477618778 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477618779 rdf:first _:807f36cf91fe4e8caa53aadeff92477618780;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618780 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477618782 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10967-1 a owl:Class;
  rdfs:label "FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES) <-> METRONIDAZOLE"@fr;
  dct:identifier "IAM_10967";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618784;
  r:natureDuRisque "Augmentation de la toxicité du fluoro-uracile par diminution de sa clairance."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618790, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618784 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618785 .

_:807f36cf91fe4e8caa53aadeff92477618785 rdf:first _:807f36cf91fe4e8caa53aadeff92477618786;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618787 .

_:807f36cf91fe4e8caa53aadeff92477618786 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:807f36cf91fe4e8caa53aadeff92477618787 rdf:first _:807f36cf91fe4e8caa53aadeff92477618788;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618788 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10580 .

_:807f36cf91fe4e8caa53aadeff92477618790 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10979-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> OLANZAPINE"@fr;
  dct:identifier "IAM_10979";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618792;
  r:natureDuRisque "Augmentation des concentrations de l’olanzapine, avec risque de majoration des effets indésirables, par diminution de son métabolisme hépatique par la fluvoxamine."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie de l’olanzapine pendant le traitement par fluvoxamine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618798, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618792 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618793 .

_:807f36cf91fe4e8caa53aadeff92477618793 rdf:first _:807f36cf91fe4e8caa53aadeff92477618794;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618795 .

_:807f36cf91fe4e8caa53aadeff92477618794 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477618795 rdf:first _:807f36cf91fe4e8caa53aadeff92477618796;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618796 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10658 .

_:807f36cf91fe4e8caa53aadeff92477618798 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10970-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_10970";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618800;
  r:natureDuRisque "Risque de majoration des effets indésirables du métoprolol, avec notamment bradycardie excessive, par inhibition de son métabolisme par la fluoxétine."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie du métoprolol pendant la durée du traitement par la fluoxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618806, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618800 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618801 .

_:807f36cf91fe4e8caa53aadeff92477618801 rdf:first _:807f36cf91fe4e8caa53aadeff92477618802;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618803 .

_:807f36cf91fe4e8caa53aadeff92477618802 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477618803 rdf:first _:807f36cf91fe4e8caa53aadeff92477618804;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618804 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477618806 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10971-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> NEBIVOLOL"@fr;
  dct:identifier "IAM_10971";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618808;
  r:natureDuRisque "Risque de majoration des effets indésirables du nébivolol avec notamment bradycardie excessive, par inhibition de son métabolisme par l’antidépresseur."@fr;
  r:conduiteATenir "Surveillance clinique accrue ; si besoin, adaptation de la posologie du nébivolol pendant la durée du traitement par l’antidépresseur et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618814, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618808 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618809 .

_:807f36cf91fe4e8caa53aadeff92477618809 rdf:first _:807f36cf91fe4e8caa53aadeff92477618810;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618811 .

_:807f36cf91fe4e8caa53aadeff92477618810 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477618811 rdf:first _:807f36cf91fe4e8caa53aadeff92477618812;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618812 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10623 .

_:807f36cf91fe4e8caa53aadeff92477618814 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10969-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> MEQUITAZINE"@fr;
  dct:identifier "IAM_10969";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618816;
  r:natureDuRisque "Risque de majoration des effets indésirables de la méquitazine, par inhibition de son métabolisme par l’inhibiteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618822, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618816 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618817 .

_:807f36cf91fe4e8caa53aadeff92477618817 rdf:first _:807f36cf91fe4e8caa53aadeff92477618818;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618819 .

_:807f36cf91fe4e8caa53aadeff92477618818 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477618819 rdf:first _:807f36cf91fe4e8caa53aadeff92477618820;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618820 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10561 .

_:807f36cf91fe4e8caa53aadeff92477618822 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10972-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10972";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618824;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec signes de surdosage, par inhibition du métabolisme de la phénytoïne."@fr;
  r:conduiteATenir "Surveillance clinique et éventuellement contrôle des concentrations plasmatiques de phénytoïne. Si besoin, adaptation posologique pendant le traitement par la fluoxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618830, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618824 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618825 .

_:807f36cf91fe4e8caa53aadeff92477618825 rdf:first _:807f36cf91fe4e8caa53aadeff92477618826;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618827 .

_:807f36cf91fe4e8caa53aadeff92477618826 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477618827 rdf:first _:807f36cf91fe4e8caa53aadeff92477618828;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618828 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477618830 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10973-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> RISPERIDONE"@fr;
  dct:identifier "IAM_10973";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618832;
  r:natureDuRisque "Augmentation de la fraction active de la rispéridone par diminution de son métabolisme hépatique par la fluoxétine, avec risque de majoration des effets indésirables."@fr;
  r:conduiteATenir "Surveillance clinique et, si besoin, adaptation posologique de la rispéridone."@fr;
  rdfs:comment "La rispéridone est majoritairement métabolisée par le CYP2D6 en 9-OH-rispéridone, métabolite actif. La fraction pharmacologiquement active de la rispéridone est ainsi constituée par la molécule mère et son métabolite hydroxylé. La fluoxétine est un inhibi"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618838, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618832 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618833 .

_:807f36cf91fe4e8caa53aadeff92477618833 rdf:first _:807f36cf91fe4e8caa53aadeff92477618834;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618835 .

_:807f36cf91fe4e8caa53aadeff92477618834 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477618835 rdf:first _:807f36cf91fe4e8caa53aadeff92477618836;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618836 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10805 .

_:807f36cf91fe4e8caa53aadeff92477618838 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10974-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_10974";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618840;
  r:natureDuRisque "Baisse de l’efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la fluoxétine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618846, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618840 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618841 .

_:807f36cf91fe4e8caa53aadeff92477618841 rdf:first _:807f36cf91fe4e8caa53aadeff92477618842;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618843 .

_:807f36cf91fe4e8caa53aadeff92477618842 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477618843 rdf:first _:807f36cf91fe4e8caa53aadeff92477618844;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618844 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:807f36cf91fe4e8caa53aadeff92477618846 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10975-1 a owl:Class;
  rdfs:label "FLUOXETINE <-> VORTIOXÉTINE"@fr;
  dct:identifier "IAM_10975";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618848;
  r:natureDuRisque "Risque d’augmentation des effets indésirables de la vortioxétine par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la vortioxétine pendant le traitement par la fluoxétine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618854, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618848 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618849 .

_:807f36cf91fe4e8caa53aadeff92477618849 rdf:first _:807f36cf91fe4e8caa53aadeff92477618850;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618851 .

_:807f36cf91fe4e8caa53aadeff92477618850 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10390 .

_:807f36cf91fe4e8caa53aadeff92477618851 rdf:first _:807f36cf91fe4e8caa53aadeff92477618852;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618852 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10999 .

_:807f36cf91fe4e8caa53aadeff92477618854 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10976-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> LIDOCAINE"@fr;
  dct:identifier "IAM_10976";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618856;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la lidocaïne avec possibilités d’effets indésirables neurologiques et cardiaques (diminution de la clairance hépatique de la lidocaïne)."@fr;
  r:conduiteATenir "Surveillance clinique, ECG et éventuellement contrôle des concentrations plasmatiques de la lidocaïne pendant et après l’arrêt de l’association. Adaptation, si besoin, de la posologie de la lidocaïne."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618862, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618856 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618857 .

_:807f36cf91fe4e8caa53aadeff92477618857 rdf:first _:807f36cf91fe4e8caa53aadeff92477618858;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618859 .

_:807f36cf91fe4e8caa53aadeff92477618858 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477618859 rdf:first _:807f36cf91fe4e8caa53aadeff92477618860;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618860 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10523 .

_:807f36cf91fe4e8caa53aadeff92477618862 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10977-1 a owl:Class;
  rdfs:label "FLUVOXAMINE <-> METHADONE"@fr;
  dct:identifier "IAM_10977";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618864;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de méthadone avec surdosage et risque majoré d’allongement de l’intervalle QT et de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Surveillance clinique et électrocardiographique renforcée ; si besoin, adaptation de la posologie de la méthadone pendant le traitement par la fluvoxamine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618870, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618864 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618865 .

_:807f36cf91fe4e8caa53aadeff92477618865 rdf:first _:807f36cf91fe4e8caa53aadeff92477618866;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618867 .

_:807f36cf91fe4e8caa53aadeff92477618866 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10398 .

_:807f36cf91fe4e8caa53aadeff92477618867 rdf:first _:807f36cf91fe4e8caa53aadeff92477618868;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618868 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10567 .

_:807f36cf91fe4e8caa53aadeff92477618870 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11017-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> PROGUANIL"@fr;
  dct:identifier "IAM_11017";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618872;
  r:natureDuRisque "Risque d’hypothyroïdie clinique chez les patients substitués par hormones thyroïdiennes."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie de l'hormone thyroïdienne pendant le traitement par l’antipaludique et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618878, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618872 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618873 .

_:807f36cf91fe4e8caa53aadeff92477618873 rdf:first _:807f36cf91fe4e8caa53aadeff92477618874;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618875 .

_:807f36cf91fe4e8caa53aadeff92477618874 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477618875 rdf:first _:807f36cf91fe4e8caa53aadeff92477618876;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618876 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10761 .

_:807f36cf91fe4e8caa53aadeff92477618878 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10966-1 a owl:Class;
  rdfs:label "FLUOROURACILE (ET, PAR EXTRAPOLATION, AUTRES FLUOROPYRIMIDINES) <-> INTERFERON ALFA"@fr;
  dct:identifier "IAM_10966";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618880;
  r:natureDuRisque "Augmentation de la toxicité gastro-intestinale du fluorouracile."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618886, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618880 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618881 .

_:807f36cf91fe4e8caa53aadeff92477618881 rdf:first _:807f36cf91fe4e8caa53aadeff92477618882;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618883 .

_:807f36cf91fe4e8caa53aadeff92477618882 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10076 .

_:807f36cf91fe4e8caa53aadeff92477618883 rdf:first _:807f36cf91fe4e8caa53aadeff92477618884;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618884 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10474 .

_:807f36cf91fe4e8caa53aadeff92477618886 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11070-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_11070";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618888;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation de sa posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618894, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618888 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618889 .

_:807f36cf91fe4e8caa53aadeff92477618889 rdf:first _:807f36cf91fe4e8caa53aadeff92477618890;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618891 .

_:807f36cf91fe4e8caa53aadeff92477618890 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477618891 rdf:first _:807f36cf91fe4e8caa53aadeff92477618892;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618892 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477618894 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11015-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_11015";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618896;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de baisse de l’efficacité des hormones thyroïdiennes par augmentation de leur métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Surveillance clinique et biologique et adaptation éventuelle de la posologie des hormones thyroïdiennes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618902, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618896 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618897 .

_:807f36cf91fe4e8caa53aadeff92477618897 rdf:first _:807f36cf91fe4e8caa53aadeff92477618898;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618899 .

_:807f36cf91fe4e8caa53aadeff92477618898 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477618899 rdf:first _:807f36cf91fe4e8caa53aadeff92477618900;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618900 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477618902 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11062-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> TRIPTANS NON MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11062";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618904;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618910, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618904 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618905 .

_:807f36cf91fe4e8caa53aadeff92477618905 rdf:first _:807f36cf91fe4e8caa53aadeff92477618906;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618907 .

_:807f36cf91fe4e8caa53aadeff92477618906 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477618907 rdf:first _:807f36cf91fe4e8caa53aadeff92477618908;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618908 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477618910 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11061-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> TRIPTANS MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11061";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618912;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618918, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618912 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618913 .

_:807f36cf91fe4e8caa53aadeff92477618913 rdf:first _:807f36cf91fe4e8caa53aadeff92477618914;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618915 .

_:807f36cf91fe4e8caa53aadeff92477618914 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477618915 rdf:first _:807f36cf91fe4e8caa53aadeff92477618916;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618916 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10157 .

_:807f36cf91fe4e8caa53aadeff92477618918 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11063-1 a owl:Class;
  rdfs:label "IMAO-B <-> INHIBITEURS SÉLECTIFS DE LA RECAPTURE DE LA SÉROTONINE"@fr;
  dct:identifier "IAM_11063";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618920;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618926, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618920 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618921 .

_:807f36cf91fe4e8caa53aadeff92477618921 rdf:first _:807f36cf91fe4e8caa53aadeff92477618922;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618923 .

_:807f36cf91fe4e8caa53aadeff92477618922 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477618923 rdf:first _:807f36cf91fe4e8caa53aadeff92477618924;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618924 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10104 .

_:807f36cf91fe4e8caa53aadeff92477618926 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11064-1 a owl:Class;
  rdfs:label "IMAO-B <-> LEVODOPA"@fr;
  dct:identifier "IAM_11064";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618928;
  r:natureDuRisque "Augmentation du risque d'hypotension orthostatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618934, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618928 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618929 .

_:807f36cf91fe4e8caa53aadeff92477618929 rdf:first _:807f36cf91fe4e8caa53aadeff92477618930;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618931 .

_:807f36cf91fe4e8caa53aadeff92477618930 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477618931 rdf:first _:807f36cf91fe4e8caa53aadeff92477618932;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618932 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477618934 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11065-1 a owl:Class;
  rdfs:label "IMAO-B <-> PETHIDINE"@fr;
  dct:identifier "IAM_11065";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618936;
  r:natureDuRisque "Manifestations d'excitation centrale évoquant un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618942, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618936 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618937 .

_:807f36cf91fe4e8caa53aadeff92477618937 rdf:first _:807f36cf91fe4e8caa53aadeff92477618938;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618939 .

_:807f36cf91fe4e8caa53aadeff92477618938 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477618939 rdf:first _:807f36cf91fe4e8caa53aadeff92477618940;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618940 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10709 .

_:807f36cf91fe4e8caa53aadeff92477618942 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11066-1 a owl:Class;
  rdfs:label "IMAO-B <-> TRAMADOL"@fr;
  dct:identifier "IAM_11066";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618944;
  r:natureDuRisque "Risque d’apparition d’un syndrome sérotoninergique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618950, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618944 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618945 .

_:807f36cf91fe4e8caa53aadeff92477618945 rdf:first _:807f36cf91fe4e8caa53aadeff92477618946;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618947 .

_:807f36cf91fe4e8caa53aadeff92477618946 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477618947 rdf:first _:807f36cf91fe4e8caa53aadeff92477618948;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618948 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477618950 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11068-1 a owl:Class;
  rdfs:label "IMAO-B <-> TRIPTANS NON MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11068";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618952;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618958, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618952 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618953 .

_:807f36cf91fe4e8caa53aadeff92477618953 rdf:first _:807f36cf91fe4e8caa53aadeff92477618954;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618955 .

_:807f36cf91fe4e8caa53aadeff92477618954 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477618955 rdf:first _:807f36cf91fe4e8caa53aadeff92477618956;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618956 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10158 .

_:807f36cf91fe4e8caa53aadeff92477618958 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11067-1 a owl:Class;
  rdfs:label "IMAO-B <-> TRIPTANS MÉTABOLISÉS PAR LA MAO"@fr;
  dct:identifier "IAM_11067";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618960;
  r:natureDuRisque "Risque d'hypertension artérielle, de vasoconstriction artérielle coronaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618966, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618960 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618961 .

_:807f36cf91fe4e8caa53aadeff92477618961 rdf:first _:807f36cf91fe4e8caa53aadeff92477618962;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618963 .

_:807f36cf91fe4e8caa53aadeff92477618962 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10004 .

_:807f36cf91fe4e8caa53aadeff92477618963 rdf:first _:807f36cf91fe4e8caa53aadeff92477618964;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618964 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10157 .

_:807f36cf91fe4e8caa53aadeff92477618966 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11059-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> SYMPATHOMIMÉTIQUES INDIRECTS"@fr;
  dct:identifier "IAM_11059";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618968;
  r:natureDuRisque "Risque de vasoconstriction et/ou de poussées hypertensives."@fr;
  r:conduiteATenir """Contre-indication :
avec le bupropion

Association déconseillée :
avec les autres sympathomimétiques indirects"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618974, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618968 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618969 .

_:807f36cf91fe4e8caa53aadeff92477618969 rdf:first _:807f36cf91fe4e8caa53aadeff92477618970;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618971 .

_:807f36cf91fe4e8caa53aadeff92477618970 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477618971 rdf:first _:807f36cf91fe4e8caa53aadeff92477618972;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618972 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10150 .

_:807f36cf91fe4e8caa53aadeff92477618974 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11069-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_11069";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618976;
  r:chapeau "Certains médicaments ont la propriété d'activer considérablement certaines voies métaboliques hépatiques par induction enzymatique. Associés à des médicaments fortement métabolisés au niveau du foie, ils sont, de ce fait, en mesure d'en modifier les conce"@fr;
  r:natureDuRisque "Diminution des concentrations sanguines et de l'efficacité de l'immunosuppresseur, par augmentation de son métabolisme hépatique par l'inducteur."@fr;
  r:conduiteATenir "Augmentation de la posologie de l'immunosuppresseur sous contrôle des concentrations sanguines. Réduction de la posologie après l'arrêt de l'inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618982, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618976 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618977 .

_:807f36cf91fe4e8caa53aadeff92477618977 rdf:first _:807f36cf91fe4e8caa53aadeff92477618978;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618979 .

_:807f36cf91fe4e8caa53aadeff92477618978 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477618979 rdf:first _:807f36cf91fe4e8caa53aadeff92477618980;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618980 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477618982 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11058-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> SYMPATHOMIMÉTIQUES ALPHA ET BÊTA (VOIE IM ET IV)"@fr;
  dct:identifier "IAM_11058";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618984;
  r:natureDuRisque "Par extrapolation à partir des IMAO non sélectifs : risque d'augmentation de l'action pressive."@fr;
  r:conduiteATenir "A n'utiliser que sous contrôle médical strict."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618990, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618984 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618985 .

_:807f36cf91fe4e8caa53aadeff92477618985 rdf:first _:807f36cf91fe4e8caa53aadeff92477618986;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618987 .

_:807f36cf91fe4e8caa53aadeff92477618986 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477618987 rdf:first _:807f36cf91fe4e8caa53aadeff92477618988;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618988 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10149 .

_:807f36cf91fe4e8caa53aadeff92477618990 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11071-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_11071";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477618992;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477618998, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477618992 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477618993 .

_:807f36cf91fe4e8caa53aadeff92477618993 rdf:first _:807f36cf91fe4e8caa53aadeff92477618994;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477618995 .

_:807f36cf91fe4e8caa53aadeff92477618994 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477618995 rdf:first _:807f36cf91fe4e8caa53aadeff92477618996;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477618996 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477618998 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11072-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_11072";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619000;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619006, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619000 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619001 .

_:807f36cf91fe4e8caa53aadeff92477619001 rdf:first _:807f36cf91fe4e8caa53aadeff92477619002;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619003 .

_:807f36cf91fe4e8caa53aadeff92477619002 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477619003 rdf:first _:807f36cf91fe4e8caa53aadeff92477619004;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619004 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477619006 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11073-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11073";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619008;
  r:natureDuRisque "Diminution des concentrations sanguines de l'immunosuppresseur, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (rejet de"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619014, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619008 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619009 .

_:807f36cf91fe4e8caa53aadeff92477619009 rdf:first _:807f36cf91fe4e8caa53aadeff92477619010;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619011 .

_:807f36cf91fe4e8caa53aadeff92477619010 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477619011 rdf:first _:807f36cf91fe4e8caa53aadeff92477619012;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619012 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477619014 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11074-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> NICARDIPINE"@fr;
  dct:identifier "IAM_11074";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619016;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunodépresseur, par inhibition de son métabolisme."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant le traitement et après l'arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619022, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619016 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619017 .

_:807f36cf91fe4e8caa53aadeff92477619017 rdf:first _:807f36cf91fe4e8caa53aadeff92477619018;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619019 .

_:807f36cf91fe4e8caa53aadeff92477619018 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477619019 rdf:first _:807f36cf91fe4e8caa53aadeff92477619020;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619020 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10630 .

_:807f36cf91fe4e8caa53aadeff92477619022 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11075-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11075";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619024;
  r:chapeau "Le jus de pamplemousse peut augmenter la biodisponibilité de quelques médicaments, notamment certains immunosuppresseurs (ciclosporine, tacrolimus, sirolimus), les dihydropyridines, certaines statines et le cisapride. Les conséquences cliniques de ces int"@fr;
  r:natureDuRisque "Augmentation de la biodisponibilité de l’immunosuppresseur et par conséquent de ses effets indésirables."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619030, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619024 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619025 .

_:807f36cf91fe4e8caa53aadeff92477619025 rdf:first _:807f36cf91fe4e8caa53aadeff92477619026;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619027 .

_:807f36cf91fe4e8caa53aadeff92477619026 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477619027 rdf:first _:807f36cf91fe4e8caa53aadeff92477619028;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619028 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477619030 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11076-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> POSACONAZOLE"@fr;
  dct:identifier "IAM_11076";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619032;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619038, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619032 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619033 .

_:807f36cf91fe4e8caa53aadeff92477619033 rdf:first _:807f36cf91fe4e8caa53aadeff92477619034;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619035 .

_:807f36cf91fe4e8caa53aadeff92477619034 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477619035 rdf:first _:807f36cf91fe4e8caa53aadeff92477619036;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619036 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10741 .

_:807f36cf91fe4e8caa53aadeff92477619038 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11077-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> PRISTINAMYCINE"@fr;
  dct:identifier "IAM_11077";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619040;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619046, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619040 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619041 .

_:807f36cf91fe4e8caa53aadeff92477619041 rdf:first _:807f36cf91fe4e8caa53aadeff92477619042;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619043 .

_:807f36cf91fe4e8caa53aadeff92477619042 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477619043 rdf:first _:807f36cf91fe4e8caa53aadeff92477619044;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619044 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10757 .

_:807f36cf91fe4e8caa53aadeff92477619046 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11093-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> MACITENTAN"@fr;
  dct:identifier "IAM_11093";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619048;
  r:natureDuRisque "Diminution des concentrations plasmatiques de macitentan par augmentation de son métabolisme par l’inducteur."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619054, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619048 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619049 .

_:807f36cf91fe4e8caa53aadeff92477619049 rdf:first _:807f36cf91fe4e8caa53aadeff92477619050;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619051 .

_:807f36cf91fe4e8caa53aadeff92477619050 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477619051 rdf:first _:807f36cf91fe4e8caa53aadeff92477619052;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619052 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10544 .

_:807f36cf91fe4e8caa53aadeff92477619054 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11094-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> MARAVIROC"@fr;
  dct:identifier "IAM_11094";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619056;
  r:natureDuRisque "En l’absence de co-administration avec un inhibiteur puissant du CYP3A4, diminution des concentrations de maraviroc par l’inducteur."@fr;
  r:conduiteATenir "La dose de maraviroc doit être augmentée à 600 mg deux fois par jour dans cette situation."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619062, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619056 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619057 .

_:807f36cf91fe4e8caa53aadeff92477619057 rdf:first _:807f36cf91fe4e8caa53aadeff92477619058;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619059 .

_:807f36cf91fe4e8caa53aadeff92477619058 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477619059 rdf:first _:807f36cf91fe4e8caa53aadeff92477619060;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619060 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10551 .

_:807f36cf91fe4e8caa53aadeff92477619062 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10425-2 a owl:Class;
  rdfs:label "AUTRES MÉDICAMENTS SÉDATIFS <-> MÉDICAMENTS SÉDATIFS"@fr;
  dct:identifier "IAM_10425";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619064;
  r:natureDuRisque """Majoration de la dépression centrale.
L'altération de la vigilance peut rendre dangereuses la conduite de véhicules et l'utilisation de machines."""@fr;
  r:conduiteATenir """Association déconseillée:
- avec l'oxybate de sodium.

A prendre en compte:
- avec les autres médicaments sédatifs."""@fr;
  rdfs:comment "A"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619066, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619064 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10120 .

_:807f36cf91fe4e8caa53aadeff92477619066 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11081-1 a owl:Class;
  rdfs:label "IMMUNOSUPPRESSEURS <-> TELAPREVIR"@fr;
  dct:identifier "IAM_11081";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619068;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'immunosuppresseur par inhibition de son métabolisme hépatique par le télaprévir."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l'immunosuppresseur, contrôle de la fonction rénale et adaptation de sa posologie pendant l'association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619074, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619068 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619069 .

_:807f36cf91fe4e8caa53aadeff92477619069 rdf:first _:807f36cf91fe4e8caa53aadeff92477619070;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619071 .

_:807f36cf91fe4e8caa53aadeff92477619070 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477619071 rdf:first _:807f36cf91fe4e8caa53aadeff92477619072;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619072 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477619074 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11028-1 a owl:Class;
  rdfs:label "HYDROXYCHLOROQUINE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11028";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619076;
  r:natureDuRisque "Risque de diminution de l'effet thérapeutique. de l’hydroxychloroquine, par augmentation de son métabolisme par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l’hydroxychloroquine pendant le traitement par rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619082, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619076 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619077 .

_:807f36cf91fe4e8caa53aadeff92477619077 rdf:first _:807f36cf91fe4e8caa53aadeff92477619078;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619079 .

_:807f36cf91fe4e8caa53aadeff92477619078 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10437 .

_:807f36cf91fe4e8caa53aadeff92477619079 rdf:first _:807f36cf91fe4e8caa53aadeff92477619080;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619080 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477619082 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10954-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10954";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619084;
  r:natureDuRisque "Risque d'accroissement des effets indésirables de la rifabutine (uvéites), par augmentation de ses concentrations et de celles de son métabolite actif."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619090, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619084 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619085 .

_:807f36cf91fe4e8caa53aadeff92477619085 rdf:first _:807f36cf91fe4e8caa53aadeff92477619086;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619087 .

_:807f36cf91fe4e8caa53aadeff92477619086 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477619087 rdf:first _:807f36cf91fe4e8caa53aadeff92477619088;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619088 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477619090 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11018-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> RÉSINES CHÉLATRICES"@fr;
  dct:identifier "IAM_11018";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619092;
  r:natureDuRisque "Diminution de l'absorption digestive des hormones thyroïdiennes."@fr;
  r:conduiteATenir "Prendre les hormones thyroïdiennes à distance de la résine (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619098, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619092 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619093 .

_:807f36cf91fe4e8caa53aadeff92477619093 rdf:first _:807f36cf91fe4e8caa53aadeff92477619094;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619095 .

_:807f36cf91fe4e8caa53aadeff92477619094 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477619095 rdf:first _:807f36cf91fe4e8caa53aadeff92477619096;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619096 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10140 .

_:807f36cf91fe4e8caa53aadeff92477619098 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11019-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> RIFABUTINE"@fr;
  dct:identifier "IAM_11019";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619100;
  r:natureDuRisque "Décrit pour la phénytoïne, la rifampicine, la carbamazépine. Risque d'hypothyroïdie clinique chez les patients hypothyroïdiens, par augmentation du métabolisme de la T3 et de la T4."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie des hormones thyroïdiennes pendant le traitement par la rifabutine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619106, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619100 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619101 .

_:807f36cf91fe4e8caa53aadeff92477619101 rdf:first _:807f36cf91fe4e8caa53aadeff92477619102;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619103 .

_:807f36cf91fe4e8caa53aadeff92477619102 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477619103 rdf:first _:807f36cf91fe4e8caa53aadeff92477619104;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619104 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477619106 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11020-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_11020";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619108;
  r:natureDuRisque "Risque d'hypothyroïdie clinique chez les patients hypothyroïdiens, par augmentation du métabolisme de la T3 et de la T4."@fr;
  r:conduiteATenir "Surveillance des concentrations sériques de T3 et de T4 et adaptation, si besoin, de la posologie des hormones thyroïdiennes pendant le traitement par la rifampicine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619114, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619108 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619109 .

_:807f36cf91fe4e8caa53aadeff92477619109 rdf:first _:807f36cf91fe4e8caa53aadeff92477619110;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619111 .

_:807f36cf91fe4e8caa53aadeff92477619110 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477619111 rdf:first _:807f36cf91fe4e8caa53aadeff92477619112;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619112 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477619114 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11021-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> SUCRALFATE"@fr;
  dct:identifier "IAM_11021";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619116;
  r:natureDuRisque "Diminution de l'absorption digestive des hormones thyroïdiennes."@fr;
  r:conduiteATenir "Prendre les hormones thyroïdiennes à distance du sucralfate (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619122, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619116 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619117 .

_:807f36cf91fe4e8caa53aadeff92477619117 rdf:first _:807f36cf91fe4e8caa53aadeff92477619118;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619119 .

_:807f36cf91fe4e8caa53aadeff92477619118 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477619119 rdf:first _:807f36cf91fe4e8caa53aadeff92477619120;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619120 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10864 .

_:807f36cf91fe4e8caa53aadeff92477619122 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11022-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> SUNITINIB"@fr;
  dct:identifier "IAM_11022";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619124;
  r:natureDuRisque "Risque de baisse de l’efficacité des hormones thyroïdiennes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619130, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619124 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619125 .

_:807f36cf91fe4e8caa53aadeff92477619125 rdf:first _:807f36cf91fe4e8caa53aadeff92477619126;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619127 .

_:807f36cf91fe4e8caa53aadeff92477619126 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477619127 rdf:first _:807f36cf91fe4e8caa53aadeff92477619128;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619128 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10877 .

_:807f36cf91fe4e8caa53aadeff92477619130 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11023-1 a owl:Class;
  rdfs:label "HUILES MINÉRALES <-> PRÉSERVATIFS EN LATEX"@fr;
  dct:identifier "IAM_11023";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619132;
  r:natureDuRisque "Risque de rupture du préservatif lors de l'utilisation avec des corps gras ou des lubrifiants contenant des huiles minérales (huile de paraffine, huile de silicone, etc...)."@fr;
  r:conduiteATenir "Utiliser un lubrifiant hydrosoluble (glycérine, polyacrylamide...)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619138, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619132 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619133 .

_:807f36cf91fe4e8caa53aadeff92477619133 rdf:first _:807f36cf91fe4e8caa53aadeff92477619134;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619135 .

_:807f36cf91fe4e8caa53aadeff92477619134 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10083 .

_:807f36cf91fe4e8caa53aadeff92477619135 rdf:first _:807f36cf91fe4e8caa53aadeff92477619136;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619136 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10136 .

_:807f36cf91fe4e8caa53aadeff92477619138 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11024-1 a owl:Class;
  rdfs:label "HYDROCORTISONE <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_11024";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619140;
  r:natureDuRisque "Risque de diminution de l'efficacité de l'hydrocortisone (augmentation de son métabolisme) ; les conséquences sont graves lorsque l'hydrocortisone est administrée en traitement substitutif ou en cas de transplantation."@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation de la posologie de l'hydrocortisone pendant l'association et après l'arrêt de l'inducteur enzymatique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619146, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619140 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619141 .

_:807f36cf91fe4e8caa53aadeff92477619141 rdf:first _:807f36cf91fe4e8caa53aadeff92477619142;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619143 .

_:807f36cf91fe4e8caa53aadeff92477619142 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477619143 rdf:first _:807f36cf91fe4e8caa53aadeff92477619144;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619144 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10432 .

_:807f36cf91fe4e8caa53aadeff92477619146 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11025-1 a owl:Class;
  rdfs:label "HYDROQUINIDINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_11025";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619148;
  r:natureDuRisque "Risque d'acouphènes et/ou de diminution de l'acuité auditive : cinchonisme lié à une diminution du métabolisme hépatique de l'antiarythmique par l'itraconazole."@fr;
  r:conduiteATenir "Surveillance des concentrations plasmatiques de l'antiarythmique et diminution éventuelle de sa posologie si nécessaire."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619154, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619148 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619149 .

_:807f36cf91fe4e8caa53aadeff92477619149 rdf:first _:807f36cf91fe4e8caa53aadeff92477619150;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619151 .

_:807f36cf91fe4e8caa53aadeff92477619150 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10434 .

_:807f36cf91fe4e8caa53aadeff92477619151 rdf:first _:807f36cf91fe4e8caa53aadeff92477619152;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619152 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477619154 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11060-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> TRAMADOL"@fr;
  dct:identifier "IAM_11060";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619156;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619162, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619156 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619157 .

_:807f36cf91fe4e8caa53aadeff92477619157 rdf:first _:807f36cf91fe4e8caa53aadeff92477619158;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619159 .

_:807f36cf91fe4e8caa53aadeff92477619158 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477619159 rdf:first _:807f36cf91fe4e8caa53aadeff92477619160;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619160 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10945 .

_:807f36cf91fe4e8caa53aadeff92477619162 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11027-1 a owl:Class;
  rdfs:label "HYDROXYCHLOROQUINE <-> METOPROLOL"@fr;
  dct:identifier "IAM_11027";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619164;
  r:natureDuRisque "Avec le métoprolol utilisé dans l'insuffisance cardiaque : risque d'augmentation des effets indésirables du métoprolol par diminution de son métabolisme hépatique par l’hydroxychloroquine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du métoprolol pendant le traitement par l’hydroxychloroquine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619170, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619164 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619165 .

_:807f36cf91fe4e8caa53aadeff92477619165 rdf:first _:807f36cf91fe4e8caa53aadeff92477619166;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619167 .

_:807f36cf91fe4e8caa53aadeff92477619166 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10437 .

_:807f36cf91fe4e8caa53aadeff92477619167 rdf:first _:807f36cf91fe4e8caa53aadeff92477619168;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619168 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10579 .

_:807f36cf91fe4e8caa53aadeff92477619170 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11016-1 a owl:Class;
  rdfs:label "HORMONES THYROÏDIENNES <-> ORLISTAT"@fr;
  dct:identifier "IAM_11016";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619172;
  r:natureDuRisque "Risque de déséquilibre du traitement thyroïdien substitutif en cas de traitement par orlistat."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619178, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619172 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619173 .

_:807f36cf91fe4e8caa53aadeff92477619173 rdf:first _:807f36cf91fe4e8caa53aadeff92477619174;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619175 .

_:807f36cf91fe4e8caa53aadeff92477619174 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477619175 rdf:first _:807f36cf91fe4e8caa53aadeff92477619176;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619176 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10667 .

_:807f36cf91fe4e8caa53aadeff92477619178 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11029-1 a owl:Class;
  rdfs:label "HYDROXYCHLOROQUINE <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11029";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619180;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir """Contre-indication :
- avec le citalopram, la dompéridone, l'escitalopram, l'hydroxyzine et la pipéraquine.

Association déconseillée:
- avec les autres médicaments susceptibles de donner des torsades de pointes."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619186, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619180 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619181 .

_:807f36cf91fe4e8caa53aadeff92477619181 rdf:first _:807f36cf91fe4e8caa53aadeff92477619182;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619183 .

_:807f36cf91fe4e8caa53aadeff92477619182 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477619183 rdf:first _:807f36cf91fe4e8caa53aadeff92477619184;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619184 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10437 .

_:807f36cf91fe4e8caa53aadeff92477619186 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10414-1 a owl:Class;
  rdfs:label "AUTRES HYPERKALIÉMIANTS <-> HYPERKALIÉMIANTS"@fr;
  dct:identifier "IAM_10414";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619188;
  r:natureDuRisque "Risque de majoration de l’hyperkaliémie, potentiellement létale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619190, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619188 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10084 .

_:807f36cf91fe4e8caa53aadeff92477619190 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10415-1 a owl:Class;
  rdfs:label "AUTRES HYPNOTIQUES <-> HYPNOTIQUES"@fr;
  dct:identifier "IAM_10415";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619192;
  r:natureDuRisque "Majoration de la dépression centrale."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619194, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619192 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10085 .

_:807f36cf91fe4e8caa53aadeff92477619194 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10416-1 a owl:Class;
  rdfs:label "AUTRES HYPOKALIÉMIANTS <-> HYPOKALIÉMIANTS"@fr;
  dct:identifier "IAM_10416";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619196;
  r:natureDuRisque "Risque majoré d'hypokaliémie."@fr;
  r:conduiteATenir "Surveillance de la kaliémie avec si besoin correction."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619198, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619196 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10086 .

_:807f36cf91fe4e8caa53aadeff92477619198 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11030-1 a owl:Class;
  rdfs:label "HYPOKALIÉMIANTS <-> SUBSTANCES SUSCEPTIBLES DE DONNER DES TORSADES DE POINTES"@fr;
  dct:identifier "IAM_11030";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619200;
  r:chapeau "Ce trouble du rythme cardiaque grave peut être provoqué par un certain nombre de médicaments, antiarythmiques ou non. L'hypokaliémie (cf. médicaments hypokaliémiants) est un facteur favorisant, de même que la bradycardie (cf. médicaments bradycardisants)"@fr;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Corriger toute hypokaliémie avant d’administrer le produit et réaliser une surveillance clinique, électrolytique et électrocardiographique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619206, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619200 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619201 .

_:807f36cf91fe4e8caa53aadeff92477619201 rdf:first _:807f36cf91fe4e8caa53aadeff92477619202;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619203 .

_:807f36cf91fe4e8caa53aadeff92477619202 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10086 .

_:807f36cf91fe4e8caa53aadeff92477619203 rdf:first _:807f36cf91fe4e8caa53aadeff92477619204;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619204 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10143 .

_:807f36cf91fe4e8caa53aadeff92477619206 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11042-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11042";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619208;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619214, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619208 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619209 .

_:807f36cf91fe4e8caa53aadeff92477619209 rdf:first _:807f36cf91fe4e8caa53aadeff92477619210;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619211 .

_:807f36cf91fe4e8caa53aadeff92477619210 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477619211 rdf:first _:807f36cf91fe4e8caa53aadeff92477619212;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619212 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477619214 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11043-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> PETHIDINE"@fr;
  dct:identifier "IAM_11043";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619216;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619222, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619216 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619217 .

_:807f36cf91fe4e8caa53aadeff92477619217 rdf:first _:807f36cf91fe4e8caa53aadeff92477619218;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619219 .

_:807f36cf91fe4e8caa53aadeff92477619218 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477619219 rdf:first _:807f36cf91fe4e8caa53aadeff92477619220;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619220 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10709 .

_:807f36cf91fe4e8caa53aadeff92477619222 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11044-1 a owl:Class;
  rdfs:label "IMAO IRRÉVERSIBLES <-> RESERPINE"@fr;
  dct:identifier "IAM_11044";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619224;
  r:natureDuRisque "Agitation psychomotrice, convulsions, hypertension."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619230, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619224 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619225 .

_:807f36cf91fe4e8caa53aadeff92477619225 rdf:first _:807f36cf91fe4e8caa53aadeff92477619226;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619227 .

_:807f36cf91fe4e8caa53aadeff92477619226 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10002 .

_:807f36cf91fe4e8caa53aadeff92477619227 rdf:first _:807f36cf91fe4e8caa53aadeff92477619228;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619228 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10792 .

_:807f36cf91fe4e8caa53aadeff92477619230 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11056-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_11056";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619232;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619238, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619232 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619233 .

_:807f36cf91fe4e8caa53aadeff92477619233 rdf:first _:807f36cf91fe4e8caa53aadeff92477619234;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619235 .

_:807f36cf91fe4e8caa53aadeff92477619234 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477619235 rdf:first _:807f36cf91fe4e8caa53aadeff92477619236;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619236 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477619238 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11057-1 a owl:Class;
  rdfs:label "IMAO-A RÉVERSIBLES, Y COMPRIS LINEZOLIDE ET BLEU DE MÉTHYLÈNE <-> PETHIDINE"@fr;
  dct:identifier "IAM_11057";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619240;
  r:natureDuRisque "Risque d'apparition d'un syndrome sérotoninergique : diarrhée, tachycardie, sueurs, tremblements, confusion voire coma."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619246, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619240 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619241 .

_:807f36cf91fe4e8caa53aadeff92477619241 rdf:first _:807f36cf91fe4e8caa53aadeff92477619242;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619243 .

_:807f36cf91fe4e8caa53aadeff92477619242 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10003 .

_:807f36cf91fe4e8caa53aadeff92477619243 rdf:first _:807f36cf91fe4e8caa53aadeff92477619244;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619244 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10709 .

_:807f36cf91fe4e8caa53aadeff92477619246 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11026-1 a owl:Class;
  rdfs:label "HYDROXYCARBAMIDE <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_11026";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619248;
  r:natureDuRisque "Dans son indication chez le patient drépanocytaire, risque théorique de maladie vaccinale généralisée."@fr;
  r:conduiteATenir """L'association ne devra être envisagée que si les bénéfices sont estimés comme étant supérieurs à ce risque. 
S'il est décidé d’interrompre le traitement par hydroxycarbamide pour effectuer la vaccination, un délai de 3 mois après l’arrêt est recommandé."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619254, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619248 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619249 .

_:807f36cf91fe4e8caa53aadeff92477619249 rdf:first _:807f36cf91fe4e8caa53aadeff92477619250;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619251 .

_:807f36cf91fe4e8caa53aadeff92477619250 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477619251 rdf:first _:807f36cf91fe4e8caa53aadeff92477619252;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619252 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10436 .

_:807f36cf91fe4e8caa53aadeff92477619254 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10876-1 a owl:Class;
  rdfs:label "ELVITÉGRAVIR <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10876";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619256;
  r:natureDuRisque "Diminution des concentrations minimales d’elvitégravir."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619262, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619256 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619257 .

_:807f36cf91fe4e8caa53aadeff92477619257 rdf:first _:807f36cf91fe4e8caa53aadeff92477619258;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619259 .

_:807f36cf91fe4e8caa53aadeff92477619258 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10321 .

_:807f36cf91fe4e8caa53aadeff92477619259 rdf:first _:807f36cf91fe4e8caa53aadeff92477619260;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619260 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477619262 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10897-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> SIMVASTATINE"@fr;
  dct:identifier "IAM_10897";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619264;
  r:natureDuRisque "Risque majoré d'effets indésirables (concentration-dépendants) à type de rhabdomyolyse (diminution du métabolisme hépatique de l'hypocholestérolémiant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619270, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619264 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619265 .

_:807f36cf91fe4e8caa53aadeff92477619265 rdf:first _:807f36cf91fe4e8caa53aadeff92477619266;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619267 .

_:807f36cf91fe4e8caa53aadeff92477619266 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477619267 rdf:first _:807f36cf91fe4e8caa53aadeff92477619268;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619268 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10838 .

_:807f36cf91fe4e8caa53aadeff92477619270 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10866-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> FOSAMPRENAVIR"@fr;
  dct:identifier "IAM_10866";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619272;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'amprénavir."@fr;
  r:conduiteATenir """Surveillance clinique et biologique régulière, notamment en début
d'association."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619278, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619272 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619273 .

_:807f36cf91fe4e8caa53aadeff92477619273 rdf:first _:807f36cf91fe4e8caa53aadeff92477619274;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619275 .

_:807f36cf91fe4e8caa53aadeff92477619274 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477619275 rdf:first _:807f36cf91fe4e8caa53aadeff92477619276;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619276 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10400 .

_:807f36cf91fe4e8caa53aadeff92477619278 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10867-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> INDINAVIR"@fr;
  dct:identifier "IAM_10867";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619280;
  r:natureDuRisque "Risque de baisse de l'efficacité de l'indinavir."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619286, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619280 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619281 .

_:807f36cf91fe4e8caa53aadeff92477619281 rdf:first _:807f36cf91fe4e8caa53aadeff92477619282;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619283 .

_:807f36cf91fe4e8caa53aadeff92477619282 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477619283 rdf:first _:807f36cf91fe4e8caa53aadeff92477619284;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619284 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10455 .

_:807f36cf91fe4e8caa53aadeff92477619286 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10868-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> PIMOZIDE"@fr;
  dct:identifier "IAM_10868";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619288;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619294, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619288 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619289 .

_:807f36cf91fe4e8caa53aadeff92477619289 rdf:first _:807f36cf91fe4e8caa53aadeff92477619290;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619291 .

_:807f36cf91fe4e8caa53aadeff92477619290 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477619291 rdf:first _:807f36cf91fe4e8caa53aadeff92477619292;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619292 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477619294 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10869-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> RIFABUTINE"@fr;
  dct:identifier "IAM_10869";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619296;
  r:natureDuRisque "Diminution d’environ la moitié des concentrations de rifabutine, par augmentation de son métabolisme hépatique par l’éfavirenz."@fr;
  r:conduiteATenir "Adaptation de la posologie de la rifabutine pendant le traitement par efavirenz."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619302, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619296 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619297 .

_:807f36cf91fe4e8caa53aadeff92477619297 rdf:first _:807f36cf91fe4e8caa53aadeff92477619298;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619299 .

_:807f36cf91fe4e8caa53aadeff92477619298 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477619299 rdf:first _:807f36cf91fe4e8caa53aadeff92477619300;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619300 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10800 .

_:807f36cf91fe4e8caa53aadeff92477619302 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10870-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10870";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619304;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité de l'éfavirenz par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique régulière, notamment en début d'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619310, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619304 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619305 .

_:807f36cf91fe4e8caa53aadeff92477619305 rdf:first _:807f36cf91fe4e8caa53aadeff92477619306;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619307 .

_:807f36cf91fe4e8caa53aadeff92477619306 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477619307 rdf:first _:807f36cf91fe4e8caa53aadeff92477619308;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619308 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477619310 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10871-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> VORICONAZOLE"@fr;
  dct:identifier "IAM_10871";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619312;
  r:natureDuRisque "Risque de baisse de l'efficacité du voriconazole par augmentation de son métabolisme hépatique par l'efavirenz."@fr;
  r:conduiteATenir "Si l'association ne peut être évitée, surveillance clinique étroite et adaptation de la posologie du voriconazole et de l'éfavirenz pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619318, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619312 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619313 .

_:807f36cf91fe4e8caa53aadeff92477619313 rdf:first _:807f36cf91fe4e8caa53aadeff92477619314;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619315 .

_:807f36cf91fe4e8caa53aadeff92477619314 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477619315 rdf:first _:807f36cf91fe4e8caa53aadeff92477619316;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619316 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10998 .

_:807f36cf91fe4e8caa53aadeff92477619318 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10872-1 a owl:Class;
  rdfs:label "ELTROMBOPAG <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10872";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619320;
  r:natureDuRisque "Risque de majoration de la toxicité des statines, par inhibition de leur recapture hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de la statine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619326, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619320 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619321 .

_:807f36cf91fe4e8caa53aadeff92477619321 rdf:first _:807f36cf91fe4e8caa53aadeff92477619322;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619323 .

_:807f36cf91fe4e8caa53aadeff92477619322 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477619323 rdf:first _:807f36cf91fe4e8caa53aadeff92477619324;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619324 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10320 .

_:807f36cf91fe4e8caa53aadeff92477619326 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10873-1 a owl:Class;
  rdfs:label "ELVITÉGRAVIR <-> ESTROPROGESTATIFS CONTRACEPTIFS"@fr;
  dct:identifier "IAM_10873";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619328;
  r:natureDuRisque "Diminution des concentrations d’éthinylestradiol, avec risque de moindre efficacité contraceptive. De plus, augmentation des concentrations du progestatif."@fr;
  r:conduiteATenir "Utiliser un estroprogestatif contraceptif avec au moins 30 µg d’éthinylestradiol."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619334, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619328 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619329 .

_:807f36cf91fe4e8caa53aadeff92477619329 rdf:first _:807f36cf91fe4e8caa53aadeff92477619330;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619331 .

_:807f36cf91fe4e8caa53aadeff92477619330 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477619331 rdf:first _:807f36cf91fe4e8caa53aadeff92477619332;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619332 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10321 .

_:807f36cf91fe4e8caa53aadeff92477619334 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10864-1 a owl:Class;
  rdfs:label "EBASTINE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10864";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619336;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long congénital)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619342, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619336 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619337 .

_:807f36cf91fe4e8caa53aadeff92477619337 rdf:first _:807f36cf91fe4e8caa53aadeff92477619338;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619339 .

_:807f36cf91fe4e8caa53aadeff92477619338 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:807f36cf91fe4e8caa53aadeff92477619339 rdf:first _:807f36cf91fe4e8caa53aadeff92477619340;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619340 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477619342 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10875-1 a owl:Class;
  rdfs:label "ELVITÉGRAVIR <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10875";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619344;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’elvitegravir par diminution de son métabolisme par le kétoconazole."@fr;
  r:conduiteATenir "Avec l’elvitegravir co-administré avec le cobicistat, surveillance clinique. Limiter la dose maximale de kétoconazole à 200 mg/j."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619350, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619344 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619345 .

_:807f36cf91fe4e8caa53aadeff92477619345 rdf:first _:807f36cf91fe4e8caa53aadeff92477619346;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619347 .

_:807f36cf91fe4e8caa53aadeff92477619346 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10321 .

_:807f36cf91fe4e8caa53aadeff92477619347 rdf:first _:807f36cf91fe4e8caa53aadeff92477619348;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619348 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477619350 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10863-1 a owl:Class;
  rdfs:label "EBASTINE <-> JOSAMYCINE"@fr;
  dct:identifier "IAM_10863";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619352;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long, congénital)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619358, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619352 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619353 .

_:807f36cf91fe4e8caa53aadeff92477619353 rdf:first _:807f36cf91fe4e8caa53aadeff92477619354;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619355 .

_:807f36cf91fe4e8caa53aadeff92477619354 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:807f36cf91fe4e8caa53aadeff92477619355 rdf:first _:807f36cf91fe4e8caa53aadeff92477619356;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619356 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477619358 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10877-1 a owl:Class;
  rdfs:label "ENOXACINE <-> ROPINIROLE"@fr;
  dct:identifier "IAM_10877";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619360;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de ropinirole avec signes de surdosage par diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et réduction de la posologie du ropinirole pendant le traitement par l'énoxacine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619366, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619360 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619361 .

_:807f36cf91fe4e8caa53aadeff92477619361 rdf:first _:807f36cf91fe4e8caa53aadeff92477619362;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619363 .

_:807f36cf91fe4e8caa53aadeff92477619362 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10323 .

_:807f36cf91fe4e8caa53aadeff92477619363 rdf:first _:807f36cf91fe4e8caa53aadeff92477619364;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619364 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10813 .

_:807f36cf91fe4e8caa53aadeff92477619366 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10878-1 a owl:Class;
  rdfs:label "ENOXACINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10878";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619368;
  r:natureDuRisque "Surdosage en théophylline par diminution importante de son métabolisme."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619374, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619368 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619369 .

_:807f36cf91fe4e8caa53aadeff92477619369 rdf:first _:807f36cf91fe4e8caa53aadeff92477619370;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619371 .

_:807f36cf91fe4e8caa53aadeff92477619370 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477619371 rdf:first _:807f36cf91fe4e8caa53aadeff92477619372;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619372 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10323 .

_:807f36cf91fe4e8caa53aadeff92477619374 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10879-1 a owl:Class;
  rdfs:label "ENTACAPONE <-> FER"@fr;
  dct:identifier "IAM_10879";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619376;
  r:natureDuRisque "Diminution de l'absorption digestive de l'entacapone et du fer par chélation de celui-ci par l'entacapone."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance de l'entacapone (plus de 2 heures si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619382, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619376 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619377 .

_:807f36cf91fe4e8caa53aadeff92477619377 rdf:first _:807f36cf91fe4e8caa53aadeff92477619378;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619379 .

_:807f36cf91fe4e8caa53aadeff92477619378 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10325 .

_:807f36cf91fe4e8caa53aadeff92477619379 rdf:first _:807f36cf91fe4e8caa53aadeff92477619380;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619380 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477619382 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10880-1 a owl:Class;
  rdfs:label "ENZALUTAMIDE <-> GEMFIBROZIL"@fr;
  dct:identifier "IAM_10880";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619384;
  r:natureDuRisque "Majoration de la fraction active de l’enzalutamide."@fr;
  r:conduiteATenir "Réduire la dose d’enzalutamide par deux en cas d’association au gemfibrozil."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619390, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619384 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619385 .

_:807f36cf91fe4e8caa53aadeff92477619385 rdf:first _:807f36cf91fe4e8caa53aadeff92477619386;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619387 .

_:807f36cf91fe4e8caa53aadeff92477619386 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10326 .

_:807f36cf91fe4e8caa53aadeff92477619387 rdf:first _:807f36cf91fe4e8caa53aadeff92477619388;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619388 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10411 .

_:807f36cf91fe4e8caa53aadeff92477619390 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10881-1 a owl:Class;
  rdfs:label "EPLERENONE <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10881";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619392;
  r:natureDuRisque "Majoration du risque d’hyperkaliémie, notamment chez le sujet âgé."@fr;
  r:conduiteATenir "Contrôle strict de la kaliémie et de la fonction rénale pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619398, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619392 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619393 .

_:807f36cf91fe4e8caa53aadeff92477619393 rdf:first _:807f36cf91fe4e8caa53aadeff92477619394;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619395 .

_:807f36cf91fe4e8caa53aadeff92477619394 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477619395 rdf:first _:807f36cf91fe4e8caa53aadeff92477619396;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619396 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10329 .

_:807f36cf91fe4e8caa53aadeff92477619398 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10891-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> GLIMEPIRIDE"@fr;
  dct:identifier "IAM_10891";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619400;
  r:natureDuRisque "Risque d'hypoglycémie par augmentation de l’absorption et des concentrations plasmatiques de l’antidiabétique."@fr;
  r:conduiteATenir "Prévenir le patient, renforcer l'autosurveillance glycémique et adapter éventuellement la posologie du sulfamide hypoglycémiant pendant le traitement par l’érythromycine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619406, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619400 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619401 .

_:807f36cf91fe4e8caa53aadeff92477619401 rdf:first _:807f36cf91fe4e8caa53aadeff92477619402;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619403 .

_:807f36cf91fe4e8caa53aadeff92477619402 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477619403 rdf:first _:807f36cf91fe4e8caa53aadeff92477619404;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619404 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10416 .

_:807f36cf91fe4e8caa53aadeff92477619406 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10892-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> IMMUNOSUPPRESSEURS"@fr;
  dct:identifier "IAM_10892";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619408;
  r:natureDuRisque "Augmentation très importante des concentrations sanguines de l'immunosuppresseur par inhibition de son métabolisme hépatique."@fr;
  r:conduiteATenir "En cas d’association, contrôle strict de la fonction rénale, dosage des concentrations sanguines de l'immunosuppresseur et adaptation éventuelle de la posologie."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619414, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619408 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619409 .

_:807f36cf91fe4e8caa53aadeff92477619409 rdf:first _:807f36cf91fe4e8caa53aadeff92477619410;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619411 .

_:807f36cf91fe4e8caa53aadeff92477619410 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10093 .

_:807f36cf91fe4e8caa53aadeff92477619411 rdf:first _:807f36cf91fe4e8caa53aadeff92477619412;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619412 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477619414 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10894-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> MIZOLASTINE"@fr;
  dct:identifier "IAM_10894";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619416;
  r:natureDuRisque "Risque de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619422, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619416 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619417 .

_:807f36cf91fe4e8caa53aadeff92477619417 rdf:first _:807f36cf91fe4e8caa53aadeff92477619418;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619419 .

_:807f36cf91fe4e8caa53aadeff92477619418 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477619419 rdf:first _:807f36cf91fe4e8caa53aadeff92477619420;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619420 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10597 .

_:807f36cf91fe4e8caa53aadeff92477619422 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10895-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> NINTÉDANIB"@fr;
  dct:identifier "IAM_10895";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619424;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du nintédanib par augmentation de son absorption par l'érythromycine."@fr;
  r:conduiteATenir "Surveillance clinique pendant l’association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619430, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619424 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619425 .

_:807f36cf91fe4e8caa53aadeff92477619425 rdf:first _:807f36cf91fe4e8caa53aadeff92477619426;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619427 .

_:807f36cf91fe4e8caa53aadeff92477619426 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477619427 rdf:first _:807f36cf91fe4e8caa53aadeff92477619428;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619428 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10637 .

_:807f36cf91fe4e8caa53aadeff92477619430 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10956-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> RIVAROXABAN"@fr;
  dct:identifier "IAM_10956";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619432;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du rivaroxaban par le fluconazole, avec majoration du risque de saignement."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619438, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619432 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619433 .

_:807f36cf91fe4e8caa53aadeff92477619433 rdf:first _:807f36cf91fe4e8caa53aadeff92477619434;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619435 .

_:807f36cf91fe4e8caa53aadeff92477619434 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477619435 rdf:first _:807f36cf91fe4e8caa53aadeff92477619436;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619436 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10808 .

_:807f36cf91fe4e8caa53aadeff92477619438 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10874-1 a owl:Class;
  rdfs:label "ELVITÉGRAVIR <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10874";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619440;
  r:natureDuRisque "Augmentation des concentrations plasmatiques d’elvitegravir par diminution de son métabolisme par l'itraconazole."@fr;
  r:conduiteATenir "Avec l’elvitegravir co-administré avec le cobicistat, surveillance clinique. Limiter la dose maximale d’itraconazole à 200 mg/j."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619446, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619440 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619441 .

_:807f36cf91fe4e8caa53aadeff92477619441 rdf:first _:807f36cf91fe4e8caa53aadeff92477619442;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619443 .

_:807f36cf91fe4e8caa53aadeff92477619442 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10321 .

_:807f36cf91fe4e8caa53aadeff92477619443 rdf:first _:807f36cf91fe4e8caa53aadeff92477619444;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619444 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477619446 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10177-2 a owl:Class;
  rdfs:label "ANTAGONISTES DES CANAUX CALCIQUES <-> ANTICONVULSIVANTS INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10177";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619448;
  r:natureDuRisque "Diminution des concentrations plasmatiques de l'antagoniste du calcium par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Association déconseillée avec la nimodipine"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619454, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619448 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619449 .

_:807f36cf91fe4e8caa53aadeff92477619449 rdf:first _:807f36cf91fe4e8caa53aadeff92477619450;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619451 .

_:807f36cf91fe4e8caa53aadeff92477619450 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10019 .

_:807f36cf91fe4e8caa53aadeff92477619451 rdf:first _:807f36cf91fe4e8caa53aadeff92477619452;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619452 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10029 .

_:807f36cf91fe4e8caa53aadeff92477619454 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11096-1 a owl:Class;
  rdfs:label "INDUCTEURS ENZYMATIQUES <-> MIANSERINE"@fr;
  dct:identifier "IAM_11096";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619456;
  r:natureDuRisque "Risque d’inefficacité de la miansérine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619462, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619456 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619457 .

_:807f36cf91fe4e8caa53aadeff92477619457 rdf:first _:807f36cf91fe4e8caa53aadeff92477619458;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619459 .

_:807f36cf91fe4e8caa53aadeff92477619458 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477619459 rdf:first _:807f36cf91fe4e8caa53aadeff92477619460;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619460 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10583 .

_:807f36cf91fe4e8caa53aadeff92477619462 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11208-1 a owl:Class;
  rdfs:label "IVABRADINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_11208";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619464;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’ivabradine et de ses effets indésirables, notamment cardiaques (inhibition de son métabolisme hépatique par le vérapamil), qui s’ajoutent aux effets bradycardisants de ces substances."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619470, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619464 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619465 .

_:807f36cf91fe4e8caa53aadeff92477619465 rdf:first _:807f36cf91fe4e8caa53aadeff92477619466;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619467 .

_:807f36cf91fe4e8caa53aadeff92477619466 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477619467 rdf:first _:807f36cf91fe4e8caa53aadeff92477619468;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619468 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477619470 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_11209-1 a owl:Class;
  rdfs:label "JOSAMYCINE <-> PIMOZIDE"@fr;
  dct:identifier "IAM_11209";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619472;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire, notamment de torsades de pointes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619478, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619472 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619473 .

_:807f36cf91fe4e8caa53aadeff92477619473 rdf:first _:807f36cf91fe4e8caa53aadeff92477619474;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619475 .

_:807f36cf91fe4e8caa53aadeff92477619474 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10499 .

_:807f36cf91fe4e8caa53aadeff92477619475 rdf:first _:807f36cf91fe4e8caa53aadeff92477619476;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619476 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10721 .

_:807f36cf91fe4e8caa53aadeff92477619478 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10017-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> CLOPIDOGREL"@fr;
  dct:identifier "IAM_10017";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619480;
  r:natureDuRisque "Majoration du risque hémorragique par addition des activités antiagrégantes plaquettaires."@fr;
  r:conduiteATenir """Association déconseillée :
- en dehors des indications validées pour cette association dans les syndromes coronariens aigus.

Précaution d'emploi :
- dans les indications validées pour cette association dans les syndromes coronariens aigus. Surveillance c"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619486, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619480 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619481 .

_:807f36cf91fe4e8caa53aadeff92477619481 rdf:first _:807f36cf91fe4e8caa53aadeff92477619482;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619483 .

_:807f36cf91fe4e8caa53aadeff92477619482 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477619483 rdf:first _:807f36cf91fe4e8caa53aadeff92477619484;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619484 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10216 .

_:807f36cf91fe4e8caa53aadeff92477619486 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10279-2 a owl:Class;
  rdfs:label "ANTI-INFLAMMATOIRES NON STÉROÏDIENS <-> PEMETREXED"@fr;
  dct:identifier "IAM_10279";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619488;
  r:natureDuRisque "Risque de majoration de la toxicité du pemetrexed (diminution de sa clairance rénale par les AINS)."@fr;
  r:conduiteATenir """Association déconseillée : 
- en cas de fonction rénale faible à modérée.

Précaution d'emploi :
- en cas de fonction rénale normale. Surveillance biologique de la fonction rénale."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619494, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619488 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619489 .

_:807f36cf91fe4e8caa53aadeff92477619489 rdf:first _:807f36cf91fe4e8caa53aadeff92477619490;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619491 .

_:807f36cf91fe4e8caa53aadeff92477619490 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477619491 rdf:first _:807f36cf91fe4e8caa53aadeff92477619492;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619492 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10700 .

_:807f36cf91fe4e8caa53aadeff92477619494 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11164-2 a owl:Class;
  rdfs:label "INHIBITEURS PUISSANTS DU CYP3A4 <-> QUININE"@fr;
  dct:identifier "IAM_11164";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619496;
  r:natureDuRisque "Risque de majoration des effets indésirables de la quinine, notamment troubles du rythme ventriculaire et troubles neurosensoriels (cinchonisme)."@fr;
  r:conduiteATenir """Association déconseillée : 
- avec les inhibiteurs de protéases

Précaution d’emploi : 
- avec les azolés antifongiques et certains macrolides.
Surveillance clinique et ECG. Adaptation éventuelle de la posologie de la quinine pendant le traitement par l’i"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619502, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619496 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619497 .

_:807f36cf91fe4e8caa53aadeff92477619497 rdf:first _:807f36cf91fe4e8caa53aadeff92477619498;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619499 .

_:807f36cf91fe4e8caa53aadeff92477619498 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477619499 rdf:first _:807f36cf91fe4e8caa53aadeff92477619500;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619500 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10777 .

_:807f36cf91fe4e8caa53aadeff92477619502 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10130-2 a owl:Class;
  rdfs:label "AMIODARONE <-> DILTIAZEM"@fr;
  dct:identifier "IAM_10130";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619504;
  r:natureDuRisque """Pour diltiazem voie injectable : risque de bradycardie et de bloc auriculo-ventriculaire

Pour diltiazem per os : risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez les personnes âgées."""@fr;
  r:conduiteATenir """Association déconseillée avec :
- le diltiazem IV
Si l'association ne peut être évitée, surveillance clinique et ECG continu."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619510, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619504 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619505 .

_:807f36cf91fe4e8caa53aadeff92477619505 rdf:first _:807f36cf91fe4e8caa53aadeff92477619506;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619507 .

_:807f36cf91fe4e8caa53aadeff92477619506 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477619507 rdf:first _:807f36cf91fe4e8caa53aadeff92477619508;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619508 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477619510 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10698-2 a owl:Class;
  rdfs:label "CYPROTERONE <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10698";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619512;
  r:natureDuRisque "Risque de diminution de l'efficacité de la cyprotérone."@fr;
  r:conduiteATenir """Association déconseillée
- dans son utilisation comme contraceptif hormonal: utiliser de préférence une autre méthode de contraception en particulier de type mécanique, pendant la durée de l'association et un cycle suivant.

Précaution d'emploi
- dans ses"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619518, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619512 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619513 .

_:807f36cf91fe4e8caa53aadeff92477619513 rdf:first _:807f36cf91fe4e8caa53aadeff92477619514;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619515 .

_:807f36cf91fe4e8caa53aadeff92477619514 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477619515 rdf:first _:807f36cf91fe4e8caa53aadeff92477619516;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619516 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff92477619518 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10911-2 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_10911";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619520;
  r:natureDuRisque "Risque de diminution des concentrations et de l’efficacité de la lamotrigine par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir """Association déconseillée :
- éviter de mettre en route une contraception orale pendant la période d’ajustement posologique de la lamotrigine."""@fr;
  rdfs:comment """Deux publications d'une même équipe montrent que les contraceptifs oraux (COs) diminuent de près de moitié les concentrations plasmatiques de la lamotrigine. Le mécanisme passerait par une induction de la glucuronidation de la lamotrigine par les COs.
Dan"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619526, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619520 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619521 .

_:807f36cf91fe4e8caa53aadeff92477619521 rdf:first _:807f36cf91fe4e8caa53aadeff92477619522;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619523 .

_:807f36cf91fe4e8caa53aadeff92477619522 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477619523 rdf:first _:807f36cf91fe4e8caa53aadeff92477619524;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619524 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:807f36cf91fe4e8caa53aadeff92477619526 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10865-1 a owl:Class;
  rdfs:label "EFAVIRENZ <-> ERGOTAMINE"@fr;
  dct:identifier "IAM_10865";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619528;
  r:natureDuRisque "Ergotisme avec possibilité de nécrose des extrémités (inhibition du métabolisme hépatique de l'alcaloïde de l'ergot de seigle)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619534, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619528 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619529 .

_:807f36cf91fe4e8caa53aadeff92477619529 rdf:first _:807f36cf91fe4e8caa53aadeff92477619530;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619531 .

_:807f36cf91fe4e8caa53aadeff92477619530 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10318 .

_:807f36cf91fe4e8caa53aadeff92477619531 rdf:first _:807f36cf91fe4e8caa53aadeff92477619532;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619532 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10334 .

_:807f36cf91fe4e8caa53aadeff92477619534 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10836-2 a owl:Class;
  rdfs:label "DOLUTÉGRAVIR <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10836";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619536;
  r:natureDuRisque "Diminution des concentrations plasmatiques de dolutégravir par augmentation de son métabolisme par l’inducteur."@fr;
  r:conduiteATenir """Association déconseillée :
- en cas de résistance à la classe des inhibiteurs d'intégrase

Précaution d'emploi :
- en l'absence de résistance à la classe des inhibiteurs d'intégrase
Adaptation de la posologie de dolutégravir à 50 mg 2 fois par jour penda"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619542, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619536 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619537 .

_:807f36cf91fe4e8caa53aadeff92477619537 rdf:first _:807f36cf91fe4e8caa53aadeff92477619538;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619539 .

_:807f36cf91fe4e8caa53aadeff92477619538 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477619539 rdf:first _:807f36cf91fe4e8caa53aadeff92477619540;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619540 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10301 .

_:807f36cf91fe4e8caa53aadeff92477619542 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10898-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> THÉOPHYLLINE (ET, PAR EXTRAPOLATION, AMINOPHYLLINE)"@fr;
  dct:identifier "IAM_10898";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619544;
  r:natureDuRisque "Surdosage en théophylline par diminution de son élimination hépatique, plus particulièrement à risque chez l'enfant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619550, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619544 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619545 .

_:807f36cf91fe4e8caa53aadeff92477619545 rdf:first _:807f36cf91fe4e8caa53aadeff92477619546;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619547 .

_:807f36cf91fe4e8caa53aadeff92477619546 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10152 .

_:807f36cf91fe4e8caa53aadeff92477619547 rdf:first _:807f36cf91fe4e8caa53aadeff92477619548;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619548 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477619550 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10031-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> TICAGRELOR"@fr;
  dct:identifier "IAM_10031";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619552;
  r:natureDuRisque """Majoration du risque hémorragique par addition des activités
antiagrégantes plaquettaires."""@fr;
  r:conduiteATenir """Association déconseillée :
- en dehors des indications validées pour cette association dans les syndromes coronariens aigus.

Précaution d'emploi :
- dans les indications validées pour cette association dans les syndromes coronariens aigus. Surveillance c"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619558, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619552 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619553 .

_:807f36cf91fe4e8caa53aadeff92477619553 rdf:first _:807f36cf91fe4e8caa53aadeff92477619554;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619555 .

_:807f36cf91fe4e8caa53aadeff92477619554 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477619555 rdf:first _:807f36cf91fe4e8caa53aadeff92477619556;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619556 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10926 .

_:807f36cf91fe4e8caa53aadeff92477619558 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10801-2 a owl:Class;
  rdfs:label "DILTIAZEM <-> ESMOLOL"@fr;
  dct:identifier "IAM_10801";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619560;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir """Association déconseillée :
- en cas d'altération de la fonction ventriculaire gauche."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619566, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619560 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619561 .

_:807f36cf91fe4e8caa53aadeff92477619561 rdf:first _:807f36cf91fe4e8caa53aadeff92477619562;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619563 .

_:807f36cf91fe4e8caa53aadeff92477619562 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10290 .

_:807f36cf91fe4e8caa53aadeff92477619563 rdf:first _:807f36cf91fe4e8caa53aadeff92477619564;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619564 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:807f36cf91fe4e8caa53aadeff92477619566 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10028-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> PEMETREXED"@fr;
  dct:identifier "IAM_10028";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619568;
  r:natureDuRisque "Risque de majoration de la toxicité du pemetrexed (diminution de sa clairance rénale par l’acide acétylsalicylique à doses anti-inflammatoires)."@fr;
  r:conduiteATenir """Association déconseillée : 
- en cas de fonction rénale faible à modérée .

Précaution d'emploi :
- en cas de fonction rénale normale. Surveillance biologique de la fonction rénale."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619574, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619568 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619569 .

_:807f36cf91fe4e8caa53aadeff92477619569 rdf:first _:807f36cf91fe4e8caa53aadeff92477619570;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619571 .

_:807f36cf91fe4e8caa53aadeff92477619570 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477619571 rdf:first _:807f36cf91fe4e8caa53aadeff92477619572;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619572 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10700 .

_:807f36cf91fe4e8caa53aadeff92477619574 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10016-2 a owl:Class;
  rdfs:label "ACIDE ACETYLSALICYLIQUE <-> ANTI-INFLAMMATOIRES NON STÉROÏDIENS"@fr;
  dct:identifier "IAM_10016";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619576;
  r:natureDuRisque "Majoration du risque ulcérogène et hémorragique digestif."@fr;
  r:conduiteATenir """Association déconseillée avec :
- des doses anti-inflammatoires d'acide acétylsalicylique (>=1g par prise et/ou >=3g par jour)
- des doses antalgiques ou antipyrétiques (>=500 mg par prise et/ou <3g par jour)"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619582, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619576 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619577 .

_:807f36cf91fe4e8caa53aadeff92477619577 rdf:first _:807f36cf91fe4e8caa53aadeff92477619578;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619579 .

_:807f36cf91fe4e8caa53aadeff92477619578 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10022 .

_:807f36cf91fe4e8caa53aadeff92477619579 rdf:first _:807f36cf91fe4e8caa53aadeff92477619580;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619580 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10012 .

_:807f36cf91fe4e8caa53aadeff92477619582 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10253-2 a owl:Class;
  rdfs:label "ANTICORPS MONOCLONAUX (HORS ANTI-TNF ALPHA) <-> VACCINS VIVANTS ATTÉNUÉS"@fr;
  dct:identifier "IAM_10253";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619584;
  r:natureDuRisque "Risque de maladie vaccinale généralisée, éventuellement mortelle."@fr;
  r:conduiteATenir """Association déconseillée avec :
- bélimumab, blinatumomab, canakinumab, obinutuzumab, ofatumumab, rituximab, tocilizumab, ustékinumab 

A prendre en compte avec :
- alemtuzumab, bevacizumab, brentuximab, cetuximab, daratumumab, dénosumab, ibritumomab, ipi"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619590, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619584 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619585 .

_:807f36cf91fe4e8caa53aadeff92477619585 rdf:first _:807f36cf91fe4e8caa53aadeff92477619586;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619587 .

_:807f36cf91fe4e8caa53aadeff92477619586 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10031 .

_:807f36cf91fe4e8caa53aadeff92477619587 rdf:first _:807f36cf91fe4e8caa53aadeff92477619588;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619588 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10159 .

_:807f36cf91fe4e8caa53aadeff92477619590 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10730-2 a owl:Class;
  rdfs:label "DAPOXÉTINE <-> MÉDICAMENTS À L'ORIGINE D'UNE HYPOTENSION ORTHOSTATIQUE"@fr;
  dct:identifier "IAM_10730";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619592;
  r:natureDuRisque "Risque de majoration des effets indésirables, notamment à type de vertiges ou de syncopes."@fr;
  r:conduiteATenir """Association déconseillée
- avec les inhibiteurs de la phosphodiestérase de type 5

A prendre en compte 
- avec les autres classes thérapeutiques"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619598, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619592 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619593 .

_:807f36cf91fe4e8caa53aadeff92477619593 rdf:first _:807f36cf91fe4e8caa53aadeff92477619594;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619595 .

_:807f36cf91fe4e8caa53aadeff92477619594 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10122 .

_:807f36cf91fe4e8caa53aadeff92477619595 rdf:first _:807f36cf91fe4e8caa53aadeff92477619596;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619596 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10250 .

_:807f36cf91fe4e8caa53aadeff92477619598 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10701-2 a owl:Class;
  rdfs:label "CYPROTERONE <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10701";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619600;
  r:natureDuRisque """Dans l'indication contraception d'urgence de l'ulipristal :
Antagonisme des effets de l’ulipristal en cas de reprise d’un contraceptif hormonal moins de 5 jours après la prise de la contraception d’urgence.

Dans l’indication fibrome de l'ulipristal :
Ant"""@fr;
  r:conduiteATenir """Association déconseillée 
Dans l'utilisation à visée contraceptive de la cyprotérone

- Dans l'indication contraception d'urgence de l'ulipristal
Dans le cas où la (re)prise d’une contraception hormonale est envisagée, utiliser une contraception additionn"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619606, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619600 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619601 .

_:807f36cf91fe4e8caa53aadeff92477619601 rdf:first _:807f36cf91fe4e8caa53aadeff92477619602;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619603 .

_:807f36cf91fe4e8caa53aadeff92477619602 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10238 .

_:807f36cf91fe4e8caa53aadeff92477619603 rdf:first _:807f36cf91fe4e8caa53aadeff92477619604;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619604 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477619606 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10860-1 a owl:Class;
  rdfs:label "DULOXETINE <-> TAMOXIFENE"@fr;
  dct:identifier "IAM_10860";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619608;
  r:natureDuRisque "Risque de baisse de l'efficacité du tamoxifène, par inhibition de la formation de son métabolite actif par la duloxetine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619614, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619608 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619609 .

_:807f36cf91fe4e8caa53aadeff92477619609 rdf:first _:807f36cf91fe4e8caa53aadeff92477619610;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619611 .

_:807f36cf91fe4e8caa53aadeff92477619610 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10314 .

_:807f36cf91fe4e8caa53aadeff92477619611 rdf:first _:807f36cf91fe4e8caa53aadeff92477619612;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619612 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10882 .

_:807f36cf91fe4e8caa53aadeff92477619614 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10861-1 a owl:Class;
  rdfs:label "EBASTINE <-> ERYTHROMYCINE"@fr;
  dct:identifier "IAM_10861";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619616;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long congénital)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619622, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619616 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619617 .

_:807f36cf91fe4e8caa53aadeff92477619617 rdf:first _:807f36cf91fe4e8caa53aadeff92477619618;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619619 .

_:807f36cf91fe4e8caa53aadeff92477619618 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:807f36cf91fe4e8caa53aadeff92477619619 rdf:first _:807f36cf91fe4e8caa53aadeff92477619620;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619620 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477619622 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10862-1 a owl:Class;
  rdfs:label "EBASTINE <-> ITRACONAZOLE"@fr;
  dct:identifier "IAM_10862";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619624;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaire chez les sujets prédisposés (syndrome du QT long congénital)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619630, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619624 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619625 .

_:807f36cf91fe4e8caa53aadeff92477619625 rdf:first _:807f36cf91fe4e8caa53aadeff92477619626;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619627 .

_:807f36cf91fe4e8caa53aadeff92477619626 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10316 .

_:807f36cf91fe4e8caa53aadeff92477619627 rdf:first _:807f36cf91fe4e8caa53aadeff92477619628;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619628 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10496 .

_:807f36cf91fe4e8caa53aadeff92477619630 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10147-2 a owl:Class;
  rdfs:label "AMIODARONE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10147";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619632;
  r:natureDuRisque """Pour vérapamil voie injectable :
-risque de bradycardie ou de bloc auriculo-ventriculaire.

Pour vérapamil per os :
-risque de bradycardie ou de bloc auriculo-ventriculaire, notamment chez les personnes âgées."""@fr;
  r:conduiteATenir """Association déconseillée avec :
- le vérapamil IV
Si l'association ne peut être évitée, surveillance clinique et ECG continu.

Précaution d'emploi avec :
- le vérapamil per os
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619638, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619632 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619633 .

_:807f36cf91fe4e8caa53aadeff92477619633 rdf:first _:807f36cf91fe4e8caa53aadeff92477619634;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619635 .

_:807f36cf91fe4e8caa53aadeff92477619634 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10066 .

_:807f36cf91fe4e8caa53aadeff92477619635 rdf:first _:807f36cf91fe4e8caa53aadeff92477619636;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619636 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477619638 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10934-1 a owl:Class;
  rdfs:label "FER <-> PENICILLAMINE"@fr;
  dct:identifier "IAM_10934";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619640;
  r:natureDuRisque "Diminution de l'absorption digestive de la pénicillamine."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance de la pénicillamine (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619646, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619640 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619641 .

_:807f36cf91fe4e8caa53aadeff92477619641 rdf:first _:807f36cf91fe4e8caa53aadeff92477619642;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619643 .

_:807f36cf91fe4e8caa53aadeff92477619642 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477619643 rdf:first _:807f36cf91fe4e8caa53aadeff92477619644;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619644 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10702 .

_:807f36cf91fe4e8caa53aadeff92477619646 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10896-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> PRAVASTATINE"@fr;
  dct:identifier "IAM_10896";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619648;
  r:natureDuRisque "Avec l'érythromycine utilisée par voie orale : augmentation de la concentration plasmatique de la pravastatine par l' érythromycine."@fr;
  r:conduiteATenir "Surveillance clinique et biologique pendant le traitement par l'antibiotique."@fr;
  rdfs:comment "La clarithromycine et l’érythromycine sont des inhibiteurs puissants du CYP3A4 et de la P-gp intestinale, transporteur qui intervient dans l’efflux de nombreux médicaments au niveau de la lumière intestinale et qui limite donc leur absorption digestive. L"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619654, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619648 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619649 .

_:807f36cf91fe4e8caa53aadeff92477619649 rdf:first _:807f36cf91fe4e8caa53aadeff92477619650;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619651 .

_:807f36cf91fe4e8caa53aadeff92477619650 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477619651 rdf:first _:807f36cf91fe4e8caa53aadeff92477619652;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619652 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10748 .

_:807f36cf91fe4e8caa53aadeff92477619654 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10925-1 a owl:Class;
  rdfs:label "FELBAMATE <-> PHÉNOBARBITAL (ET, PAR EXTRAPOLATION, PRIMIDONE)"@fr;
  dct:identifier "IAM_10925";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619656;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du felbamate et augmentation des concentrations plasmatiques du phénobarbital, avec risque de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique et contrôle des concentrations plasmatiques de phénobarbital avec adaptation de la posologie si besoin."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619662, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619656 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619657 .

_:807f36cf91fe4e8caa53aadeff92477619657 rdf:first _:807f36cf91fe4e8caa53aadeff92477619658;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619659 .

_:807f36cf91fe4e8caa53aadeff92477619658 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10131 .

_:807f36cf91fe4e8caa53aadeff92477619659 rdf:first _:807f36cf91fe4e8caa53aadeff92477619660;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619660 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10369 .

_:807f36cf91fe4e8caa53aadeff92477619662 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10926-1 a owl:Class;
  rdfs:label "FELBAMATE <-> PHÉNYTOÏNE (ET, PAR EXTRAPOLATION, FOSPHÉNYTOÏNE)"@fr;
  dct:identifier "IAM_10926";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619664;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de phénytoïne avec risque de surdosage, par inhibition de son métabolisme par le felbamate."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle des concentrations plasmatiques de phénytoïne et si besoin, adaptation de sa posologie pendant le traitement par le felbamate."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619670, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619664 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619665 .

_:807f36cf91fe4e8caa53aadeff92477619665 rdf:first _:807f36cf91fe4e8caa53aadeff92477619666;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619667 .

_:807f36cf91fe4e8caa53aadeff92477619666 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10132 .

_:807f36cf91fe4e8caa53aadeff92477619667 rdf:first _:807f36cf91fe4e8caa53aadeff92477619668;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619668 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10369 .

_:807f36cf91fe4e8caa53aadeff92477619670 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10927-1 a owl:Class;
  rdfs:label "FELBAMATE <-> VALPROÏQUE (ACIDE) ET, PAR EXTRAPOLATION, VALPROMIDE"@fr;
  dct:identifier "IAM_10927";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619672;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l'acide valproïque, avec risque de surdosage."@fr;
  r:conduiteATenir "Surveillance clinique, contrôle biologique et adaptation éventuelle de la posologie du valproate ou du valpromide pendant le traitement par le felbamate et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619678, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619672 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619673 .

_:807f36cf91fe4e8caa53aadeff92477619673 rdf:first _:807f36cf91fe4e8caa53aadeff92477619674;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619675 .

_:807f36cf91fe4e8caa53aadeff92477619674 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10160 .

_:807f36cf91fe4e8caa53aadeff92477619675 rdf:first _:807f36cf91fe4e8caa53aadeff92477619676;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619676 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10369 .

_:807f36cf91fe4e8caa53aadeff92477619678 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10928-1 a owl:Class;
  rdfs:label "FENTANYL <-> INHIBITEURS PUISSANTS DU CYP3A4"@fr;
  dct:identifier "IAM_10928";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619680;
  r:natureDuRisque "Risque d'augmentation de l’effet dépresseur respiratoire de l’analgésique opiacé par légère diminution de son métabolisme hépatique."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie de l’analgésique opiacé en cas de traitement par un inhibiteur puissant du CYP3A4."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619686, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619680 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619681 .

_:807f36cf91fe4e8caa53aadeff92477619681 rdf:first _:807f36cf91fe4e8caa53aadeff92477619682;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619683 .

_:807f36cf91fe4e8caa53aadeff92477619682 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10103 .

_:807f36cf91fe4e8caa53aadeff92477619683 rdf:first _:807f36cf91fe4e8caa53aadeff92477619684;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619684 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10374 .

_:807f36cf91fe4e8caa53aadeff92477619686 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10929-1 a owl:Class;
  rdfs:label "FENTANYL <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10929";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619688;
  r:natureDuRisque "Diminution des concentrations plasmatiques de fentanyl par augmentation de son métabolisme hépatique par la rifampicine."@fr;
  r:conduiteATenir "Préférer un autre morphinique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619694, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619688 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619689 .

_:807f36cf91fe4e8caa53aadeff92477619689 rdf:first _:807f36cf91fe4e8caa53aadeff92477619690;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619691 .

_:807f36cf91fe4e8caa53aadeff92477619690 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10374 .

_:807f36cf91fe4e8caa53aadeff92477619691 rdf:first _:807f36cf91fe4e8caa53aadeff92477619692;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619692 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477619694 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10935-1 a owl:Class;
  rdfs:label "FER <-> SELS DE FER PAR VOIE INJECTABLE"@fr;
  dct:identifier "IAM_10935";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619696;
  r:natureDuRisque "Lipothymie, voire choc attribué à la libération rapide du fer de sa forme complexe et à la saturation de la sidérophiline."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619702, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619696 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619697 .

_:807f36cf91fe4e8caa53aadeff92477619697 rdf:first _:807f36cf91fe4e8caa53aadeff92477619698;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619699 .

_:807f36cf91fe4e8caa53aadeff92477619698 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10164 .

_:807f36cf91fe4e8caa53aadeff92477619699 rdf:first _:807f36cf91fe4e8caa53aadeff92477619700;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619700 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477619702 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10930-1 a owl:Class;
  rdfs:label "FER <-> FLUOROQUINOLONES"@fr;
  dct:identifier "IAM_10930";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619704;
  r:natureDuRisque "Diminution de l'absorption digestive des fluoroquinolones."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance des fluoroquinolones (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619710, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619704 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619705 .

_:807f36cf91fe4e8caa53aadeff92477619705 rdf:first _:807f36cf91fe4e8caa53aadeff92477619706;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619707 .

_:807f36cf91fe4e8caa53aadeff92477619706 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10075 .

_:807f36cf91fe4e8caa53aadeff92477619707 rdf:first _:807f36cf91fe4e8caa53aadeff92477619708;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619708 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477619710 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10931-1 a owl:Class;
  rdfs:label "FER <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10931";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619712;
  r:natureDuRisque "Diminution de l'absorption digestive des hormones thyroïdiennes."@fr;
  r:conduiteATenir "Prendre les hormones thyroïdiennes à distance du fer (plus de 2 heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619718, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619712 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619713 .

_:807f36cf91fe4e8caa53aadeff92477619713 rdf:first _:807f36cf91fe4e8caa53aadeff92477619714;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619715 .

_:807f36cf91fe4e8caa53aadeff92477619714 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477619715 rdf:first _:807f36cf91fe4e8caa53aadeff92477619716;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619716 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477619718 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10923-1 a owl:Class;
  rdfs:label "EXEMESTANE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10923";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619720;
  r:natureDuRisque "Risque de diminution de l'efficacité de l'exemestane par augmentation de son métabolisme hépatique par l'inducteur enzymatique."@fr;
  rdfs:comment "L’exémestane est un inhibiteur de l’aromatase de structure stéroïdienne. Les résultats d'une étude d'interaction avec la rifampicine, un des plus puissants inducteurs enzymatiques, ont montré une diminution de plus de 40 % des concentrations de l'exémesta"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619726, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619720 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619721 .

_:807f36cf91fe4e8caa53aadeff92477619721 rdf:first _:807f36cf91fe4e8caa53aadeff92477619722;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619723 .

_:807f36cf91fe4e8caa53aadeff92477619722 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10364 .

_:807f36cf91fe4e8caa53aadeff92477619723 rdf:first _:807f36cf91fe4e8caa53aadeff92477619724;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619724 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477619726 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10933-1 a owl:Class;
  rdfs:label "FER <-> METHYLDOPA"@fr;
  dct:identifier "IAM_10933";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619728;
  r:natureDuRisque "Diminution de l'absorption digestive de la méthyldopa (formation de complexes)."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance de la méthyldopa (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619734, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619728 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619729 .

_:807f36cf91fe4e8caa53aadeff92477619729 rdf:first _:807f36cf91fe4e8caa53aadeff92477619730;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619731 .

_:807f36cf91fe4e8caa53aadeff92477619730 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477619731 rdf:first _:807f36cf91fe4e8caa53aadeff92477619732;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619732 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10572 .

_:807f36cf91fe4e8caa53aadeff92477619734 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10922-1 a owl:Class;
  rdfs:label "EVEROLIMUS <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10922";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619736;
  r:natureDuRisque "Augmentation des concentrations sanguines de l'évérolimus par diminution de son métabolisme hépatique par le vérapamil."@fr;
  r:conduiteATenir "Dosage des concentrations sanguines de l’immunosuppresseur, contrôle de la fonction rénale et adaptation de la posologie pendant l’association et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619742, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619736 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619737 .

_:807f36cf91fe4e8caa53aadeff92477619737 rdf:first _:807f36cf91fe4e8caa53aadeff92477619738;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619739 .

_:807f36cf91fe4e8caa53aadeff92477619738 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10363 .

_:807f36cf91fe4e8caa53aadeff92477619739 rdf:first _:807f36cf91fe4e8caa53aadeff92477619740;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619740 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477619742 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10936-1 a owl:Class;
  rdfs:label "FER <-> STRONTIUM"@fr;
  dct:identifier "IAM_10936";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619744;
  r:natureDuRisque "Diminution de l'absorption digestive du strontium."@fr;
  r:conduiteATenir "Prendre le strontium à distance des sels de fer (plus de deux heures, si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619750, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619744 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619745 .

_:807f36cf91fe4e8caa53aadeff92477619745 rdf:first _:807f36cf91fe4e8caa53aadeff92477619746;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619747 .

_:807f36cf91fe4e8caa53aadeff92477619746 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477619747 rdf:first _:807f36cf91fe4e8caa53aadeff92477619748;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619748 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10863 .

_:807f36cf91fe4e8caa53aadeff92477619750 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10937-1 a owl:Class;
  rdfs:label "FER <-> ZINC"@fr;
  dct:identifier "IAM_10937";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619752;
  r:natureDuRisque "Diminution de l’absorption digestive du zinc par le fer."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance du zinc (plus de 2 heures si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619758, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619752 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619753 .

_:807f36cf91fe4e8caa53aadeff92477619753 rdf:first _:807f36cf91fe4e8caa53aadeff92477619754;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619755 .

_:807f36cf91fe4e8caa53aadeff92477619754 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477619755 rdf:first _:807f36cf91fe4e8caa53aadeff92477619756;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619756 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_11005 .

_:807f36cf91fe4e8caa53aadeff92477619758 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10938-1 a owl:Class;
  rdfs:label "FIBRATES <-> FIBRATES (AUTRES)"@fr;
  dct:identifier "IAM_10938";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619760;
  r:natureDuRisque "Risque majoré d'effets indésirables à type de rhabdomyolyse et d'antagonisme pharmacodynamique entre les deux molécules."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619762, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619760 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:807f36cf91fe4e8caa53aadeff92477619762 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10939-1 a owl:Class;
  rdfs:label "FIBRATES <-> INHIBITEURS DE L'HMG-COA RÉDUCTASE (STATINES)"@fr;
  dct:identifier "IAM_10939";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619764;
  r:natureDuRisque "Risque d'addition d'effets indésirables (dose-dépendants) à type de rhabdomyolyse. En outre, avec le gemfibrozil, diminution du métabolisme de la simvastatine et de la rosuvastatine, ce qui majore le risque musculaire, ainsi que la néphrotoxicité de la ro"@fr;
  r:conduiteATenir """Contre-indication 
- entre le gemfibrozil et la simvastatine
- pour des doses de rosuvastatine de 40 mg

Association déconseillée 
- entre les autres fibrates et les autres statines 
- ne pas dépasser 10 mg de simvastatine (cette restriction de doses ne"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619770, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619764 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619765 .

_:807f36cf91fe4e8caa53aadeff92477619765 rdf:first _:807f36cf91fe4e8caa53aadeff92477619766;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619767 .

_:807f36cf91fe4e8caa53aadeff92477619766 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10074 .

_:807f36cf91fe4e8caa53aadeff92477619767 rdf:first _:807f36cf91fe4e8caa53aadeff92477619768;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619768 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10095 .

_:807f36cf91fe4e8caa53aadeff92477619770 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10940-1 a owl:Class;
  rdfs:label "FIDAXOMICINE <-> KETOCONAZOLE"@fr;
  dct:identifier "IAM_10940";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619772;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619778, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619772 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619773 .

_:807f36cf91fe4e8caa53aadeff92477619773 rdf:first _:807f36cf91fe4e8caa53aadeff92477619774;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619775 .

_:807f36cf91fe4e8caa53aadeff92477619774 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:807f36cf91fe4e8caa53aadeff92477619775 rdf:first _:807f36cf91fe4e8caa53aadeff92477619776;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619776 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10501 .

_:807f36cf91fe4e8caa53aadeff92477619778 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10941-1 a owl:Class;
  rdfs:label "FIDAXOMICINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10941";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619780;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de la fidaxomicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619786, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619780 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619781 .

_:807f36cf91fe4e8caa53aadeff92477619781 rdf:first _:807f36cf91fe4e8caa53aadeff92477619782;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619783 .

_:807f36cf91fe4e8caa53aadeff92477619782 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10378 .

_:807f36cf91fe4e8caa53aadeff92477619783 rdf:first _:807f36cf91fe4e8caa53aadeff92477619784;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619784 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477619786 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10942-1 a owl:Class;
  rdfs:label "FLECAINIDE <-> MIRABÉGRON"@fr;
  dct:identifier "IAM_10942";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619788;
  r:natureDuRisque "Augmentation des concentrations plasmatiques du flécaïnide par diminution de son métabolisme par le mirabégron."@fr;
  r:conduiteATenir "Surveillance clinique et réduction éventuelle de la posologie du flécaïnide pendant l'association."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619794, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619788 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619789 .

_:807f36cf91fe4e8caa53aadeff92477619789 rdf:first _:807f36cf91fe4e8caa53aadeff92477619790;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619791 .

_:807f36cf91fe4e8caa53aadeff92477619790 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:807f36cf91fe4e8caa53aadeff92477619791 rdf:first _:807f36cf91fe4e8caa53aadeff92477619792;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619792 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10591 .

_:807f36cf91fe4e8caa53aadeff92477619794 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10943-1 a owl:Class;
  rdfs:label "FLECAINIDE <-> TERBINAFINE"@fr;
  dct:identifier "IAM_10943";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619796;
  r:natureDuRisque "Risque d'augmentation des effets indésirables du flécaïnide, par diminution de son métabolisme hépatique par la terbinafine."@fr;
  r:conduiteATenir "Surveillance clinique. Si besoin, adaptation de la posologie du flécaïnide pendant le traitement par la terbinafine."@fr;
  rdfs:comment """L’effet inhibiteur enzymatique de la terbinafine sur le CYP2D6 a été suggéré sur l’observation chez 12 volontaires sains d’une diminution du métabolisme hépatique de la désipramine, marqueur de l’activité de ce cytochrome.
Afin de prendre acte de cet effe"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619802, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619796 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619797 .

_:807f36cf91fe4e8caa53aadeff92477619797 rdf:first _:807f36cf91fe4e8caa53aadeff92477619798;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619799 .

_:807f36cf91fe4e8caa53aadeff92477619798 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10380 .

_:807f36cf91fe4e8caa53aadeff92477619799 rdf:first _:807f36cf91fe4e8caa53aadeff92477619800;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619800 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10900 .

_:807f36cf91fe4e8caa53aadeff92477619802 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10944-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> HALOFANTRINE"@fr;
  dct:identifier "IAM_10944";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619804;
  r:natureDuRisque "Risque majoré de troubles du rythme ventriculaires, notamment de torsades de pointes."@fr;
  r:conduiteATenir "Si cela est possible, interrompre le fluconazole. Si l'association ne peut être évitée, contrôle préalable du QT et surveillance ECG monitorée."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619810, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619804 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619805 .

_:807f36cf91fe4e8caa53aadeff92477619805 rdf:first _:807f36cf91fe4e8caa53aadeff92477619806;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619807 .

_:807f36cf91fe4e8caa53aadeff92477619806 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477619807 rdf:first _:807f36cf91fe4e8caa53aadeff92477619808;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619808 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10425 .

_:807f36cf91fe4e8caa53aadeff92477619810 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_11206-1 a owl:Class;
  rdfs:label "IVABRADINE <-> PAMPLEMOUSSE (JUS ET FRUIT)"@fr;
  dct:identifier "IAM_11206";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619812;
  r:natureDuRisque "Augmentation des concentrations plasmatiques de l’ivabradine et de ses effets indésirables (inhibition de son métabolisme intestinal par le pamplemousse)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619818, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619812 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619813 .

_:807f36cf91fe4e8caa53aadeff92477619813 rdf:first _:807f36cf91fe4e8caa53aadeff92477619814;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619815 .

_:807f36cf91fe4e8caa53aadeff92477619814 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10130 .

_:807f36cf91fe4e8caa53aadeff92477619815 rdf:first _:807f36cf91fe4e8caa53aadeff92477619816;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619816 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10497 .

_:807f36cf91fe4e8caa53aadeff92477619818 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10932-1 a owl:Class;
  rdfs:label "FER <-> LEVODOPA"@fr;
  dct:identifier "IAM_10932";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619820;
  r:natureDuRisque "Diminution de l'absorption digestive de la lévodopa."@fr;
  r:conduiteATenir "Prendre les sels de fer à distance de la lévodopa (plus de 2 heures si possible)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619826, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619820 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619821 .

_:807f36cf91fe4e8caa53aadeff92477619821 rdf:first _:807f36cf91fe4e8caa53aadeff92477619822;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619823 .

_:807f36cf91fe4e8caa53aadeff92477619822 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10375 .

_:807f36cf91fe4e8caa53aadeff92477619823 rdf:first _:807f36cf91fe4e8caa53aadeff92477619824;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619824 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10517 .

_:807f36cf91fe4e8caa53aadeff92477619826 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10910-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> INHIBITEURS DE PROTÉASES BOOSTÉS PAR RITONAVIR"@fr;
  dct:identifier "IAM_10910";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619828;
  r:chapeau "Le ritonavir est désormais utilisé à la dose de 100 mg 2 fois par jour en association à un autre inhibiteur de protéase, dans le but d'augmenter de façon très significative la biodisponibilité de l'inhibiteur de protéase associé (ou boosté), ce qui permet"@fr;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par diminution des concentrations en contraceptif hormonal, dûe à l'augmentation de son métabolisme hépatique par le ritonavir."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique (préservatif ou stérilet), pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619834, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619828 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619829 .

_:807f36cf91fe4e8caa53aadeff92477619829 rdf:first _:807f36cf91fe4e8caa53aadeff92477619830;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619831 .

_:807f36cf91fe4e8caa53aadeff92477619830 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477619831 rdf:first _:807f36cf91fe4e8caa53aadeff92477619832;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619832 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10100 .

_:807f36cf91fe4e8caa53aadeff92477619834 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10899-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> VENLAFAXINE"@fr;
  dct:identifier "IAM_10899";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619836;
  r:natureDuRisque "Augmentation des concentrations de venlafaxine avec risque de surdosage."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619842, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619836 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619837 .

_:807f36cf91fe4e8caa53aadeff92477619837 rdf:first _:807f36cf91fe4e8caa53aadeff92477619838;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619839 .

_:807f36cf91fe4e8caa53aadeff92477619838 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477619839 rdf:first _:807f36cf91fe4e8caa53aadeff92477619840;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619840 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10979 .

_:807f36cf91fe4e8caa53aadeff92477619842 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10900-1 a owl:Class;
  rdfs:label "ERYTHROMYCINE <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10900";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619844;
  r:natureDuRisque "Bradycardie et/ou troubles de la conduction auriculo-ventriculaire, par diminution du métabolisme hépatique du vérapamil par l'érythromycine."@fr;
  r:conduiteATenir "Surveillance clinique et ECG ; s'il y a lieu, adaptation de la posologie du vérapamil pendant le traitement par l'érythromycine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619850, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619844 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619845 .

_:807f36cf91fe4e8caa53aadeff92477619845 rdf:first _:807f36cf91fe4e8caa53aadeff92477619846;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619847 .

_:807f36cf91fe4e8caa53aadeff92477619846 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10338 .

_:807f36cf91fe4e8caa53aadeff92477619847 rdf:first _:807f36cf91fe4e8caa53aadeff92477619848;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619848 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477619850 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10902-1 a owl:Class;
  rdfs:label "ESMOLOL <-> PROPAFENONE"@fr;
  dct:identifier "IAM_10902";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619852;
  r:natureDuRisque "Troubles de la contractilité, de l'automatisme et de la conduction (suppression des mécanismes sympathiques compensateurs)."@fr;
  r:conduiteATenir "Surveillance clinique et ECG."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619858, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619852 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619853 .

_:807f36cf91fe4e8caa53aadeff92477619853 rdf:first _:807f36cf91fe4e8caa53aadeff92477619854;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619855 .

_:807f36cf91fe4e8caa53aadeff92477619854 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:807f36cf91fe4e8caa53aadeff92477619855 rdf:first _:807f36cf91fe4e8caa53aadeff92477619856;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619856 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10765 .

_:807f36cf91fe4e8caa53aadeff92477619858 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10903-1 a owl:Class;
  rdfs:label "ESMOLOL <-> VERAPAMIL"@fr;
  dct:identifier "IAM_10903";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619860;
  r:natureDuRisque "Troubles de l'automatisme (bradycardie excessive, arrêt sinusal), troubles de la conduction sino-auriculaire et auriculo-ventriculaire et défaillance cardiaque."@fr;
  r:conduiteATenir """Précaution d'emploi :
- si la fonction ventriculaire gauche est normale.
Surveillance clinique et ECG."""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619866, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619860 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619861 .

_:807f36cf91fe4e8caa53aadeff92477619861 rdf:first _:807f36cf91fe4e8caa53aadeff92477619862;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619863 .

_:807f36cf91fe4e8caa53aadeff92477619862 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10341 .

_:807f36cf91fe4e8caa53aadeff92477619863 rdf:first _:807f36cf91fe4e8caa53aadeff92477619864;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619864 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10980 .

_:807f36cf91fe4e8caa53aadeff92477619866 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10904-1 a owl:Class;
  rdfs:label "ESTRAMUSTINE <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10904";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619868;
  r:natureDuRisque "Risque de majoration des effets indésirables à type d'oedème angio-neurotique (angio-oedème)."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619874, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619868 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619869 .

_:807f36cf91fe4e8caa53aadeff92477619869 rdf:first _:807f36cf91fe4e8caa53aadeff92477619870;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619871 .

_:807f36cf91fe4e8caa53aadeff92477619870 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477619871 rdf:first _:807f36cf91fe4e8caa53aadeff92477619872;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619872 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10345 .

_:807f36cf91fe4e8caa53aadeff92477619874 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10907-1 a owl:Class;
  rdfs:label "ESTROGÈNES NON CONTRACEPTIFS <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10907";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619876;
  r:natureDuRisque "Diminution de l'efficacité de l'estrogène."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant l'administration du télaprévir et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619882, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619876 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619877 .

_:807f36cf91fe4e8caa53aadeff92477619877 rdf:first _:807f36cf91fe4e8caa53aadeff92477619878;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619879 .

_:807f36cf91fe4e8caa53aadeff92477619878 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477619879 rdf:first _:807f36cf91fe4e8caa53aadeff92477619880;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619880 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477619882 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10905-1 a owl:Class;
  rdfs:label "ESTROGÈNES NON CONTRACEPTIFS <-> HORMONES THYROÏDIENNES"@fr;
  dct:identifier "IAM_10905";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619884;
  r:natureDuRisque "Risque d'hypothyroïdie clinique en cas d'estrogénothérapie substitutive."@fr;
  r:conduiteATenir "Surveillance clinique et biologique ; adaptation éventuelle des doses de l'hormone thyroïdienne chez les femmes ménopausées prenant des estrogènes."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619890, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619884 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619885 .

_:807f36cf91fe4e8caa53aadeff92477619885 rdf:first _:807f36cf91fe4e8caa53aadeff92477619886;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619887 .

_:807f36cf91fe4e8caa53aadeff92477619886 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477619887 rdf:first _:807f36cf91fe4e8caa53aadeff92477619888;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619888 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10082 .

_:807f36cf91fe4e8caa53aadeff92477619890 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10906-1 a owl:Class;
  rdfs:label "ESTROGÈNES NON CONTRACEPTIFS <-> OXCARBAZEPINE"@fr;
  dct:identifier "IAM_10906";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619892;
  r:natureDuRisque "Risque de diminution de l'efficacité du traitement hormonal, par augmentation de son métabolisme hépatique par l'oxcarbazépine."@fr;
  r:conduiteATenir "Surveillance clinique et adaptation éventuelle de la posologie du traitement hormonal pendant le traitement par l'oxcarbazépine et après son arrêt."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619898, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619892 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619893 .

_:807f36cf91fe4e8caa53aadeff92477619893 rdf:first _:807f36cf91fe4e8caa53aadeff92477619894;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619895 .

_:807f36cf91fe4e8caa53aadeff92477619894 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10072 .

_:807f36cf91fe4e8caa53aadeff92477619895 rdf:first _:807f36cf91fe4e8caa53aadeff92477619896;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619896 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10674 .

_:807f36cf91fe4e8caa53aadeff92477619898 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10915-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> TELAPREVIR"@fr;
  dct:identifier "IAM_10915";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619900;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par augmentation du métabolisme hépatique du contraceptif hormonal par le télaprévir."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive fiable, additionnelle ou alternative, pendant la durée de l'association et deux cycles suivants."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619906, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619900 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619901 .

_:807f36cf91fe4e8caa53aadeff92477619901 rdf:first _:807f36cf91fe4e8caa53aadeff92477619902;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619903 .

_:807f36cf91fe4e8caa53aadeff92477619902 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477619903 rdf:first _:807f36cf91fe4e8caa53aadeff92477619904;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619904 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10887 .

_:807f36cf91fe4e8caa53aadeff92477619906 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10924-1 a owl:Class;
  rdfs:label "EZETIMIBE <-> FENOFIBRATE"@fr;
  dct:identifier "IAM_10924";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619908;
  r:natureDuRisque "Risque de lithiase biliaire par augmentation de l’excrétion biliaire du cholestérol."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619914, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619908 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619909 .

_:807f36cf91fe4e8caa53aadeff92477619909 rdf:first _:807f36cf91fe4e8caa53aadeff92477619910;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619911 .

_:807f36cf91fe4e8caa53aadeff92477619910 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10365 .

_:807f36cf91fe4e8caa53aadeff92477619911 rdf:first _:807f36cf91fe4e8caa53aadeff92477619912;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619912 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10371 .

_:807f36cf91fe4e8caa53aadeff92477619914 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10909-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> INDUCTEURS ENZYMATIQUES"@fr;
  dct:identifier "IAM_10909";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619916;
  r:natureDuRisque "Diminution de l'efficacité contraceptive, par augmentation du métabolisme hépatique du contraceptif hormonal par l'inducteur."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619922, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619916 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619917 .

_:807f36cf91fe4e8caa53aadeff92477619917 rdf:first _:807f36cf91fe4e8caa53aadeff92477619918;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619919 .

_:807f36cf91fe4e8caa53aadeff92477619918 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477619919 rdf:first _:807f36cf91fe4e8caa53aadeff92477619920;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619920 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10094 .

_:807f36cf91fe4e8caa53aadeff92477619922 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10955-1 a owl:Class;
  rdfs:label "FLUCONAZOLE <-> RIFAMPICINE"@fr;
  dct:identifier "IAM_10955";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619924;
  r:natureDuRisque "Diminution des concentrations plasmatiques et de l'efficacité du fluconazole par augmentation de son métabolisme par la rifampicine."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619930, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619924 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619925 .

_:807f36cf91fe4e8caa53aadeff92477619925 rdf:first _:807f36cf91fe4e8caa53aadeff92477619926;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619927 .

_:807f36cf91fe4e8caa53aadeff92477619926 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10381 .

_:807f36cf91fe4e8caa53aadeff92477619927 rdf:first _:807f36cf91fe4e8caa53aadeff92477619928;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619928 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10801 .

_:807f36cf91fe4e8caa53aadeff92477619930 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10911-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> LAMOTRIGINE"@fr;
  dct:identifier "IAM_10911";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619932;
  r:natureDuRisque "Risque de diminution des concentrations et de l’efficacité de la lamotrigine par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir """Précaution d'emploi :
- surveillance clinique et adaptation de la posologie de la lamotrigine lors de la mise en route d’une contraception orale et après son arrêt."""@fr;
  rdfs:comment """Deux publications d'une même équipe montrent que les contraceptifs oraux (COs) diminuent de près de moitié les concentrations plasmatiques de la lamotrigine. Le mécanisme passerait par une induction de la glucuronidation de la lamotrigine par les COs.
Dan"""@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619938, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619932 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619933 .

_:807f36cf91fe4e8caa53aadeff92477619933 rdf:first _:807f36cf91fe4e8caa53aadeff92477619934;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619935 .

_:807f36cf91fe4e8caa53aadeff92477619934 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477619935 rdf:first _:807f36cf91fe4e8caa53aadeff92477619936;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619936 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10507 .

_:807f36cf91fe4e8caa53aadeff92477619938 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10912-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> MILLEPERTUIS"@fr;
  dct:identifier "IAM_10912";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619940;
  r:natureDuRisque "Diminution des concentrations plasmatiques du contraceptif hormonal, en raison de l'effet inducteur enzymatique du millepertuis, avec risque de baisse d'efficacité voire d'annulation de l'effet dont les conséquences peuvent être éventuellement graves (sur"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619946, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619940 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619941 .

_:807f36cf91fe4e8caa53aadeff92477619941 rdf:first _:807f36cf91fe4e8caa53aadeff92477619942;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619943 .

_:807f36cf91fe4e8caa53aadeff92477619942 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477619943 rdf:first _:807f36cf91fe4e8caa53aadeff92477619944;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619944 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10588 .

_:807f36cf91fe4e8caa53aadeff92477619946 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10913-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> MODAFINIL"@fr;
  dct:identifier "IAM_10913";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619948;
  r:natureDuRisque "Risque de diminution de l’efficacité contraceptive, pendant le traitement et un cycle après l’arrêt du traitement par le modafinil, en raison de son potentiel inducteur enzymatique."@fr;
  r:conduiteATenir "Utiliser des contraceptifs oraux normodosés ou une autre méthode contraceptive."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619954, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619948 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619949 .

_:807f36cf91fe4e8caa53aadeff92477619949 rdf:first _:807f36cf91fe4e8caa53aadeff92477619950;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619951 .

_:807f36cf91fe4e8caa53aadeff92477619950 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477619951 rdf:first _:807f36cf91fe4e8caa53aadeff92477619952;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619952 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10599 .

_:807f36cf91fe4e8caa53aadeff92477619954 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10914-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> RUFINAMIDE"@fr;
  dct:identifier "IAM_10914";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619956;
  r:natureDuRisque "Diminution modérée des concentrations d’éthinylestradiol."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619962, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619956 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619957 .

_:807f36cf91fe4e8caa53aadeff92477619957 rdf:first _:807f36cf91fe4e8caa53aadeff92477619958;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619959 .

_:807f36cf91fe4e8caa53aadeff92477619958 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477619959 rdf:first _:807f36cf91fe4e8caa53aadeff92477619960;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619960 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10818 .

_:807f36cf91fe4e8caa53aadeff92477619962 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10916-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> TOPIRAMATE"@fr;
  dct:identifier "IAM_10916";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619964;
  r:natureDuRisque "Pour des doses de topiramate >= 200 mg/jour : Risque de diminution de l’efficacité contraceptive par diminution des concentrations en estrogène."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619970, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619964 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619965 .

_:807f36cf91fe4e8caa53aadeff92477619965 rdf:first _:807f36cf91fe4e8caa53aadeff92477619966;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619967 .

_:807f36cf91fe4e8caa53aadeff92477619966 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477619967 rdf:first _:807f36cf91fe4e8caa53aadeff92477619968;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619968 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10941 .

_:807f36cf91fe4e8caa53aadeff92477619970 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10917-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> ULIPRISTAL"@fr;
  dct:identifier "IAM_10917";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619972;
  r:natureDuRisque "Risque d'antagonisme des effets du progestatif."@fr;
  r:conduiteATenir "Utiliser une méthode contraceptive additionnelle de type mécanique pendant quelques jours après l’arrêt de l’ulipristal."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619978, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619972 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619973 .

_:807f36cf91fe4e8caa53aadeff92477619973 rdf:first _:807f36cf91fe4e8caa53aadeff92477619974;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619975 .

_:807f36cf91fe4e8caa53aadeff92477619974 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477619975 rdf:first _:807f36cf91fe4e8caa53aadeff92477619976;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619976 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10964 .

_:807f36cf91fe4e8caa53aadeff92477619978 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10918-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> VÉMURAFÉNIB"@fr;
  dct:identifier "IAM_10918";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619980;
  r:natureDuRisque "Risque de diminution des concentrations des estroprogestatifs, avec pour conséquence un risque d’inefficacité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619986, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619980 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619981 .

_:807f36cf91fe4e8caa53aadeff92477619981 rdf:first _:807f36cf91fe4e8caa53aadeff92477619982;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619983 .

_:807f36cf91fe4e8caa53aadeff92477619982 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477619983 rdf:first _:807f36cf91fe4e8caa53aadeff92477619984;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619984 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10978 .

_:807f36cf91fe4e8caa53aadeff92477619986 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10919-1 a owl:Class;
  rdfs:label "ETHINYLESTRADIOL <-> ÉTORICOXIB"@fr;
  dct:identifier "IAM_10919";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619988;
  r:natureDuRisque "Augmentation des concentrations d’éthinylestradiol par l’étoricoxib."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477619994, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619988 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619989 .

_:807f36cf91fe4e8caa53aadeff92477619989 rdf:first _:807f36cf91fe4e8caa53aadeff92477619990;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619991 .

_:807f36cf91fe4e8caa53aadeff92477619990 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10351 .

_:807f36cf91fe4e8caa53aadeff92477619991 rdf:first _:807f36cf91fe4e8caa53aadeff92477619992;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477619992 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10359 .

_:807f36cf91fe4e8caa53aadeff92477619994 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10920-1 a owl:Class;
  rdfs:label "ETHINYLESTRADIOL <-> OMBITASVIR + PARITAPRÉVIR"@fr;
  dct:identifier "IAM_10920";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477619996;
  r:natureDuRisque "Augmentation de l’hépatotoxicité."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477620002, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477619996 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477619997 .

_:807f36cf91fe4e8caa53aadeff92477619997 rdf:first _:807f36cf91fe4e8caa53aadeff92477619998;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477619999 .

_:807f36cf91fe4e8caa53aadeff92477619998 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10128 .

_:807f36cf91fe4e8caa53aadeff92477619999 rdf:first _:807f36cf91fe4e8caa53aadeff92477620000;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477620000 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10351 .

_:807f36cf91fe4e8caa53aadeff92477620002 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .

this:IAM_10921-1 a owl:Class;
  rdfs:label "EVEROLIMUS <-> INHIBITEURS DE L'ENZYME DE CONVERSION"@fr;
  dct:identifier "IAM_10921";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477620004;
  r:natureDuRisque "Majoration du risque d’angio-oedème"@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477620010, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477620004 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477620005 .

_:807f36cf91fe4e8caa53aadeff92477620005 rdf:first _:807f36cf91fe4e8caa53aadeff92477620006;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477620007 .

_:807f36cf91fe4e8caa53aadeff92477620006 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10096 .

_:807f36cf91fe4e8caa53aadeff92477620007 rdf:first _:807f36cf91fe4e8caa53aadeff92477620008;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477620008 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10363 .

_:807f36cf91fe4e8caa53aadeff92477620010 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:APEC .

this:IAM_10908-1 a owl:Class;
  rdfs:label "ESTROPROGESTATIFS CONTRACEPTIFS <-> GRISEOFULVINE"@fr;
  dct:identifier "IAM_10908";
  owl:equivalentClass _:807f36cf91fe4e8caa53aadeff92477620012;
  r:natureDuRisque "Risque de diminution de l'efficacité contraceptive par augmentation de son métabolisme hépatique."@fr;
  r:conduiteATenir "Utiliser de préférence une autre méthode contraceptive, en particulier de type mécanique, pendant la durée de l'association et un cycle suivant."@fr;
  rdfs:subClassOf _:807f36cf91fe4e8caa53aadeff92477620018, r:Interaction .

_:807f36cf91fe4e8caa53aadeff92477620012 a owl:Class;
  owl:intersectionOf _:807f36cf91fe4e8caa53aadeff92477620013 .

_:807f36cf91fe4e8caa53aadeff92477620013 rdf:first _:807f36cf91fe4e8caa53aadeff92477620014;
  rdf:rest _:807f36cf91fe4e8caa53aadeff92477620015 .

_:807f36cf91fe4e8caa53aadeff92477620014 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_C_IAM_10073 .

_:807f36cf91fe4e8caa53aadeff92477620015 rdf:first _:807f36cf91fe4e8caa53aadeff92477620016;
  rdf:rest rdf:nil .

_:807f36cf91fe4e8caa53aadeff92477620016 a owl:Restriction;
  owl:onProperty r:administration;
  owl:someValuesFrom adm:Administration_GS_IAM_10422 .

_:807f36cf91fe4e8caa53aadeff92477620018 a owl:Restriction;
  owl:onProperty r:niveau;
  owl:someValuesFrom r:CI .
